0001104659-13-038211.txt : 20130507 0001104659-13-038211.hdr.sgml : 20130507 20130507155715 ACCESSION NUMBER: 0001104659-13-038211 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130507 DATE AS OF CHANGE: 20130507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ISIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 13819863 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 10-Q 1 a13-8376_110q.htm 10-Q

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

Form 10-Q

 

(Mark One)

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended March 31, 2013

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                 to

 

Commission file number 0-19125

 


 

Isis Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

33-0336973

(State or other jurisdiction of

 

(IRS Employer Identification No.)

incorporation or organization)

 

 

 

2855 Gazelle Court, Carlsbad, CA 92010

(Address of principal executive offices, including zip code)

 

760-931-9200

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, $.001 Par Value

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer x

 

Accelerated filer o

 

 

 

Non-accelerated filer o

 

Smaller reporting company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934). Yes o No x

 

The number of shares of voting common stock outstanding as of May 2, 2013 was 103,780,421.

 

 

 



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

FORM 10-Q

INDEX

 

PART I

FINANCIAL INFORMATION

 

 

 

 

ITEM 1:

Financial Statements:

 

 

 

 

 

Condensed Consolidated Balance Sheets as of March 31, 2013 (unaudited) and December 31, 2012

3

 

 

 

 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012 (unaudited)

4

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2013 and 2012 (unaudited)

5

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2012 (unaudited)

6

 

 

 

 

Notes to Condensed Consolidated Financial Statements (unaudited)

7

 

 

 

ITEM 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

 

 

 

 

Results of Operations

24

 

 

 

 

Liquidity and Capital Resources

28

 

 

 

 

Risk Factors

30

 

 

 

ITEM 3:

Quantitative and Qualitative Disclosures about Market Risk

39

 

 

 

ITEM 4:

Controls and Procedures

39

 

 

 

PART II

OTHER INFORMATION

40

 

 

 

ITEM 1:

Legal Proceedings

40

 

 

 

ITEM 2:

Unregistered Sales of Equity Securities and Use of Proceeds

40

 

 

 

ITEM 3:

Default upon Senior Securities

40

 

 

 

ITEM 4:

Mine Safety Disclosures

40

 

 

 

ITEM 5:

Other Information

40

 

 

 

ITEM 6:

Exhibits

41

 

 

 

SIGNATURES

 

42

 

TRADEMARKS

 

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.

 

Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.

 

KYNAMRO™ is a trademark of Genzyme Corporation

 

Juxtapid™ is a trademark of Aegerion Pharmaceuticals, Inc.

 

2



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

 

 

March 31,
2013

 

December 31,
2012

 

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

107,650

 

$

124,482

 

Short-term investments

 

264,261

 

249,964

 

Contracts receivable

 

1,172

 

522

 

Inventories

 

5,809

 

6,121

 

Investment in Regulus Therapeutics Inc.

 

44,863

 

33,622

 

Other current assets

 

8,074

 

8,727

 

Total current assets

 

431,829

 

423,438

 

Property, plant and equipment, net

 

89,694

 

91,084

 

Licenses, net

 

6,010

 

6,579

 

Patents, net

 

19,604

 

18,646

 

Deposits and other assets

 

5,824

 

5,939

 

Total assets

 

$

552,961

 

$

545,686

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

5,385

 

$

10,239

 

Accrued compensation

 

3,818

 

7,878

 

Accrued liabilities

 

17,758

 

15,401

 

Accrued income taxes

 

3,582

 

 

Current portion of long-term obligations

 

4,508

 

4,879

 

Current portion of deferred contract revenue

 

35,244

 

35,925

 

Total current liabilities

 

70,295

 

74,322

 

Long-term deferred contract revenue

 

58,816

 

66,656

 

23/4 percent convertible senior notes

 

145,533

 

143,990

 

Long-term obligations, less current portion

 

6,498

 

7,402

 

Long-term financing liability for leased facility

 

70,728

 

70,550

 

Total liabilities

 

351,870

 

362,920

 

Stockholders’ equity:

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized, 102,695,200 and 101,481,134 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively

 

103

 

102

 

Additional paid-in capital

 

1,091,842

 

1,077,150

 

Accumulated other comprehensive gain

 

17,784

 

12,480

 

Accumulated deficit

 

(908,638

)

(906,966

)

Total stockholders’ equity

 

201,091

 

182,766

 

Total liabilities and stockholders’ equity

 

$

552,961

 

$

545,686

 

 

See accompanying notes.

 

3



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for per share amounts)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Revenue:

 

 

 

 

 

Research and development revenue under collaborative agreements

 

$

41,921

 

$

21,818

 

Licensing and royalty revenue

 

1,439

 

1,417

 

Total revenue

 

43,360

 

23,235

 

 

 

 

 

 

 

Expenses:

 

 

 

 

 

Research and development

 

38,312

 

38,714

 

General and administrative

 

3,423

 

2,976

 

Total operating expenses

 

41,735

 

41,690

 

 

 

 

 

 

 

Income (loss) from operations

 

1,625

 

(18,455

)

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

Equity in net loss of Regulus Therapeutics Inc.

 

 

(976

)

Investment income

 

376

 

600

 

Interest expense

 

(4,795

)

(5,179

)

Gain on investments, net

 

1,058

 

17

 

 

 

 

 

 

 

Loss before income tax benefit (expense)

 

(1,736

)

(23,993

)

 

 

 

 

 

 

Income tax benefit (expense)

 

64

 

(2

)

 

 

 

 

 

 

Net loss

 

$

(1,672

)

$

(23,995

)

 

 

 

 

 

 

Basic and diluted net loss per share

 

$

(0.02

)

$

(0.24

)

Shares used in computing basic and diluted net loss per share

 

101,875

 

100,157

 

 

See accompanying notes.

 

4



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

 

 

 

 

 

 

Net loss

 

$

(1,672

)

$

(23,995

)

Unrealized gains on securities, net of tax

 

6,467

 

528

 

Reclassification adjustment for realized gain on the sale of Sarepta shares included in net loss

 

(1,163

)

 

 

 

 

 

 

 

Comprehensive income (loss)

 

$

3,632

 

$

(23,467

)

 

See accompanying notes.

 

5



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Net cash used in operating activities

 

$

(10,576

)

$

(6,711

)

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

Purchases of short-term investments

 

(64,552

)

(61,841

)

Proceeds from the sale of short-term investments

 

49,076

 

61,781

 

Purchases of property, plant and equipment

 

(222

)

(113

)

Acquisition of licenses and other assets, net

 

(702

)

(349

)

Proceeds from sale of strategic investments

 

1,094

 

 

Net cash used in investing activities

 

(15,306

)

(522

)

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

Proceeds from issuance of equity

 

11,823

 

638

 

Principal payments on debt and capital lease obligations

 

(2,773

)

(2,491

)

Net cash provided by (used in) financing activities

 

9,050

 

(1,853

)

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

(16,832

)

(9,086

)

Cash and cash equivalents at beginning of period

 

124,482

 

65,477

 

Cash and cash equivalents at end of period

 

$

107,650

 

$

56,391

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

Interest paid

 

$

113

 

$

2,211

 

Income taxes paid

 

$

2

 

$

 

 

 

 

 

 

 

Supplemental disclosures of non-cash investing and financing activities:

 

 

 

 

 

Amounts accrued for capital and patent expenditures

 

$

715

 

$

844

 

 

See accompanying notes.

 

6



Table of Contents

 

ISIS PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2013

(Unaudited)

 

1.                                      Basis of Presentation

 

The unaudited interim condensed consolidated financial statements for the three month periods ended March 31, 2013 and 2012 have been prepared on the same basis as the audited financial statements for the year ended December 31, 2012. The financial statements include all normal recurring adjustments, which we consider necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Results for the interim periods are not necessarily indicative of the results for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2012 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).

 

The condensed consolidated financial statements include the accounts of Isis Pharmaceuticals, Inc. (“we”, “us” or “our”) and our wholly owned subsidiary, Symphony GenIsis, Inc., which is currently inactive.  In addition to our wholly owned subsidiary, our consolidated financial statements include our equity investment in Regulus Therapeutics Inc. In October 2012, Regulus completed an initial public offering (IPO).  We now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus.  As a result, in the fourth quarter of 2012, we stopped using the equity method of accounting for our equity investment in Regulus and we began accounting for our investment at fair value.

 

2.                                      Significant Accounting Policies

 

Revenue Recognition

 

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In those instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

 

Research and development revenue under collaborative agreements

 

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services. Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees, profit sharing and royalties on product sales. We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and then accounted for as a single unit of accounting. When the delivered items in an arrangement have “stand-alone value” to our customer, we account for the deliverables as separate units of accounting and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a standalone basis. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. The BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

 

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense therapeutics against five cancer targets. As part of the collaboration, we received a $25 million upfront payment and are eligible to receive a $6 million payment in the second quarter of 2013 assuming the research program is continuing.  We are also eligible to receive milestone payments, license fees for the research program targets and royalties on any product sales of drugs resulting from this collaboration. In exchange, we granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3Rx and ISIS-AZ1Rx.  We also granted AstraZeneca options to license up to three drugs under the separate research program. We are responsible for completing an ongoing clinical study of ISIS-STAT3Rx and IND-enabling studies for ISIS-AZ1Rx. AstraZeneca will be responsible for all other global development, regulatory and commercialization activities for ISIS-STAT3Rx and ISIS-AZ1Rx. In addition, if AstraZeneca exercises its option for any drugs resulting from the research program, AstraZeneca will assume global development, regulatory and commercialization responsibilities for such drug.  Since this agreement has multiple elements, we evaluated the

 

7



Table of Contents

 

deliverables in this arrangement and determined that certain deliverables, either individually or in combination, have stand-alone value.  Below is a list of the four separate units of accounting under our agreement:

 

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-STAT3Rx for the treatment of cancer;

·                  The development services we will perform for ISIS-STAT3Rx;

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-AZ1Rx and the research services we will perform for ISIS-AZ1Rx; and

·                  The option to license up to three drugs under a research program and the research services we will perform for this program.

 

We determined that the ISIS-STAT3Rx license had stand-alone value because it is an exclusive license that gives AstraZeneca the right to develop ISIS-STAT3Rx or to sublicense its rights.  In addition, ISIS-STAT3Rx is currently in development and it is possible that AstraZeneca or another third party could conduct clinical trials without assistance from us.  As a result, we consider the ISIS-STAT3Rx license and the development services for ISIS-STAT3Rx to be separate units of accounting. We recognized the revenue allocated to the ISIS-STAT3Rx license on the date of the agreement because that is when we delivered the license.  We will recognize the revenue allocated to the development services for ISIS-STAT3Rx over the period of time we perform services. The ISIS-AZ1Rx license is also an exclusive license.  Because of the early stage of research for ISIS-AZ1Rx, we believe that our knowledge and expertise with antisense technology is essential for AstraZeneca or another third party to successfully develop ISIS-AZ1Rx.  As a result, we concluded that the ISIS-AZ1Rx license does not have stand-alone value and we combined the ISIS-AZ1Rx license and related research services into one unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of time we perform services. We determined that the options under the research program did not have stand-alone value because AstraZeneca cannot develop or commercialize drugs resulting from the research program until AstraZeneca exercises the respective option or options. As a result, we considered the research options and the related research services as a combined unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of our performance.

 

We determined that the allocable arrangement consideration was the $25 million upfront payment because it was the only payment that was fixed and determinable when we entered into the agreement.  There was considerable uncertainty at the date of the agreement as to whether we would earn the milestone payments, royalty payments, payments for manufacturing clinical trial materials or payments for finished drug product.  As such, we did not include those payments in the allocable consideration.

 

We allocated the $25 million upfront payment based on the relative BESP of each unit of accounting.  We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the licenses granted for ISIS-STAT3Rx and ISIS-AZ1Rx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for each drug. We then discounted the projected income for each license to present value. The significant inputs we used to determine the projected income of the licenses included:

 

·                  Estimated future product sales;

·                  Estimated royalties on future product sales;

·                  Contractual milestone payments;

·                  Expenses we expect to incur;

·                  Income taxes; and

·                  An appropriate discount rate.

 

We estimated the selling price of the research and development services by using our internal estimates of the cost to perform the specific services, marked up to include a reasonable profit margin, and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform research and development. The significant inputs we used to determine the selling price of the research and development services included:

 

·                  The number of internal hours we will spend performing these services;

·                  The estimated number and cost of studies we will perform;

·                  The estimated number and cost of studies that we will contract with third parties to perform; and

·                  The estimated cost of drug product we will use in the studies.

 

As a result of the allocation, we recognized $9.3 million of the $25 million upfront payment in December 2012 for the ISIS-STAT3Rx license.  We are recognizing the remaining $15.7 million over the estimated period of our performance. Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the ISIS-STAT3Rx  license, we determined that the revenue we would have allocated to the ISIS-STAT3Rx  license would change by approximately seven percent, or $600,000, from the amount we recorded.

 

8



Table of Contents

 

Typically, we must estimate our period of performance when the agreements we enter into do not clearly define such information.  Our collaborative agreements typically include a research and/or development project plan that includes the activities the agreement requires each party to perform during the collaboration. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition and amortize revenue over such period. If our collaborators ask us to continue performing work in a collaboration beyond the initial period of performance, we extend our amortization period to correspond to the new extended period of performance.  The revenue we recognize could be materially different if different estimates prevail.

 

From time to time, we may enter into separate agreements at or near the same time with the same customer.  We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement.  We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement.

 

In January 2012, we entered into a collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMNRx for Spinal Muscular Atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of ISIS-SMNRx through completion of Phase 2/3 clinical trials. In June 2012, we entered into a second and separate collaboration agreement with Biogen Idec to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial. In December 2012, we entered into a third and separate collaboration agreement with Biogen Idec to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.  All three of these collaboration agreements give Biogen Idec the option or options to license one or more drugs resulting from the specific collaboration.  If Biogen Idec exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the development of the drugs prior to licensing, milestone payments if Biogen Idec achieves pre-specified regulatory milestones, and royalties on any product sales of drugs resulting from these collaborations.

 

We evaluated the SMA, DMPK, and neurology agreements to determine whether we should account for them as separate agreements or as a single multiple element arrangement.  We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, the first two agreements cover two different diseases while the targets for the third agreement are yet to be defined, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other.  We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting.  For all three of these agreements, we determined that the options did not have stand-alone value because Biogen Idec cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options.  As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective research and development term, which is the estimated period of our performance.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events.  These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

 

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery.  From these research efforts, we hope to identify a development candidate.  The designation of a development candidate is the first stage in the life-cycle of our drugs.  A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.  During the first step of the development stage, we or our partners study our drugs in IND-enabling studies, which are animal studies intended to support an Investigational New Drug, or IND, application and/or the foreign equivalent.  An approved IND allows us or our partners to study our development candidate in humans.  If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients.  If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.  The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing approval from the Food and Drug Administration, or

 

9



Table of Contents

 

FDA, and/or foreign equivalents.  The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete.  If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing approval.  This stage of the drug’s life-cycle is the regulatory stage.  If a drug achieves marketing approval, it moves into the commercialization stage, during which our partner will market and sell the drug to patients.  Although our partner will ultimately be responsible for marketing and selling the drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug.  The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities.  Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow our partner to successfully commercialize our drug.  Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs.  The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

 

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization.  The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain.  As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.  Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

 

Development milestones in our partnerships may include the following types of events:

 

·                  Designation of a development candidate.  Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;

·                  Initiation of a Phase 1 clinical trial.  Generally, Phase 1 clinical trials take one to two years to complete;

·                  Initiation or completion of a Phase 2 clinical trial.  Generally, Phase 2 clinical trials take one to three years to complete;

·                  Initiation or completion of a Phase 3 clinical trial.  Generally, Phase 3 clinical trials take two to four years to complete.

 

Regulatory milestones in our partnerships may include the following types of events:

 

·                  Filing of regulatory applications for marketing approval such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe.  Generally, it takes six to twelve months to prepare and submit regulatory filings.

·                  Marketing approval in a major market, such as the United States, Europe or Japan.  Generally it takes one to two years after an application is submitted to obtain approval from the applicable regulatory agency.

 

Commercialization milestones in our partnerships may include the following types of events:

 

·                  First commercial sale in a particular market, such as in the United States or Europe.

·                  Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion.  The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

 

We assess whether a substantive milestone exists at the inception of our agreements.  When a substantive milestone is achieved, we recognize revenue related to the milestone payment.  For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with ongoing access to new technologies we discover, we have determined that all future development, regulatory and commercialization milestones are substantive. For example, for our strategic alliance with GlaxoSmithKline, or GSK, we are using our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases. Alternatively, we provide on-going access to our technology to Alnylam Pharmaceuticals, Inc. to develop and commercialize RNA interference, or RNAi, therapeutics.  We consider milestones for both of these collaborations to be substantive.  For those agreements that do not meet the following criteria, we do not consider the future milestones to be substantive.  In evaluating if a milestone is substantive we consider whether:

 

·                  Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;

·                  The achievement of the milestone involves substantive effort and can only be achieved based in whole or part on our performance or the occurrence of a specific outcome resulting from our performance;

·                  The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;

 

10



Table of Contents

 

·                  There is no future performance required to earn the milestone; and

·                  The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

 

If any of these conditions are not met, we will defer recognition of the milestone payment and recognize it as revenue over the estimated period of performance, if any.  In the first quarter of 2013, the FDA approved the NDA for KYNAMRO and we initiated a Phase 2/3 clinical study for ISIS-TTRRx, the first drug selected as part of our collaboration with GSK. We consider milestones related to progression of a drug through the development and regulatory stages of its life cycle to be substantive milestones because the level of effort and inherent risk associated with these events is high. Therefore, in the first quarter of 2013 we recognized the $25 million milestone payment from Genzyme and the $7.5 million milestone payment from GSK. Further information about our collaborative arrangements can be found in Note 7 Collaborative Arrangements and Licensing Agreements and Note 7 of our audited financial statements for the year ended December 31, 2012 included in our Annual Report on Form 10-K filed with the SEC.

 

Licensing and royalty revenue

 

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable.

 

Cash, cash equivalents and short-term investments

 

We consider all liquid investments with maturities of 90 days or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than 90 days from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

 

We have equity investments in privately- and publicly-held biotechnology companies that we have received as part of a technology license or collaboration agreement.  At March 31, 2013 we held ownership interests of less than 20 percent in each of the respective companies.

 

We account for our equity investments in publicly-held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly-held companies as a separate component of comprehensive income (loss).  We account for equity investments in privately-held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. Most of the cost method investments we hold are in early stage biotechnology companies and realization of our equity position in those companies is uncertain. In those circumstances we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

 

Inventory valuation

 

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials and historical write-offs. We did not record any inventory write-offs for the first three months of 2013 and 2012. Total inventory, which consisted of raw materials, was $5.8 million and $6.1 million as of March 31, 2013 and December 31, 2012, respectively.

 

11



Table of Contents

 

Patents

 

We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. We evaluate patents and patent applications that we are not actively pursuing and write off any associated costs. We amortize patent costs over their useful lives, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent.

 

Long-lived assets

 

We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets.

 

Equity method of accounting

 

We accounted for our ownership interest in Regulus using the equity method of accounting until Regulus’ IPO in October 2012.  In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus. Under the equity method of accounting, we included our share of Regulus’ operating results on a separate line in our condensed consolidated statement of operations called “Equity in net loss of Regulus Therapeutics Inc.”

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

 

Basic and diluted net loss per share

 

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a loss for the three months ended March 31, 2013 and 2012, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.  The following would have had an anti-dilutive effect on net loss per share:

 

·                  23/4 percent convertible senior notes;

·                  25/8 percent convertible subordinated notes;

·                  GlaxoSmithKline convertible promissory notes issued by Regulus;

·                  Dilutive stock options; and

·                  Restricted stock units.

 

We redeemed all of our 25/8 percent notes in September 2012 and in October 2012 Regulus completed an IPO, upon which we were no longer guarantors on the two convertible notes that Regulus issued to GSK.  As a result, the 25/8 percent notes and GSK convertible promissory notes are not common equivalent shares for the three months ended March 31, 2013.

 

Consolidation of variable interest entities

 

We identify entities as variable interest entities either: (1) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2) in which the equity investors lack an essential characteristic of a controlling financial interest.  We perform ongoing qualitative assessments of our variable interest entities to determine whether we have a controlling financial interest in the variable interest entity and therefore are the primary beneficiary.  As of March 31, 2013 and December 31, 2012, we had collaborative arrangements with five and six entities, respectively, that we considered to be variable interest entities.  We are not the primary beneficiary for any of these entities as we do not have both the power to direct the activities that most significantly impact the economic performance of our variable interest entities and the obligation to absorb losses or the right to receive benefits from our variable interest entities that could potentially be significant to the variable interest entities.  As of March 31, 2013, the total carrying value of our investments in variable interest entities was $47.5 million, and was primarily related to our investment in Regulus. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.

 

12



Table of Contents

 

Accumulated other comprehensive income (loss)

 

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on securities, net of taxes, and  adjustments we made to reclassify realized gains and losses on securities from other accumulated comprehensive income to our condensed consolidated statement of operations. The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March 31, 2013 and 2012 (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Beginning balance accumulated other comprehensive income (loss)

 

$

12,480

 

$

(770

)

Other comprehensive income before reclassifications, net of tax (1)

 

6,467

 

528

 

Amounts reclassified from accumulated other comprehensive income (2)

 

(1,163

)

 

Net current period other comprehensive income

 

5,304

 

528

 

Ending balance accumulated other comprehensive income (loss)

 

$

17,784

 

$

(242

)

 


(1)         Other comprehensive income for the three months ended March 31, 2013 includes income tax expense of $3.6 million.

 

(2)         Included in gain on investments, net on our condensed consolidated statement of operations.

 

Convertible debt

 

In August 2012, we completed a $201.3 million offering of convertible senior notes, which mature in 2019 and bear interest at 2¾ percent.  In September 2012, we used a substantial portion of the net proceeds from the issuance of the 2¾ percent notes to redeem our 25¤8 percent convertible subordinated notes. Consistent with how we accounted for our 25¤8 percent notes, we account for our 2¾ percent notes by separating the liability and equity components of the instrument in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our 2¾ percent notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording the debt instrument at a discount.  We are amortizing the debt discount over the life of these 2¾ percent notes as additional non-cash interest expense utilizing the effective interest method.

 

Segment information

 

We operate in a single segment, Drug Discovery and Development operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a single operating segment.

 

Stock-based compensation expense

 

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our Employee Stock Purchase Plan, or ESPP, based on the estimated fair value of the award on the date of grant using an option-pricing model. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our condensed consolidated statements of operations.  We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

 

13



Table of Contents

 

We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under the ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding.  We estimate the expected term of options granted based on historical exercise patterns.  For the three months ended March 31, 2013 and 2012, we used the following weighted-average assumptions in our Black-Scholes calculations:

 

Employee Stock Options:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

1.0

%

1.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

51.5

%

50.6

%

Expected life

 

5.1 years

 

5.1 years

 

 

ESPP:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

0.1

%

0.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

61.4

%

43.4

%

Expected life

 

6 months

 

6 months

 

 

The fair value of RSUs is based on the market price of our common stock on the date of grant.  RSUs vest annually over a four year period.  The weighted-average grant date fair value of RSUs granted to employees for the three months ended March 31, 2013 and 2012 was $14.21 and $7.60, respectively.

 

The following table summarizes stock-based compensation expense for the three months ended March 31, 2013 and 2012 (in thousands), which was allocated as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Research and development

 

$

2,546

 

$

1,935

 

General and administrative

 

323

 

332

 

Total

 

$

2,869

 

$

2,267

 

 

As of March 31, 2013, total unrecognized estimated non-cash stock-based compensation expense related to non-vested stock options and RSUs was $10.7 million and $3.8 million, respectively. We will adjust total unrecognized compensation cost for future changes in estimated forfeitures.  We expect to recognize the cost of non-cash, stock-based compensation expense related to non-vested stock options and RSUs over a weighted average amortization period of 1.4 years and 2.1 years, respectively.

 

Impact of recently issued accounting standards

 

In February 2013, the FASB issued guidance requiring enhanced disclosures related to reclassifications out of accumulated other comprehensive income (loss).  Under the guidance, we must disclose the amounts we reclassified out of accumulated other comprehensive income (loss) by component. In addition, for significant amounts that we reclassified entirely from other comprehensive income (loss) to net loss, we must disclose the line item of net loss, either on the face of the statement of operations or in the notes to the financial statements. For amounts that we did not reclassify entirely to net loss, we must cross-reference to other disclosures that provide additional detail about those amounts. The guidance is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2012 and was effective for our fiscal year beginning January 1, 2013. As this guidance relates to disclosure only, the adoption of this guidance did not have any effect on our financial statements.

 

3.                                      Investments

 

As of March 31, 2013, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard & Poor’s (S&P) or Fitch, respectively.  We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

 

14



Table of Contents

 

The following table summarizes the contract maturity of the available-for-sale securities we held as of March 31, 2013:

 

One year or less

 

47

%

After one year but within two years

 

41

%

After two years but within three years

 

12

%

Total

 

100

%

 

As illustrated above, we primarily invest our excess cash in short-term instruments with 88 percent of our available-for-sale securities having a maturity of less than two years.

 

At March 31, 2013, we had an ownership interest of less than 20 percent in each of three private companies and three public companies with which we conduct business.  The privately-held companies are Santaris Pharma A/S (formerly Pantheco A/S), Achaogen Inc., and Atlantic Pharmaceuticals Limited.  The publicly-traded companies are Antisense Therapeutics Limited, iCo Therapeutics Inc., and Regulus. We account for equity investments in the privately-held companies under the cost method of accounting and we account for equity investments in the publicly-traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. In the first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics, Inc. that we owned resulting in a realized gain of $1.1 million.

 

The following is a summary of our investments (in thousands):

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

March 31, 2013

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

97,983

 

$

59

 

$

(29

)

$

 

$

98,013

 

Debt securities issued by U.S. government agencies

 

9,932

 

1

 

(46

)

 

9,887

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

15,549

 

55

 

(11

)

 

15,593

 

Total securities with a maturity of one year or less

 

124,464

 

116

 

(86

)

 

124,494

 

Corporate debt securities

 

107,131

 

110

 

(156

)

 

107,085

 

Debt securities issued by U.S. government agencies

 

15,020

 

35

 

(3

)

 

15,052

 

Debt securities issued by the U.S. Treasury

 

12,393

 

30

 

 

 

12,423

 

Debt securities issued by states of the United States and political subdivisions of the states

 

5,203

 

7

 

(3

)

 

5,207

 

Total securities with a maturity of more than one year

 

139,747

 

182

 

(162

)

 

139,767

 

Subtotal

 

$

264,211

 

$

298

 

$

(248

)

$

 

$

264,261

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

March  31, 2013

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,525

 

$

29,338

 

$

 

$

 

$

44,863

 

Current portion (included in Other current assets)

 

1,538

 

1,961

 

 

(880

)

2,619

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,688

 

$

31,299

 

$

 

$

(880

)

$

48,107

 

 

 

$

281,899

 

$

31,597

 

$

(248

)

$

(880

)

$

312,368

 

 

15



Table of Contents

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

113,249

 

$

81

 

$

(9

)

$

 

$

113,321

 

Debt securities issued by U.S. government agencies

 

10,100

 

2

 

(66

)

 

10,036

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

16,560

 

18

 

(2

)

 

16,576

 

Total securities with a maturity of one year or less

 

140,909

 

102

 

(77

)

 

140,934

 

Corporate debt securities

 

80,166

 

112

 

(92

)

 

80,186

 

Debt securities issued by U.S. government agencies

 

8,034

 

38

 

 

 

8,072

 

Debt securities issued by the U.S. Treasury

 

12,424

 

27

 

 

 

12,451

 

Debt securities issued by states of the United States and political subdivisions of the states

 

8,306

 

31

 

(16

)

 

8,321

 

Total securities with a maturity of more than one year

 

108,930

 

208

 

(108

)

 

109,030

 

Subtotal

 

$

249,839

 

$

310

 

$

(185

)

$

 

$

249,964

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,526

 

$

18,096

 

$

 

$

 

$

33,622

 

Current portion (included in Other current assets)

 

1,579

 

4,175

 

 

(880

)

4,874

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,730

 

$

22,271

 

$

 

$

(880

)

$

39,121

 

 

 

$

267,569

 

$

22,581

 

$

(185

)

$

(880

)

$

289,085

 

 

Investments we considered to be temporarily impaired at March 31, 2013 were as follows (in thousands):

 

 

 

 

 

Less than 12 months of
temporary impairment

 

 

 

Number of
Investments

 

Estimated
Fair Value

 

Unrealized
Losses

 

Corporate debt securities

 

70

 

$

95,606

 

$

(185

)

Debt securities issued by U.S. government agencies

 

4

 

13,885

 

(49

)

Debt securities issued by states of the United States and political subdivisions of the states

 

3

 

4,537

 

(14

)

Total temporarily impaired securities

 

77

 

$

114,028

 

$

(248

)

 

We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase.  We believe it is more likely than not that we will be able to hold these securities to maturity.  Therefore we anticipate full recovery of their amortized cost basis at maturity.

 

16



Table of Contents

 

4.                                    Fair Value Measurements

 

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements.  These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and an investment in equity securities in a publicly-held biotechnology company; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Our Level 3 investments include investments in the equity securities of publicly-held biotechnology companies for which we calculated a lack of marketability discount because there are restrictions on when we can trade the securities. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian banks or from a professional pricing service.  We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian bank or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.  During the three months ended March 31, 2013 and 2012 there were no transfers between our Level 1 and Level 2 investments. We use the end of reporting period method for determining transfers between levels.

 

We measure the following major security types at fair value on a recurring basis. We break down the inputs used to measure fair value for these assets at March 31, 2013 and December 31, 2012 as follows (in thousands):

 

 

 

At March 31,
2013

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

96,072

 

$

91,072

 

$

5,000

 

$

 

Corporate debt securities (2)

 

205,098

 

 

205,098

 

 

Debt securities issued by U.S. government agencies (2)

 

24,939

 

 

24,939

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,424

 

13,424

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

20,800

 

 

20,800

 

 

Investment in Regulus Therapeutics Inc.

 

44,863

 

 

 

44,863

 

Equity securities (3)

 

2,619

 

2,619

 

 

 

Total

 

$

407,815

 

$

107,115

 

$

255,837

 

$

44,863

 

 

 

 

At December 31,
2012

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

105,496

 

$

101,496

 

$

4,000

 

$

 

Corporate debt securities (2)

 

193,507

 

 

193,507

 

 

Debt securities issued by U.S. government agencies (2)

 

18,108

 

 

18,108

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,452

 

13,452

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

24,897

 

 

24,897

 

 

Investment in Regulus Therapeutics Inc.

 

33,622

 

 

 

33,622

 

Equity securities (3)

 

4,874

 

4,146

 

 

728

 

Total

 

$

393,956

 

$

119,094

 

$

240,512

 

$

34,350

 

 


(1)         Included in cash and cash equivalents on our consolidated balance sheet.

 

(2)         Included in short-term investments on our consolidated balance sheet.

 

(3)         Included in other current assets on our consolidated balance sheet.

 

We classified the fair value measurements of our investments in the equity securities of Regulus and Sarepta Therapeutics, Inc., or Sarepta, as Level 3.  We calculated a lack of marketability discount on the fair value of these investments because there were restrictions on when we could trade the securities. We consider the inputs we used to calculate the lack of marketability discount Level 3 inputs and, as a result, we categorized these investments as Level 3.  We determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. In the

 

17



Table of Contents

 

first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics, Inc. that we owned resulting in a realized gain of $1.1 million. As of March 31, 2013, our Level 3 investments consisted of our investment in Regulus, with a gross fair value of $54.6 million and a lack of marketability discount of $9.7 million.  As of December 31, 2012, our Level 3 investments consisted of our investment in Regulus and Sarepta with a gross fair value of $44.4 million and $1.0 million, respectively, and a lack of marketability discount of $10.8 million and $296,000, respectively.

 

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2013 (in thousands):

 

 

 

Investments

Valued Using

Level 3 Inputs

 

Balance at December 31, 2012

 

$

34,350

 

Total gains and losses:

 

 

 

Included in gain on investments

 

(1,163

)

Included in accumulated other comprehensive income (loss)

 

11,716

 

Cost basis of shares sold

 

(40

)

Balance at March 31, 2013

 

$

44,863

 

 

Other Fair Value Disclosures

 

Our 2¾ percent convertible notes had a fair value of $258.0 million at March 31, 2013.  We determine the fair value of our 2¾ percent convertible notes based on quoted market prices for these notes, which is a Level 2 measurement.

 

5.                                      Concentration of Business Risk

 

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Partner A

 

58

%

71

%

Partner B

 

23

%

9

%

 

Contract receivables from four significant partners comprised approximately 88 percent of our contract receivables at March 31, 2013. Contract receivables from four significant partners comprised approximately 83 percent of our contract receivables at December 31, 2012.

 

6.                                      Income Taxes

 

Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income.  In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, we must allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During the first quarter of 2013, we recorded unrealized gains on our investments in available-for-sale securities in other comprehensive income net of taxes.  As a result, we recorded a $64,000 tax benefit on our condensed consolidated statements of operations and a $3.6 million tax expense in other comprehensive income for the three months ended March 31, 2013.

 

7.                                      Collaborative Arrangements and Licensing Agreements

 

Traditional Pharmaceutical Alliances and Licensing

 

Biogen Idec

 

We have established three strategic collaborations with Biogen Idec that broaden and expand our severe and rare disease franchise.  In January 2012, we entered into a global collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy, or SMA. Under the terms of the agreement, we received an upfront payment of $29 million and are eligible to receive up to $45 million in substantive milestone payments associated with the clinical development of ISIS-SMNRx prior to licensing.  We are responsible for developing ISIS-SMNRx. Biogen Idec has the option to license ISIS-SMNRx until completion of the first successful Phase 2/3 study or the completion of two Phase 2/3 studies.  If Biogen Idec exercises its option, it will pay us a license fee and will assume global development, regulatory and commercialization responsibilities. In April 2013, we initiated a Phase 2 study of ISIS-SMNRx in infants with SMA, which initiates the Phase 2/3 program for ISIS-SMNRx.

 

18



Table of Contents

 

We will earn a $3.5 million milestone payment from Biogen Idec when we dose the first infant in this Phase 2 study, which we project will be May 2013. The $3.5 million milestone payment is the first of four payments under the March 2013 amendment to the payment terms for the next potential $18 million milestone payment we could earn for the progression of this Phase 2/3 study in infants.  We are also eligible to receive up to $150 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.  In addition, we are eligible to receive up to double-digit royalties on any product sales of ISIS-SMNRx.

 

In June 2012, we and Biogen Idec entered into a second and separate collaboration and license agreement to develop and commercialize a novel antisense drug targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1.  Under the terms of the agreement, we received an upfront payment of $12 million and are eligible to receive up to $59 million in substantive milestone payments associated with the development of the DMPK-targeting drug prior to licensing. We are responsible for global development of the drug through the completion of a Phase 2 clinical trial.  Biogen Idec has the option to license the drug through the completion of the Phase 2 trial.  We are also eligible to receive up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones. In addition, we are eligible to receive up to double-digit royalties on any product sales of the drug. We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for our DMPK program.

 

In December 2012, we and Biogen Idec entered into a third and separate collaboration to develop and commercialize novel antisense drugs to three targets to treat neurological or neuromuscular diseases.  We are responsible for the development of the drugs through the completion of the initial Phase 2 clinical study.  Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 studies. Under the terms of the agreement, we received an upfront payment of $30 million and are eligible to receive development milestone payments to support research and development of each program including a $10 million milestone payment per program upon initiation of an IND-enabling toxicology study.  We are also eligible to receive up to another $200 million in a license fee and regulatory milestone payments per program including up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.  In addition, we are eligible to receive double-digit royalties on any product sales of drugs resulting from each of the three programs.  We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for a development candidate identified under this collaboration.

 

During the three months ended March 31, 2013 and 2012, we earned revenue of $3.9 million and $1.8 million, respectively, from our relationships with Biogen Idec.  Our balance sheets at March 31, 2013 and December 31, 2012 included deferred revenue of $59.2 million and $62.6 million, respectively, related to the upfront payments.

 

Genzyme Corporation, a Sanofi company

 

In January 2008, we entered into a strategic alliance with Genzyme focused on the licensing and co-development of KYNAMRO. The license and co-development agreement provides Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to KYNAMRO, including the key product related patents and their foreign equivalents pending or granted in various countries outside the United States, including in the European Union via the European Patent Convention, Japan, Canada, Australia, South Africa and India.  In addition, we agreed that we would not develop or commercialize another oligonucleotide-based compound designed to modulate apo-B by binding to the messenger RNA, or mRNA, encoding apo-B, throughout the world.

 

The transaction included a $175 million licensing fee, a $150 million equity investment in our stock in which we issued Genzyme five million shares of our common stock, and a share of worldwide profits on KYNAMRO and follow-on drugs ranging from 30 percent to 50 percent of all commercial sales. In January 2013 we earned a $25 million milestone payment when the FDA approved the NDA for KYNAMRO. We may also receive over $1.5 billion in substantive milestone payments if Genzyme achieves pre-specified events, including up to $700 million for the achievement of regulatory milestones and up to $825 million for the achievement of commercialization milestones.  The next milestone payment we could earn under our agreement with Genzyme is $25 million upon the earlier of an NDA approval for the use of KYNAMRO to treat patients who have heterozygous FH or annual net revenue equal to or greater than $250 million in a calendar year.

 

Under this alliance, Genzyme is responsible for the continued development and commercialization of KYNAMRO.  We agreed to supply the drug substance for KYNAMRO for the Phase 3 clinical trials and initial commercial launch.  Genzyme is responsible for manufacturing the finished drug product for KYNAMRO, including the initial commercial launch supply, and Genzyme will be responsible for the long term supply of KYNAMRO drug substance and finished drug product.  As part of the agreement, we contributed the first $125 million in funding for the development costs of KYNAMRO.  In 2011, we satisfied our development funding obligation.  As such, we and Genzyme shared development expenses equally in 2012.  Our shared funding of development expenses will end when KYNAMRO is profitable.

 

19



Table of Contents

 

The license and co-development agreement for KYNAMRO will continue in perpetuity unless we or Genzyme terminate it earlier under the following situations:

 

·                  Genzyme may terminate the license and co-development agreement at any time by providing written notice to Isis;

·                  We may terminate the license and co-development agreement on a country-by-country basis or in its entirety upon Genzyme’s uncured failure to use commercially reasonable efforts to develop and commercialize KYNAMRO in the United States, France, Germany, Italy, Spain, the United Kingdom, Japan and Canada; and

·                  Either we or Genzyme may terminate the license and co-development agreement upon the other party’s uncured failure to perform a material obligation under the agreement.

 

Upon termination of the license and co-development agreement, the license we granted to Genzyme for KYNAMRO will terminate and Genzyme will stop selling the product.  In addition, if Genzyme voluntarily terminates the agreement or we terminate the agreement in a country or countries for Genzyme’s failure to develop and commercialize KYNAMRO, then the rights to KYNAMRO will revert back to us and we may develop and commercialize KYNAMRO in the countries that are the subject of the termination, subject to a royalty payable to Genzyme.

 

If we are the subject of an acquisition, then within 180 days following the acquisition, Genzyme may elect to purchase all of our rights to receive payments under the KYNAMRO license and co-development agreement for a purchase price to be mutually agreed to by us and Genzyme, or, if we cannot agree, a fair market value price determined by an independent investment banking firm.

 

Genzyme has agreed to monthly limits on the number of shares it can sell of the Company’s stock that it purchased in February 2008.  In addition, Genzyme has agreed that until the earlier of the 10 year anniversary of the KYNAMRO license and co-development agreement or the date Genzyme holds less than two percent of our issued and outstanding common stock, Genzyme will not acquire any additional shares of our common stock without our consent.

 

The price Genzyme paid for our common stock represented a significant premium over the then fair value of our common stock.  In May 2012, we finished amortizing this $100 million premium along with the $175 million licensing fee that we received in the second quarter of 2008.  During the three months ended March 31, 2013 and 2012, we earned revenue of $25.0 million and $16.4 million, respectively, from our relationship with Genzyme, which represented 58 percent and 71 percent, respectively, of our total revenue for those periods.  Our balance sheets at both March 31, 2013 and December 31, 2012 included deferred revenue of $3.8 million that Genzyme paid for KYNAMRO drug substance.

 

GlaxoSmithKline

 

In March 2010, we entered into a strategic alliance with GSK, which covers up to six programs, in which we use our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.  This alliance allows us to control and facilitate rapid development of drugs while still being eligible to receive milestone payments as we advance these drugs in clinical development.

 

Under the terms of the original agreement, which includes five programs in addition to the transthyretin, or TTR, program, we are eligible to receive on average up to $20 million in milestone payments per program up to Phase 2 proof-of-conceptGSK has the option to license drugs from these programs at Phase 2 proof-of-concept, and will be responsible for all further development and commercialization.  In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for ISIS-TTRRxUnder the amended terms of the agreement, we received a $2.5 million upfront payment in December 2012, and we received a $7.5 million milestone payment in February 2013 when we initiated the Phase 2/3 clinical study for ISIS-TTRRx.  We have already earned $17.5 million in milestone payments from GSK related to the development of ISIS-TTRRx, and we are eligible to earn an additional $50 million in pre-licensing milestone payments associated with the ISIS-TTRRx Phase 2/3 study.  In addition, GSK has increased the regulatory and commercial milestone payments we can earn should ISIS-TTRRx achieve registration and meet certain sales thresholds.

 

Under the terms of the amended agreement, if GSK successfully develops all six programs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.3 billion, including up to $231.5 million for the achievement of development milestones, up to $594.5 million for the achievement of regulatory milestones and up to $545 million for the achievement of commercialization milestones.  We will earn the next milestone payment of $2 million upon dosing the 10th patient in the Phase 2/3 clinical study for ISIS-TTRRx. In addition, we are eligible to receive up to double-digit royalties on sales from any product that GSK successfully commercializes under this alliance.

 

20



Table of Contents

 

During the three months ended March 31, 2013 and 2012, we earned revenue of $9.9 million and $2.0 million, respectively, from our relationship with GSK, which represented 23 percent and nine percent, respectively, of our total revenue for those periods.  Our balance sheets at March 31, 2013 and December 31, 2012 included deferred revenue of $17.6 million and $19.9 million, respectively, related to the upfront and expansion payments.

 

Roche

 

In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington’s disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial.  Prior to option exercise, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We will also work collaboratively with Roche on the discovery of an antisense drug utilizing Roche’s “brain shuttle” program.  If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for all drugs arising out of the collaboration.  Under the terms of the agreement, we received an upfront payment of $30.0 million in April 2013 and we are eligible to receive up to $362.0 million in a license fee and substantive milestone payments including up to $67.0 million for the achievement of development milestones, up to $170.0 million for the achievement of regulatory milestones and up to $80.0 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed as well as up to $50.0 million in commercial milestones if a drug using Roche’s proprietary brain shuttle technology is successfully commercialized.  We are also eligible to receive tiered royalties on any product sales of drugs resulting from this alliance. We will earn the next milestone payment of $22.0 million upon initiation of a Phase 1 Trial for a drug targeting HTT protein.

 

External Project Funding

 

CHDI Foundation, Inc.

 

Since November 2007, CHDI has provided financial and scientific support to our HD drug discovery program through our development collaboration.  In April 2013, we formed an alliance with Roche to develop treatments for HD. Under the terms of our agreement with CHDI, we will reimburse CHDI for its support of our program out of the payments we receive from Roche. In April 2013, we paid CHDI $1.5 million associated with the signing of the Roche agreement, which we will record as research and development expense in the second quarter of 2013.  We will also pay CHDI $1.5 million when we select a development candidate and if we achieve certain milestones under our collaboration with Roche we will make additional payments to CHDI.  During the three months ended March 31, 2013 and 2012, we earned revenue of $293,000 and $1.2 million, respectively, from our relationship with CHDI. Our balance sheet at December 31, 2012 included deferred revenue of $229,000 related to our relationship with CHDI.

 

ITEM 2.                        MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

In this Report on Form 10-Q, unless the context requires otherwise, “Isis,” “Company,” “we,” “our,” and “us,” means Isis Pharmaceuticals, Inc. and its subsidiaries.

 

Forward-Looking Statements

 

In addition to historical information contained in this Report on Form 10-Q, this Report includes forward-looking statements regarding our business, the therapeutic and commercial potential of our technologies and products in development, and the financial position of Isis Pharmaceuticals, Inc.  Any statement describing our goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements.  Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning our programs are described in additional detail in our Annual Report on Form 10-K for the year ended December 31, 2012, which is on file with the U.S. Securities and Exchange Commission, and those identified within this Item in the section entitled “Risk Factors” beginning on page 30 of this Report.

 

21



Table of Contents

 

Overview

 

We are the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs.  Our strategy is to do what we do best—to discover and develop unique antisense drugs.  The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases, including cardiovascular, severe and rare, neurologic and metabolic diseases and cancer. 

 

Our partnering strategy provides us the flexibility to license each of our drugs at the optimal time to maximize the near- and long-term value for each drug.  In this way, we can expand our and our partners’ pipelines with antisense drugs that we design to address significant medical needs while remaining small and focused.  Our strong financial position is a result of the successful execution of our business strategy as well as our focused research and development capabilities.

 

Our flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH.  Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies.  In January 2013, the FDA approved the marketing application for KYNAMRO for patients with HoFH and Genzyme is also pursuing marketing approval in other markets.  Genzyme is executing a comprehensive plan to address a global commercial market that consists of patients who are in desperate need of new treatment options.  Genzyme has substantial expertise in successfully marketing drugs in the United States and internationally for severe and rare diseases and plans to leverage its infrastructure in these markets.  By concentrating marketing and sales efforts on lipid specialists, and physicians who refer patients to these specialists, Genzyme plans to quickly reach patients with HoFH in the United States.

 

Our pipeline goes well beyond KYNAMRO. We have a pipeline of 28 drugs in development that represents the potential for significant commercial opportunities in many therapeutic areas.  We believe that several of the drugs in our pipeline could reach the market by 2017.  For instance, we designed our TTR amyloidosis and spinal muscular atrophy, or SMA, drugs to treat patients with severe and rare diseases who have very limited therapeutic options.  Because of the significant unmet medical need and the severity of these diseases, new therapeutic approaches could warrant an accelerated path to market.  In addition, several of the drugs in our pipeline are advancing through Phase 2 clinical programs and could represent significant near-term licensing opportunities.  These drugs, including ISIS-APOCIIIRx, ISIS-CRPRx and ISIS-FXIRx, represent substantial commercial opportunities with the potential for Phase 2 data within the next 12 to 18 months.

 

To maximize the value of our drugs and technologies, we have a multifaceted partnering strategy.  We form traditional partnering alliances that enable us to discover and conduct early development of new drugs, outlicense our drugs to partners, such as Genzyme, and build a broad base of license fees, milestone payments and royalty income.  We also form preferred partner transactions that provide us with a vested partner, such as AstraZeneca, Biogen Idec, GSK, and Roche early in the development of a drug.  Typically, the drugs we partner early in development are in therapeutic areas of high risk, like severe neurological diseases, or in areas where Phase 2 results would likely not provide a significant increase in value, like cancer.  These preferred partner transactions allow us to develop select drugs that could have significant commercial potential with a knowledgeable and committed partner with the financial resources to fund later-stage clinical studies and expertise to complement our own development efforts.  As in our other partnerships, we benefit financially from upfront payments, milestone payments, licensing fees and royalties.  This allows us to expand and broaden our drug discovery efforts to new disease targets in therapeutic areas that are outside of our expertise or in areas where our partners will provide tools and resources that will complement our drug discovery efforts.  For example, through our oncology partnership with AstraZeneca, we are capitalizing on AstraZeneca’s development experience and research in oncology.

 

The broad applicability of our drug discovery technology and the clinical successes of the drugs in our pipeline continue to create new partnering opportunities.  Since January 2012, we have initiated five new partnerships that involve neurological diseases or cancer, including a strategic alliance with Roche to discover and develop antisense drugs to treat Huntington’s disease, three strategic alliances with Biogen Idec to discover and develop antisense drugs for the treatment of neurologic diseases, and a strategic alliance with AstraZeneca to discover and develop antisense drugs to treat cancer.  We have received more than $125 million in upfront payments and have the potential to earn more than $2.8 billion in future milestone payments and licensing fees from these partnerships.  Since 2007, our partnerships have generated an aggregate of more than $1 billion in payments from upfront and licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered programs we have the potential to earn up to $5.5 billion in future milestone payments. We also have the potential to share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, or royalty arrangements.

 

22



Table of Contents

 

We also work with a consortium of smaller companies that can exploit our drugs and technologies. We call these smaller companies our satellite companies.  In this way, we benefit from the disease-specific expertise of our satellite company partners, who are advancing drugs in our pipeline in areas that are outside of our core focus. In addition, we can maintain our broad RNA technology leadership through collaborations with companies such as Alnylam Pharmaceuticals, Inc., or Alnylam, and Regulus Therapeutics Inc., or Regulus, a company we co-founded with Alnylam focused on microRNA therapeutics.  In October 2012, Regulus completed an initial public offering.  As of March 31, 2013, the carrying value of our investment in Regulus was $44.9 million, demonstrating the value of our satellite company strategy. All of these different types of relationships are part of our unique business model and create near and long-term shareholder value.

 

We protect our proprietary technologies and products through our substantial patent estate. As an innovator in RNA-targeting drug discovery and development, we design and execute our patent strategy to provide us with extensive protection for our drugs and our technology.  With our ongoing research and development, we continue to add to our substantial patent estate. Our patents not only protect our key assets—our technology and our drugs—they also form the basis for lucrative licensing and partnering arrangements.  To date, we have generated over $400 million from our intellectual property sale and licensing program that helps support our internal drug discovery and development programs.

 

Recent Events

    

Corporate and Drug Development Highlights

 

·    We and Genzyme were successful in bringing KYNAMRO to the market in the United States for patients with HoFH.  These patients are at high cardiovascular risk and may not be able to reduce their LDL-C sufficiently with currently available lipid-lowering therapies.

·                  Genzyme launched KYNAMRO in the United States for the treatment of patients with HoFH.

·                  We received a $25 million milestone payment from Genzyme related to the marketing approval of KYNAMRO by the FDA.

·                  Genzyme continues to enroll the FOCUS FH study, which is designed to provide 60-week safety and efficacy data in FH patients to support an additional regulatory filing.  Genzyme reached an agreement with the FDA on the design of the FOCUS FH study via a Special Protocol Assessment, or SPA.

·    We and our investigators reported positive data from a number of drugs in our pipeline.

·                  Dr. Claudia Chiriboga reported Phase 1 data on ISIS-SMNRx at the American Academy of Neurology.  In this open-label study conducted in a small population, ISIS-SMNRx was well tolerated in children with SMA and functional activity improvements in muscle function were observed in a number of these children.

·                  We reported positive Phase 1 data on ISIS-CRPRx demonstrating that, in healthy volunteers, ISIS-CRPRx can selectively blunt severe increases in CRP following an endotoxin challenge, which produces immune responses similar to those seen with bacterial infections.

·                  We published data in the journal Circulation Research demonstrating that antisense inhibition of ApoC-III produced significant reductions of ApoC-III and triglycerides in multiple species including man.  We presented these data in an oral presentation at the 2013 Duell Meeting in March 2013.

·    We continued to advance our pipeline by initiating clinical studies in numerous disease areas.

·                  We initiated a Phase 2 study of ISIS-SMNRx in infants with SMA and will earn a $3.5 million milestone payment from Biogen Idec when the first patient is dosed in this study.

·                  We initiated a Phase 2/3 study of ISIS-TTRRx in patients with familial polyneuropathy and received a $7.5 million milestone payment from GSK related to the initiation of this study.

·                  AstraZeneca initiated a Phase 1b/2a study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma.

·                  We initiated a Phase 1 study of ISIS-APOARx, an antisense drug designed to reduce levels of Lp(a), an atherogenic lipoprotein.

·    We formed a new alliance with Roche to discover and develop antisense drugs to treat Huntington’s disease.

·                  We received a $30 million upfront payment and we are eligible to receive up to $362 million in a license fee, pre-licensing and post-licensing milestone payments, including up to $80 million in commercial milestones.

·                  In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed plus up to $50 million in commercial milestones if a drug using Roche’s proprietary brain shuttle technology is successfully commercialized.

·                  We are also eligible to receive tiered royalties on sales of drugs arising from the alliance.

 

23



Table of Contents

 

Critical Accounting Policies

 

We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon the information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our quarterly or annual results of operations and financial condition. Each quarter, our senior management discusses the development, selection and disclosure of such estimates with our audit committee of our board of directors. In the following paragraphs, we describe the specific risks associated with these critical accounting policies.  For all of these policies, we caution that future events rarely develop exactly as one may expect, and that best estimates may require adjustment.

 

Historically, our estimates have been accurate as we have not experienced any material differences between our estimates and our actual results. The significant accounting policies, which we believe are the most critical to aid in fully understanding and evaluating our reported financial results, require the following:

 

·                  Assessing the propriety of revenue recognition and associated deferred revenue;

 

·                  Determining the proper valuation of investments in marketable securities and other equity investments;

 

·                  Assessing the recoverability of long-lived assets, including property and equipment, intellectual property and licensed technology;

 

·                  Determining the proper valuation of inventory;

 

·                  Determining the appropriate cost estimates for unbilled preclinical studies and clinical development activities;

 

·                  Estimating our net deferred income tax asset valuation allowance;

 

·                  Determining the fair value of convertible debt without the conversion feature;

 

·                  Determining when we are the primary beneficiary for entities that we identify as variable interest entities; and

 

·                  Determining the fair value of stock-based compensation, including the expected life of the option, the expected stock price volatility over the term of the expected life and estimated forfeitures.

 

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Annual Report on Form 10-K for the year ended December 31, 2012.

 

Results of Operations

 

Revenue

 

Total revenue for the three months ended March 31, 2013 was $43.4 million compared to $23.2 million for the same period in 2012.  Our revenue fluctuates based on the nature and timing of payments under agreements with our partners, including license fees, milestone-related payments and other payments. For example, our revenue in the first quarter of 2013 was significantly higher than in the first quarter of 2012 primarily as a result of the $25 million milestone payment from Genzyme for FDA approval of the KYNAMRO NDA and the $7.5 million milestone payment from GSK for the initiation of the Phase 2/3 study of ISIS-TTRRx.  Also in the first quarter of 2013 we began amortizing revenue from our new alliance with AstraZeneca and our third collaboration with Biogen Idec. Our increase in revenue was offset, in part, by the completion of the amortization of the upfront payments associated with our Genzyme collaboration.

 

In April 2013, we formed a new alliance with Roche to develop treatments for Huntington’s disease, or HD.  As a result, we received an upfront fee of $30 million, which we will begin amortizing into revenue over our period of performance starting in the second quarter of 2013.

 

24



Table of Contents

 

Research and Development Revenue Under Collaborative Agreements

 

Research and development revenue under collaborative agreements for the three months ended March 31, 2013 was $41.9 million compared to $21.8 million for the same period in 2012. The increase in the first quarter of 2013 was primarily a result of the $25 million milestone payment from Genzyme, the $7.5 million milestone payment from GSK, and new revenue from our recent alliance with AstraZeneca and our third collaboration with Biogen Idec partially offset by the completion of the amortization period for the upfront payments associated with our Genzyme collaboration.

 

Licensing and Royalty Revenue

 

Our revenue from licensing activities and royalties was unchanged at $1.4 million for the three months ended March 31, 2013 and March 31, 2012.

 

Operating Expenses

 

Operating expenses for the three months ended March 31, 2013 and 2012 were $41.7 million.

 

In order to analyze and compare our results of operations to other similar companies, we believe it is important to exclude non-cash compensation expense related to equity awards from our operating expenses. We believe non-cash compensation expense is not indicative of our operating results or cash flows from our operations. Further, we internally evaluate the performance of our operations excluding it.

 

Research and Development Expenses

 

Our research and development expenses consist of costs for antisense drug discovery, antisense drug development, manufacturing and operations and R&D support costs.

 

The following table sets forth information on research and development costs (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Research and development expenses

 

$

35,766

 

$

36,779

 

Non-cash compensation expense related to equity awards

 

2,546

 

1,935

 

 

 

 

 

 

 

Total research and development

 

$

38,312

 

$

38,714

 

 

For the three months ended March 31, 2013, our total research and development expenses were $35.8 million, slightly lower compared to $36.8 million for the same period in 2012 primarily due to lower development costs because of the timing of when studies were initiated and lower expenses related to KYNAMRO offset, in part, by higher litigation costs for our patent infringement lawsuit against Santaris Pharma A/S. All amounts exclude non-cash compensation expense related to equity awards.

 

Antisense Drug Discovery

 

We use our proprietary antisense technology to generate information about the function of genes and to determine the value of genes as drug discovery targets. We use this information to direct our own antisense drug discovery research, and that of our antisense drug discovery partners. Antisense drug discovery is also the function within Isis that is responsible for advancing antisense core technology.

 

As we continue to advance our antisense technology, we are investing in our drug discovery programs to expand our and our partners’ drug pipelines. We anticipate that our existing relationships and collaborations, as well as prospective new partners, will continue to help fund our research programs and contribute to the advancement of the science by funding core antisense technology research.

 

25



Table of Contents

 

Our antisense drug discovery expenses were as follows (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Antisense drug discovery expenses

 

$

9,397

 

$

8,364

 

Non-cash compensation expense related to equity awards

 

769

 

565

 

Total antisense drug discovery

 

$

10,166

 

$

8,929

 

 

Antisense drug discovery costs for the three months ended March 31, 2013 were $9.4 million, compared to $8.4 million for the same period in 2012.  The higher expenses in the first quarter of 2013 compared to the same period in 2012 were primarily due to higher expenses for personnel and laboratory supplies required to support our research efforts. All amounts exclude non-cash compensation expense related to equity awards.

 

Antisense Drug Development

 

The following table sets forth research and development expenses for our major antisense drug development projects (in thousands):

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2013

 

2012

 

KYNAMRO

 

$

1,943

 

$

3,035

 

ISIS-TTRRx

 

767

 

1,269

 

Other antisense development products

 

9,878

 

10,928

 

Development overhead costs

 

1,816

 

1,901

 

Non-cash compensation expense related to equity awards

 

856

 

657

 

Total antisense drug development

 

$

15,260

 

$

17,790

 

 

Antisense drug development expenses were $14.4 million for the three months ended March 31, 2013, compared to $17.1 million for the same period in 2012. Expenses in the first quarter of 2013 were lower compared to the same period in 2012 primarily due to the timing of when studies were initiated and lower expenses related to KYNAMRO. For example, we initiated a Phase 2/3 clinical study for ISIS-TTRRx in February 2013 and we expect expenses for this study to increase throughout the year. All amounts exclude non-cash compensation expense related to equity awards.

 

We may conduct multiple clinical trials on a drug candidate, including multiple clinical trials for the various indications we may be studying. Furthermore, as we obtain results from trials we may elect to discontinue clinical trials for certain drug candidates in certain indications in order to focus our resources on more promising drug candidates or indications. Our Phase 1 and Phase 2 programs are clinical research programs that fuel our Phase 3 pipeline. When our products are in Phase 1 or Phase 2 clinical trials, they are in a dynamic state in which we continually adjust the development strategy for each product. Although we may characterize a product as “in Phase 1” or “in Phase 2,” it does not mean that we are conducting a single, well-defined study with dedicated resources. Instead, we allocate our internal resources on a shared basis across numerous products based on each product’s particular needs at that time. This means we are constantly shifting resources among products. Therefore, what we spend on each product during a particular period is usually a function of what is required to keep the products progressing in clinical development, not what products we think are most important. For example, the number of people required to start a new study is large, the number of people required to keep a study going is modest and the number of people required to finish a study is large. However, such fluctuations are not indicative of a shift in our emphasis from one product to another and cannot be used to accurately predict future costs for each product. And, because we always have numerous products in preclinical and early stage clinical research, the fluctuations in expenses from product to product, in large part, offset one another. If we partner a drug, it may affect the size of a trial, its timing, its total cost and the timing of the related cost. We have partnered 16 of our 28 drug candidates, which substantially reduces our development costs. As part of our collaboration with Genzyme, we have transitioned development responsibility for KYNAMRO to Genzyme.  We and Genzyme share development costs equally until KYNAMRO is profitable.

 

26



Table of Contents

 

Manufacturing and Operations

 

Expenditures in our manufacturing and operations function consist primarily of personnel costs, specialized chemicals for oligonucleotide manufacturing, laboratory supplies and outside services. This function is responsible for providing drug supplies to antisense drug discovery and antisense drug development, including the analytical testing to satisfy good laboratory and good manufacturing practices requirements.

 

Our manufacturing and operations expenses were as follows (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Manufacturing and operations

 

$

4,220

 

$

4,571

 

Non-cash compensation expense related to equity awards

 

354

 

262

 

Total manufacturing and operations

 

$

4,574

 

$

4,833

 

 

Manufacturing and operations expenses were $4.2 million for the three months ended March 31, 2013 and decreased slightly compared to $4.6 million for the same period in 2012.  All amounts exclude non-cash compensation expense related to equity awards.

 

R&D Support

 

In our research and development expenses, we include support costs such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of our intellectual property, information technology costs, procurement costs and waste disposal costs. We call these costs R&D support costs.

 

The following table sets forth information on R&D support costs (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Personnel costs

 

$

2,340

 

$

2,267

 

Occupancy

 

1,646

 

1,729

 

Depreciation and amortization

 

1,080

 

1,139

 

Insurance

 

287

 

309

 

Other

 

2,392

 

1,267

 

Non-cash compensation expense related to equity awards

 

567

 

451

 

Total R&D support expenses

 

$

8,312

 

$

7,162

 

 

R&D support costs for the three months ended March 31, 2013 were $7.8 million, compared to $6.7 million for the same period in 2012.  Expenses increased in the first quarter of 2013 compared to the same period in 2012 primarily due to litigation costs for our patent infringement lawsuit against Santaris Pharma A/S.  All amounts exclude non-cash compensation expense related to equity awards.

 

General and Administrative Expenses

 

General and administrative expenses include corporate costs required to support our company, our employees and our stockholders. These costs include personnel and outside costs in the areas of legal, human resources, investor relations, and finance. Additionally, we include in general and administrative expenses such costs as rent, repair and maintenance of buildings and equipment, depreciation, utilities, information technology and procurement costs that we need to support the corporate functions listed above.

 

The following table sets forth information on general and administrative expenses (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

General and administrative expenses

 

$

3,100

 

$

2,644

 

Non-cash compensation expense related to equity awards

 

323

 

332

 

Total general and administrative expenses

 

$

3,423

 

$

2,976

 

 

27



Table of Contents

 

General and administrative expenses were $3.1 million for the three months ended March 31, 2013, and increased slightly compared to $2.6 million for the same period in 2012 primarily due to higher personnel expenses. All amounts exclude non-cash compensation expense related to equity awards.

 

Equity in Net Loss of Regulus Therapeutics Inc.

 

We did not recognize any equity in net loss of Regulus for the three months ended March 31, 2013, compared to equity in net loss of Regulus of $976,000 for the same period in 2012.  We used the equity method of accounting to account for our investment in Regulus until Regulus’ IPO in October 2012.  In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus.

 

Investment Income

 

Investment income for the three months ended March 31, 2012 was $376,000, compared to $600,000 for the same period in 2012.  The decrease in investment income was primarily due to a lower average return on our investments resulting from current market conditions.

 

Interest Expense

 

Interest expense for the three months ended March 31, 2013 was $4.8 million, compared to $5.2 million for the same period in 2012. The decrease in interest expense is primarily because the debt discount we are amortizing as additional non-cash interest expense for the 23/4 percent convertible senior notes is less than the amount we were amortizing for the 25/8 percent convertible subordinated notes we redeemed in September 2012.

 

Gain on Investments, net

 

Gain on investments for the three months ended March 31, 2013 was $1.1 million, compared to $17,000 for the same period in 2012. The gain on investments in the first quarter of 2013 was due to the $1.1 million we realized when we sold the stock we held in Sarepta Therapeutics. This gain demonstrates the value that we are realizing from our satellite company strategy.

 

Income Tax Benefit (Expense)

 

We recorded a tax benefit of $64,000 for the three months ended March 31, 2013, compared to tax expense of $2,000 for the same period in 2012.  The tax benefit we recorded in 2013 is primarily related to the unrealized gain associated with our investment in Regulus. This unrealized gain reflects the increase in Regulus’ stock price during the first three months of 2013.

 

Net Loss and Net Loss per Share

 

Net loss for the three months ended March 31, 2013 was $1.7 million, compared to $24.0 million for the same period in 2012. Basic and diluted net loss per share for the three months ended March 31, 2013 was $0.02 per share, compared to $0.24 per share for the same period in 2012.  Our net loss was significantly lower than the same period in 2012 primarily due to the improvement in our operating results.

 

Liquidity and Capital Resources

 

We have financed our operations with revenue primarily from research and development collaborative agreements. Additionally, we have earned revenue from the sale or licensing of our intellectual property. We have also financed our operations through the sale of our equity securities and the issuance of long-term debt. From our inception through March 31, 2013 we have earned approximately $1.2 billion in revenue from contract research and development and the sale and licensing of our intellectual property.  From the time we were founded through March 31, 2013, we have raised net proceeds of approximately $845.1 million from the sale of our equity securities and we have borrowed approximately $784.4 million under long-term debt arrangements to finance a portion of our operations.

 

As of March 31, 2013, we had cash, cash equivalents and short-term investments of $371.9 million and stockholders’ equity of $201.1 million.  In comparison, we had cash, cash equivalents and short-term investments of $374.4 million and stockholders’ equity of $182.8 million at December 31, 2012. At March 31, 2013, we had consolidated working capital of $361.5 million, compared to $349.1 million at December 31, 2012.  We maintained our strong cash position primarily due to the $32.5 million in milestone payments we received in the first quarter of 2013. Our cash at March 31, 2013 does not include the $30 million upfront payment we received from Roche for our HTT collaboration. Our working capital increased in 2013 primarily due to an increase in current assets resulting from an increase in our investment in Regulus. At March 31, 2013, the carrying value of our investment in Regulus was $44.9 million compared to $33.6 million at December 31, 2012.

 

28



Table of Contents

 

As of March 31, 2013, our debt and other obligations totaled $283.0 million, compared to $284.1 million at December 31, 2012.  The decrease was primarily due to rent and principal payments we made in the first three months of 2013 on our lease obligations and notes payable.

 

The following table summarizes our contractual obligations as of March 31, 2013. The table provides a breakdown of when obligations become due. We provide a more detailed description of the major components of our debt in the paragraphs following the table:

 

 

 

Payments Due by Period (in millions)

 

Contractual Obligations
(selected balances described below)

 

Total

 

Less than
1 year

 

1-3 years

 

3-5 years

 

After
5 years

 

23/4 percent Convertible Senior Notes (principal and interest payable)

 

$

240.0

 

$

5.5

 

$

11.1

 

$

11.1

 

$

212.3

 

Facility Rent Payments

 

$

142.3

 

$

5.9

 

$

12.5

 

$

13.2

 

$

110.7

 

Equipment Financing Arrangements (principal and interest payable)

 

$

9.1

 

$

4.6

 

$

4.5

 

$

 

$

 

Other Obligations (principal and interest payable)

 

$

1.4

 

$

0.1

 

$

0.1

 

$

0.1

 

$

1.1

 

Capital Lease

 

$

0.5

 

$

0.2

 

$

0.3

 

$

 

$

 

Operating Leases

 

$

27.2

 

$

1.5

 

$

2.7

 

$

2.8

 

$

20.2

 

Total

 

$

420.5

 

$

17.8

 

$

31.2

 

$

27.2

 

$

344.3

 

 

Our contractual obligations consist primarily of our publicly traded convertible debt. In addition, we also have facility leases, equipment financing arrangements and other obligations.

 

In August 2012, we completed a $201.3 million convertible debt offering, which raised proceeds of approximately $194.7 million, net of $6.6 million in issuance costs. The $201.3 million of convertible senior notes mature in 2019 and bear interest at 23¤4 percent, which is payable semi-annually. We used a substantial portion of the net proceeds from the issuance of these notes to redeem the entire $162.5 million in principal of our 25¤8 percent convertible subordinated notes.  The 2¾ percent notes are convertible under certain conditions, at the option of the note holders, into approximately 12.1 million shares of our common stock at a conversion price of $16.63 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We can redeem the 2¾ percent notes at our option, in whole or in part, on or after October 5, 2016 if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the trading day immediately preceding the date we provide the redemption notice exceeds 130 percent of the applicable conversion price for the 2¾ percent notes on each such day. The redemption price for the 2¾ percent notes will equal 100 percent of the principal amount being redeemed, plus accrued and unpaid interest, plus $90 per each $1,000 principal amount being redeemed. Holders of the 2¾ percent notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing the 2¾ percent notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.

 

In October 2008, we entered into a loan agreement related to an equipment financing and in September 2009 and June 2012, we amended the loan agreement to increase the aggregate maximum amount of principal we could draw under the agreement.  Each draw down under the loan agreement has a term of three years, with principal and interest payable monthly.  Interest on amounts we borrow under the loan agreement is based upon the three year interest rate swap at the time we make each draw down plus 3.5 or four percent, depending on the date of the draw. We are using the equipment purchased under the loan agreement as collateral.  In June 2012, we drew down $9.1 million in principal under the loan agreement at an interest rate of 4.12 percent. As of March 31, 2013, our outstanding borrowings under this loan agreement were at a weighted average interest rate of 4.57 percent and we can borrow up to an additional $6.0 million in principal to finance the purchase of equipment until April 2014.  The carrying balance under this loan agreement at March 31, 2013 and December 31, 2012 was $8.7 million and $10.0 million, respectively. We will continue to use equipment lease financing as long as the terms remain commercially attractive.

 

29



Table of Contents

 

In March 2010, we entered into a lease agreement with an affiliate of BioMed Realty, L.P.  Under the lease, BioMed constructed a new facility in Carlsbad, California. The lease has an initial term of 20 years with an option to extend the lease for up to four five-year periods.  Our rent under this lease is based on a percentage of the total construction costs spent by BioMed to acquire the land and build the new facility. To gain early access to the facility, we agreed to modify our lease with BioMed to accept additional responsibility.  As a result, accounting rules required us to record the cost of the facility as a fixed asset with a corresponding liability.  We are depreciating the building over its economic life and we will apply our rent payments, which began on January 1, 2012, against the liability over the term of the lease.

 

In addition to contractual obligations, we had outstanding purchase orders as of March 31, 2013 for the purchase of services, capital equipment and materials as part of our normal course of business.

 

We plan to continue to enter into collaborations with partners to provide for additional revenue to us and we may incur additional cash expenditures related to our obligations under any of the new agreements we may enter into. We currently intend to use our cash, cash equivalents and short-term investments to finance our activities. However, we may also pursue other financing alternatives, like issuing additional shares of our common stock, issuing debt instruments, refinancing our existing debt, or securing lines of credit. Whether we use our existing capital resources or choose to obtain financing will depend on various factors, including the future success of our business, the prevailing interest rate environment and the condition of financial markets generally.

 

RISK FACTORS

 

Investing in our securities involves a high degree of risk. You should consider carefully the following information about the risks described below, together with the other information contained in this report and in our other public filings in evaluating our business.  If any of the following risks actually occur, our business could be materially harmed, and our financial condition and results of operations could be materially and adversely affected. As a result, the trading price of our securities could decline, and you might lose all or part of your investment. We have marked with an asterisk those risk factors that reflect substantive changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2012.

 

Risks Associated with our Drug Discovery and Development Business

 

If the market does not accept KYNAMRO or our other drugs, we are not likely to generate revenues or become consistently profitable.

 

Even though KYNAMRO is approved for HoFH in the United States, and if any of our other drugs is approved for marketing, our success will depend upon the medical community, patients and third party payors accepting our drugs as medically useful, cost-effective and safe. Even when the FDA or foreign regulatory authorities approve our or our partners’ drugs for commercialization, doctors may not use our drugs to treat patients. We and our partners may not successfully commercialize additional drugs.

 

In particular, even though KYNAMRO is approved for HoFH in the United States it may not be commercially successful.

 

Additionally, in many of the markets where we may sell our drugs in the future, if we cannot agree with the government regarding the price we can charge for our drugs, then we may not be able to sell our drugs in that market.

 

The degree of market acceptance for KYNAMRO, and any of our other drugs, depends upon a number of factors, including the:

 

·                  receipt and scope of regulatory approvals;

 

·                  establishment and demonstration in the medical and patient community of the efficacy and safety of our drugs and their potential advantages over competing products;

 

·                  cost and effectiveness of our drugs compared to other available therapies;

 

·                  patient convenience of the dosing regimen for our drugs; and

 

·                  reimbursement policies of government and third-party payors.

 

Based on the profile of our drugs, physicians, patients, patient advocates, payors or the medical community in general may not accept and/or use any drugs that we may develop.  In addition, cost control initiatives by governments or third party payors could decrease the price received for KYNAMRO or our other drugs or increase patient coinsurance to a level that makes KYNAMRO or our other drugs unaffordable.

 

30



Table of Contents

 

If our drug discovery and development business fails to compete effectively, our drugs will not contribute significant revenues.

 

Our competitors engage in all areas of drug discovery throughout the world, are numerous, and include, among others, major pharmaceutical companies and specialized biopharmaceutical firms. Other companies engage in developing antisense technology. Our competitors may succeed in developing drugs that are:

 

·                  priced lower than our drugs;

 

·                  safer than our drugs;

 

·                  more effective than our drugs; or

 

·                  more convenient to use than our drugs.

 

These competitive developments could make our drugs, including KYNAMRO, obsolete or non-competitive.

 

Certain of our partners are pursuing other technologies or developing other drugs either on their own or in collaboration with others, including our competitors, to treat the same diseases our own collaborative programs target. Competition may negatively impact a partner’s focus on and commitment to our drugs and, as a result, could delay or otherwise negatively affect the commercialization of our drugs, including KYNAMRO.

 

Many of our competitors have substantially greater financial, technical and human resources than we do. In addition, many of these competitors have significantly greater experience than we do in conducting preclinical testing and human clinical studies of new pharmaceutical products and in obtaining FDA and other regulatory approvals of products for use in health care. Accordingly, our competitors may succeed in obtaining regulatory approval for products earlier than we do.  Marketing and sales capability is another factor relevant to the competitive position of our drugs, and we will rely on our partners to provide this capability.

 

Regarding KYNAMRO, some competitors are pursuing a development or commercialization strategy that competes with our strategy for KYNAMRO.  Other companies are currently developing products that could compete with KYNAMRO.  Products such as microsomal triglyceride transfer protein inhibitors, or MTP inhibitors, and other lipid lowering drugs other companies are developing or commercializing could potentially compete with KYNAMRO.  For example, Aegerion Pharmaceuticals, Inc. received approval from the FDA to market its MTP inhibitor, Juxtapid, as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density-lipoprotein cholesterol in patients with HoFH. Aegerion has also submitted a marketing authorization application for Juxtapid to the European Medicines Agency seeking approval of Juxtapid as an adjunct to a low fat diet and other lipid-lowering therapies to reduce cholesterol in patients with HoFH. Our revenues and financial position will suffer if KYNAMRO cannot compete effectively in the marketplace.

 

Following approval, KYNAMRO is, and any of our other drugs could be subject to regulatory limitations.

 

Following approval of a drug, we and our partners must comply with comprehensive government regulations regarding the manufacture, marketing and distribution of drug products. Even if approved, we or our partners may not obtain the labeling claims necessary or desirable for successfully commercializing our drug products, including KYNAMRO.

 

The FDA and foreign regulatory authorities have the authority to impose significant restrictions on an approved drug product through the product label and on advertising, promotional and distribution activities.  For example:

 

·                  KYNAMRO is approved in the United States as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol in patients with HoFH;

·                  the KYNAMRO label contains a Boxed Warning citing a risk of hepatic toxicity; and

·                  KYNAMRO is available only through a Risk Evaluation and Mitigation Strategy called the KYNAMRO REMS.

 

In addition, when approved, the FDA or a foreign regulatory authority may condition approval on the performance of post-approval clinical studies or patient monitoring, which could be time consuming and expensive.  If the results of such post-marketing studies are not satisfactory, the FDA or a foreign regulatory authority may withdraw marketing authorization or may condition continued marketing on commitments from us or our partners that may be expensive and/or time consuming to fulfill.

 

31



Table of Contents

 

If we or others identify side effects after any of our drug products are on the market, or if manufacturing problems occur subsequent to regulatory approval, we or our partners may lose regulatory approval, or we or our partners may need to conduct additional clinical studies and/or change the labeling of our drug products including KYNAMRO.

 

We depend on our collaboration with Genzyme for the development and commercialization of KYNAMRO.

 

We have entered into a collaborative arrangement with Genzyme to develop and commercialize KYNAMRO.

 

We entered into this collaboration primarily to:

 

·                  fund some of our development activities for KYNAMRO;

 

·                  seek and obtain regulatory approvals for KYNAMRO; and

 

·                  successfully commercialize KYNAMRO.

 

In general, we cannot control the amount and timing of resources that Genzyme devotes to our collaboration. If Genzyme fails to further develop and commercialize KYNAMRO, or if Genzyme’s efforts are not effective, our business may be negatively affected. We are relying on Genzyme to obtain additional marketing approvals for and successfully commercialize KYNAMRO.  Our collaboration with Genzyme may not continue or result in the successful commercialization of KYNAMRO.  Genzyme can terminate our collaboration at any time.  If Genzyme stopped developing or commercializing KYNAMRO, we would have to seek additional sources for funding and may have to delay or reduce our development and commercialization programs for KYNAMRO.  If Genzyme does not successfully commercialize KYNAMRO, we may receive limited or no revenues for KYNAMRO.  In addition, Sanofi’s acquisition of Genzyme could disrupt Genzyme or distract it from performing its obligations under our collaboration.

 

If Genzyme cannot manufacture finished drug product for KYNAMRO or the post-launch supply of the active drug substance for KYNAMRO, KYNAMRO may not achieve or maintain commercial success.

 

We rely on Genzyme to manufacture the finished drug product for KYNAMRO, including the initial commercial launch supply.  In addition, Genzyme is responsible for the long term supply of both KYNAMRO drug substance and finished drug product.  Genzyme may not be able to reliably manufacture KYNAMRO drug substance and drug product to support the long term commercialization of KYNAMRO.  If Genzyme cannot reliably manufacture KYNAMRO drug substance and drug product, KYNAMRO may not achieve or maintain commercial success, which will harm our ability to generate revenue.

 

If we or our partners fail to obtain regulatory approval for our drugs, including additional approvals for KYNAMRO, we or our partners cannot sell them in the applicable markets.*

 

We cannot guarantee that any of our drugs will be safe and effective, or will be approved for commercialization.  In addition, we cannot guarantee that KYNAMRO will be approved outside the United States or for additional indications. We and our partners must conduct time-consuming, extensive and costly clinical studies to show the safety and efficacy of each of our drugs, including KYNAMRO, before a drug can be approved for sale. We must conduct these studies in compliance with FDA regulations and with comparable regulations in other countries.

 

We and our partners may not obtain necessary regulatory approvals on a timely basis, if at all, for any of our drugs.  It is possible that other regulatory agencies will not approve KYNAMRO for marketing.  If the FDA or another regulatory agency believes that we or our partners have not sufficiently demonstrated the safety or efficacy of any of our drugs, including KYNAMRO, the agency will not approve the specific drug or will require additional studies, which can be time consuming and expensive and which will delay or harm commercialization of the drug.  For example, in March 2013 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency maintained a negative opinion for Genzyme’s marketing authorization application for KYNAMRO as a treatment for patients with HoFH.

 

Failure to receive marketing approval for our drugs, including KYNAMRO outside the United States, or delays in these approvals could prevent or delay commercial introduction of the drug, and, as a result, could negatively impact our ability to generate revenue from product sales.

 

32



Table of Contents

 

If the results of clinical testing indicate that any of our drugs are not suitable for commercial use we may need to abandon one or more of our drug development programs.

 

Drug discovery and development has inherent risks and the historical failure rate for drugs is high. Antisense drugs are a relatively new approach to therapeutics. If we cannot demonstrate that our drugs are safe and effective for human use, we may need to abandon one or more of our drug development programs.  There are ongoing clinical studies for KYNAMRO and sales to patients, adverse events from which could negatively impact our pending or planned marketing approval applications and commercialization of KYNAMRO.

 

In the past, we have invested in clinical studies of drugs that have not met the primary clinical end points in their Phase 3 studies. Similar results could occur in any additional clinical studies for KYNAMRO and in clinical studies for our other drugs. If any of our drugs in clinical studies, including KYNAMRO, does not show sufficient efficacy in patients with the targeted indication, it could negatively impact our development and commercialization goals for the drug and our stock price could decline.

 

Even if our drugs are successful in preclinical and human clinical studies, the drugs may not be successful in late-stage clinical studies.

 

Successful results in preclinical or initial human clinical studies, including the Phase 3 results for KYNAMRO and the Phase 2 results for some of our other drugs in development, may not predict the results of subsequent clinical studies, including subsequent studies of KYNAMRO.  There are a number of factors that could cause a clinical study to fail or be delayed, including:

 

·                  the clinical study may produce negative or inconclusive results;

 

·                  regulators may require that we hold, suspend or terminate clinical research for noncompliance with regulatory requirements;

 

·                  we, our partners, the FDA or foreign regulatory authorities could suspend or terminate a clinical study due to adverse side effects of a drug on subjects in the trial;

 

·                  we may decide, or regulators may require us, to conduct additional preclinical testing or clinical studies;

 

·                  enrollment in our clinical studies may be slower than we anticipate;

 

·                  the cost of our clinical studies may be greater than we anticipate; and

 

·                  the supply or quality of our drugs or other materials necessary to conduct our clinical studies may be insufficient, inadequate or delayed.

 

Any failure or delay in the clinical studies, including any further studies under the development program for KYNAMRO, could reduce the commercial potential or viability of our drugs.

 

If we cannot manufacture our drugs or contract with a third party to manufacture our drugs at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.

 

To successfully commercialize any of our drugs, we or our partner would need to establish large-scale commercial manufacturing capabilities either on our own or through a third party manufacturer. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. We have limited experience manufacturing pharmaceutical products of the chemical class represented by our drugs, called oligonucleotides, on a commercial scale for the systemic administration of a drug. There are a small number of suppliers for certain capital equipment and raw materials that we use to manufacture our drugs, and some of these suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing.  Further, we must continue to improve our manufacturing processes to allow us to reduce our drug costs.  We may not be able to manufacture our drugs at a cost or in quantities necessary to make commercially successful products.

 

Also, manufacturers, including us, must adhere to the FDA’s current Good Manufacturing Practices regulations and similar regulations in foreign countries, which the applicable regulatory authorities enforce through facilities inspection programs. We and our contract manufacturers may not comply or maintain compliance with Good Manufacturing Practices, or similar foreign regulations. Non-compliance could significantly delay or prevent receipt of marketing approval for our drugs, including KYNAMRO, or result in enforcement action after approval that could limit the commercial success of our drugs, including KYNAMRO.

 

33



Table of Contents

 

We depend on third parties to conduct our clinical studies for our drugs and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.

 

We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our drugs and expect to continue to do so in the future. For example, Medpace is the primary clinical research organization for the ongoing clinical studies for KYNAMRO. We rely heavily on these parties for successful execution of our clinical studies, but do not control many aspects of their activities. For example, the investigators are not our employees. However, we are responsible for ensuring that these third parties conduct each of our clinical studies in accordance with the general investigational plan and approved protocols for the study. Third parties may not complete activities on schedule, or may not conduct our clinical studies in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations or a termination of our relationship with these third parties could delay or prevent the development, approval and commercialization of our drugs, including any expanded product label for KYNAMRO.

 

Risks Associated with our Businesses as a Whole

 

We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.*

 

Because drug discovery and development requires substantial lead-time and money prior to commercialization, our expenses have generally exceeded our revenue since we were founded in January 1989. As of March 31, 2013, we had an accumulated deficit of approximately $908.6 million and stockholders’ equity of approximately $201.1 million.  Most of the losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Most of our revenue has come from collaborative arrangements, with additional revenue from research grants and the sale or licensing of our patents, as well as interest income. We may incur additional operating losses over the next several years, and these losses may increase if we cannot increase or sustain revenue. We may not successfully develop any additional products or achieve or sustain future profitability.

 

Since corporate partnering is a key part of our strategy to fund the development and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.*

 

To date, corporate partnering has played a key role in our strategy to fund our development programs and to add key development resources. We plan to continue to rely on additional collaborative arrangements to develop and commercialize our unpartnered drugs.  However, we may not be able to negotiate favorable collaborative arrangements for these drug programs.  If we cannot continue to secure additional collaborative partners, our revenues could decrease and the development of our drugs could suffer.

 

Our corporate partners are developing and/or funding many of the drugs in our development pipeline, including AstraZeneca, ATL, Atlantic Pharmaceuticals, Biogen Idec, iCo, Genzyme, GSK, OncoGenex, Pfizer and Teva Pharmaceutical Industries Ltd.  If any of these pharmaceutical companies stops developing and/or funding these drugs, our business could suffer and we may not have, or be willing to dedicate, the resources available to develop these drugs on our own.

 

Our collaborators can terminate their relationships with us under certain circumstances, many of which are outside of our control. In the past, based on the disappointing results of Phase 3 clinical studies, we had a partner discontinue its investment in one of our drugs.

 

Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development programs.*

 

In addition to receiving funding, we enter into collaborative arrangements with third parties to:

 

·                  conduct clinical studies;

 

·                  seek and obtain regulatory approvals; and

 

·                  manufacture, market and sell our drugs.

 

34



Table of Contents

 

Once we have secured a collaborative arrangement to further develop and commercialize one of our drug development programs, such as our collaborations with AstraZeneca, Biogen Idec, Genzyme, and GSK, these collaborations may not continue or result in commercialized drugs, or may not progress as quickly as we first anticipated.

 

For example, a collaborator such as AstraZeneca, Biogen Idec, Genzyme, or GSK, could determine that it is in its financial interest to:

 

·                  pursue alternative technologies or develop alternative products that may be competitive with the drug that is part of the collaboration with us;

 

·                  pursue higher-priority programs or change the focus of its own development programs; or

 

·                  choose to devote fewer resources to our drugs than it does for its own drugs.

 

If any of these occur, it could affect our partner’s commitment to the collaboration with us and could delay or otherwise negatively affect the commercialization of our drugs, including KYNAMRO.

 

If we do not progress in our programs as anticipated, the price of our securities could decrease.*

 

For planning purposes, we estimate and may disclose the timing of a variety of clinical, regulatory and other milestones, such as when we anticipate a certain drug will enter the clinic, when we anticipate completing a clinical study, or when we anticipate filing an application for marketing approval. We base our estimates on present facts and a variety of assumptions. Many underlying assumptions are outside of our control. If we do not achieve milestones in accordance with our or our investors’ expectations, including milestones for additional approvals or sales expectations of KYNAMRO, the price of our securities would likely decrease.

 

For example, in March 2013 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency maintained a negative opinion for Genzyme’s marketing authorization application for KYNAMRO as a treatment for patients with HoFH.

 

If we cannot protect our patents or our other proprietary rights, others may compete more effectively against us.

 

Our success depends to a significant degree upon whether we can continue to develop and secure intellectual property rights to proprietary products and services. However, we may not receive issued patents on any of our pending patent applications in the United States or in other countries. In addition, the scope of any of our issued patents may not be sufficiently broad to provide us with a competitive advantage. Furthermore, our issued patents or patents licensed to us may be successfully challenged, invalidated or circumvented so that our patent rights would not create an effective competitive barrier or revenue source.

 

Intellectual property litigation could be expensive and prevent us from pursuing our programs.

 

From time to time we have to defend our intellectual property rights. In the event of an intellectual property dispute, we sometimes need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the United States Patent and Trademark Office or the International Trade Commission or foreign patent authorities. Intellectual property litigation can be extremely expensive, and this expense, as well as the consequences should we not prevail, could seriously harm our business.  For example, in September 2011 we filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California.  This lawsuit may be costly and may not be resolved in our favor.

 

If a third party claims that our drugs or technology infringe its patents or other intellectual property rights, we may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We may not be able to obtain a license to needed intellectual property on favorable terms, if at all. There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business.  This is especially true since patent applications in the United States are filed confidentially for the first 18 months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain unresolved.

 

35



Table of Contents

 

If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.*

 

Many of our drugs are undergoing clinical studies or are in the early stages of research and development. All of our drug programs will require significant additional research, development, preclinical and/or clinical testing, regulatory approval and/or commitment of significant additional resources prior to their successful commercialization. As of March 31, 2013, we had cash, cash equivalents and short-term investments equal to $371.9 million.  If we do not meet our goals to commercialize KYNAMRO or our other drugs, or to license our drugs and proprietary technologies, we will need additional funding in the future. Our future capital requirements will depend on many factors, such as the following:

 

·                  additional marketing approvals and successful commercial launch of KYNAMRO;

 

·                  changes in existing collaborative relationships and our ability to establish and maintain additional collaborative arrangements;

 

·                  continued scientific progress in our research, drug discovery and development programs;

 

·                  the size of our programs and progress with preclinical and clinical studies;

 

·                  the time and costs involved in obtaining regulatory approvals;

 

·                  competing technological and market developments, including the introduction by others of new therapies that address our markets; and

 

·                  the profile and launch timing of our drugs.

 

If we need additional funds, we may need to raise them through public or private financing. Additional financing may not be available at all or on acceptable terms. If we raise additional funds by issuing equity securities, the shares of existing stockholders will be diluted and the price, as well as the price of our other securities, may decline. If adequate funds are not available or not available on acceptable terms, we may have to cut back on one or more of our research, drug discovery or development programs. For example, in January 2005 we terminated the development of two lower priority drugs, ISIS 14803 and ISIS 104838. Alternatively, we may obtain funds through arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or drugs.

 

The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.

 

We are dependent on the principal members of our management and scientific staff. We do not have employment agreements with any of our executive officers that would prevent them from leaving us. The loss of our management and key scientific employees might slow the achievement of important research and development goals. It is also critical to our success that we recruit and retain qualified scientific personnel to perform research and development work. We may not be able to attract and retain skilled and experienced scientific personnel on acceptable terms because of intense competition for experienced scientists among many pharmaceutical and health care companies, universities and non-profit research institutions. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified scientific personnel.

 

If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss.

 

The market price of our common stock, like that of the securities of many other biopharmaceutical companies, has been and is likely to continue to be highly volatile. These fluctuations in our common stock price may significantly affect the trading price of our securities. During the 12 months preceding March 31, 2013, the market price of our common stock ranged from $7.02 to $19.53 per share.  Many factors can affect the market price of our securities, including, for example, fluctuations in our operating results, announcements of collaborations, clinical study results, technological innovations or new products being developed by us or our competitors, governmental regulation, regulatory approval, developments in patent or other proprietary rights, public concern regarding the safety of our drugs and general market conditions.

 

36



Table of Contents

 

We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.

 

Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of therapeutic products, including potential product liability claims related to KYNAMRO.  We have clinical study insurance coverage and commercial product liability insurance coverage.  However, this insurance coverage may not be adequate to cover claims against us, or be available to us at an acceptable cost, if at all.  Regardless of their merit or eventual outcome, products liability claims may result in decreased demand for our drug products, injury to our reputation, withdrawal of clinical study volunteers and loss of revenues.  Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.

 

Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.

 

Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store these materials and various wastes resulting from their use at our facilities in Carlsbad, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause:

 

·                 interruption of our research, development and manufacturing efforts;

 

·                 injury to our employees and others;

 

·                 environmental damage resulting in costly clean up; and

 

·                 liabilities under federal, state and local laws and regulations governing health and human safety, as well as the use, storage, handling and disposal of these materials and resultant waste products.

 

In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected.

 

We depend on Regulus for development of our microRNA technology.

 

Regulus is a company that we and Alnylam established to focus on discovering, developing, and commercializing microRNA therapeutics. We exclusively licensed to Regulus our intellectual property rights covering microRNA technology. Regulus operates as an independent company and Regulus and its employees are ultimately responsible for researching and developing our microRNA technology.  If Regulus is not successful, the value of our microRNA technology would be harmed and we would lose part or all of our investment in Regulus.  In addition, Regulus’ directors, executive management team, and strategic partners, including Alnylam, Isis, AstraZeneca, GSK, Biogen Idec and Sanofi have agreed that until October 4, 2013, subject to specified exceptions, not to offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of Regulus’ common stock or securities convertible into or exchangeable or exercisable for any shares of Regulus’ common stock.

 

If a natural or man-made disaster strikes our research, development or manufacturing facilities, it could delay our progress developing and commercializing our drugs.

 

We manufacture our research and clinical supplies in a manufacturing facility located in Carlsbad, California. The facilities and the equipment we use to research, develop and manufacture our drugs would be costly to replace and could require substantial lead time to repair or replace. Our facilities may be harmed by natural or man-made disasters, including, without limitation, earthquakes, floods, fires and acts of terrorism; and if our facilities are affected by a disaster, our development and commercialization efforts would be delayed. Although we possess insurance for damage to our property and the disruption of our business from casualties, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.

 

37



Table of Contents

 

Provisions in our certificate of incorporation, other agreements and Delaware law may prevent stockholders from receiving a premium for their shares.

 

Our certificate of incorporation provides for classified terms for the members of our board of directors. Our certificate also includes a provision that requires at least 66 2¤3 percent of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.

 

Our certificate of incorporation also requires that any action required or permitted to be taken by our stockholders must be taken at a duly called annual or special meeting of stockholders and may not be taken by written consent. In addition, only our board of directors, chairman of the board or chief executive officer can call special meetings of our stockholders.  We have in the past, and may in the future, implement a stockholders’ rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire our company on a hostile basis.  In addition, our board of directors has the authority to fix the rights and preferences of, and issue shares of preferred stock, which may have the effect of delaying or preventing a change in control of our company without action by our stockholders.

 

The provisions of our convertible senior notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or a portion of their notes, which may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then current market prices.

 

In addition, our collaboration agreement with Genzyme regarding KYNAMRO provides that if we are acquired, Genzyme may elect to purchase all of our rights to receive payments under the KYNAMRO collaboration agreement for a purchase price to be mutually agreed to by us and Genzyme, or, if we cannot agree, a fair market value price determined by an independent investment banking firm.  This provision may make it more difficult or complicated for us to enter into an acquisition agreement with a potential acquirer.

 

These provisions, as well as Delaware law, including Section 203 of the Delaware General Corporation Law, and other of our agreements, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.

 

Future sales of our common stock in the public market could adversely affect the trading price of our securities.

 

Future sales of substantial amounts of our common stock in the public market, or the perception that such sales could occur, could adversely affect trading prices of our securities.  For example, we may issue approximately 12.1 million shares of our common stock upon conversion of our convertible senior notes. The addition of any of these shares into the public market may have an adverse effect on the price of our securities.

 

Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.

 

Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management’s time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board, or PCAOB, or The Nasdaq Global Market. Any such action could adversely affect our financial results and the market price of our common stock.

 

The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. On July 21, 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted.  There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt, or where the SEC has adopted, additional rules and regulations in these areas such as “say on pay” and proxy access.  Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business.

 

38



Table of Contents

 

Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.

 

The global credit markets, the financial services industry, the U.S. capital markets, and the U.S. economy as a whole have been experiencing a period of substantial turmoil and uncertainty characterized by unprecedented intervention by the U.S. federal government and the failure, bankruptcy, or sale of various financial and other institutions.  The impact of these events on our business and the severity of the economic crisis are uncertain.  It is possible that the crisis in the global credit markets, the U.S. capital markets, the financial services industry and the U.S. economy may adversely affect our business, vendors and prospects as well as our liquidity and financial condition.  More specifically, our insurance carriers and insurance policies covering all aspects of our business may become financially unstable or may not be sufficient to cover any or all of our losses and may not continue to be available to us on acceptable terms, or at all.

 

ITEM 3.                       QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to changes in interest rates primarily from our long-term debt arrangements and, secondarily, investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government agencies with strong credit ratings.  We typically hold our investments for the duration of the term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.

 

ITEM 4.                        CONTROLS AND PROCEDURES

 

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2013. There have been no significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to March 31, 2013.

 

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives.

 

39



Table of Contents

 

PART II — OTHER INFORMATION

 

ITEM 1.                                  LEGAL PROCEEDINGS

 

In September 2011, we filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California. Our infringement lawsuit alleges that Santaris’ activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies infringes U.S. Patent No. 6,326,199, entitled “Gapped 2’ Modified Oligonucleotides” and U.S. Patent No. 6,066,500, entitled “Antisense Modulation of Beta Catenin Expression.” In the lawsuit we are seeking monetary damages and an injunction enjoining Santaris from conducting or participating in the infringing activities. In December 2011, Santaris filed an answer to our complaint, denying our allegations, and seeking a declaration from the court that Santaris has not, and does not, infringe the patents we asserted against Santaris in the suit. In January 2012, Santaris filed a motion for summary judgment asking the court to decide as a matter of law that Santaris’ activities do not infringe the patents we assert in the suit.  In September 2012, the court denied Santaris’ motion for summary judgment and opened limited discovery related to whether Santaris’ alleged infringing activities are permitted by the safe harbor under 35 U.S.C. Section 271(e)(1).  In April 2013, we amended our complaint related to the lawsuit to include additional claims alleging that Santaris’ activities providing antisense drugs and antisense drug discovery services to a pharmaceutical company infringes U.S. Patent No. 6,440,739 entitled “Antisense Modulation of Glioma-Associated Oncogene-2 Expression”; and that Santaris induced its actual and prospective pharmaceutical partners to infringe U.S. Patent No. 6,326,199.

 

ITEM 2.                                  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Not applicable

 

ITEM 3.                                  DEFAULT UPON SENIOR SECURITIES

 

Not applicable

 

ITEM 4.                                  MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5.                                  OTHER INFORMATION

 

Not applicable

 

40



Table of Contents

 

ITEM 6.                                  EXHIBITS

 

a.                            Exhibits

 

Exhibit
Number

 

Description of Document

10.1

 

Letter agreement dated March 3, 2013 between the Registrant and Biogen Idec International Holding Ltd.

 

 

 

31.1

 

Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2

 

Certification by Chief Financial Offic5er Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1

 

Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101

 

The following financial statements from the Isis Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in Extensive Business Reporting Language (XBRL): (i) condensed consolidated balance sheets, (ii) condensed consolidated statements of operations, (iii) condensed consolidated statements of comprehensive loss, (iv) condensed consolidated statements of cash flows and (v) notes to condensed consolidated financial statements (detail tagged).

 

Isis Pharmaceuticals, Inc.

 

(Registrant)

 

41



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signatures

 

Title

 

Date

 

 

 

 

 

/s/ Stanley T. Crooke

 

Chairman of the Board, President, and Chief Executive Officer
(Principal executive officer)

 

May 7, 2013

Stanley T. Crooke, M.D., Ph.D.

 

 

 

 

 

/s/ Elizabeth L. Hougen

 

Senior Vice President, Finance and Chief Financial Officer
(Principal financial and accounting officer)

 

May 7, 2013

Elizabeth L. Hougen

 

42


EX-10.1 2 a13-8376_1ex10d1.htm EX-10.1

Exhibit 10.1

 

March 13, 2013

 

Richard Brudnick

Vice President, Co-Head Business Development/M&A

Biogen Idec MA Inc.

14 Cambridge Center

Cambridge, MA 02142

 

M Tonesan Naa-Lamle Amissah

Biogen Idec International Holding Ltd.

Appleby (Bermuda) Ltd.

Canon’s Court, 22 Victoria Street

Hamilton HM 12

Bermuda

 

Dear Richard,

 

Isis and Biogen Idec are parties to the Development, Option and License Agreement dated January 3, 2012 (the “SMA Agreement”) and wish to specify the payment schedule for the $18 million Initiation of the CS3 Study Pre-Licensing Milestone Event under the SMA Agreement.

 

As such, Isis and Biogen Idec agree the $18 million payment for the Initiation of the CS3 Study Pre-Licensing Milestone Event under the SMA Agreement is due as follows and payable within 45 days of receipt of invoice following the applicable event:

 

a.              $3.5 million will be due upon the dosing of the first patient in the first cohort of the ISIS 396443-CS3A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with Infantile-Onset Spinal Muscular Atrophy) (the “CS3A Study”);

 

b.              $2.0 million will be due upon the dosing of the first patient in the second cohort of the CS3A Study;

 

c.               $1.5 million will be due upon the dosing of the eighth patient in the second cohort of the CS3A Study; and

 

d.              $11 million will be due upon the dosing of the first patient in the Infantile-Onset Spinal Muscular Atrophy Registration Study (CS3B).

 



 

Except as set forth above, any other provisions of the SMA Agreement will remain in full force and effect.  Capitalized terms used but not defined herein will have the meaning ascribed to such terms in the SMA Agreement.

 

This letter agreement may be signed in counterparts, each of which will be deemed an original. Facsimile signatures and signatures transmitted via electronic mail in PDF format will be treated as original signatures.

 

IN WITNESS WHEREOF, Isis and Biogen Idec have caused this letter agreement to be executed by their representatives as of the date hereof.

 

 

BIOGEN IDEC INTERNATIONAL HOLDING LTD

 

 

 

/s/ M. Tonesan N. Amissah

 

M. Tonesan N. Amissah

 

 

 

Director, Biogen Idec International Holding Ltd.

 

 

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

/s/ B. Lynne Parshall

 

/s/ B. Lynne Parshall

 

Chief Operating Officer

 

 


EX-31.1 3 a13-8376_1ex31d1.htm EX-31.1

EXHIBIT 31.1

 

CERTIFICATION

 

I, Stanley T. Crooke, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Isis Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, condensed consolidated results of operations and condensed consolidated cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 7, 2013

 

/s/ Stanley T. Crooke

 

 

 

Stanley T. Crooke, M.D., Ph.D.

 

Chief Executive Officer

 

 


EX-31.2 4 a13-8376_1ex31d2.htm EX-31.2

EXHIBIT 31.2

 

CERTIFICATION

 

I, Elizabeth L. Hougen, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Isis Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, condensed consolidated results of operations and condensed consolidated cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 7, 2013

 

/s/ Elizabeth L. Hougen

 

 

 

Elizabeth L. Hougen

 

Chief Financial Officer

 

 


EX-32.1 5 a13-8376_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Stanley T. Crooke, the Chief Executive Officer of Isis Pharmaceuticals, Inc., (the “Company”), and Elizabeth L. Hougen, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

 

1.              The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2013, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.              The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and the results of operations of the Company for the period covered by the Periodic Report.

 

Dated: May 7, 2013

 

 

 

 

 

/s/ Stanley T. Crooke

 

/s/ Elizabeth L. Hougen

Stanley T. Crooke, M.D., Ph.D.

 

Elizabeth L. Hougen

Chief Executive Officer

 

Chief Financial Officer

 

A signed original of this written statement required by Section 906 has been provided to Isis Pharmaceuticals, Inc. and will be retained by Isis Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.INS 6 isis-20130331.xml XBRL INSTANCE DOCUMENT 0000874015 2012-12-31 0000874015 2013-05-02 0000874015 2013-03-31 0000874015 2012-01-01 2012-03-31 0000874015 2013-01-01 2013-03-31 0000874015 2012-03-31 0000874015 2011-12-31 0000874015 us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:AstraZenecaMember 2012-12-01 2012-12-31 0000874015 isis:CHDIFoundationIncMember us-gaap:CollaborativeArrangementMember 2012-12-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember isis:CollaborativeArrangementDecember2012Member 2012-12-01 2012-12-31 0000874015 us-gaap:CollaborativeArrangementMember isis:AstraZenecaMember us-gaap:ScenarioForecastMember 2013-04-01 2013-06-30 0000874015 us-gaap:CollaborativeArrangementMember isis:AstraZenecaMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:AstraZenecaMember 2013-01-01 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2013-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 us-gaap:MaximumMember 2013-01-01 2013-03-31 0000874015 us-gaap:SeniorNotesMember 2013-03-31 0000874015 us-gaap:ConvertibleSubordinatedDebtMember 2012-09-30 0000874015 isis:GlaxoSmithKlineMember us-gaap:FinancialGuaranteeMember isis:RegulusTherapeuticsMember 2012-10-30 2012-10-31 0000874015 2012-01-01 2012-12-31 0000874015 us-gaap:SeniorNotesMember 2012-08-01 2012-08-31 0000874015 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-03-31 0000874015 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-03-31 0000874015 us-gaap:EmployeeStockMember 2012-01-01 2012-03-31 0000874015 us-gaap:EmployeeStockMember 2013-01-01 2013-03-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember isis:EmployeeMember 2012-01-01 2012-03-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember isis:EmployeeMember 2013-01-01 2013-03-31 0000874015 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-03-31 0000874015 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-03-31 0000874015 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember isis:CollaborativeArrangementJanuary2012Member 2012-01-01 2012-01-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2012-12-31 0000874015 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-03-31 0000874015 us-gaap:EmployeeStockOptionMember 2013-03-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2013-03-31 0000874015 us-gaap:RestrictedStockUnitsRSUMember 2013-01-01 2013-03-31 0000874015 us-gaap:SalesRevenueGoodsNetMember isis:RevenueFromPartnerAMember 2012-01-01 2012-03-31 0000874015 us-gaap:SalesRevenueGoodsNetMember isis:RevenueFromPartnerAMember 2013-01-01 2013-03-31 0000874015 us-gaap:SalesRevenueGoodsNetMember isis:RevenueFromPartnerBMember 2013-01-01 2013-03-31 0000874015 us-gaap:AccountsReceivableMember isis:AccountsReceivableSignificantPartnersMember 2013-01-01 2013-03-31 0000874015 us-gaap:AccountsReceivableMember isis:AccountsReceivableSignificantPartnersMember 2012-01-01 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:DebtSecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USTreasurySecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USTreasurySecuritiesMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2012-12-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:DebtSecuritiesMember 2012-12-31 0000874015 us-gaap:DebtSecuritiesMember 2012-12-31 0000874015 us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 isis:RegulusTherapeuticsMember us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:OtherCurrentAssetsMember us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:EquitySecuritiesMember 2012-01-01 2012-12-31 0000874015 us-gaap:OtherCurrentAssetsMember us-gaap:EquitySecuritiesMember 2012-01-01 2012-12-31 0000874015 us-gaap:CorporateDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:USStatesAndPoliticalSubdivisionsMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:CorporateDebtSecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:DebtSecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesOneYearOrLessMember us-gaap:USTreasurySecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:CorporateDebtSecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USTreasurySecuritiesMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2013-03-31 0000874015 isis:DebtSecuritiesMaturitiesMoreThanOneYearMember us-gaap:DebtSecuritiesMember 2013-03-31 0000874015 us-gaap:DebtSecuritiesMember 2013-03-31 0000874015 isis:RegulusTherapeuticsMember us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:OtherCurrentAssetsMember us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:EquitySecuritiesMember 2013-01-01 2013-03-31 0000874015 us-gaap:OtherCurrentAssetsMember us-gaap:EquitySecuritiesMember 2013-01-01 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2012-12-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2012-12-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2012-12-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0000874015 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2013-03-31 0000874015 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2013-03-31 0000874015 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember isis:DevelopmentMilestonesMember isis:CollaborativeArrangementJanuary2012Member 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember isis:CollaborativeArrangementJanuary2012Member isis:RegulatoryMilestonesMember 2013-03-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember 2012-12-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GenzymeCorporationMember us-gaap:MinimumMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GenzymeCorporationMember us-gaap:MaximumMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GenzymeCorporationMember isis:PreSpecifiedEventsMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GenzymeCorporationMember isis:RegulatoryMilestonesMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GenzymeCorporationMember isis:CommercializationMilestonesMember 2013-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-01-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2012-12-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2012-10-01 2012-10-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GlaxoSmithKlineMember isis:DevelopmentMilestonesMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GlaxoSmithKlineMember isis:RegulatoryMilestonesMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GlaxoSmithKlineMember isis:CommercializationMilestonesMember 2013-03-31 0000874015 us-gaap:SalesRevenueGoodsNetMember isis:RevenueFromPartnerBMember 2012-01-01 2012-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:GlaxoSmithKlineMember isis:PrelicensingMilestonesMember isis:PhaseTwoByThreeMember isis:IsisTtrMember 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember 2012-01-01 2012-12-31 0000874015 us-gaap:CollaborativeArrangementMember isis:BiogenIdecMember 2012-01-01 2012-03-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:SareptaTherapeuticsIncMember 2013-01-01 2013-03-31 0000874015 us-gaap:EquitySecuritiesMember 2012-12-31 0000874015 us-gaap:EquitySecuritiesMember 2013-03-31 0000874015 us-gaap:EquitySecuritiesMember 2013-01-01 2013-03-31 0000874015 isis:SareptaTherapeuticsIncMember 2012-12-31 0000874015 isis:RegulusTherapeuticsMember 2012-12-31 0000874015 isis:RegulusTherapeuticsMember 2013-03-31 0000874015 isis:RegulusTherapeuticsMember 2013-01-01 2013-03-31 0000874015 isis:RegulusTherapeuticsMember 2012-01-01 2012-12-31 0000874015 isis:SareptaTherapeuticsIncMember 2012-01-01 2012-12-31 0000874015 isis:AstraZenecaMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:DevelopmentMilestonesMember isis:GlaxoSmithKlineMember isis:IsisTtrMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:RocheMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-01 2013-04-30 0000874015 isis:CHDIFoundationIncMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:CHDIFoundationIncMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-01 2013-04-30 0000874015 isis:DevelopmentMilestonesMember isis:CHDIFoundationIncMember us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-01 2013-04-30 0000874015 isis:CHDIFoundationIncMember us-gaap:CollaborativeArrangementMember 2012-01-01 2012-03-31 0000874015 isis:PreSpecifiedEventsMember isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 us-gaap:MaximumMember isis:RegulusTherapeuticsMember 2013-01-01 2013-03-31 0000874015 isis:NewDevelopmentCandidateMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:NewDevelopmentCandidateMember us-gaap:MinimumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseOneMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseTwoMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseTwoMember us-gaap:MinimumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseOneMember us-gaap:MinimumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseThreeMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseThreeMember us-gaap:MinimumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 us-gaap:CollaborativeArrangementMember isis:CommercializationMilestonesMember 2013-01-01 2013-03-31 0000874015 isis:RegulatoryMilestonesMember us-gaap:MaximumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:RegulatoryMilestonesMember us-gaap:MinimumMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:DevelopmentMilestonesMember isis:CollaborativeArrangementJune2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:RegulatoryMilestonesMember isis:CollaborativeArrangementJune2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:NewDevelopmentCandidateMember isis:CollaborativeArrangementJune2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2012-05-01 2012-05-31 0000874015 isis:GlaxoSmithKlineMember us-gaap:CollaborativeArrangementMember 2013-02-01 2013-02-28 0000874015 isis:CollaborativeArrangementJune2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2012-06-01 2012-06-30 0000874015 isis:PhaseTwoByThreeMember isis:CollaborativeArrangementJanuary2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PhaseTwoByThreeMember isis:CollaborativeArrangementJanuary2012Member isis:BiogenIdecMember us-gaap:ScenarioForecastMember us-gaap:CollaborativeArrangementMember 2013-05-30 2013-05-31 0000874015 isis:RegulatoryMilestonesMember isis:CollaborativeArrangementDecember2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:NewDevelopmentCandidateMember isis:CollaborativeArrangementDecember2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:GenzymeCorporationMember us-gaap:CollaborativeArrangementMember 2008-01-01 2008-01-31 0000874015 isis:GlaxoSmithKlineMember isis:IsisTtrMember us-gaap:CollaborativeArrangementMember 2012-12-01 2012-12-31 0000874015 isis:PreSpecifiedEventsMember isis:RocheMember isis:AntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 isis:DevelopmentMilestonesMember isis:RocheMember isis:AntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 isis:RegulatoryMilestonesMember isis:RocheMember isis:AntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 isis:CommercializationMilestonesMember isis:RocheMember isis:AntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 isis:RocheMember isis:AntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-01 2013-04-30 0000874015 isis:NewDevelopmentCandidateMember isis:CollaborativeArrangementDecember2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:ClinicalAndRegulatoryMilestonesMember isis:CollaborativeArrangementDecember2012Member isis:BiogenIdecMember us-gaap:CollaborativeArrangementMember 2013-03-31 0000874015 isis:PhaseTwoByThreeMember isis:GlaxoSmithKlineMember isis:IsisTtrMember us-gaap:CollaborativeArrangementMember 2013-01-01 2013-03-31 0000874015 isis:PreSpecifiedEventsMember isis:RocheMember isis:AdditionalDrugsExcludingAntisenseDrugTargetingHTTProteinMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 isis:CommercializationMilestonesMember isis:RocheMember isis:DrugUsingProprietaryBrainShuttleTechnologyMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2013-04-30 0000874015 us-gaap:CollaborativeArrangementMember isis:GlaxoSmithKlineMember isis:PhasesPriorToPhaseTwoProofOfConceptMember 2013-03-31 iso4217:USD xbrli:shares xbrli:pure isis:item isis:security isis:company iso4217:USD xbrli:shares 124482000 103780421 249964000 522000 6121000 33622000 8727000 423438000 91084000 6579000 18646000 5939000 545686000 10239000 7878000 15401000 4879000 35925000 74322000 66656000 143990000 7402000 70550000 362920000 102000 1077150000 12480000 -906966000 182766000 545686000 107650000 431829000 552961000 70295000 0.001 200000000 351870000 201091000 552961000 101481134 101481134 0.001 200000000 102695200 5385000 103000 102695200 21818000 1417000 23235000 38714000 2976000 41690000 -18455000 -976000 600000 5179000 17000 -23993000 2000 -23995000 -0.24 41921000 1439000 43360000 41735000 1625000 528000 6467000 -1736000 -1672000 -0.02 38312000 3423000 -23467000 3632000 -6711000 61841000 61781000 113000 349000 -522000 638000 2491000 -1853000 -9086000 2211000 844000 -15306000 9050000 -16832000 113000 715000 2000 56391000 65477000 <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Significant Accounting Policies</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Revenue Recognition</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In those instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Research and development revenue under collaborative agreements</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services. Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees, profit sharing and royalties on product sales. We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and then accounted for as a single unit of accounting. When the delivered items in an arrangement have &#8220;stand-alone value&#8221; to our customer, we account for the deliverables as separate units of accounting and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a standalone basis. We use the following hierarchy of values to estimate the selling price of each deliverable: (i)&#160;vendor-specific objective evidence of fair value; (ii)&#160;third-party evidence of selling price; and (iii)&#160;best estimate of selling price, or BESP. The BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In December&#160;2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense therapeutics against five cancer targets. As part of the collaboration, we received a $25 million upfront payment and are eligible to receive a $6 million payment in the second quarter of 2013 assuming the research program is continuing.&#160; We are also eligible to receive milestone payments, license fees for the research program targets and royalties on any product sales of drugs resulting from this collaboration. In exchange, we granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.</font><font style="FONT-SIZE: 10pt;" size="2">&#160; We also granted AstraZeneca options to license up to three drugs under the separate research program. We are responsible for completing an ongoing clinical study of ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">and IND-enabling studies for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. AstraZeneca will be responsible for all other global development, regulatory and commercialization activities for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. In addition, if AstraZeneca exercises its option for any drugs resulting from the research program, AstraZeneca will assume global development, regulatory and commercialization responsibilities for such drug.&#160; Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that certain deliverables, either individually or in combination, have stand-alone value.&#160; Below is a list of the four separate units of accounting under our agreement:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">for the treatment of cancer;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The development services we will perform for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and the research services we will perform</font> <font style="FONT-SIZE: 10pt;" size="2">for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The option to license up to three drugs under a research program and the research services we will perform for this program.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We determined that the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license had stand-alone value because it is an exclusive license that gives AstraZeneca the right to develop ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;or to sublicense its rights.&#160; In addition,&#160;ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;is currently in development and it is possible that AstraZeneca or another third party could conduct clinical trials without assistance from us.&#160; As a result, we consider the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license and the development services for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;to be separate units of accounting. We recognized the revenue allocated to the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license on the date of the agreement because that is when we delivered the license.&#160; We will recognize the revenue allocated to the development services for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;over the period of time we perform services. The ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license is also an exclusive license.&#160; Because of the early stage of research for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">, we believe that our knowledge and expertise with antisense technology is essential for AstraZeneca or another third party to successfully develop ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.&#160; As a result, we concluded that the ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license does not have stand-alone value and we combined the ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license and related research services into one unit of accounting.&#160; We will recognize revenue for the combined unit of accounting over the period of time we perform services. We determined that the options under the research program did not have stand-alone value because AstraZeneca cannot develop or commercialize drugs resulting from the research program until AstraZeneca exercises the respective option or options. As a result, we considered the research options and the related research services as a combined unit of accounting.&#160; We will recognize revenue for the combined unit of accounting over the period of our performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We determined that the allocable arrangement consideration was the $25 million upfront payment because it was the only payment that was fixed and determinable when we entered into the agreement.&#160; There was considerable uncertainty at the date of the agreement as to whether we would earn the milestone payments, royalty payments, payments for manufacturing clinical trial materials or payments for finished drug product.&#160; As such, we did not include those payments in the allocable consideration.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We allocated the $25 million upfront payment based on the relative BESP of each unit of accounting.&#160; We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the licenses granted for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for each drug. We then discounted the projected income for each license to present value. The significant inputs we used to determine the projected income of the licenses included:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Estimated future product sales;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Estimated royalties on future product sales;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Contractual milestone payments;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Expenses we expect to incur;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Income taxes; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">An appropriate discount rate.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We estimated the selling price of the research and development services by using our internal estimates of the cost to perform the specific services, marked up to include a reasonable profit margin, and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform research and development. The significant inputs we used to determine the selling price of the research and development services included:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The number of internal hours we will spend performing these services;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated number and cost of studies we will perform;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated number and cost of studies that we will contract with third parties to perform; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated cost of drug product we will use in the studies.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As a result of the allocation, we recognized $9.3 million of the $25 million upfront payment in December&#160;2012 for the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license.&#160; We are recognizing the remaining $15.7 million over the estimated period of our performance. Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">license, we determined that the revenue we would have allocated to the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">license would change by approximately seven percent, or $600,000, from the amount we recorded.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Typically, we must estimate our period of performance when the agreements we enter into do not clearly define such information.&#160; Our collaborative agreements typically include a research and/or development project plan that includes the activities the agreement requires each party to perform during the collaboration. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition and amortize revenue over such period. If our collaborators ask us to continue performing work in a collaboration beyond the initial period of performance, we extend our amortization period to correspond to the new extended period of performance.&#160; The revenue we recognize could be materially different if different estimates prevail.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">From time to time, we may enter into separate agreements at or near the same time with the same customer.&#160; We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement.&#160; We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In January&#160;2012, we entered into a collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;for Spinal Muscular Atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;through completion of Phase 2/3 clinical trials. In June&#160;2012, we entered into a second and separate collaboration agreement with Biogen Idec to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial. In December&#160;2012, we entered into a third and separate collaboration agreement with Biogen Idec to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.&#160; All three of these collaboration agreements give Biogen Idec the option or options to license one or more drugs resulting from the specific collaboration.&#160; If Biogen Idec exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the development of the drugs prior to licensing, milestone payments if Biogen Idec achieves pre-specified regulatory milestones, and royalties on any product sales of drugs resulting from these collaborations.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 39pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We evaluated the SMA, DMPK, and neurology agreements to determine whether we should account for them as separate agreements or as a single multiple element arrangement.&#160; We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, the first two agreements cover two different diseases while the targets for the third agreement are yet to be defined, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other.&#160; We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting.&#160; For all three of these agreements, we determined that the options did not have stand-alone value because Biogen Idec cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options.&#160; As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective research and development term, which is the estimated period of our performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 39pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events.&#160; These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery.&#160; From these research efforts, we hope to identify a development candidate.&#160; The designation of a development candidate is the first stage in the life-cycle of our drugs.&#160; A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.&#160; During the first step of the development stage, we or our partners study our drugs in IND-enabling studies, which are animal studies intended to support an Investigational New Drug, or IND, application and/or the foreign equivalent.&#160; An approved IND allows us or our partners to study our development candidate in humans.&#160; If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients.&#160; If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.&#160; The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing approval from the Food and Drug Administration, or FDA, and/or foreign equivalents.&#160; The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete.&#160; If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing approval.&#160; This stage of the drug&#8217;s life-cycle is the regulatory stage.&#160; If a drug achieves marketing approval, it moves into the commercialization stage, during which our partner will market and sell the drug to patients.&#160; Although our partner will ultimately be responsible for marketing and selling the drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner&#8217;s ability to successfully sell the drug.&#160; The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities.&#160; Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow our partner to successfully commercialize our drug.&#160; Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner&#8217;s ability to sell our drugs without competition from generic drugs.&#160; The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization.&#160; The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain.&#160; As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.&#160; Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Development milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Designation of a development candidate.&#160; Following the designation of a development candidate,&#160;IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation of a Phase 1 clinical trial.&#160; Generally, Phase 1 clinical trials take one to two years to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation or completion of a Phase 2 clinical trial.&#160; Generally, Phase 2 clinical trials take one to three years to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation or completion of a Phase 3 clinical trial.&#160; Generally, Phase 3 clinical trials take two to four years to complete.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Regulatory milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Filing of regulatory applications for marketing approval such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe.&#160; Generally, it takes six to twelve months to prepare and submit regulatory filings.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Marketing approval in a major market, such as the United States, Europe or Japan.&#160; Generally it takes one to two years after an application is submitted to obtain approval from the applicable regulatory agency.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Commercialization milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">First commercial sale in a particular market, such as in the United States or Europe.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion.&#160; The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We assess whether a substantive milestone exists at the inception of our agreements.&#160; When a substantive milestone is achieved, we recognize revenue related to the milestone payment.&#160; For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with ongoing access to new technologies we discover, we have determined that all future development, regulatory and commercialization milestones are substantive. For example, for our strategic alliance with GlaxoSmithKline, or GSK, we are using our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases. Alternatively, we provide on-going access to our technology to Alnylam Pharmaceuticals,&#160;Inc. to develop and commercialize RNA interference, or RNAi, therapeutics.&#160; We consider milestones for both of these collaborations to be substantive.&#160; For those agreements that do not meet the following criteria, we do not consider the future milestones to be substantive.&#160; In evaluating if a milestone is substantive we consider whether:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The achievement of the milestone involves substantive effort and can only be achieved based in whole or part on our performance or the occurrence of a specific outcome resulting from our performance;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">There is no future performance required to earn the milestone; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The consideration is reasonable relative to all deliverables and payment terms in the arrangement.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">If any of these conditions are not met, we will defer recognition of the milestone payment and recognize it as revenue over the estimated period of performance, if any.&#160; In the first quarter of 2013, the FDA approved the NDA for KYNAMRO and we initiated a Phase 2/3 clinical study for ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">, the first drug selected as part of our collaboration with GSK. We consider milestones related to progression of a drug through the development and regulatory stages of its life cycle to be substantive milestones because the level of effort and inherent risk associated with these events is high. Therefore, in the first quarter of 2013 we recognized the $25 million milestone payment from Genzyme and the $7.5 million milestone payment from GSK. Further information about our collaborative arrangements can be found in Note 7 <i>Collaborative Arrangements and Licensing Agreements</i> and Note 7 of our audited financial statements for the year ended December&#160;31, 2012 included in our Annual Report on Form&#160;10-K filed with the SEC.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Licensing and royalty revenue</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash, cash equivalents and short-term investments</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We consider all liquid investments with maturities of 90 days or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than 90 days from date of purchase. We classify our short-term investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We have equity investments in privately- and publicly-held biotechnology companies that we have received as part of a technology license or collaboration agreement.&#160; At March&#160;31, 2013 we held ownership interests of less than 20 percent in each of the respective companies.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We account for our equity investments in publicly-held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly-held companies as a separate component of comprehensive income (loss).&#160; We account for equity investments in privately-held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. Most of the cost method investments we hold are in early stage biotechnology companies and realization of our equity position in those companies is uncertain. In those circumstances we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Inventory valuation</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials and historical write-offs. We did not record any inventory write-offs for the first three months of 2013 and 2012. Total inventory, which consisted of raw materials, was $5.8 million and $6.1 million as of March&#160;31, 2013 and December&#160;31, 2012, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Patents</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. We evaluate patents and patent applications that we are not actively pursuing and write off any associated costs. We amortize patent costs over their useful lives, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-lived assets</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity method of accounting</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We accounted for our ownership interest in Regulus using the equity method of accounting until Regulus&#8217; IPO in October&#160;2012.&#160; In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus&#8217; common stock and we no longer have significant influence over the operating and financial policies of Regulus. Under the equity method of accounting, we included our share of Regulus&#8217; operating results on a separate line in our condensed consolidated statement of operations called &#8220;Equity in net loss of Regulus Therapeutics Inc.&#8221;</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Basic and diluted net loss per share</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a loss for the three months ended March&#160;31, 2013 and 2012, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.&#160; The following would have had an anti-dilutive effect on net loss per share:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">3</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">4</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible senior notes;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible subordinated notes;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">GlaxoSmithKline convertible promissory notes issued by Regulus;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Dilutive stock options; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Restricted stock units.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We redeemed all of our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes in September&#160;2012 and in October&#160;2012 Regulus completed an IPO, upon which we were no longer guarantors on the two convertible notes that Regulus issued to GSK.&#160; As a result, the 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes and GSK convertible promissory notes are not common equivalent shares for the three months ended March&#160;31, 2013.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Consolidation of variable interest entities</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We identify entities as variable interest entities either: (1)&#160;that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest.&#160; We perform ongoing qualitative assessments of our variable interest entities to determine whether we have a controlling financial interest in the variable interest entity and therefore are the primary beneficiary.&#160; As of March&#160;31, 2013 and December&#160;31, 2012, we had collaborative arrangements with five and six entities, respectively, that we considered to be variable interest entities.&#160; We are not the primary beneficiary for any of these entities as we do not have both the power to direct the activities that most significantly impact the economic performance of our variable interest entities and the obligation to absorb losses or the right to receive benefits from our variable interest entities that could potentially be significant to the variable interest entities.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2013, the total carrying value of our investments in variable interest entities was $47.5 million, and was primarily related to our investment in Regulus. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Accumulated other comprehensive income (loss)</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Accumulated other comprehensive income (loss) is comprised of</font> <font style="FONT-SIZE: 10pt;" size="2">unrealized gains and losses on securities, net of taxes,</font> <font style="FONT-SIZE: 10pt;" size="2">and&#160; adjustments we made to reclassify realized gains and losses on securities from other accumulated comprehensive income to our</font> <font style="FONT-SIZE: 10pt;" size="2">condensed consolidated statement of operations</font><font style="FONT-SIZE: 10pt;" size="2">.</font> <font style="FONT-SIZE: 10pt;" size="2">The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March&#160;31, 2013 and 2012 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Beginning balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,480</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(770</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Other comprehensive income before reclassifications, net of tax (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6,467</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Amounts reclassified from accumulated other comprehensive income (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1,163</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Net current period other comprehensive income</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,304</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Ending balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,784</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(242</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Other comprehensive income for the three months ended March&#160;31, 2013 includes income tax expense of $3.6 million.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in g</font><font style="FONT-SIZE: 10pt;" size="2">ain on investments, net</font> <font style="FONT-SIZE: 10pt;" size="2">on our condensed consolidated statement of operations.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Convertible debt</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In August&#160;2012, we completed a $201.3 million offering of convertible senior notes, which mature in 2019 and bear interest at 2&#190; percent.&#160; In September&#160;2012, we used a substantial portion of the net proceeds from the issuance of the 2&#190; percent notes to redeem our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#164;</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible subordinated notes. Consistent with how we accounted for our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#164;</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes, we account for our 2&#190; percent notes by separating the liability and equity components of the instrument in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our 2&#190; percent notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording the debt instrument at a discount.&#160; We are amortizing the debt discount over the life of these 2&#190; percent notes as additional non-cash interest expense utilizing the effective interest method.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Segment information</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We operate in a single segment, Drug Discovery and Development operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a single operating segment.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Stock-based compensation expense</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our Employee Stock Purchase Plan, or ESPP, based on the estimated fair value of the award on the date of grant using an option-pricing model. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our condensed consolidated statements of operations.&#160; We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under the ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding.&#160; We estimate the expected term of options granted based on historical exercise patterns.&#160; For the three months ended March&#160;31, 2013 and 2012, we used the following weighted-average assumptions in our Black-Scholes calculations:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 30.25pt; TEXT-INDENT: -10.1pt;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Employee Stock Options:</font></i></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">51.5</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">50.6</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">ESPP:</font></i></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">61.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">43.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The fair value of RSUs is based on the market price of our common stock on the date of grant.&#160; RSUs vest annually over a four year period.&#160; The weighted-average grant date fair value of RSUs granted to employees for the three months ended March&#160;31, 2013 and 2012 was $14.21 and $7.60, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following table summarizes stock-based compensation expense for the three months ended March&#160;31, 2013 and 2012 (in thousands), which was allocated as follows:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Research and development</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,546</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,935</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">General and administrative</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">323</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">332</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,869</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,267</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As of March&#160;31, 2013, total unrecognized estimated non-cash stock-based compensation expense related to non-vested stock options and RSUs was $10.7&#160;million and $3.8 million, respectively. We will adjust total unrecognized compensation cost for future changes in estimated forfeitures.&#160; We expect to recognize the cost of non-cash, stock-based compensation expense related to non-vested stock options and RSUs over a weighted average amortization period of 1.4 years and 2.1 years, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Impact of recently issued accounting standards</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In February&#160;2013, the FASB issued guidance requiring enhanced disclosures related to reclassifications out of accumulated other comprehensive income (loss).&#160; Under the guidance, we must disclose the amounts we reclassified out of accumulated other comprehensive income (loss) by component. In addition, for significant amounts that we reclassified entirely from other comprehensive income (loss) to net loss, we must disclose the line item of net loss, either on the face of the statement of operations or in the notes to the financial statements. For amounts that we did not reclassify entirely to net loss, we must cross-reference to other disclosures that provide additional detail about those amounts. The guidance is effective retrospectively for fiscal years, and interim periods within those years, beginning after December&#160;15, 2012 and was effective for our fiscal year beginning January&#160;1, 2013. As this guidance relates to disclosure only, the adoption of this guidance did not have any effect on our financial statements.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">3.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Investments</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As of March&#160;31, 2013, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard&#160;&amp; Poor&#8217;s (S&amp;P) or Fitch, respectively.&#160; We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following table summarizes the contract maturity of the available-for-sale securities we held as of March&#160;31, 2013:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 63.34%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="63%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">One year or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 18.94%; PADDING-TOP: 0in;" valign="bottom" width="18%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">47</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">After one year but within two years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 18.94%; PADDING-TOP: 0in;" valign="bottom" width="18%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">41</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">After two years but within three years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="18%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="18%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">100</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As illustrated above, we primarily invest our excess cash in short-term instruments with 88 percent of our available-for-sale securities having a maturity of less than two years.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">At March&#160;31, 2013, we had an ownership interest of less than 20 percent in each of three private companies and three public companies with which we conduct business.&#160; The privately-held companies are Santaris Pharma A/S (formerly Pantheco A/S), Achaogen Inc., and Atlantic Pharmaceuticals Limited.&#160; The publicly-traded companies are Antisense Therapeutics Limited, iCo Therapeutics Inc., and Regulus. We account for equity investments in the privately-held companies under the cost method of accounting and we account for equity investments in the publicly-traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. In the first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics,&#160;Inc. that we owned resulting in a realized gain of $1.1 million.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following is a summary of our investments (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Amortized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">March&#160;31,&#160;2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Short-term investments:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">97,983</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">59</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(29</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">98,013</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9,932</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(46</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9,887</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,001</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,549</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">55</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(11</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,593</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of one year&#160;or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">124,464</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">116</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(86</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">124,494</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,131</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">110</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(156</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,085</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,020</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">35</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,052</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,393</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">30</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,423</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,203</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">7</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,207</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of more than one year</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">139,747</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">182</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(162</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">139,767</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 40pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">264,211</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">298</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 1pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">264,261</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">March&#160;&#160;31,&#160;2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Basis</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (Regulus Therapeutics Inc.)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,525</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">29,338</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (included in Other current assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,538</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,961</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-term portion (included in Deposits and&#160;other assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,688</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31,299</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">48,107</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">281,899</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31,597</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">312,368</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Amortized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">December&#160;31,&#160;2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Short-term investments:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">113,249</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">81</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(9</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">113,321</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">10,100</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(66</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">10,036</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,001</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">16,560</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">16,576</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of one year&#160;or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">140,909</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">102</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(77</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">140,934</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">80,166</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(92</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">80,186</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,034</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">38</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">27</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,451</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,306</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(16</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,321</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of more than one year</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">108,930</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">208</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">109,030</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 40pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">249,839</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">310</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 1pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">249,964</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">December&#160;31,&#160;2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Basis</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (Regulus Therapeutics Inc.)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,526</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,096</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (included in Other current assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,579</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,175</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,874</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-term portion (included in Deposits and&#160;other assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,730</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">22,271</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">39,121</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">267,569</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">22,581</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">289,085</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investments we considered to be temporarily impaired at March&#160;31, 2013 were as follows (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.6%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Less&#160;than&#160;12&#160;months&#160;of<br /> temporary&#160;impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Number&#160;of<br /> Investments</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated<br /> Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized<br /> Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">70</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">95,606</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,885</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(49</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,537</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(14</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total temporarily impaired securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">77</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">114,028</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase.&#160; We believe it is more likely than not that we will be able to hold these securities to maturity.&#160; Therefore we anticipate full recovery of their amortized cost basis at maturity.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 55pt; TEXT-INDENT: -35pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Fair Value Measurements</font></b></p> <p style="MARGIN: 0in 0in 0pt 55pt; TEXT-INDENT: -35pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements.&#160; These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and an investment in equity securities in a publicly-held biotechnology company; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Our Level 3 investments include investments in the equity securities of publicly-held biotechnology companies for which we calculated a lack of marketability discount because there are restrictions on when we can trade the securities. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian banks or from a professional pricing service.&#160; We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian bank or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.&#160; During the three months ended March&#160;31, 2013 and 2012 there were no transfers between our Level 1 and Level 2 investments. We use the end of reporting period method for determining transfers between levels.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We measure the following major security types at fair value on a recurring basis. We break down the inputs used to measure fair value for these assets at March&#160;31, 2013 and December&#160;31, 2012 as follows (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">At&#160;March&#160;31,<br /> 2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Quoted&#160;Prices&#160;in<br /> Active&#160;Markets<br /> (Level&#160;1)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant&#160;Other<br /> Observable<br /> Inputs<br /> (Level&#160;2)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant<br /> Unobservable<br /> Inputs<br /> (Level&#160;3)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash equivalents (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">96,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">91,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">205,098</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">205,098</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,939</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,939</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">20,800</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">20,800</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investment in Regulus Therapeutics Inc.</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities (3)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">407,815</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,115</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">255,837</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">At&#160;December&#160;31,<br /> 2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Quoted&#160;Prices&#160;in<br /> Active&#160;Markets<br /> (Level&#160;1)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant&#160;Other<br /> Observable<br /> Inputs<br /> (Level&#160;2)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant<br /> Unobservable<br /> Inputs<br /> (Level&#160;3)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash equivalents (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">105,496</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">101,496</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">193,507</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">193,507</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,452</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,452</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,897</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,897</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investment in Regulus Therapeutics Inc.</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities (3)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,874</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,146</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">728</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">393,956</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">119,094</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">240,512</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">34,350</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in cash and cash equivalents on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in short-term investments on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in other current assets on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We classified the fair value measurements of our investments in the equity securities of Regulus and Sarepta Therapeutics,&#160;Inc., or Sarepta, as Level 3.&#160; We calculated a lack of marketability discount on the fair value of these investments because there were restrictions on when we could trade the securities. We consider the inputs we used to calculate the lack of marketability discount Level 3 inputs and, as a result, we categorized these investments as Level 3.&#160; We determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. In the first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics,&#160;Inc. that we owned resulting in a realized gain of $1.1 million. As of March&#160;31, 2013, our Level 3 investments consisted of our investment in Regulus, with a gross fair value of $54.6 million and a lack of marketability discount of $9.7 million.&#160; As of December&#160;31, 2012, our Level 3 investments consisted of our investment in Regulus and Sarepta with a gross fair value of $44.4 million and $1.0 million, respectively, and a lack of marketability discount of $10.8 million and $296,000, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March&#160;31, 2013 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 73.34%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="73%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.82%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Investments</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Valued&#160;Using</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Level&#160;3&#160;Inputs</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Balance at December&#160;31, 2012</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.42%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 20.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="20%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">34,350</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total gains and losses:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Included in g</font><font style="FONT-SIZE: 10pt;" size="2">ain on investments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1,163</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Included in accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">11,716</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cost basis of shares sold</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.82%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="21%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(40</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Balance at March&#160;31, 2013</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.42%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 20.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="20%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Other Fair Value Disclosures</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our 2&#190; percent convertible notes had a fair value of $258.0 million at March&#160;31, 2013.&#160; We determine the fair value of our 2&#190; percent convertible notes based on quoted market prices for these notes, which is a Level 2 measurement.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">7.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Collaborative Arrangements and Licensing Agreements</font></b></p> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Traditional Pharmaceutical Alliances and Licensing</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Biogen Idec</font></i></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We have established three strategic collaborations with Biogen Idec that broaden and expand our severe and rare disease franchise.&#160; In January&#160;2012, we entered into a global collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;for the treatment of spinal muscular atrophy, or SMA. Under the terms of the agreement, we received an upfront payment of $29 million and are eligible to receive up to $45 million in substantive milestone payments associated with the clinical development of ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;prior to licensing.&#160; We are responsible for developing ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. Biogen Idec has the option to license ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;until completion of the first successful Phase 2/3 study or the completion of two Phase 2/3 studies.&#160; If Biogen Idec exercises its option, it will pay us a license fee and will assume global development, regulatory and commercialization responsibilities. In April&#160;2013, we initiated a Phase 2 study of ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;in infants with SMA, which initiates the Phase 2/3 program for ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.&#160; We will earn a $3.5 million milestone payment from Biogen Idec when we dose the first infant in this Phase 2 study, which we project will be May&#160;2013. The $3.5 million milestone payment is the first of four payments under the March&#160;2013 amendment to the payment terms for the next potential $18 million milestone payment we could earn for the progression of this Phase 2/3 study in infants.&#160; We are also eligible to receive up to $150 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.&#160; In addition, we are eligible to receive up to double-digit royalties on any product sales of ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In June&#160;2012, we and Biogen Idec entered into a second and separate collaboration and license agreement to develop and commercialize a novel antisense drug targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1.&#160; Under the terms of the agreement, we received an upfront payment of $12 million and are eligible to receive up to $59 million in substantive milestone payments associated with the development of the DMPK-targeting drug prior to licensing. We are responsible for global development of the drug through the completion of a Phase 2 clinical trial.&#160; Biogen Idec has the option to license the drug through the completion of the Phase 2 trial.&#160; We are also eligible to receive up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones. In addition, we are eligible to receive up to double-digit royalties on any product sales of the drug. We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for our DMPK program.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In December&#160;2012, we and Biogen Idec entered into a third and separate collaboration to develop and commercialize novel antisense drugs to three targets to treat neurological or neuromuscular diseases.&#160; We are responsible for the development of the drugs through the completion of the initial Phase 2 clinical study.&#160; Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 studies. Under the terms of the agreement, we received an upfront payment of $30 million and are eligible to receive development milestone payments to support research and development of each program including a $10 million milestone payment per program upon initiation of an IND-enabling toxicology study.&#160; We are also eligible to receive up to another $200 million in a license fee and regulatory milestone payments per program including up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.&#160; In addition, we are eligible to receive double-digit royalties on any product sales of drugs resulting from each of the three programs.&#160; We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for a development candidate identified under this collaboration.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">During the three months ended March&#160;31, 2013 and 2012, we earned revenue of $3.9 million and $1.8 million, respectively, from our relationships with Biogen Idec.&#160; Our balance sheets at March&#160;31, 2013 and December&#160;31, 2012 included deferred revenue of $59.2 million and $62.6 million, respectively, related to the upfront payments.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Genzyme Corporation, a Sanofi company</font></i></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In January&#160;2008, we entered into a strategic alliance with Genzyme focused on the licensing and co-development of KYNAMRO. The license and co-development agreement provides Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to KYNAMRO, including the key product related patents and their foreign equivalents pending or granted in various countries outside the United States, including in the European Union via the European Patent Convention, Japan, Canada, Australia, South Africa and India.&#160; In addition, we agreed that we would not develop or commercialize another oligonucleotide-based compound designed to modulate apo-B by binding to the messenger RNA, or mRNA, encoding apo-B, throughout the world.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The transaction included a $175 million licensing fee, a $150 million equity investment in our stock in which we issued Genzyme five million shares of our common stock, and a share of worldwide profits on KYNAMRO and follow-on drugs ranging from 30 percent to 50 percent of all commercial sales. In January&#160;2013 we earned a $25 million milestone payment when the FDA approved the NDA for KYNAMRO. We may also receive over $1.5 billion in substantive milestone payments if Genzyme achieves pre-specified events, including up to $700 million for the achievement of regulatory milestones and up to $825 million for the achievement of commercialization milestones.&#160; The next milestone payment we could earn under our agreement with Genzyme is $25 million upon the earlier of an NDA approval for the use of KYNAMRO to treat patients who have heterozygous FH or annual net revenue equal to or greater than $250 million in a calendar year.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Under this alliance, Genzyme is responsible for the continued development and commercialization of KYNAMRO.&#160; We agreed to supply the drug substance for KYNAMRO for the Phase 3 clinical trials and initial commercial launch.&#160; Genzyme is responsible for manufacturing the finished drug product for KYNAMRO, including the initial commercial launch supply, and Genzyme will be responsible for the long term supply of KYNAMRO drug substance and finished drug product.&#160; As part of the agreement, we contributed the first $125 million in funding for the development costs of KYNAMRO.&#160; In 2011, we satisfied our development funding obligation.&#160; As such, we and Genzyme shared development expenses equally in 2012.&#160; Our shared funding of development expenses will end when KYNAMRO is profitable.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The license and co-development agreement for KYNAMRO will continue in perpetuity unless we or Genzyme terminate it earlier under the following situations:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Genzyme may terminate the license and co-development agreement at any time by providing written notice to Isis;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">We may terminate the license and co-development agreement on a country-by-country basis or in its entirety upon Genzyme&#8217;s uncured failure to use commercially reasonable efforts to develop and commercialize KYNAMRO in the United States, France, Germany,&#160;Italy, Spain, the United Kingdom, Japan and Canada; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Either we or Genzyme may terminate the license and co-development agreement upon the other party&#8217;s uncured failure to perform a material obligation under the agreement.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Upon termination of the license and co-development agreement, the license we granted to Genzyme for KYNAMRO will terminate and Genzyme will stop selling the product.&#160; In addition, if Genzyme voluntarily terminates the agreement or we terminate the agreement in a country or countries for Genzyme&#8217;s failure to develop and commercialize KYNAMRO, then the rights to KYNAMRO will revert back to us and we may develop and commercialize KYNAMRO in the countries that are the subject of the termination, subject to a royalty payable to Genzyme.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">If we are the subject of an acquisition, then within 180 days following the acquisition, Genzyme may elect to purchase all of our rights to receive payments under the KYNAMRO license and co-development agreement for a purchase price to be mutually agreed to by us and Genzyme, or, if we cannot agree, a fair market value price determined by an independent investment banking firm.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Genzyme has agreed to monthly limits on the number of shares it can sell of the Company&#8217;s stock that it purchased in February&#160;2008.&#160; In addition, Genzyme has agreed that until the earlier of the 10 year anniversary of the KYNAMRO license and co-development agreement or the date Genzyme holds less than two percent of our issued and outstanding common stock, Genzyme will not acquire any additional shares of our common stock without our consent.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The price Genzyme paid for our common stock represented a significant premium over the then fair value of our common stock.&#160; In May&#160;2012, we finished amortizing this $100 million premium along with the $175 million licensing fee that we received in the second quarter of 2008.&#160; During the three months ended March&#160;31, 2013 and 2012, we earned revenue of $25.0 million and $16.4 million, respectively, from our relationship with Genzyme, which represented 58 percent and 71 percent, respectively, of our total revenue for those periods.&#160; Our balance sheets at both March&#160;31, 2013 and December&#160;31, 2012 included deferred revenue of $3.8 million that Genzyme paid for KYNAMRO drug substance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">GlaxoSmithKline</font></i></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In March&#160;2010, we entered into a strategic alliance with GSK, which covers up to six programs, in which we use our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.&#160; This alliance allows us to control and facilitate rapid development of drugs while still being eligible to receive milestone payments as we advance these drugs in clinical development.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Under the terms of the original agreement, which includes five programs in addition to the transthyretin, or TTR, program,</font> <font style="FONT-SIZE: 10pt;" size="2">we are eligible to receive on average up to $20 million in milestone payments per program up to Phase 2 proof-of-concept</font><font style="FONT-SIZE: 10pt;" size="2">.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">GSK has the option to license drugs from these programs at Phase 2 proof-of-concept, and will be responsible for all further development and commercialization.&#160; In October&#160;2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Under the amended terms of the agreement, we received a $2.5 million upfront payment in December&#160;2012, and we received a $7.5 million milestone payment in February&#160;2013 when we initiated the Phase 2/3 clinical study for ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.&#160; We have already earned $17.5 million in milestone payments from GSK related to the development of</font> <font style="FONT-SIZE: 10pt;" size="2">ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">, and we are eligible to earn an additional $50 million in pre-licensing milestone payments associated with the</font> <font style="FONT-SIZE: 10pt;" size="2">ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;Phase 2/3 study.&#160; In addition, GSK has increased the regulatory and commercial milestone payments we can earn should</font> <font style="FONT-SIZE: 10pt;" size="2">ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;achieve registration and meet certain sales thresholds.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Under the terms of the amended agreement, if GSK successfully develops all six programs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.3 billion, including up to $231.5 million for the achievement of development milestones, up to $594.5 million for the achievement of regulatory milestones and up to $545 million for the achievement of commercialization milestones.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">W</font><font style="FONT-SIZE: 10pt;" size="2">e will earn the next milestone payment of $2 million upon dosing the 10</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">th</font><font style="FONT-SIZE: 10pt;" size="2">&#160;patient in the Phase 2/3 clinical study for ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. In addition, we are eligible to receive up to double-digit royalties on sales from any product that GSK successfully commercializes under this alliance.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">During the three months ended March&#160;31, 2013 and 2012</font><font style="FONT-SIZE: 10pt;" size="2">, we earned revenue of $9.9 million and $2.0 million, respectively, from our relationship with GSK, which represented 23 percent and nine percent, respectively, of our total revenue for those periods.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Our balance sheets at March&#160;31, 2013 and December&#160;31, 2012 included deferred revenue of $17.6 million and $19.9 million, respectively, related to the upfront and expansion payments.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Roche</font></i></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In April&#160;2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington&#8217;s disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial.&#160; Prior to option exercise, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We will also work collaboratively with Roche on the discovery of an antisense drug utilizing Roche&#8217;s &#8220;brain shuttle&#8221; program.&#160; If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for all drugs arising out of the collaboration.&#160; Under the terms of the agreement, we received an upfront payment of $30.0 million in April&#160;2013 and we are eligible to receive up to $362.0 million in a license fee and substantive milestone payments including up to $67.0 million for the achievement of development milestones, up to $170.0 million for the achievement of regulatory milestones and up to $80.0 million for the achievement of commercialization milestones.</font> <font style="FONT-SIZE: 10pt;" size="2">In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed as well as up to $50.0 million in commercial milestones if a drug using Roche&#8217;s proprietary brain shuttle technology is successfully commercialized.&#160; W</font><font style="FONT-SIZE: 10pt;" size="2">e are also eligible to receive tiered royalties on any product sales of drugs resulting from this alliance. We will earn the next milestone payment of $22.0 million upon initiation of a Phase 1 Trial for a drug targeting HTT protein.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">External Project Funding</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">CHDI Foundation,&#160;Inc.</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Since November&#160;2007, CHDI has provided financial and scientific support to our HD drug discovery program through our development collaboration.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">In April&#160;2013, we formed an alliance with Roche to</font> <font style="FONT-SIZE: 10pt;" size="2">develop treatments for HD.</font> <font style="FONT-SIZE: 10pt;" size="2">Under the terms of our agreement with CHDI,</font> <font style="FONT-SIZE: 10pt;" size="2">we will reimburse CHDI for its support of our program out of the payments we receive from Roche. In April&#160;2013, we paid CHDI $1.5 million associated with the signing of the Roche agreement, which we will record as research and development expense in the second quarter of 2013.&#160; We will also pay CHDI $1.5 million when we select a development candidate and if we achieve certain milestones under our collaboration with Roche we will make additional payments to CHDI.&#160; During the three months ended March&#160;31, 2013 and 2012</font><font style="FONT-SIZE: 10pt;" size="2">, we earned revenue of $293,000 and $1.2 million, respectively, from our relationship with CHDI.</font> <font style="FONT-SIZE: 10pt;" size="2">Our balance sheet at December&#160;31, 2012 included deferred revenue of $229,000 related to our relationship with CHDI.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Concentration of Business Risk</font></b></p> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 1in; WIDTH: 73.34%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="73%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Partner A</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="16%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">58</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="16%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">71</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Partner B</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 16.36%; PADDING-TOP: 0in;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">23</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 16.36%; PADDING-TOP: 0in;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Contract receivables from four significant partners comprised approximately 88 percent of our contract receivables at March&#160;31, 2013. Contract receivables from four significant partners comprised approximately 83 percent of our contract receivables at December&#160;31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Revenue Recognition</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In those instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Research and development revenue under collaborative agreements</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services. Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees, profit sharing and royalties on product sales. We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and then accounted for as a single unit of accounting. When the delivered items in an arrangement have &#8220;stand-alone value&#8221; to our customer, we account for the deliverables as separate units of accounting and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a standalone basis. We use the following hierarchy of values to estimate the selling price of each deliverable: (i)&#160;vendor-specific objective evidence of fair value; (ii)&#160;third-party evidence of selling price; and (iii)&#160;best estimate of selling price, or BESP. The BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In December&#160;2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense therapeutics against five cancer targets. As part of the collaboration, we received a $25 million upfront payment and are eligible to receive a $6 million payment in the second quarter of 2013 assuming the research program is continuing.&#160; We are also eligible to receive milestone payments, license fees for the research program targets and royalties on any product sales of drugs resulting from this collaboration. In exchange, we granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.</font><font style="FONT-SIZE: 10pt;" size="2">&#160; We also granted AstraZeneca options to license up to three drugs under the separate research program. We are responsible for completing an ongoing clinical study of ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">and IND-enabling studies for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. AstraZeneca will be responsible for all other global development, regulatory and commercialization activities for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">. In addition, if AstraZeneca exercises its option for any drugs resulting from the research program, AstraZeneca will assume global development, regulatory and commercialization responsibilities for such drug.&#160; Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that certain deliverables, either individually or in combination, have stand-alone value.&#160; Below is a list of the four separate units of accounting under our agreement:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">for the treatment of cancer;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The development services we will perform for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and the research services we will perform</font> <font style="FONT-SIZE: 10pt;" size="2">for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The option to license up to three drugs under a research program and the research services we will perform for this program.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We determined that the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license had stand-alone value because it is an exclusive license that gives AstraZeneca the right to develop ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;or to sublicense its rights.&#160; In addition,&#160;ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;is currently in development and it is possible that AstraZeneca or another third party could conduct clinical trials without assistance from us.&#160; As a result, we consider the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license and the development services for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;to be separate units of accounting. We recognized the revenue allocated to the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license on the date of the agreement because that is when we delivered the license.&#160; We will recognize the revenue allocated to the development services for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;over the period of time we perform services. The ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license is also an exclusive license.&#160; Because of the early stage of research for ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">, we believe that our knowledge and expertise with antisense technology is essential for AstraZeneca or another third party to successfully develop ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">.&#160; As a result, we concluded that the ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license does not have stand-alone value and we combined the ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font> <font style="FONT-SIZE: 10pt;" size="2">license and related research services into one unit of accounting.&#160; We will recognize revenue for the combined unit of accounting over the period of time we perform services. We determined that the options under the research program did not have stand-alone value because AstraZeneca cannot develop or commercialize drugs resulting from the research program until AstraZeneca exercises the respective option or options. As a result, we considered the research options and the related research services as a combined unit of accounting.&#160; We will recognize revenue for the combined unit of accounting over the period of our performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We determined that the allocable arrangement consideration was the $25 million upfront payment because it was the only payment that was fixed and determinable when we entered into the agreement.&#160; There was considerable uncertainty at the date of the agreement as to whether we would earn the milestone payments, royalty payments, payments for manufacturing clinical trial materials or payments for finished drug product.&#160; As such, we did not include those payments in the allocable consideration.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We allocated the $25 million upfront payment based on the relative BESP of each unit of accounting.&#160; We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the licenses granted for ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and ISIS-AZ1</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for each drug. We then discounted the projected income for each license to present value. The significant inputs we used to determine the projected income of the licenses included:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Estimated future product sales;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Estimated royalties on future product sales;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Contractual milestone payments;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Expenses we expect to incur;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Income taxes; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">An appropriate discount rate.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We estimated the selling price of the research and development services by using our internal estimates of the cost to perform the specific services, marked up to include a reasonable profit margin, and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform research and development. The significant inputs we used to determine the selling price of the research and development services included:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The number of internal hours we will spend performing these services;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated number and cost of studies we will perform;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated number and cost of studies that we will contract with third parties to perform; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The estimated cost of drug product we will use in the studies.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As a result of the allocation, we recognized $9.3 million of the $25 million upfront payment in December&#160;2012 for the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;license.&#160; We are recognizing the remaining $15.7 million over the estimated period of our performance. Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">license, we determined that the revenue we would have allocated to the ISIS-STAT3</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">license would change by approximately seven percent, or $600,000, from the amount we recorded.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Typically, we must estimate our period of performance when the agreements we enter into do not clearly define such information.&#160; Our collaborative agreements typically include a research and/or development project plan that includes the activities the agreement requires each party to perform during the collaboration. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition and amortize revenue over such period. If our collaborators ask us to continue performing work in a collaboration beyond the initial period of performance, we extend our amortization period to correspond to the new extended period of performance.&#160; The revenue we recognize could be materially different if different estimates prevail.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">From time to time, we may enter into separate agreements at or near the same time with the same customer.&#160; We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement.&#160; We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In January&#160;2012, we entered into a collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;for Spinal Muscular Atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of ISIS-SMN</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">&#160;through completion of Phase 2/3 clinical trials. In June&#160;2012, we entered into a second and separate collaboration agreement with Biogen Idec to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial. In December&#160;2012, we entered into a third and separate collaboration agreement with Biogen Idec to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.&#160; All three of these collaboration agreements give Biogen Idec the option or options to license one or more drugs resulting from the specific collaboration.&#160; If Biogen Idec exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the development of the drugs prior to licensing, milestone payments if Biogen Idec achieves pre-specified regulatory milestones, and royalties on any product sales of drugs resulting from these collaborations.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 39pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We evaluated the SMA, DMPK, and neurology agreements to determine whether we should account for them as separate agreements or as a single multiple element arrangement.&#160; We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, the first two agreements cover two different diseases while the targets for the third agreement are yet to be defined, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other.&#160; We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting.&#160; For all three of these agreements, we determined that the options did not have stand-alone value because Biogen Idec cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options.&#160; As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective research and development term, which is the estimated period of our performance.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 39pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events.&#160; These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery.&#160; From these research efforts, we hope to identify a development candidate.&#160; The designation of a development candidate is the first stage in the life-cycle of our drugs.&#160; A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.&#160; During the first step of the development stage, we or our partners study our drugs in IND-enabling studies, which are animal studies intended to support an Investigational New Drug, or IND, application and/or the foreign equivalent.&#160; An approved IND allows us or our partners to study our development candidate in humans.&#160; If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients.&#160; If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.&#160; The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing approval from the Food and Drug Administration, or FDA, and/or foreign equivalents.&#160; The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete.&#160; If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing approval.&#160; This stage of the drug&#8217;s life-cycle is the regulatory stage.&#160; If a drug achieves marketing approval, it moves into the commercialization stage, during which our partner will market and sell the drug to patients.&#160; Although our partner will ultimately be responsible for marketing and selling the drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner&#8217;s ability to successfully sell the drug.&#160; The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities.&#160; Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow our partner to successfully commercialize our drug.&#160; Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner&#8217;s ability to sell our drugs without competition from generic drugs.&#160; The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization.&#160; The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain.&#160; As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.&#160; Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Development milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Designation of a development candidate.&#160; Following the designation of a development candidate,&#160;IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation of a Phase 1 clinical trial.&#160; Generally, Phase 1 clinical trials take one to two years to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation or completion of a Phase 2 clinical trial.&#160; Generally, Phase 2 clinical trials take one to three years to complete;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Initiation or completion of a Phase 3 clinical trial.&#160; Generally, Phase 3 clinical trials take two to four years to complete.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Regulatory milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Filing of regulatory applications for marketing approval such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe.&#160; Generally, it takes six to twelve months to prepare and submit regulatory filings.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Marketing approval in a major market, such as the United States, Europe or Japan.&#160; Generally it takes one to two years after an application is submitted to obtain approval from the applicable regulatory agency.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Commercialization milestones in our partnerships may include the following types of events:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">First commercial sale in a particular market, such as in the United States or Europe.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion.&#160; The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We assess whether a substantive milestone exists at the inception of our agreements.&#160; When a substantive milestone is achieved, we recognize revenue related to the milestone payment.&#160; For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with ongoing access to new technologies we discover, we have determined that all future development, regulatory and commercialization milestones are substantive. For example, for our strategic alliance with GlaxoSmithKline, or GSK, we are using our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases. Alternatively, we provide on-going access to our technology to Alnylam Pharmaceuticals,&#160;Inc. to develop and commercialize RNA interference, or RNAi, therapeutics.&#160; We consider milestones for both of these collaborations to be substantive.&#160; For those agreements that do not meet the following criteria, we do not consider the future milestones to be substantive.&#160; In evaluating if a milestone is substantive we consider whether:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The achievement of the milestone involves substantive effort and can only be achieved based in whole or part on our performance or the occurrence of a specific outcome resulting from our performance;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">There is no future performance required to earn the milestone; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The consideration is reasonable relative to all deliverables and payment terms in the arrangement.</font></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">If any of these conditions are not met, we will defer recognition of the milestone payment and recognize it as revenue over the estimated period of performance, if any.&#160; In the first quarter of 2013, the FDA approved the NDA for KYNAMRO and we initiated a Phase 2/3 clinical study for ISIS-TTR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">Rx</font><font style="FONT-SIZE: 10pt;" size="2">, the first drug selected as part of our collaboration with GSK. We consider milestones related to progression of a drug through the development and regulatory stages of its life cycle to be substantive milestones because the level of effort and inherent risk associated with these events is high. Therefore, in the first quarter of 2013 we recognized the $25 million milestone payment from Genzyme and the $7.5 million milestone payment from GSK. Further information about our collaborative arrangements can be found in Note 7 <i>Collaborative Arrangements and Licensing Agreements</i> and Note 7 of our audited financial statements for the year ended December&#160;31, 2012 included in our Annual Report on Form&#160;10-K filed with the SEC.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Licensing and royalty revenue</font></i></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash, cash equivalents and short-term investments</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We consider all liquid investments with maturities of 90 days or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than 90 days from date of purchase. We classify our short-term investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We have equity investments in privately- and publicly-held biotechnology companies that we have received as part of a technology license or collaboration agreement.&#160; At March&#160;31, 2013 we held ownership interests of less than 20 percent in each of the respective companies.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We account for our equity investments in publicly-held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly-held companies as a separate component of comprehensive income (loss).&#160; We account for equity investments in privately-held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. Most of the cost method investments we hold are in early stage biotechnology companies and realization of our equity position in those companies is uncertain. In those circumstances we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Inventory valuation</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials and historical write-offs. We did not record any inventory write-offs for the first three months of 2013 and 2012. Total inventory, which consisted of raw materials, was $5.8 million and $6.1 million as of March&#160;31, 2013 and December&#160;31, 2012, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Patents</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. We evaluate patents and patent applications that we are not actively pursuing and write off any associated costs. We amortize patent costs over their useful lives, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-lived assets</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity method of accounting</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We accounted for our ownership interest in Regulus using the equity method of accounting until Regulus&#8217; IPO in October&#160;2012.&#160; In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus&#8217; common stock and we no longer have significant influence over the operating and financial policies of Regulus. Under the equity method of accounting, we included our share of Regulus&#8217; operating results on a separate line in our condensed consolidated statement of operations called &#8220;Equity in net loss of Regulus Therapeutics Inc.&#8221;</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Basic and diluted net loss per share</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a loss for the three months ended March&#160;31, 2013 and 2012, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.&#160; The following would have had an anti-dilutive effect on net loss per share:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">3</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">4</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible senior notes;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible subordinated notes;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">GlaxoSmithKline convertible promissory notes issued by Regulus;</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Dilutive stock options; and</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Restricted stock units.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We redeemed all of our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes in September&#160;2012 and in October&#160;2012 Regulus completed an IPO, upon which we were no longer guarantors on the two convertible notes that Regulus issued to GSK.&#160; As a result, the 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt;" size="2">/</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes and GSK convertible promissory notes are not common equivalent shares for the three months ended March&#160;31, 2013.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Consolidation of variable interest entities</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We identify entities as variable interest entities either: (1)&#160;that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest.&#160; We perform ongoing qualitative assessments of our variable interest entities to determine whether we have a controlling financial interest in the variable interest entity and therefore are the primary beneficiary.&#160; As of March&#160;31, 2013 and December&#160;31, 2012, we had collaborative arrangements with five and six entities, respectively, that we considered to be variable interest entities.&#160; We are not the primary beneficiary for any of these entities as we do not have both the power to direct the activities that most significantly impact the economic performance of our variable interest entities and the obligation to absorb losses or the right to receive benefits from our variable interest entities that could potentially be significant to the variable interest entities.&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">As of March&#160;31, 2013, the total carrying value of our investments in variable interest entities was $47.5 million, and was primarily related to our investment in Regulus. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Convertible debt</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In August&#160;2012, we completed a $201.3 million offering of convertible senior notes, which mature in 2019 and bear interest at 2&#190; percent.&#160; In September&#160;2012, we used a substantial portion of the net proceeds from the issuance of the 2&#190; percent notes to redeem our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#164;</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent convertible subordinated notes. Consistent with how we accounted for our 2</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol;" size="2">&#164;</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: 1pt;" size="1">8</font><font style="FONT-SIZE: 10pt;" size="2">&#160;percent notes, we account for our 2&#190; percent notes by separating the liability and equity components of the instrument in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our 2&#190; percent notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording the debt instrument at a discount.&#160; We are amortizing the debt discount over the life of these 2&#190; percent notes as additional non-cash interest expense utilizing the effective interest method.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Segment information</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We operate in a single segment, Drug Discovery and Development operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a single operating segment.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Stock-based compensation expense</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our Employee Stock Purchase Plan, or ESPP, based on the estimated fair value of the award on the date of grant using an option-pricing model. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our condensed consolidated statements of operations.&#160; We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under the ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding.&#160; We estimate the expected term of options granted based on historical exercise patterns.&#160; For the three months ended March&#160;31, 2013 and 2012, we used the following weighted-average assumptions in our Black-Scholes calculations:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 30.25pt; TEXT-INDENT: -10.1pt;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">Employee Stock Options:</font></i></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">51.5</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">50.6</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.25in;"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman;" size="2">ESPP:</font></i></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">61.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">43.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The fair value of RSUs is based on the market price of our common stock on the date of grant.&#160; RSUs vest annually over a four year period.&#160; The weighted-average grant date fair value of RSUs granted to employees for the three months ended March&#160;31, 2013 and 2012 was $14.21 and $7.60, respectively.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following table summarizes stock-based compensation expense for the three months ended March&#160;31, 2013 and 2012 (in thousands), which was allocated as follows:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Research and development</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,546</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,935</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">General and administrative</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">323</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">332</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,869</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,267</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">As of March&#160;31, 2013, total unrecognized estimated non-cash stock-based compensation expense related to non-vested stock options and RSUs was $10.7&#160;million and $3.8 million, respectively. We will adjust total unrecognized compensation cost for future changes in estimated forfeitures.&#160; We expect to recognize the cost of non-cash, stock-based compensation expense related to non-vested stock options and RSUs over a weighted average amortization period of 1.4 years and 2.1 years, respectively.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt;" size="2">The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March&#160;31, 2013 and 2012 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 851px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="851" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Beginning balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,480</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(770</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Other comprehensive income before reclassifications, net of tax (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6,467</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Amounts reclassified from accumulated other comprehensive income (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1,163</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Net current period other comprehensive income</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,304</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Ending balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,784</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(242</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Other comprehensive income for the three months ended March&#160;31, 2013 includes income tax expense of $3.6 million.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in g</font><font style="FONT-SIZE: 10pt;" size="2">ain on investments, net</font> <font style="FONT-SIZE: 10pt;" size="2">on our condensed consolidated statement of operations.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p></div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 875px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="875" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">61.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">43.4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6 months</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following table summarizes stock-based compensation expense for the three months ended March&#160;31, 2013 and 2012 (in thousands), which was allocated as follows:</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 863px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="863" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Research and development</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,546</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,935</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">General and administrative</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">323</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">332</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,869</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,267</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p></div> 5 3 9300000 25000000 6000000 15700000 4 3 3000 25000000 0.20 0.0275 0.02625 6 5 201300000 0.011 0.010 0.001 0.001 0.000 0.000 0.000 0.000 0.506 0.434 0.515 0.614 P6M P6M P5Y1M6D P5Y1M6D 7.60 14.21 1935000 332000 2267000 2546000 29000000 19900000 264261000 323000 2869000 10700000 3800000 P1Y4M24D P2Y1M6D 0.71 0.58 0.23 4 4 0.88 ISIS PHARMACEUTICALS INC 0000874015 10-Q 2013-03-31 false --12-31 Yes Large Accelerated Filer 2013 Q1 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <table style="text-align:left;MARGIN-LEFT: 1in; WIDTH: 794px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="794" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Partner A</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="16%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">58</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 16.36%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="16%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">71</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 59.1%; PADDING-TOP: 0in;" valign="bottom" width="59%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Partner B</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 16.36%; PADDING-TOP: 0in;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">23</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 16.36%; PADDING-TOP: 0in;" valign="bottom" width="16%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p></div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following table summarizes the contract maturity of the available-for-sale securities we held as of March&#160;31, 2013:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 835px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="835" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">One year or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 18.94%; PADDING-TOP: 0in;" valign="bottom" width="18%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">47</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">After one year but within two years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 18.94%; PADDING-TOP: 0in;" valign="bottom" width="18%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">41</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">After two years but within three years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="18%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 75.54%; PADDING-TOP: 0in;" valign="bottom" width="75%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.94%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="18%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">100</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 1.58%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following is a summary of our investments (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 1007px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="1007" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Amortized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">March&#160;31,&#160;2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Short-term investments:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">97,983</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">59</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(29</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">98,013</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9,932</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(46</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">9,887</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,001</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,549</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">55</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(11</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,593</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of one year&#160;or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">124,464</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">116</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(86</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">124,494</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,131</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">110</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(156</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,085</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,020</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">35</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,052</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,393</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">30</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,423</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,203</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">7</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,207</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of more than one year</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">139,747</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">182</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(162</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">139,767</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 40pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">264,211</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">298</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 1pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">264,261</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 993px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="993" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">March&#160;&#160;31,&#160;2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Basis</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (Regulus Therapeutics Inc.)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,525</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">29,338</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (included in Other current assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,538</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,961</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-term portion (included in Deposits and&#160;other assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,688</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31,299</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">48,107</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">281,899</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31,597</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">312,368</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p> <table style="text-align:left;WIDTH: 1005px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="1005" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Amortized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">December&#160;31,&#160;2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Short-term investments:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">113,249</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">81</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(9</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">113,321</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">10,100</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(66</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">10,036</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,001</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">16,560</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">16,576</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of one year&#160;or less</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">140,909</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">102</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(77</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">140,934</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">80,166</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(92</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">80,186</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,034</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">38</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">27</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,451</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United&#160;States and political subdivisions of&#160;the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,306</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">31</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(16</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">8,321</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total securities with a maturity of more than one year</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">108,930</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">208</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">109,030</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 40pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">249,839</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">310</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 1pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">249,964</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 994px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="994" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Other-Than-</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Temporary</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Cost</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 22.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="22%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">December&#160;31,&#160;2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Basis</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Gains</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Loss</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 36.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (Regulus Therapeutics Inc.)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">15,526</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,096</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.7%; PADDING-TOP: 0in;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Current portion (included in Other current assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1,579</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,175</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10%; PADDING-TOP: 0in;" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,874</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Long-term portion (included in Deposits and&#160;other assets)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="10%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">625</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Subtotal</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,730</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">22,271</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="8%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">39,121</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.5%; PADDING-TOP: 0in;" valign="bottom" width="36%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">267,569</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">22,581</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(880</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="8%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">289,085</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></div> <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investments we considered to be temporarily impaired at March&#160;31, 2013 were as follows (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 963px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="963" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.6%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Less&#160;than&#160;12&#160;months&#160;of<br /> temporary&#160;impairment</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Number&#160;of<br /> Investments</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Estimated<br /> Fair&#160;Value</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Unrealized<br /> Losses</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">70</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">95,606</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(185</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,885</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(49</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">3</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,537</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(14</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 48.64%; PADDING-TOP: 0in;" valign="bottom" width="48%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total temporarily impaired securities</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">77</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">114,028</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.9%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(248</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></div> 1.00 0.47 0.41 0.12 0.88 3 3 625000 625000 113249000 10100000 16560000 140909000 1000000 80166000 8034000 12424000 8306000 108930000 249839000 81000 2000 18000 102000 1000 112000 38000 27000 31000 208000 310000 22271000 9000 77000 66000 2000 92000 108000 185000 16000 113321000 10036000 16576000 140934000 1001000 80186000 8072000 12451000 8321000 109030000 249964000 15526000 1579000 17730000 267569000 18096000 4175000 22581000 185000 880000 880000 880000 33622000 4874000 39121000 289085000 70 4 3 77 95606000 13885000 4537000 114028000 -185000 -49000 -14000 -248000 625000 625000 97983000 9932000 15549000 124464000 1000000 107131000 15020000 12393000 5203000 139747000 264211000 15525000 1538000 281899000 17688000 59000 1000 55000 116000 1000 110000 35000 30000 7000 182000 298000 31299000 29338000 1961000 31597000 29000 86000 46000 11000 156000 162000 248000 3000 248000 880000 880000 880000 98013000 9887000 15593000 124494000 1001000 107085000 15052000 12423000 5207000 139767000 264261000 44863000 2619000 312368000 48107000 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We break down the inputs used to measure fair value for these assets at March&#160;31, 2013 and December&#160;31, 2012 as follows (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 1010px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="1010" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">At&#160;March&#160;31,<br /> 2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Quoted&#160;Prices&#160;in<br /> Active&#160;Markets<br /> (Level&#160;1)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant&#160;Other<br /> Observable<br /> Inputs<br /> (Level&#160;2)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant<br /> Unobservable<br /> Inputs<br /> (Level&#160;3)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash equivalents (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">96,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">91,072</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">205,098</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">205,098</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,939</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,939</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,424</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">20,800</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">20,800</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investment in Regulus Therapeutics Inc.</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities (3)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2,619</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">407,815</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">107,115</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">255,837</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 1005px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="1005" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">At&#160;December&#160;31,<br /> 2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Quoted&#160;Prices&#160;in<br /> Active&#160;Markets<br /> (Level&#160;1)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant&#160;Other<br /> Observable<br /> Inputs<br /> (Level&#160;2)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Significant<br /> Unobservable<br /> Inputs<br /> (Level&#160;3)</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cash equivalents (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">105,496</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">101,496</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,000</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Corporate debt securities (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">193,507</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">193,507</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by U.S. government agencies (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">18,108</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by the U.S. Treasury (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,452</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">13,452</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Debt securities issued by states of the United States and political subdivisions of the states (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,897</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">24,897</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Investment in Regulus Therapeutics Inc.</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">33,622</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Equity securities (3)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,874</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">4,146</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">728</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in;" valign="bottom" width="41%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">393,956</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">119,094</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">240,512</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="10%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">34,350</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in cash and cash equivalents on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in short-term investments on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(3)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in other current assets on our consolidated balance sheet.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p></div> 105496000 101496000 4000000 96072000 91072000 5000000 193507000 193507000 18108000 18108000 13452000 13452000 24897000 24897000 4874000 4146000 728000 393956000 119094000 240512000 34350000 407815000 107115000 255837000 44863000 205098000 205098000 24939000 24939000 13424000 13424000 20800000 2619000 2619000 1172000 258000000 20800000 45000000 150000000 44863000 8074000 9900000 0.23 2000000 0.09 62600000 59200000 0.30 0.50 1500000000 700000000 825000000 89694000 250000000 25000000 25000000 6010000 19604000 5824000 3818000 25000000 16400000 0.58 0.71 3800000 3800000 6 5 20000000 17758000 231500000 594500000 545000000 3582000 4508000 35244000 58816000 145533000 6498000 70728000 1091842000 0.20 -908638000 0.09 50000000 3900000 1800000 17600000 17784000 -770000 -242000 528000 6467000 -1163000 0.83 376000 1100000 44863000 44863000 33622000 33622000 34350000 44863000 -1163000 11716000 1000000 44400000 54600000 0 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.3pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March&#160;31, 2013 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 834px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="834" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.82%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Investments</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Valued&#160;Using</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Level&#160;3&#160;Inputs</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Balance at December&#160;31, 2012</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.42%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 20.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="20%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">34,350</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Total gains and losses:</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Included in g</font><font style="FONT-SIZE: 10pt;" size="2">ain on investments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1,163</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Included in accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.82%; PADDING-TOP: 0in;" valign="bottom" width="21%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">11,716</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Cost basis of shares sold</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.82%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="21%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(40</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.4%; PADDING-TOP: 0in;" valign="bottom" width="73%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Balance at March&#160;31, 2013</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.4%; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.42%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 20.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="20%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">44,863</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p></div> 5809000 9700000 10800000 296000 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 873px; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="873" border="0"> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="3"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended<br /> March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Risk-free interest rate</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.1</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Dividend yield</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">0.0</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Volatility</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">51.5</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">50.6</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">%</font></p></td></tr> <tr style="padding:0;PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Expected life</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5.1 years</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div> 3 4795000 1100000 1058000 -64000 -10576000 64552000 49076000 222000 17500000 702000 11823000 2773000 100157000 101875000 100157000 101875000 <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Income Taxes</font></b></p> <p style="MARGIN: 0in 0in 0pt 56.15pt; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Intraperiod tax allocation rules&#160;require us to allocate our provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income.&#160; In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, we must allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During the first quarter of 2013, we recorded unrealized gains on our investments in available-for-sale securities in other comprehensive income net of taxes.&#160; As a result, we recorded a $64,000 tax benefit on our condensed consolidated statements of operations and a $3.6 million tax expense in other comprehensive income for the three months ended March&#160;31, 2013.</font></p> </div> 1094000 <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The unaudited interim condensed consolidated financial statements for the three month periods ended March&#160;31, 2013 and 2012 have been prepared on the same basis as the audited financial statements for the year ended December&#160;31, 2012. The financial statements include all normal recurring adjustments, which we consider necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Results for the interim periods are not necessarily indicative of the results for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2012 included in our Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The condensed consolidated financial statements include the accounts of Isis Pharmaceuticals,&#160;Inc. (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) and our wholly owned subsidiary,&#160;Symphony GenIsis,&#160;Inc., which is currently inactive.&#160; In addition to our wholly owned subsidiary, our consolidated financial statements include our equity investment in Regulus Therapeutics Inc. In October&#160;2012, Regulus completed an initial public offering (IPO).&#160; We now own less than 20 percent of Regulus&#8217; common stock and we no longer have significant influence over the operating and financial policies of Regulus.&#160; As a result, in the fourth quarter of 2012, we stopped using the equity method of accounting for our equity investment in Regulus and we began accounting for our investment at fair value.</font></p> </div> 293000 1200000 229000 3600000 5304000 528000 P4Y 7500000 2 1500000 1500000 1300000000 0.10 600000 0.07 12000000 30000000 3 3 P12M P18M P1Y P2Y P1Y P3Y P2Y P4Y P6M P12M 1000000000 P1Y P2Y 47500000 -40000 59000000 130000000 10000000 125000000 P180D 0.02 100000000 175000000 7500000 30000000 3600000 18000000 3500000 130000000 10000000 150000000 5000000 P10Y 2500000 362000000 67000000 170000000 80000000 22000000 10000000 175000000 4 200000000 2000000 136500000 50000000 <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Accumulated other comprehensive income (loss)</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Accumulated other comprehensive income (loss) is comprised of</font> <font style="FONT-SIZE: 10pt;" size="2">unrealized gains and losses on securities, net of taxes,</font> <font style="FONT-SIZE: 10pt;" size="2">and&#160; adjustments we made to reclassify realized gains and losses on securities from other accumulated comprehensive income to our</font> <font style="FONT-SIZE: 10pt;" size="2">condensed consolidated statement of operations</font><font style="FONT-SIZE: 10pt;" size="2">.</font> <font style="FONT-SIZE: 10pt;" size="2">The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March&#160;31, 2013 and 2012 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;">&#160;</p> <table style="text-align:left;MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse;" cellspacing="0" cellpadding="0" width="86%" border="0"> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 30.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="30%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">Three&#160;Months&#160;Ended</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt;" size="1">March&#160;31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman;" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Beginning balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">12,480</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(770</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Other comprehensive income before reclassifications, net of tax (1)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">6,467</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.84%; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Amounts reclassified from accumulated other comprehensive income (2)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1,163</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid;" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">&#8212;</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Net current period other comprehensive income</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">5,304</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="13%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">528</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 65.4%; PADDING-TOP: 0in;" valign="bottom" width="65%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Ending balance accumulated other comprehensive income (loss)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">17,784</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in;" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 2.25pt double; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double;" valign="bottom" width="12%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right;" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(242</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 1.16%; PADDING-TOP: 0in;" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">)</font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(1)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Other comprehensive income for the three months ended March&#160;31, 2013 includes income tax expense of $3.6 million.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">(2)</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">Included in g</font><font style="FONT-SIZE: 10pt;" size="2">ain on investments, net</font> <font style="FONT-SIZE: 10pt;" size="2">on our condensed consolidated statement of operations.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in;">&#160;</p> </div> EX-101.SCH 7 isis-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 1020 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 1030 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 1040 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 1050 - Disclosure - Concentration of Business Risk link:presentationLink link:calculationLink link:definitionLink 1060 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 1070 - Disclosure - Collaborative Arrangements and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 2020 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 3020 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 3030 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 3040 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 3050 - Disclosure - Concentration of Business Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 4020 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 4021 - Disclosure - Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 4022 - Disclosure - Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 4023 - Disclosure - Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 4024 - Disclosure - Significant Accounting Policies (Details 5) link:presentationLink link:calculationLink link:definitionLink 4025 - Disclosure - Significant Accounting Policies (Details 6) link:presentationLink link:calculationLink link:definitionLink 4026 - Disclosure - Significant Accounting Policies (Details 7) link:presentationLink link:calculationLink link:definitionLink 4030 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 4031 - Disclosure - Investments (Details 2) link:presentationLink link:calculationLink link:definitionLink 4040 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 4041 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 4050 - Disclosure - Concentration of Business Risk (Details) link:presentationLink link:calculationLink link:definitionLink 4060 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 4070 - Disclosure - Collaborative Arrangements and Licensing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 8000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 8020 - Disclosure - New Facility link:presentationLink link:calculationLink link:definitionLink 8030 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 8040 - Disclosure - Lease Agreements link:presentationLink link:calculationLink link:definitionLink 8060 - Disclosure - Investment in Regulus Therapeutics Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 8070 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 8080 - Disclosure - Investment in Regulus Therapeutics Inc. link:presentationLink link:calculationLink link:definitionLink 8090 - Disclosure - Long-Term Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 8100 - Disclosure - Organization and Significant Accounting Policies (Details 15) link:presentationLink link:calculationLink link:definitionLink 8110 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 8140 - Disclosure - Organization and Significant Accounting Policies (Details 10) link:presentationLink link:calculationLink link:definitionLink 8150 - Disclosure - New Facility (Details) link:presentationLink link:calculationLink link:definitionLink 8160 - Disclosure - Lease Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 8170 - Disclosure - Investment in Regulus Therapeutics Inc. (Details 4) link:presentationLink link:calculationLink link:definitionLink 8180 - Disclosure - Investment in Regulus Therapeutics Inc. (Details 2) link:presentationLink link:calculationLink link:definitionLink 8190 - Disclosure - Investment in Regulus Therapeutics Inc. (Details 3) link:presentationLink link:calculationLink link:definitionLink 8210 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 8220 - Disclosure - Organization and Significant Accounting Policies (Details 16) link:presentationLink link:calculationLink link:definitionLink 8230 - Disclosure - Employment Benefits link:presentationLink link:calculationLink link:definitionLink 8240 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 8250 - Disclosure - Concentration of Business Risk (Tables1) link:presentationLink link:calculationLink link:definitionLink 8260 - Disclosure - Subsequent Events (Details 2) link:presentationLink link:calculationLink link:definitionLink 8270 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 8280 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 8290 - Disclosure - Long-Term Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 8300 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 8310 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 8320 - Disclosure - Investment in Regulus Therapeutics Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 8330 - Disclosure - Long-Term Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 8340 - Disclosure - Long-Term Obligations and Commitments (Details 2) link:presentationLink link:calculationLink link:definitionLink 8350 - Disclosure - Long-Term Obligations and Commitments (Details 3) link:presentationLink link:calculationLink link:definitionLink 8360 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 8370 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 8380 - Disclosure - Stockholders' Equity (Details 3) link:presentationLink link:calculationLink link:definitionLink 8390 - Disclosure - Stockholders' Equity (Details 4) link:presentationLink link:calculationLink link:definitionLink 8400 - Disclosure - Stockholders' Equity (Details 5) link:presentationLink link:calculationLink link:definitionLink 8410 - Disclosure - Stockholders' Equity (Details 6) link:presentationLink link:calculationLink link:definitionLink 8420 - Disclosure - Stockholders' Equity (Details 7) link:presentationLink link:calculationLink link:definitionLink 8430 - Disclosure - Income Taxes (Details 6) link:presentationLink link:calculationLink link:definitionLink 8440 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 8450 - Disclosure - Income Taxes (Details 3) link:presentationLink link:calculationLink link:definitionLink 8460 - Disclosure - Income Taxes (Details 4) link:presentationLink link:calculationLink link:definitionLink 8470 - Disclosure - Income Taxes (Details 5) link:presentationLink link:calculationLink link:definitionLink 8480 - Disclosure - Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 8490 - Disclosure - Quarterly Financial Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 8500 - Disclosure - Organization and Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 8510 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 8520 - Disclosure - Organization and Significant Accounting Policies (Details 7) link:presentationLink link:calculationLink link:definitionLink 8530 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 8540 - Disclosure - Organization and Significant Accounting Policies (Details 9) link:presentationLink link:calculationLink link:definitionLink 8550 - Disclosure - Organization and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 8560 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 8570 - Disclosure - Significant Accounting Policies (Details 9) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 isis-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 9 isis-20130331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Significant Accounting Policies Accounting Standards Update 2009-17 [Member] As Adjusted Adoption of accounting standard to deconsolidate Accounts payable Accounts Payable, Current Accounts Receivable [Member] Contract receivables Accrued Income Taxes, Current Accrued income taxes Accrued Liabilities, Current Accrued liabilities Less accumulated depreciation Accumulated depreciation included in book value of facility Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive gain Beginning balance accumulated other comprehensive income (loss) Ending balance accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss) [Member] Accumulated other comprehensive income (loss) Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Additional paid in capital Adjustments for New Accounting Pronouncements [Axis] 2 3/4 percent convertible senior notes, equity portion, net of issuance costs Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 2 5/8 percent convertible subordinated notes redemption, equity portion Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation expense Excess tax benefits on share-based compensation Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Allocated Share-based Compensation Expense Stock-based compensation expense (benefit) related to employee and non-employee stock options and the ESPP Stock-based compensation expense Amortization of Debt Discount (Premium) Amortization of 2 5/8 percent convertible subordinated notes discount Non-cash interest expense related to the amortization of the debt discount and debt issuance costs Amortization of Financing Costs Amortization of debt issuance costs Area of Real Estate Property Area of leased facilities Approximate area occupied for laboratory and office space (in square feet) Arrangements and Non-arrangement Transactions [Domain] Asset Impairment Charges [Abstract] Long-lived assets Assets Total assets Total Assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Total assets Available-for-sale Debt Securities, Amortized Cost Basis Amortized Cost, Debt Securities Available-for-sale Equity Securities, Amortized Cost Basis Amortized Cost, Equity Securities Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract] Temporarily impaired investments Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses Total temporarily impaired securities, less than 12 months of temporary impairment, Unrealized Losses Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Temporarily impaired securities, Less than 12 months of temporary impairment, Estimated Fair Value Available-for-sale Securities, Debt Maturities [Abstract] Contract maturity of available-for-sale securities Available-for-sale Securities, Debt Securities, Current Securities with a maturity of one year or less, Estimated Fair Value Short-term investments Available-for-sale Securities, Fair Value Disclosure Available-for-sale securities Estimated Fair Value Available-for-sale Securities, Gross Unrealized Gains Unrealized Gains Available-for-sale Securities, Gross Unrealized Losses Unrealized Losses Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Temporarily impaired securities, Number of Investments Award Type [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Building and Building Improvements [Member] Building and building systems Building Improvements [Member] Building systems and improvements Building [Member] Building Business Acquisition, Cost of Acquired Entity, Purchase Price Total purchase price of acquired entity Capital Lease Obligations Incurred Capital lease obligations Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosures of non-cash investing and financing activities: Class of Stock [Domain] Class of Stock [Line Items] Class of stock Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares granted to the members of Symphony GenIsis Holdings LLC Class of Warrant or Right, Outstanding Number of shares for purchase under warrant Collaborative Arrangement Disclosure [Text Block] Collaborative Arrangements and Licensing Agreements Collaborative Arrangement [Member] Collaborations Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Research and development revenue under collaborative agreements Collaborations Regulus Investments Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Common Stock, Capital Shares Reserved for Future Issuance Common shares reserved for future issuance Common Stock [Member] Common stock Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common stock, shares authorized to issue Number of common stock available to purchase Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized, 102,695,200 and 101,481,134 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively Employment Benefits Components of Deferred Tax Assets and Liabilities [Abstract] Component of deferred tax assets and liabilities Comprehensive Income [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Comprehensive loss: Computer Equipment [Member] Computer software and hardware Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of credit risk Concentration Risk Disclosure [Text Block] Concentration of Business Risk Concentration Risk [Line Items] Concentration of business risk Concentration Risk, Percentage Concentration percentage Concentration Risk [Table] Concentration Risk Type [Domain] Consolidation, Policy [Policy Text Block] Basis of Presentation Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation of variable interest entities Construction in Progress, Gross Construction in progress costs, BioMed facility Construction in Progress [Member] Construction in progress Contractual Obligation Total minimum payments Contractual Obligation, Due after Fifth Year Thereafter Contractual Obligation, Due in Fifth Year 2017 Contractual Obligation, Due in Fourth Year 2016 Contractual Obligation, Due in Next Twelve Months 2013 Contractual Obligation, Due in Second Year 2014 Contractual Obligation, Due in Third Year 2015 2016 Convertible Debt, Noncurrent 2 3/4 percent convertible senior notes Convertible Notes Payable, Noncurrent 2 5/8 percent convertible subordinated notes Convertible Subordinated Debt [Member] 2 5/8 percent convertible subordinated notes Corporate Debt Securities [Member] Corporate debt securities Cost Method Investments Amortized Cost, Long-term Equity Securities Cost Method Investments, Fair Value Disclosure Estimated Fair Value, Long-term Equity Securities Counterparty Name [Axis] Current Federal Tax Expense (Benefit) Federal Current Income Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Current State and Local Tax Expense (Benefit) State Debt and Capital Leases Disclosures [Text Block] Long-Term Obligations and Commitments Number of shares to be exchanged for convertible notes Debt Conversion, Converted Instrument, Shares Issued Long-Term Obligations and Commitments Debt Instrument, Basis Spread on Variable Rate Percentage added to variable rate basis Long-term Debt, Gross Principal amount of convertible notes Subtotal Principal and accrued interest payable Carrying value of equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Debt Instrument, Convertible, Number of Equity Instruments Number of shares to be issued upon debt conversion Debt Instrument, Description of Variable Rate Basis Basis for variable interest rate Debt Instrument, Face Amount Principal drawn down under loan agreement Principal amount of convertible notes outstanding Debt Instrument, Increase, Additional Borrowings Debt issued Principal amount of loan Debt Instrument, Interest Rate, Effective Percentage Interest rate on new draw down (as a percent) Debt Instrument, Interest Rate, Stated Percentage Interest rate on convertible debt (as a percent) Debt Instrument [Line Items] Long-term obligations Annual debt and other obligation maturities Amount of debt redeemed Debt Instrument, Repurchased Face Amount Schedule of Long-term Debt Instruments [Table] Debt Instrument, Unamortized Discount Less: debt discount Unamortized portion of liability component Debt Instrument, Unamortized Discount (Premium), Net Debt, Policy [Policy Text Block] Convertible debt Debt Securities [Member] Short-term investments Title of Individual [Axis] Deferred Federal Income Tax Expense (Benefit) Federal Deferred Finance Costs, Noncurrent, Gross Issuance costs Deferred Foreign Income Tax Expense (Benefit) Foreign Deferred Income Tax Expense (Benefit) Provision for deferred income taxes Total deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred: Deferred Rent Credit Deferred rent Deferred rent Deferred Revenue Deferred revenue Upfront payment to be recognized over the remaining performance period Deferred Revenue, Current Current portion of deferred contract revenue Deferred Revenue, Noncurrent Long-term deferred contract revenue Deferred State and Local Income Tax Expense (Benefit) State Deferred Tax Assets, Deferred Income Deferred revenue Deferred Tax Assets, Gross Total deferred tax assets Deferred Tax Assets, Gross [Abstract] Deferred Tax Assets: Deferred Tax Assets, in Process Research and Development Capitalized R&D Deferred Tax Assets, Net Net deferreds Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryovers Deferred Tax Assets, Other Other Deferred Tax Assets, Tax Credit Carryforwards, Research R&D credits Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Accrued restructuring Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Liabilities, Gross [Abstract] Deferred Tax Liabilities: Deferred Tax Liabilities, Financing Arrangements Convertible debt Defined Contribution Plan, Cost Recognized Employers matching contributions Depreciation Depreciation Board of Directors Director [Member] Discontinued Operation, Amount of Other Income (Loss) from Disposition of Discontinued Operations, before Income Tax Other income, net Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale of Ibis Biosciences, Inc., before tax Discontinued Operations and Disposal Groups [Abstract] Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation Gain on sale of Ibis Biosciences, Inc., income tax expense Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Components of discontinued operations Disposal Group, Including Discontinued Operation, Operating Expense Total operating expenses Disposal Group, Including Discontinued Operation, Operating Income (Loss) Loss from operations Disposal Group, Including Discontinued Operation, Revenue Revenue Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Name [Domain] Domestic Tax Authority [Member] Federal Earnings Per Share, Basic and Diluted Basic and diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Basic and diluted net loss per share (in dollars per share) Earnings Per Share, Policy [Policy Text Block] Basic and diluted net loss per share Effective Income Tax Rate, Continuing Operations Effective rate (as a percent) Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] Reconciliation between the effective tax rate on income from continuing operations and the statutory U.S. tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Statutory rate (as a percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance Net change in federal valuation allowance (as a percent) Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Expense) Noncontrolling interest (as a percent) Effective Income Tax Rate Reconciliation, Other Adjustments Other items (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes State income tax net of federal benefit (as a percent) Effective Income Tax Rate Reconciliation, Tax Credits Tax credits (as a percent) Employee-related Liabilities, Current Accrued compensation Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized compensation cost Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Allocation of stock-based compensation expense Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Unrecognized estimated non-cash stock-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Weighted average period over which cost is expected to be recognized Unrecognized compensation cost related to RSUs Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options Employee Stock [Member] ESPP: Employee Stock Purchase Plan (ESPP) Employee Stock Option [Member] Employee Stock Options: Non-vested stock option Equipment [Member] Other Equipment Equity Component [Domain] Equity Method Investee, Name [Domain] Equity Method Investments Investment in Regulus Therapeutics Inc. Amortized Cost, equity method investments Investment in Regulus Therapeutics Inc. Equity Method Investments and Joint Ventures Disclosure [Text Block] Investment in Regulus Therapeutics Inc. Equity Method Investments, Policy [Policy Text Block] Equity method of accounting Equity Method Investment, Summarized Financial Information [Abstract] Equity method of accounting Summarized financial information Equity Method Investment, Summarized Financial Information, Assets Total Assets Total assets Equity Method Investment, Summarized Financial Information, Cost of Sales Operating expenses Equity Method Investment, Summarized Financial Information, Current Assets Current assets Equity Method Investment, Summarized Financial Information, Current Liabilities Current liabilities Net assets Equity Method Investment Summarized Financial Information, Equity Equity Method Investment, Summarized Financial Information, Income (Loss) from Continuing Operations before Extraordinary Items Loss from operations Total liabilities Equity Method Investment, Summarized Financial Information, Liabilities Equity Method Investment, Summarized Financial Information, Net Income (Loss) Net loss Non-current assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities Non-current liabilities Equity Method Investment, Summarized Financial Information, Revenue Net revenues Equity Securities [Member] Equity securities Investments Valued Using Level 3 Inputs Estimate of Fair Value, Fair Value Disclosure [Member] Total Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of assets measured at fair value on a recurring basis Fair Value by Asset Class [Domain] Investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Summary of investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Asset Class [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value Inputs, Discount Rate Nonconvertible debt borrowing rate (as a percent) Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Measurement Frequency [Domain] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Recurring basis Total gains and losses included in gain on investments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Total gains and losses included in accumulated other comprehensive income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Cost basis of shares sold Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Fair Value of Financial Instruments, Policy [Policy Text Block] Fair value of financial instruments Financial Guarantee [Member] Convertible notes guarantee obligation Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2013 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2017 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Three 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Intangible assets cost Finite-Lived Intangible Assets [Line Items] Licenses and Patents Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Asset, Useful Life Estimated useful life Foreign Tax Authority [Member] Foreign Furniture and Fixtures [Member] Furniture and fixtures Gain (Loss) on Investments Gain on investments, net Realized gain on sale of common stock Recognized Gain (loss) on investments (Gain) loss on investments, net Gain (Loss) on Sale of Previously Unissued Stock by Subsidiary or Equity Investee, Nonoperating Income Gain on investment in Regulus Therapeutics Inc. Gain (loss) on change in ownership interest percentage Gain on investment in Regulus Therapeutics Inc. Gain (loss) from change in ownership percentage Gain (Loss) on Sale of Property Plant Equipment Gain from the sale of property, plant and equipment Realized gain on sale of common stock Gain on Sale of Investments Gains (Losses) on Extinguishment of Debt Loss on early retirement of debt Loss on redemption of debt Loss on early retirement of debt Early redemption premium Gains (Losses) on Extinguishment of Debt, before Write off of Deferred Debt Issuance Cost General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative General Business Tax Credit Carryforward [Member] Orphan Drug Credits Guarantor Obligations, Nature [Axis] Guarantor Obligations, Maximum Exposure, Undiscounted Principal plus accrued interest guaranteed on Regulus convertible notes Guarantor Obligations, Nature [Domain] Impairment of Intangible Assets, Finite-lived Write-off of patent costs to estimated net realizable values Non cash charges related to write-down of patent costs Charge Impairment of Long-Lived Assets Held-for-use Impairment charge Long-lived assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income tax benefit (expense) Pre tax loss Equity in net loss of Regulus Therapeutics Inc. Income (Loss) from Equity Method Investments Equity in net loss of Regulus Therapeutics Inc. Recognized losses in excess of net investment CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Discontinued operations Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Taxes Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid Income tax payments made to various taxing authorities Income Taxes Paid, Net Income taxes paid Income Taxes Receivable, Current Income tax receivable Income Tax Expense (Benefit), Continuing Operations [Abstract] Provision for taxes on earnings from continuing operations Reconciliation between income taxes on income from continuing operations and statutory U.S. taxes Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract] Income tax benefit (expense) Income tax benefit Income Tax Expense (Benefit) Income Tax Expense (Benefit), Intraperiod Tax Allocation Income tax benefit Income Tax, Policy [Policy Text Block] Income Taxes Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance Net change in valuation allowance Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate Statutory rate Income Tax Reconciliation, Noncontrolling Interest Income (Expense) Noncontrolling interest Income Tax Reconciliation, Other Adjustments Other Income Tax Reconciliation, State and Local Income Taxes State income tax net of federal benefit Income Tax Reconciliation, Tax Credits Tax credits Income Taxes Income Tax Uncertainties [Abstract] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Income Taxes Payable Income taxes payable Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Deferred Liabilities Deferred rent Increase (Decrease) in Deferred Revenue Deferred contract revenue Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Employee Related Liabilities Accrued compensation Increase (Decrease) in Other Operating Assets Other current and long-term assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Intangible Assets, Finite-Lived, Policy [Policy Text Block] Patents Interest Expense Interest expense Interest Paid Interest paid Interest payment Interest Payable Accrued interest payable on the notes Less: fixed and determinable interest Inventory, Policy [Policy Text Block] Inventory valuation Inventory, Raw Materials and Supplies, Net of Reserves [Abstract] Inventory valuation Inventory, Raw Materials, Net of Reserves Raw materials Inventories Investment Holdings [Line Items] Investments Cash, cash equivalents and short-term investments Investment Holdings [Table] Investment Income, Net Investment income Investment Income, Net, Amortization of Discount and Premium Amortization of premium on investments, net Investment Owned, at Fair Value Value of investments Shares owned Investment Owned, Balance, Shares Shares of Regulus owned Common stock owned Investments Investments by Secondary Categorization [Domain] Investments Classified by Contractual Maturity Date [Table Text Block] Summary of contract maturity of available-for-sale securities Investment Secondary Categorization [Axis] Investments, Fair Value Disclosure Estimated Fair Value, Investments Investment Type [Axis] Investment Type Categorization [Domain] Isis Pharmaceuticals Inc. Investor [Member] Issuance of Debt [Member] Loan agreement Item Effected [Line Items] Balance sheet impact of deconsolidation of Regulus as a result of adoption of new accounting standard Land Land Land Improvements [Member] Land improvements Land [Member] Land Operating Leases, Rent Expense Rent expense Leasehold Improvements [Member] Leasehold improvements Leases [Abstract] Leases of Lessee Disclosure [Text Block] Lease Agreements Leases, Operating [Abstract] Operating Leases Legal Matters and Contingencies [Text Block] Legal Proceedings Liabilities Total liabilities Total Liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Licensing Agreements [Member] Licenses Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases Maximum borrowing capacity for equipment purchases Line of Credit Facility, Increase, Additional Borrowings Additional principal amount drawn during the period Line of Credit Facility, Interest Rate at Period End Weighted average interest rate (as a percent) Loans Payable [Member] Equipment Financing Arrangement Long-term Debt and Capital Lease Obligations Total Long-Term Obligations Long-term Debt and Capital Lease Obligations [Abstract] Long-term obligations Long-term Debt and Capital Lease Obligations, Current Current portion of long-term obligations Less: current portion Less: current portion Long-term Debt, Fair Value Fair value of convertible notes Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge Period of interest rate swap Maximum [Member] Maximum Less than Minimum Minimum [Member] Net Cash Provided by (Used in) Continuing Operations Net decrease in cash and cash equivalents Net Cash Provided by (Used in) Discontinued Operations Cash and cash equivalents classified as assets from discontinued operations (in dollars) Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities: Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Regulus Therapeutics Inc. New Accounting Pronouncements or Change in Accounting Principle [Table] Noncontrolling Interest [Member] Noncontrolling interests in Regulus Nonoperating Income (Expense) [Abstract] Other income (expense): Notes Payable, Fair Value Disclosure Fair value of convertible notes Number of operating segments Number of Operating Segments Office Equipment [Member] Office Equipment Operating Expenses Total operating expenses Operating expenses Operating Expenses [Abstract] Expenses: Operating Income (Loss) Income (loss) from operations Income (loss) from operations Operating Leases, Future Minimum Payments Due Total minimum payments Operating Leases, Future Minimum Payments Due, Next Twelve Months 2013 Operating Leases, Future Minimum Payments, Due in Five Years 2017 Operating Leases, Future Minimum Payments, Due in Four Years 2016 Operating Leases, Future Minimum Payments, Due in Three Years 2015 Operating Leases, Future Minimum Payments, Due in Two Years 2014 Operating Leases, Future Minimum Payments, Due Thereafter Thereafter Operating Leases, Future Minimum Payments Receivable [Abstract] Annual future minimum payments under operating leases Operating Loss Carryforwards Net operating loss carryforwards Operating Loss Carryforwards [Line Items] Operating loss carryforwards Operating Loss Carryforwards [Table] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Basis of Presentation Other Assets, Current Other current assets Other comprehensive income before reclassifications, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax Income tax expense included in other comprehensive income Other Comprehensive Income (Loss), Available-for-sale Securities, before Reclassification Adjustments, Tax Net current period other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax Amounts reclassified from accumulated other comprehensive income Reclassification adjustment for realized gain on the sale of Sarepta shares included in net loss Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gains on securities, net of tax Change in unrealized gains (losses) Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized gains on available-for-sale securities, amount of tax recorded in other comprehensive income Tax benefit from other unrealized gains on securities Other Current Assets [Member] Other current assets Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities Other-Than-Temporary Impairment Loss Parent [Member] Isis Pharmaceuticals, Inc. Stockholders' Equity Patents [Member] Patents Payments to Acquire Available-for-sale Securities, Debt Purchases of short-term investments Payments to Acquire Interest in Joint Venture Equity ownership in VIE (as a percent) Payments to Acquire Land Held-for-use Purchase of land Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Pension and Other Postretirement Benefits Disclosure [Text Block] Employment Benefits Plan Name [Axis] Plan Name [Domain] Preferred Stock, Dividend Rate, Percentage Dividend rate (as a percent) Preferred Stock [Member] Preferred Stock Preferred Stock, Shares Authorized Preferred stock, shares authorized to issue Previous Accounting Guidance [Member] As Originally Reported Milestone payment received Proceeds from Collaborators Proceeds from Convertible Debt Proceeds from issuance of 2 3/4 percent convertible senior notes, net of issuance costs Proceeds raised net of issuance cost Proceeds from Issuance of Common Stock Proceeds from stock purchase by Genzyme Corporation, net of fees Equity investment in entity made by strategic alliance partner Net proceeds from transactions Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds from issuance of equity Net proceeds from transactions Proceeds from Sale and Maturity of Available-for-sale Securities Proceeds from the sale of short-term investments Proceeds from Sale of Land Held-for-use Proceeds from land sold to BioMed Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of property, plant and equipment Proceeds from Stock Options Exercised Cash received from exercise of stock options Products and Services [Axis] Products and Services [Domain] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Net loss Net income (loss) Property, Plant and Equipment [Abstract] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment Disclosure [Text Block] New Facility Property, Plant and Equipment [Line Items] Property, plant and equipment Property, Plant and Equipment, Net Property, plant and equipment, net Book value of facility and associated parcel of land Property, Plant and Equipment, Policy [Policy Text Block] Property, plant and equipment Property, Plant and Equipment [Table Text Block] Schedule of property, plant and equipment estimated useful life Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Useful Life Estimated useful life Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Quarterly Financial Data (Unaudited) Range [Axis] Range [Domain] Receivables, Long-term Contracts or Programs Contracts receivable Contract receivable (in dollars) Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Summary the gross amounts of unrecognized tax benefits Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Principal payments on debt and capital lease obligations Repayments of Subordinated Debt Principal and premium payment on redemption of the 2 5/8 percent convertible subordinated notes Amount of debt redeemed including accrued interest Counterparty Name [Domain] Research and Development Expense Research and development Research and Development Expense [Abstract] Research and development expenses Research and Development Expense [Member] Research and development Research and Development Expense, Policy [Policy Text Block] Research and development expenses Research Tax Credit Carryforward [Member] Research and development Restatement Adjustment [Member] Effect of Change Restricted Stock Units (RSUs) [Member] Restricted stock units RSUs Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated deficit Revenue Recognition, Milestone Method, Revenue Recognized Milestone payment recognized Milestone payment received and recognized in revenue Milestone payment earned Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block] Research and development revenue under collaborative agreements Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Revenues Total revenue Revenue Revenue from research and development under agreement and licensing and royalty revenue Revenue earned Revenues [Abstract] Revenue: Concentration of Business Risk Sale of Stock, Consideration Received Per Transaction Amount raised by investee through stock financing Amount raised through stock financing Issuance of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Equity ownership after other investments (as a percent) Sale of Stock, Percentage of Ownership after Transaction Sales Revenue, Goods, Net [Member] Revenue Scenario, Actual [Member] As Adjusted Forecast Scenario, Forecast [Member] Scenario, Unspecified [Domain] Summary of changes in other accumulated other comprehensive income (loss) related to unrealized gains and losses on securities Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of provision for income taxes on income from continuing operations Schedule of Comprehensive Income (Loss) [Table Text Block] Summarizes changes in other accumulated other comprehensive income (loss) related to unrealized gains and losses on securities Schedule of Long-term Debt Instruments [Table Text Block] Schedule of long-term obligations Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of significant components of deferred tax assets and liabilities Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation between effective tax rate on income from continuing operations and the statutory tax rate Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Equity Method Investee, Name [Axis] Schedule of Equity Method Investments [Line Items] Equity method of accounting Basis of presentation Schedule of Equity Method Investments [Table] Schedule of Expected Amortization Expense [Table Text Block] Schedule of estimated amortization expense related to intangible assets Schedule of Finite-Lived Intangible Assets [Table] Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of future minimum payments under operating leases Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Summary of balance sheet impact of deconsolidation of Regulus as a result of adoption of new accounting standard Schedule of Property, Plant and Equipment [Table] Schedule of Quarterly Financial Information [Table Text Block] Schedule of quarterly data Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] (Deprecated 2012-01-31) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Summary of the RSU activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions used for valuation of ESPP Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions used for valuation of stock options Schedule of Stock by Class [Table] Schedule of Temporary Impairment Losses, Investments [Table Text Block] Schedule of investments temporarily impaired Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of revenue from significant partners Segment Reporting [Abstract] Segment information Segment Reporting Disclosure [Text Block] Concentration of Business Risk Segment information Segment Reporting, Policy [Policy Text Block] Senior Notes [Member] 2 3/4 percent convertible senior notes Series A Preferred Stock [Member] Series A preferred stock Series B Preferred Stock [Member] Series B Share-based Compensation Share-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Cancelled/forfeited (in shares) Cancelled/forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value (in dollars per share) Granted (in dollars per share) Non-vested at the beginning of the period (in shares) Non-vested at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Non-vested at the beginning of the period (in dollars per share) Non-vested at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average grant date fair value (in dollars per share) Weighted Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted-average assumptions Dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Volatility (as a percent) Award Activity Stock Option Plans Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Percentage of employee compensation, maximum Annual increase in reserve of common shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Number of shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at the end of the period (in shares) Options exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Cancelled/forfeited/expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of options outstanding (in shares) Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Percentage of fair market value as a purchase price Award Type [Domain] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cancelled/forfeited/expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based compensation expense Shares, Issued Balance (in shares) Balance (in shares) Short-term Investments [Abstract] Short-term investments Significant Accounting Policies [Text Block] Significant Accounting Policies State and Local Jurisdiction [Member] California Class of Stock [Axis] Equity Components [Axis] Statement [Line Items] Statement CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CONDENSED CONSOLIDATED BALANCE SHEETS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Scenario [Axis] Statement [Table] Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Stockholders' Equity Balance Balance Total Stockholders' Equity Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stockholders' Equity, Period Increase (Decrease) Stockholders' Equity, Policy [Policy Text Block] Comprehensive loss Stock Issued During Period, Shares, New Issues Equity investment in entity made by strategic alliance partner (in shares) Issuance of common ctock (in shares) Stock Issued During Period, Shares, Period Increase (Decrease) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Shares issued for stock option exercises and ESPP purchases Stock Issued During Period, Shares, Share-based Compensation, Gross Options exercised and employee stock purchase plan issuances (in shares) Options exercises and employee stock purchase plan issuances (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock to Genzyme Stock Issued During Period, Value, Share-based Compensation, Gross Options exercised and employee stock purchase plan issuances Stock Option [Member] Stock Option Activity Stock options Subsequent Event [Line Items] Subsequent Events Subsequent Event Subsequent Event [Member] Subsequent Events Subsequent Events [Text Block] Subsequent Events Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Sale of stock by equity method investee Subsidiary or Equity Method Investee [Line Items] Cash, cash equivalents and short-term investments Share price of common stock issued by investee (in dollars per share) Subsidiary or Equity Method Investee, Price-Per-Share Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Summary of Income Tax Contingencies [Table Text Block] Summary of the gross amounts of unrecognized tax benefits Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information: Tax Credit Carryforward, Amount Tax credit carryforwards Tax Credit Carryforward [Axis] Tax Credit Carryforward [Line Items] Tax credit carryforwards Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward [Table] Title of Individual with Relationship to Entity [Domain] Type of Adoption [Domain] Type of Arrangement and Non-arrangement Transactions [Axis] Unrealized Gain (Loss) on Investments Unrealized gains on investments Unrealized Gain (Loss) on Investments [Table Text Block] Summary of investments Unrecognized Tax Benefits Beginning balance of unrecognized tax benefits Ending balance of unrecognized tax benefits Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions Decrease for prior period tax positions Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions Increase for current period tax positions Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions Increase for prior period tax positions Use of Estimates, Policy [Policy Text Block] Use of estimates US Government Agencies Debt Securities [Member] Debt securities issued by U.S. government agencies US States and Political Subdivisions Debt Securities [Member] Debt securities issued by states of the United States and political subdivisions of the states US Treasury Securities [Member] Debt securities issued by the U.S. Treasury Carrying value of investments in variable interest entities Variable Interest Entity, Nonconsolidated, Carrying Amount, Assets Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract] Consolidation of variable interest entities Weighted Average Number of Shares Outstanding, Diluted Shares used in computing diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic Shares used in computing basic net loss per share (in shares) Write off of Deferred Debt Issuance Cost Write-off of unamortized debt discount and debt issuance cost Amendment Description Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity [Domain] Entity Filer Category Entity Public Float Entity Registrant Name Entity Voluntary Filers Entity Well-known Seasoned Issuer Legal Entity [Axis] Investment Issuer [Axis] Investment Issuer [Domain] Investments Investment [Text Block] Abbott Molecular Inc [Member] Abbott Molecular Inc. AMI Represents the information pertaining to Abbott Molecular Inc. Accounts Receivable Significant Partner One [Member] Significant Partner 1 Represents significant partner 1 for which the entity discloses the concentration of accounts receivable. Accounts Receivable Significant Partners [Member] Represents the significant partners for which the entity discloses the concentration of accounts receivable. Significant Partners Accounts Receivable, Significant Partner Two [Member] Significant Partner 2 Represents significant partner 2 for which the entity discloses the concentration of accounts receivable. Accumulated Other Comprehensive Income (Loss) Net of Tax [Roll Forward] Summary of changes in accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss) Disclosure of accounting policy for accumulated other comprehensive income (loss). Accumulated Other Comprehensive Income (Loss) [Policy Text Block] Achaogen Inc [Member] Achaogen, Inc. Represents the information pertaining to Achaogen, Inc. Achievement of Milestone [Axis] Information by categories of milestones achieved. Different categories of achievement of milestones. Achievement of Milestone [Domain] Additional Drugs Excluding Antisense Drug Targeting HTT Protein [Member] Represents additional drugs excluding an antisense drug targeting the HTT protein. Additional drugs Adjustments to Additional Paid in Capital Tax Effect from Share Based Compensation Expected Expected increase in shareholders' equity when deferred tax assets on non-qualified stock options and incentive stock options are ultimately realized Represents the excess tax benefits associated with any equity-based compensation plan that is expected to increase the stockholders' equity when the benefits are realized. Alnylam Represents activity related to Alnylam Pharmaceuticals, Inc.. Alnylam [Member] Amortization of Debt Discount Premium One Amortization of 2 5/8 percent convertible subordinated notes discount Amount of noncash expense included in interest expense to amortize debt discount and premium associated with debt instrument one. Amortization of Debt Discount Premium, Two Amortization of 2 3/4 percent convertible subordinated notes discount Amount of noncash expense included in interest expense to amortize debt discount and premium associated with debt instrument two. Amortization of Financing Costs, Period Debt issuance costs, amortization period Represents the amortization period for financing costs. Amortization of licenses Amortization of Licenses The aggregate expense that is charged against the earnings to allocate the cost of licenses in a systematic and rational manner to the periods expected to benefit from such asset. Amortization of Long Term Financing Liability for Leased Facility Amortization of long-term financing liability for leased facility Represents the amount of noncash expense to amortize long-term financing liability for leased facility. Amortization of patents Amortization of Patents The aggregate expense that is charged against the earnings to allocate the cost of patents in a systematic and rational manner to the periods expected to benefit from such asset. Amount of payments receivable Amount of Eligible Milestone Payment Receivable Represents the total milestone payments receivable by the collaborative partners under the collaborative and licensing agreement. Antisense Drug Targeting HTT Protein [Member] Represents an antisense drug targeting the HTT protein. Drug targeting HTT protein Represents the information pertaining to Antisense Therapeutics Limited. Antisense Therapeutics Limited [Member] Antisense Therapeutics Limited Assumed Change in Estimated Selling Price of Product Assumed change in estimated selling price of ISIS-STAT3 (as a percent) Represents the percentage change in the selling price of a product assumed for sensitivity analysis. Astra Zeneca [Member] AstraZeneca Represents information pertaining to AstraZeneca. Atlantic Pharmaceuticals Limited [Member] Atlantic Pharmaceuticals Limited, formerly Atlantic Healthcare (UK) Limited Represents the information pertaining to Atlantic Pharmaceuticals Limited, formerly Atlantic Healthcare (UK) Limited. After one year but within two years (as a percent) The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date. Available For Sale Securities, Debt Maturities, after One Through Two Years, Percentage Available For Sale Securities, Debt Maturities, after Two Through Three Years, Percentage After two years but within three years (as a percent) The percentage of available-for-sale debt securities that mature beyond two years but within three years of the balance sheet date. Available For Sale Securities, Debt Maturities, Total Percentage Total (as a percent) The aggregate percentage of all available-for-sale debt securities, regardless of maturity. Available For Sale Securities, Debt Maturities, within One Year, Percentage One year or less (as a percent) The percentage of available-for-sale debt securities that mature within one year of the balance sheet date. Available For Sale Securities, Debt Maturities within Two Years Percentage Percentage of available-for-sale securities with a maturity of less than two years The percentage of available-for-sale debt securities that mature within two years of the balance sheet date. Average Duration to Completion Completion period Represents the completion period. Average Maximum Milestone Payment Receivable Per Program Average maximum milestone payments receivable per program Represents the average maximum amount of milestone payments receivable per program under the collaborative and licensing agreement. Biogen Idec [Member] Biogen Idec Represents information pertaining to Biogen Idec. BioMed Realty, L.P. Represents details pertaining to BioMed Realty, L.P. with whom the entity has entered into a lease agreement. BioMed Realty [Member] Board of Director Stock Options: Stock options awarded to the Board of Directors as a form of incentive compensation. Board of Director Stock Option [Member] Bristol Myers Squibb [Member] Bristol-Myers Squibb Represents the information pertaining to Bristol-Myers Squibb. 2000 Broad Based Equity Incentive Plan Represents the 2000 Broad-Based Equity Incentive Plan in which non-qualified stock options are issued to the entity's employees, directors and consultants. Broad Based Equity Incentive Plan 2000 [Member] Capitalized Costs and Financing Liability Element represents the amount of costs capitalized and the financing liability associated with a leased facility. Capitalized costs and financing liability associated with leased facility Long-term obligations, less current portion Long-term financing obligation related to the purchase of land which was subsequently sold back to the lessor, who constructed the company's primary research and development facility. Since the company has the option to purchase the facility, including the land, the company has continuing involvement in the land which requires the company to account for the purchase and sale of the land as a financing transaction. Capital Lease and Other Long Term Borrowings, Non Current Cash, Cash Equivalents and Short Term Investments [Policy Text Block] Disclosure of accounting policy for cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities. Cash, cash equivalents and short-term investments Cash Flow Impact upon Adoption of New Accounting Standard Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of new accounting standard. Change in Amount of Revenue from Product for Assumed Change in Selling Price Amount by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price Represents the amount of change in the revenue recognized from a product that would result from the change in the selling price of the product assumed for sensitivity analysis. CHDI Foundation Inc [Member] CHDI Foundation, Inc. Represents the information pertaining to CHDI Foundation, Inc. Represents information pertaining to certain clinical and regulatory events on the basis of which certain milestones are achieved. Clinical and regulatory milestones Clinical and Regulatory Milestones [Member] Clinical, Regulatory and Sales Milestones [Member] Clinical, regulatory and sales milestones Represents information pertaining to certain clinical, regulatory and sales events on the basis of which certain milestones are achieved. Cold Spring Harbor Laboratory [Member] Cold Spring Harbor Laboratory Represents the information pertaining to Cold Spring Harbor Laboratory. Represents the number of drugs to be developed and commercialized under the collaboration agreement, for which milestone payments would be received. Number of drugs to be developed and commercialized Collaboration Agreement, Number of Drugs to be Developed and Commercialized Collaboration Agreement, Number of Drugs Under License Option Number of drugs collaborative partner may license under the separate research program Represents the number of drugs the collaborative partner has the option to license under a collaboration agreement. Collaboration Agreement, Number of Programs Under Which Drugs are to be Developed and Commercialized Represents the number of programs under which drugs are to be developed under the collaborative and licensing agreement. Number of programs under which drugs are to be developed Agreement entered into in August 2003 Information pertaining to collaborative arrangements entered into by the entity in August 2003. Collaborative Arrangement August 2003 [Member] Collaborative Arrangement December 2012 [Member] Agreement entered into in December 2012 Represents information pertaining to the collaborative arrangements entered into by the entity in December 2012. Collaborative Arrangement Earn Out Payments, Percentage of Cumulative Net Sales Represents earn out payments to be received as consideration for the sale of a subsidiary or equity investee, as a percentage of the cumulative net sales of the former subsidiary or equity investee. Earn out payments receivable as a percentage of cumulative net sales of sold subsidiary Collaborative Arrangement, Financing Raised Amount raised by collaborative partner Represents the amount raised in an equity offering by the collaborative partner. Collaborative Arrangement January 2005 [Member] Agreement entered into in January 2005 Information pertaining to collaborative arrangements entered into by the entity in January 2005. Collaborative Arrangement January 2012 [Member] Information pertaining to collaborative arrangements entered into by the entity in January 2012. Agreement entered into in January 2012 Collaborative Arrangement June 2012 [Member] Agreement entered into in June 2012 Information pertaining to collaborative arrangements entered into by the entity in June 2012. Collaborative Arrangement, Maximum Period for Purchase of Rights by Collaborator upon Acquisition Period following an acquisition within which collaborator may purchase rights to receive payments Represents the period within which the collaborator may purchase all of the entity's rights to receive payments under the agreement, in the event the entity is the subject of an acquisition. Collaborative Arrangement, Payments Received Throughout Arrangement Cumulative payments earned under collaborative arrangement at period end Cumulative amount of payments received under the collaborative arrangement as of the end of the reporting period. Represents the entity's percentage share of total milestone payments receivable by the collaborative partners under the collaborative arrangement, for milestone payments up to $370 million. Collaborative Arrangement, Percentage Share of Milestone Payments for Milestone Payments up to 370 Million Collaborative arrangement percentage share of milestone payments for milestone payments up to $370 million Collaborative Arrangement, Period Strategic Partner will Not Acquire Additional Entity Common Stock without Entity Consent Period for which additional shares of Isis common stock will not be purchased without consent Represents the period following the agreement date for which the strategic partner to a collaborative arrangement has agreed to not acquire additional shares of the entity's common stock without the entity's consent, unless the partner's ownership in the entity's common stock falls beneath a specified percentage. Collaborative Arrangement, Revenue Recognized Throughout Sublicensing Arrangement Cumulative amount of licensing revenue recognized under a collaborative arrangement as of the end of the reporting period. Cumulative licensing revenue recognized under collaborative arrangement Collaborative Arrangements and Licensing Agreements Represents the number of phase studies required to be completed until the entity has the option to license the product. Number of phase studies required to be completed for revocation of option to license Collaborative Arrangements Option to License Product Phase Studies Completion Number Stock received as part of collaborative arrangement (in shares) Collaborative Arrangement, Stock Received The amount of stock received as part of the collaborative arrangement. Collaborative Arrangement Threshold Cumulative Net Sales Cumulative net sales, threshold for earnout payments Represents the level of cumulative net sales of a former subsidiary or equity investee used to determine earn out payments to be received. Represents the information pertaining to certain commercialized events on the basis of which certain milestones are achieved. Commercialization milestones Commercialization Milestones [Member] Construction Facility by Type [Axis] Information pertaining to different types of long-lived physical assets related to the construction facility. Construction Facility, Gross Cost of new facility Gross amount, at the balance sheet date, of long-lived physical assets related to the construction of a new facility. Construction Facility [Line Items] New facility Table of long-lived, physical assets related to the construction facility. Construction Facility [Table] Construction Facility Type [Domain] Listing of long-lived physical assets related to the construction facility. Cumulative Net Sales, Tier One [Member] Cumulative net sales from $140 million to $2.1 billion Represents the scenario in which cumulative net sales are over $140 million and up to $2.1 billion. Cumulative Net Sales, Tier Two [Member] Cumulative net sales over $2.1 billion Represents the scenario in which cumulative net sales are over $2.1 billion. Debt Instrument, Additional Redemption Price Per Principal Amount Represents the ratio of the additional redemption price to principal amount of the debt instrument. Ratio of additional redemption price of debt instrument to principal amount Debt Instrument Conversion Obligation, Common Stock Closing Sales Price, Number of Trading Days Within 30 consecutive trading days, number of days with closing price of the entity's common stock at least 130% of the conversion price to trigger the conversion option Within a period of 30 consecutive trading days, the minimum number of trading days with a closing price of the entity's common stock in excess of a specified percentage of the conversion price upon which the conversion option is triggered. Debt Instrument, Conversion Obligation, Conversion Price Percentage Closing price of the entity's common stock as percentage of the conversion price, used as threshold for conversion eligibility conditions The entity's last reported sale price of common stock as a percentage of the conversion price that is used as a threshold for conversion eligibility. Debt Instrument, Conversion Obligation, Number of Consecutive Trading Days Number of consecutive trading days during which a closing price of the entity's common stock of at least 130% of the conversion price for at least 20 days triggers the conversion option Represents the number of consecutive trading days during which the closing price of the entity's common stock at or above a specified percentage of the conversion price for at least 20 days triggers the debt instrument to be convertible. Debt Instrument Maturity Period Maturity period Represents the maturity period of the debt instrument. The periods over which the redemption price is in effect. Debt Instrument, Redemption Period [Axis] February 15, 2012 and February 14, 2013 Debt Instrument, Redemption Period between February 152012 and February 142013 [Member] The period between February 15, 2012 and February 14, 2013. February 15, 2013 and February 14, 2014 Debt Instrument, Redemption Period between February 152013 and February 142014 [Member] The period between February 15, 2013 and February 14, 2014. The period between February 15, 2014 and thereafter. February 15, 2014 and thereafter Debt Instrument, Redemption Period between February 152014 and Thereafter [Member] Debt Instrument, Redemption Period [Domain] The period over which the redemption price is in effect. Debt Instrument Redemption Period on or after July 01 2019 [Member] On or after July 1, 2019 The period on or after July 1, 2019. On or after October 5, 2016 The period on or after October 5, 2016. Debt Instrument Redemption Period on or after October 05 2016 [Member] Debt Instrument, Term Debt discount, amortization period Represents the expected term of the debt instrument, which is the period that any debt discount will be amortized. Debt maturities of more than one year This item represents debt securities with an expected maturity of more than one year from the balance sheet date. Debt Securities Maturities More than One Year [Member] Debt maturities of one year or less This item represents debt securities with an expected maturity of one year or less from the balance sheet date. Debt Securities Maturities One Year or Less [Member] Net deferred tax asset Represents the amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. Deferred Tax Assets (Liabilities) before Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment and Goodwill and Intangible Assets The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of capital assets and intangible assets and the basis of capital assets and intangible assets computed in accordance with generally accepted accounting principles. Intangible and capital assets The limit of annual employee contributions to the plan per calendar year by eligible employees who are over 50 years of age. Defined Contribution Plan, Employee Contribution Limit by Plan Participants over Fifty Years Age Employee contribution limit per calendar year for employees over 50 years of age Employee contribution limit per calendar year for employees under 50 years of age The limit of annual employee contributions to the plan per calendar year by eligible employees who are under 50 years of age. Defined Contribution Plan, Employee Contribution Limit by Plan Participants under Fifty Years Age Deposits and other assets Deposits and Other Assets, Noncurrent Primarily includes carrying amount of debt issuance costs and noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Development and Regulatory Milestones [Member] Development and regulatory milestones Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Development milestones Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Development Milestones [Member] Development, Regulatory and Commercial Milestones [Member] Development, regulatory and commercial milestones Represents information pertaining to certain development, regulatory and commercial events on the basis of which certain milestones are achieved. Document and Entity Information Drug Using Proprietary Brain Shuttle Technology [Member] Represents a drug using Roche's proprietary brain shuttle technology. Drug using Roche's proprietary brain shuttle technology Economic Entity [Axis] Economic entities which constitute neither defined legal entities nor reportable segments of the reporting entity. Economic Entity [Domain] The grouping representing facts about an entire economic entity. Effective Income Tax Rate Reconciliation, Deferred Tax Deferred tax true-up (as a percent) The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to deferred tax. Effective Income Tax Rate Reconciliation Gain (Loss) on Sale of Previously Unissued Stock by Subsidiary or Equity Investee Nonoperating Income Gain on investment in Regulus Therapeutics Inc. (as a percent) The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to profit or loss on sales of previously unissued stock by subsidiaries or equity investees made to investors outside the consolidated group that is not reported as operating income. Effective Income Tax Rate Reconciliation, Intraperiod Tax Allocation Intraperiod tax allocation (as a percent) The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to intraperiod tax allocation. The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate that can be explained by net operating loss carryforwards expired during the period. Expired NOL's (as a percent) Effective Income Tax Rate Reconciliation, Net Operating Loss, Carryforwards Expired Employee [Member] Employees Person hired to provide services to a company on a regular basis in exchange for compensation. Entity Stock Ownership Percentage for Strategic Partner to Acquire Additional Entity Common Stock without Entity Consent, Less Than Ownership percentage of Isis stock below which strategic partner may acquire additional shares without prior consent The threshold percentage ownership of the entity's common stock held by a strategic partner below which the strategic partner may acquire additional shares of the entity's common stock without the entity's consent before the end of the specified period during which such acquisitions are otherwise prohibited. Equipment and computer software Represents the tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services and a set of computer instructions, aggregating into, for example, an application program, control module or operating system, that perform one or more particular functions or tasks. Equipment and Computer Software [Member] Equity and Liability Components Debt Instruments [Abstract] Summary of equity and liability components of the 2 3/4 percent and 2 5/8 percent notes Represents the stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards, which the entity's Board of Directors adopted, and the stockholders subsequently approved. Equity Incentive Plan 2011 [Member] 2011 Equity Incentive Plan Equity Investment Gross Fair Value Represents the gross fair value of the equity investment in a company with which the entity conducts business. Gross fair value of investment Equity Investment in Subsidiary Sold, Sale Price Sale price of interest owned in subsidiary Represents the sale price of the equity investment in subsidiary sold during the period. Equity Investments Other than Equity Method, Ownership Percentage Equity investments not classified as equity method, ownership percentage The ownership percentage represented by the entity's equity investments in companies with which it conducts business and which are not accounted for under the equity method of accounting. Ownership percentage Ownership percentage in equity investments Ownership interest percentage Ratio of common shares received to preferred shares previously held Equity Method Investment, Stock Conversion Ratio Represents the ratio of common stock shares received in a conversion to preferred stock shares previously held in an equity method investee. Income tax benefit (expense) The amount of other income tax benefit (expense) reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information, Income Tax (Benefit) Expense Equity Method Investment Summarized Financial Information Income Tax Expense Benefit Income tax benefit (expense) The amount of income tax expense (benefit) reported by an equity method investment of the entity. The amount of net assets reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information, Net Assets Net assets The amount of non-cash stock-based compensation expenses included in operating expense which is reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information, Non Cash Stock Based Compensation Expenses Non-cash stock-based compensation expenses included in operating expense Equity Method Investment Summarized Financial Information Operating Expenses Operating expenses The amount of operating expenses reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information Operating Income Loss Loss from operations The amount of operating income (loss) reported by an equity method investment of the entity. The amount of other expenses reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information Other Expenses Other expense Equity Method Investment Summarized Financial Information, Other Income (Expense) Other income (expense) The amount of other income (expense) reported by an equity method investment of the entity. Estimated maximum potential future payments Estimated Maximum Potential Future Payments under Lease Agreement Excaliard Pharmaceuticals Inc [Member] Excaliard Pharmaceuticals, Inc. Represents the information pertaining to Excaliard Pharmaceuticals, Inc. Eyetech Pharmaceuticals Inc [Member] Eyetech Pharmaceuticals, Inc. Represents the information pertaining to Eyetech Pharmaceuticals, Inc. Fair Value Assets, Transfer Between Level 1 and Level 2 Amount Amount of transfer between Level 1 and Level 2 investments Represents the amount of transfers of assets measured at fair value on a recurring basis between Level 1 and Level 2 of the fair value hierarchy. Fair Value Inputs Lack of Marketability Discount Lack of marketability discount Represents the adjustment to fair value for lack of ability to convert business interests into cash quickly. Genzyme Corporation [Member] Genzyme Corporation Represents the information related to Genzyme Corporation. Glaxo Smith Kline Represents the information related to GlaxoSmithKline. Glaxo Smith Kline [Member] GSK Guarantee Obligation, Number of Convertible Notes Previously Guaranteed Number of convertible notes no longer guaranteed Represents the number of convertible notes issued by the investee and previously but no longer guaranteed by the entity. iCo Therapeutics Inc [Member] iCo Therapeutics Inc. Represents the information pertaining to iCo Therapeutics Inc. Idera Pharmaceuticals Inc [Member] Idera Pharmaceuticals, Inc., formerly Hybridon, Inc. Represents the information pertaining to Idera Pharmaceuticals, Inc., formerly Hybridon, Inc. Non-cash losses related to patents, licensing and property, plant and equipment Income (Losses) Related to Patents and Property, Plant and Equipment The non cash losses that are related to patents, capitalized in-licensing cost and property, plant and equipment. Represents the entity's proportionate share of the cumulative net loss of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied, which has not been recognized due to such losses exceeding the principal plus accrued interest guaranteed by the entity. Suspended net losses Income (Loss) from Equity Method Investments, Suspended Income Tax Reconciliation, Deferred Tax Deferred tax true-up The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred tax. Income Tax Reconciliation Gain (Loss) on Sale of Previously Unissued Stock by Subsidiary or Equity Investee Nonoperating Income Gain on investment in Regulus Therapeutics Inc. The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to gain (loss) on sale of previously unissued stock by subsidiary or equity investee. Income Tax Reconciliation Intraperiod Tax Allocation Intraperiod tax allocation The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to intraperiod tax allocation. Expired NOL's The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to net operating loss carryforwards expired during the period. Income Tax Reconciliation, Net Operating Loss Carryforwards Expired Contracts receivable The net change during the reporting period in the amount to be collected from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. Increase (Decrease) in Contracts Receivable, Net Initial Development Costs Contributed to Collaborative Arrangement Initial development cost contributed Represents the initial amount contributed by the entity for development costs under the collaborative arrangement. Initial Term of Lease Represents the initial term of the lease under the lease agreement. Initial term of lease Interest Rate Swap Period Interest rate swap period, used to calculate interest Represents the period of the interest rate swap agreement. Investments Equity, Investments Other than Equity Method [Abstract] Ownership interests in private and public companies Represents the net total realized and unrealized gain (loss) for contingent payments included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity. Isis Stat 3 [Member] ISIS-STAT3 Represents the ISIS-STAT3 product. Isis Ttr [Member] ISIS-TTR Represents the ISIS-TTR product. Laboratory and office space Represents laboratory and office space under lease agreements. Laboratory and Office Space [Member] Operating lease - adjacent building for laboratory, office space and manufacturing support Represents the facility under operating lease, used for laboratory and office space and to support manufacturing activities. Laboratory Office and Manufacturing Support Facility [Member] Land Purchase Amount Represents the purchase price of land acquired. Purchase price of land, BioMed Operating Leases Leased Assets [Line Items] Represents the number of extension options under the lease agreement. Lease, Option to Extend, Number Operating lease agreement, number of times it may be extended for facility expire in 2031 Lease period under lease extension for new facility expiring in 2031 Number of lease extension options Lease period under lease extension for facility expire in 2031 Represents the period of the extension options under the lease agreement. Lease, Option to Extend, Period Period of lease extension options Leases and Other Obligations [Member] Leases and other obligations Details pertaining to leases and other obligations not separately disclosed in the financial statements. Leases, Number of Buildings Number of buildings in Carlsbad, California Represents the number of buildings leased and occupied by the entity. Legal Proceedings Lease agreements - Operating and other Lessee Leased Assets [Line Items] License Fee Received and Amortization Completed During the Period Represents the license fee received for which the amortization was completed during the period. License fee for which amortization was completed during the period License fee received Represents the amount of license fee received during the period and subject to amortization over the performance obligation period. License Fee Received and Amortized Licenses, net Licenses, Net Net carrying amount as of the balance sheet date of certain rights acquired to practice particular intellectual rights on an exclusive basis and which is deemed to have a finite economic life. Licensing and royalty revenue Licensing and Royalty Revenue Revenue from arrangements that include licensing and royalty revenues, profit sharing and/or earn out payments. Licensing revenue represents revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements typically include, but are not limited to, rights to use intellectual property on an exclusive or non-exclusive basis. Royalty, profit sharing and/or earn out payments are derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's intellectual property. Draw down period Represents the draw down period of the debt instrument. Loan Agreement, Draw Down Period Represents the current and noncurrent portions of the aggregate liability for long-term debt instruments and other borrowing or financing arrangements. Long Term Debt and Other Total Long-term debt Long Term Debt and Other, Noncurrent Represents the noncurrent portion of the aggregate liability for long-term debt instruments and other borrowing or financing arrangements. Total Long-Term Obligations Long-term obligations excluding long-term financing liability for leased facility Represents the aggregate of all debt instruments of the entity, including capital leases and other financing arrangements, excluding the long-term financing liability for a leased facility. Long Term Debt and Other Obligations Excluding Financing Liability for Leased Facility [Member] Redemption price as a percentage of principal The percentage of principal amount used in the computation of the redemption price at which the entity may redeem its convertible debt instruments. Long Term Debt, Redemption Price as Percentage of Principal Amount Long Term Financing Liability for Leased Facility [Member] Long-term financing liability for leased research and development facility Represents the information pertaining to long-term financing liability for leased facility. Long Term Financing Obligation Long-term financing liability for leased facility Long-term financing obligation related to the purchase of land which was subsequently sold back to the lessor, who constructed the company's primary research and development facility. Since the company has the option to purchase the facility, including the land, the company has continuing involvement in the land which requires the company to account for the purchase and sale of the land as a financing transaction. Represents tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services for manufacturing purpose. Manufacturing Equipment [Member] Manufacturing equipment Manufacturing Suites for Drug Development [Member] Operating lease - manufacturing suites for drug development business Represents the facility under operating lease, which houses manufacturing suites for the entity's drug development business. Represents manufacturing suites under lease agreements. Manufacturing Suites [Member] Manufacturing suites Maximum Amount of Milestone Payment Payable Represents the maximum amount of milestone payments payable under the collaborative and licensing agreement. Maximum amount of milestone payments payable under strategic alliance Maximum amount of milestone payments payable per drug under strategic alliance Represents the maximum amount of milestone payments payable per drug under the collaborative and licensing agreement. Maximum Amount of Milestone Payment Payable Per Drug Amount of payments receivable Maximum amount of payments receivable Maximum Amount of Payment Receivable Represents the maximum amount of pre-specified payments receivable under the collaborative and licensing agreement. Maximum Amount of Payment Receivable in Next Two Years Maximum amount of payments receivable over next two years Represents the maximum amount of pre-specified payments receivable under the collaborative and licensing agreement within the next two years. Represents the maximum amount of payments receivable per drug under the collaborative and licensing agreement. Maximum amount of payments receivable per drug under strategic alliance Maximum Amount of Payment Receivable Per Drug Maximum Number of Programs under Strategic Alliance Maximum number of programs under strategic alliance Represents the maximum number of programs covered under collaborative and licensing agreement. Represents the number of milestones payments. Milestones Payments, Number Number of milestones payments Minimum Annual Net Revenues to Earn Next Milestone Payments Minimum annual net revenues to earn next milestone payment Represents the minimum annual amount of net revenues that serves as one potential trigger to earn the next milestone payment. Represents information pertaining to the new development candidate phase of the arrangement. IND-enabling toxicology study New Development Candidate [Member] New development candidate Amounts accrued for capital and patent expenditures Non-cash Capital and Patent Expenditures Future cash outflow to pay for purchases of fixed assets and patents that have occurred. 2002 Nonemployee Directors Stock Option Plan Represents the 2002 Non-Employee Directors Stock Option Plan, which provided for the issuance of stock options to the entity's non-employee directors for the purchase of common stock. Nonemployee Directors Stock Option Plan 2002 [Member] Number of Buildings Number of buildings occupied Represents the number of buildings the entity occupies. Number of categories of milestone events Represents the number of categories of milestone events. Number of Categories of Milestone Events Represents the number of independent products required to achieve pre-specified milestone events in order to receive substantive milestone payments. Number of independent products required to achieve pre-specified milestone events Number of Independent Products Achievement of Pre Specified Milestone Events as Condition to Receive Substantive Milestone Payments Number of privately-held companies in which the entity has an equity ownership interest of less than 20% Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method. Number of Privately Held Companies in which Entity has Equity Investment Number of Programs Under Strategic Alliance Not Accelerated Number of programs under strategic alliance, not accelerated Represents the number of programs covered under the collaborative and licensing agreement which were not subject to accelerated development plans under an amendment to the agreement. Number of publicly-held companies in which the entity has an equity ownership interest of less than 20% Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for as available-for-sale securities. Number of Publicly Held Companies in which Entity has Equity Investment Number of publicly-held companies in which the entity has an equity interest Represents the number of significant partners. Number of significant partners Number of Significant Partners Number of stages of life-cycle of drugs Represents the number of stages of life-cycle of drugs. Number of Stages of Life Cycle of Drugs Number of collaborations Represents the number of strategic collaborations entered into during the period with the collaborative partner. Number of collaborative agreements Number of Strategic Collaborations Number of targets Represents the number of targets for the research and development of drugs under a collaborative agreement. Number of Targets for Collaborative Agreement OncoGenex Represents the information related to OncoGenex. OncoGenex [Member] Operating Leases Obligations, Initial Lease Period Initial lease period under the lease with BioMed Represents the initial lease period of the operating lease agreement. Other Equipment [Member] Other equipment Represents other tangible personal property used to produce goods and services, not separately identified. Patent, Clinical and Regulatory Milestones [Member] Patent, clinical and regulatory milestones Represents information pertaining to certain patent, clinical and regulatory events on the basis of which certain milestones are achieved. Patents, net Patents, Net Gross carrying amount, less accumulated amortization and any impairment charges, of the costs pertaining to the exclusive legal rights granted to the owner of a patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply for and receive patent rights, or to acquire such rights. Payment Following First Commercial Sale The payment receivable by the entity following the first commercial sale of the product in the event the collaborative partner is subject to a change of control. Payment following first commercial sale of product if change in control of collaborative partner Payment Received in Form of Securities, Value Payment received in form of securities Represents the amount of consideration recognized during the period in the form of equity. Acquisition of licenses and other assets, net Payments to Acquire Licenses and Other Assets The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy. Investment in Regulus Therapeutics Inc. Payments to Acquire Previously Unissued Stock Sold by Subsidiary or Equity Investee The cash outflow associated with the purchase of previously unissued stock sold by subsidiaries or equity investees. Purchase of common stock at offering price Percentage Change in Amount of Revenue from Product for Assumed Change in Selling Price Percentage by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price Represents the percentage change in the revenue recognized from a product that would result from the change in the selling price of the product assumed for sensitivity analysis. Represents the percentage limit on state income tax liability offset with research and development tax credit carryforwards as per the tax regulations. Percentage Limit of State Income Tax Liability, Offset with Research and Development Tax Credit Carryforward California income tax liability offset with research and development tax credit carryforwards, percentage limitation Percentage Share of Payment Receivable by Investee Percentage share of payments receivable by investee Represents the entity's share of potential future payments receivable by an investee under a collaborative agreement. Period for Obtaining Regulatory Approval Time to obtain approval Represents the typical period within which approval is obtained once regulatory filings have been prepared and submitted. Time to prepare and submit regulatory filings Represents the typical period within which regulatory filings are prepared and submitted. Period for Preparing and Submitting Filings Phase One [Member] Phase 1 Represents the information pertaining to phase 1 of the arrangement. Information by phases of arrangements. Phases of Arrangements [Axis] Phases of Arrangements [Domain] Different phases of arrangements. Phase Three [Member] Phase 3 Represents the information pertaining to phase 3 of the arrangement. Phase 2/3 Represents information pertaining to phase 2/3 of the arrangement. Phase Two by Three [Member] Represents the information pertaining to phase 2 of the arrangement. Phase Two [Member] Phase 2 Prelicensing Milestones [Member] Represents information pertaining to certain pre-licensing events on the basis of which certain milestones are achieved. Pre-licensing milestones Premium Received and Amortization Completed During the Period Premium for which amortization was completed during the period Represents the premium received for which the amortization was completed during the period. Pre Specified Events [Member] Pre-specified events Represents information pertaining to certain pre-specified events on the basis of which certain milestones are achieved. Prespecified Sales Threshold Example Example of sales threshold as milestone event Represents an example of a sales threshold that could be used as a pre-specified event to trigger a milestone payment. Proceeds from Equipment Financing Arrangement Proceeds from equipment financing arrangement The cash inflow from a loan agreement to finance the purchase of equipment. The cash inflow associated with the sale of equity investments in privately- and publicly-held biotechnology companies. Proceeds from the Sale of Strategic Investments Proceeds from sale of strategic investments Profit Share as Percentage of Commercial Sales Profit share as percentage of commercial sales Share of profits receivable under the agreement, as a percentage of all commercial sales of the collaborative product. Property, Plant and Equipment Gross, Excluding Land Property, plant and equipment, gross Gross amount, at the balance sheet date, of long-lived physical assets excluding land used in the normal conduct of business and not intended for resale. This can include buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Tangible assets excluding land that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Property, Plant and Equipment Net, Excluding Land Property plant and equipment excluding land, net Represents a next prospective milestone payment. Next prospective milestone Prospective Milestone Payment Purchases of Strategic Investments Purchases of strategic investments The cash outflow associated with the purchase of equity investments in privately and publicly-held biotechnology companies. Quarterly Results Disclosure [Abstract] Quarterly financial data RBS Asset Finance Inc [Member] RBS Asset Finance, Inc Represents the information pertaining to RBS Asset Finance, Inc. Represents the period within which payment is receivable by the entity following the first commercial sale of the product in the event the collaborative partner is subject to a change of control. Receivable Period for Payment Following First Commercial Sale Period due for payment following first commercial sale of product Regulatory Milestones [Member] Regulatory milestones Represents the information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Regulus Therapeutics [Member] Regulus Regulus Therapeutics Inc. Represents the information related to Regulus Therapeutics Inc. Regulus Therapeutics Reimbursement Payments to Collaborators Expense reimbursement paid Represents the cash outflow for payments made to the collaborative partner for the reimbursement of expenses under the collaborative arrangement. Remaining Payment Following First Commercial Sale The remaining payment receivable by the entity following the first commercial sale of the product in the event the collaborative partner is subject to a change of control. Remaining payment following first commercial sale of product The number of reporting segments previously reported by the entity. Number of reporting segments prior to 2011 Reporting Segments, Previous Number Research and development revenue under collaborative agreements Research and Development Revenue under Collaborative Agreements Revenue recognized during the period from collaborations where the entity receives payments for expenditures relating to research and development activities, contractual milestone payments, and the manufacture and sale of drug inventory to collaboration partners. Revenue recognized Represents the research facility which will be leased upon completion of construction. Research Facility [Member] Research facility Partner A Represents partner A for which the entity discloses the concentration of revenue. Revenue from Partner A [Member] Partner B Represents partner B for which the entity discloses the concentration of revenue. Revenue from Partner B [Member] Revenue from Partner C [Member] Partner C Represents partner C for which the entity discloses the concentration of revenue. Revenue Percentage of Entity Percent of total revenue Represents the percentage of total revenue of the entity. Revenue Recognition, Licensing and Royalty Fees [Policy Text Block] Disclosure of accounting policy for revenue recognition for licensing fees, which is consideration paid to the entity (licensor) by another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, or trademark. Also includes the disclosure of accounting policy for revenue recognition for royalty fees, which is consideration or a share of the proceeds paid by another party to the owner of a right (that is, the entity) for its use. Licensing and royalty revenue Revenue Recognition Milestone Method, Revenue Recognized Per Milestone Payment The amount of consideration recognized during the period for each milestone payment received. Amount recognized per milestone payment Revenue Recognition, Multi-deliverable Arrangement, Number of Units of Accounting Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement. Number of units of accounting Roche [Member] Roche Represents information pertaining to Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd. Roche Molecular Systems [Member] Roche Molecular Systems Represents the information pertaining to Roche Molecular Systems. Royalties as percentage of sales Represents royalties to be received as a percentage of sales. Royalties as Percentage of Sales Royalty Due Period from First Commercial Sale Royalty due period from first commercial sale Represents the period for royalties receivable by the entity on a country by country basis following the first commercial sale in the relevant country. Percentage of equity investee's stock owned by an investor (other than the entity) after stock transaction. Sale of Stock, Percentage of Investor Ownership after Transaction Equity ownership by other investor (as a percent) Ownership interest percentage Sanofi Sanofi Aventis [Member] Represents the information related to Sanofi-aventis ("Sanofi"). Sarepta [Member] Sarepta Represents information related to Sarepta. Sarepta Therapeutics, Inc [Member] Sarepta Therapeutics, Inc. Information pertaining to Sarepta Therapeutics, Inc., formerly AVI BioPharma, Inc., formerly Ercole Biotech, Inc. Schedule of Equity and Liability Components Debt Instruments [Table Text Block] Summary of equity and liability components of debt instruments Tabular disclosure of equity and liability components of debt instruments at the end of the period. Schedule of Equity Method Investment Income Statement and Balance Sheet Disclosures [Table Text Block] Summary of financial information and balance sheet for Regulus Tabular disclosure of income statement and balance sheet information reported by an equity method investment of the entity. Schedule of Future Minimum Rental Payments for Leases and New Facility [Table Text Block] Schedule of annual future minimum payments under leases and new facility Tabular disclosure of future minimum payments, as of the latest balance sheet date, in the aggregate and for each of the five succeeding fiscal years for operating leases, capital leases and the new facility having initial or remaining noncancelable lease terms in excess of one year. Schedule of Leased Assets [Table] Schedule of long-lived, depreciable assets that are subject to lease agreements and are used in the normal conduct of business to produce goods and services. Schedule of Lessee Leased Assets [Table] Schedule of long-lived, depreciable assets that are subject to a lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Schedule of Maturities of Long Term Debt and Other Obligations [Table Text Block] Schedule of annual debt and other obligation maturities, including fixed and determinable interest Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings and other obligations for each of the five years following the date of the latest balance sheet date presented. Schedule of Property Plant and Equipment Components [Table Text Block] Tabular disclosure of the components of property, plant and equipment. Schedule of property, plant and equipment at cost Schedule of summarized financial information of equity method investee, assets and liabilities Tabular disclosure of the summarized balance sheet information of an equity method investment of the entity. Schedule of Summarized Financial Information of Equity Method Investee, Assets and Liabilities [Table Text Block] Schedule of summarized financial information of equity method investee, net loss Tabular disclosure of the summarized income statement information of an equity method investment of the entity. Schedule of Summarized Financial Information of Equity Method Investee, Net Income (Loss) [Table Text Block] Securities Amortized Cost, Basis Amortized Cost, Investments This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. For equity investments accounted for under the cost method, represents the aggregate carrying amount included in the balance sheet. The annual vesting percentage for a share-based award. Annual vesting percentage Share Based Compensation Arrangement by Share Based Payment Award, Award Annual Vesting Percentage Share Based Compensation Arrangement by Share Based Payment Award, Award Expiration Date Award term The period of time an equity-based award is valid as specified in the award agreement. Share Based Compensation Arrangement by Share Based Payment Award, Minimum Holding Period Minimum holding period of purchased stock Represents the minimum holding period of purchased stock under the plan. Weighted-average fair value of options exercised (in dollars per share) The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology. Share Based Compensation Arrangement by Share Based Payment Award, Options Exercises in Period Weighted Average Fair Value Share Based Compensation Arrangement by Share Based Payment Award, Options Outstanding and Exercisable Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding and Exercisable Weighted Average Remaining Contractual Term [Abstract] Average Remaining Contractual Term Share Based Compensation Arrangement by Share Based Payment Award, Purchase Period Duration Period for purchase of common stock Represents the period for purchase of common stock under the plan. Share Based Compensation Expense, Attributable to Noncontrolling Interest Non-cash compensation expense related to stock options included in equity in net loss of Regulus Therapeutics Inc. The amount of stock-based compensation expense attributable to the noncontrolling interest during the period, net of related tax effect, per each share of the common stock or unit outstanding during the reporting period. The amount of stock-based compensation expense derived from continuing operations during the period, net of related tax effect, per share of common stock or unit outstanding during the reporting period. Share Based Compensation Expense from Continuing Operations Non-cash compensation expense related to stock options included in continuing operations Non-cash compensation benefit related to stock options included in discontinued operations The amount of stock-based compensation expense derived from discontinued operations during the period, net of related tax effect, per share of common stock or unit outstanding during the reporting period. Share Based Compensation Expense from Discontinued Operations Exercise price (in dollars per share) Share Based Compensation Shares Issued Exercise Price Range The range of exercise prices for shares issued under an employee stock purchase plan. Significant Equity Investment Investment in Regulus Therapeutics Inc. Represents an equity investment in a company with which the entity conducts business and is a significant shareholder. Stock Based Compensation Expense, Net Income (Loss) Attributable to Noncontrolling Interest Per Share Net loss per share related to stock options included in equity in net loss of Regulus Therapeutics Inc. (in dollars per share) The amount of net income (loss) arising out of the stock-based compensation expense attributable to the noncontrolling interest during the period, net of related tax effect, per share of common stock or unit outstanding during the reporting period. The amount of net income (loss) arising out of the stock-based compensation expense derived from continuing operations during the period, net of related tax effect, per share of common stock or unit outstanding during the reporting period. Stock Based Compensation Expense, Net Income (Loss) from Continuing Operations Per Share Net loss per share included in continuing operations (in dollars per share) Stock Based Compensation Expense, Net Income (Loss) from Discontinued Operations Per Share Net income per share included in discontinued operations (in dollars per share) The amount of net income (loss) arising out of the stock-based compensation expense derived from discontinued operations during the period, net of related tax effect, per share of common stock or unit outstanding during the reporting period. Stock Based Compensation Expense, Net Income (Loss) Per Share Total (in dollars per share) The amount of net income (loss) arising out of the stock-based compensation expense, net of related tax effect, per share of common stock or unit outstanding during the reporting period. Basic and diluted stock-based compensation expense, per share: Stock Based Compensation Expense Per Share [Abstract] Warrants exercised (in shares) Stock Issued During Period, Shares, Warrants Exercised The number of shares of stock issued during the period pursuant to the exercise of warrants. Warrants exercised The value of stock issued pursuant to the exercise of warrants during the period. Stock Issued During Period, Value, Warrants Exercised Stock Option Plan 1989 after Grant Date One [Member] Represents options granted under the 1989 Stock Option Plan after May 26, 2004, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants. 1989 Stock Option Plan - Options Granted After May 26, 2004 Stock Option Plan 1989 before Grant Date One [Member] Represents options granted under the 1989 Stock Option Plan before May 26, 2004, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants. 1989 Stock Option Plan - Options Granted Before May 26, 2004 Represents the 1989 Stock Option Plan, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants. Stock Option Plan 1989 [Member] 1989 Stock Option Plan Represents the amount of technology access fees received. Technology access fee Technology Access Fee, Received University of Massachusetts [Member] University of Massachusetts Represents the information pertaining to University of Massachusetts. Represents the increase (decrease) in deferred tax assets due to unrecognized tax benefits. Unrecognized Tax Benefits Increase (Decrease) in Deferred Tax Asset Net effect on the deferred tax assets resulting from unrecognized tax benefits Represents the amount of upfront fees received and receivable under the terms of the collaborative and licensing agreement. Upfront and near-term payments Up Front Fee Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement. Up Front Fee Received Upfront fee received Upfront fee received by investee Upfront Fee Received by Investee Represents the amount of upfront fees received by the investee during the period under the terms of the collaborative and licensing agreement. Represents the amount of upfront fees received during the period in the form of equity securities. Upfront fee in the form of equity securities Upfront Fee Received in Form of Equity Securities, Value Variable Interest Entity, Not Primary Beneficiary, Number of Entities Number of variable interest entities in which the entity is not primary beneficiary Number of Variable Interest Entities (VIE) or potential VIEs in which the entity is not a primary beneficiary. Represents the information pertaining to Verva Pharmaceuticals Ltd. Verva Pharmaceuticals Ltd [Member] Verva Pharmaceuticals Ltd. Warrants [Abstract] Warrants Xenon Pharmaceuticals Inc [Member] Xenon Pharmaceuticals Inc. Represents the information pertaining to Xenon Pharmaceuticals Inc. Phases Prior to Phase Two Proof of Concept [Member] Up to Phase 2 proof-of-concept Represents information pertaining to the phases of the arrangement up to phase 2 proof-of-concept. EX-101.PRE 10 isis-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 11 isis-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 7) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Allocation of stock-based compensation expense    
Stock-based compensation expense $ 2,869,000 $ 2,267,000
Non-vested stock option
   
Allocation of stock-based compensation expense    
Unrecognized estimated non-cash stock-based compensation expense 10,700,000  
Weighted average period over which cost is expected to be recognized 1 year 4 months 24 days  
RSUs
   
Allocation of stock-based compensation expense    
Unrecognized estimated non-cash stock-based compensation expense 3,800,000  
Weighted average period over which cost is expected to be recognized 2 years 1 month 6 days  
Research and development
   
Allocation of stock-based compensation expense    
Stock-based compensation expense 2,546,000 1,935,000
General and administrative
   
Allocation of stock-based compensation expense    
Stock-based compensation expense $ 323,000 $ 332,000
XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments
3 Months Ended
Mar. 31, 2013
Investments  
Investments

3.                                      Investments

 

As of March 31, 2013, we have primarily invested our excess cash in debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard & Poor’s (S&P) or Fitch, respectively.  We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

 

The following table summarizes the contract maturity of the available-for-sale securities we held as of March 31, 2013:

 

One year or less

 

47

%

After one year but within two years

 

41

%

After two years but within three years

 

12

%

Total

 

100

%

 

As illustrated above, we primarily invest our excess cash in short-term instruments with 88 percent of our available-for-sale securities having a maturity of less than two years.

 

At March 31, 2013, we had an ownership interest of less than 20 percent in each of three private companies and three public companies with which we conduct business.  The privately-held companies are Santaris Pharma A/S (formerly Pantheco A/S), Achaogen Inc., and Atlantic Pharmaceuticals Limited.  The publicly-traded companies are Antisense Therapeutics Limited, iCo Therapeutics Inc., and Regulus. We account for equity investments in the privately-held companies under the cost method of accounting and we account for equity investments in the publicly-traded companies at fair value. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. In the first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics, Inc. that we owned resulting in a realized gain of $1.1 million.

 

The following is a summary of our investments (in thousands):

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

March 31, 2013

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

97,983

 

$

59

 

$

(29

)

$

 

$

98,013

 

Debt securities issued by U.S. government agencies

 

9,932

 

1

 

(46

)

 

9,887

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

15,549

 

55

 

(11

)

 

15,593

 

Total securities with a maturity of one year or less

 

124,464

 

116

 

(86

)

 

124,494

 

Corporate debt securities

 

107,131

 

110

 

(156

)

 

107,085

 

Debt securities issued by U.S. government agencies

 

15,020

 

35

 

(3

)

 

15,052

 

Debt securities issued by the U.S. Treasury

 

12,393

 

30

 

 

 

12,423

 

Debt securities issued by states of the United States and political subdivisions of the states

 

5,203

 

7

 

(3

)

 

5,207

 

Total securities with a maturity of more than one year

 

139,747

 

182

 

(162

)

 

139,767

 

Subtotal

 

$

264,211

 

$

298

 

$

(248

)

$

 

$

264,261

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

March  31, 2013

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,525

 

$

29,338

 

$

 

$

 

$

44,863

 

Current portion (included in Other current assets)

 

1,538

 

1,961

 

 

(880

)

2,619

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,688

 

$

31,299

 

$

 

$

(880

)

$

48,107

 

 

 

$

281,899

 

$

31,597

 

$

(248

)

$

(880

)

$

312,368

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

113,249

 

$

81

 

$

(9

)

$

 

$

113,321

 

Debt securities issued by U.S. government agencies

 

10,100

 

2

 

(66

)

 

10,036

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

16,560

 

18

 

(2

)

 

16,576

 

Total securities with a maturity of one year or less

 

140,909

 

102

 

(77

)

 

140,934

 

Corporate debt securities

 

80,166

 

112

 

(92

)

 

80,186

 

Debt securities issued by U.S. government agencies

 

8,034

 

38

 

 

 

8,072

 

Debt securities issued by the U.S. Treasury

 

12,424

 

27

 

 

 

12,451

 

Debt securities issued by states of the United States and political subdivisions of the states

 

8,306

 

31

 

(16

)

 

8,321

 

Total securities with a maturity of more than one year

 

108,930

 

208

 

(108

)

 

109,030

 

Subtotal

 

$

249,839

 

$

310

 

$

(185

)

$

 

$

249,964

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,526

 

$

18,096

 

$

 

$

 

$

33,622

 

Current portion (included in Other current assets)

 

1,579

 

4,175

 

 

(880

)

4,874

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,730

 

$

22,271

 

$

 

$

(880

)

$

39,121

 

 

 

$

267,569

 

$

22,581

 

$

(185

)

$

(880

)

$

289,085

 

 

Investments we considered to be temporarily impaired at March 31, 2013 were as follows (in thousands):

 

 

 

 

 

Less than 12 months of
temporary impairment

 

 

 

Number of
Investments

 

Estimated
Fair Value

 

Unrealized
Losses

 

Corporate debt securities

 

70

 

$

95,606

 

$

(185

)

Debt securities issued by U.S. government agencies

 

4

 

13,885

 

(49

)

Debt securities issued by states of the United States and political subdivisions of the states

 

3

 

4,537

 

(14

)

Total temporarily impaired securities

 

77

 

$

114,028

 

$

(248

)

 

We believe that the decline in value of these securities is temporary and primarily related to the change in market interest rates since purchase.  We believe it is more likely than not that we will be able to hold these securities to maturity.  Therefore we anticipate full recovery of their amortized cost basis at maturity.

 

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-O;&QA8F]R871I=F5?07)R86YG96UE M;G1S7V%N9#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93$\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=? M4&]L:6-I93,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I938\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/D-O;F-E;G1R871I;VY?;V9?0G5S:6YE#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;&QA8F]R871I=F5?07)R86YG96UE;G1S7V%N9#$\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T M&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2`P,BP@,C`Q,SQB2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!&:6QE3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^3&%R9V4@06-C96QE2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D+"`Q,#(L-CDU+#(P,"!A;F0@ M,3`Q+#0X,2PQ,S0@3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#0S.3QS<&%N/CPO'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E*3H\ M+W-T"!B96YE9FET("AE>'!E;G-E*3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S"!B96YE9FET("AE>'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D M(&=A:6YS(&]N('-E8W5R:71I97,L(&YE="!O9B!T87@\+W1D/@T*("`@("`@ M("`\=&0@8VQAF5D(&=A:6X@;VX@=&AE('-A;&4@;V8@ M4V%R97!T82!S:&%R97,@:6YC;'5D960@:6X@;F5T(&QO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2`H=7-E9"!I;BD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T* M("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN.R<^/&(^/&9O;G0@ MF4],T0R/C$N/"]F M;VYT/CPO8CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@ M1D].5"U325I%.B`S<'0[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^/"]B/B`\8CX\9F]N="!S M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R<@ M6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/E1H92!U;F%U9&ET960@:6YT97)I;2!C M;VYD96YS960@8V]N2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!O=7(@9FEN86YC:6%L('!O M65A2!O=VYE9"!S=6)S:61I87)Y+"8C,38P M.U-Y;7!H;VYY($=E;DES:7,L)B,Q-C`[26YC+BP@=VAI8V@@:7,@8W5R'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^ M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CLG/@T*/'`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`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N M-S5I;CL@5$585"U)3D1%3E0Z("TP+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R<@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/E=E(&=E;F5R86QL>2!R96-O9VYI>F4@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW M-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQI/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R<@2!C;VYT86EN M(&UU;'1I<&QE(&5L96UE;G1S+"!O6%L=&EE2!M965T M('1H92!C2!A2!V96YD;W(@ M;W(@=&AE(&-U2!E=FED96YC92!O9B!S96QL:6YG('!R:6-E M.R!A;F0@*&EI:2DF(S$V,#MB97-T(&5S=&EM871E(&]F('-E;&QI;F<@<')I M8V4L(&]R($)%4U`N(%1H92!"15-0(')E9FQE8W1S(&]UF4@ M=&AE(')E=F5N=64@2!O=F5R(&]U&-H M86YG92P@=V4@9W)A;G1E9"!!&-L=7-I=F4@;&EC M96YS92!T;R!D979E;&]P(&%N9"!C;VUM97)C:6%L:7IE($E325,M4U1!5#,\ M+V9O;G0^/&9O;G0@F4],T0Q/E)X/"]F;VYT/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C,38P M.V%N9"!)4TE3+4%:,3PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#8N-7!T.R!03U-)5$E/3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#LG('-I>F4],T0R/F%N9"!)3D0M96YA8FQI;F<@F4],T0Q/E)X/"]F M;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R M/BX@07-T2!A;F0@8V]M;65R M8VEA;&EZ871I;VX@86-T:79I=&EE6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[ M(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXN($EN(&%D9&ET:6]N+"!I9B!!&5R8VES97,@:71S M(&]P=&EO;B!F;W(@86YY(&1R=6=S(')EF%T:6]N M(')E6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW M-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O M;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.SPO9F]N=#X@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/ M4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N M=#X@/&9O;G0@F4Z(#$P<'0[ M)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!D979E M;&]P;65N="!S97)V:6-EF4],T0Q/E)X/"]F;VYT M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CL\ M+V9O;G0^/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/ M4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF M(S$V,#MA;F0@=&AE(')E6QE/3-$)T9/3E0M M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S M:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[)R!S:7IE/3-$,CX[(&%N9#PO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C(U M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$ M,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!O<'1I;VX@=&\@;&EC M96YS92!U<"!T;R!T:')E92!D6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R M96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V,#ML:6-E M;G-E(&AA9"!S=&%N9"UA;&]N92!V86QU92!B96-A=7-E(&ET(&ES(&%N(&5X M8VQU6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE4 M24]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V M,#MI2!C M;W5L9"!C;VYD=6-T(&-L:6YI8V%L('1R:6%L6QE/3-$)T9/3E0M4TE:13H@ M-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$ M,3Y2>#PO9F]N=#X@/&9O;G0@6QE/3-$)T9/3E0M4TE: M13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`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`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X@ M/&9O;G0@F4],T0Q/E)X/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CYL:6-E;G-E(&%N9"!R96QA=&5D(')EF4@&5R8VES M97,@=&AE(')EF4@6UE M;G0@=&AA="!W87,@9FEX960@86YD(&1E=&5R;6EN86)L92!W:&5N('=E(&5N M=&5R960@:6YT;R!T:&4@86=R965M96YT+B8C,38P.R!4:&5R92!W87,@8V]N M6%L='D@<&%Y;65N=',L('!A>6UE;G1S(&9O6QE/3-$)T9/3E0M4TE:13H@ M-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$ M,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXF(S$V,#MB>2!U2!M971H;V0N(%5N9&5R('1H:7,@;65T:&]D+"!W92!E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT M('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#LG('-I>F4],T0R/D5S=&EM871E9"!R;WEA;'1I97,@;VX@9G5T=7)E('!R M;V1U8W0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF M;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S M.SPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4] M,T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@6UE;G1S.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C(U:6X[)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O M;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#LG('-I>F4],T0R/D5X<&5N6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@F4Z(#$P<'0[)R!S M:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%N(&%P<')O<')I M871E(&1I6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I M;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/E=E(&5S=&EM871E9"!T:&4@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)T9/ M3E0M4TE:13H@,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@ M+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@6UE;G0@:6X@ M1&5C96UB97(F(S$V,#LR,#$R(&9OF4] M,T0Q/E)X)B,Q-C`[/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CYL:6-E;G-E+"!W92!D971EF4],T0Q/E)X M)B,Q-C`[/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M)R!S:7IE/3-$,CYL:6-E;G-E('=O=6QD(&-H86YG92!B>2!A<'!R;WAI;6%T M96QY('-E=F5N('!E6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)' M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE7!I8V%L;'DL('=E(&UU'1E;F1E9"!P M97)I;V0@;V8@<&5R9F]R;6%N8V4N)B,Q-C`[(%1H92!R979E;G5E('=E(')E M8V]G;FEZ92!C;W5L9"!B92!M871E6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/D9R;VT@=&EM92!T;R!T:6UE+"!W92!M87D@96YT97(@:6YT;R!S97!A M2!S:&]U;&0@8F4@ M86-C;W5N=&5D(&9O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`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`^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@ M,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C(U:6X[)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O M;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#LG('-I>F4],T0R/D1E2!T86ME(#$R('1O(#$X(&UO;G1H6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@65A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4 M+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@ M/&9O;G0@6QE M/3-$)T9/3E0M4TE:13H@,W!T.R<@65A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW M-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5. M5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E)E9W5L M871O2!I;F-L M=61E('1H92!F;VQL;W=I;F<@='EP97,@;V8@979E;G1S.CPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$58 M5"U)3D1%3E0Z("TP+C(U:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C(U M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$ M,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D9I;&EN9R!O9B!R96=U;&%T M;W)Y(&%P<&QI8V%T:6]NF%T:6]N($%P<&QI M8V%T:6]N+"!O2!F:6QI;F=S+CPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z M("TP+C(U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!S M:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DUA2!A9V5N8WDN/"]F;VYT/CPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@ M+3`N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/D-O;6UEF%T:6]N(&UI;&5S=&]N97,@:6X@ M;W5R('!A6QE/3-$ M)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN M.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@&ES=',@870@=&AE(&EN8V5P=&EO;B!O9B!O=7(@86=R965M96YT M6UE;G0N)B,Q-C`[($9OF%T:6]N M(&UI;&5S=&]N97,@87)E('-U8G-T86YT:79E+B!&;W(@97AA;7!L92P@9F]R M(&]U2P@=V4@<')O=FED92!O;BUG;VEN9R!A8V-E M6QA;2!0:&%R;6%C975T:6-A M;',L)B,Q-C`[26YC+B!T;R!D979E;&]P(&%N9"!C;VUM97)C:6%L:7IE(%). M02!I;G1E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@ M+3`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`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@ M+3`N,C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/DEF(&%N>2!O9B!T:&5S92!C;VYD:71I;VYS(&%R92!N M;W0@;65T+"!W92!W:6QL(&1E9F5R(')E8V]G;FET:6]N(&]F('1H92!M:6QE MF4],T0Q/E)X/"]F;VYT/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BP@=&AE(&9I M6UE;G0@9G)O;2!'96YZ>6UE(&%N9"!T:&4@)#6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!4 M15A4+4E.1$5.5#H@+3`N,C5I;CLG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R<@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/E=E(&]F=&5N(&5N=&5R(&EN=&\@86=R965M96YT2!P871E;G0@6%L=&EE2!A2!T:&5M(&%T(&9A:7(@ M;6%R:V5T('9A;'5E(&)AF5D(&=A:6YS(&%N9"!L;W-S M97,@87,@82!S97!A2!I;G9E2UH96QD(&)I;W1E8VAN;VQO9WD@8V]M M<&%N:65S('1H870@=V4@:&%V92!R96-E:79E9"!A2!L:6-E;G-E(&]R(&-O;&QA8F]R871I;VX@86=R965M96YT+B8C M,38P.R!!="!-87)C:"8C,38P.S,Q+"`R,#$S('=E(&AE;&0@;W=N97)S:&EP M(&EN=&5R97-T2UH96QD(&-O;7!A;FEE2P@;F5A2!A;F0@;W5R(&-U6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P M+C5I;CLG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!H879E(&%L=&5R;F%T:79E(&9U='5R92!U2!R87<@;6%T97)I86P@8V]S=',@9F]R M(&1R=6=S('1H870@=V4@;6%N=69A8W1U2!S:6YG;&4@9')U9RX@1F]R(&5X86UP;&4L(&EF(&]N92!O9B!O=7(@9')U M9W,@9F%I;&5D+"!W92!C;W5L9"!U2!P97)I;V1I M8V%L;'D@86YD(')E9'5C92!T:&4@8V%RF%B;&4@=F%L=64L(&EN8VQU9&EN9R!S:&5L9B!L:69E(&]F(')A=R!M M871E2!I;G9E;G1OF4] M,T0R/E!A=&5N=',\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&-A M<&ET86QI>F4@8V]S=',@8V]N2!O9B!O=71S M:61E(&QE9V%L(&-OF5D('!A M=&5N="!C;W-T2!I;F-L M=61E(&-O6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P M+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&5V86QU871E M(&QO;F2!B87-I2!N;W0@8F4@86)L92!T;R!R96-O=F5R('1H M92!C87)R>6EN9R!A;6]U;G0@;V8@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S-7!T.R<^/&(^/&9O;G0@F4],T0R/D5Q=6ET>2!M971H M;V0@;V8@86-C;W5N=&EN9SPO9F]N=#X\+V(^/"]P/@T*/'`@F4] M,T0R/E5S92!O9B!E6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/E1H92!PF4],T0R M/D)AF4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I M>F4],T0R/C(\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4] M,T0R/B\\+V9O;G0^/&9O;G0@F4],T0Q/C0\+V9O M;G0^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[ M(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^/&9O;G0@6QE M/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/ M4TE424]..B!R96QA=&EV93L@5$]0.B`M,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE4 M24]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3XX/"]F;VYT/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C,38P M.W!E6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@&]3;6ET:$ML:6YE(&-O;G9E6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR M-6EN.R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T M.R<@F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\ M+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#LG('-I>F4],T0R/E)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU M:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(')E9&5E;65D(&%L M;"!O9B!O=7(@,CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#8N M-7!T.R!03U-)5$E/3CH@F4],T0Q M/C4\+V9O;G0^/&9O;G0@F4],T0Q/C4\+V9O;G0^/&9O;G0@2!N;W1EF4],T0R/D-O;G-O;&ED871I M;VX@;V8@=F%R:6%B;&4@:6YT97)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/E=E(&ED96YT:69Y(&5N=&ET:65S(&%S('9A2!I;G9E"!E;G1I=&EE2!O9B!T M:&5S92!E;G1I=&EE2!R96QA=&5D M('1O(&]U6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SX\ M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R<@F5D(&=A:6YS(&%N9"!L;W-S97,@;VX@&5S+#PO9F]N=#X@/&9O;G0@2!R96%L:7IE9"!G86EN6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/F-O;F1E;G-E9"!C;VYS;VQI M9&%T960@F5S(&-H86YG97,@:6X@86-C=6UU;&%T M960@;W1H97(@8V]M<')E:&5N6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P M.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[34%21TE. M+4Q%1E0Z(#`N-6EN.R!724142#H@.#8N-C8E.R!"3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#@V)2!B;W)D97(],T0P/@T*#0H\='(@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E(&-O;'-P86X],T0U M/@T*/'`@6QE/3-$<&%D9&EN9SHP M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O M;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C8L-#8W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,S!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@ M6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C4L,S`T/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145& M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\ M+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN M.R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4 M.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN8VQU9&5D M(&EN(&<\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/F]N(&]U6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S M-7!T.R<^/&(^/&9O;G0@F4],T0R/D-O;G9E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S M-7!T.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)V9O M;G0MF4],T0R/B8C,38T.SPO9F]N=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#8N-7!T.R!03U-)5$E/3CH@6QE/3-$ M)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`M M,W!T.R<@F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V-#L\+V9O;G0^/&9O;G0@F4],T0Q/C@\+V9O;G0^/&9O;G0@FEN9R!T:&4@9&5B="!D M:7-C;W5N="!O=F5R('1H92!L:69E(&]F('1H97-E(#(F(S$Y,#L@<&5R8V5N M="!N;W1E2!A;F0@1&5V96QO<&UE;G0@;W!E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE2!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,L(')E65E(%-T;V-K(%!U2!E>'!E8W0@ M=&\@=F5S="!A'!E8W0@=&AE;2!T;R!B M92!O=71S=&%N9&EN9RXF(S$V,#L@5V4@97-T:6UA=&4@=&AE(&5X<&5C=&5D M('1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A M;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B M;&4@6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4 M.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0Q/E1H6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T9/3E0M M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P,3(\+V9O;G0^/"]B/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$<&%D9&EN9SHP.SX- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1I M=FED96YD('EI96QD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/E9O;&%T:6QI='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T'!E8W1E9"!L:69E/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@F4],T0R/D534%`Z/"]F;VYT/CPO:3X\+W`^ M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P M/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M-05)'24XM3$5& M5#H@,"XU:6X[(%=)1%1(.B`X-BXV-B4[($)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C`N,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T6QE M/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C8@;6]N=&AS/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D2!O=F5R(&$@9F]U6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/E1H6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4 M+5-)6D4Z(#AP=#LG('-I>F4],T0Q/CQB6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/E)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$ M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(L-30V/"]F;VYT/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@'0@ M,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G M8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C(L.#8Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU M:6X[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE'!E;G-E(')E;&%T M960@=&\@;F]N+79EF%T:6]N('!E M65A65A28C M,38P.S$L(#(P,3,N($%S('1H:7,@9W5I9&%N8V4@3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA3I4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E. M1$5.5#H@+3`N-6EN.R<^/&(^/&9O;G0@F4],T0R/C,N/"]F;VYT/CPO8CX\8CX\9F]N="!S='EL M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`S<'0[)R!S:7IE M/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#L\+V9O;G0^/"]B/B`\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@ M8F]L9#L@1D].5"U325I%.B`Q,'!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN.R<^)B,Q-C`[/"]P/@T* M/'`@2!R979I97<@86YD(&UO9&EF>2!T:&5S M92!G=6ED96QI;F5S('1O(&UA>&EM:7IE('1R96YD2!A M;F0@;&EQ=6ED:71Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@F5S('1H92!C;VYT2!O9B!T:&4@879A:6QA8FQE+69O M6QE/3-$)W1E M>'0M86QI9VXZ;&5F=#M-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`V,RXS M-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C0W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^ M/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1% M3E0Z("TQ,'!T.R<^/&9O;G0@65A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/D%F=&5R('1W;R!Y96%R6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3@E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$R/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE65A6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S M-2XS<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE2!086YT:&5C;R!!+U,I+"!!8VAA;V=E;B!);F,N+"!A;F0@071L86YT M:6,@4&AA2UT2!I;G9E6QE/3-$)W1E M>'0M86QI9VXZ;&5F=#M724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S93LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Q,#`E(&)O6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0U/@T* M/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M5T5) M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0Q/D5S=&EM871E9#PO9F]N=#X\+V(^/"]P M/CPO=&0^#0H\=&0@6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,S8N-24[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,S8E/@T*/'`@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-) M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0Q/DUA6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4 M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0Q/DQO6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/E-H;W)T+71E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/ M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@ M,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN M.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B@R.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/CDX+#`Q,SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/CDL.#@W/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z M("TQ,'!T.R<^/&9O;G0@2!T:&4@52Y3+B!43PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$L,#`Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@ M2!S=&%T97,@;V8@=&AE(%5N:71E9"8C,38P.U-T871E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&(&-O M;'-P86X],T0R/@T*/'`@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B@Q,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P M86X],T0R/@T*/'`@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$ M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE2!O9B!O;F4@>65A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS M<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C$R-"PT.30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$Q,#PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q-38\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-# M145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^ M/&9O;G0@2!5+E,N(&=O=F5R;FUE;G0@86=E;F-I97,\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$U+#`R,#PO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B@S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$U M+#`U,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/D1E8G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$R+#,Y,SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C$R+#0R,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D2!O9B!M;W)E('1H86X@;VYE('EE M87(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(] M,T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@-#!P=#L@5$58 M5"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/ M33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(V-"PR,3$\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W M=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(Y.#PO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4 M15A4+4%,24=..B!R:6=H=#LG(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@ M'0@,7!T('-O;&ED.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q% M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2 M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0Q/E1E;7!O3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4 M.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0Q/D-O6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0U/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/D5S=&EM871E9#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,S8N M-24[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S8E/@T* M/'`@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DUA6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4 M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0Q/D=A:6YS/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DQO M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D9A:7(F(S$V M,#M686QU93PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$<&%D9&EN M9SHP.SX-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,S8N-24[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I M=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R M/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C$U+#4R-3PO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(Y M+#,S.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@ M6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C$L-3,X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/DQO;F6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@ M,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,S!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O M;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN M9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$W M+#8X.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`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`Z(#!I;CL@0D]21$52+4)/5%1/ M33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@8F=C;VQO'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@8F=C;VQO'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU4 M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@ M6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C,Q+#4Y-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M'0@,BXR-7!T(&1O=6)L93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C,Q,BPS-C@\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ;&5F M=#M724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$<&%D9&EN M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0U/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/D5S=&EM871E9#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,S8N M-24[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S8E/@T* M/'`@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D1E8V5M8F5R M)B,Q-C`[,S$L)B,Q-C`[,C`Q,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DQO M6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X] M,T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E-H;W)T+71E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C$Q,RPS,C$\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@2!T:&4@52Y3+B!43PO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C$L,#`Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!S=&%T M97,@;V8@=&AE(%5N:71E9"8C,38P.U-T871E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T M97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B M9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X] M,T0R/@T*/'`@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B@R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149& M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$V+#4W-CPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/E1O=&%L('-E8W5R:71I97,@=VET:"!A M(&UA='5R:71Y(&]F(&]N92!Y96%R)B,Q-C`[;W(@;&5S6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C$T,"PY,#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$ M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/D-O6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-# M145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS M<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C,X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/D1E8G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$R+#0R-#PO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$R+#0U,3PO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P M86X],T0R/@T*/'`@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B@Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/ M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/E1O=&%L('-E8W5R:71I97,@=VET:"!A(&UA='5R:71Y(&]F(&UO65A6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149& M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$P."PY,S`\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O M;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C$P.2PP,S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R M:6=H=#LG(&%L:6=N/3-$6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H=#LG(&%L M:6=N/3-$6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/ M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@ M=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(T.2PY-C0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/D]T:&5R+51H86XM/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3DF5D/"]F;VYT/CPO M8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/DEM<&%I6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/DQO6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/D5Q=6ET>2!S96-U6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5)) M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q% M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0 M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145& M1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C0L,36QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0L.#6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z M("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/ M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8F=C;VQO6QE/3-$)U!! M1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W M=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2 M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B@X.#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C,Y+#$R,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@ M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#@E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C(V-RPU-CD\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$ M)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T M(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q M.#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E(&-O;'-P86X],T0U/@T* M/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DYU;6)E6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!& M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0Q/D5S=&EM871E9#QBF5D M/&)R("\^#0I,;W-S97,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3,N.#0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]- M.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS M)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO M;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-# M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/CDU+#8P-CPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/D1E8G0@6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C$S+#@X-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O M;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z M("TQ,'!T.R<^/&9O;G0@2!S=&%T97,@;V8@=&AE(%5N:71E9"!3=&%T97,@ M86YD('!O;&ET:6-A;"!S=6)D:79I6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C0L-3,W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E1O=&%L('1E;7!O6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B@R-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@F5D(&-O6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`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`@:71S(&]W M;B!A2!D:7-C;W5N M="!B96-A=7-E('1H97)E(&%R92!R97-T2!O9B!O=7(@ M2!U M;F1E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M24Y$14Y4.B`S-2XS<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)' M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,S4N,W!T.R<^/&9O;G0@ M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X] M,T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/D-A6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/CDV+#`W,CPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/ M5%1/33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/ M5%1/33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C(T+#DS.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/D1E8G0@6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/C$S+#0R-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0T+#@V M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI M9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-# M145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G M8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(L-C$Y/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P M86X],T0R/@T*/'`@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@ M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ M(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,3`N-R4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C(U-2PX,S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)' M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3`N-R4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P M86X],T0R/@T*/'`@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-A M6QE M/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C$P-2PT.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$ M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E M8G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!T:&4@52Y3+B!42`H,BD\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$S+#0U,CPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C(T+#@Y-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C,S+#8R,CPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/D5Q=6ET>2!S96-U6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C0L.#6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$ M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E1O=&%L/"]F M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$Q.2PP.30\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W M=&5X="`R+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@ M'0@,7!T('-O;&ED.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5.5#H@+3`N M,C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q*3PO9F]N=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$ M14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN8VQU M9&5D(&EN('-H;W)T+71E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^/&9O;G0@6QE/3-$)T9/3E0M M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P M/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&-L M87-S:69I960@=&AE(&9A:7(@=F%L=64@;65A2!D:7-C;W5N="!O;B!T:&4@9F%I2!D:7-C;W5N="!,979E;"`S(&EN M<'5TF5D(&=A:6X@;V8@ M)#$N,2!M:6QL:6]N+B!!2P@86YD(&$@;&%C:R!O9B!M87)K971A M8FEL:71Y(&1I6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`S-2XS<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!O9B!O=7(@ M:6YV97-T;65N=',@;65A6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M-05)'24XM3$5&5#H@ M,"XU:6X[(%=)1%1(.B`W,RXS-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M5T5) M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0Q/DEN=F5S=&UE;G1S/"]F;VYT/CPO8CX\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%, M24=..B!C96YT97([)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@ M6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#LG('-I>F4],T0R/F%I;B!O;B!I;G9E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$Q+#6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,C$N.#(E.R!0041$24Y'+51/4#H@,&EN M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#(Q)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS M<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XT,B4[(%!! M1$1)3D'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@ M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^ M)B,Q-C`[/"]P/@T*/'`@F4],T0R/D]T:&5R($9A:7(@5F%L=64@1&ES M8VQO6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D]U7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`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`P M<'0@-38N,35P=#L@5$585"U)3D1%3E0Z("TP+C5I;CLG/B8C,38P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&AA=F4@ M:&ES=&]R:6-A;&QY(&9U;F1E9"!O=7(@;W!E6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,S8E(&-O;'-P86X],T0S/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B M;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0Q/C(P,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5)) M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q% M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,38N,S8E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!B9V-O;&]R/3-$(T-# M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/E!A6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/D-O;G1R86-T(')E8V5I=F%B;&5S(&9R;VT@9F]U2`X M."!P97)C96YT(&]F(&]U7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S/"]T9#X-"B`@("`@("`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`P<'0@-38N,35P=#L@5$585"U)3D1% M3E0Z("TP+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/DEN=')A<&5R:6]D('1A>"!A;&QO8V%T:6]N(')U M;&5S)B,Q-C`["!PF5D(&=A:6YS(&]N M(&]U'1087)T7V4T934V,C(W7V(S,CE?-#(W85]B-S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CLG/@T*/'`@F4],T0R/CF4],T0R/E1R861I=&EO;F%L(%!H87)M86-E=71I8V%L($%L;&EA;F-E MF4],T0Q/E)X/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C,38P.W!R:6]R('1O(&QI M8V5N6QE/3-$)T9/3E0M4TE:13H@ M-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$ M,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXN($)I;V=E;B!)9&5C(&AAF4],T0Q M/E)X/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I M>F4],T0R/B8C,38P.W5N=&EL(&-O;7!L971I;VX@;V8@=&AE(&9I2!A;F0@8V]M;65R8VEA;&EZ871I;VX@6QE/3-$)T9/3E0M M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S M:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[)R!S:7IE/3-$,CXF(S$V,#MI;B!I;F9A;G1S('=I=&@@4TU!+"!W:&EC M:"!I;FET:6%T97,@=&AE(%!H87-E(#(O,R!P6UE;G0@9G)O;2!":6]G96X@261E8R!W:&5N('=E(&1O6UE;G1S M('5N9&5R('1H92!-87)C:"8C,38P.S(P,3,@86UE;F1M96YT('1O('1H92!P M87EM96YT('1E6UE;G0@=V4@8V]U;&0@96%R;B!F;W(@=&AE('!R M;V=R97-S:6]N(&]F('1H:7,@4&AAF4],T0Q/E)X/"]F;VYT/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BX\+V9O;G0^/"]P/@T* M/'`@F4@82!N;W9E;"!A;G1I6]T;VYI8R!D>7-T6UE;G0@;V8@)#$R(&UI;&QI;VX@86YD(&%R92!E;&EG:6)L M92!T;R!R96-E:79E('5P('1O("0U.2!M:6QL:6]N(&EN('-U8G-T86YT:79E M(&UI;&5S=&]N92!P87EM96YT6UE;G1S(&EF($)I;V=E;B!) M9&5C(&%C:&EE=F5S('!R92US<&5C:69I960@2!M:6QE6%L=&EE2!S='5D>2XF(S$V,#L@5V4@87)E(&%L6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1U6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R<@GEM92!#;W)P;W)A=&EO;BP@82!386YO M9FD@8V]M<&%N>3PO9F]N=#X\+VD^/"]P/@T*/'`@28C,38P.S(P,#@L('=E(&5N=&5R960@:6YT;R!A('-T&-L=7-I=F4@=V]R;&1W:61E(')I9VATF4@86YO=&AE6UE(&9I=F4@;6EL;&EO;B!S:&%R97,@;V8@;W5R(&-O M;6UO;B!S=&]C:RP@86YD(&$@6UE(&%C:&EE=F5S('!R92US<&5C:69I960@979E;G1S+"!I M;F-L=61I;F<@=7`@=&\@)#2!M:6QE6UE(&ES("0R-2!M:6QL:6]N('5P;VX@=&AE(&5A65AGEM92!I2!T M:&4@9')U9R!S=6)S=&%N8V4@9F]R($M93D%-4D\@9F]R('1H92!0:&%S92`S M(&-L:6YI8V%L('1R:6%LGEM92!IGEM92!W:6QL(&)E(')E2!O9B!+64Y!35)/(&1R=6<@6UE('-H87)E9"!D979E;&]P;65N="!E>'!E;G-E6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`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`P M<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T* M/'`@6UE('9O;'5N=&%R:6QY('1E6UE)B,X,C$W.W,@9F%I;'5R92!T;R!D979E M;&]P(&%N9"!C;VUM97)C:6%L:7IE($M93D%-4D\L('1H96X@=&AE(')I9VAT M2!D979E;&]P(&%N9"!C;VUM97)C:6%L:7IE($M93D%-4D\@:6X@=&AE(&-O M=6YT6%B;&4@=&\@1V5N>GEM92X\ M+V9O;G0^/"]P/@T*/'`@6UE(&UA>2!E;&5C="!T;R!P M=7)C:&%S92!A;&P@;V8@;W5R(')I9VAT6UE;G1S M('5N9&5R('1H92!+64Y!35)/(&QI8V5N2!A;B!I;F1E<&5N9&5N="!I;G9EGEM92!H87,@86=R965D('1O M(&UO;G1H;'D@;&EM:71S(&]N('1H92!N=6UB97(@;V8@GEM92!H87,@86=R965D('1H870@=6YT:6P@=&AE(&5A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/E1H92!P6UE('!A:60@9F]R(&]U M6UE+"!W:&EC:"!R97!R97-E;G1E9"`U."!P M97)C96YT(&%N9"`W,2!P97)C96YT+"!R97-P96-T:79E;'DL(&]F(&]UGEM92!P86ED(&9OF4],T0R/D=L87AO4VUI=&A+;&EN93PO9F]N=#X\ M+VD^/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/G=E(&%R92!E M;&EG:6)L92!T;R!R96-E:79E(&]N(&%V97)A9V4@=7`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`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF M(S$V,#MA8VAI979E(')E9VES=')A=&EO;B!A;F0@;65E="!C97)T86EN('-A M;&5S('1H6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E5N9&5R('1H92!T97)M"!P M6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E<\+V9O;G0^ M/&9O;G0@'0@;6EL97-T;VYE('!A>6UE;G0@;V8@)#(@;6EL M;&EO;B!U<&]N(&1O6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV M93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXN($EN(&%D9&ET:6]N+"!W M92!AF5S('5N9&5R('1H:7,@86QL:6%N M8V4N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@ M,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BP@=V4@96%R;F5D(')E=F5N=64@ M;V8@)#DN.2!M:6QL:6]N(&%N9"`D,BXP(&UI;&QI;VXL(')E2P@9G)O;2!O=7(@2P@;V8@;W5R('1O=&%L(')E=F5N=64@9F]R('1H;W-E('!E2P@6UE;G1S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97([)R!A M;&EG;CTS1&-E;G1EF4],T0R/E)O8VAE M/"]F;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@ M,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE&5R8VES92P@=V4@87)E(')EFEN9R!2 M;V-H928C.#(Q-SMS("8C.#(R,#MB&5R8VES97,@:71S(&]P=&EO;BP@:70@ M=VEL;"!B92!R97-P;VYS:6)L92!F;W(@9VQO8F%L(&1E=F5L;W!M96YT+"!R M96=U;&%T;W)Y(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!A8W1I=FET:65S(&9O M6UE;G0@;V8@)#,P+C`@;6EL;&EO;B!I M;B!!<')I;"8C,38P.S(P,3,@86YD('=E(&%R92!E;&EG:6)L92!T;R!R96-E M:79E('5P('1O("0S-C(N,"!M:6QL:6]N(&EN(&$@;&EC96YS92!F964@86YD M('-U8G-T86YT:79E(&UI;&5S=&]N92!P87EM96YT2!M:6QE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN(&%D9&ET:6]N+"!W M92!A2!D979E;&]P960@87,@=V5L;"!A2!BF5D M+B8C,38P.R!7/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#LG('-I>F4],T0R/F4@87)E(&%L2!P6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R<@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#LG('-I>F4],T0R/E5N9&5R('1H92!T97)M6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/G=E('=I;&P@'!E;G-E(&EN('1H92!S96-O;F0@<75A6UE;G1S('1O M($-(1$DN)B,Q-C`[($1U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4U M-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0MF4],T0R/E)E=F5N=64@4F5C;V=N:71I M;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UEFEN9R!T M:&4@FEN9R!R979E;G5E+"!W92!I;F-L=61E('1H92!A M;6]U;G1S(&EN(&1E9F5RF4],T0R/E)E7!I8V%L;'D@8V]N=&%I;B!M=6QT M:7!L92!E;&5M96YT2!L:6-E;G-E7!E2!S:&]U;&0@8F4@8V]M M8FEN960@=VET:"!O=&AE2!B>2!A;GD@=F5N9&]R(&]R('1H M92!C=7-T;VUE2!O9B!V86QU97,@=&\@97-T:6UA=&4@=&AE('-E;&QI;F<@<')I M8V4@;V8@96%C:"!D96QI=F5R86)L93H@*&DI)B,Q-C`[=F5N9&]R+7-P96-I M9FEC(&]B:F5C=&EV92!E=FED96YC92!O9B!F86ER('9A;'5E.R`H:6DI)B,Q M-C`[=&AI2!S;VQD('1H92!D96QI=F5R86)L92!O;B!A('-T86YD+6%L;VYE(&)A MF4@=&AE(')E=F5N=64@86QL;V-A=&5D('1O(&5A M8V@@=6YI="!O9B!A8V-O=6YT:6YG(&%S('=E(&1E;&EV97(@=&AE(')E;&%T M960@9V]O9',@;W(@2!P6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R M96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V,#MA;F0@ M25-)4RU!6C$\+V9O;G0^/&9O;G0@F4],T0Q/E)X M/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4] M,T0R/BX\+V9O;G0^/&9O;G0@F4],T0Q M/E)X/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CYA;F0@24Y$+65N86)L:6YG('-T=61I97,@9F]R($E325,M05HQ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE4 M24]..B!R96QA=&EV93L@5$]0.B`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`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CX[/"]F;VYT M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN M.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R M/F9O6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M24Y$14Y4.B`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`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CYL:6-E;G-E(&]N('1H92!D871E(&]F('1H92!A9W)E96UE;G0@ M8F5C875S92!T:&%T(&ES('=H96X@=V4@9&5L:79E6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE4 M24]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V M,#MO=F5R('1H92!P97)I;V0@;V8@=&EM92!W92!P97)F;W)M('-EF4] M,T0Q/E)X/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG M('-I>F4],T0R/B8C,38P.VQI8V5N&-L=7-I=F4@ M;&EC96YS92XF(S$V,#L@0F5C875S92!O9B!T:&4@96%R;'D@6QE/3-$)T9/ M3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[ M)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXL('=E(&)E;&EE=F4@=&AA="!O=7(@:VYO=VQE M9&=E(&%N9"!E>'!E2!I MF4],T0Q/E)X/"]F;VYT/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BXF(S$V,#L@07,@ M82!R97-U;'0L('=E(&-O;F-L=61E9"!T:&%T('1H92!)4TE3+4%:,3PO9F]N M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#8N-7!T.R!03U-)5$E/3CH@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/FQI8V5N6QE/3-$)T9/3E0M4TE: M13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE M/3-$,3Y2>#PO9F]N=#X@/&9O;G0@F4@9')U9W,@2!A="!T:&4@9&%T92!O9B!T:&4@86=R965M96YT M(&%S('1O('=H971H97(@=V4@=V]U;&0@96%R;B!T:&4@;6EL97-T;VYE('!A M>6UE;G1S+"!R;WEA;'1Y('!A>6UE;G1S+"!P87EM96YT6UE;G0@8F%S M960@;VX@=&AE(')E;&%T:79E($)%4U`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`P<'0@,"XW-6EN M.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@&5S.R!A;F0\+V9O;G0^/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,W!T M.R<@'!E8W1E M9"!C87-H(&]U=&9L;W=S('1O('1H:7)D('!A'!E8W1E9"!P97)I;V0@=&AA="!W M92!W:6QL('!E6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN M.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5. M5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE M/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.SPO9F]N=#X@/&9O;G0@F4Z(#$P<'0[)R!S:7IE/3-$ M,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P M+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D%S(&$@F5D("0Y+C,@;6EL;&EO M;B!O9B!T:&4@)#(U(&UI;&QI;VX@=7!FF4],T0Q/E)X/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C,38P.VQI8V5NFEN9R!T:&4@6QE/3-$)T9/3E0M4TE:13H@-BXU M<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2 M>"8C,38P.SPO9F]N=#X@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/ M4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>"8C,38P M.SPO9F]N=#X@/&9O;G0@2!S M979E;B!P97)C96YT+"!O2!T;R!P97)F;W)M(&1U M6]N9"!T:&4@:6YI=&EA;"!P97)I;V0@ M;V8@<&5R9F]R;6%N8V4L('=E(&5X=&5N9"!O=7(@86UOF%T:6]N('!E MF4@8V]U;&0@8F4@;6%T97)I86QL>2!D:69F97)E;G0@:68@9&EF9F5R96YT M(&5S=&EM871E6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[ M(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXF(S$V,#MF;W(@4W!I;F%L($UU6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R M96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$V,#MT:')O M=6=H(&-O;7!L971I;VX@;V8@4&AA6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S.7!T.R<^/&9O;G0@2!O9B!T:&5S92!A M9W)E96UE;G1S('1H870@87)E(&5S6UE;G0@=&5R;7,@86YD(&9E97,@=6YD97(@ M96%C:"!A9W)E96UE;G0@87)E(&EN9&5P96YD96YT(&]F(&5A8V@@;W1H97(N M)B,Q-C`[(%=E(&%LF%T:6]N(&]F M('1H92!D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S.7!T.R<^)B,Q-C`[/"]P/@T*/'`@ M6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P M+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E!R:6]R('1O('1H M92!F:7)S="!S=&%G92!I;B!T:&4@;&EF92UC>6-L92!O9B!O=7(@9')U9W,L M('=E('!E2XF(S$V,#L@1G)O;2!T:&5S92!R97-E87)C:"!E9F9O2!S869E='D@86YD(&5F9FEC86-Y(&EN('!R96-L:6YI8V%L(&%N M:6UA;"!S='5D:65S('1O('=A2!I;B!H=6UA M;G,N)B,Q-C`[($1U2!O=7(@9')U M9W,@:6X@24Y$+65N86)L:6YG('-T=61I97,L('=H:6-H(&%R92!A;FEM86P@ M2!L87)G97(@2!S869E='D@ M86YD(&5F9FEC86-Y(&1A=&$@=&\@2!T;R!S=6-C97-S9G5L;'D@2!D:7-C;W9E2!S;VQD(&9O6UE;G1S('=E(&UA>2!E87)N M(&9R;VT@;W5R('!A6-L92P@=&AE('9A;'5E(&]F('1H92!D2!I;F-R M96%S97,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I M;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E=F5L;W!M96YT(&UI M;&5S=&]N97,@:6X@;W5R('!A6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN M.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO M9F]N=#X@/&9O;G0@2P@4&AAF4Z(#$P<'0[ M)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN:71I871I M;VX@;W(@8V]M<&QE=&EO;B!O9B!A(%!H87-E(#(@8VQI;FEC86P@=')I86PN M)B,Q-C`[($=E;F5R86QL>2P@4&AA65A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4 M+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@2!A M<'!L:6-A=&EO;G,@9F]R(&UA2P@:70@=&%K M97,@6QE/3-$)T9/3E0M4TE:13H@,W!T M.R<@65A7!E6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E. M1$5.5#H@+3`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`P<'0@,"XW-6EN.R!415A4 M+4E.1$5.5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@ M6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6UE;G0@=&5R;7,@ M:6X@=&AE(&%R6UE;G0@86YD(')E8V]G;FEZ92!I="!A2XF(S$V M,#L@26X@=&AE(&9I6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA M=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3Y2>#PO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXL('1H92!F:7)S="!D MGEM92!A;F0@=&AE("0W+C4@;6EL;&EO M;B!M:6QEF4],T0R/DQI8V5N2!R M979E;G5E/"]F;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I M;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C(U:6X[)SXF(S$V M,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4 M+4E.1$5.5#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE&-L=7-I=F4@;W(@ M;F]N+65X8VQU&-H86YG92!F;W(@;&EC96YS92!F M965S(&%N9"]O2!R96-O9VYI>F4@ M87,@2!T:&]S92!L:6-E;G-I;F<@9F5E6QE/3-$)V9O;G0M2!T:&5M(&%T(&9A:7(@;6%R:V5T('9A M;'5E(&)AF5D(&=A:6YS(&%N9"!L;W-S97,@87,@82!S M97!A2!I;G9E2UH96QD(&)I;W1E8VAN;VQO9WD@8V]M<&%N:65S('1H M870@=V4@:&%V92!R96-E:79E9"!A2!L M:6-E;G-E(&]R(&-O;&QA8F]R871I;VX@86=R965M96YT+B8C,38P.R!!="!- M87)C:"8C,38P.S,Q+"`R,#$S('=E(&AE;&0@;W=N97)S:&EP(&EN=&5R97-T M2UH96QD(&-O;7!A;FEE2P@;F5A2!A;F0@;W5R M(&-U6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CPO9&EV/CQS<&%N M/CPO'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@F4],T0R/DEN=F5N=&]R>2!V M86QU871I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4 M.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&-A<&ET M86QI>F4@=&AE(&-O2!O;B!T:&4@8F%L M86YC92!S:&5E="!A="!T:&4@;&]W97(@;V8@8V]S="!O2!A;F0@6EN9R!V86QU92!O9B!I=&5MF%B;&4@=F%L=64N(%=E(&-O;G-I9&5R('-E=F5R86P@9F%C=&]R2!W2P@ M=VAI8V@@8V]N6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^#0H\+V1I=CX\3I4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQB M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!P=7)S=6EN9R!A;F0@=W)I=&4@;V9F(&%N>2!A'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@F4],T0R/DQO;F2P@<&QA;G0@86YD(&5Q=6EP;65N="P@<&%T96YT(&-O2!M971H;V0@;V8@86-C;W5N=&EN9SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=F M;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG M/@T*/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E(&%C8V]U;G1E9"!F;W(@;W5R M(&]W;F5R2!M971H;V0@;V8@86-C M;W5N=&EN9RP@=V4@:6YC;'5D960@;W5R('-H87)E(&]F(%)E9W5L=7,F(S@R M,3<[(&]P97)A=&EN9R!R97-U;'1S(&]N(&$@2!I;B!N970@;&]S6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`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`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^/&9O M;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@2!N;W1EF4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R M/D1I;'5T:79E('-T;V-K(&]P=&EO;G,[(&%N9#PO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5. M5#H@+3`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4],T0R/B8C,3@S.SPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@ M6QE M/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0 M.B`M,W!T.R<@6QE/3-$ M)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q M<'0[)R!S:7IE/3-$,3XX/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#LG('-I>F4],T0R/B8C,38P.W!E6QE/3-$)T9/3E0M4TE:13H@-BXU M<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`M,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[ M(%!/4TE424]..B!R96QA=&EV93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3XX/"]F M;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R M/B8C,38P.W!E'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@F4],T0R/D-O;G-O M;&ED871I;VX@;V8@=F%R:6%B;&4@:6YT97)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`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`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT M+6%L:6=N.FQE9G0[34%21TE.+4Q%1E0Z(#`N-6EN.R!724142#H@.#8N-C8E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@V)2!B;W)D97(],T0P/@T*#0H\ M='(@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,S`E(&-O;'-P86X],T0U/@T*/'`@6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$ M)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#L@ M5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C8L-#8W/"]F;VYT/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^ M/&9O;G0@6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149& M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C4L,S`T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE'0@,BXR-7!T(&1O=6)L M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-% M149&/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1% M6%0M24Y$14Y4.B`M,"XR-6EN.R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG M('-I>F4],T0R/DEN8VQU9&5D(&EN(&<\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG M('-I>F4],T0R/F]N(&]U'0^/&1I=B!S='EL93TS1"=F;VYT M+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T* M/'`@F4],T0Q/C4\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV M93L@5$]0.B`Q<'0[)R!S:7IE/3-$,3XX/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C,38P.W!E6QE/3-$)V9O;G0M MF4],T0R/B8C,38T.SPO9F]N=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#8N-7!T.R!03U-)5$E/3CH@2!A;F0@97%U:71Y(&-O;7!O;F5N=',@ M;V8@=&AE(&EN'0^/&1I=B!S='EL93TS1"=F;VYT M+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T* M/'`@F4],T0R/E-E9VUE;G0@:6YF;W)M871I;VX\+V9O;G0^/"]B/CPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/E=E(&]P97)A=&4@:6X@82!S:6YG;&4@'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV('-T>6QE/3-$)V9O;G0M6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/E=E(&UE87-U2UC;&%SF4@=&AE('9A;'5E(&]F('1H92!P;W)T:6]N(&]F M('1H92!A=V%R9"!T:&%T('=E('5L=&EM871E;'D@97AP96-T('1O('9E'!E;G-E(&9O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$ M14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E=E('5S M92!T:&4@0FQA8VLM4V-H;VQE'!E8W1E9"!T97)M(&]F M(&]P=&EO;G,@9W)A;G1E9"!B87-E9"!O;B!H:7-T;W)I8V%L(&5X97)C:7-E M('!A='1E6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,S`N,C5P=#L@5$585"U)3D1%3E0Z("TQ,"XQ<'0[)SX\:3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D5M<&QO>65E M(%-T;V-K($]P=&EO;G,Z/"]F;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE M/3-$)W1E>'0M86QI9VXZ;&5F=#M-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1( M.B`X-BXV-B4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P M/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C`N,#PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\ M+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C4N,2!Y96%R6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C4N,2!Y96%R6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO M=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N,C5I M;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,"XR-6EN.R<^/&D^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,S`E(&-O;'-P86X],T0S/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@ M6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/E)I6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C`N,3PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/C`N,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6EE;&0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C`N,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$58 M5"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C8Q+C0\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0S+C0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/D5X<&5C=&5D(&QI9F4\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C8@;6]N=&AS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E1H92!F86ER('9A;'5E(&]F(%)3 M57,@:7,@8F%S960@;VX@=&AE(&UA65A2X\+V9O;G0^/"]P/@T*/'`@F5S('-T;V-K+6)A'!E;G-E(&9O6QE/3-$)W1E>'0M M86QI9VXZ;&5F=#M-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`X-BXV-B4[ M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!! M1$1)3D6QE M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#LG('-I>F4] M,T0Q/DUA6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P M,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5)) M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q% M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@ M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[ M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145& M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C$L.3,U/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O M;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C,S,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52 M+4)/5%1/33H@=VEN9&]W=&5X="`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`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)V9O;G0MF5S(&-H86YG97,@:6X@86-C=6UU;&%T960@;W1H97(@8V]M<')E M:&5N6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C,38P.SPO<#X-"CQT86)L92!S M='EL93TS1"=T97AT+6%L:6=N.FQE9G0[34%21TE.+4Q%1E0Z(#`N-6EN.R!7 M24142#H@.#4Q<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@ M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E(&-O;'-P86X],T0U/@T*/'`@6QE/3-$)W!A9&1I;F6QE M/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$ M)W!A9&1I;F'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-30E.R!0 M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145& M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'0@,7!T('-O;&ED.R!0041$24Y'+4Q% M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-30E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-# M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\ M+V9O;G0^/"]P/CPO=&0^/"]T#L@4$%$1$E. M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#L@5$585"U)3D1%3E0Z("TQ M,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C8L-#8W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/D%M;W5N=',@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G M8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q+#$V,SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/DYE="!C=7)R96YT M('!E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0 M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N M,C5P="!D;W5B;&4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L M6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C4R.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W!A9&1I;F'0@,BXR-7!T(&1O=6)L93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149& M/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@ M,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M M24Y$14Y4.B`M,"XR-6EN.R<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU M:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I M>F4],T0R/DEN8VQU9&5D(&EN(&<\+V9O;G0^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#LG('-I M>F4],T0R/F]N(&]U6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M- M05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`X-S-P>#L@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S93L@5$585"U!3$E'3CH@;&5F=#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-S,@8F]R9&5R/3-$,#X- M"@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3,E/@T*/'`@6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C`N,#PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O M;G0^/"]P/CPO=&0^/"]T#L@4$%$1$E.1RU" M3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O M;G0@3PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C4Q+C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C4P+C8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F'!E8W1E9"!L M:69E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)W1E>'0M86QI9VXZ M;&5F=#M-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`X-S5P>#L@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U!3$E'3CH@;&5F=#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-S4@8F]R9&5R M/3-$,#X-"@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!! M1$1)3D6QE/3-$)W!A M9&1I;F6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3,E/@T*/'`@6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'+51/4#H@ M,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C`N,#PO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B4\+V9O;G0^/"]P/CPO=&0^/"]T#L@4$%$ M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@3PO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C8Q+C0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C0S+C0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)W!A M9&1I;F'!E M8W1E9"!L:69E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P M+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E1H92!F;VQL;W=I M;F<@=&%B;&4@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/B8C M,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[34%2 M1TE.+4Q%1E0Z(#`N-6EN.R!724142#H@.#8S<'@[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E. M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S`E(&-O M;'-P86X],T0U/@T*/'`@6QE/3-$ M)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@ M6QE/3-$)W!A9&1I;F'0@ M,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3(N-30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/ M33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$L.3,U/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D=E;F5R86P@86YD(&%D;6EN M:7-T6QE/3-$)U!!1$1) M3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C,R,SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0 M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P M="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU4 M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@ M5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@'0@,BXR-7!T(&1O=6)L93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149& M/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(L.#8Y/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O M=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$ M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B M;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E. M1$5.5#H@,"XU:6X[)SXF(S$V,#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%? M8C'0O:'1M;#L@ M8VAA2!O9B!C;VYT2!O9B!A=F%I;&%B;&4M9F]R+7-A M;&4@'0^ M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@#L@4$%$1$E.1RU"3U143TTZ(#!P M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/D]N92!Y96%R(&]R(&QE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D65A6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C0Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^ M/"]P/CPO=&0^/"]T#L@4$%$1$E.1RU"3U14 M3TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/D%F=&5R('1W;R!Y96%R6QE/3-$ M)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E(&)G8V]L;W(],T0C M0T-%149&/@T*/'`@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C$R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3@N.30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#(N,C5P="!D;W5B;&4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4 M+4%,24=..B!R:6=H=#LG(&%L:6=N/3-$6QE/3-$ M)U!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T2!O M9B!I;G9E'0^ M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F(&]U#L@4$%$1$E.1RU"3U143TTZ M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D]T:&5R+51H86XM/"]F;VYT M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U14 M3TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E1E;7!O3PO9F]N M=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C(E(&-O;'-P86X],T0U/@T* M/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M5T5) M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0Q/D5S=&EM871E9#PO9F]N=#X\+V(^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4 M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0Q/D-O6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/D=A:6YS/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DQO6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D9A:7(F(S$V,#M686QU M93PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$ M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS M<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B@R.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/CDX M+#`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@T-CPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z M(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$58 M5"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!S=&%T97,@;V8@=&AE(%5N:71E M9"8C,38P.U-T871E6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/ M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145& M1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O M;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q,3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E M(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,S!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C$Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@X-CPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T M97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O M;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`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`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!5 M+E,N(&=O=F5R;FUE;G0@86=E;F-I97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C$U+#`R,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B@S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$U+#`U,CPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C,P/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E. M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ M,'!T.R<^/&9O;G0@2!S=&%T97,@;V8@=&AE(%5N:71E9"8C,38P.U-T871E M6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C<\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T M97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI M9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE M/3-$)W!A9&1I;F2!O9B!M;W)E('1H86X@;VYE M('EE87(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L M;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E-U8G1O=&%L M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52 M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B@R-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T.R!415A4+4%,24=..B!R:6=H=#LG(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4 M15A4+4%,24=..B!R:6=H=#LG(&%L:6=N/3-$6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R M/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^ M)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M7 M24142#H@.3DS<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@ M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D]T M:&5R+51H86XM/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/E1E;7!O3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E5N6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U14 M3TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0Q/DQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU, M1494.B`P<'@[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I M=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R M/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU" M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@ M,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$ M(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!! M1$1)3D#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-U M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C0T+#@V,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C$L.38Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/C(L-C$Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/DQO;F6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0 M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P M="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E-U8G1O=&%L/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@8F=C;VQO'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@ M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@ M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C,Q+#(Y.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$."4@8F=C;VQO6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8F=C;VQO6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8F=C;VQO6QE/3-$ M)U!!1$1)3D#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D6QE M/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@ M6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C(X,2PX.3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/ M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T M.R<^/&9O;G0@6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@R-#@\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\ M+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T M.R!415A4+4%,24=..B!C96YT97([)R!A;&EG;CTS1&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)W!A9&1I M;F6QE/3-$)U!!1$1)3DF5D M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E5N6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U14 M3TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE M/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E-H;W)T+71E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C@Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/D1E8G0@6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B@V-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!T:&4@52Y3+B!43PO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$L,#`Q/"]F;VYT/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/ M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145& M1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E. M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,S!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/C$P,CPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@W M-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN M.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN M.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4 M5$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU" M3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@2!5+E,N(&=O=F5R;FUE;G0@86=E;F-I97,\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C@L,#,T/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@ M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!T:&4@52Y3 M+B!43PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B@Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P M86X],T0R/@T*/'`@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F2!O9B!M;W)E('1H86X@;VYE('EE87(\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149& M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O M;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/E-U8G1O=&%L/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/ M5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ M(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN M9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/ M5%1/33H@=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q.#4\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4 M+4%,24=..B!R:6=H=#LG(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R M:6=H=#LG(&%L:6=N/3-$6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T* M/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@.3DT<'@[ M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@4$%$1$E.1RU"3U14 M3TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D]T:&5R+51H86XM/"]F M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU" M3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(&-E;G1E6QE M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E1E;7!O3PO M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T9/3E0M M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E5N6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$ M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/DQO M6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X] M,T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS M<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/ M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-U6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C,S+#8R,CPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C0L,36QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0L.#6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/DQO;F6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=( M5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/@T*/'`@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`E.R!0041$24Y'+51/4#H@,&EN M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/E-U8G1O=&%L/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D'0@,7!T('-O M;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO'0@,7!T('-O;&ED M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@."XW)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@ M=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@ M=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C(R+#(W,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@ M,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@8F=C;VQO M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$."4@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3DF4],T0R/B0\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$."4@8F=C;VQO6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@'0@,BXR-7!T(&1O=6)L93LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(V-RPU-CD\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@ M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R M+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L M93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#@E/@T*/'`@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B@Q.#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO M9&EV/CQS<&%N/CPO6QE M/3-$)W1E>'0M86QI9VXZ;&5F=#M-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1( M.B`Y-C-P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U!3$E' M3CH@;&5F=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Y-C,@8F]R9&5R/3-$,#X-"@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D28C,38P.VEM<&%I6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU" M3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q M/DYU;6)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/D5S=&EM871E9#QBF5D/&)R("\^#0I,;W-S97,\+V9O;G0^/"]B/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU"3U143TTZ(#!P M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/D-O'0@,7!T M('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!724142#H@,3(N-30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@ M;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B@Q.#4\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!5+E,N(&=O=F5R M;FUE;G0@86=E;F-I97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@ M2!S=&%T97,@;V8@=&AE(%5N:71E9"!3=&%T97,@86YD('!O;&ET:6-A;"!S M=6)D:79I6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N M.#0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T M97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G M8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0L-3,W/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D2!I;7!A:7)E9"!S96-U6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,BXR-7!T(&1O=6)L93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@ M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R M+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO M=&0^/"]T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S-2XS<'0[ M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^#0H\=&%B;&4@#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0Q/D%T)B,Q-C`[36%R8V@F(S$V,#LS,2P\8G(@+SX-"C(P M,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/E%U;W1E9"8C M,38P.U!R:6-E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X] M,T0R/@T*/'`@6QE/3-$)W!A M9&1I;F6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ M,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I M;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU2 M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1) M3D'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/CDQ+#`W,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ M(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3D#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!5+E,N(&=O=F5R M;FUE;G0@86=E;F-I97,@*#(I/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C(T+#DS.3PO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!T:&4@52Y3+B!42`H,BD\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$S+#0R-#PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$ M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/DEN=F5S=&UE;G0@:6X@4F5G=6QU6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D5Q=6ET>2!S96-U M6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&(&-O M;'-P86X],T0R/@T*/'`@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CLG('-I>F4],T0R/C(L-C$Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R M)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U) M3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E. M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414 M2#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O M;G0@'0@,7!T('-O;&ED M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D'0@,BXR-7!T(&1O M=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(U M-2PX,S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/ M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7 M24142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@ M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^ M/&9O;G0@'0@,7!T('-O M;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1) M3D'0@,BXR-7!T M(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU"3U143TTZ M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3(E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$P,2PT M.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2 M1$52+4)/5%1/33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2 M1$52+4)/5%1/33H@;65D:75M(&YO;F4[)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU224=(5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ M,'!T.R<^/&9O;G0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/C$Y,RPU,#<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/C$Y,RPU,#<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU4 M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/D1E8G0@6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B8C M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@#L@4$%$ M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D1E8G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C$S+#0U,CPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@2!S M=&%T97,@;V8@=&AE(%5N:71E9"!3=&%T97,@86YD('!O;&ET:6-A;"!S=6)D M:79I6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/C(T+#@Y-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C,S+#8R,CPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#LG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149& M(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/C0L,30V/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3(E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$ M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U M<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,7!T('-O;&ED.R!0041$24Y'+4Q% M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D'0@,BXR-7!T(&1O=6)L93LG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D'0@,BXR M-7!T(&1O=6)L93LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@ M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU224=(5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C(T,"PU,3(\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@ M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R M+C(U<'0@9&]U8FQE.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@'0@,BXR-7!T(&1O=6)L93LG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^ M/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,W!T.R<@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B@R*3PO9F]N=#X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO9F]N=#X@/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN.R<^)B,Q M-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN8VQU9&5D(&EN(&]T:&5R(&-U#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$ M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M5T5) M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,R8C,38P.TEN<'5T M6QE/3-$)W!A9&1I;F6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XT,B4[(%!!1$1) M3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/C,T+#,U,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)U!!1$1)3D#L@ M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ M,'!T.R<^/&9O;G0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I M>F4],T0R/B@Q+#$V,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/DEN8VQU9&5D(&EN(&%C M8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/D-O6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,C$N.#(E.R!0041$24Y' M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI M9#LG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)2!B9V-O;&]R/3-$(T-# M145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P M>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@ M5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/C0T+#@V,SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ M(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;CLG/B8C M,38P.SPO<#X\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D6QE/3-$ M)W!A9&1I;F6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CLG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0Q/C(P M,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$ M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T M.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R M/C6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO M=&0^/"]T#L@4$%$1$E.1RU"3U143TTZ(#!P M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T.R<^/&9O;G0@ M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CLG('-I>F4] M,T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CLG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA3QB&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^36%R+B`S,2P@,C`Q,SQB&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M36%R+B`S,2P@,C`Q,SQB&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S M,2P@,C`Q,SQB2`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S6UE($-OGEM92!#;W)P;W)A=&EO;CQB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!L:6-E M;G-E('5N9&5R('1H92!S97!A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!W:&EC:"!E87)N960@ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6-L92!O9B!D'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S65A65A'0^,B!Y96%R65A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-B!M;VYT:',\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&%M<&QE(&]F('-A;&5S M('1H'1087)T7V4T M934V,C(W7V(S,CE?-#(W85]B-S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM=6T\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-&4U M-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!I2!B96YE9FEC M:6%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA&EM=6T\+W1D/@T* M("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!O9B!C:&%N9V5S(&EN(&%C M8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*3PO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7V4T934V,C(W7V(S,CE?-#(W85]B-S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65A7,\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M-B!M;VYT:',\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E M;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.#8Y+#`P,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D(&5S=&EM871E9"!N;VXM M8V%S:"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@P,"PP,#`\'!E M8W1E9"!T;R!B92!R96-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XR('EE87)S(#$@;6]N=&@@-B!D87ES/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4T-BPP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3QB65A'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!O9B!L97-S('1H86X@='=O('EE87)S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XX."XP,"4\2!H87,@86X@97%U:71Y(&]W;F5R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!H87,@86X@97%U:71Y(&]W;F5R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!396-U2!);7!A:7)M96YT($QO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I M;7!A:7)E9"!S96-U2!I;7!A:7)M96YT+"!5;G)E86QI>F5D($QO'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR.3@\65AF5D($-O'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF5D($QO2!I;7!A:7)E9"!I;G9E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!I;7!A:7)E9"!S96-U'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!I;7!A:7)E9"!S96-U2!I;7!A:7)M96YT+"!%'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!I;7!A:7)E9"!S96-U2!I;7!A:7)M96YT+"!5;G)E86QI M>F5D($QO65AF5D($-OF5D($-OF5D($QO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!5+E,N(&=O=F5R;FUE;G0@86=E;F-I97,@?"!$96)T(&UA='5R:71I97,@ M;V8@;VYE('EE87(@;W(@;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!5+E,N(&=O=F5R;FUE M;G0@86=E;F-I97,@?"!$96)T(&UA='5R:71I97,@;V8@;6]R92!T:&%N(&]N M92!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\F5D($-O2!T:&4@52Y3+B!42!\($1E8G0@;6%T M=7)I=&EE65AF5D($-O M2!T:&4@52Y3+B!42!\ M($1E8G0@;6%T=7)I=&EE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!I;7!A:7)E9"!S96-U2!I;7!A:7)M96YT+"!%'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!S=&%T97,@;V8@=&AE(%5N:71E9"!3=&%T M97,@86YD('!O;&ET:6-A;"!S=6)D:79I'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F5D($=A:6YS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D($=A:6YS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PR.3D\F5D($-O2!396-UF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ+#DV,3QS<&%N/CPO2!);7!A:7)M96YT($QO2!S96-U M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!S96-U'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!S96-U7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M&5S("A$971A:6QS*2`H55-$("0I/&)R/CPO"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#8T+#`P,#QS<&%N/CPOF5D(&=A:6YS(&]N(&%V M86EL86)L92UF;W(M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2`R,#$R/&)R/D1E=F5L;W!M96YT(&UI;&5S=&]N97,\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB2!M:6QEGEM92!#;W)P;W)A=&EO;CQBGEM92!#;W)P;W)A=&EO;CQB6UE($-OGEM92!#;W)P;W)A=&EO;CQB6UE($-O6UE($-O&EM=6T\8G(^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB6UE($-OGEM M92!#;W)P;W)A=&EO;CQB6UE($-OF%T:6]N(&UI;&5S=&]N97,\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q,SQB&\@4VUI=&@@2VQI;F4\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB&\@4VUI=&@@2VQI;F4\8G(^57`@=&\@4&AA&\@4VUI M=&@@2VQI;F4\8G(^4&AA&\@4VUI=&@@2VQI;F4\8G(^4')E+7-P96-I9FEE M9"!E=F5N=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R M+B`S,2P@,C`Q,SQB&\@4VUI=&@@2VQI;F4\8G(^1&5V96QO<&UE;G0@;6EL M97-T;VYE2!M:6QE2!B'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!S=')A=&5G:6,@86QL:6%N M8V4@<&%R=&YE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S6UE;G0@'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&EM=6T@86UO=6YT(&]F('!A>6UE;G1S(')E8V5I=F%B;&4@<&5R M(&1R=6<@=6YD97(@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!P=7)C:&%S M92!R:6=H=',@=&\@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,3@P(&1A>7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,3`@>65AF%T:6]N('=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N('=A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&EM=6T@;6EL97-T;VYE('!A>6UE M;G1S(')E8V5I=F%B;&4@<&5R('!R;V=R86T\+W1D/@T*("`@("`@("`\=&0@ M8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E-&4U-C(R-U]B,S(Y7S0R-V%?8C&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 16 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Details 2) (Investments Valued Using Level 3 Inputs, USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Investments Valued Using Level 3 Inputs
 
Investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3)  
Balance at the beginning of the period $ 34,350
Total gains and losses included in gain on investments (1,163)
Total gains and losses included in accumulated other comprehensive income (loss) 11,716
Cost basis of shares sold (40)
Balance at the end of the period $ 44,863
XML 17 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Details) (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Fair Value Measurements    
Amount of transfer between Level 1 and Level 2 investments $ 0  
Assets measured at fair value on a recurring basis    
Investment in Regulus Therapeutics Inc. 44,863,000 33,622,000
Sarepta Therapeutics, Inc.
   
Assets measured at fair value on a recurring basis    
Realized gain on sale of common stock 1,100,000  
Gross fair value of investment   1,000,000
Lack of marketability discount   296,000
Regulus Therapeutics Inc.
   
Assets measured at fair value on a recurring basis    
Gross fair value of investment 54,600,000 44,400,000
Lack of marketability discount 9,700,000 10,800,000
2 3/4 percent convertible senior notes
   
Assets measured at fair value on a recurring basis    
Interest rate on convertible debt (as a percent) 2.75%  
Significant Other Observable Inputs (Level 2) | 2 3/4 percent convertible senior notes
   
Assets measured at fair value on a recurring basis    
Fair value of convertible notes 258,000,000  
Recurring basis | Total
   
Assets measured at fair value on a recurring basis    
Cash equivalents 96,072,000 105,496,000
Investment in Regulus Therapeutics Inc. 44,863,000 33,622,000
Total assets 407,815,000 393,956,000
Recurring basis | Total | Corporate debt securities
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 205,098,000 193,507,000
Recurring basis | Total | Debt securities issued by U.S. government agencies
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 24,939,000 18,108,000
Recurring basis | Total | Debt securities issued by the U.S. Treasury
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 13,424,000 13,452,000
Recurring basis | Total | Debt securities issued by states of the United States and political subdivisions of the states
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 20,800,000 24,897,000
Recurring basis | Total | Equity securities
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 2,619,000 4,874,000
Recurring basis | Quoted Prices in Active Markets (Level 1)
   
Assets measured at fair value on a recurring basis    
Cash equivalents 91,072,000 101,496,000
Total assets 107,115,000 119,094,000
Recurring basis | Quoted Prices in Active Markets (Level 1) | Debt securities issued by the U.S. Treasury
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 13,424,000 13,452,000
Recurring basis | Quoted Prices in Active Markets (Level 1) | Equity securities
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 2,619,000 4,146,000
Recurring basis | Significant Other Observable Inputs (Level 2)
   
Assets measured at fair value on a recurring basis    
Cash equivalents 5,000,000 4,000,000
Total assets 255,837,000 240,512,000
Recurring basis | Significant Other Observable Inputs (Level 2) | Corporate debt securities
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 205,098,000 193,507,000
Recurring basis | Significant Other Observable Inputs (Level 2) | Debt securities issued by U.S. government agencies
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 24,939,000 18,108,000
Recurring basis | Significant Other Observable Inputs (Level 2) | Debt securities issued by states of the United States and political subdivisions of the states
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities 20,800,000 24,897,000
Recurring basis | Significant Unobservable Inputs (Level 3)
   
Assets measured at fair value on a recurring basis    
Investment in Regulus Therapeutics Inc. 44,863,000 33,622,000
Total assets 44,863,000 34,350,000
Recurring basis | Significant Unobservable Inputs (Level 3) | Equity securities
   
Assets measured at fair value on a recurring basis    
Available-for-sale securities   $ 728,000
XML 18 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentration of Business Risk (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2013
Revenue
Partner A
Mar. 31, 2012
Revenue
Partner A
Mar. 31, 2013
Revenue
Partner B
Mar. 31, 2012
Revenue
Partner B
Mar. 31, 2013
Contract receivables
Significant Partners
item
Dec. 31, 2012
Contract receivables
Significant Partners
item
Concentration of business risk            
Concentration percentage 58.00% 71.00% 23.00% 9.00% 88.00% 83.00%
Number of significant partners         4 4
XML 19 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Details) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Income Taxes    
Income tax benefit $ 64,000 $ (2,000)
Unrealized gains on available-for-sale securities, amount of tax recorded in other comprehensive income $ 3,600,000  
XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies
3 Months Ended
Mar. 31, 2013
Significant Accounting Policies  
Significant Accounting Policies

2.                                      Significant Accounting Policies

 

Revenue Recognition

 

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In those instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

 

Research and development revenue under collaborative agreements

 

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services. Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees, profit sharing and royalties on product sales. We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and then accounted for as a single unit of accounting. When the delivered items in an arrangement have “stand-alone value” to our customer, we account for the deliverables as separate units of accounting and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a standalone basis. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. The BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

 

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense therapeutics against five cancer targets. As part of the collaboration, we received a $25 million upfront payment and are eligible to receive a $6 million payment in the second quarter of 2013 assuming the research program is continuing.  We are also eligible to receive milestone payments, license fees for the research program targets and royalties on any product sales of drugs resulting from this collaboration. In exchange, we granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3Rx and ISIS-AZ1Rx.  We also granted AstraZeneca options to license up to three drugs under the separate research program. We are responsible for completing an ongoing clinical study of ISIS-STAT3Rx and IND-enabling studies for ISIS-AZ1Rx. AstraZeneca will be responsible for all other global development, regulatory and commercialization activities for ISIS-STAT3Rx and ISIS-AZ1Rx. In addition, if AstraZeneca exercises its option for any drugs resulting from the research program, AstraZeneca will assume global development, regulatory and commercialization responsibilities for such drug.  Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that certain deliverables, either individually or in combination, have stand-alone value.  Below is a list of the four separate units of accounting under our agreement:

 

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-STAT3Rx for the treatment of cancer;

·                  The development services we will perform for ISIS-STAT3Rx;

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-AZ1Rx and the research services we will perform for ISIS-AZ1Rx; and

·                  The option to license up to three drugs under a research program and the research services we will perform for this program.

 

We determined that the ISIS-STAT3Rx license had stand-alone value because it is an exclusive license that gives AstraZeneca the right to develop ISIS-STAT3Rx or to sublicense its rights.  In addition, ISIS-STAT3Rx is currently in development and it is possible that AstraZeneca or another third party could conduct clinical trials without assistance from us.  As a result, we consider the ISIS-STAT3Rx license and the development services for ISIS-STAT3Rx to be separate units of accounting. We recognized the revenue allocated to the ISIS-STAT3Rx license on the date of the agreement because that is when we delivered the license.  We will recognize the revenue allocated to the development services for ISIS-STAT3Rx over the period of time we perform services. The ISIS-AZ1Rx license is also an exclusive license.  Because of the early stage of research for ISIS-AZ1Rx, we believe that our knowledge and expertise with antisense technology is essential for AstraZeneca or another third party to successfully develop ISIS-AZ1Rx.  As a result, we concluded that the ISIS-AZ1Rx license does not have stand-alone value and we combined the ISIS-AZ1Rx license and related research services into one unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of time we perform services. We determined that the options under the research program did not have stand-alone value because AstraZeneca cannot develop or commercialize drugs resulting from the research program until AstraZeneca exercises the respective option or options. As a result, we considered the research options and the related research services as a combined unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of our performance.

 

We determined that the allocable arrangement consideration was the $25 million upfront payment because it was the only payment that was fixed and determinable when we entered into the agreement.  There was considerable uncertainty at the date of the agreement as to whether we would earn the milestone payments, royalty payments, payments for manufacturing clinical trial materials or payments for finished drug product.  As such, we did not include those payments in the allocable consideration.

 

We allocated the $25 million upfront payment based on the relative BESP of each unit of accounting.  We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the licenses granted for ISIS-STAT3Rx and ISIS-AZ1Rx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for each drug. We then discounted the projected income for each license to present value. The significant inputs we used to determine the projected income of the licenses included:

 

·                  Estimated future product sales;

·                  Estimated royalties on future product sales;

·                  Contractual milestone payments;

·                  Expenses we expect to incur;

·                  Income taxes; and

·                  An appropriate discount rate.

 

We estimated the selling price of the research and development services by using our internal estimates of the cost to perform the specific services, marked up to include a reasonable profit margin, and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform research and development. The significant inputs we used to determine the selling price of the research and development services included:

 

·                  The number of internal hours we will spend performing these services;

·                  The estimated number and cost of studies we will perform;

·                  The estimated number and cost of studies that we will contract with third parties to perform; and

·                  The estimated cost of drug product we will use in the studies.

 

As a result of the allocation, we recognized $9.3 million of the $25 million upfront payment in December 2012 for the ISIS-STAT3Rx license.  We are recognizing the remaining $15.7 million over the estimated period of our performance. Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the ISIS-STAT3Rx  license, we determined that the revenue we would have allocated to the ISIS-STAT3Rx  license would change by approximately seven percent, or $600,000, from the amount we recorded.

 

Typically, we must estimate our period of performance when the agreements we enter into do not clearly define such information.  Our collaborative agreements typically include a research and/or development project plan that includes the activities the agreement requires each party to perform during the collaboration. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition and amortize revenue over such period. If our collaborators ask us to continue performing work in a collaboration beyond the initial period of performance, we extend our amortization period to correspond to the new extended period of performance.  The revenue we recognize could be materially different if different estimates prevail.

 

From time to time, we may enter into separate agreements at or near the same time with the same customer.  We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement.  We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement.

 

In January 2012, we entered into a collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMNRx for Spinal Muscular Atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of ISIS-SMNRx through completion of Phase 2/3 clinical trials. In June 2012, we entered into a second and separate collaboration agreement with Biogen Idec to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial. In December 2012, we entered into a third and separate collaboration agreement with Biogen Idec to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.  All three of these collaboration agreements give Biogen Idec the option or options to license one or more drugs resulting from the specific collaboration.  If Biogen Idec exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the development of the drugs prior to licensing, milestone payments if Biogen Idec achieves pre-specified regulatory milestones, and royalties on any product sales of drugs resulting from these collaborations.

 

We evaluated the SMA, DMPK, and neurology agreements to determine whether we should account for them as separate agreements or as a single multiple element arrangement.  We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, the first two agreements cover two different diseases while the targets for the third agreement are yet to be defined, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other.  We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting.  For all three of these agreements, we determined that the options did not have stand-alone value because Biogen Idec cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options.  As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective research and development term, which is the estimated period of our performance.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events.  These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

 

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery.  From these research efforts, we hope to identify a development candidate.  The designation of a development candidate is the first stage in the life-cycle of our drugs.  A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.  During the first step of the development stage, we or our partners study our drugs in IND-enabling studies, which are animal studies intended to support an Investigational New Drug, or IND, application and/or the foreign equivalent.  An approved IND allows us or our partners to study our development candidate in humans.  If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients.  If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.  The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing approval from the Food and Drug Administration, or FDA, and/or foreign equivalents.  The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete.  If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing approval.  This stage of the drug’s life-cycle is the regulatory stage.  If a drug achieves marketing approval, it moves into the commercialization stage, during which our partner will market and sell the drug to patients.  Although our partner will ultimately be responsible for marketing and selling the drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug.  The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities.  Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow our partner to successfully commercialize our drug.  Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs.  The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

 

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization.  The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain.  As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.  Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

 

Development milestones in our partnerships may include the following types of events:

 

·                  Designation of a development candidate.  Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;

·                  Initiation of a Phase 1 clinical trial.  Generally, Phase 1 clinical trials take one to two years to complete;

·                  Initiation or completion of a Phase 2 clinical trial.  Generally, Phase 2 clinical trials take one to three years to complete;

·                  Initiation or completion of a Phase 3 clinical trial.  Generally, Phase 3 clinical trials take two to four years to complete.

 

Regulatory milestones in our partnerships may include the following types of events:

 

·                  Filing of regulatory applications for marketing approval such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe.  Generally, it takes six to twelve months to prepare and submit regulatory filings.

·                  Marketing approval in a major market, such as the United States, Europe or Japan.  Generally it takes one to two years after an application is submitted to obtain approval from the applicable regulatory agency.

 

Commercialization milestones in our partnerships may include the following types of events:

 

·                  First commercial sale in a particular market, such as in the United States or Europe.

·                  Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion.  The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

 

We assess whether a substantive milestone exists at the inception of our agreements.  When a substantive milestone is achieved, we recognize revenue related to the milestone payment.  For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with ongoing access to new technologies we discover, we have determined that all future development, regulatory and commercialization milestones are substantive. For example, for our strategic alliance with GlaxoSmithKline, or GSK, we are using our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases. Alternatively, we provide on-going access to our technology to Alnylam Pharmaceuticals, Inc. to develop and commercialize RNA interference, or RNAi, therapeutics.  We consider milestones for both of these collaborations to be substantive.  For those agreements that do not meet the following criteria, we do not consider the future milestones to be substantive.  In evaluating if a milestone is substantive we consider whether:

 

·                  Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;

·                  The achievement of the milestone involves substantive effort and can only be achieved based in whole or part on our performance or the occurrence of a specific outcome resulting from our performance;

·                  The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;

·                  There is no future performance required to earn the milestone; and

·                  The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

 

If any of these conditions are not met, we will defer recognition of the milestone payment and recognize it as revenue over the estimated period of performance, if any.  In the first quarter of 2013, the FDA approved the NDA for KYNAMRO and we initiated a Phase 2/3 clinical study for ISIS-TTRRx, the first drug selected as part of our collaboration with GSK. We consider milestones related to progression of a drug through the development and regulatory stages of its life cycle to be substantive milestones because the level of effort and inherent risk associated with these events is high. Therefore, in the first quarter of 2013 we recognized the $25 million milestone payment from Genzyme and the $7.5 million milestone payment from GSK. Further information about our collaborative arrangements can be found in Note 7 Collaborative Arrangements and Licensing Agreements and Note 7 of our audited financial statements for the year ended December 31, 2012 included in our Annual Report on Form 10-K filed with the SEC.

 

Licensing and royalty revenue

 

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable.

 

Cash, cash equivalents and short-term investments

 

We consider all liquid investments with maturities of 90 days or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than 90 days from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

 

We have equity investments in privately- and publicly-held biotechnology companies that we have received as part of a technology license or collaboration agreement.  At March 31, 2013 we held ownership interests of less than 20 percent in each of the respective companies.

 

We account for our equity investments in publicly-held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly-held companies as a separate component of comprehensive income (loss).  We account for equity investments in privately-held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. Most of the cost method investments we hold are in early stage biotechnology companies and realization of our equity position in those companies is uncertain. In those circumstances we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

 

Inventory valuation

 

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials and historical write-offs. We did not record any inventory write-offs for the first three months of 2013 and 2012. Total inventory, which consisted of raw materials, was $5.8 million and $6.1 million as of March 31, 2013 and December 31, 2012, respectively.

 

Patents

 

We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. We evaluate patents and patent applications that we are not actively pursuing and write off any associated costs. We amortize patent costs over their useful lives, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent.

 

Long-lived assets

 

We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets.

 

Equity method of accounting

 

We accounted for our ownership interest in Regulus using the equity method of accounting until Regulus’ IPO in October 2012.  In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus. Under the equity method of accounting, we included our share of Regulus’ operating results on a separate line in our condensed consolidated statement of operations called “Equity in net loss of Regulus Therapeutics Inc.”

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

 

Basic and diluted net loss per share

 

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a loss for the three months ended March 31, 2013 and 2012, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.  The following would have had an anti-dilutive effect on net loss per share:

 

·                  23/4 percent convertible senior notes;

·                  25/8 percent convertible subordinated notes;

·                  GlaxoSmithKline convertible promissory notes issued by Regulus;

·                  Dilutive stock options; and

·                  Restricted stock units.

 

We redeemed all of our 25/8 percent notes in September 2012 and in October 2012 Regulus completed an IPO, upon which we were no longer guarantors on the two convertible notes that Regulus issued to GSK.  As a result, the 25/8 percent notes and GSK convertible promissory notes are not common equivalent shares for the three months ended March 31, 2013.

 

Consolidation of variable interest entities

 

We identify entities as variable interest entities either: (1) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2) in which the equity investors lack an essential characteristic of a controlling financial interest.  We perform ongoing qualitative assessments of our variable interest entities to determine whether we have a controlling financial interest in the variable interest entity and therefore are the primary beneficiary.  As of March 31, 2013 and December 31, 2012, we had collaborative arrangements with five and six entities, respectively, that we considered to be variable interest entities.  We are not the primary beneficiary for any of these entities as we do not have both the power to direct the activities that most significantly impact the economic performance of our variable interest entities and the obligation to absorb losses or the right to receive benefits from our variable interest entities that could potentially be significant to the variable interest entities.  As of March 31, 2013, the total carrying value of our investments in variable interest entities was $47.5 million, and was primarily related to our investment in Regulus. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.

 

Accumulated other comprehensive income (loss)

 

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on securities, net of taxes, and  adjustments we made to reclassify realized gains and losses on securities from other accumulated comprehensive income to our condensed consolidated statement of operations. The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March 31, 2013 and 2012 (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Beginning balance accumulated other comprehensive income (loss)

 

$

12,480

 

$

(770

)

Other comprehensive income before reclassifications, net of tax (1)

 

6,467

 

528

 

Amounts reclassified from accumulated other comprehensive income (2)

 

(1,163

)

 

Net current period other comprehensive income

 

5,304

 

528

 

Ending balance accumulated other comprehensive income (loss)

 

$

17,784

 

$

(242

)

 

(1)         Other comprehensive income for the three months ended March 31, 2013 includes income tax expense of $3.6 million.

 

(2)         Included in gain on investments, net on our condensed consolidated statement of operations.

 

Convertible debt

 

In August 2012, we completed a $201.3 million offering of convertible senior notes, which mature in 2019 and bear interest at 2¾ percent.  In September 2012, we used a substantial portion of the net proceeds from the issuance of the 2¾ percent notes to redeem our 25¤8 percent convertible subordinated notes. Consistent with how we accounted for our 25¤8 percent notes, we account for our 2¾ percent notes by separating the liability and equity components of the instrument in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our 2¾ percent notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording the debt instrument at a discount.  We are amortizing the debt discount over the life of these 2¾ percent notes as additional non-cash interest expense utilizing the effective interest method.

 

Segment information

 

We operate in a single segment, Drug Discovery and Development operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a single operating segment.

 

Stock-based compensation expense

 

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our Employee Stock Purchase Plan, or ESPP, based on the estimated fair value of the award on the date of grant using an option-pricing model. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our condensed consolidated statements of operations.  We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

 

We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under the ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding.  We estimate the expected term of options granted based on historical exercise patterns.  For the three months ended March 31, 2013 and 2012, we used the following weighted-average assumptions in our Black-Scholes calculations:

 

Employee Stock Options:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

1.0

%

1.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

51.5

%

50.6

%

Expected life

 

5.1 years

 

5.1 years

 

 

ESPP:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

0.1

%

0.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

61.4

%

43.4

%

Expected life

 

6 months

 

6 months

 

 

The fair value of RSUs is based on the market price of our common stock on the date of grant.  RSUs vest annually over a four year period.  The weighted-average grant date fair value of RSUs granted to employees for the three months ended March 31, 2013 and 2012 was $14.21 and $7.60, respectively.

 

The following table summarizes stock-based compensation expense for the three months ended March 31, 2013 and 2012 (in thousands), which was allocated as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Research and development

 

$

2,546

 

$

1,935

 

General and administrative

 

323

 

332

 

Total

 

$

2,869

 

$

2,267

 

 

As of March 31, 2013, total unrecognized estimated non-cash stock-based compensation expense related to non-vested stock options and RSUs was $10.7 million and $3.8 million, respectively. We will adjust total unrecognized compensation cost for future changes in estimated forfeitures.  We expect to recognize the cost of non-cash, stock-based compensation expense related to non-vested stock options and RSUs over a weighted average amortization period of 1.4 years and 2.1 years, respectively.

 

Impact of recently issued accounting standards

 

In February 2013, the FASB issued guidance requiring enhanced disclosures related to reclassifications out of accumulated other comprehensive income (loss).  Under the guidance, we must disclose the amounts we reclassified out of accumulated other comprehensive income (loss) by component. In addition, for significant amounts that we reclassified entirely from other comprehensive income (loss) to net loss, we must disclose the line item of net loss, either on the face of the statement of operations or in the notes to the financial statements. For amounts that we did not reclassify entirely to net loss, we must cross-reference to other disclosures that provide additional detail about those amounts. The guidance is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2012 and was effective for our fiscal year beginning January 1, 2013. As this guidance relates to disclosure only, the adoption of this guidance did not have any effect on our financial statements.

XML 21 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements and Licensing Agreements (Details) (USD $)
Share data in Millions, unless otherwise specified
3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Collaborations
Biogen Idec
Mar. 31, 2012
Collaborations
Biogen Idec
Dec. 31, 2012
Collaborations
Biogen Idec
item
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in January 2012
Phase 2/3
item
May 31, 2013
Collaborations
Biogen Idec
Agreement entered into in January 2012
Phase 2/3
Forecast
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in January 2012
Development milestones
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in January 2012
Regulatory milestones
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in June 2012
IND-enabling toxicology study
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in June 2012
Development milestones
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in June 2012
Regulatory milestones
Dec. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in December 2012
item
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in December 2012
IND-enabling toxicology study
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in December 2012
Clinical and regulatory milestones
Mar. 31, 2013
Collaborations
Biogen Idec
Agreement entered into in December 2012
Regulatory milestones
Jan. 31, 2013
Collaborations
Genzyme Corporation
May 31, 2012
Collaborations
Genzyme Corporation
Jan. 31, 2008
Collaborations
Genzyme Corporation
Mar. 31, 2013
Collaborations
Genzyme Corporation
Mar. 31, 2012
Collaborations
Genzyme Corporation
Dec. 31, 2012
Collaborations
Genzyme Corporation
Mar. 31, 2013
Collaborations
Genzyme Corporation
Minimum
Mar. 31, 2013
Collaborations
Genzyme Corporation
Maximum
Mar. 31, 2013
Collaborations
Genzyme Corporation
Pre-specified events
Mar. 31, 2013
Collaborations
Genzyme Corporation
Regulatory milestones
Mar. 31, 2013
Collaborations
Genzyme Corporation
Commercialization milestones
Feb. 28, 2013
Collaborations
Glaxo Smith Kline
Oct. 31, 2012
Collaborations
Glaxo Smith Kline
item
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
item
Mar. 31, 2012
Collaborations
Glaxo Smith Kline
Dec. 31, 2012
Collaborations
Glaxo Smith Kline
Dec. 31, 2012
Collaborations
Glaxo Smith Kline
ISIS-TTR
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Up to Phase 2 proof-of-concept
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Phase 2/3
ISIS-TTR
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Pre-specified events
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Development milestones
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Development milestones
ISIS-TTR
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Pre-licensing milestones
Phase 2/3
ISIS-TTR
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Regulatory milestones
Mar. 31, 2013
Collaborations
Glaxo Smith Kline
Commercialization milestones
Apr. 30, 2013
Collaborations
Roche
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Drug targeting HTT protein
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Pre-specified events
Drug targeting HTT protein
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Pre-specified events
Additional drugs
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Development milestones
Drug targeting HTT protein
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Regulatory milestones
Drug targeting HTT protein
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Commercialization milestones
Drug targeting HTT protein
Subsequent Event
Apr. 30, 2013
Collaborations
Roche
Commercialization milestones
Drug using Roche's proprietary brain shuttle technology
Subsequent Event
Mar. 31, 2013
Collaborations
CHDI Foundation, Inc.
Mar. 31, 2012
Collaborations
CHDI Foundation, Inc.
Dec. 31, 2012
Collaborations
CHDI Foundation, Inc.
Apr. 30, 2013
Collaborations
CHDI Foundation, Inc.
Subsequent Event
Apr. 30, 2013
Collaborations
CHDI Foundation, Inc.
Development milestones
Forecast
Subsequent Event
Collaborations                                                                                                                
Number of targets                             3                                                                                  
Upfront fee received           $ 29,000,000         $ 12,000,000       $ 30,000,000                                       $ 2,500,000                 $ 30,000,000                        
Number of collaborations         3                                                                                                      
License fee received                                         175,000,000                                                                      
Equity investment in entity made by strategic alliance partner                                         150,000,000                                                                      
Equity investment in entity made by strategic alliance partner (in shares)                                         5                                                                      
Profit share as percentage of commercial sales                                                 30.00% 50.00%                                                            
Maximum number of programs under strategic alliance                                                               6                                                
Number of programs under strategic alliance, not accelerated                                                             5                                                  
Milestone payment recognized               3,500,000                     25,000,000     25,000,000               7,500,000   7,500,000                                                
Cumulative payments earned under collaborative arrangement at period end                                                                               17,500,000                                
Maximum amount of payments receivable                 45,000,000 150,000,000     59,000,000 130,000,000                         1,500,000,000 700,000,000 825,000,000                 1,300,000,000 231,500,000   50,000,000 594,500,000 545,000,000     362,000,000   67,000,000 170,000,000 80,000,000 50,000,000          
Number of milestones payments             4                                                                                                  
Next prospective milestone             18,000,000         10,000,000       10,000,000           25,000,000                             2,000,000               22,000,000                      
Maximum amount of payments receivable per drug under strategic alliance                               10,000,000 200,000,000 130,000,000                                                         136,500,000                  
Minimum annual net revenues to earn next milestone payment                                           250,000,000                                                                    
Initial development cost contributed                                           125,000,000                                                                    
Period following an acquisition within which collaborator may purchase rights to receive payments                                           180 days                                                                    
Period for which additional shares of Isis common stock will not be purchased without consent                                         10 years                                                                      
Ownership percentage of Isis stock below which strategic partner may acquire additional shares without prior consent                                           2.00%                                                                    
Premium for which amortization was completed during the period                                       100,000,000                                                                        
License fee for which amortization was completed during the period                                       175,000,000                                                                        
Revenue earned 43,360,000 23,235,000 3,900,000 1,800,000                                   25,000,000 16,400,000                 9,900,000 2,000,000                                     293,000 1,200,000      
Percent of total revenue                                           58.00% 71.00%                 23.00% 9.00%                                              
Deferred revenue     59,200,000   62,600,000                                 3,800,000   3,800,000               17,600,000   19,900,000                                       229,000    
Average maximum milestone payments receivable per program                                                                       20,000,000                                        
Expense reimbursement paid                                                                                                             $ 1,500,000 $ 1,500,000
XML 22 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 107,650 $ 124,482
Short-term investments 264,261 249,964
Contracts receivable 1,172 522
Inventories 5,809 6,121
Investment in Regulus Therapeutics Inc. 44,863 33,622
Other current assets 8,074 8,727
Total current assets 431,829 423,438
Property, plant and equipment, net 89,694 91,084
Licenses, net 6,010 6,579
Patents, net 19,604 18,646
Deposits and other assets 5,824 5,939
Total assets 552,961 545,686
Current liabilities:    
Accounts payable 5,385 10,239
Accrued compensation 3,818 7,878
Accrued liabilities 17,758 15,401
Accrued income taxes 3,582  
Current portion of long-term obligations 4,508 4,879
Current portion of deferred contract revenue 35,244 35,925
Total current liabilities 70,295 74,322
Long-term deferred contract revenue 58,816 66,656
2 3/4 percent convertible senior notes 145,533 143,990
Long-term obligations, less current portion 6,498 7,402
Long-term financing liability for leased facility 70,728 70,550
Total liabilities 351,870 362,920
Stockholders' equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 102,695,200 and 101,481,134 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively 103 102
Additional paid-in capital 1,091,842 1,077,150
Accumulated other comprehensive gain 17,784 12,480
Accumulated deficit (908,638) (906,966)
Total stockholders' equity 201,091 182,766
Total liabilities and stockholders' equity $ 552,961 $ 545,686
XML 23 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS    
Net cash used in operating activities $ (10,576) $ (6,711)
Investing activities:    
Purchases of short-term investments (64,552) (61,841)
Proceeds from the sale of short-term investments 49,076 61,781
Purchases of property, plant and equipment (222) (113)
Acquisition of licenses and other assets, net (702) (349)
Proceeds from sale of strategic investments 1,094  
Net cash used in investing activities (15,306) (522)
Financing activities:    
Proceeds from issuance of equity 11,823 638
Principal payments on debt and capital lease obligations (2,773) (2,491)
Net cash provided by (used in) financing activities 9,050 (1,853)
Net decrease in cash and cash equivalents (16,832) (9,086)
Cash and cash equivalents at beginning of period 124,482 65,477
Cash and cash equivalents at end of period 107,650 56,391
Supplemental disclosures of cash flow information:    
Interest paid 113 2,211
Income taxes paid 2  
Supplemental disclosures of non-cash investing and financing activities:    
Amounts accrued for capital and patent expenditures $ 715 $ 844
XML 24 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 4) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Summary of changes in accumulated other comprehensive income (loss)    
Beginning balance accumulated other comprehensive income (loss) $ 12,480,000 $ (770,000)
Other comprehensive income before reclassifications, net of tax 6,467,000 528,000
Amounts reclassified from accumulated other comprehensive income (1,163,000)  
Net current period other comprehensive income 5,304,000 528,000
Ending balance accumulated other comprehensive income (loss) 17,784,000 (242,000)
Income tax expense included in other comprehensive income $ 3,600,000  
XML 25 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 6) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Employee Stock Options:
   
Weighted-average assumptions    
Risk-free interest rate (as a percent) 1.00% 1.10%
Dividend yield (as a percent) 0.00% 0.00%
Volatility (as a percent) 51.50% 50.60%
Expected life 5 years 1 month 6 days 5 years 1 month 6 days
ESPP:
   
Weighted-average assumptions    
Risk-free interest rate (as a percent) 0.10% 0.10%
Dividend yield (as a percent) 0.00% 0.00%
Volatility (as a percent) 61.40% 43.40%
Expected life 6 months 6 months
RSUs
   
Weighted-average assumptions    
Vesting period 4 years  
RSUs | Employees
   
Weighted-average assumptions    
Weighted-average grant date fair value (in dollars per share) 14.21 7.60
XML 26 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 27 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation
3 Months Ended
Mar. 31, 2013
Basis of Presentation  
Basis of Presentation

1.                                      Basis of Presentation

 

The unaudited interim condensed consolidated financial statements for the three month periods ended March 31, 2013 and 2012 have been prepared on the same basis as the audited financial statements for the year ended December 31, 2012. The financial statements include all normal recurring adjustments, which we consider necessary for a fair presentation of our financial position at such dates and our operating results and cash flows for those periods. Results for the interim periods are not necessarily indicative of the results for the entire year. For more complete financial information, these financial statements, and notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2012 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).

 

The condensed consolidated financial statements include the accounts of Isis Pharmaceuticals, Inc. (“we”, “us” or “our”) and our wholly owned subsidiary, Symphony GenIsis, Inc., which is currently inactive.  In addition to our wholly owned subsidiary, our consolidated financial statements include our equity investment in Regulus Therapeutics Inc. In October 2012, Regulus completed an initial public offering (IPO).  We now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus.  As a result, in the fourth quarter of 2012, we stopped using the equity method of accounting for our equity investment in Regulus and we began accounting for our investment at fair value.

XML 28 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Mar. 31, 2013
Dec. 31, 2012
CONDENSED CONSOLIDATED BALANCE SHEETS    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 102,695,200 101,481,134
Common stock, shares outstanding 102,695,200 101,481,134
XML 29 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2013
Fair Value Measurements  
Schedule of assets measured at fair value on a recurring basis

We break down the inputs used to measure fair value for these assets at March 31, 2013 and December 31, 2012 as follows (in thousands):

 

 

 

At March 31,
2013

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

96,072

 

$

91,072

 

$

5,000

 

$

 

Corporate debt securities (2)

 

205,098

 

 

205,098

 

 

Debt securities issued by U.S. government agencies (2)

 

24,939

 

 

24,939

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,424

 

13,424

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

20,800

 

 

20,800

 

 

Investment in Regulus Therapeutics Inc.

 

44,863

 

 

 

44,863

 

Equity securities (3)

 

2,619

 

2,619

 

 

 

Total

 

$

407,815

 

$

107,115

 

$

255,837

 

$

44,863

 

 

 

 

At December 31,
2012

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

105,496

 

$

101,496

 

$

4,000

 

$

 

Corporate debt securities (2)

 

193,507

 

 

193,507

 

 

Debt securities issued by U.S. government agencies (2)

 

18,108

 

 

18,108

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,452

 

13,452

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

24,897

 

 

24,897

 

 

Investment in Regulus Therapeutics Inc.

 

33,622

 

 

 

33,622

 

Equity securities (3)

 

4,874

 

4,146

 

 

728

 

Total

 

$

393,956

 

$

119,094

 

$

240,512

 

$

34,350

 

 

(1)         Included in cash and cash equivalents on our consolidated balance sheet.

 

(2)         Included in short-term investments on our consolidated balance sheet.

 

(3)         Included in other current assets on our consolidated balance sheet.

 

Summary of investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3)

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2013 (in thousands):

 

 

 

Investments

Valued Using

Level 3 Inputs

 

Balance at December 31, 2012

 

$

34,350

 

Total gains and losses:

 

 

 

Included in gain on investments

 

(1,163

)

Included in accumulated other comprehensive income (loss)

 

11,716

 

Cost basis of shares sold

 

(40

)

Balance at March 31, 2013

 

$

44,863

 

 

XML 30 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
3 Months Ended
Mar. 31, 2013
May 02, 2013
Document and Entity Information    
Entity Registrant Name ISIS PHARMACEUTICALS INC  
Entity Central Index Key 0000874015  
Document Type 10-Q  
Document Period End Date Mar. 31, 2013  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   103,780,421
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q1  
XML 31 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentration of Business Risk (Tables)
3 Months Ended
Mar. 31, 2013
Concentration of Business Risk  
Schedule of revenue from significant partners

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Partner A

 

58

%

71

%

Partner B

 

23

%

9

%

 

XML 32 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenue:    
Research and development revenue under collaborative agreements $ 41,921 $ 21,818
Licensing and royalty revenue 1,439 1,417
Total revenue 43,360 23,235
Expenses:    
Research and development 38,312 38,714
General and administrative 3,423 2,976
Total operating expenses 41,735 41,690
Income (loss) from operations 1,625 (18,455)
Other income (expense):    
Equity in net loss of Regulus Therapeutics Inc.   (976)
Investment income 376 600
Interest expense (4,795) (5,179)
Gain on investments, net 1,058 17
Loss before income tax benefit (expense) (1,736) (23,993)
Income tax benefit (expense) 64 (2)
Net loss $ (1,672) $ (23,995)
Basic and diluted net loss per share (in dollars per share) $ (0.02) $ (0.24)
Shares used in computing basic net loss per share (in shares) 101,875 100,157
Shares used in computing diluted net loss per share (in shares) 101,875 100,157
XML 33 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
3 Months Ended
Mar. 31, 2013
Income Taxes  
Income Taxes

6.                                      Income Taxes

 

Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income.  In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as other comprehensive income, we must allocate the tax provision to the other categories of earnings. We then record a related tax benefit in continuing operations. During the first quarter of 2013, we recorded unrealized gains on our investments in available-for-sale securities in other comprehensive income net of taxes.  As a result, we recorded a $64,000 tax benefit on our condensed consolidated statements of operations and a $3.6 million tax expense in other comprehensive income for the three months ended March 31, 2013.

XML 34 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentration of Business Risk
3 Months Ended
Mar. 31, 2013
Concentration of Business Risk  
Concentration of Business Risk

5.                                      Concentration of Business Risk

 

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Partner A

 

58

%

71

%

Partner B

 

23

%

9

%

 

Contract receivables from four significant partners comprised approximately 88 percent of our contract receivables at March 31, 2013. Contract receivables from four significant partners comprised approximately 83 percent of our contract receivables at December 31, 2012.

 

XML 35 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 5) (USD $)
In Millions, unless otherwise specified
1 Months Ended
Aug. 31, 2012
2 3/4 percent convertible senior notes
Mar. 31, 2013
2 3/4 percent convertible senior notes
Sep. 30, 2012
2 5/8 percent convertible subordinated notes
Long-term obligations      
Interest rate on convertible debt (as a percent)   2.75% 2.625%
Debt issued $ 201.3    
XML 36 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details) (USD $)
3 Months Ended 0 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Oct. 31, 2012
GSK
Convertible notes guarantee obligation
Regulus
security
Mar. 31, 2013
Collaborations
item
Mar. 31, 2013
Collaborations
New development candidate
Minimum
Mar. 31, 2013
Collaborations
New development candidate
Maximum
Mar. 31, 2013
Collaborations
Phase 1
Minimum
Mar. 31, 2013
Collaborations
Phase 1
Maximum
Mar. 31, 2013
Collaborations
Phase 2
Minimum
Mar. 31, 2013
Collaborations
Phase 2
Maximum
Mar. 31, 2013
Collaborations
Phase 3
Minimum
Mar. 31, 2013
Collaborations
Phase 3
Maximum
Mar. 31, 2013
Collaborations
Regulatory milestones
Minimum
Mar. 31, 2013
Collaborations
Regulatory milestones
Maximum
Mar. 31, 2013
Collaborations
Commercialization milestones
Dec. 31, 2012
Collaborations
AstraZeneca
item
Mar. 31, 2013
Collaborations
AstraZeneca
item
Mar. 31, 2013
Collaborations
AstraZeneca
Maximum
item
Jun. 30, 2013
Collaborations
AstraZeneca
Forecast
Mar. 31, 2013
Collaborations
Biogen Idec
Mar. 31, 2012
Collaborations
Biogen Idec
Dec. 31, 2012
Collaborations
Biogen Idec
item
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Dec. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in December 2012
item
Jan. 31, 2013
Collaborations
Genzyme Corporation
Mar. 31, 2013
Collaborations
Genzyme Corporation
Mar. 31, 2012
Collaborations
Genzyme Corporation
Dec. 31, 2012
Collaborations
Genzyme Corporation
Feb. 28, 2013
Collaborations
GSK
Mar. 31, 2013
Collaborations
GSK
Mar. 31, 2012
Collaborations
GSK
Dec. 31, 2012
Collaborations
GSK
Research and development revenue under collaborative agreements                                                                  
Number of targets                               5                 3                
Upfront fee received                               $ 25,000,000     $ 6,000,000       $ 29,000,000 $ 12,000,000 $ 30,000,000                
Number of drugs collaborative partner may license under the separate research program                                   3                              
Number of units of accounting                                 4                                
Revenue earned 43,360,000 23,235,000                           9,300,000       3,900,000 1,800,000           25,000,000 16,400,000     9,900,000 2,000,000  
Deferred revenue                                 15,700,000     59,200,000   62,600,000         3,800,000   3,800,000   17,600,000   19,900,000
Assumed change in estimated selling price of ISIS-STAT3 (as a percent)                               10.00%                                  
Percentage by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price                               7.00%                                  
Amount by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price                               600,000                                  
Number of collaborative agreements                                           3                      
Number of convertible notes no longer guaranteed     2                                                            
Number of categories of milestone events       3                                                          
Number of stages of life-cycle of drugs       3                                                          
Completion period         12 months 18 months 1 year 2 years 1 year 3 years 2 years 4 years                                          
Time to prepare and submit regulatory filings                         6 months 12 months                                      
Time to obtain approval                         1 year 2 years                                      
Example of sales threshold as milestone event                             1,000,000,000                                    
Milestone payment recognized                                                   $ 25,000,000 $ 25,000,000     $ 7,500,000 $ 7,500,000    
XML 37 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2013
Significant Accounting Policies  
Summarizes changes in other accumulated other comprehensive income (loss) related to unrealized gains and losses on securities

The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March 31, 2013 and 2012 (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Beginning balance accumulated other comprehensive income (loss)

 

$

12,480

 

$

(770

)

Other comprehensive income before reclassifications, net of tax (1)

 

6,467

 

528

 

Amounts reclassified from accumulated other comprehensive income (2)

 

(1,163

)

 

Net current period other comprehensive income

 

5,304

 

528

 

Ending balance accumulated other comprehensive income (loss)

 

$

17,784

 

$

(242

)

 

(1)         Other comprehensive income for the three months ended March 31, 2013 includes income tax expense of $3.6 million.

 

(2)         Included in gain on investments, net on our condensed consolidated statement of operations.

 

Schedule of weighted-average assumptions used for valuation of stock options

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

1.0

%

1.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

51.5

%

50.6

%

Expected life

 

5.1 years

 

5.1 years

 

Schedule of weighted-average assumptions used for valuation of ESPP

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

0.1

%

0.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

61.4

%

43.4

%

Expected life

 

6 months

 

6 months

 

Schedule of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three months ended March 31, 2013 and 2012 (in thousands), which was allocated as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Research and development

 

$

2,546

 

$

1,935

 

General and administrative

 

323

 

332

 

Total

 

$

2,869

 

$

2,267

 

 

XML 38 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements and Licensing Agreements
3 Months Ended
Mar. 31, 2013
Collaborative Arrangements and Licensing Agreements  
Collaborative Arrangements and Licensing Agreements

7.                                      Collaborative Arrangements and Licensing Agreements

 

Traditional Pharmaceutical Alliances and Licensing

 

Biogen Idec

 

We have established three strategic collaborations with Biogen Idec that broaden and expand our severe and rare disease franchise.  In January 2012, we entered into a global collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy, or SMA. Under the terms of the agreement, we received an upfront payment of $29 million and are eligible to receive up to $45 million in substantive milestone payments associated with the clinical development of ISIS-SMNRx prior to licensing.  We are responsible for developing ISIS-SMNRx. Biogen Idec has the option to license ISIS-SMNRx until completion of the first successful Phase 2/3 study or the completion of two Phase 2/3 studies.  If Biogen Idec exercises its option, it will pay us a license fee and will assume global development, regulatory and commercialization responsibilities. In April 2013, we initiated a Phase 2 study of ISIS-SMNRx in infants with SMA, which initiates the Phase 2/3 program for ISIS-SMNRx.  We will earn a $3.5 million milestone payment from Biogen Idec when we dose the first infant in this Phase 2 study, which we project will be May 2013. The $3.5 million milestone payment is the first of four payments under the March 2013 amendment to the payment terms for the next potential $18 million milestone payment we could earn for the progression of this Phase 2/3 study in infants.  We are also eligible to receive up to $150 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.  In addition, we are eligible to receive up to double-digit royalties on any product sales of ISIS-SMNRx.

 

In June 2012, we and Biogen Idec entered into a second and separate collaboration and license agreement to develop and commercialize a novel antisense drug targeting DMPK for the treatment of myotonic dystrophy type 1, or DM1.  Under the terms of the agreement, we received an upfront payment of $12 million and are eligible to receive up to $59 million in substantive milestone payments associated with the development of the DMPK-targeting drug prior to licensing. We are responsible for global development of the drug through the completion of a Phase 2 clinical trial.  Biogen Idec has the option to license the drug through the completion of the Phase 2 trial.  We are also eligible to receive up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones. In addition, we are eligible to receive up to double-digit royalties on any product sales of the drug. We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for our DMPK program.

 

In December 2012, we and Biogen Idec entered into a third and separate collaboration to develop and commercialize novel antisense drugs to three targets to treat neurological or neuromuscular diseases.  We are responsible for the development of the drugs through the completion of the initial Phase 2 clinical study.  Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 studies. Under the terms of the agreement, we received an upfront payment of $30 million and are eligible to receive development milestone payments to support research and development of each program including a $10 million milestone payment per program upon initiation of an IND-enabling toxicology study.  We are also eligible to receive up to another $200 million in a license fee and regulatory milestone payments per program including up to $130 million in substantive milestone payments if Biogen Idec achieves pre-specified regulatory milestones.  In addition, we are eligible to receive double-digit royalties on any product sales of drugs resulting from each of the three programs.  We will earn the next milestone payment of $10 million if we initiate an IND-enabling toxicology study for a development candidate identified under this collaboration.

 

During the three months ended March 31, 2013 and 2012, we earned revenue of $3.9 million and $1.8 million, respectively, from our relationships with Biogen Idec.  Our balance sheets at March 31, 2013 and December 31, 2012 included deferred revenue of $59.2 million and $62.6 million, respectively, related to the upfront payments.

 

Genzyme Corporation, a Sanofi company

 

In January 2008, we entered into a strategic alliance with Genzyme focused on the licensing and co-development of KYNAMRO. The license and co-development agreement provides Genzyme with exclusive worldwide rights for all therapeutic purposes to our patents and know-how related to KYNAMRO, including the key product related patents and their foreign equivalents pending or granted in various countries outside the United States, including in the European Union via the European Patent Convention, Japan, Canada, Australia, South Africa and India.  In addition, we agreed that we would not develop or commercialize another oligonucleotide-based compound designed to modulate apo-B by binding to the messenger RNA, or mRNA, encoding apo-B, throughout the world.

 

The transaction included a $175 million licensing fee, a $150 million equity investment in our stock in which we issued Genzyme five million shares of our common stock, and a share of worldwide profits on KYNAMRO and follow-on drugs ranging from 30 percent to 50 percent of all commercial sales. In January 2013 we earned a $25 million milestone payment when the FDA approved the NDA for KYNAMRO. We may also receive over $1.5 billion in substantive milestone payments if Genzyme achieves pre-specified events, including up to $700 million for the achievement of regulatory milestones and up to $825 million for the achievement of commercialization milestones.  The next milestone payment we could earn under our agreement with Genzyme is $25 million upon the earlier of an NDA approval for the use of KYNAMRO to treat patients who have heterozygous FH or annual net revenue equal to or greater than $250 million in a calendar year.

 

Under this alliance, Genzyme is responsible for the continued development and commercialization of KYNAMRO.  We agreed to supply the drug substance for KYNAMRO for the Phase 3 clinical trials and initial commercial launch.  Genzyme is responsible for manufacturing the finished drug product for KYNAMRO, including the initial commercial launch supply, and Genzyme will be responsible for the long term supply of KYNAMRO drug substance and finished drug product.  As part of the agreement, we contributed the first $125 million in funding for the development costs of KYNAMRO.  In 2011, we satisfied our development funding obligation.  As such, we and Genzyme shared development expenses equally in 2012.  Our shared funding of development expenses will end when KYNAMRO is profitable.

 

The license and co-development agreement for KYNAMRO will continue in perpetuity unless we or Genzyme terminate it earlier under the following situations:

 

·                  Genzyme may terminate the license and co-development agreement at any time by providing written notice to Isis;

·                  We may terminate the license and co-development agreement on a country-by-country basis or in its entirety upon Genzyme’s uncured failure to use commercially reasonable efforts to develop and commercialize KYNAMRO in the United States, France, Germany, Italy, Spain, the United Kingdom, Japan and Canada; and

·                  Either we or Genzyme may terminate the license and co-development agreement upon the other party’s uncured failure to perform a material obligation under the agreement.

 

Upon termination of the license and co-development agreement, the license we granted to Genzyme for KYNAMRO will terminate and Genzyme will stop selling the product.  In addition, if Genzyme voluntarily terminates the agreement or we terminate the agreement in a country or countries for Genzyme’s failure to develop and commercialize KYNAMRO, then the rights to KYNAMRO will revert back to us and we may develop and commercialize KYNAMRO in the countries that are the subject of the termination, subject to a royalty payable to Genzyme.

 

If we are the subject of an acquisition, then within 180 days following the acquisition, Genzyme may elect to purchase all of our rights to receive payments under the KYNAMRO license and co-development agreement for a purchase price to be mutually agreed to by us and Genzyme, or, if we cannot agree, a fair market value price determined by an independent investment banking firm.

 

Genzyme has agreed to monthly limits on the number of shares it can sell of the Company’s stock that it purchased in February 2008.  In addition, Genzyme has agreed that until the earlier of the 10 year anniversary of the KYNAMRO license and co-development agreement or the date Genzyme holds less than two percent of our issued and outstanding common stock, Genzyme will not acquire any additional shares of our common stock without our consent.

 

The price Genzyme paid for our common stock represented a significant premium over the then fair value of our common stock.  In May 2012, we finished amortizing this $100 million premium along with the $175 million licensing fee that we received in the second quarter of 2008.  During the three months ended March 31, 2013 and 2012, we earned revenue of $25.0 million and $16.4 million, respectively, from our relationship with Genzyme, which represented 58 percent and 71 percent, respectively, of our total revenue for those periods.  Our balance sheets at both March 31, 2013 and December 31, 2012 included deferred revenue of $3.8 million that Genzyme paid for KYNAMRO drug substance.

 

GlaxoSmithKline

 

In March 2010, we entered into a strategic alliance with GSK, which covers up to six programs, in which we use our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.  This alliance allows us to control and facilitate rapid development of drugs while still being eligible to receive milestone payments as we advance these drugs in clinical development.

 

Under the terms of the original agreement, which includes five programs in addition to the transthyretin, or TTR, program, we are eligible to receive on average up to $20 million in milestone payments per program up to Phase 2 proof-of-concept GSK has the option to license drugs from these programs at Phase 2 proof-of-concept, and will be responsible for all further development and commercialization.  In October 2012, we and GSK amended the original agreement to reflect an accelerated clinical development plan for ISIS-TTRRx Under the amended terms of the agreement, we received a $2.5 million upfront payment in December 2012, and we received a $7.5 million milestone payment in February 2013 when we initiated the Phase 2/3 clinical study for ISIS-TTRRx.  We have already earned $17.5 million in milestone payments from GSK related to the development of ISIS-TTRRx, and we are eligible to earn an additional $50 million in pre-licensing milestone payments associated with the ISIS-TTRRx Phase 2/3 study.  In addition, GSK has increased the regulatory and commercial milestone payments we can earn should ISIS-TTRRx achieve registration and meet certain sales thresholds.

 

Under the terms of the amended agreement, if GSK successfully develops all six programs for one or more indications and achieves pre-agreed sales targets, we could receive license fees and substantive milestone payments of more than $1.3 billion, including up to $231.5 million for the achievement of development milestones, up to $594.5 million for the achievement of regulatory milestones and up to $545 million for the achievement of commercialization milestones.  We will earn the next milestone payment of $2 million upon dosing the 10th patient in the Phase 2/3 clinical study for ISIS-TTRRx. In addition, we are eligible to receive up to double-digit royalties on sales from any product that GSK successfully commercializes under this alliance.

 

During the three months ended March 31, 2013 and 2012, we earned revenue of $9.9 million and $2.0 million, respectively, from our relationship with GSK, which represented 23 percent and nine percent, respectively, of our total revenue for those periods.  Our balance sheets at March 31, 2013 and December 31, 2012 included deferred revenue of $17.6 million and $19.9 million, respectively, related to the upfront and expansion payments.

 

Roche

 

In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for Huntington’s disease, or HD, based on our antisense technology. Roche has the option to license the drugs from us through the completion of the first Phase 1 trial.  Prior to option exercise, we are responsible for the discovery and development of an antisense drug targeting huntingtin, or HTT, protein. We will also work collaboratively with Roche on the discovery of an antisense drug utilizing Roche’s “brain shuttle” program.  If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for all drugs arising out of the collaboration.  Under the terms of the agreement, we received an upfront payment of $30.0 million in April 2013 and we are eligible to receive up to $362.0 million in a license fee and substantive milestone payments including up to $67.0 million for the achievement of development milestones, up to $170.0 million for the achievement of regulatory milestones and up to $80.0 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed as well as up to $50.0 million in commercial milestones if a drug using Roche’s proprietary brain shuttle technology is successfully commercialized.  We are also eligible to receive tiered royalties on any product sales of drugs resulting from this alliance. We will earn the next milestone payment of $22.0 million upon initiation of a Phase 1 Trial for a drug targeting HTT protein.

 

External Project Funding

 

CHDI Foundation, Inc.

 

Since November 2007, CHDI has provided financial and scientific support to our HD drug discovery program through our development collaboration.  In April 2013, we formed an alliance with Roche to develop treatments for HD. Under the terms of our agreement with CHDI, we will reimburse CHDI for its support of our program out of the payments we receive from Roche. In April 2013, we paid CHDI $1.5 million associated with the signing of the Roche agreement, which we will record as research and development expense in the second quarter of 2013.  We will also pay CHDI $1.5 million when we select a development candidate and if we achieve certain milestones under our collaboration with Roche we will make additional payments to CHDI.  During the three months ended March 31, 2013 and 2012, we earned revenue of $293,000 and $1.2 million, respectively, from our relationship with CHDI. Our balance sheet at December 31, 2012 included deferred revenue of $229,000 related to our relationship with CHDI.

XML 39 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2013
Significant Accounting Policies  
Revenue Recognition

Revenue Recognition

 

We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In those instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.

 

Research and development revenue under collaborative agreements

 

Our collaboration agreements typically contain multiple elements, or deliverables, including technology licenses or options to obtain technology licenses, research and development services, and in certain cases manufacturing services. Our collaborations may provide for various types of payments to us including upfront payments, funding of research and development, milestone payments, licensing fees, profit sharing and royalties on product sales. We evaluate the deliverables in our collaboration agreements to determine whether they meet the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and then accounted for as a single unit of accounting. When the delivered items in an arrangement have “stand-alone value” to our customer, we account for the deliverables as separate units of accounting and we allocate the consideration to each unit of accounting based on the relative selling price of each deliverable. Delivered items have stand-alone value if they are sold separately by any vendor or the customer could resell the delivered items on a standalone basis. We use the following hierarchy of values to estimate the selling price of each deliverable: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price, or BESP. The BESP reflects our best estimate of what the selling price would be if we regularly sold the deliverable on a stand-alone basis. We recognize the revenue allocated to each unit of accounting as we deliver the related goods or services. If we determine that we should treat certain deliverables as a single unit of accounting, then we recognize the revenue ratably over our estimated period of performance.

 

In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense therapeutics against five cancer targets. As part of the collaboration, we received a $25 million upfront payment and are eligible to receive a $6 million payment in the second quarter of 2013 assuming the research program is continuing.  We are also eligible to receive milestone payments, license fees for the research program targets and royalties on any product sales of drugs resulting from this collaboration. In exchange, we granted AstraZeneca an exclusive license to develop and commercialize ISIS-STAT3Rx and ISIS-AZ1Rx.  We also granted AstraZeneca options to license up to three drugs under the separate research program. We are responsible for completing an ongoing clinical study of ISIS-STAT3Rx and IND-enabling studies for ISIS-AZ1Rx. AstraZeneca will be responsible for all other global development, regulatory and commercialization activities for ISIS-STAT3Rx and ISIS-AZ1Rx. In addition, if AstraZeneca exercises its option for any drugs resulting from the research program, AstraZeneca will assume global development, regulatory and commercialization responsibilities for such drug.  Since this agreement has multiple elements, we evaluated the deliverables in this arrangement and determined that certain deliverables, either individually or in combination, have stand-alone value.  Below is a list of the four separate units of accounting under our agreement:

 

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-STAT3Rx for the treatment of cancer;

·                  The development services we will perform for ISIS-STAT3Rx;

·                  The exclusive license we granted to AstraZeneca to develop and commercialize ISIS-AZ1Rx and the research services we will perform for ISIS-AZ1Rx; and

·                  The option to license up to three drugs under a research program and the research services we will perform for this program.

 

We determined that the ISIS-STAT3Rx license had stand-alone value because it is an exclusive license that gives AstraZeneca the right to develop ISIS-STAT3Rx or to sublicense its rights.  In addition, ISIS-STAT3Rx is currently in development and it is possible that AstraZeneca or another third party could conduct clinical trials without assistance from us.  As a result, we consider the ISIS-STAT3Rx license and the development services for ISIS-STAT3Rx to be separate units of accounting. We recognized the revenue allocated to the ISIS-STAT3Rx license on the date of the agreement because that is when we delivered the license.  We will recognize the revenue allocated to the development services for ISIS-STAT3Rx over the period of time we perform services. The ISIS-AZ1Rx license is also an exclusive license.  Because of the early stage of research for ISIS-AZ1Rx, we believe that our knowledge and expertise with antisense technology is essential for AstraZeneca or another third party to successfully develop ISIS-AZ1Rx.  As a result, we concluded that the ISIS-AZ1Rx license does not have stand-alone value and we combined the ISIS-AZ1Rx license and related research services into one unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of time we perform services. We determined that the options under the research program did not have stand-alone value because AstraZeneca cannot develop or commercialize drugs resulting from the research program until AstraZeneca exercises the respective option or options. As a result, we considered the research options and the related research services as a combined unit of accounting.  We will recognize revenue for the combined unit of accounting over the period of our performance.

 

We determined that the allocable arrangement consideration was the $25 million upfront payment because it was the only payment that was fixed and determinable when we entered into the agreement.  There was considerable uncertainty at the date of the agreement as to whether we would earn the milestone payments, royalty payments, payments for manufacturing clinical trial materials or payments for finished drug product.  As such, we did not include those payments in the allocable consideration.

 

We allocated the $25 million upfront payment based on the relative BESP of each unit of accounting.  We engaged a third party, independent valuation expert to assist us with determining BESP. We estimated the selling price of the licenses granted for ISIS-STAT3Rx and ISIS-AZ1Rx by using the relief from royalty method. Under this method, we estimated the amount of income, net of taxes, for each drug. We then discounted the projected income for each license to present value. The significant inputs we used to determine the projected income of the licenses included:

 

·                  Estimated future product sales;

·                  Estimated royalties on future product sales;

·                  Contractual milestone payments;

·                  Expenses we expect to incur;

·                  Income taxes; and

·                  An appropriate discount rate.

 

We estimated the selling price of the research and development services by using our internal estimates of the cost to perform the specific services, marked up to include a reasonable profit margin, and estimates of expected cash outflows to third parties for services and supplies over the expected period that we will perform research and development. The significant inputs we used to determine the selling price of the research and development services included:

 

·                  The number of internal hours we will spend performing these services;

·                  The estimated number and cost of studies we will perform;

·                  The estimated number and cost of studies that we will contract with third parties to perform; and

·                  The estimated cost of drug product we will use in the studies.

 

As a result of the allocation, we recognized $9.3 million of the $25 million upfront payment in December 2012 for the ISIS-STAT3Rx license.  We are recognizing the remaining $15.7 million over the estimated period of our performance. Assuming a constant selling price for the other elements in the arrangement, if there was an assumed ten percent increase or decrease in the estimated selling price of the ISIS-STAT3Rx  license, we determined that the revenue we would have allocated to the ISIS-STAT3Rx  license would change by approximately seven percent, or $600,000, from the amount we recorded.

 

Typically, we must estimate our period of performance when the agreements we enter into do not clearly define such information.  Our collaborative agreements typically include a research and/or development project plan that includes the activities the agreement requires each party to perform during the collaboration. We estimate the period of time over which we will complete the activities for which we are responsible and use that period of time as our period of performance for purposes of revenue recognition and amortize revenue over such period. If our collaborators ask us to continue performing work in a collaboration beyond the initial period of performance, we extend our amortization period to correspond to the new extended period of performance.  The revenue we recognize could be materially different if different estimates prevail.

 

From time to time, we may enter into separate agreements at or near the same time with the same customer.  We evaluate such agreements to determine whether they should be accounted for individually as distinct arrangements or whether the separate agreements are, in substance, a single multiple element arrangement.  We evaluate whether the negotiations are conducted jointly as part of a single negotiation, whether the deliverables are interrelated or interdependent, whether fees in one arrangement are tied to performance in another arrangement, and whether elements in one arrangement are essential to another arrangement. Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that they are, in effect, part of a single arrangement.

 

In January 2012, we entered into a collaboration agreement with Biogen Idec to develop and commercialize ISIS-SMNRx for Spinal Muscular Atrophy, or SMA. As part of the collaboration, we received a $29 million upfront payment and we are responsible for global development of ISIS-SMNRx through completion of Phase 2/3 clinical trials. In June 2012, we entered into a second and separate collaboration agreement with Biogen Idec to develop and commercialize a novel antisense drug targeting DMPK, or dystrophia myotonica-protein kinase. As part of the collaboration, we received a $12 million upfront payment and we are responsible for global development of the drug through the completion of a Phase 2 clinical trial. In December 2012, we entered into a third and separate collaboration agreement with Biogen Idec to discover and develop antisense drugs against three targets to treat neurological or neuromuscular disorders. As part of the collaboration, we received a $30 million upfront payment and we are responsible for the discovery of a lead antisense drug for each of three targets.  All three of these collaboration agreements give Biogen Idec the option or options to license one or more drugs resulting from the specific collaboration.  If Biogen Idec exercises an option, it will pay us a license fee and will assume future development, regulatory and commercialization responsibilities for the licensed drug. We are also eligible to receive milestone payments associated with the development of the drugs prior to licensing, milestone payments if Biogen Idec achieves pre-specified regulatory milestones, and royalties on any product sales of drugs resulting from these collaborations.

 

We evaluated the SMA, DMPK, and neurology agreements to determine whether we should account for them as separate agreements or as a single multiple element arrangement.  We determined that we should account for the agreements separately because we conducted the negotiations independently of one another, the first two agreements cover two different diseases while the targets for the third agreement are yet to be defined, there are no interrelated or interdependent deliverables, there are no provisions in any of these agreements that are essential to the other agreement, and the payment terms and fees under each agreement are independent of each other.  We also evaluated the deliverables in each of these agreements to determine whether they met the criteria to be accounted for as separate units of accounting or whether they should be combined with other deliverables and accounted for as a single unit of accounting.  For all three of these agreements, we determined that the options did not have stand-alone value because Biogen Idec cannot pursue the development or commercialization of the drugs resulting from these collaborations until it exercises the respective option or options.  As such, for each agreement we considered the deliverables to be a single unit of accounting and we are recognizing the upfront payment for each of the agreements over the respective research and development term, which is the estimated period of our performance.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events.  These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraph.

 

Prior to the first stage in the life-cycle of our drugs, we perform a significant amount of work using our proprietary antisense technology to design chemical compounds that interact with specific genes that are good targets for drug discovery.  From these research efforts, we hope to identify a development candidate.  The designation of a development candidate is the first stage in the life-cycle of our drugs.  A development candidate is a chemical compound that has demonstrated the necessary safety and efficacy in preclinical animal studies to warrant further study in humans.  During the first step of the development stage, we or our partners study our drugs in IND-enabling studies, which are animal studies intended to support an Investigational New Drug, or IND, application and/or the foreign equivalent.  An approved IND allows us or our partners to study our development candidate in humans.  If the regulatory agency approves the IND, we or our partners initiate Phase 1 clinical trials in which we typically enroll a small number of healthy volunteers to ensure the development candidate is safe for use in patients.  If we or our partners determine that a development candidate is safe based on the Phase 1 data, we or our partners initiate Phase 2 studies that are generally larger scale studies in patients with the primary intent of determining the efficacy of the development candidate.  The final step in the development stage is Phase 3 studies to gather the necessary safety and efficacy data to request marketing approval from the Food and Drug Administration, or FDA, and/or foreign equivalents.  The Phase 3 studies typically involve large numbers of patients and can take up to several years to complete.  If the data gathered during the trials demonstrates acceptable safety and efficacy results, we or our partner will submit an application to the FDA and/or its foreign equivalents for marketing approval.  This stage of the drug’s life-cycle is the regulatory stage.  If a drug achieves marketing approval, it moves into the commercialization stage, during which our partner will market and sell the drug to patients.  Although our partner will ultimately be responsible for marketing and selling the drug, our efforts to discover and develop a drug that is safe, effective and reliable contributes significantly to our partner’s ability to successfully sell the drug.  The FDA and its foreign equivalents have the authority to impose significant restrictions on an approved drug through the product label and on advertising, promotional and distribution activities.  Therefore, our efforts designing and executing the necessary animal and human studies are critical to obtaining claims in the product label from the regulatory agencies that would allow our partner to successfully commercialize our drug.  Further, the patent protection afforded our drugs as a result of our initial patent applications and related prosecution activities in the United States and foreign jurisdictions are critical to our partner’s ability to sell our drugs without competition from generic drugs.  The potential sales volume of an approved drug is dependent on several factors including the size of the patient population, market penetration of the drug, and the price charged for the drug.

 

Generally, the milestone events contained in our partnership agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization.  The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain.  As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.  Therefore, as a drug progresses through the stages of its life-cycle, the value of the drug generally increases.

 

Development milestones in our partnerships may include the following types of events:

 

·                  Designation of a development candidate.  Following the designation of a development candidate, IND-enabling animal studies for a new development candidate generally take 12 to 18 months to complete;

·                  Initiation of a Phase 1 clinical trial.  Generally, Phase 1 clinical trials take one to two years to complete;

·                  Initiation or completion of a Phase 2 clinical trial.  Generally, Phase 2 clinical trials take one to three years to complete;

·                  Initiation or completion of a Phase 3 clinical trial.  Generally, Phase 3 clinical trials take two to four years to complete.

 

Regulatory milestones in our partnerships may include the following types of events:

 

·                  Filing of regulatory applications for marketing approval such as a New Drug Application, or NDA, in the United States or a Marketing Authorization Application, or MAA, in Europe.  Generally, it takes six to twelve months to prepare and submit regulatory filings.

·                  Marketing approval in a major market, such as the United States, Europe or Japan.  Generally it takes one to two years after an application is submitted to obtain approval from the applicable regulatory agency.

 

Commercialization milestones in our partnerships may include the following types of events:

 

·                  First commercial sale in a particular market, such as in the United States or Europe.

·                  Product sales in excess of a pre-specified threshold, such as annual sales exceeding $1 billion.  The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.

 

We assess whether a substantive milestone exists at the inception of our agreements.  When a substantive milestone is achieved, we recognize revenue related to the milestone payment.  For our existing licensing and collaboration agreements in which we are involved in the discovery and/or development of the related drug or provide the partner with ongoing access to new technologies we discover, we have determined that all future development, regulatory and commercialization milestones are substantive. For example, for our strategic alliance with GlaxoSmithKline, or GSK, we are using our antisense drug discovery platform to seek out and develop new drugs against targets for rare and serious diseases. Alternatively, we provide on-going access to our technology to Alnylam Pharmaceuticals, Inc. to develop and commercialize RNA interference, or RNAi, therapeutics.  We consider milestones for both of these collaborations to be substantive.  For those agreements that do not meet the following criteria, we do not consider the future milestones to be substantive.  In evaluating if a milestone is substantive we consider whether:

 

·                  Substantive uncertainty exists as to the achievement of the milestone event at the inception of the arrangement;

·                  The achievement of the milestone involves substantive effort and can only be achieved based in whole or part on our performance or the occurrence of a specific outcome resulting from our performance;

·                  The amount of the milestone payment appears reasonable either in relation to the effort expended or to the enhancement of the value of the delivered items;

·                  There is no future performance required to earn the milestone; and

·                  The consideration is reasonable relative to all deliverables and payment terms in the arrangement.

 

If any of these conditions are not met, we will defer recognition of the milestone payment and recognize it as revenue over the estimated period of performance, if any.  In the first quarter of 2013, the FDA approved the NDA for KYNAMRO and we initiated a Phase 2/3 clinical study for ISIS-TTRRx, the first drug selected as part of our collaboration with GSK. We consider milestones related to progression of a drug through the development and regulatory stages of its life cycle to be substantive milestones because the level of effort and inherent risk associated with these events is high. Therefore, in the first quarter of 2013 we recognized the $25 million milestone payment from Genzyme and the $7.5 million milestone payment from GSK. Further information about our collaborative arrangements can be found in Note 7 Collaborative Arrangements and Licensing Agreements and Note 7 of our audited financial statements for the year ended December 31, 2012 included in our Annual Report on Form 10-K filed with the SEC.

 

Licensing and royalty revenue

 

We often enter into agreements to license our proprietary patent rights on an exclusive or non-exclusive basis in exchange for license fees and/or royalties. We generally recognize as revenue immediately those licensing fees and royalties for which we have no significant future performance obligations and are reasonably assured of collecting the resulting receivable.

Cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments

 

We consider all liquid investments with maturities of 90 days or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than 90 days from date of purchase. We classify our short-term investments as “available-for-sale” and carry them at fair market value based upon prices for identical or similar items on the last day of the fiscal period. We record unrealized gains and losses as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.

 

We have equity investments in privately- and publicly-held biotechnology companies that we have received as part of a technology license or collaboration agreement.  At March 31, 2013 we held ownership interests of less than 20 percent in each of the respective companies.

 

We account for our equity investments in publicly-held companies at fair value and record unrealized gains and losses related to temporary increases and decreases in the stock of these publicly-held companies as a separate component of comprehensive income (loss).  We account for equity investments in privately-held companies under the cost method of accounting because we own less than 20 percent and do not have significant influence over their operations. Most of the cost method investments we hold are in early stage biotechnology companies and realization of our equity position in those companies is uncertain. In those circumstances we record a full valuation allowance. In determining if and when a decrease in market value below our cost in our equity positions is temporary or other-than-temporary, we examine historical trends in the stock price, the financial condition of the company, near term prospects of the company and our current need for cash. If we determine that a decline in value in either a public or private investment is other-than-temporary, we recognize an impairment loss in the period in which the other-than-temporary decline occurs.

 

Inventory valuation

Inventory valuation

 

We capitalize the costs of raw materials that we purchase for use in producing our drugs because until we use these raw materials they have alternative future uses. We include in inventory raw material costs for drugs that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single drug. For example, if one of our drugs failed, we could use the raw materials for that drug to manufacture our other drugs. We expense these costs when we deliver the drugs to our partners, or as we provide these drugs for our own clinical trials. We reflect our inventory on the balance sheet at the lower of cost or market value under the first-in, first-out method. We review inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value. We consider several factors in estimating the net realizable value, including shelf life of raw materials, alternative uses for our drugs and clinical trial materials and historical write-offs. We did not record any inventory write-offs for the first three months of 2013 and 2012. Total inventory, which consisted of raw materials, was $5.8 million and $6.1 million as of March 31, 2013 and December 31, 2012, respectively.

 

Patents

Patents

 

We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. We evaluate patents and patent applications that we are not actively pursuing and write off any associated costs. We amortize patent costs over their useful lives, beginning with the date the United States Patent and Trademark Office, or foreign equivalent, issues the patent.

Long-lived assets

Long-lived assets

 

We evaluate long-lived assets, which include property, plant and equipment, patent costs, and exclusive licenses acquired from third parties, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets.

Equity method of accounting

Equity method of accounting

 

We accounted for our ownership interest in Regulus using the equity method of accounting until Regulus’ IPO in October 2012.  In the fourth quarter of 2012, we began accounting for our investment at fair value because we now own less than 20 percent of Regulus’ common stock and we no longer have significant influence over the operating and financial policies of Regulus. Under the equity method of accounting, we included our share of Regulus’ operating results on a separate line in our condensed consolidated statement of operations called “Equity in net loss of Regulus Therapeutics Inc.”

Use of estimates

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Basic and diluted net loss per share

Basic and diluted net loss per share

 

We compute basic net loss per share by dividing the net loss by the weighted-average number of common shares outstanding during the period. As we incurred a loss for the three months ended March 31, 2013 and 2012, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.  The following would have had an anti-dilutive effect on net loss per share:

 

·                  23/4 percent convertible senior notes;

·                  25/8 percent convertible subordinated notes;

·                  GlaxoSmithKline convertible promissory notes issued by Regulus;

·                  Dilutive stock options; and

·                  Restricted stock units.

 

We redeemed all of our 25/8 percent notes in September 2012 and in October 2012 Regulus completed an IPO, upon which we were no longer guarantors on the two convertible notes that Regulus issued to GSK.  As a result, the 25/8 percent notes and GSK convertible promissory notes are not common equivalent shares for the three months ended March 31, 2013.

Consolidation of variable interest entities

Consolidation of variable interest entities

 

We identify entities as variable interest entities either: (1) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2) in which the equity investors lack an essential characteristic of a controlling financial interest.  We perform ongoing qualitative assessments of our variable interest entities to determine whether we have a controlling financial interest in the variable interest entity and therefore are the primary beneficiary.  As of March 31, 2013 and December 31, 2012, we had collaborative arrangements with five and six entities, respectively, that we considered to be variable interest entities.  We are not the primary beneficiary for any of these entities as we do not have both the power to direct the activities that most significantly impact the economic performance of our variable interest entities and the obligation to absorb losses or the right to receive benefits from our variable interest entities that could potentially be significant to the variable interest entities.  As of March 31, 2013, the total carrying value of our investments in variable interest entities was $47.5 million, and was primarily related to our investment in Regulus. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.

Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss)

 

Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on securities, net of taxes, and  adjustments we made to reclassify realized gains and losses on securities from other accumulated comprehensive income to our condensed consolidated statement of operations. The following table summarizes changes in accumulated other comprehensive income (loss) for the three months ended March 31, 2013 and 2012 (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Beginning balance accumulated other comprehensive income (loss)

 

$

12,480

 

$

(770

)

Other comprehensive income before reclassifications, net of tax (1)

 

6,467

 

528

 

Amounts reclassified from accumulated other comprehensive income (2)

 

(1,163

)

 

Net current period other comprehensive income

 

5,304

 

528

 

Ending balance accumulated other comprehensive income (loss)

 

$

17,784

 

$

(242

)

 

(1)         Other comprehensive income for the three months ended March 31, 2013 includes income tax expense of $3.6 million.

 

(2)         Included in gain on investments, net on our condensed consolidated statement of operations.

 

Convertible debt

Convertible debt

 

In August 2012, we completed a $201.3 million offering of convertible senior notes, which mature in 2019 and bear interest at 2¾ percent.  In September 2012, we used a substantial portion of the net proceeds from the issuance of the 2¾ percent notes to redeem our 25¤8 percent convertible subordinated notes. Consistent with how we accounted for our 25¤8 percent notes, we account for our 2¾ percent notes by separating the liability and equity components of the instrument in a manner that reflects our nonconvertible debt borrowing rate. As a result, we assigned a value to the debt component of our 2¾ percent notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording the debt instrument at a discount.  We are amortizing the debt discount over the life of these 2¾ percent notes as additional non-cash interest expense utilizing the effective interest method.

Segment information

Segment information

 

We operate in a single segment, Drug Discovery and Development operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a single operating segment.

Stock-based compensation expense

Stock-based compensation expense

 

We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our Employee Stock Purchase Plan, or ESPP, based on the estimated fair value of the award on the date of grant using an option-pricing model. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our condensed consolidated statements of operations.  We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.

 

We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under the ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding.  We estimate the expected term of options granted based on historical exercise patterns.  For the three months ended March 31, 2013 and 2012, we used the following weighted-average assumptions in our Black-Scholes calculations:

 

Employee Stock Options:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

1.0

%

1.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

51.5

%

50.6

%

Expected life

 

5.1 years

 

5.1 years

 

 

ESPP:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Risk-free interest rate

 

0.1

%

0.1

%

Dividend yield

 

0.0

%

0.0

%

Volatility

 

61.4

%

43.4

%

Expected life

 

6 months

 

6 months

 

 

The fair value of RSUs is based on the market price of our common stock on the date of grant.  RSUs vest annually over a four year period.  The weighted-average grant date fair value of RSUs granted to employees for the three months ended March 31, 2013 and 2012 was $14.21 and $7.60, respectively.

 

The following table summarizes stock-based compensation expense for the three months ended March 31, 2013 and 2012 (in thousands), which was allocated as follows:

 

 

 

Three Months Ended
March 31,

 

 

 

2013

 

2012

 

Research and development

 

$

2,546

 

$

1,935

 

General and administrative

 

323

 

332

 

Total

 

$

2,869

 

$

2,267

 

 

As of March 31, 2013, total unrecognized estimated non-cash stock-based compensation expense related to non-vested stock options and RSUs was $10.7 million and $3.8 million, respectively. We will adjust total unrecognized compensation cost for future changes in estimated forfeitures.  We expect to recognize the cost of non-cash, stock-based compensation expense related to non-vested stock options and RSUs over a weighted average amortization period of 1.4 years and 2.1 years, respectively.

XML 40 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments (Tables)
3 Months Ended
Mar. 31, 2013
Investments  
Summary of contract maturity of available-for-sale securities

The following table summarizes the contract maturity of the available-for-sale securities we held as of March 31, 2013:

 

One year or less

 

47

%

After one year but within two years

 

41

%

After two years but within three years

 

12

%

Total

 

100

%

 

Summary of investments

The following is a summary of our investments (in thousands):

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

March 31, 2013

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

97,983

 

$

59

 

$

(29

)

$

 

$

98,013

 

Debt securities issued by U.S. government agencies

 

9,932

 

1

 

(46

)

 

9,887

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

15,549

 

55

 

(11

)

 

15,593

 

Total securities with a maturity of one year or less

 

124,464

 

116

 

(86

)

 

124,494

 

Corporate debt securities

 

107,131

 

110

 

(156

)

 

107,085

 

Debt securities issued by U.S. government agencies

 

15,020

 

35

 

(3

)

 

15,052

 

Debt securities issued by the U.S. Treasury

 

12,393

 

30

 

 

 

12,423

 

Debt securities issued by states of the United States and political subdivisions of the states

 

5,203

 

7

 

(3

)

 

5,207

 

Total securities with a maturity of more than one year

 

139,747

 

182

 

(162

)

 

139,767

 

Subtotal

 

$

264,211

 

$

298

 

$

(248

)

$

 

$

264,261

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

March  31, 2013

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,525

 

$

29,338

 

$

 

$

 

$

44,863

 

Current portion (included in Other current assets)

 

1,538

 

1,961

 

 

(880

)

2,619

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,688

 

$

31,299

 

$

 

$

(880

)

$

48,107

 

 

 

$

281,899

 

$

31,597

 

$

(248

)

$

(880

)

$

312,368

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Amortized

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Cost

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

113,249

 

$

81

 

$

(9

)

$

 

$

113,321

 

Debt securities issued by U.S. government agencies

 

10,100

 

2

 

(66

)

 

10,036

 

Debt securities issued by the U.S. Treasury

 

1,000

 

1

 

 

 

1,001

 

Debt securities issued by states of the United States and political subdivisions of the states

 

16,560

 

18

 

(2

)

 

16,576

 

Total securities with a maturity of one year or less

 

140,909

 

102

 

(77

)

 

140,934

 

Corporate debt securities

 

80,166

 

112

 

(92

)

 

80,186

 

Debt securities issued by U.S. government agencies

 

8,034

 

38

 

 

 

8,072

 

Debt securities issued by the U.S. Treasury

 

12,424

 

27

 

 

 

12,451

 

Debt securities issued by states of the United States and political subdivisions of the states

 

8,306

 

31

 

(16

)

 

8,321

 

Total securities with a maturity of more than one year

 

108,930

 

208

 

(108

)

 

109,030

 

Subtotal

 

$

249,839

 

$

310

 

$

(185

)

$

 

$

249,964

 

 

 

 

 

 

 

 

 

 

Other-Than-

 

 

 

 

 

 

 

 

 

 

 

Temporary

 

 

 

 

 

Cost

 

Unrealized

 

Impairment

 

Estimated

 

December 31, 2012

 

Basis

 

Gains

 

Losses

 

Loss

 

Fair Value

 

Equity securities:

 

 

 

 

 

 

 

 

 

 

 

Current portion (Regulus Therapeutics Inc.)

 

$

15,526

 

$

18,096

 

$

 

$

 

$

33,622

 

Current portion (included in Other current assets)

 

1,579

 

4,175

 

 

(880

)

4,874

 

Long-term portion (included in Deposits and other assets)

 

625

 

 

 

 

625

 

Subtotal

 

$

17,730

 

$

22,271

 

$

 

$

(880

)

$

39,121

 

 

 

$

267,569

 

$

22,581

 

$

(185

)

$

(880

)

$

289,085

 

 

Schedule of investments temporarily impaired

Investments we considered to be temporarily impaired at March 31, 2013 were as follows (in thousands):

 

 

 

 

 

Less than 12 months of
temporary impairment

 

 

 

Number of
Investments

 

Estimated
Fair Value

 

Unrealized
Losses

 

Corporate debt securities

 

70

 

$

95,606

 

$

(185

)

Debt securities issued by U.S. government agencies

 

4

 

13,885

 

(49

)

Debt securities issued by states of the United States and political subdivisions of the states

 

3

 

4,537

 

(14

)

Total temporarily impaired securities

 

77

 

$

114,028

 

$

(248

)

 

XML 41 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 3) (USD $)
In Millions, unless otherwise specified
3 Months Ended 12 Months Ended
Mar. 31, 2013
item
Dec. 31, 2012
item
Consolidation of variable interest entities    
Number of variable interest entities in which the entity is not primary beneficiary 5 6
Carrying value of investments in variable interest entities $ 47.5  
Maximum
   
Equity method of accounting    
Ownership percentage 20.00%  
Regulus Therapeutics Inc. | Maximum
   
Equity method of accounting    
Ownership percentage 20.00%  
XML 42 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
company
Mar. 31, 2012
Contract maturity of available-for-sale securities    
One year or less (as a percent) 47.00%  
After one year but within two years (as a percent) 41.00%  
After two years but within three years (as a percent) 12.00%  
Total (as a percent) 100.00%  
Percentage of available-for-sale securities with a maturity of less than two years 88.00%  
Ownership interests in private and public companies    
Number of privately-held companies in which the entity has an equity ownership interest of less than 20% 3  
Number of publicly-held companies in which the entity has an equity ownership interest of less than 20% 3  
Realized gain on sale of common stock $ 1,058 $ 17
Maximum
   
Ownership interests in private and public companies    
Equity investments not classified as equity method, ownership percentage 20.00%  
Sarepta Therapeutics, Inc.
   
Ownership interests in private and public companies    
Realized gain on sale of common stock $ 1,100  
XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)    
Net loss $ (1,672) $ (23,995)
Unrealized gains on securities, net of tax 6,467 528
Reclassification adjustment for realized gain on the sale of Sarepta shares included in net loss (1,163)  
Comprehensive income (loss) $ 3,632 $ (23,467)
ZIP 44 0001104659-13-038211-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-13-038211-xbrl.zip M4$L#!!0````(`"Q_IT+\9]M.5AP!`-0D$P`1`!P`:7-I'&E(2SF%$G4"+JM^_62R2(!8A"PDEC/1,>T6 MD'GRG.^L>4B^_.U]KI^\8682@WX]E3])IR>8JH9&Z/3KJ6V>(5,EY/1OO_WO M_WSYO[.SDTN&D86UDY?ER1UFC.CZR:7!%@9#%A_@Y.S,O_$;IICYM][8_R&6 M:9^,J,5GLM`4G_SKGXAJ)Q>2W!]X3[V_,)U\%O]_PFFBIO,G^7HZLZS%Y_/S MGS]_?A*_?#+8]+PE2TW,T#J3Y+/U'!HF\4_P"S&W MBUNTR!,>0=US]^+J5C/,FI^*?Z=\_J^[VXDZPW-TMLDBH]V2>VE,=>_P'^`( MF"*T6#WPBLP7YV;O0LPB;(LECC\XYU=72]B0@+<(>3`8G#M73SDP3DZ^B#\_ MF\Z2'O'KB7/IL[5OI2"S`G69U'5.+6$OOM]6O1!._OQ+,3AQ2<(AT7["7HS]/?Y/X M__J]MB1WOIQ''_:G.H^9RYMI@1DQM(WY'5E:OSD MPM-XH?Q=GHRKQ@_E3.J<2:V"^%%!;B@%H.-*`*\BW.`K9M85=S^_^?9)6O%C M?2WR$*9:X)$@"_TK^V!A50`58J&2GX5*,2P<50B%(8M=B$X*;E2.%W(QWLM3 MKN=+0]?1BQ.1ON$A8XA.^7*I=8?G+Y@=@5EKE<)30 M$&.*Z4C#6;"\PJIS@QBZVA"M@BF-BF6_T\8OT!Q2[=Z@:L+E)_Z7B52ANV90 MJ[?&2\.]@1O/YH]8GBW+'>"$.V76DD*B)\*+(T"W`!N92Z"^";Q"K]8$ZS: MC%@$FW?(\O_B_N-IANB8XO_'B'F0_3[Y9KQA1ATA\PA3Y7=&1J@TDD?.SJWC M73'GEH;8\I)S>VHP\LM).P.(RL6Y?:)\3:10O+"N;2N@QAG;;YC^6LYQH#NA MVDA-,75)2VU*C*+O.AX8G,3IQ$J>C`%/^HLVS<+^A4<\M77;?)IAAA;8MHA:<84_9I2Q8N[X12=3)^PV+S@5 M/"V,P#-)'ON@QFT]#J2((].T,0LP(E'HQ]I?D0)JL>7^BE145T@E>J<^WLU8 MV`:58XJD/H00A]4AJ9^_H;5?&`3DY^OY0C>6&$\L0_TQ7E2_VC+\B9BV*?_$ M=1X+!^5J;`8<-#RCC+4']4<`V(`D&P"R;Y3>/_(DA!&5Y]X.;[Y38IF/D^]> M^NGSK9:@2%WZ/O/.*_R*&B&8C?3)##%\@ M$VL/:.DT[5TLGXBEX_'K^J9`LA@6$5@TQZ(!J@'5M;35&#%U-N3CXC>L&PNQ MVNMWP?Z*@UF\_:[9`@XK5XW9&U'Q&C@AG.FZH3I_C5\?L6I,*?G%H>5P]M(P M!;H>\<)@UBVAF_J1Q40PH@[NWI_Y`U$9L"2]/[2W`K/7+4QMPJ9`'D`M[DQ;Z[:#? M;BVS@[Q%JT"D6_](MSRAQRBNY@[[;E5OY M?N(X03HV'WER36W\S3`T\Q[[":/WZPTSY@^<3NX1A]6&R27/>?BS[FM*C\3\ M<;&\P%2=S1'[$>FU2N3*?O.S#7K6(/;Z)Q-$4*$` MWF.C]P+0&T#O4%5%W8>+2L7D#;WH?I%K\\*$\-S[E:@\D/586?%.[>W1G,2E MPV(YAT@`W7(+L`W8/F[47.`9GTE'B7A'B(S9+3;-U7Z%>ZP#AG-7,IFU3]2G MG;J2*I/Z[&CD!RN<%U1JW);XM*`20=@Y<5%LT#\8.K]-1?K$?A%MI8+1`.#C M`G@;X309OF!M2P-6L*Q1R_K$,#)MM@2`E@*@R0)I"DSC3[V$E*N,1UU"T@7' MM%85NY!X;0=C"!!*!UP($>*A"E6"4L,6Z@19$(8`H42`;6`P4!/`-5.6UW_9 MG*(F2#-^I7639^(IH361=('GI`+0\@!M;'$&7]J,B4S8-+%5+YSYPKQ`.J+B MK3B,K5OO%;BPN),8`7#;XTG9-4-5>>59TG:K*[`Y8'-*CM'UQRIKO>M4_@V= M@M_H;C,*Q16JP18L<6CNKG973,/<$K1WUP:YS?6RT.!=&PA# MT``MWI6!*UA7:/(N.41+U<%U)*!"FW=U.F$@_8(.V2KA%>PK],A6%+B0:D&7 M;*4@V\B0H":0:ZHTH;,2.BL/!#7H*VBF1>9\N/'K#2+L'TBW\>J/*V*JNF':S#\T=G7ESJG5N=]@>Q1L M981.JXWBU=HNEJL_?^=SB,\V+F_%1QLCF,K!N'WB/$!G0`HW#/]E8ZHNPT1N M([`CN-]"WXU:K7E$%[9E.J*3`<`;`$[A$^#UR'AM`5ZWPNN6'^H$O.XW8868 M`6*&FJ3L/J8A:H"HH?J(A;@!XH9R(K:`2D,]6P\AIM@#<7?H/P83=4!S_"K` M,:1:M`98[G[)4F>'5_=12SW@#X^CD25Z&:G4>^6@SE0UB3]"MG2J<$TR)P>X-"S2FD"KEK4&G M%F9S`,(3IUA.-IU@4Q MIIB.-*QZ/UP)-!D+YQ:B8],RJ&^8$L?Z`U$;L:7H>*RV)@I`C5\#*XOV+:3Q MA+DXG0V._: MX[DL5/?>H&K"Y2?^EXE4\648,T#TUI@%U=^:5>ZG$I%EL&44"*#YU=+\DBO= M_HQ7,F3KH_CBHV`MKOC?=/1N3.;$FOVI$XHSU+O:BINB+[%LV*?2%&HT]@6[ MT*?!6OD_#=8J\M-@.5U454%:1^]2@%DL^'TI`!N`[6#?9\T`VS=,?RWGV.^$ MYWSS+MP12N;V'"!8-`23)+#/Z1_%RL)K#\GW*#%`>3X/^F%=0>^@*W76E:!\ M&ZXK6P8QB;KRP/!D@54!7^WZ363VH#955IOMJAY)4J]/O/51O8!29C,UHPGU MP(_JQJ4QGV.F$J237^[OH"(-4I%,\=='4_Q,Y$Z2T]2A:07T`X3]U:NA[Y83 MR`7ES\Y^#R`6$%N971\%$`N(/=XW@G<,A@%ZC8!>05N0KJ=N/]_)$G1G0'=& MHI^6I=Q^FC]RO&IS+)13^D2KBN-*%`R*4JC"NX.K%4+LK!=0:FZ@6D"=.4,K MH,C<7.5H6(59U.HFB*_PD7.%VOB;86CF/;96_L'Y]889\P*7R8(1,__32X*&8,^X^,N#">+%9M^(,#V*8_)1$:>Z/"@9@9DD3P M9:58!.Z3_0_,T&S5&K,)9F]\M8&Y0SBOE[.#COM2*?JQ.NY+VDYY!:\?`3[W M$W"%-@SVO;4/"`6$UB\EJ"I,83NK-*'E!#&\L-#3##.TP+9%5'-$*VH%"7WC MF<_GD?,O\?3(-&W,`NA*6VW#(SGO:^^QY_@]W_RC:EB(.7UK:)K8NM216=:S M"PM^;QMD6\]R.,CV&+(MM1D'KWYHKWZHSVL[^^"V&5QK7<6:N-1ZR528[\2E M5M""5TNP!?ME$"PX9;]*#J:[2L6^XLK1$)T=M^92+C@(+S$T+8;^C2E6D><= M0D>V-.^EA@V&[+,"_-$3J9@B/NF-P7A&;%H-4K^JI#N'L`'BPVMB MB3X<(A8@%B1@A,`(15JA(0"%`#01K^5KC$XZ>[D1!P`5>SQU54I]E5"C`YZN M&MHM@"`_W^.? M@?#\$E&-<(_KF^LZ;W1N\]9T*G=@UQ/4)D%M@I\_`K4YK-KD^?04J,UAU<;! MS9B">PD,0"@% MBG'`4`H4H^2*$3QF$8*I,$,@G`+EP.`WCJ,Y%G4M7L7/4 M2P[CY(\QU#\4*O!+%1`6-5-EZAX@E5AE(%@JG\IL\]YO$@/_L"D6+8G>;=&S M9ANI70=KCH]GK3FDVKU!U83+3_PO$ZDBVC)#H=@V`CY0@V/>(XMK9RD.]^VK M%#\).E\VCPHJ#RI?=*<;:'WI>N)`[>NK]B7-"=R7U\0;M)W$3\O73.6W>?$& MOCP?@]K6F=3)_PI;I\#BSYW4:L3;:O"NV(Y6MI7?RK;.6OWBK&P7XBX(>9JH MC%P3N_F=1[?``Z/BO^R:""%$;<26S='04GR:]$#F(2I;L!"-3XK<8X4Z2@%V M(N'4(3`?8#Y*8SZ.?B92)>U7)Q"N;&F_BDB//[#G=$?J.]5T&?:`8`\H#;52/S=JW4>*VKEL M/]_)27M`=?Y:21EVA.!#(=L5ON6\NU`%?15K%#@M._'PS^!G1X9\Q2:7`+YB M]O0)L2FV")W^_O3$)6]AXKL&."Z[).>%%O1]E!0]WPXA>RU,P5G9^3/-X+'7 M^VTLSCY['PQ*%5XQ`)L"-J5<-B6E>`TFI0*5;+`H8%'*95$R3R$`PW+40Q[` MOH!]J9I]2?IB*U@/4%E0V?I\Y&L$^^JPKP[[ZN6T&8<[1>%2)Y2H2.?`@>:Z M_64.VW`5#`(8A/(8A/27B)K7CU"2=G]HABB=+I:TZ2U0&%2D+=LA-(T(VX]T MD32:U^^J;FL\:X1<']HD,JH-'T(.5"%J6#@,VY]\6Q,"+=]-CA0.DP4CF%O1 MY05#A$YFMF7I^`FK,VKHQG0)I@5Y^?/[BAO3\3I^O>19,UY4U'24YC3]8R8R6V=PVR"@VHF^38FK+M\G5Q$LSS$R M;88Y.XQV2^Y]YG?X`_F7@H.+D6)'GLP0PV;"X!YOG%MV&OV!WYDZ]H+_N=/( M(PO/$UG"$4+X]=T8@E6;<:FG#6YZ]^PT`??\"T13QU?=6W8:G@/A`3-'K)$I M-/+&S544N>+!>YO'(J+8&574K7$6Q';\B('IKC`UYH2F3YB%O>B,FX/Z5P/K MWN3>RM(A4.Z8W*L2\38D@XC?G5=6^OT1$SA_+>CNW*KW>ZWN/OX6H?YP-7=L6\*^B"3.IZX5I&YT?[-)'O>\DW&`1-\(R)+2ZTMGXQF`3OAQ/E0@VK_"+M?ZO2YLQOE:?7B4W-UOMP:#;#G$SY]QA MPA^QBKD`^-/FK4&G3YC-N1>Q&%(M<\RX7YDR-#=]>MNYZ>VTPJ+?;KXPC2,J M`E*#+1_1SSO$G3)/'KEIZ/=:O1!; M-@>/*$#&&8Q-F4"R!`[,^%)2VW\EN&@1)89]9$<6A;39[?C';:G6Z_&X.S MR#RJ*M(`\P$MA6M.GV*,!G7\X5N+#%^Q#H7DG9+T`O1X_R) MG-\`]OJ]L+YE3K;!(F:GTI3?`LH=GFA&N10_2Y@8WZ4(Q^<$&`MB(?T6BZ_; MONADZI2;-@C,;Q[;_5Y8BKDF#M-\A5\Q_UE[Q-SQV!L8RV]#E+WLR07(7'3PK1VL*3=;J>;QH@D\\(CDC=N[PG71R'0&&)V ML+9M92`P$PR#DZ8)&.`@DGS;Z(/MPF#,^,EC46$G(T)KY3?(O;84"#OR3AST M@]YM-SPGH2J_;:T"*_+RF^R>U.E(`<>8/$DBL%>SYS??*/;PW3#;>?T/N*VOP6FF>=?2GJ0O+,'4V3+$0H MUJX1HP+W@<&X31'5M16M^0WVV4#J#KK=2)Z4-6&80(?9,T/7,#/=-&%%4'[S M+?=;O0@]F^,G:AFW%LG4*/G->$RLEC7;!PH<2J9I5_XNQ^A&-Z(:.6HE(ETS+'B$WIR/W>EKXTQ9)D&MJ8J?FOTD`N MQK)EVMGM]":G;8L*;V2:]AHE;6DGE,B2W.[+LM).08D[408U,37:MEP828GE MV1QJW]ZJAGQ$Q6\K.0G`?W\*<,NWO<*YI3[;I[Y-RF79?[]'R;MPDT?S#^7&]T9$:1B]?O"U&)7E&0 M&BW([0D'*7&&ROF&*F?.&RE";$TI,RY5>E+#4@#F)-8->.,/(F"RR M\[(0.[Y=&\J4&D8G3-Z1(T7HR.`1[4&$"EZ-:9Q`=K&Y;6276SR64L9#)04<.V5U#B>\`$\J5UPP_-*.'[X8&ZK%+\VU'5##150 MNSLY@)@E;CUSF&R.[#6+5AT(3T8@2O"RE@MD$G5%]BY>PQ%/V![EG#ZRG>;5 MU/P0W+E%.""BV]8ZJ.V&'$EK"U+7><"9]*D5R%0R9MQG^-3-=#EQ]2)YX+5! M'#!\ZF;ZIK@8N:UL[([G#Y^ZF0XHMJBF=*4MPJ?$:*";Z6)B1=-3$GQQ[FB@ MF^EFXCC>;>6,!9+*Z]\IPZ+I'VN_<]WD`ZQ=QKI+:WB*Y6^(D=[&O>=P_9V M<8U*NZ7LGL/&J'_4V/1V2MM:2M3CB/\J=O0>F"$: MJ[6+Y7<3\W1SY1*'*F>PN_T48S561.^2[IUU>[(R2 M,7;E7C^RA-VHR)!"8N?IJL5VESQ0_B][[]K<-G+L#[]/5;X#RF?S+V\5Q25X M$V5GMTJV[(W.VI9CR=DGYTT*!(8D8A#@XB*9^^F?Z9X98$""XA4D2/:IY(2B MB<%;RV+0@X/$\FUV-Q"&>=30.!>#'*Y'`**Z+ID#C([O&8X(AQOQ MGXD\>+SN[R;Y96]BONS.Q&^7.M/92W\B,7(W*([(G"?_WB86TF9[QHF\SIM7 M`F@:UK8B0#>ZFLU>I[4*0E>W85F]A@+ZX:,]%!:[RYV#H+P6SIG#:Y MJYM-^UVQC]7>%DIO',3 M%?7"Y,AYJ0UVRUUKI;OGIPQQR[G]B3\248 M6_[K%_]O&+_^ZU]@B(D:X./UEU]O/[TR&JXO_CN)C4;]LN/ZKXV'=__?P\7M MIYMWGQY>&1>-.GR)8\`(??4!WJA&>W_WZ>'B]W>WO_Z#/]$//.>U@5_=W_[? MNU>&"1,47[R__GC[X=^OC+DI&K`8,`S!\,TZO.`G>(-ZVT_]+2;0XN]7;S#% M2JSQY/7_F-T&?=K7I^(3-;;!5!XU&J49&:D9BM:>@=1/DYU12'Z]*XZ[7^I2 M[K`;_-7)DR$Q/+,\(LC0^P_+YOX>9894,XT!UZ9G?L;WU'(>0;V&6:B%9M/`Y=:-6Y__'8"M&>(Q@WGB-S4C"/G&>WQ?0ZQJ49.01[I+Z[D9GK15PL\#:67C MU![T<=B"']:`<12?;20*R_&?P+_PQVT6XC`VE(8R^"*3`7`M<,BF/ZX;I#A3]XUR32%M:,N$L@<]%_:!F#!(1>HS,H'CF M-6.L2OUI#WHJB,,8,%@4G]#`Y:L<6;@`Y'X8VP%6.WY`$U%@C_-J#Y;%.2GC M`GG"609R&?TP8'."9T\XX+_G:N+8]?$F`#,RC#(UQISGX'AVZ&(5$&3.G'B$ MA,'9$VR8%?$-GE@AO!R4"-PT*Q-"^$]RHT:C(/$<&(=K8GU(\#.>W'AD!/B3 MW-1AW3'<37-OM`S8+4^\,?]"OAWPB+8/X(H%=S3R:_Z?K*J88/6".'O-9N,U M1G-?6!X<#^PH2__-?(U@U?@_,G?Y7IS7W-8OVQI8'XPA`LS$V0'[YUB4Y\1? MR2R.HOEE\JLA@LO6EU>;)QA;Q-#7SA'BBEL)']=F53=N9G9%W/JS"S?<@3@O MN*/YA>2D2^&\H,^_]J<&YZ\.$+-8NMH7O@0X8*``?H\7G0,`4+Q1O)`OQ14P M3B*Q"P..5DRO-D8NGS&D`6#UUCMV=)%OS)>NC]F/%C,^R(2U7]M MSH+^"]+*(Y`1U/03@PPL-Q1O?,T?UY^/1V[H7&!=O-P3N7F\QN/E#^I/]B%2 M(YW[["/(2=^\N_]<-Q[XLN`3W\8!B%(10F_N\:>1%1=LP9,B,7Z(3X`.:&<0 M\H/#@YS!J78<%[/GDS*0\H>&0>#@+9`QYMN!^+'B M0S&LZXDI9A%S,3-.>?PLC3W##&J"?SPM6@G',\JN`@R!6'1%L/[(!EY15_XALFF#70N;'T+P(]R_'@;7HBA'L_1I"+_Z/*R$V M7B..&]FXZ=K]R#_+0M1P1A"!F\2NS<]W:(&@;@R`0FTX!HXG+%/-D7,=&4"( M<$Z"?6ISJ,F#%X*\9?S0[,#UZ\'T9F[O5*'AV!I".0J8I-(X^)/=]$'U@.M+ MPN,R M6'A@*#JD]]#<*^6&SALH/9WM1?H-1E6+?[1%%OO`0B2]+9HMBACMT!62"MB,R,V_O;>ZX27#^TYNAM`;*[]0Y` M^_/=_>W#[1TG%74COI;$00GA`,@QUMM1!,RGFPL&5A-43_C<74FZ54=2[M"? MP$[3GS\KL!L):7[H!7U^.CG])TQ[*\T1OKPX4F]?MB7$"W9V@K=@M!(U:VH@ M'^HGRK[#46"\/DB<2-3B2/DEL>!.F"?BVCQ*\#IDF^$AA93\?]P"NFTEYKWAVS M8.2C=IUM<4&!ZCDOKVFR';_69Z7Y*DER:RY72W3O[,YE0QVL/(W>+:G"B?&!17C1884F'10Q=:0.1N"@"2.QS%^IUQ1/L""`^XFM]7ZP0E%Q<4 MZ1JR;LW(OCZB=8))7915\Z8B+"B34C&V`4]^$D3"OH:GG;.\@G$FD.YU-W0, MX984/EAP38!=/[63QMC+`STR01*#6<85$5#"FI/D]O8Z$EPJ\6*TERC7]*%( M;$U^K("CV&JA_'\4\K[F><8`C.=,/WFWK;/8;WMG%A7/F,4=P._E4#/N-KQ75W!SGPJ"`N6-S_S;,;]B8;N4=)&YY1]&1Z15 MI!=%)/Q41;=EWK@J4"/AQ$2`1&P-62Z`ZPCT".3.?0YVCD]!!&#Y_>8'3QYS MAH(#LN^0SNR"=@GN>,W5G@7>\9UC402AN/RJ@'6O<-'@)6USM$2#!.S<.5&C MNENVY)[#B-U9@7*?J]F033H!YTC\E!8%=R\,V"IW@*OH'Q@(J/EI+:;Q?/6%\J,;$:U5;N0Z;R+#A8#O)XY ME%)/%_CH&8=_+8"P$(Q`'=']H_G(U2=+P.6YF"M-NU4_#WQ^AZA_%U&`_%\& M[G<(X-(?EXM!RHJ$.#B[,A`R'2V?:QZ!!Z<3EEYE<7[&4:6%XBXIE M?E)1EARN0C8MBLT2D593[9LTG!P0F8]3SVMIQEBU7@0"RSTV@$I&([Y@H&H5 MO#5SHX&#'"E0,9,L#04R7]+Q9!A;=J2Y8SQ#P&M2_S+X%D9@8]2NBD%>RJZ8 M/^0")P0G:D(5)%`X#/*CX34B2@$F(&0X0*%0W"$?`:4Y116`(A$_#$.GH:R% M,=*:2A2E[H8C4V:.(.!&B_V>\O/*0D*YM#X0U[!B$F.LW%PWODK)@(OCXBL1 MK9([3I%(!N?H8D9[S?"9B`^!U/8:'J2(@H<8&8`#!D)CV*W(I,"++@P@\AU9 M)XR2/::%:4[@3I8X9$(GC+1\4]>?)#&:J)-(J,IZ&'?!.V:Q)QF3LW6`RK[3 MV\BSLB?/RKL4^H,$"D;DXY7)&UZI3SLYYUR$.AUZY3]M<>A0'D=EF,^+T'3. ME?JT#7&K4N`@RWP'$P+("BXT?*5#KM2G+0Y9E%<20BA%MU3NTQ8G>^T;UH1? MP5Q_!.N(4B0@@W(+L]CQAY^LH&4OK6)@I*HAV!M=L&;Y_#940T=9+S(K#9*51+4T_$4IB1G%.I3UNB(>/\$A^?!66YR6#;H+$W7FY&X$SXAS[&6JX2D15VDU3I5Y`&&!QTJIG>72Y;K$65DL+@86!J^X\%"3"8L M7*$!:V3]T&TT:@W^WRR.23I$)5\(N2ZW1>Q"Y;GC@RK+B&@9)[FR8()@YXM7 MB7B97%!+E(;/B.`9)\!8$=L3T;`.&X!BC<467!_'$5$A&:N9*:F8JZVI58_4 MS1"9,OX34G2FCTM?L3'Q+%]&.3$8=9*$ MDR`2AIFT;EE6P%A4KAH'7(C4XMUPYGAN8F`LL9:O`QE`7=WH&P21\+V2]:B8 MKKT^!>$W+)HX4]JKSZ:!C-MS81*65SQ]$;?P/0:E&&M1B%F*090]"%X=BLU* M>9C/82^>6UR(+8/@0YXY9L%_MBJ#IT*I`-+N8,!"O%8&VA^9^6O"A[)<[]PB MG]XC(P5`PAFX8W%X4!U58P]IXHE&XQ!M'O(3LV1I)PN&P*!8H>+(KU1UR-GX M)U6W%+&Z4EG2K(!HOBQHKMP*IRK'A:8HG)MH`D$4A@P@L2#X3R5&U MK,3@;"49??!%2]/?Y[-AP`E&!K^&3*5H\37\-W`Q"J^7&R]=" M#)FP3*EHVD!:D]-@LNQAK!8'M6']?!0GC!&[0IS0.1'63A4"74Z`PXAR.:8N MZ16-FR470`C;_&BB0"_+`MY<_S'P(+-1-P'_-W&&(CRT""*6,0R#9(*[EQWI M&#,A(76*LQN/RX-G\,N<,^+_YPZQO_:_F)%4[S M&M/:A2#?N,&0BR&W7))?I73,QT^55\"`^=Q/7#`'?TPB&TJM&M=Q&$Q&4Y16 M[S]>KUNG\NK9.I4%$@;,8;ZZ5E81[PBV,1YQPAV.TE)_0I7_/`)MK_E3:S:) M%2N9_6_BL^5XE#4ZT4&E^/UN,&IQ<9G_FY9.A78=46P31*B;CY]_$P72IQ%" MPK6,\32(`UC*!9=W8\:I^!L'3\36!(G9W!U(\"K!F$C2O^SH%H"XMTR8)/ZRJU MW.PXQ"-7)Y+?YC7)UF%G%3.9+E5>LG+F,TT#QKE&`=HP,[T.UM`]9NV'"]^M MOTXO\"\SLYYT!65.?]&R5#QD7BCT"[D>*Z\;`S<$/OP4Z.\1#!R^S/1OS@,9 MMNYX&KF>,*XHOIT6Z!,W1Y:/Q0ESRF+9E$*8JIR:-"?#/_K!$FUHIFQG[DGL M"1+)92+)I$Q5/VC8W#G5)K-]IS^MI9F.:7(;/R`1-(.JF$@'11Z?7Z*>"J32 MBG#P68,_\JAG2YIF-\CL,I[I`7+X%B!K=?_0-N6]K$4\92=G/' M(4]_\?[G99V\^VE6+,H+-7G.E_6,2->T,(H+SJ\FC:]NM+(C:U?WF';O5%A_ M+VA])#JO*PAEXT.4D#U:U4(\M=)QD_3ED1&_!GY$4R"B9(%M`/*'8'?.(Y+L47[&!7 MOUG7A5B'E>G9A4\ISK;ZON=8_N)!K?D=%-L#A=,=-@87?VAE\A^4>H%CB:P! MBP4M\UW@S]M8OXQS@-0^8/G0M/0KSK1=\&_M@HX7C+3?DF M<]JI-;-)>E?J0;RP%W@"@2AY#CJ[#_T995<(M2'PGJ+."XH)H*:7GS*`")U0 M6.9F,N&'#8JJ[+@NFF'RGP/%W/!7H*6'OZ(&'FRNTEG*0?>3E&$Y6AB`EJ4M ME'.G)&/LP:+`1T'?_E,$*O#LRF`ZV>**C[9H4V]50'3&BSE!V%/U7H$Q7$'! M?@IG'Q];6(+,N;IRKM9%,[LQF,\U)`](?PSB6!9%.V)<*1U-C<`RV`#\E51DQ-^$[/WAZBI]3L&F9Z3#U#;?B.7(Z_6C;_A;7*!C7S M08#(;](VK!XP'4X!?(^8AK=T*9GU@'/",5`<@E$$CVGY_BCN*`(L((^%?&>` M%FND*M9/^LY?@`;) M.#$\#81D7#NP/.0\:!+B._W^YKJF:&F>CF8%A_EY:[$(Z%42)R#A*%L]RJU' M`05"$*QOJH(K!*'P@^,:IQ5*A[D(!"@@+URVV"20@C)&)LE$XZH1R,YL$F-: M1M$6"GT@*H";##E/^F,7F9+.DWS\G6DWT!N-,MA\-&97;+$/9L:LN9G@%;`,;*DM*S+O,PH>;_<8L%[ MYK9(#"YMSJHE(1J[@T+&<>U!=5#($1-2D/Q)C:T0-+%=5:N&`ZB=QWD'J356G2CGWW%%9:/*+ M):@ZM\"K.66*=D:PZ7@-DM M`46=@E#O%HS>$3R<@3H"%\\@F,#1XR4G&14?C\F+3^>XF@D10USM$=Q?3N9& MPA/?4B4MJ\G/?C347Y5T)6`^9R60/:S1&YF3W$;N)&^AY@<'':$U&2S@_QQ% M\DPRB"&<E:"3MK,6,@.^8ML#H)A`,2->22YZIKRSA#AUQ`F5RCJ M86\I^(T;9X#%(,3L`L-6L&A05>F@',PC=SCB_Y;61"LT&^:W-G52J7`QJ(>& MNS(C&@NA*V\`<-A0VF8YX7_#L"`A$BQ@V;5=7"51#0W&H(RPU\!A8AFZ5D=.=THEK9+%Y1&>;24#54< M[W.SDK4K[\9)0;:RM4SO!:!;?&;,.X+]+62C&G=`3=!L`HUPO\>-13@ND MQ,Y*?=H"H+?"AC,3]31KZ](!JDD=BPQC"!^X+4&3?0KFK0B$GTI]VA%^PE5C MZ)Y#T^R/9]"$SB["4[4_E8RGV>#89_$T%TDK\`1LB0,(>\L6&#DKEX:\6;-*ZSQ]"? M\@G\*84F.92*/Z:#7@NCKC2YSP[S\5H,\RX)@PE;P'G<&)D,V*F_"QF(@3$@ MDZ,G(020,5E$"ET:VHH'N`TE%T,@7.\/UQ_G$8MYIF/KORF>:RF(YQ!:DV@# M_/VO-;'\0MAEJ)N3O*U!C(Z7G-,,_"T(/9E-+XSX!:Y*^1#X8.8\Z16\*?=C M1GH[YYP[_#U)QJ1*,(H2KT<(#,JLZ>BP$9P$JRJ)C)Y9=K+HSE,W&%TR%?JT M!3H^YW)<7&P')YTJUDRD*FC1T2CPG`PEEN\GJ0L0GF2.J)QC]$6:UZS/)@MF M5>TI=A8"L'8&KYT%7A.8R>]QOVDQA#T#UW[.JM""&4-]3?*0-?Y2J4FU!* MC[KO.4M$L!ED[XNH"96?'QE]-N1[E;6J2/O+G.G%!KD5X&>*M!QS61H@SN>` ML>]N)"HBQ%@:`P)[-(=AYF#,I6Z`3W#1B!"?*4#DY&M>:95`/+WZSYQ?;C8A M`H,>OF-IA&&6=29#LAJ6(O(7PD]D\#@@UW"@W4!-;8+': MP=1Q!]EW"XPB(GT"ME-$<@U=&][IBDH[L))?/>M[<,_)=O0;5U\8:DN_WO]6 M4]N8A3O/9'MF^SGA,Q6E?B&V@7TSL&NO%B^$OHM\TJL6S!RF*A5D0211FF95 MAR`GJ&`*RY)5A-2)!/[%[`G`'//!U]>>/_6L,9B4PC%G)`E&:42ZW\6WZ\\G M3W_Y="VBM#$'S!8;Q+]T12J6-<%1\\2B=2'6S@G6V@]B+;EI)M5!]LW5CG*& M+$17K-G,+ED.:BMFR9)(1"8AJ%@(NM>`H[>Z4W=5M""3IR!^IO!BPT>S/%3R.U3JTQ;` M>5B&B:PXCP8Q$4^9!E!C.\=^.I`CX^E1H`@\)CH;AA@Z-Y.>9Z@:DK:=A'@] MR$H\*I&'WX38:V(F87)F&,)CI3YMB\>9BO?7RV]A1(_]'+ M:4"!$3>+^!<*E^@>CDDW#N/Z8:[BZ6+^CSD(RD3B8L_F7$741;4!R[;II=W09M%Q#S1YTZX_" M)#^D%L?KU-:",,2'\2=R1&4T31RT>T.VJB]\/."PR9JAP[+!J6L(*6Z^$EW+ MK!E8VU\U>5+>R&MAX?_",*V;;\![OA79(/-`+>=V_>UN=](`5109W M=09^__#O#_P;-[8\UUZ+J7_(69)51VO)>^=WS#VS.^]W)JNM:,64\_67TC)[ M,]4O9*I="`5L5[9_:E=GNYXS!Q7)`X)4VGF.E"#:D7F&71<:/L]EX;4$-?*"D"TZ@%^`$3__1?"W->V$X%6NS.$%;K@JT4,71T-*7 M3*#4?XA-%K%(.Q;'D857(Y>+*%8HK"BJR`:?:@SK45+^P(42&6D;@]]5@P\C M\?DF>"@MH>L+9^4%F!(HBL1E!6;'?!K2F@-_A&P$S`NW%XV(+^&Y'Z6,)T*2 M?`8AB(M>P&$)WZD'1:URM9Y2KC:57PTN6<(2#TVJ48QU",C1P8LN-77$JP)V4J6,)(]/`*QKE( M*`KQR%1AZ8I7?[FJ=5M@?\OL&POGLQ&/FJWZJ6W),E*9>;^H.)JR',F/\M4< MM3JP'+[%6,4]"+0ZF;EVO0.^V2C>2?.+"R4IF:HE;'R4W&YV&KD[%VJK>8X, M/3%$:R)1D&81J8O3S978U``S"2)7]I>0TFSVI!MIV>_"\(,_<$,[&8MV(%'6 M98J?("3F&UG+"JS5(1JE\8?U0DUH5G*$>&#E&IGE[TVFBGW@?DA==6;F.,\, MD$`/H,Y?P-E6@RO>T'&G!W*DLFBKT`NCM`5A=/S964L,#S61*P7U(!2ZD1^4<(`:L5I M/3/]3&`T65(;RQQA4RKP=J=X$2>K%%;IPDJ+HZ2A?^I0:[(BO18L*,:1"B M'@>/LL1YT.=Z&DM+(W-!1^L/G2J3Z#S$H?,^D/D(1L(LSM=<$^) M2=EZF,O-$^0JR,UCH&VN-0W36Q2KW8FD7K2;:_IE5C-0V/PCG7?AS9B^VE%N M`3&H\'N&HO!C6CY7=;7+"KRK:UR.+\,4YDOYR?+/F;"0\:NTJ>%*8SRQU*5O M2=(1G1'23@'`'_A>B2M2`@MA\'=8MQ!W541B3Y?Z))SVRA*9)%D,1V2_C4?8.`/ M+SQI5(O8>?.)E%"\V5U)6U5(N@1O'PMC?LE!VV,!2,"N`ECZ#(6@;XMPQ`@3!==A\I$`>*(BF4` MG1V=B2B6Y$TAT'75%@2FM((I$CQ$_6;=LM+HFU2\RF(Y9<9=A.W,*DI.K8[> M7&H?U/1.6'R*S'*[IRMM>=4FJWPO(*EMS)C5`:18KB6)M#1&MG@_I2HMGU&. M+O/RM7'[^0Y&N^,R^5QWPZ(`L0#":F9">T0;1'XO0;F![)UJ_IH%*V^AUFRO M/E@$%]E?^5L*9@ZI5E@@&XQ[,OC,#Y`;\9FM8*A59EIY4V=&P4G`V8[T0\H7 MU_G5JG2Q9_:Y)B+@9!2.\$6"?%"\@NS]L@8Z)9I+_6SO?]%"5\!5&D]7X#0PK`VN&0##,P#3*(] M:YVEJ7YNZ"*`U7!1`=-1A8U04;JP>8GV@$JF`3=,.MG*"@H'(+LW7'"S9?U[ M+U'F)N1A$R9Y[-F2XN_"(<6W!05(=)3B]V'BEVYCN0%"!XQ\!WB2[+^EII)3`2S M/F>K2B4+98!3^@2"0(8*P-PR_55-,Z5;V)>40RT&3RXN6C2CD)T)4([H,_!H M\\D;[2VFE6VZ4B'XO8U=5;`)$?-=#"OFM^Q6F8U$(>=!(9UJ M4DBO/`I)^D'([WCAV2,ZJ=JG+>ADIF1/[MBAV90;1>#6Q$,7S@`'A$1I)R`8 M5.G3%C"X4>*H#.44"O'6"=YTQ-4YXB^R$QU:">&0L7']5DG9^\E/*Z>\.7J: M'8AKQW9S*AB)Y(8MY09Y4_C&/9CGQG-.!)ER4NQA2.W/J@P_*LRWG^]J(J\F M3;%[8J%NW1\F%G19AC`B&5T%E8_UNTQ,"PU\ZAWR-HL#3!#64QOT\#@8C$"Q M$U#`R?.M?E[&4.$3"VTYZUN/=F@Z+3?Y=B_)D:G%6EK!'JU0=%=-O8F0M06. M]',VH:8][=5F0##=XJV2$?NOC)?FC]G*])**P@&90+0-ML&&\OB"UAZ5CA/Y*7\S+[GL@E5N5J5\K9L5LHNO&#\J:HR(N3ZVB+I\$G;B9PI2H'MLH)HC0W\)M1OYF,U:&J&B8F[%;==? MN."9SL&_9\%L"Y8M^LGIM6UT:!:BV*0,S:$#E-76P9HG/48XI_S M/9XAHD?^.@U+S^73+P6+*AJ29=YC,:,^OW[Z*O]-WBY8?D"&\C"L,X"KCJ.L MZ-YSJ(0E")=>VEM7U`740Q!D\;65#F,;R?]90`H))\;PX_E(\'R\1B22E!8N M&R.2VUI%%A&^!5]G60]Z`&@^&B2+8A%9XF/KNSM.QA#"'X@0ST`X2/(EH*/G MMA"2I&8JB2]=Y;D&.U_;=C).Q-:*-(IGTC+/5CA8:Y<`?OC/;H0Q_-N0\7-9 MNUA17Z7/U]"5""S9^L[_VN:=8/_)+@3+^6^BY:B.+4=%.ZIR"RO.4#)1D>2H M[6?A3@I&L[._\M@@?BW>MUZ MM_NWU\:;NR\W[[Y3Z\2CGU_TNG][88`LS4+X6LQ-SBY44Y//O6J\?J%-WE'__/GZYN;VTZ\7 M7P2;;L!,U7=R^OI7;^X>'NX^RB_EBKJ=>OMOV4]098=_?P%7&+:KY[)5'(S3 M>7<[?WNQ[8V%GV*GI"4UZ[W>6DMJKKPB`;7K#[>_\G^PL?X4'U:.*O[>9-$2 M3G+-4!V*BR8^ED$MV@_Y?G/] M]K=?O]Q]_73SRO@?VV9L,"CA,C?Z0X[7@"N6__/V[;MW[]^ON(W28I4/NS"S M>W^'IJXW:6JY*E:REN5A@;5@>_RN?4";\.U-SVV6N:S8+(H#.R!)QGA([1W)LP\XDKX:H? MC>K^O%!R(>7K1`(FFO4FOQ8-)TCZWG-VTZ/1^6JMQGP!*$(GH;,2Z"2+Q#E: M)/87A_-.%-BD(!RR1*SL]=Z`WU9)%SZ8"SR_655Q@V]PFL?E$S]\D0\ M8E;$K(A9$;/:D>F[V2X(T]\GJQ+[>I8Q/.(CY(9ORUWW7\)RF4=E?B<.5\12 MG\F:E0R>"1?:H!B!+/,?I?4@K.]I5]=@8/S0JG=5O9GJ5;/<,X(*/,]'B:!; MU3.)[^)\]Z\UZI?PYP-?+^Z#<6G;3"W8I`%3]8!Y\'9O;[4JD`[KQ_,[U%]W MKXZRQ]NM;UPGPR2*\Z5092?LM`RJ\0/_MMY*>_L&T"D(&S$/%G8S4(T7QQ8V M-76ABYIYA=5=^LP*LVI9%I?4Y.NO&J]5H[69?F\+"KK69&-SF&.4]*$=3"RZ MIH6JQ*1J,3,)`R[/.)%J<,2P!JLJWB8JK<[-0I5N#62]WHJ5Z5V]1G6W/>_K MK6B]UN>+_]>-M[(M-?\I5B,-\'@*JFO*;L^YQ]7/L]:4JLF]*'>X>/E6I->!Y0=Q85O12"N+*.7F M).8'GKY4]*`24KK\H>AF24WG,NJ[9T.)?:PX"EN\>Y'E2&H@_JZ:I3+!"J#G M+,H>0]'"^29,AL8-H)@#>"IKWCXR+Y@(T3B5BVMIIS64J42L">L:UJ%!Q`7? M3UF3D?,,42Y7\H]S!OZ865B,-EJR1W@5B\OT0@LDMYZLT.&XETU-L2ZP5L\V MUW\%ZSD7-.W`"MY?[K_*]NCB7R9):(_X;(0)-.*_A`;%0`'ON!(13!DS\%B- MS^J'GSW+QZ'>W7_^7#/$4F3_A$57)]9JAB6H'X+:"_\PA`8,LOLTITJQ@@N^ M2JBQ:(P#AWEU`YMNV,'0YULJ:Q]KX\YH#.(UJH8UIWB<$-\NV&`;RR<_HO(2 M+3^+]"+%QK"1&P.S"A]=6_6J7+6OQGZP^5CG=9(^!1E7KSC=0N_[B MWAX%T#P800BP4=L@6ICG14.=_L3V8Q.2YZD,Q@$BJF/S3X%/H&<&->X7#1JR M"3\EQ%36,Q7!#X>O<*_`/N*:KRC>KO58"_W[)O*QH)XGQWU-E&LWH[9DF2^4/DL[0A]@5^4:'^J*V& M],C,Q@/53=VPYJX.]ON'?W_@W[BQY;GV>N%">7Y_-UFT6>ZNB9]*]E)]1RI^ M=^"2O:V=[_IF6D=9)7M52=V__H6*WE:O>!XQ16**E7&?83>U(XQ=9E7 MT,+JN)7#`UEQ-BN76%FFUBCQUC\H,`Y[G1/0J@*TTBM?G-BU2$J_/(Q_!1`Z M`+'.U9'Z*J_GER;N;E:D^'B4BXY9GT]2."><'<5]3;B=PVVCWJW0=I-63%KQ MLI`W%>P(B3*GJ?N04KPE4ZN;QI19843P('A4#1[5*>4H/JY>7L7828V,?#F, M_41)WW_^3#'1)R)J4/A?!9SVF[D?*2::8J)//.:*F"(Q10H>I9AH@C7!FF*B MJW<_DWN48J(I)KJ(#Y]BR&>C2B&?9^>4)0(A`B'O[QE8'R@FFOQ[E6)J%!-- M,=$G##2*B2:EGV*B*2:ZXLI%UZR?=YNWH[BO";>S>]UN50FWI!635DPQT:04 M;WL9RRJ^A`Y"1\70<;P1T!AKA0Z-!@PW"C?%V!LA=^PDYWC`&,!2'XLA2Z_A3,;JY6N"B.CV\J MF+DJ."0_\Z1A@2N&O*_(&1PPQG.M`+VLI2"LM]%"0O5"X@DEDXL MO3*1W1E+;QXI2Z?D!8+XZ4.<$AD.?F]33(-*9&`1`[D2[05.UGJV.AZ\RDN='<;8;T,?^_>M-&N==H5JK!$W M(FY$W.ALN9%9NVI5J%+I`:*;SM/@MD>)_%?FL]#R4""WG+'KNU$,3=0?*32) MC!W5XXBM9H'%CG!)N#PT+EL%9K;C-JY5X@(FRYF*Z0EBRZN.*$B*Z3X54XUI M-NO-#@>>$R1]C[34H]-2-SC)XU)9F[5>]XKX%/$IXE/$IRK-IYK=R^KPJ2J; MUL3'4T^TN(X@16%!?'O-B$'^-A(_9'8P]/ESCL&BV!UC0#NGL0O;BD;+0^M# MYEDR^P$>@H0+YJ@4C0G\-$)3'*9*B,R&1OTRF]#8]3P8#S,=N,YMR"]F$AZ, MWQD'BN<9EO/?)(J+9I^;GAWP'T'8_R")DY`9]LCRAWRS^`%DJ^3_/F`N_'ND MYX#P5S%,:81%I2_`!`()V/+%L/$%^KLR/O:GA1E$".VW;0>+'D%\2 MQ7PWK=`IR$?K5WL+=\4Z;GWC/>N'B15.LVE*ML&IX/WU_1NU;\/$=2S?!IS_ MD;@A[!_S1_"-8SAN9'M!!/2EDP'?>L^*(G?@VI;`?Y#@F?`S2,:)^%W`7X09 M7Y.0C3@A<2ASXN5_,^,E'S/Z4:?8K[[#1(:/FDZ-TY`Q!DXA)R'HE],1/^0( M_C&;!;QM@PD8_2G^,Q='_+AN\#T#`U&,O`LX3\1O.5PC/Q/UWGADQ7,OYX^[ M?'NFQB`,QBN\%S@)BPWX8\$R/=?G#\5LC+PJ_2WG=3"VS)P;6"*S#CYSR/-? M\XE@JAUG,.I@0L,5O_:#F)\B?S4^ZOI\DUW.@=,'H[KQGO]Z=J&."Y=)G"UX MFBVWYGKBK8+HL>N'C^QN,W MXR]__8MA_-WUX;9\=8O_`V]+_]UPG9]?/%C#JQY8TWT0Z[^PP<\O;F!+_FF^ M^`5>SM^MF"',[P(XW"LN?0`WQ"\&%A.&*ME(NQV!27=Y:>H!;K55P M"-ODSK3F\W2RRXH^[>=3\8D:VV!J]I)79+4+06<%:JBPP+-$5^*7$[+$";\` MK-`%J=&7@CSP1?;=9E%DH,+$9^VP?LS_-XK#!'=77;)?Z_?\&@J9Q?DQ9\49 M-X7?(=Q)_X_7*[Y&`2. MO&MZ3?/R-9_(O92*9\`*_S4^!T&H_]IX>9_^X^S>DE.Y<(-YG/E M:KD;C:1DR4"2D<(CW)%XI?%]R(1'7"A7YY*0"P%*-!A;_+;F_S4B:\#B*?[& M<[E\RG=(Z)+B%N=C0%V`D#VZ'!@X$O^2RRC\N"*FSX"_>&Q]=\>H"'+)Q$%5 M$LO`1IEXH.K8BY,!(03EN&#L1JA8%,UF<^VL\E2U)&U?*-1^'()*)H]PJHC% M>N22'#QQP>6BB\B"1YFM3AD(DF\])-XOIMO-<_'+S;[OMNJM]FZR[[NMO67? MKVT!O.PL,,TN-`%>'H?G^LX7`C_P-8\S_NH875OUJ_5V?)O2>"7FT*YO;>ZM MNW*S=U36_7:E3/N=]5R0E?*)5;TFX&9LLW),\AH-((%BE7TN"RF+R5-PP`;( MF[#(PS/$W?.^ZG*Z\GJ"[)JIG3,+(W$PS^E2KI9C=5AOK%QF=WI"XI%$$"UB MNUL&B!^77%I4C&&OP*ZW+CLP9Y)-23:M1NCY$4F?U/V*\S$'S%Q[7#_#:KOE,5F_MU9+B>EV#.*X0U@8<''5BSOJLBSU4T"L+X M@B]SG/-?H9NIUP.GB:UB1/C#SYOH1]8C.IIREGTPEX*+1K,"5#8\K=6IMTK1 M%^(ECD9TW`5//@NCD3O)/$NY_6LVTN.`F$;+'@G/"2@<_*@?H5@U.)\L'PX# M7$[RWSB7=&WMG_!P95%C],62%8\NX_NG>>,FQ,68AA]UG_J\C9@?P]8\UX]H>6<&0^<:M;]>%G_,Z M]OAO^.S$\S9+8O#01<8'=^QR-,]-!M?"YQ*#:W-V-M=\J`A#,/EO0VN"HZ5C MU0SW;9#_EVPB7]@PX32$GD(9&(CA.1#B%D\UIVJDPJ,6[DN2AJ9A[.B8Q2,1 MNZD%'&(LT,IO6KSH6"M/CG.'X-70P3!9SL4@2'9HN3+>%,*NX"'^'TZV$RM4 MB,%X-ICAXG#,(AK\0OXM.$[]6"@^Z0C#)L3$64AWYT_$BM$L^$@ MHP>N+SE0:ELY!O-%X`<<="&;Q%;N*&L94.!0TV@T("H'G-")AQO/IV7EIPXC M_F#6316&O#/NE.,F%;X_\CY;%]&!+MNI8OLZ)O/%T;LI"M^JVZN::*SIX<=!=6)8;ZXG7C7++=-*9TYG3F=.9TYF? MWIE[>RG!?`?Y&!'<`4?Z`ND+1.(G3>+[N5.N14FD9WN4$N`*UERY MH+_F@BW<+I"ZV3R%)KU?T]`-@CGQU7T@#DJDN6%Q#SM"'"%N]XA[IPHR'AAP M)ZLI5.[&7Z1W;'?CKZV<[`?>!7WGN?Q:S+2W3`,\"<[^-HA(BB!X MGRJ\?X58=\(WX?M$\?T!,S@(X`3P$P8XP9O@?:+P?F^Y6NGQ?T%:()E8CL[$ MLL.:-:O:759J/0[FEB,HSW2OY[2GF8N+4A6WA_\&'=W6O@&H'-.&M\!*P$;F M/[?#Y77MK48)58(AP9!@2#`D&!(,"88$0X(AP7!CM7U?G5Q/*F3::.Y-*7XK M>PPQT:PH*]M6FEI\&!OHH<*XBKN+5[&DX@8MPG>P0;WZY5H;5.7:G5>7M:M> M010/$0X1#A'.,SO8N2*B(:(AHEEK!U\V3Y-J=KA%/QYD@X@*SX@*TV:GS=0]''(!2";O5^JV@-C%F;1SSL3_SUDW>J&6X490P!QI; M+VJE71H83\[D7YJ->8/4QST:XG?)_FI7K4.WS2+`G1'@RNNH26`CL,T:*-K= MR/`,;$-?Q'EZ@U]MBKE"!RC!`A>!`\R'=&0"&@$%#V)9,0$\L.#O-,A@!/`3QC@+\U# MAQ746Y<=F/29^GJ):HZ0:LB]3/?#>2`=I/RK\H*\R:5=39=V:V]6F8<@!G-* M9I9Y66-!<2#"9L;RZM7AY%7*>IB M:VW^"*(N]E^CD`RG%3:<5K(\ZRX9:N.R9K8.[5,CZG:*X@2CE"8\81$`Q=!:<*A$3Y.`!\O3[/SR6'U6L(;^<0)*-L+-YWRRNR2 M?_K<_=-5**EV<@:OTFPA9U-)TFS66E7*NR'$G3KB6N3;);2=E`)`L"/8$>P( M=H>''9?FVLT*27/D4SP;G^*1U;8['J,=);)4B<-V:LW&:?HP")7'B\KR>H$0 M(@F157?T4LXUP?R$]7QBP83-3475PP@&Y-'>6O/?V*-=K8IJXR!D1CRR_*RV M6F6,4U4WAYY2-L?YU+%L7=4NVQ7JS4@H)Y3O'N4]ZDA/"#]EA+\TNX>&.!6L M)[(Y-K*AN`>Z(,X#Z2CH=RLDZ%.LQ5YB+=I[LZ_<)_T83"QD6*Z@8;G>*H$; M'LX1]<->Y;/";=G=X?3JE[L_G-[*A[/_NZC9;=>:)3;8(D9!C((8Q2DPBJL> M,0EB$L0DB$D\8_ILMO?')4P*W"*N0UR'N`Y%TA&S(&9!S&)U@T?W,`:/B@0W MBH]6WV/;CB_W"(92SP-&+G!!KSPVB%^G+B#P`4E4O;W[\.'Z\ST_/COP/&L2 M09U>FWG@NK%=?_CSBX;X6]K[\>_4[X..GR!T6`C?BVFC,3RP,;2_+BH>3OK">0&.]`72%XC$3YK$]W.GO`VB MF*Z3(P_<:"[8PNV"`YI-'>"=(P7X5S]D_.5_,H=@3BQU'XB['4\L-X2FJX0X M0MP^$/'^T0GNDG6WZJ676LC^: M#;.@'BTQW*.29*M:S//P//Z-%;D%K1((WX3OD\#WKY;K$[X)WZ>*[P]!%!7U MNB&`$\!/!N`$;X+WB<+[O>6&V>G^R_(21M:6H[.V[+!6XJHF&/W9RW?WMR;/OPV"4/&AYH$8>P&OO'R"QLF7A(9#R,66A.6Q*X=&;>^ M7=^@F&"E#:*'"N\J+E%V(M7'=K!!"\J$'64%,+-3ZS0[1#A$.$0X:Y8`K[5: M5`6<"(<(APK4$O40]1#U$/40]52;>MKM6J];D,%PQ)$DE;!"K6VEV\@TM7'P MQ@&-5:YO>XG#'(-/!:L1&K;\B15%+([*LUF=G`&_-(OQ!NF,1]IKM=8I464E MP!'@Y@!W56)W`0(<`>X`ZA'!CF`W`[N7O5[CG/&VPZVLD$!\/OAMUKKF584V MGF(X3BN&XT/@#R]B%HZ+%>,;-@DB-XX,RW>RPPA072Y;33X>8R M=6P_53>6'TD:64EMYJMC)ZYHX_D=GF%9W>@W/L,#^(\O:]T>12P0S6S<5D=68QB+/<28[FD;O0)-1VNF,"]K\NF66]R&<)P@J3O M/5>,[ZC2QBMW+NM?("N>2Y6SU9L]L]8KT<)(?(+X!/&)X^<3+;/6N2I/M"0V M06R"V,3QLXF7S?;^ZA6*_=H;GSA90QKQ'>([Q\YWRC3T$]^I$KZ)[U3S7,Z2 M[[3,9JW5/4R)YHID3XB/%C_"34YIS;Z4H5`*4+?/J5QP;QZS2A!S)Z M)/C>WGWX-8D`;C;S(#7'=OWASR\:XF_I","_TRP>K+D1A`X+ MX7LQC9/R()R>HZ"D/K^[H-H-"KZ4V'27SIS.G,ZXL(+?_]9>D!.UHQ9J>1!H#D3B1.)TYG3F=.9TYG7D5SWP_ M&L,#&T^"T`JGI"^<.^!(7R!]@4C\I$E\/W?*]1B*?O_)'+I3CCR>M;E@"[=+ MY&LV=91WCA3E7_V0\9<3S(FO[@EQM^.)Y89C_EY"'"%N'XA[%\7NV(H/SN). M5E.HW(V_2._8[L9?6SG9#[QOF,W&?19FQ]LR:]D?S8;9)$Y[Y")L58N)'YZY MOPTB$B0(WJ<*[U\MUX\(WX3O$\7WAR"*&`&<`'[*`"=X$[Q/%-[O+5=3//]E M>0DC*\O165EV6#1Q5=.+_FPY_8B6%+$K(HM-^Q&-@C`6G8)=_Y%%,5BWHU?S MA$`EK(^ZINM*M\!*P-YWU_52'`T$0X(AP9!@2#`D&!(,"88$0X+AQC"DRNY[ MJ>S>W)M2_#8((2A&[M%QOZCMH$>*I*KN&C9B=0BV\$&+:@> M=I1%P4RS56NVJ:8Z40Y1SGH[V#.):(AHB&C6JWU[FC?-#G=H@[*W1(1$A%7K MA4M7&%'/:5(/:$RMYF&$OXJ442['<+6V86\C:];&01_[LV_=Y*U:AAM%"7., M_M3X6K^O&\/@D84^!((8UI#Y=IF&KY.S^9=F9-X@_7&/EOA=\K]&S6PZ,$%>09$A@(["59*'H=L\9;D=AR2#X'E2W/P(8$]?,1$WKQ0\BL*"FJU$DVS0U,3?NOY[,?3E5KE*B]$D1.`2($#X('N<\( M*`04`LJ^9!)R*))#AEF5Z;/?B7RW?,2:!QY^U+<^( MDK[C/KJ1&_CP8/9K&$&,5QT[0-4M3Z>4@K1!D9(C-79U:YTN>4`)Y"<-\O(: MQ1/`">"'!_C+0X<5U%N7'9CSF?IZB6B.D&C(O4S7PWD@'83\2_)HGYM'N[4W MH\Q#$(,U);/*/+GQR+",L17#-U,PRG#Z-*;,TNI@!J'AL:*ZKV=G3Z92KI5B ME^U&[:IQFMF=A,LCQF6C/#6/,$F8W,CR<'FY/TQN;V4@FP+AO++&`N+!A,V- MY=56FX(N*.CB9*H4DN&TPH;32A9HW2'<>XV:>=ZIDX3M4\6V6=3GEH!-P#YV M8+^\.FM@GZRQ@@CE"$T91T`P=!.<*L!!?.]52'RG<(>S2>#?>U&[X[$9[\+8 M>*(Y<[U:XT#F6X+(D4"D55X*`^'C!/!!_DD""@&%@+)3H>3R,/%FY%/>6F4Z M`I]R%:J@G9R9JC03QOE4?VS6VLWRE#%"'"%N!G'-\B)H"6V$-O+^$.P(=@2[ MLX0=2'.=\LK1D2N07($G4H[N>&QVE'Q2)0[;J[4:Y<5:$"H)E1NY2ZGN.4&R M6I!\:>Z135*F-.'\A#5]XL&$S0V%5>IV?78^[6K501L'(3/BD>5G%=$J8YZJ MND'TE+(PSJ?Z9*-7NVI1C7E"^2FCO-F@(O.$\%-&^$OSX!"G,O-$-L=&-A3Y M0!?$>2#=;%S5&E42]"G:8B_1%NV]V5?NDWX,)A8R+%?0L%QOE<`-#^>(^F&O M\EGAMNSN<'KUR]T?3F_EPSF`.MZ^JO5:5,.?&`4Q"F(4ST8*E2>P$I,@)D%, MX@28Q$NSU]D;ES`I<(NX#G$=XCH424?,@I@%,8N5#1Y7W;-N`B,^6GV/;3N^ MW",82CT/&+G`!;WRV"!^G;J`P`O& M=OWASR\:XF]I[\>_4[\/.GZ"T&$A?"^F<5*.@D-5Z"KO'LN1N/(PL_V)>QDW?3Y`["\CM?_TE:3@[6K&F!)'&0"1.)$YG3F=.9TYG M3F=>Q3/?C\;PP,;0M+JH?#CI"^<%.-(72%\@$C]I$M_/G?(VB&*Z3HX\<*.Y M8`NW"PYH-G6`=XX4X%_]D/&7_\D<@CFQU'T@[G8\L=P0NJ42X@AQ^T#6JVF>_[*\A)&9Y>C,+#LLDKBJ[45_MIP^`.;>ZM2]^R.!:O]9 M(X!7\S1`I3]/O_3G2IC>=\7/:O2@)1@2#`F&!$."(<&08$@P)!@2#*EN^U[K MMC?WI@^_3<*0\:$F01B[@6^\_,*&B9=$QL.(A=:$);%K1\:M;]*ZBFN3G4C9L1ULT(+Z8$=9^LOLU#K-/3:7)L(APCD-PNG5&E=$.$0X1#A4 MF9:HAZB'J(>HAZBGVM33:M6ZS8(,AB..)*F$%6IM*]U&IJF-@S<.:*QR?=M+ M'.88?"I8AM"PY4^L*&)Q5)[-ZN0,^*59C#?(8SS2)JNUSF5Y;>T(<`2X&<"U M:^9E>A5J7;Y_O.UP*RLD$)\/?MNUWF5Y[7\H MAN/<8S@^!/[P(F;AN%@QOF&3('+CR+!\)SN,`-7ELM7DXS%V4B);E5AFM[F_ MKJZ$2<)D5;0?PB9AD[!)V"1L$C8)FZFLU?&-_=6MOBOE]TH^#V/*J M8_NINK'\2-+(2NHO7QT[<44[SN_P#,MJ0[_Q&1X@8.&R=MDZ:\\*,2=B3L2< M*LF*,2<*A"(.11R*.%1U.50%8N;JK^,3)&M*([Q#?.7:^4Z:AG_A.E?!-?*>:YW*6 M?*?9NZHU]BCR;&5=+\>6+CY:_`BW'7_E$U96[D:]`TO>]:'>^H\LBL?,CR/C MB1EVX$>NPT+F&'%@])D1L_$D"*W0]::&.YY8+OR3%1L?K=`>90MKF36CV3!; M?(R0&59D#`+/"YXBJ$M@Q*,@B2S?B7Y>6P0OQ;C M*:SA1J:4W*UWNW]+*??MW84VVZP]_?M$0?TLO M"OZM:!=35(*0;Q]\+>:V?^]+NU?OMMKR2YHZ0NR;O@>:UZ M;[V#-%LGL.SC.^O*B2>M1KV[^_B`5B[%L[/S3??VT_*=15%VOO'(\K._S&;V M>"5SCKI9>/ZGT&B;;DCB MFB4IVXONVRU#XTJXE/?#*C\EXSX+%[-`37R_IP]JJPW>475 M<*,H88[1GQI?Z_=U8Q@\LM`?8ZO+(?/M,G79`]G:3S[08C_-AP@6!X3%413! M-ENUWH$B.?&GYCC'A*EGLVI9G1$G?<1_=R`W\]/?BZ>HH%&1KW:_O8`-G[_'HRBW" M->%Z9EF#T/W79XI@8H63[)\KETFQ^@95)QJN$> M`G>.R*IU$M&2JZ:H5]G&>EF>+$%PW`*.5"]A7X[JDGW2&QS1AK'L^S&XF^U: MH]DCBSOQ#.(9Q#-6T^6:[?TQC)DZ3Z?K@1$?3ZF$R^_,Z#//98_,B$=6C/X* MA]F>ZS.#S^,1TM*D'R-B>>=(JG--A0\D=,="_PJ9!^EN4`0&AK-'EC_$T?B_ M?V,Q_Q2SD$6Q$:(#)7)]FQF3).0_C%@]VRU#FYP;PQO'0<@,S_W&^%L@^Y[3 M>BSF_<0XF#P/JLY@,1?^[E'@.?/SYO\PMF+X:ZJ_ZF'$IS2`X?E(EA^[MCN! M!)!!P@<-F0WQ,U.Y$6YH6'PF,:0R&7;`%]*W(CX[/HULZ&)8;0^9GQSW$?[Z M^T\N9M"^RA)I'SCS>N,%]K=?_OH7P_A[$ET,+6OR"A(-,;WPQHUL+X@2OO?I M3PW7^?G%@S6\N@(;E0_\[PL;_/SB!@KR_--\\0N\D[]2S1B6=`$`>F4VZC!= M_&)@C?G!OYJ#VHK&@DYGWEC0ZNCDOD%ZVOI6WH)#ZV\Q@18L()JN,*Y1SZ83S6(NSQI"Q M"\YE0V,`.R4NCQ'_&^I]38'U\DLB`$;\)\.KP?4G21S!XP[<#T&2>W*L[?$, MK^;O@_?P:\BWO<1AKXP/_);P#+/&;Z\!O[P'\<=N&)NUJ/E>C"U"_ZNB\CRV1>Q+PDPC%=;IL6_"JM?@ER5Q\R''YU1CSRQBVR\_^2O>]<,\&[G<\;SZY MN47S[\8LM%V^ZQ-KPE^QQJZ]QA'$2ENYE2;^/!3XZL3.^==\"7Z@3M*Q M8LM@W]T(CCU.98,0CB!T_2$<#J`C1E0[\,I@PH44OL`G'_"2C"0<#;).A`F'_Z_ M0.$H*\%A:XL868\@T/%1\H2_HQY;>*_<0()@P&+("0'4,67!`<(<.`HGQ$W04%Q0.Y;?0+]*8>7 MPWE1S-$'(\.CZBWCP.$/('_K3X4TG)LFS/*YZ<$_/D)-144<$RL4[^"$J,U/ MBMK:-UPDY2_EQZ8A7X);D+>^\ILD5#-')FZ(`E81%KJ(@HJ"3H*![_EZN"7.E6KM5[D"CRA/%7:K& MY;^_17'\>0)J$@$1`9T#`>6HX*MF]%N?9EJ'IIFRNI:<;CG"]778(TA*?&M% M(S0(\V6@O?%ED3ATN%24M1D[I:)0G:1R3NP@=9(:JW7S6NWL&D>5^GG5K34N MF\2,B!D1,R)F=&AF9!(S(F9$S(B840684:?6:%2JN#;Q(N)%Q(O.DA<)6NPU MS69!A/3!:MKNN:Q#E1L*EA5Z4X6&*<;+(M_347N<#A305.P`*M6WLY_&\`TN M+%T=*KF90'(4(-G''49`.0&@$#FY3EV:^$J$MN>QQK_7X,I8K*)VUQV:[=M4JKT0[(8X0=PR6*(+=J<..&!TACA@=F=Q/R^2^6,'` M%B6@9#RH(B1DA">+R+*67NWFH5J_$48((X21D\#(H2VK!!0""IG@R02_1$+> M13L_,M>336&_GNU:CV**"7&G=4<3[`AVQ.@(<<3HR%Q_TN;ZVUPE[R]LF'A) MA%TGK`E+N+(1&;>^O:AB+5E-R&K"QVJW:[UN>0VW"2,G@)%#6]8(*`04`LHI M`>6`MPZ9Z4_?3/]NKMG)RZ+:BZ3^'W7MA++*EQZGQ:%9ZYH4D4H8)XP3Q@GC MQXOQ2EJ.">F$]/-`.OE(]N`C:>Y-$WP(8LLC6U0%FT^L5OE.8X;->K/#L>,$ M2=][O@S>6ONX0[!5M.C=A@>T8GV[#4ZHL5ECB?U8)AN7M9[9(99!+(-8!K&, ME;*8.,LPB640RR"602QC14-FIU/KM2Z)91#+()9!+(-")E:Q@(F/V'IQR_'E M'L%0ZGG`R04NZ)7'!O'K%&R-OZ7(>GOWXG;@>=8D`BS9S`-3J^WZ MPY]?-,3?TC:'?Z?8PA+O0>BP$+X7TS@AH]ZA0J2H#RSU@2VK#^RUUC_YAMEL MW&>AUL[5K.$\TGZOS899T"VJOT]63=1`U%`6-?PS"6+F9.?[.71M%F5_NWZ> M'*[MV'UDV;]_M,)O;%F/Y*).M$1!1$$G04%Z7_'TD._B$;]5T<4HRGAE+=09L\K*QH9[(_$Y)&Q(V(&Q$W.C@W,HD;$39,@@G06C%S'!FZJ%3 M5Z!=.01.M/"3>=6J=1H4^$P@H3)R!!3B)@22D^)\?]0?H"8=?,8?#( M0A\K=5M#YMMEB\HG9S(J33$]FX8$9J]F-GJ$.$+<*=V[!#N"'3$Z0APQ.C*Y MG[3)?;&"@>U&0&4C/!D$5G>=KU3D*E*&"&,$$8((U42?`@H!!0R MP9,)?@L).8JMF'\1#(2L[+LQ__Y>?&GYCC$)//Z(;7E&E/0=]]&-W,!/?R^? M)G,]V13V62"P7>M=E>?8)L01XH[!BD6P.W78$:,CQ!&C(W/]:9GK;_U'%L48 M\,/?_84-$R^)C(<1"ZT)2[BR$1FWOETGJPE931:#J-6J=9MD@B6,5-BR1D`A MH!!03@DH![QUR$Q_^F;Z=W\D;CS-Y8P655\D]?^H:R=0H]M\?9#>99LP3A@_ M:8R;;:K'11@_98Q7TG),2">D[QSIE\T*9="0;V0/OI'FWC3`AR"V/+)!5;#M M!'6^W/)55K7)5G@=V M(&^C:G`7:5&H+W,TG?2;&LF7.AB+;7N(P!P*1;>@O M""F/]FRCP<`W@B0T[,!'WF!!BF3?\BS?9D8T8BQ>%*N\DW,[!CP4Y'\>/1ZB M41#&%S$+Q_PO%;%.8%@.AH*0I:,'0P!]J`T["4.L4QI%[#BA,#-BJU-OE2'` M_0*3ZPW!!NX(1Q(0E*,3%)3@/<0YW"^$SA"387#,=_J[)% M@$_?6R&;Q%8NGI]E>);] M#5XUML)OC%_?K@?3<-S(#A*^.X$_NQZ1"Q^QW"+ZS+82_AW@AAE/\/]"_H^A M:\Q1X_(S'@<,'Y^L2>VL9H^D$B$_4(."S-H()["#\Q)I, MPN"[.U:+MX,HAG>.F#.$L46%@H!/A+_2]?!O[1`,YCM\BV_E@;HA?_J/Q`KY M.F"49L-LX89PXN:X\#Q5],`.QF/^M!B9?[<"#OES5@QC!4^P06*W88H_*FK^F4Z>PTD8ATWS&;C M/@OGEM+<=BDYIO#CNW*K[?#?5%#4YGPCA"^#RFM=57S?6\7G[4YE47 MFI_E1]S\3MBJ87EEKH8'H+7`\X(GQ#\PGR@9\WV=%MT%\J[@1Q#G3E&0#=S' M,$K?XO"0#"7BN\&O'=OBTTVTQO>*Y[V4`/N1ST+PU'@4,GXK\?6-(N`)_&T+ MB,UXB7=3D$3\?*,?7VU^E$O.";5&]3R8!"[PE%]Y;!"_%N,I95C("5+SO6S5 M6^V_I::%MW_OQ!;VN;0A&:K@L+V5&:PYDUX=S?.G?GF7SGY6]R_@ M_TX&X*_`]$]PG7A+:3>0+D_"/;9TR26;6.NM7DE6UATQ,*R]7[RP72_8_S*N[J?DQT*OBZ6;4ZUU_5A?'2 M$E,WXV+'F3#YTJR9W59U0'<`F6N'N[E"09B3E>$.PWPMVT[&,CY`!H($XTG( M1LR/W$?P+/&_F?$2Y+S#=)O779@4F3M'GDTN9!7&@+ M0H](K*Q>&,JJ/C#*O3M4[MVJGJ[U3ZA9Y=R[=KO6*]'@OK=GE(N MQ%NV"25:&PYW:+-X#^&S&#YEW+B1[0406+O#$+&B!9:P8;NBD;LD-)IR@E>- MU\:$A1!EE,>//W-N+LB0*DDB"E6?$ M-3LP1?G&'TD`1BD1E6Y,0M?F_RKCFB/YZYKQ-'+MD0BU%L'/33T'9XN`]"6' M_)/C/L)??_\IB2Z&EC5Y!1A$"&H(?.!<]XT7V-]^^>M?#./OZJ=O(6*Y'X06 MA,U?AZ'E#W&ZV9/I@X;K_/SBP1J:#0AGY@OA__"%#7Y^<0,G\$_SQ2\P&SX9 MM198[`6`X979J,-"\(N!Q8]S^FH.-BNRCTZW;G;F!<8#T/MEP9'VMYC`'M+T MZ-,ZB8S9B1K;8&K69J01G*%1G`AB^,!YBX\9%M?#D+%=Q1>O0C:;W2)[);F' MT')<2"JS/./SR`K'EHV)8/S/:WY%@'(WLXV[N'A+NV3=U6_;^X=_?^#?N#$7 M[^SUE%XW&#+?N'68/;\9[MJ;<912"!<)1A8G-Q:!I.I&(TR?A'RD*`XA$=.U M1>Z.($S(',7,-FWO1&YA/PPLAXG$,_9]`O\#\D3$[_N0X;>AQ3\X;L1O?BYY M<.JV1_P/73ZY]8W_M?S$"J?9ER(Q[XG/$`*OT1\&F9?&T`OZ'-RYN1F6X@P% MDPRX[,-ECV`B:BP$XS$7;UQ,?#1N[V_O+^X_?IJ#P8)M[M:18WR^N[]]N+T# MK8IYR+;XH8'"8[A?L;,IOQ%7!1TS>2R2"$V4VLJ7K)#\VK M?"(F/TS&%2J4"OGFRL?YH_#7#^U.^FLH99#T.;Y\9.S\:PXVKB2KT2&G-PKX M48`DB>>&2:Z>ZR/[DJ>FYG$T1\6%83BLP/`4QYT1Q2V1DCV!W%+81#A;N5BX MY2J^T'J.ND96A*>6Y4:+51\1:8D4;7"L>PP7(:E$Y&5'BYW6#W`:R[\"-(LZI72A*@-M8XY\Y07@>4(H! M^<7IK@Z8X*GXKYQ\DC%3'%&C%TC\'4+<0!!.Y[B>X)@I`"&A&#/^.1.^YMCU M`Y47!<]>IV6FL<9^Z>=YB<4&+,X6(3Y-=0"$`415%XPWI&-&, M.`;N,\&*GMB2*U\8K"\<_N^Q$093RQ,U4T!^*Q`#(=K)'=QY<7RB-D!2(?\OQ&;6*!"S,KHD)`@K[%,7G]6 M/+<,/P"S(2`^P@>=,!D:L14.&58QN?GX^3>C4#8>3P..:Z[$.--(B,5&/)TP MPT3I^.:CJ0-^)W*RV5Q'3NY<;2DGSXC'\!7LQD6V.;A7!=+H(AET7HY0`XM= M'X5!,AP5R#R94)`*[W'(CU#?XM6$QA5>IEW0\V]9E:NV]L55R^6E:KOJ^1L_ MO=SFKS%1+R9;_$`7[P#9G+]<,!],`E#'*/CN0CC(<"KO,H`)7,1(=U(XVIIC M'IGEA)_H?+;QJFR22PCALUSR67Y8Q`TC(>2`Y4:0OO@">"$'01+"\2%)\J/# MOU-S@33)%(DELZQA`<.1[W^65@6XO'D6@8A:GT58@D&@T,HX+:KWB"V0F'QN M4KKX_[Z)A:P&O[+*)E,@C"&(V`@V^)P,WN/ZU:ZB8L!XZ*D MF4[;\\0_X*D'QDOHP!:-7S-MD?S*P"W&P9.800W-E";^)< M?>1.YHWY.I0@0B%73C1Z)LX`)["X_(:D5P8\;,#"<&8EG:MZ7FS^H=O,*O_- MK@67(*I/PH[.\.'H6,"U%R?7K\S_DV^+\38()Y+X:IQR[SE/'KAX)7(.=+;N MKV*/4Z-7Y''*'&*6]*@*ZE$[/`CL1(;%8`'2U%\M!+B+F^"]$D)^P<$'=T#@K#&I, M$HX#L#/S-0E;6IRZV+_YP=/%*'C2"4Q.LZ9=N+"Z;RR[MM2O]:'X;]P0)L#< MH9\K9C[A/`]&`4TSY!>T2'%[M+B"FL`MD?A7;"^*7%?\BW_]&U\E]_QIEQ&O`?X6H"$OA?BP._9KRU?,NQ M:L9U`L?+C[5FW/,WCXSK0RM#T?DI#56G]!`R&6>5(0/PEF+ MAI2(`BXK!'YB>RR(^6(O1&`54"7?!^"54$U2',28;S:6V;4FP<4;*&#;=\5. M2C;(<<[5@2$?]0G2\S@W1&Q%Q"K>&_:I9862$Z7PP6O=Y8FM?U,VNX&T4)'S[E%5(L MQ6%D>I2,P-.K^ZKJK_@+^$%&XISX!JZH`2Y)%'\K*IM>\&^E#&GYPU2"Y!*R MBNGCF.ED?X'4[WD:1H4H6E_DD6]I`HD%L8C/6W]S+2HF/\H2S9_X M%\"B4D[(9=>Q-17:A)*<^:]#$&PZ'.YK"/=JHQ<(]B!ZQ#E.(K6(2TU#41JO M'$,Q[D*E`#=?CM'3]F/!&/..N&+]XF&Q`)_W1`A!&_`S$P.A-H)+X/HYH=Z' M5E,11T\^SR#H#T:>NG["\K:#8]ZL)(3,JO;S/A!7"FV;V6$EX-M,)-WVY M,*FT9LR_@C:4_4?C,9Z5^/9(?_F@+GVTX+@YA^<,W12%YCDN(N2/P$CT$=3H M09\++%*#STT_2NQ1:OA46XC75AZ)[/L$!-U(,`$/W:*@'\[JG?+1]+V#XE&$ MJ0,"(>"644?@1O)ZA.2+\L++#\\A5E8==&K%/5-\`O:?2P$3%J,HD_C\FL'V M#OP!=8PB8P`M.W%Z7V2N]ZR8>N3&B;`M;%&9?,>L>M>]9^ZGXW[@%0>7]%KS M8=*'ZSRSGU#P-7O:*$R!G)?A*EX5QU:,!M.84P5H0$(C!N@]A6[,=3S0NO@X M<'7=1FY4$+5.L#E&V/R^,6*P4X.P*DPO^M,+^5$5IP@Q+B<&2VSLA@Q8($C& M$J9B\KVF>?D:@HUL[`0QL%R/?P",@62<21/\-N/2;!3XV#R!#3C3%;ZAK&HOP9`Q:?V`P$LW]U-48L#*+*TCO(0)P#G@:X MI1P4-TO@6!J_,]NU6#Y8'T(H2F1_$ZQ;!%`+NEF90V>S1FLOF.6PRU?2QV!7 MY9[-3KR6_ALZ$83O=PI6'$OZB.72S\VZ<3M0#O.9#81KR_XC<2,)0SQ8L&7Q MV9F]AN%8TTA3.H1U3?N]S@^9)W=^DH0V6B=D'S7TA*9`4<;&@L!B=?XKJUE6 M]B[,AX;Q^WPV22P4WLRXTI\J%,HI@]&^)EWQMN6#!P%_75/IWS+/6F1LB]&U MMG=]"/+G0'48^%@$S:66Z;[E?T/[@!N>7:B60@1$$V7;CRYX?B">.Y:&=`R7 M2,"!K54MFP)]0$$#?UGO6#^==C`O9;M%L8=BL MAZ!FLX4_S0::1\'4RD$<1K*5V=KH598CX-WI)`+/B0PT"J")%O):-*\!MDL3 MK@V1\1>#V0LULKP?(W<3(;"!9#$S<)JN'?P."WTAR`+`::5:GFY7.N`H@?PP M4F2O]I,K`$X:CIG;KI!-(';,%^DZ>EL?'0MW[B>/QK._!/;^I M1K]Q`9Z=<\3.?*Y78ZUXG?O?%,'9P`(CZ;>-W.]I1&4MY[Q'!RBX5O/Y)]A] ME0_`I7E.V*@0PS",?8.+4`_8-7R^&N&0M[`M1YP&:0/\,3->!(.+*!@5DIT/ M=1D`T>O_+)Z!TL_`!UV1G@]MG[$G*8>)X_.+.^]/UIR)\"%X@KZEV,<9W$R! M)QQ6E@WYH"`(A-;$G0L\%DOA^X--0H6C#-Y9%/I:F,>"HK_SB+,0I8+$D'S7 MBQ*_CX43[-KS.Q.*'G"-!5/]=0>A3%Q%!AR)P)(T^MW-Y$H5)811+_%H&D)R M$$8)/3Q\J:E':MM8I9Z)?X9[DE.*-4QS;YHY3_^28&_QC(K8Y]\&@PO^'PY9 MFTWBW63+;N75N/_MF50%`6T4`P36T_/A=^&B1=6R_.X")S1HL8,D1(O=4D?_ MC.QV9\?!XJ056`HFSDIO\SSFQ+D.4+-&7=WF6G:($8"%11LX<_2SS&F.ME7/ MZW"9T]M@(:/==!M722?A%%'7PW/RJ27NXF0C:<721[I\/J6Z6".%H"Z9\)WE M^>?3X/,Y.T=VIH8J=6-Y(;/X]*5@S_6.>F<)+T+:!;GP.Q[/PNT3H+!CEK$?J M2KNG/!JA*M6RD%CXP&`H"!.AQ@&A3L]Y20<4%D<#-EEE?&L=; MF,?)9YIF][>7C[$TGKC3WE4\\58A&%N0Y!HYBZU+LR=P&/`4]3;)`,>%SHR*7D.3YB.4M4^.I=,:$+HJ7&%8PD(>?*U.1 MS7E'Y6'J.>-(`14NLK3,U*YJ=9OU)<54EF5)SFH\W=E8/L;R M!,H5!GE>X]G&NK&6U/N#V>HN-Q_R)6#U%LU*)EW=\ZHS@`IT550>*;T''C#P65;"R?-HSI13GEP=W^5>.Q*\^\[Y)+8C MD(5@WXMA"APEI^!Q>N=B"=KK+8 M"HNI]RZ(GY^X;#+K^&I?[8HZ5'9:3$W6//G' MS5P`AW0T*S%P-O]UD52PY46SKA`NA*8XV.:UBX3OFZUNS0+IJ*`8`1S9MB$& M,IC?'?>3D+-A1`$L``1(=<[R[>I4-?%.=XFHJP9O#-S:9ZN?8[0:ONX'W3)< M5)05HRU%VC+\*8YM+F@C6XP=A'CK+RSV)Q.>GPM\G&OUE>D!4#Y^?N+*VQN) M(/E%U=PP>5_$ZDMWBG*<:))'5GXB7\920ZU:[=CZQG1!2"]Z")/<7?AF">:P MYE6KUF@T5+6UY@:F,+'&71JGP#:UL?VIV;S"%6F6I57G/7MAS+=;6Z.'VFSS M-1^L3`)%7]SHV[-=UTSJNL:'[U#7M=/[5'RB.^VZIE$:<(0WH#M"O@>0W0Z$ M]?(:K.VU0197*.,`2L*!1@QE2625%*ZPJ\98R/2+FF79LO8BP^Q:'T*.15TO MY<'C0T9C,$MEV4?I+T7,DHV)A\R1ZF8NG4,X3""V4B6V"?Y>-[XH/PG,+/>, M'%WKS!T9_@;Z( M5QX;Q*_%>+)!L)GOS=Z"]LNRV?+;NP\?KC_?^%C/;?[?YSE7=7*N[<>>JU);HE>[QOHT3ZYDU M5ZX-?(LSV'7[P&?-SA=O=/=O(%[PGHK\V]3ILQQO2$[X8^H M0&1_OP-&CE,)C9_$"N?5BJ6W8+D44F)+\QV1B/@8:NLGGD@\\9`\T>S6.?_: M.4\TN[O?Z?WP0=")#\S'"-6$ZMVC>M[,1[?SGF_G-]=O?_OUR]W73S>OC/^Q M;<8&@Q*N;*,_A!8D7/_ZG[=OW[U[_WY5$YTY;RRX,'/^T%T9"SX+M=JX7J`( M;X_$M;=Z`Z:[Z49O)"V5R&-7WZO=,5[]X6?Y[<:;G&,*6,(HXPGXY\Y1W>F= M,YQWN)%_6W\?B3PJ3QZ79G7(8Q-AY*CHXU0M#0<04MZ4!MO#*($'LM4LY'T[ M5[?VPLV:!5:"$X#%86]Q@MGL)EX=9A/+T]4/?!F*C^`E7>O(CRQOZ2W4J+*P MY1R$[L%RI=M]@&VW"CS;"%+NVCTQ7E_=6.G MTVFM.IW%H5[E9<86A78MC]#*QW3)8(0OS`Z&/D;_?0X\UYX6!'0U#Q?0M=^8 M+16@H6W*4G/F*>0Y_\Z,(>/T()LFX.+_9&E@H@I-Q=B7K"N1)1O7`%4DN9KS M4=IM.^W`,(7(7"Q>[)0,\2M(DDF M$;\=5/S.3-7H+.@S^QD68!-E[C#Q22PTFX:,T[GU91HSE`:$7T>Y^H.X#6EJ MV4:ORR)VF`H(E64](*X(GYP/#_736KO@/\#PT%S@:7526ZJ4U?%E41"WVE<1 M+)W+R\R"PZ/Y/3VWM(^[N3#R;'>,>#J107C`"3`,'4AY`AU7//$;3(MUF`?% ML/'6S#6"R_+<9+XD=H$1J:>B*VX?ARWX86UQ@'[$PD?^JZ@FF]VE0?(V%NK, M=Z]3/ZX;'GBNZ+LC_R);#R<&U44Q()QN&S6QQA( MC-H,9'5%;>JRL[$__T8(R?2'GGAC_H5\.U1K"CD8U*B-F:S/R?^3!<8+5J]E M56,Y]0LHE=`S:)PC>*%V)S*(1Q(JL%9/TF M1BZ?-RG.//T%1G_DM>%(D)C*)1`9X"&'/<)`S.-6.XV+V/#)941.@4L`Z MS^%35!V6[\E`RA\:!H&#MT#&F$5WDHP/J1+TDEF(!KB*Q\_2V#/,0+4S6;02 MCF>47;$V/^RPVEQ'EKC!&T"T7SJF&ND[K%RRJ!#J?`7P!5>,8._74!'P_[@2 M8N,UHG)!HB_"ZP)BR)73NKX8W%EFTXAE`5J:O/]G+-S6&^YNOBDJ]* MH2E*CN=/9D6#M+JNBW,#41D::_J/$`94AJ0;J8Z@<&'E\PB?3=-?+#S(JGSJ M'II[I2J`/B=+K)GEGT_-!56*?;='<*'6]*99^G%;^!LOB?0:@L]VF<):;?-TK_]OWC%9C5^E0I M7EM=T3,O)^<$QT7DN"U?K_B.H(F8:+E*G[:DY?G:QXO,(-:\B6YELI!6/C?* MBOV6":(*VZ=_9W,J&>Q@Y6_P;$\53D:64^"$ZS/H+\F@1#-H@86&5%CTT(56 M+KF;`H`$L:3ZG7%$^R(J?$=)7ZT3E%S10GY1ZZ;LZR-:)YC4DS#D0JDW%6%! M^?:"XN0G023L:WC:.%A]5 M1$"IRNSZWEY'@DLE7BR;`0G7]*%(;$U^K#=AG^T>EW+6HY#W-<\S!F`\9_K) MNVV=Q7[;XSI$53M?^KUSI>!3+HG$X49I/&,6=P"_ET,5E>UE%$PD]5=%OFC:L"-1).3`1(J,)NJ1!V!'H$ MY0U37G4Z=MN7# M$XKZA,=`J^@?$!67E;:;A;/6U\H,[(9U5;M0J;S+CI8#/!Z MYE!*/5TL:WZ^X5\+("P$(U!'=/]H/G+U27:#>B[F2M-NU<\#G]\AZM]%%"`4 M/'6_8WW^S`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`@ M=<4*SYQ6V$,%.?YP56^E;CKYZ^<\=^ZBLB9IG,`1.<&*XQI%$879`HAC2S@) M?S`[]PW/'!U66$=$R3G)EP03!SA>O$O$RN:"6*`V?$<$S3H"Q(K8GHF%% MDV)1;,'U<1P1%9*QFIF2BKG:FEKU2-T,D2GC/R%%9_JX]!4;$\_R932W>$X$ M!VF50?*A.2'[(W'YP,)WG0:F*O."(^)KYNI#Y<(DBN+ZD#&F=6&E!(>%:-CL MA`:!]LO9"C8@%Z8!ZC/OL*)G3@Q&G23A)(B$82:M6Y85,!:5J\8!%R*U>#>< M.9Z;&!A+K.7K0`905S?Z!D$D?*]D/2JF:Z]/0?@-BR;.E/;JLVD@X_9'8K-2'N9SV(OG%A=BRR#XD&>.6?"?K5$?5V$.:>*+1 MN(5-RWU.TT)NM6`(#(H5*H[\2E6'G(U_4G5+$:LKE27-"HCFRX+FRJUPJG)< M?J8^YR::P!'-E",M7E'((`(+DL]$D7C9LD%$,(V/YHHT,NR@#?7?PP\ MR&S43<#_39RA"`\M@HAE#,,@F>#N94<<(>CM-2?4.4_CT#;:_[4FDUBQ4IF_YOX;#D>98U.=%`I?K\;C%I< M7.;_IJ53H5U'%-L$$>KFX^??1('T:820<"UC/`WB`)9RP>7=F'$J_L;!$[$U M06(V=P<2O$IPYO(09*Z$=A"6.HJ9@\!S6+U(K+!Y;GX4S]>-%6DNJF"LJ+J@ M*I^"7(-UA'V6A)#PAFM`V87_/5:4R]\`ZF.X;FW95F.3X\"-EVN:BFWFNIGHJTJ%_6/Y;;A'\6$HX5;&V'!@/S>C@KR>?1"%G"A0\I"$#Z3391Z MH_-ZEC9)KH;HK\URBZ"LYT16)8RET\0"OS@6OTM+W(K-U&H*RNC`'=04U**2 MG2QN>LUZO#"MP'91LD@EX`74!LJ&*PH=I!T`BAH$@*JB;QH'`J1ZHJZBJIAC M[E2ZZG0,V2%AXXJ_2W>4VR==A9Q4RF2Y67 MK)SY3-.`<:Y1@#;,3*^#-72/6?OAPG?KK],+_,O,K"==09G37[0L%0^9%PK] M0J['RNO&P`V!#S\%^GL$`X1JXGC"N*;Z<%^L3-D>5C<<*< MLE@VI1"F*JQ)[@D1RF4@R*5/5#QHV=TZUR6S?Z4]K M::9CFMS&#T@$S:`J)M)!D:VM7UMV(BKLZ;92+N)`FCA,TS_[#@,LK=""MP M8)FBRY>^1F:N+B>H[,!4JM!DKKF4W=QQR--?O/]Y62?O?IH5B_)"39[S93TC MTC4MC.*"\ZM)XZL;K>S(VM4]IMT[%=;?"UH?BQKYDE7W!3 MQ>:D**(DF[Q`LIY,!A;.V`7]M3VF(("DELML]D[+.),KH^6+B'DLM@",A,NDZPC#3"Z86A-1I65 MA$J"T&9&,@@F2!?0#BMT!GWB.2_$%.]C5;]9U(=9A97IVX5.*LZV^[SF6OWA0 M:WX'Q?9`X72'C<'%'UJ9_`>E7N!8(FO`8D'+?!?X\S;6+^,<(+4/6#YGPEX6 M"1483RBR+`A\%??M/$:C`LRN# MZ62+*S[:HDV]50'1&2_F!&%/U7L%QG`%!?LIG'U\;&$),N?JRKE:%\WLQF`^ MUY`\(/TQB&-9%.V(<:5T-#4>`P_D.[DP3NJ@T,\>$[/7M[ MB)Y2LVN8Z3'U#+7A.W(Y_FK9_!?6*AO4S`TJ5D MU@/."<=`<0A&$3RFY?NCN*,(L(`\%O*=`5JLD:I^#$\#00DG'MP/*B6!G;^$Z_O[FN M*5J:IZ-9P6%^WEHL`GJ5Q`E(.,I6CW+K44"!$`3KFZK@"D$H_."XQFF%TF$N M`@$*R`N7+38)I*",D4DRT;AJ!+(SFV`K\<(M%/I`5``W&7*>],2WXS@1A4732EJ8@?])KFY>M(OX'<:);#X*,SNV2) M>S8U9,W/`*V`8V1):5F7>9E1\GZYQ8+WS&V1&%S:G%5+0C1V!X6,X]J#ZIC# M@I%`,QLK"\F<+5=;A)_%HZFWU41_.2$P+#9E*S.\J&0(B*A)?R3&UH@:6*ZJ MU,(!U4_BO(/4FZI.E7+NN:.RT.0Y7[L8X>F4OZ+<2#O8-Q% MX!BP(_D^0G-5@&`-^?,00I@Z.ZY7VTG:OCKC<5(Z@)_@W9HR%_3D\W6+RU`U MM15%?2QWG,8^YI>D%>'*W\=9W+BPV8$.<`?S[9SD)GSEH_`? MW<>"__E.BJG_LXB">B;LD<7%U`3FJ=\]-;`HHZ!:'>+1B](W@X`W4$+IY!,(&C MQTM.,BH^'I,7G\YQ-1,BAKC:([B_G,R-A">^I4I:5I.?_6BHORKI2L!\SDH@ M>UBC-S(GN8W<2=Y"S0\..D)K,EC`_SF*Y)ED$$,XY0P=*.]D]*P$G;29L9`= M\A?9'`3#`(@;\TARU37EG2'"KR%,KE#4P]Y2\!LWS@"+08C9!8:M8-&@JM)! M.9A'[G#$_RVMB59H-LQO;>JD4N%B4`\-=V5&-!9"5]X`X+"AM,URPO^&84%" M)%C`LI$GJ=0)/!#DE-F=D5E]X*[*Y!(Q:V&VU?W=F3RNHLRKZ^`JB6AN-`1E MAK\""A'-TK,Z"T"W^,R8 M=P3[6\A&->Z`FJ#9!`YE]KA>XL>CG!9(B9V5^K0%0&^%#65N#&!TO.:<9 M^%L0>C*;7ACQ"UR5\B'PP\TBJ!>'KUGSF_W&Q"!`8]?,?2",,LZTR&9"](%M3#^D1* M"OKRG#1N+$U@+*CIDM9@%?-$KUL0BOP:>?-G,3:0!.(/`YP1NCUA76"?3T-_ M95%%]4H1>0OA)[-Y'!!JN%%NH":VP&*U@ZGC#K+O%AA%1/H$;*>(Y!JZ-KS3 M%95V8"6_>M;WX)Z3[>@WKKXPU)9^O?^MIK8Q"W>>R?;,]G/"9RI*_4)L`_MF M8-=>+5X(?1?YI%:# MKZ\]?^I98S`IA6/.2!*,THATOXMOUY]/GO[RZ5I$:6,.F"TVB'_IBE0L:X*C MYHE%ZT*LG1.LM1_$6G+33*J#[)NK'>4,68BN6+.97;(]%;,DB61B$Q"4+$0=*\!1V]U MI^ZJ:$$F3T'\3.'%AH]F>:CD=ZC4IRV`\[`,$UEQ'@UB(IXR#:#&=H[]="!' MQM.C0!%X3'0V##%T;B8]SU`U)&T["?%ZD)5X5"(/OPFQU\1,PN3,,(3'2GW: M%H\Y=6=.U@7#')KWM%8'S$61W?5E'9LL.%Y"%1H48(I/EMO&_!%@1X=]/G(L M[2O/A8`QE76OUJ?M,!:BN.4':=WW"G8>SYNO6I"O\S!?^_AL[2F0_J.7TX`"(VX6\2\4+M$]')-N',;UPUS% MT\7\'W,0E(G$Q9[-N8JHBVH#Y(J6NCC!&>TLRT/](^$2BTA@;#;,5BW+M%*1 MUO#%)_X%J*6__?O3]<CU]UG8#13 MT1Y^IU>PG\E5G@Q]3$L\>VF..:44H MU??!$I+@?AB?@I@9E\A<7>$&U!^]UA^%27Y(+8[7J:T%88@/XT_DB,IHFCAH M]X9L55_X>,!ADS5#AV6#4]<04MQ\);J663.PMK]J\J2\D=?"PO^%85HWWX#W M?"NRY\S&Q6\0>:`7\KI_][8ZZ0$KB@SNZ@S\_N'?'_@W;FQYKKT64_^0LR2K MCM:2]\[OF'MF=][O3%9;T8HIY^LOI67V9JI?R%2[$`K8JI1)]IT#.<(Z/R&_ M+_V+[`NN7[O*UR7*Z0.-:/7S(F6C3TO"(2_.(MVS^U.[/-WQF#FN2!P2IM+, M=:`&U8K,Y8JAHW6>"]1ZWD^!2']RW$?XZ^\_)='%T+(FK[Z(=7[)A(S/`5_A](%]C]]X M@?WME[_^Q3#^[O+-??76BD;PWW=9`NRU[]R/.!-YX+*>J`V!YSHSAN$Z/[]X ML(9FH_4"4]'X/WQA@Y]?W,`%\$_SQ2\P.3XWA3B8_P7`Z)79J`/D\(N!Q1G[ M]-4@JC`77P,@I!5"G#^G4,HK(KR-6=/:@(B-1);4@S2 MMPO)S^/D#"5R@L5OX]Q'G$VOV6R\MJ`F/U#V!6<8%^"43__1?"W-C6$X%6NS M.(.Q7!7XH8JUH>4QF4#K@1";/F+1>"S6(PO!1BZG+"L45AU5](-/-8;U**UC MX$+)CK2MPN^JX8B1^'P3/)3>T!6'L_("3%$41>NR@K=C/@UI78(_0C8"9HK; MBT;-E_#L0I"&['"Z'[)_PRL_E?(P9U M#MU`5N^WAD.Q\U*">OE_[7G4@%A5J=*Y8AK@'XUPD%(6!9.JR#`U0?[FJE1P('ZF]9>%\-N)1LU5(M2U91BHS M[Q<54%.6(_E1OKJD5I>6P[<8J[@'@5:W,]<^>,`W&\5-:0YRH40F4[6-C8^2 MV\U.(W?G0JTWSY&A,(9HE20*Y"PB=7&ZN9*?&F`F0>3*?A=2NLZ>=",M&U\8 MHO`';F@G8]&>),JZ7O$3A$(!1M9"`VN'B,9M_&&]Y.I MXB.X'U)WGIDYSC,#)-`#F!NW> MK*ZX&@`F+FH(NECG1'!!Y7+(&=&S6DUXBVH]:L4JP/H+PREA$$;*[P9<'ZI. MO7H4!JOI]:1J8H#<\J'H]%MAW:R*D#DIM*2TIORAA9[;BM&R!$GJ_1PZ2E,:]"D$9;J4&NR\+\6DRG&D7.6&``!:*XG#JJCHA2R*-BEH":U MV;[EH;4M&D%,HPSHXA>\<$0(76]&<<[D,G1<7+A^37X"=X&0C^2+'UU.I=D[ MQ0TFJRX*$8CC05(IJ.M`<6EDA="Z]>!&Z:L!^6,M M#7>J(Z./%H?.NYKF`^W5XUFUM_DQ:EI`/M\Y;R`\2K,\II;C`$#ZZ6')&%VP M4^2.3`,95I7+A*(GB#"]"`8#<:JJ%+V2\_RIMM'9;U.7B.R\@-4!9)JE\C3! MB\`A4C<>@A@S[^0XJA`N[E84"VOKS`JA3^\/G7HO]3+!:#]TZV;V!;YID?:) M%3X7^FAJFFKI;9%+M[K8LDSDF!5,N,2-76"NN3H61^_!',8^@.(NGLLDE,XY M2RB?T6MQWI;;3"H1_%]2E>Q1S16:"?)%O(]BX$YR')8E?M-!(6TH`A^-[)2YYS?..DQ6-FE0/W-R2-3V? M,V2N'!MP^W)&AFE.N(M9FR;5!CB?&OA9SII/XR&T'`:WHW$'!7I%RL)\151^ M7T11(JMIB^FLZY%:RFEF&%.J0]Z%-V[$]7++NQM\"/PA/B+&N%67V.S@8L2% MRE;WG%D9[.&%)TVSL%GGS-12JO9F=R5MP"*9"/BP61ASF0*:>0OJ`0*165@Z MC=9DS5WEPY:6;DA]D_&6,O,>^C]A7B_0+WIO,LL)"!XQ],Z+P&HC@VL@^!P= MXLK0!=*?BM`!RP^ZR%$*S!O4H)>P+;B!4L*FR)T@ECWK`9?&E*72;!:A+/-( M(VS2MR;M[YZ8\]SB'5KO/J+H/F>3R>C^LC)TW^KHO=WV0?9BBPJMT+MG`-KR MJDW_^59<4@N=\2(!-6&UI"32LHC9XOV4)A;YC/+KFI>OC=O/=S#:'=?5YIJ+ M%L5G!A#5-A-9)[J0\ML>JGUD[U3SUPRV>8>,YFKPP0"^R-W`WU(P<\ATQ/KT M<)'*V$\_0+;)9[:"7T)Y):3\D]G`)T"DTNTN7USG`HO2T9_9YYH(0)5!<,+U M#E)7\0JR]\L6!,AB,P>1LHH+SP!89R(4QWRNGF/U3">+U$,A-_6R&&`0X/^L MN???*5<1JM]H!<]FA2&4*AO4@+Q2S?>_)FM]EO/EF>37B-T-WDG;0I1QQ5YE MN.(!I*&O$>)%F5S.5Q@25;H%,4B'U`(J*(Q:\F5A>PF1GX#B"XP& M,;'9N]99FFK9B%XW6`V7FS#C7-BG%3<1]E;1`50)>.#93">[KM24I]<9@<<* M0=6+/K/P'GC>0E7GZIR)^PV7E6W92,-+E$$5N?&$R=OB;`G^=^%)YMN".H5= ML#=&'RKT/[J.;DO&G_0Q,HW?OQ#&RYP+"ZS0:?,A&6*!`@.,$Z%%"-J-PD!: M_R`5='8=R:L<7-G@],>79(UR-:.OB(I_SAJ;RDC*Q*Q4.`2!C/&!N67V#37- ME#O`OJ1\<#%X<@D6HJN-;'&"$E&?02@"9X$7ZM5S/:O2`@S:8R/LEYY_4(T> M^`73J%2U!$KZJT[27W/5#5J6;74QOX.M5<XMI99NNE"%^ M=V)[)NQFQGP7\Q/X;;Q5BC11R'E02*>:%-(KCT*2?A#R.U[XKHE.JO9I"SJ9 MJ?V5.W;H6N=&$3CN\="%L\@!(5%:/`@&5?JT!0QNE#@J8["%VKUUI0@ZXNH< M\1?9TA+MG7#(B>\N<_EL>;R[T9++Z9.`D0@.)*1@WTH5;D=RPY9R@[PI?.,> MC(#C.7>(S!4K]I6DEG35SP,5YMO/=S61$)?FZCZQ4/=3#!,+VK5#H)R,'X02 MZOI=)J:%9D3U#GF;Q0%6&M!SDO0`4!B,0+$34,#)\ZU^7L90X34+;3GK6X_6 M-=`N,<+F+;9O4SLSOS'_9878\OA6NAC?^;$;3V?&2_-'[.5Z;5AA2LW@6@P[.<[E_0& M;F75W'0"N46QK#$7RY[%PHG"L%"-%H"O>A=;CDAYPJ8NFKZH^5Z2"7AK,!;M M95.;9RYU*#A:YI`YJHBG;'T%&8SX"%$*9HBPQ43"T(1"OS[)5JHV:R M_V0]A[2&\Q^)Y;FQK"*#-;2%BT@*!<_L>RX-6=7=5KFRRV:E[-(+QI^JW;7_A@F=:H/^>!5LN6+9HC*D7Z=+)):MX+*SV@>J1C&D$V-D^3!V* M&:!QUF/(,,@WJX<@+OGK-/$C5QAD*5A4]:.LA`A69>OSZZ^O$F?E[89U5&3T M%L."*;CJ.,JJASZ'2EB"<%RF3<)%@5,]F$-6D5SI,+;1/)X%I)"P8@SPG\^U MR$>^1"*[<>&R,>:_K966$A%[\'665Z0'*.?C:K)X(%%>8FQ]=\?)&))D`A&" M'`@'3;Z6??3<%D)VY4Q+A*6K7%=>65D$R4LN-ZP?+_(OF\W*R"C[#ZE[J\FG M#M^DW*\DB:ST%(%S?B!?UMOI7DU`41*R'X>B_PL*@H7 MJ[-@>!8?XPJIM0\9TBD=<3[6E*^_XE>"5"AF8NH6J)HUF53HZ&TK,#(MU'.S MP>^*?>R9$V6]LT`[5&Q=Z(!SLU!*92`M"14S(*QN/>NV5[:>'5J3?-XM43?> MRI0P_E.44T;!$R9MS,6#TCF5K_'7M*W7-GX1(?6G*FI3Q9%X_"IS/24)2\T@ MK?B15DZ`?B)AHNYPZ,[G^TQFPLHLTPC?[0>^/SE4?>7YU[`_,>@YF:KMJD;P0C"\K.^'@V;(R+4L&N?$E M8+W1`4,&JMBIF+8(ATLBF8.9=:3/C6F(LA'0PB7Q9Q4D[,>OE1$QXAB+O*',I%W31FI0-C) M2T/W;`B[(HIL\M<_GVIDGG5E/+E7>E'6<[;5B(AQV<]/YO5'8HMJHJ7MC=YX MBJO?6M>I--J\E@:=8:3ZR&4#J)CB(IU#>&PH4R>C!2'O4&%K&+*A%3,MFTB$ MV0KVIX6VBR)*8J[9<'+6ZQ+72K0S0VY@6'T#I>[>*0YZSI0X9A8JZM&2/=+*?EW(&H_0 M7=%ZLD*'$Z*>]JSI^CG?.-JZ"ARJHCG8_5>9+2B+1*E:+K(\KBA5`23YCJM1 MP90Q`X_5^*Q^"+C'H=[=?_Y8S'&"9C>X M@@O5=G$<.,Q+"T2*:D]SK41F=";QFK1PBRR=*)^^,R/2R)H>JT$CV^$@'#`79*RT7R)VS4QW590+ M>71%@1Y0,_DJ@+.+N4=8ODQD%.AC;9Q/L$TUB4K0J`JK?@-V_8M[&_HK10*$ MF.TOMT$DRN6%8YW^Q/:C@_AY*H-Q@(BPPKW$)]`SU&!;.&C()OR41,WKK,19 MVC)5XEZ!/:M3J\7#S\`OMZZY6=G^+T0 M>(HV:^W*\\NV*$8#M7P>9*<+/OFA_\IC@_BU&._BP[OWZ8X;O]_>//SCE='K MUKO=O[TVWMQ]N7GWY>+MW8K1132)&%^AS3POFEAPG?S\HB'^GH"Z M)_]^`GV*GI"4UZ[W>6DMJKKPB0377'VY_Y?]@8U\`/JP<5?R] MR:(EG.2:H6I_,@:S`,M6H>^'_#DNK/#'RS9*#B!^EAM!;B'G$IUNT1ZJ1]5P MG#DZP1-0$%C1#!1$%F]TJ_$WT%:`//@_MG:^ZYMI';V5[VU39I'R:R4[X8]X MOV1_OX.+!J<2&C^)%<[?.DL5DW))Q*R;A<>[\.3,?9.(^!AJZR>F2$SQH$S1 M;-5[A;#8CBF:K=WO]'X8(4C.!V9D!&N"=0FPGG>(TOV\Y_OYS?7;WW[]^$UX\*;[OI'X5"++77VS=L>']8>?9;\;;W*. M1Z`!,6,1^.?.06[6&V<-Z!UNY=_6WT@BD",@$+,Z!+*)>')4!'*JUH<]BBTW M4%.)^8XQ=9FW*''Z:)7#`UEQ%K+`G:MA>V%JC1)O_8,"X[#7.0&M*D`K48\_ MR6N1E'YY&/\*('0`HKVK(_557L\O3=S=B!D>D7+1,>OS:1KGA+.CN*\)MW.X M;=2[%=INTHI)*UX6\J:"'2%5Z#1U'U**MV1J==.8,BLL*/E"\"!X'!8>I2NT M*WN=Q4>(XUV1R6]?C6^N_MY^HJ3O/W^FF.@3$34H_*\"3OO-W(\4$TTQT2<> M#A[E2Z-!@ M`%H+YOH"C*WP&_8R<[-NE+*-LJQR7M`60"\BCJ.*NOV^GV#[`RS.;QD#&`M" M\&4I=/TIF-U8:?;(6N#-NGNN%$\A_Q3=2F&`!P[Y[QQI2."J(?\+0@8WG&%^#CB03"DH^UV4 ML%"]@$ABZ<32*Q/9G;'TYI&R=$I>((B?/L0ID>'@]S;%-*A$!A8QD"O17N!D MO7"KX\&K?(3#D01JUUN["].NDH_TA_6ANL6)%5Y991]=L][988S]-O2Q?]]* ML]9I5ZC&&G$CXD;$C(+KI/`UN>Y3(?V4^"RT/!7++&;N^ M&\701/V10I/(V%$]CMAJ%ECL")>$RT/CLE5@9CMNXUHE+F"RG*F8GB"VO.J( M@J28[E,QU9AFL][L<.`Y0=+W2$L].BUU@Y,\+I6U6>MUKXA/$9\B/D5\JM)\ MJMF]K`Z?JK)I37P\]42+ZPA2%!;$M]>,&.1O(_%#9@=#GS_G&"R*W3$&M',: MN["M:+0\M#YDGB6S'^`A2+A@CDK1F,!/(S3%8:J$R&QHU"^S"8U=SX/Q,-.! MZ]R&_&(FX<'XG7&@>)YA.?]-HKAH]KGIV0'_$83]#Y(X"9EACRQ_R#>+'T"V M2O[O`^;"OT=Z#@A_%<.41EA4^@),(,!A^:ZJ_:GM>(-DAHK*0#%4!HHU#L+8 M_5.,++)68!IFO2UZ28AT!=598IUDD9\<]Q'^^OM/270QM*S)J_N1%;(WL*"W MVGKN<*K7OG/K0QP*'_FS9_G19\[D[>DO?_V+8?P]'<`>,2?QV-T`!@C9B(_! M?\\?#,;L0Q!%#T!Z#YP5O_%@%USGYQ;)IZF(`I9R`4A_Q:$$5(%?#"R.G.FK69I8DX+*)N"U\EHTT%JVG8P3@:2` M(Q&3H;*]Y3^!S35>>GQ[?]QAOLN1Y+-TS,GWY])9BBTN@**TF:R-&7+4+8,9+]88^&P0A1`?8GA5%[L"UTU0R?88A!;'TW7IKE:18'LB0= MR/R[8=GX8\C4Z-;:)09^$4Q.!":=9N\@(#F&A)[*7(D5M\?M[^:\'@>)'T?: M_0CQ>F$P7MDNUR2CW,EIP25Z9^9V^RB8^DNS9G;+2R!>[>SJK(Z3>`2/[#7-9D$TU1G9*$Y)@#J43:&Y-\GH$XL-.PE#QH=3F0`+Q2!2 M"T\DR&35G+6CT49KK49Y;>X(G81.LI6<^%5?<5O)'OLO^@X%+I&-A`H;["%L M(+]950D=./GB!N9E[;)7H;;(Q*R(61&S(F95;)1OMLNKG;C2B8E]/L)"$?2W;V#BI_G"/^O5[5E4]">K'_39FL):KY^LT'DG6V/?0^&CSPFG9?X+ M*"'T+\M+NHR@9BX)(BPH$=8^F0-`2GK!QH9O+3GF%;BX[5.B&"AF<09;W M7@K=M(XTRWO50C>J$,U?_T*E8DX\2YPX+''8R@2;'2=7I?(P!.O3A#65A#FM MRY["*E1K9S?Z=C$`.Z0+)\VBV`BMN+R02G)"5CPP?K4$_<)X^,KZJAIU\ZP! MO<.M_-M>W;Q$(&=((,?MR%V!0(Y+5#J0762/,M"-^^@ZS'>,J5#0AH50%:Z5D9=,>2.6+IR?XK\*S8]=QX6AUY MM/(6B-($\OK[_#OI7, M,3QW0,4?2(LJNMEE6#VA@]!1,714I_R!^*BRB/"O9\+E=Q[QOBBT/AV2A8^N MS8H[]5Y[?`C1LW?P)6V/_!E+!;T-HC@J"*R_/)K`^KVTSE[2EW=IS^?=]=^M M&4\CUQYAYVQ+'"RTA8[D]*(CZ<_;;967MM!M4=H"!=6>0?0A]>>E_KSINRCI MXL3C,.E^H/NA,M'I)]&\E!(P".(G#G%*QC@M(8"B'U0R!HL82+QH)W'8(_." M"5C:JN/KJWPLQ)$$FU.G2^IT>81%WYJU3KM+W(BX$7$CXD8'YT9F[:K5J0XW MHJ8VQV@*W*-X_ROS66AY*-U;SMCUW2B&VGB/%,1$9ICJL==6L[R>>X1+PN7& MN&R55WCZ.`*WCN`V)YN>BK(*8LNKCI!**C/U="#]F?HY%)CV>MTKXE/$IXA/ M$9^J-)]J=B^KPZ>J;/03']?H$K-6L#Q^>B9?9,=I'");Q(W!^%;"+'O!\*8=CT,F6@_D69^]%X8#K/=L>5%/[^X_?1^/A&D^<_V M?SZ:S?_D1PI#RQ_B6!\9O/,_UV"Q^S_F,]L2W[PP$M\5P]S&;/SBE\[??UIK MDENMZVI7ZWKC!D/FW_+!Y!>+?G_#;/P!#+U@!UH;[8`"T!?VR/P$.MW(138; M^B(O.J6_7+4:\'\9F-5_9XS#E?'W.-E$S=Q$"]IX M[&JBS4Y#SG3!G%:<<'/9A%O_7'^R_[FWF6]Q`N8'SK^,XN(U=%=:@CJ)&S9@ M8<@<>2+9$EK/@>-69'AMO=]FYW(&&3/ST?9;?B.9&7"VCXD7NP[S^+M#8,;: M!!2)?.6_C.X&U[8=)'X,Z5CI`MM+27S+%0JB;6\;%TNMI0U+9A4'GO7CY;KP`' MX6,")E^LS7\Y,T(AA%LY^*Z[I$(6K6/$]5@4(>^G@Y!>MH-9ZE587L>^:[0?@IB`M`J5;3:%YV=+:ZZERV M7X.Y=`W-?[8X%/G^AK'+:>4^@01,UX+C_XCRNS-6UVZUSW,+ERD-ZS*_ MCMDYSXU<6XU8N(5=LRI8["]_;W\=-OS`PG%FLFU?K4ZQOWSN?IS9E%(FM_=- MZ#16A\KI;H*Y[B7XR^?.O\V/W9O3W(X%UNK*;L]$94_G_8*CIE=G(_9KC=W82@I]X"N50W.XOF]DP5` MT]WK/.?GU."-Q2VN?>4*JYES-32[EWN?:&_91%N;8:C9:7W(_=>/2;Y_IL MR;:VPFKD3Z'6OMI[H2H&HGP*,H^!7)%RO$69MZ?\.P:B?@OC? M+"Z(:NFVEQ'+JB8+01.-V7"STI:P]YWJK+)3STI:4\3,?[<_-MLW>]BBPKE78]^*J_\OP=HOGYLS2NPAM^YMX$.DD(AY M`[]H%CJD+;2W@JX)=U:!2\U7>:Y MR6VRC%5BY7:TC$ZOM&5<-G:]C#>+(P-;ZRPC'PCKMB0L^9EYKKN:YO*@N`.O93V`+3,ME7`V"G"] MM>C&8>XK$7SWA0U13O7C3]8X$Q$OVPL:M-S>W]X;G_]Q_>7C]=MW7Q]NWUY_ MN#=N/[W]^T^+QIQ]XUN!?_%,/JS\V/)JZ$=US9U=TZEXOZV,#_7C1:%RTS/WAN MF.PMU_S?'/CW]YZ5)1Q<]A:,/N``8V+@W)/9@%+I>>]&MN5!S/K]:)BY,Q6_^\(F00A)!Q!-FV2$WBOV8KSXY=\LRIUIX3"S+WOO>BQ\ M"\D"09C!IU?@),!W?("<)X-3%^./83<;'$!_;V[$^;//EO^>?Z,MJYC$Q>GG MSWUFB$7O4()'[BT+]+-?_FD6O4,;HKBK4W0WR#&(NP&PB#=3#.ZR[#@(Y_LU M]1:Q`\@\W'N_IM6[`IE:>NCE5;NTGD!\[)/K"=2YJIMKI=-VKO[V8C>IO\]- MJ[5F;9H-F]^=<$W[5K=N-DMHZ]/5BU:UCK2F_:IM?53;G;_^I8*-<5KKU>N@ MFOC[9Y+5;8Q##';KJH#=>JN$OFEF=_<[O1^F6H%>.(1J0O4IMK^AJ_Z@I3(W MNO^/H%2FM#<:U]4I[[0!!ZR(JTD)'N7!'<3ZG3P_3? M*!L6AQ4)"&:SFUA>U>\#61$.?+.*CXH'QQ(P1\QS#BN#W M\]Y``W;^U0+8KB`"+0'ANB$18CA%^KU6I[2@B!Y4BSO"H(BU=97+SH**\`L9 MZ.5Q-,RY\YDQ959H!"$_^RBJCGK8JE]5VQI8FE[<6W?E9N^HC!#M2G44Z)`1 MHCJ,>?<\N'(<]WH0,\YN%=_M)S&?;CSB\XB?`ORN/":\:WY[>.ZZ>T9:7;99 MGNUVUQR2^"$)JJ6PS91%YO@F!'26S#E/3WP]$F_=(AZ^94C2<4G,15%(>P5V MO779@3F3U%S%6^(,I.9R&_L>D5QV\'YDYWOC;Z(K?.HCQF7O(` ML=[S!11\OIB7*/>:#DB0.SCD]K]^RO\D]8/X!?$+.G,ZHFTD7U!%'\S07 M;.%VX9;-IH[RSI&B/(OG()@37]T'XF['$\L-(;*%$$>(VP?BWD6Q.X86"@<& M'*D=JZ@=E1,?%BDQV]>=7TO3V0^M%)2%3_^H0#WDH^/9E4-S\0VP9>;125P3 MT%*/X$WP/E%X0[Q^02XIX9OP?1+XAEP41@`G@)\RP`G>!.\3A?=[RPVST_V7 MY26,[#7G;:_98ZAHM7KK M6$K"_7"0$^_5+]?:H"K7'KRZK%WU#M.OC`B'".=X":=SF/9K1#1$-,=+-"^; MITDU.]RB'P^R042%9T2%@LGWFF;S]4E2(]UA1#TE:DR]6F%&QA&'QIR>$6S] M)CN;6,8VCD;9GZWL)F\A,]PH2IAC]*?&U_I]W1@&CRST(4+%L(;,M\LTHIV< M,Z(TZ_<&Z:)[=!'LDI?6KEJ';DA$@#LCP)77^)#`1F";M7:TN^<,MZ,PBA!\ M#VHF.`(8$]?^P"21`Y1H@0/`@>Y-4CH!!0""C[DDD.<^F0HY,ZJW+#DSZ M3+W01#5'2#7D^*;[X3R0#E+^57FQ[.1L/P-G>VMO)IZ'(`;;3&;C>7+CD6$9 M8RN&;Z9@XN'$;DR9I=4T#4+#8T4U?,_.U$UE>2O%>YOM6KO;)EP2+JN%2[.\ MJ&7")&%R(SM&;X^8W-YD008*PGEE+0_$@PF;&\NK5X>15RD>A.)!*E\DDDRZ M%3;I5K+8[BZY<^.R9K8.[>TCQ>6T%/-->S4&DTJ M@$`8>08CK?)N1\+'">#CY6GVL3FLDDQX(V\]`65[X:937IUC\IR3YWPOJMW^ M:MJ=G"FN-"O-V=0%-9NU5I5RE0AQIXZX%GF="6TGI4T0[`AV!#N"W>%AQZ6Y M=K-"TAQY.\G;>0;%!8_'G$C)/U5BUYU:LW&:WA5"Y?&BLKPV,81(0F357="4 MITXP/V&C`;%@PN:FHNIA!`/RM9^(K[U:)>W&0&3Y67&[RIC-JFZH/:4, MF/.I2MJZJEVV*]0#E%!.*-\]RGOE1002P@GAAT?X2[-[:(A3^P$BFV,C&XK( MH`OB/)".@GZW0H(^18$<7Q1(>V_&FOND'X.]ADS>%31YUULEL-;#NI[;-OQ MY1[!4.IYP,@%+NB5QP;Q:[GTJZL6V/$EK-[>??AP_?F>GY\=>)XUB5@>"?CD M"\-F'KB&;-/$PLOR+>1$Z?3]![BP@M__UEZ1`[6C%FHY%Z@>I'Q6@ MES/G%W3F=.9TYG3F=.8GHGX\L#'T2B^JYT[*QWD!CI0/4CY(^:@RO52+7^SG M@GH;1#'=34<>L=)6&X( M'7H)<82X?2#N712[8RL^.(LCC6,5C:-RXL,B_64[\6%M)6<_M/+1"NV1!I3T M4\NL97\T&V9!O6'BWDU6.OA+XPW5N06M,(@?!.^3P+?OUJN3_@F?)\J MOC\$4534RX@`3@`_&8`3O`G>)PKO]Y8;9J?[+\M+&)ENSMMTL\-:F*O:<_1G MRVGW8.ZM@N"[/Q)HZI#U>W@U3U!4X?7T*[RNA.E]%W:M1@MD@B'!D&!(,"08 M$@P)A@1#@B'!D,KS/Z/M[\"L4F9Y_N;>E.NW21@R/M0D"&,W\(V77]@P\9+( M>!BQT)JP)';MR+CU[?H&Q2(K;:H]5!1;<0FZ$ZDNMX,-6E`&[B@KO)F=6J?9 M(<(APB'"6;/$>ZW5HBKO1#A$.%2`F*B'J(>HAZB'J*?:U--NUWK=@MR*(XYQ M.3V3UMKVPXWL7!N'E1S0\N7ZMIJ1=?FN=$O5?`AP!;@YP5R6VHB#`$>`.H&L1[`AV,[![V>LUSAEO.]S* M"@G$YX/?9JUK7E5HXRFZA*)+%H+U0^`/+V(6CHNU[!LV"2(WC@S+=[*3#5#W M+EOG/AXS+"7_58G_=BF>@S!9,4R2VXJP2=@D;!(V"9N$S=/`YJ'D3/*DGX@G MO;4W+?\^Z<=!;'G5L4I5W8Q_)*EWQ<%;6S+@*EFP-XCYVN+H"C>JY#-<$%^V MW1GVMCC#`WBV+VO='L52$',BYD3,J6K,J676FE<5\N<1/G$RVSUKDJ3TXE-D%L@MC$\;.)E\WV_FH\BOW:&Y\X M6:L<\1WB.\?.=\KT&A#?J1*^B>]4\US.DN^TS&:MU3U,6>N*Y'6(CQ8_PDU. M:LTU:C1`0N_A-_;NP\?KC_?\S.V`\^S)A'+ MSP,??<&GXT$BD>WZPY]?-,3?TM.`?Z)KL'+SQST_02YLX#<_M=?DI:UHQ5KBABI'Z1^5(!>SIQ? MT)G3F=.9TYG3F9^(^O'`QI,@M,(I*1_G#CA2/DCY(.6CRO12+7ZQGPOJ>@R5 MV/]D#EU01Q[*VURPA=LE1#:;.LH[1XKRKW[(^,L)YL17]X2XV_'$R'5FZ8S<9]%F98:9FU M[(]FPVP2VSYR>;BJY>(/?U.\#2*22@C>IPKO7RW7CPC?A.\3Q?>'((H8`9P` M?LH`)W@3O$\4WN\M5U,\_V5Y"2.3S7F;;'98%G-5.X[^;#D=IY94%BRBL4T[ M3HV",!:-I5W_D44QV-VC5_-4147*C[IJ[TI7RDK`QIMD;H?+ZP18B@N$8$@P M)!@2#`F&!$."(<&08$@PW!B&5+N_'-M*F;7[FWO3L-\&(>2QQ,QP6)^/R.PD M=&.WR`UQU-;90P6L%9>E.Y%JM6-3_.FV>$.;5#8F(B0B+!JK9/I"B/J.4WJ`8VIU3R,\%>10ME' M8`5;V^2XD6ELXW"4_1G+;O(F,L.-HH0Y1G]J?*W?UXUA\,A"'T)4#&O(?+M, M*]K)>2-*,W]OD#*Z1Q_!+IEIHV8V#MTEG1!W1H@KR*4DL!'82C)W=+OG#+>C M,(L0?`]J*#@"&!/7W+M0V&A5B'%2-$HYUHS3B$99K&#'(R:4[(>065%25'>5 MK*T;&,'V7U!I/VROUBA1%2:(G`)$"!X$#W+L$5`(*`24?##[-8P@ MQJN.A:+J-K%32MO:H$K,D9KANK5.EWRS!/*3!GF/`$X`/V&`OSQTP$.]==F! M.9^I%YJ(Y@B)AAS?=#V#!A89]FJ- M`QF6"2)'`I%6>9D:A(\3P`=Y3@DH!!0"RDZ%DLO#1,*1MYN\W4=8AN[D#&BE M&5?.IY9GL]9NEJ?9$>((<3.(:Y87*$QH([217XI@1[`CV)TE[$":ZY17#Y"< ME.2DW(M*?&3U`(_'FD@).U5BU[U:JU%>2`FADE"YD2.7JM@3)*L%R9?F'MDD M99<3SD_8;$`\F+"YH;!*7=4K;C.HN+>]6H7HQD'(C'AD^5E)NLH8SJINJCVE MS)7SJ27:Z-6N6M0Q@%!^RBAO-JAE`"'\E!'^TCPXQ*EI`)'-L9$-Q630!7$> M2#<;5[5&E01]B@,YOCB0]MZ,-?=)/P9[#9F\*VCRKK=*8*V'BWJR$",@A@%,8IG8YC*DWZ)21"3("9Q`DSB MI=GK[(U+F!121ER'N`YQ'8KQ(V9!S(*8QV'5_N$0RE MG@>,7.""7GEL$+^62[^Z:H,=7\+J[=V'#]>?[_GYV8'G69.(Y9&`3[XP;.:! M:\AV_>'/+QKB;^E/P+_E1O&Q7QC]('18"%^+B9$?XA"9Y(>Y)G/8L9D?LS!C M(^+O`ZWY`(7B*K5^.G,Z(X4EX7\W%M9 M?#;Q-7?QB(47#R/+OY@7H=/W$^3.`G+[7W])"M2.5JSI6*1^D/I1`7HY,O_Q/YA#,B:7N`W&WXXGEAM!:EQ!' MB-L'XMY%L3NVXH.S.-(X5M$X*B<^+-)?MA,?UE9R]D,K-\QFXSX+,ZRTS%KV M1[-A%C24)+9]5/)P5:NT'OZF>&-%;D$7#,(WX?LD\/VKY?J$;\+WJ>+[0Q!% M16V,".`$\),!.,&;X'VB\'YON9KF^2_+2QC9;,[;9K/#(IBK&G+T9\OI\V#N MK73@NS\2Z.:0-7IX-4]05-KU]$N[KH3I?5=TK4;W8X(AP9!@2#`D&!(,"88$ M0X(AP9#J\C^C[>_`K%)F7?[FWI3KMTD8,C[4)`AC-_"-EU_8,/&2R'@8L=": ML"1V[WZ!E4B*VVJ/53X6G'MN1,I*[>##5I0_^TH2[N9G5JGN<>VYD0X M1#BG03B]6N.*"(<(APB'*@\3]1#U$/40]1#U5)MZ6JU:MUF06W'$,2ZG9]): MVWZXD9UKX["2`UJ^7-_V$HX`NA;!CF`W`[N7O5YY;4./`&\[ MW,H*"<3G@]]VK7=97J\HBBZAZ)(=@O5#X`\O8A:.B[7L&S8)(C>.#,MWLI,- M4/;IR)GG2 M3\23WMJ;EG^?].,@MKSJ6*6J;L8_DM2[XN"M+1EPE2S8&\1\;7%TA1M5\ADN MB"_;[@Q[6YSA`4(I+FN7K;/V^1!S(N9$S*F2S*G9K#4O36).Q)R(.1%SJAAS MHA`MXE#$H8A#59=#52":K]ZZ[,"LSS2BC]A=-8Z.V-T9L+O65_KYFK6FUP@,9P@Z7O/54,\JE3[RIW+^K?1BN=2 MY0S_9O>RUNF6EY=*?(+X!/&)$^`3S5JG5YZ<2FR"V`2QB>-G$R_-WOZ"',5^ M[8U/G*Q5CO@.\9UCYSME>@V([U0)W\1WJGDN9\EWFKVK6F./(L]6IOIR#//B MH\6/<"?C.^XC?/[[3TET,;2LR:NO?LCXDOYD#C2*AU[#=_ZM_\BB>,S\.'J` M-S]P.+WQ`OO;+W_]BV'\73UZ;X^8DWCL;O#`QI,@M,+I[7ABN2$\*=IR+QS) M<)V?7SQ80[-W">E%/B#V"QO\_.*FV3!;_S1?_`+3Y;-52X7COP!LO#(;=5@G M?C&PQJXW?36+HC4QMQ;^E0^@4>^X_NYYE;9CQA.#K8E+`Z#,CEEO- MEVVXN-O\GZS8^&B%]B@[]I99,V`G^1@A,ZS(&`2>%SQ%4$_"B$=!$EF^$_VX MJ#/H-CB3M`C'K9Z'T[U`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`@V*E?3Z%;6-#(2WQ7??$Y"]N(7L]YH M_/VG;=Z_P0I^=^.1Z]_Y[-_,"HM6AB% M03(.L;G1\GJ]C2#Z[.F)//>[P>?0?;1BYDW_P3SG;<`YD.\"Y_E]Y-JC=W[L MQM-_6-&[/Q+^(>-'V8I:^HIN/[U?MB;QBNF+7UIR3=M-I&A%_"IW[8T7U-[9 M@C:91[Y0W=L@BC^R>!0X>G6U=*H=?:H7K?F9-K5Y?KV_>?%+M]EI`.M^]@4K MS`&2P#'U^\:-;"^(.%"S:77+F5;!._,SG:4.H(F,0J['01A#%B\,_L;B)Y7- M^'+IC/^3'RPC-7D/W(50L.^\UF%I-QK$2D+MJ/;Z59A M.YJ-QFZW8R4LM!M7C2I0!U_=KL'P$#*+<['I_<[LC)U--O-:FS"/VKK&`GB]^Y)+@9PV\>=AO,'4N`&PK$O0/OPHXEP=78VJ&/ M?@OA;WOQ]Y`+W[FTMZ9YX-`'7X)LMQGS:QV:[DL0\%8E@N;E@=>^%O\?$=="$K"'+")K_T3)K-R]V#<; M+!#6]KP5.Q?9UF,+U=B$G4MK*YJ?*K'X]<6U!:IVIQ++V;G4M:DK;B^[\8QW MO=D\I!G.-%NMY@*A9Y55[&0#*F**X]O06A4.)6U%JQKFN&[G\M`;<0B+7+MQ MM<3[5OZZ#VF4.S`?:!W6+M=KF+U#H[XREKE>XW)5F:^LO3B@;(E MT<.(A=:$)1RFZBY;S8IG=CK-Y]GX\@GO;,'M%>2YNY@O]6T2AL"BN581K[O> MR^>M=JLN%T.=5UO5"L+9BI._O)1$MO3M:T]RN20U1R?=RT[W:IWI;&>Z;J\@ M\&Q-#KW&U0)RV)>%OKV"5+,E$;3-RP5FC;TM@P\#_PNQ@Z,.0M_X[*_1=?QA]8O'B_DN%ZWFKN/>56/F8MLF M5RW;AEL_?P-^#B(7B##Z9\*_Y#JY^ZB-FB8;JE]E:UHID7%EHY?\I^F+7RY7 M0M*6R]C[;G56VJT-#&39QK5/<=^Z*^[;FM:D;-=:I[AKEZOL6C'U759H/][R M2;M^$B11\>O`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`=41Z6YG4=EP7Z<#T?[65,6U;O7!1VLW>5K^5Y6R7 MZN"!2T1=;65"VT(+[!VX0MK5)O)@L?)W=>`Z3U=0\L=RQOU%"@Q;;,SM7N6>.ZB3/+FRN4JC0V*U&K M:WE#A3(TA97S],M<>VMY]X1]JUM.H.M5` M10D^R)66WZU"T;+6\D8**XN2B\*;]KR@4GR&&U6.K<1V;!+>M=NCW&N&8^OY M)@@WQ0NN0,[BGG=I:0KMZFK7^6W>TB3:'>@^%=C5C?)+6\M;-I0;`]GC+SAH MAFUK>;N&O44_]GJK9HN4M1X))BG_*W8N1=WU8C'J\-6#6PM[^A0 MJN/JL`7"6LN[.)0?Y3B;.;[_32@EAFWC^,;.88LPM)9W=2@WLK'=/#0S+,&A MNW%,XZ'OR!)2>( M':A`_#A7=2+LJ"Y+:WE/AT)_3[/5S5M,=E\RIK6\Q\+J*GN[9\XPO74FG/Y` MG2E<.LRY`WV3'S;7,C'R\8'/[8T7V-^R)72*K3&__#\O?LW9M!'%4X_]_&+` M?W,1<;WUE=FH-R;Q:_QB8(U=;_KJP1US7?P3>S*^!&/+?_W^[M/#Q?WM_[U[ M99CP6P._>'_]\?;#OU\9L[]^\?^&\>N__@5>.%&O^WC]Y=?;3Z^,ANN+_\(H M#^_^OX>+VT\W[SX]O#):G7J+?XD/PZ,P'_7TFN\W8%T_OVCB6+\SH\_O[&^& M$SSY!J<6P_4G21P92<0<(PZ,L=A;8\"WW'C$G'FNM,,O(V98N/V&%1L?K=`> M_3]K/'G]/V:W\;IEU@S86L/R'>.&V8B!N7]N\@'X:)X7/$7&2Q?>'R01?R3Z M\14L\B=8I5KQ3Y,5-T[L4?JNV6=C(%_U/`#APO+0; M^?VU\>;NR\V[+Q=O[SY\N/Y\S_?7YI.U)A&3IW/]X?97_G9\E`.+>5XTL6P. MOY]?-,3?$\MQU-]/KA./?GX!@[\P^D'HL!"^%U.3DPO5S.2#KQJO/U_?W-Q^ M^O7BR^VO_^!(P(FI[SZ\>S_[U9N[AX>[CS-?/MQ]%M]HZ(L=]:[9-[C^W!OT MK](WP)=RQ]KFWV;?Y@+6'G%S?W[1#^(X&*=[P'^^*ATL/$[\%#LE+:A9[ZRU MHN;*"\I!Q^;\CH5\6#FJ^'N3-4NLRB6/F>,F8\,/?):M0M\.^7-<6.&/E^V3 M'$#\+#>"(J)FT0:JY]183Z[/60_0H6%..$OC8K.S>)?YF,#`@5\ MH/Y"%OO[.[%__W,M,U\377<7:V\XP3)Q$:/XFU`1>=YX7]/%[[!+;'IGF]DEBCQ4EA]KY;?%/76*E>%_NAS7&7+'=XA M>']8'ZE;G%CA55KVT37JE[L[N\86AY>[)$)W.(JS.P+_W/GI7G5KC)%Q(N(%Q$O.C`O$K38:YK-U]7A M2&M;2DOE1\=E&#U(4-`^+9XJS\%P6)^/F"7CO2SRBAVU+^Q`H5;%KJE2O4Y[ MX77-!I>\KGH$$@+)82]$`LH)`(6X"8&D\MRDK)B#TY.;*:``Q[J9$:K=*$J8 M8_2GQM?Z?=T8INFUAB7S:TN5NT_.F%6:RKP!`YU;]U&PU&:[=M6Z(L01XD[I M$B?8$>R(T1'BB-&1,X"<`=MK*Y`YCQJ+JH!#[@&RU3P/)K-5:S?;A!'""&&$ M,%)M*8J`0D`AYP`Y!ZHB;D=89M$(!D+P]MV8?R]J+V+)J8FJOFA$6OE%]7OY M-#D2R-JQ5P=^K4=QV(2XT[KP"78$.V)TA#AB=.1(($?"JH#-BAT;_-VR'+>A MU^,V;GV[3O8MU"XJ#$D8((U6Q^1%0""@$E%,"R@%O'7(@D`-A M+:R*7B2YI-VBLIQDF#CJ2AAE5;8]3EM(L]8U*8J7,$X8)XP3QH\7XY6T:1/2 M">GG@73RWAR;]Z:Y-[7R(8@MCZQD%6QRLEI11(VS-NO-#L>.$R1][_D*B6OM MXP[!5M%ZB!L>T(JE#SZ))9!+(-8!K$,"N98Q9PF/F*+SRW'EWL$0ZGG`2<7 MN*!7'AO$KU.P-3I@=)/8>GOWX=8D8GDDX*,O#)MY8,NU77_X M\XN&^%L:__#O%&^-S@NC'X0."^%[,36R&E8K.HP:&E-#X[(:&E]KC/5OB-+6OV7=0%F2B(*.@D*.B>O]<=N+;E:Q?+73SBMTJ.*.[Z M$0L?493.?7_K3Y)E!%14BH,(B`CHY`@H1P5?_6`+FBD*9=\KS92EPN^(8C0M M_PC47TK9P+'>6M'(8'\D+E\&/^G(>%DD6U'\XU''/U+O4NI=>GR]2\U&I]:^ MZA(W(FY$W(BXT<&YD4GI#(H'W:/(-P$H16S`QGIN(]-9':E:OB1*MQF5>M6J=!,=\$$JKM1T`A;D(@ M.7EN4I'$@2.0FRFD`,=:W$8*.[8.@T<6^EB+W1HRWRY;[CXY8U9I*O/9]*\P M>S6ST2/$$>).Z1(GV!'LB-$1XHC1D3.`G`';:RO8ZA8TEH>065$23LD]0+:: M)?=MJ];N%&3W$D8((X01PDB5I"@""@&%G`/D'*B*N!W%5LR_"`9"\/;=F']_ M+[ZT?,>8!!Y_Q+8\(TKZCOOH1F[@I[^73Y,C@:P=^RP!V:[UKLKSWQ/B"''' M8%\CV)TZ[(C1$>*(T9$C@1P)"P%[ZS^R*,:X)O[N+VR8>$ED/(Q8:$U8PC67 MR+CU[3K9<\B>LQA$K5:MVR3C,&&DPC8_`@H!A8!R2D`YX*U##@1R(*R%U7=_ M)&X\S27M%A7F),/$45?"H([-^6HOO9H*L0QB&<0R3HIEF.95K7%5G@&/6`:Q#&(9)\4RFNU&K5/4)YA8!K$,8AG$ M,@H4DW:MU2FO)\01!'&(C]C<<\OQ5S!1->H=V(&\C:K!<01+W_79%C5E7#!V M"]:5:X>J+7`WG_29&,N6.1LD;7N)PQP(D;:A]21D=MJS/2@#WPB2T+`#'WF# M!9F@?%$4]4[.[1CP4)#F>O1XB$9!&%_$+!SSOU0L/8%A.1@* MXI^.'@P!]#LW["0,L5!L%+$J0@$_.>XC?/[[3TET,;2LR:OWEAO^R_(2=HW3 M_HC5HYASYW^!H+70]8=OK,B-'KCD\<8+[&^__/4OAO%W]31TY+WV'?B?=QE/ M3,>\<2/;"V!`PW5^?O%@#5O-[@O#8;8[MKSHYQ<7+7`1^B#7?&&#GU_<-AMF M\S_OHIC_>\SN!NE(!4-^9.,^"_^3_HN<.A)B.GGQHQ=&XKOB#5_O;U[\8C8Z M[:MNH]'(]F'EE6R]`9?+-R!]7K3ZQM[>YE;K-0^WWMYFZVUNL=YV`__O$*N] M6K;:UC_-\@'.#_NR>9@=:#56V8%=(_S*/-R"S4T7O`W$.SN"^/6CY7J@AKP/ MPGO^S'T:J_SLFIL'X.+_27LA06&6;*(+>-X5US`OY* M^Q#@^7K_:UK,_UK6\E]IQWIFHW?@#>OL`4;'O#^'D"GYAJE:JTNWJ-7N-`^\ M17N0.H]L1U:02\L`C:@2QF_JSZI&V+U6(JQXNYKMWM6AF?92P78G/.A(=Z>] M5.@M`TPBO6P9K;5[E^T#[\Y2"7D'S&?%S3#;W0-OQ@JB<]%FM':_&9?-W5W< M:#UZ=MTKR,*EZ\6MJ]959P8`BV:^]@)7$&MW;M@QKQI7[9+6LP>I7#G5-7I]%J7Y:RHL[&Y;QNZ:K=[W=9&"]KHSNZL9.([L,&KV>@TK@ZLB7>6 M"C>[P/<1[LM2X:<<`&UJU&FVN:!TX"U;*D[M!$K'O$-+!;2R0+6&F:=Y8-VS MLU3JVX4,<61[76X'GP%S M'^'9Z$/@#Q]8.'[+5Q9:=AS=A9_#8!A:_S][U][;N*WLOXK0O]9*!9MJY5%'SV2=3_]F:%>U/MAR7;VNL`6L2V1,T-R MYC?#(6=C!7(8E`'#21\^MG-=KM,HH0\4UM5I6]9$8&C59 M?UG>QBB^-UU`71-3<'`8Y'E$%08=6!_NE6_:QME,-M0Q[-D29(IDAC,FE$<4 M<0[2Y3&E.E"!4%I[)1/35(P5X]OC]DJC`(GNH!WOBVL4&-VR1S28GS8U_&F0 MV=8_%<-1S!W&5S*#VF6B^RW7%6-Q84[D`_E.ZVSYPP75_;EB5[+TY';7+J6K!,3OM[<%H:``RC M'LJHUFS,9'%NDL`A>I39Y#>>= M]K?[?0'+([D.E/55%\S_+3'MW5P'9`4.!H(K!K4?2`B<1F7\G`1=XT%LESBO M+WX@7"TU,0#0ZO"3;V>?Z(UB&@_0;2`2C[E0J8QR/9`]M4K2Z8Q-MNJ$IZ(; M&"L*:#!+(9SS7V?`9OQ>EO)E7"0XEDL&K4Q\U'Q9H,^PZ M+J20Q_X1!C>T$UGT<5Q\TL!^6,2*+)XZ7L=`E+C.N69YD2DV3J%(7V6"K,GT M[('8XS@-FN7ZNB9;:FDVAB`X_^>!&HN8CS4J$[5,(*J1S!%0U%=TS=QLMCK= M$9A5.AYW^Z0I+YK.@AIQ]V]4)F"82*882=%MO,+^"AR6<:'#TLHD3G=:LJG, M#=D%?DHSJD0:])IPK<9R>X`R#4*.RGE79:GOEG$,]Q:X3_U0:L8W'/?*>%P- M391N/*)9RTD<]_=V9\NNOW($\[#MP<%V`+9Y$?=G0R7FHXUY!RMM,=%UC1WF M#7B)&)>[A]M6HC5W-MF`38H"S'*4^&!VI/%@NC$9*>7`T:'A8S*_^I] MO9?$9ICM>\S6(9KC>?(*7ZV([X[&D$,(RF'Y>3V$'(^:<#-293%?*X`FYJ9& MS2?*/CR]4>B?+M'O!7ZV^3$PWU)7YRZVZ[)8F$ZNS1[7L=G2<-B/Y=YD=53# M_^N)I;:S:@U,SE9'8BBZGF/?GJ?;$PL#?[4Y+>_2]\>]]AEM8N,J2^]4].?[ MM;:F8C/]SEC0#7E2OB665$^LLQO3!8B>MJ*2_43)\?>2,;N)'13>:K:B?R*@ MGE@H`PE28^K)];SN$;2 M((^8+'<+S`,H?5N#B8=R3:.GELKN]?O=:')M9D_<`N?'U'<7_6&_HJ9)WS1C MA:YC?`2E.DD3@YZ7TEFK;SY,X#UVJQF`'N"Q<#Z&%)9)_TV&/_WC-47]Q+2& MJK*`C:+/%0T6M<<;ZBYJ/-IT\5=(5YU8H"2.I5$OID$*^^0D%M_SM9BXG]:* MX?[B!IAF;P8QK;6V#;V9D.XB_XK%Q_AM@Z]>B6*^0G'V1J8O\]J4QCUR6P$C MHF+D$.<1Z%MGX["0`ZQ4;:%Q<[E,TFI\1"['XFC0'<6\[J(^$[H`:7<=H,^: M]5?(C!12UR_AU[(M%D_S?*14Q>A3,`CLVUN3;N:*:8/8KG(W/,L05P(:+#\^O=D]KD_BOW.'U2+:9@2#J[(%DA8)ZTK"!@%71GFHW M/W,AF[C"W`IY?^*DN!>?3EQ&O*$GM^8O)!V?2KOHW/IF2@I4[]8D:YR(K\1% M=I^HA6MQM@2(%S)4RP0,AZ->'$)6Z;XAV@L/1215Y7`HG@#AQ2<]4[2\'#>Z M^Y">]T9V;N%$_=-Q3>$565(3MW]TQ;)8,A?JYO#W%*9S?97K=*;[L1/&!R/[ MZ-+*=9NNLT#M8'CJXLINS*-CM@PI\2])O#.@([>-I*1R';@,25U*4NS\WR%H MK@&YY*+,&ODKZ`%$`U:(`CP[D_R!R[ST`%@V"AYUJP`P_\D0+`>LA[SD>I,9 M(]4=1GW;E`ZB%'P$W#LSW%'AH'M`1;?4IMVC8I*MK?#^`O278:JEF*7.(*%: MJFVOW+UP[1_0KIB\6YZ_VAGWS9S\;9J=D[B?HCN0Y5:XJWDYQ5Z7'U1DQE]^ M:7U]`;3];-`7BYA,$[HD8OJ*L=!TS55LD1MK6:H":R840HD;+=+/&'V]_;WX M:H>FZ3Z45$J=D"PME^31_'JW26BK\DTEMRD3K]P:U"`Z^S1V M8JCN`44W7!AR42?FXU-8H^,,79%_87QB746757"??,A5AC_Q"]Y;KVJO_GWX M>&'^)=[$_T$2.W@O/_MBJ6PT??@PA1`P\$_DQ!A`_RM+8$86/W@7C$7 MZ[#:0%>Z$'#+Z4N@ MUMC)XAZ#]]U5DZVLC>I8Y5;5T?LRPD?R0P]H79^HK>C"2M$,BQ65U:EE$2LK M2O)>W>`C^?697FFK#F>VHCNX`%IT"KX_97/BB%\^F$[B"]HF/?GRA7$5+(AK M\+'ITS',I^XFM,5W39688+T])=EDB6GI0AIT3V?2'0$--BC-9+GN=Z[PCX4N MCZ/)E3#)W"]3SJ?[PY\-SBQ)NAA*@Z-,DS.H_7Y` M[>$<[2FU;"_I@2X%"Z^6M#`>IYX./#AU3/H^0M=M;D6_4QC<.W9$M-,=]I'H M,PX^11OQ_4=9N3W,C#2U,^`]O:2BLIN0G"*7.S(H&D&ESHN>OR-YWG]L(NVK MY%9C]1'"?<>3-:B]WL6HQ;C2^W!^W#\QZ;:DNO?2;J/Z7H3IH!D%?:O:*_Z= MU.?!GW^/BS51'7;V'=UB6#I$]>ZCF;PI MILJN?9IMV<5LV+Y[.'-=2AW><^;Z6<.>->Q!`BW=SJBJ'U]"PTHM MG),[C%9-CP@>5"N>I_5Y6KPOX]WV5TN\58" M#4>:6+:`93].9W>_CD(_;^_75^KECJ;MDT-QA*RKSK%W\H\[H1L4Y7\?=!_N MO$`.M4"DTUD@=;#.NUH@[PLJ'2DNJ*S;+N3@=/'KR M$8C6@'@MS?J.W)Z^U.G_OYYG[\+XG^=M8MZ*G?;.$)[]]?>-);Y_?_WFVY8L M\#RVKBW;VZDXN^OOV(OJ=R1A1Q2SO:M3SM/C/#U.U=6N>1B%?4H<&FDVS9VO M=QT6"8475B9A)44>'$S8GRVO36=E/1LJ,3^Q(=RXB61:'7[I^O>PZM,?/R[C[[6C-X)&`L7YN M->^,(G&]X;@?.QP3:3U9(0XKJ\R,M/IP_=P:'XW5ATL04(G&W`H>&4*2Q/ZH M*AEN&9HGY9LGR"N82DO-OL-:@%MB:E2%WR8Z3.UHQ?-^;C&TK**,@UYL$"MU M'J7\@=A3Q5K/38J[&^K5[AD6[ITQ@Q?A:6,U6<"49T6`ID"99CA84MW]$59M MR$CN6:W,ZI)B/U:V<#]RHJQYZL=ZHI/%OQW-)-FE/*_)2WB*J%]8@36UIFB_ M'ZT[6['[&.TF!9]*M;`&.#X[,=1[Q<;'=[-E=D,A#W7JHO;&8FPX:I)1,`[0 M*@R9O9OK"E@'0\5J/MM(&;U^G6*ELEPP`)G]IIN;B*;W&W.+A!+U:6U29[6F MCLT]%-*?6Z/;+X!TC9?>4T9!H@9Z>MGT2`WT\E;)JT;=Y\_D[<4H)["$E#UC M9H&`6;TN]Q1I*)HZU4V'(E?@L&2/V0OJ#F`'WEC@8177!M^QTJTH"T,-(0P6 M&X.VF7K!:>,5(P.MPP.:@+E!':LL22.YF[GL&BH MCJ#AJ;+5;$5/T2Z#W)*K60?.OB`^H7`'-'-NR M%4/USBDO0JH+T4"TLK;;'*OK)O6C!:,K$=`([16!0DB[-!KV6Z;]6M,=^#;1 M0DA](3K85_)9)#1$?T5$4%WZY>@/D%Y8!#=Y,G@P:.%D<-GP7G_0D?K)")][ M?;/S*SON@D_3:7_8@H,O=P"O%'>CS7X?Y*WU$A7WF5.).3[RG$Y88::*< M5)GUD'DPOD)MQ-CZ:NZ&T\"%%&SEFZ"$'JSI`&`-:3<)0V*"8PDV]9\CK'KB M%GTY"]_!^H;>1:@V"EAX<:MA,G7E^G("#7U+O+'?NTL5VEI1$R$(70K$*ZY[ M(5C.8BTH5LZ-JYV01.'.$%Q>++RQ]6VMPO[M**8-_4$G:%48H6[; MT*9CF$318?JH7LD%H#)>/A.ORO7=QDN8#Y>6@I<_*6V]YR<\ZOSQWVO*66 MQGY1;!=GH;@])`D/4G\;P<,*[B\+Q5H+2YV^^6Q3,.:>X#O"9^])7R+^R/HC M`T(&SNR`6C`,\(RJ+5A@E:&5-0GZ\UO!Z)WIBKQ$ M\(>;]84"GQB&`^U])EMJ,M@%K&["]R3Q\C?H5H<7`FJX<".R=/-ML<:HLS"E MFXUF,>C[H]O"2);%GQ]OIL$GZ>>?\C%332UQXEJGBH[QUR,;]P6[KHZI+8W&_"#![N-]@2O"#%:S+MS75 M8=G0-P/AM_,"ZU^#=<\1\+C;;-?4V`D?B8&TQFCSU0!=VFBP.^!"TR@0,QL8=/(4L)E=!&\ MXRL$\#NPU!/0C4K.>=&U!8S:DC`U^N/=?/83S^07U$AOR)$`3CHJ!'A;%E%E MX;8!CK?7@3\:TO!G[`ML#K"&.!E'Y@V;`1<85I_I6A9+6QG:$B8'XVRI.P3O M?::OQ-41H7K%UWFM#/1ZOJG7<:;SIKGF:@GB!(40]3=EYML!@=LMNIN6[YMZ M8M\04-TJ/NO-;/P=]5?AT'CYMX"P\+LT"M>!5G50VO:G8EOY;P2 MP^&V:49RP768N`DY_?7Z[A88=@D)DC,J;B[*X_C>CDM+$87=PDM'&R-1DF/I M)>DT7A-85@"H%MC*"8@XS&?LK'&]PHP',0B_D5 M$#W,Y3"))32P$U/#->1&>>9^IDC(<9F;;>/4=P9;9O:B\-2V9[H7#'Y/?M1G92)?E?LE6*W)#4ML588P)%36)-'[7&6OFG- MK8VK77H>(?O?[Z"-@PDAA6RF!W6^`H0'>C`7G.V#/P.;UN?'9V_Y_3+O_<'E M,39(6*KRPUNR5P9#($'2QSVS7-$',(Q:G%^7GB923>$$>2'U*>7"BQ_!9`,^ M(&0&*&7%I.=OTGL9K$> M&,Z@2>^',G=7>XIG!TK8BUONR0TGE\]$V[PXIA5)LGFBX5!1TRH<UDI$DH3)$M\-C7FY4)O^`;L$!I^!D$G#J[5,1BY=+ M/-D@KIPMO1?G`7HO^"+P-!YN7W@/PR2+-D^A]1%G)R8]:DLRW2UP*Y2=!3D`H5E=\QK=S4P# MG\NMXT*G;A`*0V9I%#V0-\Y83S%O#<-E_CD:S2A_CN:7.4P)7W-GD]$>L54. M_0"QHW:)G:_!R9@9=47YQT&)JR8Z^0#$/;W1TY4<1UPUR74/01SN0-:3W4$& MEB>OFO1ZUP2_DM%D0[N M0VA3@IKVR:^H)>7Z])O$\KT>3!FR<.2M-=75FV\*#A0=>#5NS=P_4X#?XIHII[G!6,H?!.[=4>(PK><@V'D^KW7F4 MAZ`"F5>1#V7S!1S_1"$^*UJ)+UJVC[7,YFEQM/OK#=LU"^/QF37K+GM1EINF MM68T99`>3R%^->7@5V`?/';4M=A,0[SU?X,<6 MP_\#,1\W'YD,<6S?N7O_//'4LMDA:+;30E0^_!@EHX1<"HSD1V+\#11-J;GU M+C/(BD/T([SM0W6),[G>M`EAA6,NF%>R_(R'K*RK'1^1?=Y2@QT8]5+$FI0# M^H+B=<')VKW(Y<3AF@_W2.>;04QKK6W#J!<>QO;SJN>*:<,#X0ET+_5%T=TV MIBSE@[6$RIDZMO^]@;D(GX@%8$8QLH-XOD;)$DSYI1'$\?R=EX-S&<6=&\W9 M^.$F0*F@FDP[R-SPDG+<;>FG-7&'M%1(L-^`K*(X-(2A-6CFF/9.47-AMM/D M>QC5,;7)/L#N[+THG^`.;7X$.&=/[C-=K'T&FMA4*QGG+9.`D'T7Q1594A-; MU!7+8LEK;$,_3#W&E)?VTESV)ZXQ\./'G:YV?``E$_0HAJ.8NP9QSZ@:[FEQ M93*%U&U!(AD[T!671:.KO0A;@S+$'8!VW(;D7L^A70>/O2-[$"W(H:(7D7^U M"`>1\F4@CIA9:P+Q\7D5Q9>?K')UE;B)RWXNAWR^:KC]0NQX$;EP>X`^)?Q2X0RWPL0_(\;>YF[]X2>Z7 M03F5@SNIT4@7J&5F"_$(;@*2LQ`ZHWY\4LP5P2#\KT]/L`!MHAE-`KV!7$EI M-R^1O(C?D80R&!Y9)CGV_$@BD8:UXX(-R:1P.^A8HAFU'3$MZ?<=D&4YJC3* M!4J;@[LGBO2J`]Z\"$E1]E?C>*]"]"9J&8-UZ.?;NBE-97*FCN?XNDE8/7_H M,GAH9?I.`;W@,4Z0YTDX;K*X[SQN(_K1`MH[C-+*MF%=L23^"[`URP"\^>;= M%7E(>]\=]/>;$\V8?1!9-<./5#Q;+%&8_J>]:^MM$X;"[Y/V'WCHI%1B)$`" M*)LFM5,?)G5KI?X"`C1%(A"1T*;_?CZV$T!&$6P"S/R4%Z=\AGVZGR%9 M3E\$.?E;Y[L@QHD8+(_3:0+\8+<-4)^,DWR@E)7PWGSXVP:F`N\U9C7NW&W% M*TXPC<$&;JC%PJ1C(9T8'V,,X^O4B:J([%F/4)=@LC8=.!4\X#8AD?Q/KN`= M$G8Y8CT]8L]42Q+&@CI/<8[R+,YXEO#LXA4)=>X2T\D@;/0^\!9_#.2[8+/1 M?702%3ZFXB*:`G)<0*KGP\_DWK)UKD8H3=67:$Z+,D`QR1S(G+#\4#.' M'%=Y:.I.])FC2O=-6KS:8T0KWTB(%4P1V80O_Q:@7'C\` M_#5+`Z@E:0"A()^;GHIOL:XDDI\=H(U6R*FA%SRB]<0@G4'Z$"`]4TJN'J1C M"=<3I$LCA708F?8,:LS%F8NW[.(2Z[?[[K=+JSQ7ZLRKRCQW*"9\;ZUM%S:: M<2O=@8RD^J-5HLM6=K MN^DD85&HVRW6>'7>C^XEC46)GVLS!D<,CA@<,3CJ'8XFJCH@,*HRX!_.JU)@ MD'FI<3Y.[FPB\)0]U%_AS5SA&C#=S15;A.8F8GN3@9[B-3T%63/#)ZU&1CJ! M186?*RIS$^8F^6ZRD+1>G*3%P!B+>@VILR.YA;M(EP8J*)"P5#3Z);'0U\7- M-5MQ0X/!%Y44E9D.O4T059Q4+#_3E[MW,9]O)%?!V2'/AWI;`X\8:RC)XA=8< MUYJXJ/*JUMX0CX$5`RL&5@RL&@I]2_.4-/TNH8K8]2IS>,A7V!M>%UT+C/'I MSO+X('^&C&^WP"R1EB634;:TXMN<*&9[42$N/P8-25IY'Z4%_2)N;P':Q+OI( M:?PEZ'K/1:6\6Y2X!.>EU;DU5)P7@'>7X13IQS&GIOT.1T?UMTJ$2+^^?ODY M/:Q\QU[")SK\#U!+`P04````"``L?Z="BN!LH-\,```!IP``%0`<`&ES:7,M M,C`Q,S`S,S%?8V%L+GAM;%54"0`#I%R)4:1`L``00E#@``!#D!``#M M75MSV[@5?N],_X/J?59DQVFGR<3=D6];S]B11W:ZZ5,'HB`)NQ2A`J!L]=<7 MX$TB"8``+R+B[$MV+9YS<"X?@(,#`OS\\^O:'VPAH0@'%R=G[TY/!C#P\!P% MRXN3D`X!]1`Z^?D??_[3Y[\,AX,K`@&#\\%L-WB`A"#?'UQALL$$,"Y@,!RF MA+_``)*4]#;\#3$:#NX"QEMB8`D'WWX%P7QP>7KV]X][KAS3W?3N:?#M"5HD_46\$UN,=>1'QQLF)L\VDT>GEY>?GYZ.,2TDA_AJF9$/QT_#L_?#\[-TKG9\,N-,"&K5MT$A*SC7, M4;^<.\-!K'_ M"/;A%"X&XK]?IW7,1/]MMX,4)1>N- M#]/?5@0N+DX$-W?>RVGPZ81_55N`2^L/=I!2&KHT6>OX$B3XQ#=0T# M-EETUI.,I':CM*QQ(8ZID(:J'2-J.=C&A)NXQ92 M)@33:\@`\FMY4"^O%45O`2+_`GX('R`0?[>GLEYR*\H_H66`%L@#`1M['@X# MQ@?[1^PC#\&TJ0_-K#!LXM`<#_A>Z$<#]SW_.]<\?&4PF,-YJH`PR'RDBAI) MF_&QEQ/MB\D"D[QIB>1HH%T`.HO&3SX9+@'8\%'W[/T(^HRFOP@GO!^>GB6S MPT_)S__Y`IE0XI'@+>+*7^Z^4CB_"ZZP\$;('3+9)--:AAD?S*!_<5*#DR$F M?&+%.7+,,XENP7+L,;1%C&.EOK,LA>G]9RPL[](#3(])WKN`>&G3_']+@,[/ M\0G%B(;K=21MB/CXF_(O"%[7PPQNV7L']GX:6"@T8%A%;JP()G-(D@SV!:+E MBO$_W,-X/"6UA'%+87J,&PM[*QBOY[T.,&ZL2(+Q]ZY@_!'LHOSD&8^]_X:( MP/&6S^Q@YL-;3)Z`#Y^@%Y+(H&LX8P50U^1.XF#-[1QL;?&'F[K,!+J&2@DT M6RL34JX$W@@!P)>/V,->X4RP!^&$=3,I*;SK M2GD3,&_%A6W#O:Y22X^]`A[@Z&]><5%(/W9/'$Q#;$$GD'%43--&_$)YG8*_C> M!/IJNJG#R;M"#3D"_^K*=*WPQ2T*0."U5%>P%*:O*Q@+L*];S705W! M6!'9[.[*0NR.TE#LU_'NN@($TJ\!U_6._\`-V8HD//KY$G"+Q7X9GU0BJT1* M0SF9'XJM[">&O=\G&UD7.$I;DK&_@[:X6YQ[*:2O+B1=X4I79_+UZ=%5O0H)*=>%I,]RBF?/^NN0 M!;=BO=JYGA,3BAY08'%M2!;].^J,="4J.UN^Z.&==S<%+P^`08*`3WER.UE,(85D6UIMF#,D;C1AJ9A=V6Y?N2U$V8`R,5M+Z6!HE=)8-*H;L=*.W'#[)D\2PW!.7@J-661&+'$-GF93RE0HF%I^2CE-ZD+T8 ML7_@DM^5"JNZP`&]P1L%K7K]&FXP1:SP9L,7''C2FD3S,9! MP#ICB7"L+'B@G3[O5!.7@.I!VR^*&#:Q01;40P(J4VYFP)DQO3)YXSH'<5&;:F&H#$0*3CI7H.]+]>XR#25/JFNN)Q-MD7'_<7:WUT*PS) MQ58>S;($QPO/X_DLPJIU'.8KB>MSHG=1G\%JN1=;AWE/ M.551'\5X:4"YS[34E'W>D[+W=W9FZAD?S'@)\BX!15[!^IK<^YM0[+C[Z]XF M8<9-_9'K])H6D[M,[%IR/-7538)3Z/F`TN@41A3M^6]A?`(C.=LW6>S/\\77 M0HA]PLQ%BJY[S"8/CU-TWJ3SW:0'S]OTK>.HYWA"IW+"UX!`X*/_P?D_^?C" M$X]?>!8B/#,)]H:/"9_O@^4U_S-8/D*"\-RR$[;53$7':][,=]O96O9P&QVL MN4HV:_,^$][D>S!_9'W66=]1STRG:HJ[JF3W^US"!2;PX)6DFU=&`$<="@#9 MW?%H1^8>:NKX^2#]P4OYL6)I)J"G2)$!&T1]FCP$\;.*7'"X[U"J:^F7:.(Z]Y)6@ M\N4J^9^S.F7Z<7A!F;11S:W<+PD$,INI&XL)XMS;3G]`:,4>=R>0W+P21N*,5.[ M@6.#+#Z(+NYU#.93O`,^VR5Z%M^@J23,'=*7$[J%`V.3E('627!\US0;[FY> M-]%5!*KLHOB\F%OLGSL[_%?98C(/2&1875W:RS0N&X82_8TFB0*M=B+(:!V` M02G.RE%?;J$<$*E4]1"?27,\P8N_G.USY&(77BNTIJ1_%A M9V4U0BKE.3Y!Y-=%\3;\`V0K/%=__,2*1UJ@4?*\^65K'=\=//1,?'-,`"KT4*\0'R\ MYH9OHFUL_FSL1QJ43VS5Y,XEE1;M6U>,G8K_,BKJ+`JK^6/_E2,/_K&3/@/T(B/@4%EL7DH*$4HT\H:*2T5V\V M5>%7Q%8HF`3PWQ"0QFZID&;I'J6T'J_8;(B/RF]3V/HR?V5G/>VJOVIAH%7G M.RBF&HX7?$+G"CZO"`Z7J^<7+%2EC;%M+-<2Y09R?PB\V_KWV,@WT*_SR[RM M=.4:IKIRH;#%7F`FN4X_J)+\X_0$*Q_WTA>J--26A7K,0F\!(M$Q[0<(Q-\- M\]$V/^B7J;;7MMA/J^AR'_J3TCGV/;QJFZWYM-_%,_#)\2]MUQFC_$Y>M0"M"?:Y3=5/*T=LUB%3+[?;X:E)+ MX*XX;-QEG/*O1#6SI^I4`>CD M@?AG!BCDO_P?4$L#!!0````(`"Q_IT(3"*3TRW,``,Y?"``5`!P`:7-I&UL550)``.D7(E1I%R)475X"P`!!"4.```$.0$``.V] M67?D-K(N^G[7NO_!U^?9KL%VN]VK?<_26*V]596ZDLJ]^[[THIC(3+:91)J# MJN1??P`.F1P"(T$"I/C2KE8&`C%\``-`(/#W__UU'W[SC.(DP-&OW[[[_NVW MWZ#(Q^L@VO[Z;99\YR5^$'S[O__?__O_^OO_\]UWWUS$R$O1^INGEV\^HC@. MPO";"QP?<.REA,$WWWU7$7Y`$8HKTNOL/T&:9-_<1"GI*?6VZ)O_^:<7K;\Y M?_ONK[^<6C4:W=S?/'SS/^?WMQ4OVL%5M`TB5#0(@^CWO]'_>?(2],W7)/A; MXN_0WKO%?D[\Z[>[-#W\[O?_NAW???TW6WWY#C!8E>=\2G53D1,(&]95-_NNWQ-#??%.8 M.L8AND>;;^A_/]_?-!H&29`<=EZ\_]['^S>4XLUED/@A3K(877M!_)L79N@C M\NC_WZ,H32Y1Z@5A\IX(DW-/7P[HUV^38'\(4?6W78PVOWY+>1,/O/OA[0^% M_?^7-.LW0XL_G/2&A%_%6R\*_LP'Q%FT?@BV4;`)?"]*SWP?9U%*!OH=#@,_ M0%7/O_132J]'(\K>XFC[B.+]ZBD,MKD`"9'@`N_W06K.:_*]&%%*QH`_]=-( MLHM1?=1S8E#HQHA:%S@,O:?\._B,SN+8B[;%<":]W@8^BA)BTK-MC`Q.'[I] M&E'X)GI&26[*F^@>;;,P2QYWY#-]0%D:^,E-Y!O14:&;T4;;\(/-D#+G'OEU MM;F+44(,F(\"(RKP^!H&EQF;0_P&$K3GO`4R-(/L["E!?V2$\]6S,<,RF8XV M&'\8?C3^,,"420T7K`,O?BD[^=' MW]&`U#/L'3/.E?XH&IN,Q/W86JWT'#=Z/8X&RKX#2ZZ+82>'@>:&$;WPE^&] M\)>AO=!7!P[?807O^X'G\!U6\)XS$X_O0((_>D\A,CY>*ZZVOA`_C_Z%^'G$ MN:FG=J.JPT)TW^TK#E\S>U;(2Y#AS1L6S]%'B8E!K]/?J+N)/3\B"MT,N5;O M&PTRN1K:`HU\PK8XJ5MMSK,DB%"2W`?)[X:V.\7\C2CR"7VY]OP@-!7"0OP, MK0/)']&C]]74;@C(<"!1>V]X``R'_^H:"9$&GAX?4B_-ORJK3??3J".Z@&%= M5"_V*VG+?]8%/IY'!U'Z9AWLWY0T;[PP%`O&.-BNCL'I*?U/N;PY-P-2D7_3 M0Q0R^(#(K896U"WIS5=WNT?T*Q26&;?`U(NB-"Q7[VA+X[&L*@O"!W MLWA`&R\+TV$`4?&N2TS^&$0!_?+=DO_;Z!9]35&T1NNJ8RJJJ>2,7()*AA#[ MC8Y#FFB#8U#A7-F-ESSE&F?)=UO/.Q#-W[U_@\(TJ?Y"YYGWW[U]5V;6_*_R MS_\^2G66)"A-2MG6J^@>^5DYOINV%_(LVB`<:G(U:O^3F]U)!4;3P]4-6(<1-2M;WB4XX!/5!J8130H`J%= M&I,!#V>"QI)V,1_Z=(6BN&4),]_Y^\(+_2S,_WF/P_`:QU^\>#W(',[ORN@L MSNIJTN-HP*6TE&LFL;9F:>+B=P/:Z_QGD.XZ*B9-'9L&RY0?('WAQCMZ'[`'S^>!J??W\#Y"393E9R)5\ MI-H$?1WGET[\%WZ&DJA%-U>)W<*EK"4#<,8ZAC*-?BAWB2W*5+87CV+S*>%$VE"0A@QPF2^_HR,!59GK`"VT\E4\)0F9,ENT<7 M9\VK)`WV7HI6FZ/<)@4K] MNHC&H[C%IFL^V-[Q@T$V97O&@RBG!BUYM7LAB=N-TY_3FL#OI8'S7AHX[^<$ M'%AMX\!YSP>.(V>7-8%_D`;.#]+`^6%.P('5-@Z<'_C`^=$J<#YZ_\'Q(^DE M66TNT5-*5BKMA'Q@O:G8JK2L=*OYK3CU##;8DE-:'!?G.@GAP?6F2F'-YA5F]<82H[()[9U*TI34%M):^L^K8P&IJ*X+H](45 M=.(B=#X_?,#/*(YH]'"V15%15U.((M5FI67EFTT)6YK&T(:9?'\NKB,_/SS& M>4@@NB$K)CRBBDTX+1Q)*MP#.>P>7`RG/C_DM?UH1$D+$*:![X4/V=,Z>`YH MM,'"C4JC(X;D&DT+3QJ&Z($MN=Y<7&G.]L:^%FZ4K^`KX43M3OU/5G%!"RNG M*-Y3I:A^P'8#CZ0T%4PROXT$"5,,MFL`]^WB7-.6%-P/X!,Q<&5_I<]%`(`0 MX1H>8@BYV^75^0.*`AQ_PBGCN\+\O;0'\+NEKXG`?5BL"\^WIT\$P&4XQR;( M_WZ+GXD=Z&M2A5N+?[<=6OSUW[5GIY(D0S'P4>"1E):`2>;W49`PQ6`?!;CO MX0*-WE`"OP5\(@:<['\+N(X'@"'\%D`,(2\/\RWHEIVG?_GW@Q>C0^JUWIV# MYWD)TFK*YY):FOT%#L-*&O(<6_L0NSU[8.&@_97VU#UI4VU6'+O+M;"K3QHL8PEIM2Y\HMIT;E/N8;E`X*PIF]E2`%42= M7APJ=@=/'X]V#"6FK$(H'N7;T]!H;QX)J$J[,JGF!C0Y/*04$3<.*]G$O'O M*"V4>Z$3*GT`L@4R]8:,M'U>P[F!3]MHX]2)D9`*!N5?K7Y2\T.B.^\E7]$( MXSA)ZM+P0NJY053-/(/B4B@*#,9?K(*1GF3>1$D:9_F^9Y2BF,SO]UZ*\M2H M]1V*Z1/1WK:-2_6&I0]4&LX-K=I&&Q2X*E(Q#C#>.E#*!34$*=F7/@<"E2.%;I:ZF4O=S*5NYO3",WES+74SE[J92]W,"05W M@^!0*N"SCT1!Z#<$%&7CP#'`:/E-]Z6(ZU+$U;VI<2GBNA1Q78JX+D5*Z%'%=BKARQ7%B(NL[JW3W<07L:0P*/NZ$Q)O0LWVE? M"@8O!8.7@L%+P6`YQ"T%@UW%T5(P>"D8O!0,7@H&V\7-W`H&+R4AEY*0AJ:8 MI21D#4VOHR3D4C%PLA4#^44^>54]>64\G?<63P>E0IU.;UR03X(7!G^B-2WG M+`1&U[=-,TQ<&U+\/"N'+F]76+E:/]_[%\@##\@##\@##JWR`H<\Q%IGGXS0@:[N' M[(F(%$2TQ`;5AW&4)4E_/,X2TCL+!%5=Y8`AP764B+SZ-;$D6@];7GYW\`D:#=OC;S*[9W%BE];2&''(U>7#Q@N,5>5-6E8B"+17"$ M3I?`86P(M)%U?I>-V3TWUCQ!@46#ZE6Z0W$MSH9])T==.5)$[:Y7E?24=+&( MIXL%>9O%NCHK7;`Z6W<]#)5BNW6@+%-3(JC`$H<"U,I&T2.1]3N5X$2%B!@, MN\7;1BD.-/*!#L]4ZD\X`MQ4'V.TNX*X]Z(MM*O1^7NU%W_ZN\MN9(DOX;M: M4Q>3@7+QX..4[B]UIXWR4>;NS72=@GE2UWUU;'KTD,O+Y_M05>!OU5YY,W?+,6YT-#!?,$[KBJH\HSN9C,7Q]5' M[RO;7=!OQ[3_KPZ[BR,XSUW-9J-L.C6_F/=HC?9YCW([2+PA%U^@ISKSXY1T=(^_/HO7Q#S]2CAJPU&$LA50UQK,` M;P];FL>SFC",!Z[>OGUK&^4_M&7^T1#*18RU4WWYC4Z]Q*SU-MK$3P+V%CO9[F4'RU%^UCU$S'$NA\JP: M/D0:)#`02A*+B4D:ONRB`-*TG:4DWQ$`@;*#49;=4->?<$3ONZ#.R[MRQ!SG MUXEG`0.F]N8!4>_*Q=S4NQC["*V3:V+F6J(V5:$%(PG*THIW3(8G]7IOVCLSWPS+Q""\9"#FPQ08BIVJ$OQ"3Z<_$Q>"*J]Y)? MG%UMVM>3VIEH$J3'^@L\TLFA24'S?C#B=^3B^^WT`GE";Y"C9!5=?:5O7&=! MLJ,Z%'6*6B"2IB_M*4$_.3BIVJ`?IB1Z$S^J;@%9_XP#^M[(A@I9?+_S239) MLNHCWH*6?(/2KC(-)@DBQ__M%B!/R"7CP0I3D8E8#Z#'VR#)N>^F]R$R01OAS M(-J3_RR@;-+&YB'?4SK&T-"M&J`]-"KAR&\)\K,T>$9]1H(<.VG@B]C-$.=* M%AP:UB)A&"C6/?+I,<$W/CUW*/8)I;?EEX70XJ0P:3,YS1"VLG8;?B)FRL$` MJ^[AD118S];KH.BPE@16"D;^&_G!P0LESH@T^(!`5>(S<9CJV\PD2)6D8$!4 M]_!)(C&G)=19U@48(2?N^Y23DY),GKW0]"W'X8V+%[&M4*/[TX?J&%W,7A&TP*+R5: MI).#CX+F1A<#K8X8`'+GXL01_IRPJD,#Q$PUFLEA1497<]%.K0<&.NR>C32_ MJ53B:DZ\B]$^R/;^%/D,#F`];=3/\AI]<\`H4LUB263HR4SHAU(@^X# ME$[8))4`K=%C-VX2ISZ[%'-_CKQB"D;KULS["?&!)-42Q):@Y1S@IF(O==E7+Z84QXA@_5;Z(4Q2C) MM]L>OG@'$`=\HN-SO##1Y+POI6T_Q[.Z8/C>M5])L7![2. M+;!MKM@*_'IQ6DT.57KV,+DURNF3@3N[MQUO@PBM-A3'5.'3 M%1WRY#3).,?AE8M+MS!VE`%"?_(JOK9R\(:1ARC>.'`_*#3>#?9?$! M$WO0BD2/.R\B/]%D8W175FF0^V&R]1 MXL?!H3B#K(?S>9S/#37DFH*1AJCIY*#=PS(FXPQ1Q\9+-YN#Y"G7OMSM1.N3 M7@\[CWRJZ`5JM(8NQ9'JY?(__[FY8!R7?Y]^(7X(>&:='7%$5K=`R=&\;]\N7+ M]]3]!P*Z_?<^WK_)34L/"4.<9#%Z"+81_:Y[47KFYP>'0;2]PV'@!RBY1"F) M`)*?OK69[,=Z$!:^\@4Q MA)X1'N8E+^L.[SQL9=GET'->>C[G/MEEQNMV5QP/*`IP_`FGZ/C,?P"_6_S:<@8M%NO"\^VIY#_`Q<7A7,M+:)62"HZBH'#`FN M+LX`S6#PMOV$`1AW=ZC`X+M&Y8AVC>=>X15%XT%8<$E14`P);B\,FY`66;^[ M9`#4D'Q+`F3$F>&H%NOT;S121^M?OR7MT.F/.$I)Y'\5YODOOWZ;H.U^\#2T MOD\`2\3J$H_^PEQ<_%*PC\,>4CJ!:9QNLAH*CS:[#=U]V$5;?:V!R.?O_H=% M(:]#O2$#5P[FMQ!>F^2-G-]X'> M+_M`CFP+N+4I,/]]($$5F&/MAF.Z^S6.\VWB=76F"JX,M=NW[C`KM'=VY=C7 M%G(K28U>K+WH5IN.K[[Z849KQO5%FG'^G.?$>O)W'JE#V5(-R0:E<'\)M>RA M+'LHRQ[*J]I#N2!.HJ?KF1>>IK=+6O'H$_'=XQ<4/J./A&;7GA/4&Y[VWZ4; MNKO6U59?Z-GSIG%Y]2 M94O^N`MB->!T6@AQ4VLQ1=BP%.Z-FAICLS?!AP;--<[B=*>$FFX3(6SJ3::( M&Z;*O8%3YPPCQV[-'X[DP485..T68MR<6DP2-@R%^Z/FQ-C%-YM9@I]M2-2O MBANXD0`Z[4;30P]7[9X`:O-V\5%F4'89R,@@9'*`,.A_-Q](KH[![[P7NDMP M43P:?A:M3R^(MYROT*)5YX3;PEU@J"LL"1,IQDX^7MM4"JA#QMW/Y-#+UI%S M&2^JRFKM@8)LG7R)MGH6])X6]\IOG';`P2(XHJ%+X++[!>I(^[O+Q\F'5.7N M2_&/)@6-X/-&9B-WP:&EMB1@9'F+GS>UEI-T@4."#QQ[M&;(61Q[T185]0)I M44&?'IQ$VV/]MRI#J6>"4H+\[[?XF7CZF7R,"]P7_VXCOO@KB9GH?_)D+WJ? M,P;RDG@DQZ@((NDYBGOK`J8C\8D8^MA/1^(Z`4NJ51]\$,,BD(,9C9*.=(^V M69@ECSL4>P>4I8$/WSP2TI4*<^@LS:L"/V%YW7C./"59<+BY>%9Z3V=)8`[J M_+UR\.GO=F6&8=K]I2[W*%#DSBI=LV*>U'7('9OF**LW<1%7'XG<^VP/>@G\ MK=2X]9NE20/R".8+WG%5046=U6KFI+N\KVQW0;]5[FK^YIB[.(+SW-5LYF8F M`CO4I?L_C)\?R;\2S\]#^^(#=#!J^N`@(,4C6+X^[9A4(K\+/X#PPZ9)CCAH:<;B:E-3%HAYN32E M`QDT5M,_!T0MEK-*'=;FI:'@9DCA8BS5U=2#E0.C+WK4$P)#ON[4;G/"VU!MNO[NYM:I,^]PP_>*[V)4 M5NY&ZZMG.D6!@82(K%2=368K>)`9IUA:/[%K3T=#;):CC.1+(EN(#WD(4@D' M^U:"\IA=PZ%TW,/R6JHXF[JL8J[I?@;?8*&`L%A"3PO9"L%Z7'O%*;"@UR;5Q'A(;F2JB0X\_Z M!/QD]'OOI33+5P,?&BVK:$"EI>-8T;>"4JR@TLMX+WP<@]63.&4AOV+2DU\I M*#+H+B"D&3B.I]XVT5QN2'?&1)?IP*4$>T.P!X^((_G=DF_8^GC)-'0<1=HV MT/F,R73"1(WA0*>&:)5OF6JS[OPS[:^8IOZ:2M,WPIUIL04997T'=@Z<<8D(.G.R?9@G]S<"$\"2+Q9CE MVU%/L3ZA+[79Z\*+UL&:!.3@ET2*MC2`@-;2-T/"?UA-3Y&C3Q\)`==1O)U+ M^/@%PXM>\,?ZF*W]Z+0#N9K(>ZS-9I1]ZZK3\Y='0@7 MNOM:W$;9FB[Z%CA0X+N)N5E]@F M(ZRZ0"%'PDXJ8HB."+9DJ-JJQMR48N>UM+<6D0R'(?9CH] M/1Q(NS\]Z:.'$"/,*N3T9.8THDP:2AYI/7L=9F./=OJ9)L22W@YQ@%(O?CF/ MB<@/NRPE"CXB?Q?A$&_A5\=TFU?'N2,A?WJ4KVP'W'AA2N%C8O)+P0[EB!A4EG M;_.!CPHLKUT#.A#3HEP)DYF+VP^]$=!9GMO'`+3]H`\"[OZ#.1C8W>NNQ+W& M,?*]!#XQX1.UW-\FLA20B,%@<*V[OLUME,V-BVQ/T]?(9^H32O.4 MQ\<`Q:L(/LF4I*[24$74+OM8355I9PO9,C=+1G$\*UM$DIKK>/OY)#T<+Y-? MHN%X8;X)<3PPT\\J"K]GU-@=/O*N]>SBNS+'8.$B]))DM7E(L?\[;W''HFLO M\+IT,X:7K'5&7.AU)8'A]XO=@EHU*<$8GTUPO(?2)7!@7<<$`I;0"8SFVQR+ M2R5=3L9/0@Q--"@.4')V%Y?/I>0RPR&]F+*:;'B4EK[_'.=B%=T:Y4L[//.A MSN.E@H)93<42+WH,/PO#0CCY[--#]I2@/S(B:EXGA]9OA#[_?*IJ/+*H9HPW M.'D6U2`M/`6GXB.C3P'@@$!-&#TB","F"T#!$YO]/9%07>CUSH. MP(W>'D#@;_4:A()3$P(<&/)H8`#8W@P2#N^NZ\5;0"RF@-N'V>[#@^0-B6 M%OS(*+<[%G&3;F(NBFS7RP4B%]7.I;_=G6Z]Y*0][+%2N\=R7 M+'_JX2[?44ZG/Z#HSY<]NL#Q(?_X83A#5T16:L\FFY*+)975=C6;_R@W83Z$ MWE?\L`_2W7\38C@-@4M3.1NFF92G)=34=S/,?)2J!U=??2\,O'A]1Q^Q]OS\ M?5@O3&XB>,J6IB^-(D$_)1RHJJ^-"8F.#.^3L\HY8[(R`J$`_%(%:O5?IN1> MMDK:CFRP'*@<\S\N;ZZ)`.O\$\$:N0*J:I^`134E-\JIJNU2)OM1BF:ER6W`8G>T9I_JUG8H'VCF=-@4JY7-8`^'B1Z,IO>QP))&GI$ M%K\5O'-AHM"D`HI4DTE!1=T(^F"1ZHNQR#)<+N'F`M$T_4B,Z&>A%S/7:P*RZOO. M))N2]R65U?^.,_DS?&YX/^;J!:7(W\GNG\M15[OG(NHI`4%-=?V=&49P$ZBNO4!44S)Z6(5M?T,LF:XUNX=(`,7%,`[)$:Y MGN8<,UQG?5-E",N/<;G%D-S'[-7WTQY5K(^T6;[F1M8H7P#!?1NST#1"V[<5'1]&G5LUTQM(\*TC=T>2X"*3BV-IA+M1+&G_RXLR+WZA MXTMI)##;"7`.M+-5$\CXU,U!L2YI1KI>QA+E$?BZ&,OC8#04`A!J^!A`*#38Z$"&)1KD'QQ+H M+-MF2?K^[5OXR2G59@(@=IN]!A@*C#4Z"+ORC/)TL3`P>/N37D#8;B<;$)[: MO084BLQE+R`\"33*!;-/&>ULM2D>:DJN<=R4L-I+;\%0M5EI5OEFTP7A;1"A M&YI_4L>AIKT,P_`H&D6BO$BC!(B?#]S))@$56($0#`S M&`EM,"1@H,Y'"=<^!B%*4ARAY,Y[R34HL-L"B(BL-!&;;&9@D;3'D)!AB\"L M9_"3T13M/3T"7FVNPF`;/(7H*$\I3@'D^AE=E;2MW+!*XU9H.#.\:=ML2`2J M",6J#_Z#X4VXV\"G]Q9K$RE1C@@:I\&?G<^>''%I21'QS!"G9)LA4282Q&PH M;^Q!>Q^A=4(^ZGM:D=V+_#QG8+_'45XVOP5$:?K3\_8B^IG!4=5"0R)20A:S MU2Q,/;U#1,O?!UA?9C0/[P[%`5X_[+P8)9_0E_RG[CL\*HV.C_+(-9H91K5L M-210905BH=5HO$A&S29(\[[/$B((F=53;UL.'/)_`R_,GQ#K3HU*S4XSI&2S MF8%0TUX#SY>2(HU2-.:C]S789_MJCX9(MXV]??(Y(IT]I$0MM`W\LS`,Z+S> M7@?KM*T6QVIM9X;+/I8;=!FM)M\>/:,HHVL\O"VL==Q.^(C2'5XW";J+>7T&QZKHZ@QF MAO;>-AP2ZSK"C5-UB*5IM3%;;5P\[F*<;74DYDAV8@MAYUU]01DXOD7^SL#[4FY_>?F*GY^ MTR=#WQ%6W.R)SG#";-E?_8C@*B)ZOL"N9],UL0#1S1,<0HN,@!9(!L.5`LW, M*Y=H@^(85=M&+8PQ?BWMV/EU9GCB:S\DBCH]CU-B\.P9Q02RY>*7GS&K495-F-&@QFAKK>-APTVU%#N'$J(MZC8/^4Q4ECE_`1GPR`XV[P)-_D M^#&5:3(S1&K8:=A/K(PXXQ19Q+(^S\ZK>&C[H^ M'S:MBRKG+S?1,YD+`1R(28_(X)'.#BO2=AD6/3PQF'@:J6A&LLK[?L1E^C?Y MI*XS/[VC10@?TFP=H*3SNHTC5RVIF4/'\`%9 ME?MS$ZW1`9'_(2%!(5]RYN\"LGZB*M#<(/1P0'ZP"=#Z&+9>/>?F(N)'ZZ#0 ML9P&'K*G)*4/.G5/;-I1I$4)6CEJHTHPLR%KWXMC9,B-JAUS"M`]VC1_+8FW M.A32`=>0YKT.E+7(6->.I%9\!&^&3R*[,>--=(WC_6IS]4<6I"\/R,]BHCY* M?O/"SI:J9FOF&D'0>F80[&>]<5<2`LF8<#5\GE13E+B]*KI1?1$NXVR;/.)S M=$D^`B$^Y.>DIRLI0(JQ,7[=A80NOYF!W+2%1UHTZ,K*'`B&3S<>D;^+<(BW M+_0>0)*P*\%(4):FY5+.#);R5AD2<%PIF%`R?-C02@]M![_D/^+T7T$C.`F8 MV6AF6-.RU8@)P4R!F`@T?/#`TJ]S_>.4($]6:V&^@Q-$6_6K%_J,!1N&.HQG MAO;!;&YCNU!':-:H&>N.4EXC@!$,*+418+W5YI7`F&&!)@UF17HNMU1KIZ)2-D`+]8N9QG M1`WF>#1\='2/7[R0;L@TZW%`]5=D2(^O*O-(9X9G!;L,FA'$%8.))\-7K`HI M7BZS\B8!W:*^#N(D;59X`:$EW:J!,HE6LP2NI6&O0<3$8:)N2,7UFIY?W2,8!C=13V8W+,S]5C M,C.L&K'EL#F\>@(R$:U[BX:):.HS6BQ0`\?J38_H56DZ.\QJVVU8I*J(Q<2G M[EF6H:JG'GVN-]_WN"`*!FM4'-A5FR!D$-8,T`*T7N/C(^%JC6<&ZEZV&[0J MJJ)@3&`;/ED[W>@YP%D2OGR.@KR*:R[T`P[7YR\T`2U8!U[\ MLHJ+-`M&&KYIMLTXV`#;F>%^('N/$%$;$)DY5NP6%RP$S!,]OT1H?>Z%M"QB M40>Y-5QD2$N7\$EG!FL%NPP)5;X8+/B]USU,,P._#\19MSA)5E'Q[6$,+][0 M(K;"A_Q#%6UOB-GV[6E^T#Y*QP[4Q\Q&RAB>&'*(#20_EZY M76EAA78S@Z6NQ8;$I(),3$".]&(SK7NWRHYE!AH/-V3[+,SI/Z$4.C4VRE.0 M;J'(X+"1C/#II:M1MC/$PK$1*#A(T6Y&P1DRJ>7 MIK2NCK3:*MT@.;:=&2S[6,[^?9*C7$R0&KXCQ[_.UWA@YY^[P-_E%_S.8F3P M!FG?3J2NE>IW,K/Q,8HO[%U`U5>`.>*&O4K8V9VYRIT:%7F/) M]T7:C6>&_%ZVL_GV2%LP)E)'NG)X'41>Y`?1]MX+$NGK4XQ6@M5>I]7,0*EG M+1NKNHY$S,?M#=_ANZ&:>F$Y=U-1+G"2TNI$:1P\92E:UVN!-H7N''/W9W4\ M!N_#:F8H-FC788_1^XC)?";"Z(/1K/[+C\0I>S:+?5J0;[6Y#[:[-#E_.;7$ M\><#P1+-:DD"(,%OT#X$$WK//F8V<,;PA(V/14_YF4/M+R/=SZ7OQ:=Q\9[L MG1>G$5E,!&&8/RF;YXJ=K8O2>%YXE;_V0%<3.,I3!/X9I/3N>_7W*.E^ARST M++Z]:[[G5S)8A_>:I;N]YK5B#NR?C28;Y)WF8M!\N3C9!8?3T1J9CMI:'5-` M%16Z14GRN//:WU=K_5?)#^/W/[.A;MN#@R9CC*\;<]C_U>2P+\M5UPJ$Z3T: MV)M/Z<0>?&8VG$Q9=,AAT4-&]@."[\;<.98Z2A2UDMPK?B7'AY+6LKD[+#@R M?/>#V?V)ZJ#E^)%HG,>P:N4+J%MU[9G4,P.;FG7&J!?/E`0&5RWM[.]O6CXA M_'\O?@%^:'@+?4UIB?KC9-_PUY;;,P(T$'BKT#RM+`3VXB_Q*E7A`FW_:["),@__LM?B:XH?T5UV"*?[#3W^W*#,.T^TM= M[E&@R)U5NF;%/*GKD#LVS5%6;^(BKJJG02$O@;\U5QB6)PW((Y@O>,=5!54M M5G?974/$LH)3C5YALN#Q.2W6]LJR^#NTSNCU4@,*/0(EYX?KH"KO,D`'0PY] M+PS'66J=_HPLXM/[UVS3.[PF4?\112A:$5V'.]]=O M$[2%4F9&'+2/I(/5IJ8L$$1Q::JG0V":(=&_(RUC/WM"WQV#E>9H&!"U6,XJ M=5B;ER9_0`26PL6/.4&YM+[;FXPKWM40=DF!7%%7*7;QZ MO/W[_400AS9>%J;#0JYCC#%!IUO;8=@5"(@Q.6)1SJ'=-:;N;,3+#Q3-6XI] MP6<4PK.VQX>.66L_"TQ<;:]G42W/A+T(O2H#BNDS'W>$)8KCL@@;&"E(4%8S#8_25HH!V[-81;?&+E&'9S[.>;Q>YS=> MXAA^^/D7%@)VB&XM+%,!?!:E*#YX9;`0 MQW6A7KZBH<->="AO"1UO];>E!3_TRNV.&0S2[>R%!5S08'WEFZ<)W3Z*!`=I MWL/DK'P(O:_X81^DN_\FQ'`B`)>FJN`+T]@ZG"\`_E;M%C9_FY+S>&II.ZW%M.?6'L-9#UZ$-\'9,Y$D@#>! M.13'%T$`BBFY3ZRBMA-!UFXLO)879)879&X;20)&7I`Q/$$MS\?,`O3+\S'= M0CK+VS'3QO2$WXYYM[PN'_U>'<8Y\KXMIRL<]+B M>-4[CP#SL\;U322%;>FF75Q+-)TOIE7M-A*>)<1R,?.G&T9]1.D.KZM@*G]( MBHS57*TVF'7:5FA6:SLW./>PW*!X5I,+!K3A1Q6ZS%]+J$L!NZ%-]$&Q_OR M'.`919TGE0QPXF-T/< M*,\>X`=X+L-`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`A`AI0++/O'/A*>9^)#>`3$9L[V]##'0;P3`DK]F/8820WG&_ MJVJLXGX)WN.\;D.?D4H:87("Q`DBLNKU&2;9C&,$2=L,'R&P!3%;,%H!2F!T M(";DP,E^9"#T-P,3PJB`Q9CEVU$C`@/>[21*..!?*`VDGX.YZ2"&7'R(`QP' MZ0OQ\E`?AD_HRR7Y@(7X0`6Y\*)UL/92^`!>BK:TAH#64D@@,5ZQFIXBKY]" M`0'7\4;WXQ<,NA?^L3Z&:S\Z[4"N)O(>:[,99?E==$I(X#'(^KGAIOK/$W`4 M4QM55]49C1<+K1@/2L,_UAVULOZ$M(*;6)HH.JG&QL54S,E4[@$71PPIS+Z!9BK5I)#P\E\*$>GZCE^S:1I<^*V*E8 M4K'FC,'@6G=]FYNTWV"[`0+KX/?4&O MZ:'XX,7IRR=O#YU>\TB.IQ`0R8Q1)F&3X5$&"^%$''^/#EGLTP7'V9:L"O,M MEY:T8+"EW.YX[BG=SEXPQ@4-UE>^F?C:[:,X")7F/UWF`MRBZ62,?#+-8 M/Y1>MH^!1B[N!MB(#(%%P]&N9J[ M[?8*EBA#6'Z,58TAN1F#S&Z55P/:*=T]T.9K;J39OPYC>BB8&5W"KXPAL0T- MJI'39F&!_LN+,B]^H8-+:1@PVPE@#K2;;FDT^2L[(G,91JGX7@\@D%T<9A%2 M!R'82(3`5J-7`3^>H<;'7DN:4?986,)<(C\70QE\[(8"`$(-7P,(A08;'8B0 M1&9W?\S$N!_(5.V1Q3!:/87!-M^L2L[)HCC-8NA\29:\VD(2DL]X4:=HJ^%7 M:V*!8(3:?1(-DKJ0&3R5DB7G(+1);F\I)`T@!M@X:M?!)NJ&!9TF>Q>WR0Q# MIW./P1GP0'X-C2/S8/1D_EKX_B@^&<2*RTF9L,DLAFO2<@:5U%.&B MSI[B@LUVE"7CIXQVMMH\>O$6IN,$;TS)6%\KX8[<21. MK98,E7"7<;9-/D>DY]O`1U&"5KD\[#,@=1[=XR`5'C.#IPE+#@E:3?E&R2<% M8L(L3(,U"HER,3U`J&E8B?R94-(;[,?WP\0KB1Y,V:L++:8S`_\@MAYY%:(E ML-GKZO+#0[!DND/QD>3.>P$V$8WRU%YZ@SSG/S9Z6]JM!3HHK\S[DXX2/4TJG2=Q#%D[9MZ M6W2QH[+?1&=[&NFO-F7(0U_>OHOQ.O/3:QR?)4FV1^N*]@&%(7W%.B8+Z!9" MS3.NBM,99#PSK`]F\R$'A$FAX5&C>V;&VH,T.U`,NVH9%.U-RND,A:$&@/:M M3N9=^(8(5TD:[+T4K>NRK#:ER"VX:[4]WJ%7:CLS(/>QW)"H593+;)TOP2'D M!3VLPG%`Z[X>]VNNGJFVC(-(B1:MPTANBYEA4-U*8QQ*1>C M@Q>33S31Y2%[V@"[#NA7N_/XDE*CTU)=JM',D*9EJX&7V%(",?"GFULH MPM_J*26N(5V?WJ$[.QQB_.R%+/1)-&ECC]MDKLB3M],HN..*PT"=X;1$`OUC M8>X'C\2(]$&.9(?#]=57CT[!;?%^^]]O'^3N^PR2/PP/Y<] M]\BO=(F,$KH32GNX1&3$A,FW_0ZE$N1_O\7/!"VTXG9Q)%7\NWT85?SUW[SZ MX.7`D"@A#I/T/&#KK0MX`YE/Q-#'_D5UKA.`.N_"*^D00ZA6^_@O`&=D+).8 M^8"R-/`Y#P#SZ.KO_\)TEN9F@9^PO&X\9[9>_(6YN5A.X)Y._,`#3 MW^W*#,.T^TM=;ON5`+MFQ3RI&S5?JZ;'9S9)Z.A:M1.0=C[G3,K.-QV@=$C31I$CII;-4D@L M#4NJ(6'KA2'K"\?V")95"?[(=1@W`Y<60P[`J5;K]&\T*D?K7[]-X_RZ7OE' M'*4DRK\*\X7(K]\F:#M\ZK:PGI;(;.I/_C`XJK[;8_\-*PG3L,((27O4F@M+ M5EA;6Y[D3Y8UY;*F?/5KR@3.GG*I-$KW65 M7:+:VMZTQ'O[^@>CN?GRR8O9"Y+I>E+(TC0 M3^DE0E7UM5\FE.C(Q5ES.2Q9#DN6PY+EL&1JAR7`=0GWC""S!2!I$`8KZ>+G M[AE'(AB7M`W,Z5CM^YW)\*MV0';U1Q:D+[4_K-(=BA]W7E3\4M2"8I3DZ,VG M\R52YF/]G$'RJ]7/0%K?->4N1WF$0$ZHU9<(Q3#K">7B\S4?B!=O<9*LHIHA6I#FTE1E%6$:ZQ#DQJ0RBBG$FPQV M0K<[E!WX?DD/7-(#7V]ZX'+E[)5?.5N.3Y;C$V/')\MYR2#G)78#YI.D=`N? M&ZZT"3JCY40P'4\SE%+V\XF/V]\!*F=58>[/O#@#&!'(-P!1`#=P(=SK^+N# M!@EE8714K+O`@%F^$J!T'G]W""K0P_=]L<)][-XT6NP6^[]$3^D#\K.8:(?@ MI06/Y/AF)D1B?4$AG`NPE'9L[T/,BYNH@,B+O`$N/Q(R1EV3QBQ`Y(L(C5MB$SJ)#4C\`8X_3:2I@5]N;B M:FH$V'$VYYP!'G^3SCCR)/?O!L>>X:3`5ICGI>6_5A'Z%_+B57R+$JDM/)F6 M\,X>OZ7UB$IZ2NIN_"G8A)&])^@;V!?D]SE*?@E+HH\X1C3QL)1,"571%::DDWF>@@OJ:!DU,[F MYL1"'Q(/#(G$A!S'VX^TA4YE.%X83+,8LWQOJ'J$,][O1'L.^!\*>/L!@!O3 M]H2`W5D_O^1PD<4Q/>=($I3",:R(K#0+F\Q2#"$QIK&T=B*GG\(!-D,GQOT% M3M+B.@O[E@>7YGC.#-)8CQ>Y"9\RBBFD>S+8N1CA@:)>>T'\FQ=FZ'0/1`8) MG&8\<(#-)H@7L?I](03VX.))X]FS%X0TW+W&,7UMJ[D4.MOC.`W^1&NJ9/ZT M50M=NLV/CY:J-G<;;3W-H8`Z]9YE%KAL8;KJ/SP[SA6.J0.^:H^2=X/LFVYSQ=1,W MGPCN],S1X\LF[@E&WU_M[P_1$XQ'M*?9U/'+S?Y`EB94[4+PVIKECD[@.+I' M/MY&5+6;Z,J+Z5//R2>4LL!C^XNA' M0+Q_H]56./U/<">GCR&,3/P*>SKOWKJ2.B4&F-*^V+0W`X?:`M3;^'MG]QB! M#?0+'*5!E.&L%>;VC$'>^X@,NN'QK,]O37@ M#\'>DKN8T:UO-)K;F2\=OJ#P&7TDU+O3E];89TBJE][?)D$O,Q^2)GTPYH#L M*;>+"07L5;2LLN_>%XJ>;;WJ.M#]I2@/S(2PU\](V/OOB]OJRYOJRYOJRYOJRYOJ\[A;=76-X)1R5)` M566XL*AJY/1G]`T9\O>U25.PP8E69%9-7++4RR M*;T++:FL]G/0;/ZC%`[X$'I?\<,^2'?_38@1[&\>3>5LF&92GI904]_-,',7 M]V);W^5;QCL5(C(XRKEUX(6*=E0"/$_!(V$$[Q8>IA"Z`(C5!4]2L%A"Z@A*.$`<&:L(PWR?2AM$6UJ?M"APG)\-_&#M<*#SK'RU>&$\-U_[N[T%&94! M?A:L^TM=;ON;\5VS8I[4C3"J:IHO@>I-7-P)^.A]#?;9'O02^%NI<>LW6W$Q MX!',%[SCJM,&=:N9B^YZ\'=HG87D^U)_>K66(\N,;I4;5F&A0D-WS0+&Q$J- M9,UA)6Y6=R[6U+_QJ9?N-H\7);OC##L#X;A#H.S^%2'&9JP)5I(`YK.R&ZFJ M`58"X@IV4P+^:9'42P`7OT`LB<&M=3GB1D%\-K'%(T03,,**YE`!'$^`4UU] M=LOXO5$O.)IHO5?.YFWJQVOD(@K6_ MHA<.U+B-,@@*>6J2'"^*UR5=?8E0G.R"PQVQ'J'RMNVE4F\^C7E7BX^M-!*M MI94I>^FOMGI(X.(9'BU"0U/*5Q'-O`T^2MQ5*H',C=Y<8"AG1$>3;7E`=-8 MW!@JQ/@<)0?D!YL`K>&T6Q'=<4N'26=QSUYF)>+8>X]^0R7,]S9^C]9\4UF;%L(*8\;%QQ*ER$@ MKZ(T$K@L72PA3L/2J\T&^2E:=X+IJL@4CZ:J+0736-/K$_I22[*)2<"HI[Y\OV.SAFD4/X(ZIL.K9X?3 M/>H]32;)-8XY9@!6,%IMJ^O-:FVM[KV:02/N9[`ZC'L)E-^65A/$Q?"RS%5= M%V*!D0:/I%EQH$5B;^VIAQ`LI6OC$K1*/[74X!9_%X%QTH2LN>D#C^OD\V%- M8J?W;]_^\NYGN%2#2IMJ!I-K8RE.Y>(!ZVD,%&)H\,]G%CF^KAZS&9OJ97;W MC$[IC`Z%:T5[6>MT,WJ'0R)04NQ"E]NV[Y=4]255?5ZIZD1N9JHZ]%N5JM[\ MS;%4=8[@O%3U9C,GW;7<+%"[66#YEBSYPJ!S+Z&/#.T/9+XI7FL]W6([?SF1 MW'DO^1[:%Q*9L+:ES#&L-K$-,'0@&5RH1L+2@W^)P1#?3IIX;[[C7H4PASH\ MG'4;&]:])6XFFO>6=+K;<'>A%S%N4$`_5<>EC9\B%:-RDD9+MI?9+:?@=TF]E9'`YFMK=)]M4A3K M0$/0D(T,9L,I`$-.:V5<,-F:35MAP.(\QMXZ#_>J5&=Z72!X1E2\]V_?O@4Q MH=BJ-(UT*^?0H*"/KKS4:'(V<7' MX*]*^7.QX0F"35%-"Q"%6ZO321XJ,;4\*1>MN1M`0W8A>_"DU87%]#@0K7@46S;2Y^IRY,N>0?IW M<4^S]BT7K:9%BV;;5SF&Q`P66T+I*$U#EM9RW.6,"WJ[)0YH5GXN\&=BEN3^ MX3/S_I"0MG:#B$,[4^"I6&@,$`KDD?[\SR'>4JO*8B#6$A9NL7M-3#N'H'K= M./\U.6?#&SW`?)0S$L\R86-2,VS]3HH M-!IZZ(E[,C4(>3TMPU')%PX.3)[LPQPZ:8M<_$\495[X&XF:Z$T/5F6S0?OH M.[#X?;SN(:5@?X<&$U_J40Y[^LE^]?40%,]ZT6-HHX,)9FUD#+59+T.';VW7 M1DQ;6!?/N[0U+#:6DE66)O2R)YD3BD^NJ<$EXM]WA+'YO^YA)FEWA\8:6V(7 M3R/[JGGUE7QZ@X1N\0PRX)C\#0TX@/\RX"3L[MZ``R1FU`N=YH!K[>T\>T%( M=;W&14+C0)N-K&X,[SEVNWG=HU#-"PX-1J'@\)C\99ICLKR2?,P]RIX2/PYR MY>X-KNPDN^D[)H7=O.XQJ>8%A\:D4'#&.?Q;^X/R2:SN4UO=N_(![KLX\-%J M0UKO<90?]Y;;1-"P'+2C^L`'%D1X M8S$BAW?OP!#D_;J'C(2]'1HPL+2,X6(Y#8M^^V[R1V+(P#Y*6RPH80-`>;]Z M'.J9P:H>MMN`-3KR,3`MN&KG'#OA62%Q.6V9!'?Y1F04C.^'`ONQ"YB M,0^\]K?>6-.T2"@&8G]RH4!JL(V"3>![1-M3X5<$;KFR@E&@1/(3I+$@0\ M?5DZ4J5):2:Y)@Z4-N4(RJ]=*MNP4YQ4W'#4ZJ-*SL4]+%`?.3*=-DN$BCN; M;@U0CF[G+Q^]_^#X(O02Z"$>C9;B`=IMZ!IOV0EVEB?`;7V_BWD@#E^D:^NLLT.6Z<73NY2CY(<:)PF*[ M02X.&4ORR4,)U-LLC*HNIK>;>N;[V3X+R;=H?;;'<1K\"65/Z#,0PXS)8/K` MD[.-82@R.V6"T]7/9E*7_^HK/31'G]#7]/$+"I_11QRE.X793X&9!&AEF,T` MP,HV,PUF&0&8P+:;M*:FUK^0%S]^P;WPW.*A!>,CCUFB%[;0\*`]]LO$JFX2 MFC6LDN[EES-27/3Q6G"9+V(!*XV$V:)G)FIU2^C80NTUSMK[5_V8:&.V8#); MR`(V&@>Q1<=,P-HM9:.A#J'M#]@:$WW`YDSF"]BNC48";-XQ$[!V2\'<[`]> M$-,CBM6FK4^A:DA5;2%4L55I;NE6$\&@GA5T0"?=$Q-E?W4@H?PF>D9)2K6X MB>[1-@NSY'&'8N^`LC3PDYO(+[/*WR]9Y4M6N>&L"`;F,\F2(&[IK%OY]#YE&LN:P<<]# MP[E84W\X#TG4;?.^![^[Z=[U$&G8_2M"-+L-"'Y,L))$+)^5(RET4@B5P+2" MW920?LRVZR>`BY\Y8&FC. MCWBUA%G1\!4FRYI(CDB0__T6/[]9HZ`8AN0?[=%'_O3O6[3UPJN(*/0"?"(8 MOU8W#-J_3LRM?.WTG-OA.5P^M*R+"VG@J13XJ9HX&S_9FR993L)O.:W'( MIZY&2[-?1%;M(2_"F^#LF:`E@*]K<"BJ,`NBL+2L!HV/9;2H^Z;.)0]MH-;S M^9`H[C?J34'B3F"#VLUS@K5ZR/9[+W]Q[;B'T2P298 M,<-'%5:V:G9I+=4-6DU_`=]/"!?O'I5EQY)'?.83Y>AA:HIBHMA-]%^8./4W M\B,9F"T(*[8Z7NJ3;&7KFV$"8EC7.HWO3@])BBN"DA+(7%VR=JZ_BK=>5.:] MG$5KF;IQ/RXG_,L)_[Q.^(.E:)Q2T;@E(6-2"1F6PY\8DU54^G(7TJ]*M*8? MW@/]='9BT"KRD6Y0!3T2#1PXKF&*R3\VE&O6.881-1OUZ%#!I5A;]_HP$7?8 M/$81=33=XT*F9N\S7$C(]N?@I M9JM&>@;WFQ5:B,!5;V$O2E9!"0]43/VEIK539UP\U3MY-7CJU!ES"5%0^37S MD.*66AL>5(;?\SGV3*2@!?NS%,4/>)-^\6)XJ2W?H+;I*VI@:?V@,H%@#=6E MD''JJ]JR%?7AXFQSG@7Y\SI$[.J?-_M#C)\YM?>4VI0FE6PS#4#I&$`#4Y+= MN+C@O?6BM1!'?*(JO8)!-`VD2*FH`0T6W^%2:7I@`7D)VN%0`A!BRF/2#8=R M(M"05E8''SSF+AY\7VS4?KZ^`K_1>,$3%A=06#0S@-A$BKJ@$0'F\8 M'[JE-!@!["K=H?@H'.AJ'DFI.4PR#?=*J*?A6)@K[%+=8A,,EW[THFSC^6G^ MWAW?M3*DQR,+'NDT7*V@KH;+^=QAU]LMVU"MD/@@$5"5!F-230,:Y"XLI^5UKDH]EHI\'__BA(^E]Q>D-Q6FNP@88_M`?@GP#J@D M/8%#*K6+*>*C*,?KN-.U/["3`NR;N#<*;J&S;D!Z]7/L@LDPF^U,"?*RVE=? M_3"C`PUPC$9+T0$-U'(2;M:WA3H:E/IR<=.L5B7[$AUBY`=Y?BKY=XC*1-5Z MO3:FOBT\FF9;.L@2`KJL/9G!^Z(R%P*67P@UJ>R%S MBOW?:0H2$;I0HXR3K87)#ZF7YK-4_MKM:I-+")4$%-%5%\W8=/9.UFNB@)<% MV`35>3I`8+$^G-`76$*GQDD0BV-^:`YP&`9>R`0,&I=,PD-%. M'@8,;B[.]A=XO\<1V_G,WT_ID.W?G9SD17J(9WB`@Y,.K0G/VH_CT@#AF@M[ M<*>,JERD\Y=<0'X=#R9EIW0'0#GJ?AS?(UA%*1:2;^$R'``[SN=J>EMS,H;# M\HMP.,FOPSJW,9NEBP%!\YOUL/-B$L]DZ0[GM?FX*P`6,;@6Z!([\,$`QYR2 MDE+#3L31Q0]*4^;+X#E8HVA]3[#-W/15:0)BA-5D&DB14E@#+RR^+B84UJ*E M"^\0I%Y8H/T>)2A^1NMK'%]G]!K@39)D7N2W(:3=OAN7RK9W%5Q]32&%-(U. MG+C:E4M,94+KR_Q"&AD8`5X7PN?_>^Z14(7>3B+109Z6F.?D=O;@^[$Y;M'K MLG$5?(8,(Q>4:OAG:*JV>3VOK_9XA<875+*04*6C(E2>4\N5QL6C7U?X0XA=4 MI/JM54K M1$@^4X@IVFD,I(E%(:;.?#$UAA]5G.Y3.IE>;+$4/^?0;J[ MB=;TQ"DKSP+JEB#6>:1&76U.1,"">]A.2K<.UPE#2>_BY-\1 ME6IWC\+B8=E=<'C$5^P7IC5;EPY4;FUOEV!@0..^IJR/A6%DI0-#6487=QM& M17SG%H>KF(=NKC@'>NZ=&.=A;W>BKQ8E8(`/_UB%/:T?+87UNA,D%JA7QY!B M'WFPT.(]SJ7I,OCGKM:X"[7I.I.K7D]GMGF[.)"U3W2OO2#^S0LS=)8DV3Y7 M*B%+R^(2-@[Q]J7]&G??7`OU'OLF8ZCTZ.KVA%H.P>B^&2"[8`P=9C^4[X/D M]^L8'=^JI\F[0PYD7G]##&.XOZD-8HUA9WJ42SC.R!B75]7X)`"KZ.)JU*C: M5U\/B!ZTUO/WAYP">/T-,07`_2U3P!".F_H4`*LX^RC@GRC8[HC:9\\H]K;H M-TR7.R%9Y`P]%TAU/,2D(.AXF1T&=>74IPF!KBX>J.;*/8GU?U*9)A]1O'\' MS0^#=E2?#P;JZ!6-_S%<96N\#Z2;B]F'VF:MRBT2TV7YF<:QW&*1A)1\("S2 MY"8JKKNUIK[\QTLRZQW-9BI<&$JNOM&$>;E>T63CAL&=F)O<,(6+[U5HFR?_ MG]]0DAXOYX+!B6'6?2<4D/4R)_1TQY2&-:B-\)%B]VH9+S?%EYOBRTWQY:;X M6F^')3 MW/[3JZ\H]H,$=4:;-H-ZJ*;(8+ZCIJ\U1QH9&F+. M\3M$3+)!`7UP?JB/$:<'0U\DL(?Y#K#!_3&-;Q.HAXMYO09-^"F#=A*&XF]^ MJ5;Q7P:GIB^F,30!+5R\O=97S3(TH(=7@PQ,)G]#`Q/@OPQ,35],8V`"6LRJ M;E:IYMEZ'10*G=*I$M-9C"I]&1JP@KZF-G@'V?M4\8=[6Z`"Z2<9WC*/9&1* M_57+[[LX\)4K1L4;/4QO62@.QUZET7S>:_&ASU>UW]*VAIAL[LWTU MKI2R,CEH=6YJ?E#L?)DB!G3FM&8)14VGL8DM4AK8"QQSJM#LWM1DH=S],ET, MZM!I31C*NDYR$2*_Y6)RXC#;J_G]^&6:&-]];LT.IE2<^?[^B)."8J_FSP*6 M26%\]TUJ4I!6T>S9`J/*12[JDUB;)_$4=Q:MV;K=(PI.0G6!H]R4F1?29Y1X MYPH.B=7WK3'C8DUM(F&?5CAASC$.-IQ0U-E(PXQU).WQ?KCI1E4"\S.+O`0V M)Q$G1L,@4Y$F`CJSC@,6,CQWR5O&G1.8'IJKV]W8(ZK])3`T+VE)L,Q+QN:E M_@B8Z[RD99F>!SZ\19B9?::F66^(_$&4!'Y1T&N8'"[-WLWOQ\KU/I^5DS6? MN9?YI:S/'!,W:T9HJCW<@(?[,3^TV_U,;1#W''9F1SS7:0.E8LNH:W@B:*OI MY/5;^DJ"?Q3!0M8MY#$M(``/PKVYM M#8LN-`P5(BKW.]2W@MWO+$:*+3]-X*O!U@0>N;^X_&S)C\NS);;$V6,:+2U/RBVOF"ROF/3JW\6!<8^2-`Y\$F7G MD>MG8I+D_N$S^&:#%&UI7@&MJTNWGF\YJ%AHC'<=!/*X",AA7]"NGF\>X]WY MH3J97]0RBCL&"W^&DM[%8V_-)ZG+8=?O[7KEUO8"FX$!C?N:LCX6AI&5#@QE M&9W\'K6>JV]^1\`?J_F_]>/T7I'GJM?S%?DV;[.S'>,PIOUT?<.9\(^EMNT? MI^=,KGH]G=GF[>)`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`U0=2V?\#-(5/+(,=S7',3>D-P8?C8:%%YY,6=M@7L5;+PK^+&P6 MK1^";11L`M\C-O)]G$5I$&WO-I]?X^;S4C+;Y"[A+$IFOW=@1>7V$FJ0\&/Y&BY?P^5KN'P- MEZ^AJU_#)3=@@B!\E;D!(UZ[.`MS"L;>.!N*MHF\Y#81:/XX+Z'&=8E>;6M%$59O/0HVG[G+_< MHP..4^H$8"4Z5G<#C>]N=XYLUP\Q/@>8``3N@D\##.HVQ(S0U6F^<=-)4W"# M9=A.C$91W4[L;;*,-LIDKYGV==&0X[BMG/0-4PVEEH%LM)-_OY_74$8;+PO3 MN8WECI?F/9KM[J7=HP019.W.HO4E>D8A/M#UP-57JB?\B)I"B]-&K[B%I9VV M@3]'6,=>YE>D;?G*C5^Q7"Y^@#Z@",5>2.0^6^^)H9(T)KH_(QYHE=J4;I!L M,UO@ZMAL'.A*2B8]W\YMU:R>\&9XB=L2P(DO72E]O6I+7;D2.^W$!:5&54:# M9*-)SQS@?JV6N0;>@)65R<7H;+#*13K+K3[]#%VC:XZ#:2RG##S^!E3C597E M*^Q[C>/R3Y3NW5CCF-OYT(.;T?DRXHVZ;ZK3`$,WX=,\#E7>*W-W?[*6N[LD MM=2XS^8H?$EJ69):EJ26.8SD):EE3MMS2U++DM1B_2Q\7B?A2U++U(_!K=]Q M6H[!EV/PY1A\.09_?T MOD=>F+[`=9Z9!%5E9X#`UH<.&B%80H?&MZC&)*^6##1V,=:YB_$!Q>D+O3V< MDN\=/38Y%-7A&!5'%%J4=I)JX9X%J&S@;*/00F2!>@M[GP\5EV(=_>LC1:(S M.H"D.AFEQ/VM]X1C2OU"Q%AM-C34/'@^O`Z0(ZZ"'0&QI0E1Q;]8464I))SZ MH4@0\1\%!!^]*-MX?IK%0;1]R((4):#_A72E'3ATEKPNZ48LKV,C;N%RIV[F MLS\D]V M2H4$Y7&IRJ$T)_II0[K;(3\/04#?.7-DTH^:'R#C`*RN9G,1Q>RB>>+&9&WX M`-W:.:S(=KQHCQGOP\8\ M"\(U^5BWIU#F[Z6:P.^V8AZYN4:DD,+<`K`:Q69I/D&8Z[2M)@3R_9?/2^!OML?X=3,C$24:XS$BJCLAI< M\CDBG3=W_=M[I+T95?NI/1BY#1AC)E(`5I\^80#^Q>Z&8BGP(S[SR6<\1K=> MM/X'"FD>^>?.K"-)76VCB:C=AI>:L@H8$C*&@?*S`P>5*F\9Y6%/WT-,?61? M4PN@V^`9K6^BU(NV`1&'OYA4:5*Z7:Z)`_FW'$'YRU+9AIWUJ;CAJ`M5)>?B M'A:HSP0RG3;7L.+.9I,D@"'6AHMQ>.UV]*1A:HT_G`? MR\"K65'?%+Q*?;IXJLI1X"0^\S$#S=9B0,*M[9T[ZF"+#TD)^TC.IFT!!+B$ M.W81F[>!3UT2;4_I8?!)IHBNV@9GTUD*QW7Q@>65E@01U%V^;\?NQD7(W'DI M$R;@;\?U6CIM./"4ZPF!%FL7:Z34KD)\/2#ZD,79'L=IN5HKN[S#];V M#984NR7%;DFQ4\VNNL;Q99QM:S>'9/.M1"W9&5CLEM-(W=$WAD8^CU)G(R=J M%@EF1/:6D`=ZU8>;X-6+1R>M4XG'-#!FPD"]DD"5NATGN:P,04@$YD4^$>8V M\)YR,43%>53 M%&TG)RJD):HD)$JD(G;8#7MN8S&-;I1LQ,'S$'L/]T24:">@J@]YB,I:MH1@ M#,FI)35^F*QBFJX-CRNHBLJI7-)'/5[Y**23F>S6N\ MSW7QY.HCOLHWN`H00B.81UL>^2AXII^>LR=:7\)O)VSV8U):5Y>)JZ@R8A0IR.GV!./Q M)^?Q>)FABRR.NXG#>HT5\%=O;`EW/6$E"4RFE>J`U!-%%K%U$5P\:I;4X29Z M_(+_A;RX'1)KMU?#:[W]W"'+M-6HJ*U+X6+P+J\&Z17U@VZ'@S)X:QQ>`7Q9 M]AH;P#4Y7'Q@0UJ1:YS%O1#<8:`*X!J#^>.79:V1X5L38ZIKKD*/X+G?_-MA MH(S>$X-7@%Z&M<9&[TF,":_0'G9>3BC'.)-BB.42[J!?EOT-ZP9!.4%H$(7/6P4!DI]T)<7!S&9[Z?[;.0 MUD.X1(<8^4&>TDW^':+RBG@]6YUY8-\^,C7,MCIB-<;65?0-9#BY(UQC?<-( M_\5T]FFTOLMB?T2)2@ M+*W'I705+?+J28&#RXZ)A7<.7#U\R)X2]$=&0HRKY]I-P_?6;AJV!&+<+A10 M53G7+"I[UY&[$H%W!X5T;`WMWQ,4.0?+Z]=(?(;9YBGF;'8N)HC<)$GF13Y: M;2[1$WPGD$=2%;,$22S-N&*'8BFE!`X_77*!>;GH[98:G>\1/.2[GRUPQ-_V MNO\RS*0&W9/AD#"F,@LW8X0N`&8NP:T8%DMHUII%66Z>>>")7W3?!>#(F/-' MO-QR1?\<9'FSWYP_Y*KFX@8QN M(A]^B49`5KU%PR2S]=H>;UQA:;W8+JR].,-D-7?)(W5C!@,&?@HZR02"?I8LIMF61]UL4;=/=:O-(IKI_H/66ENRZ M(2%IC)+TWDO1A9?LKD/\)?_M70LLO7@3;]AS&+LXLY1-.M?L&("Y$9*=L6P;9!#`A MJ:,J(MAL79PI@#F0D:,B0G$8K/X",O$5UUYL6FO64K1Z(1G17$A&-!?3^'[)*M@KHKG@^]:%6X%-A>Y03/_@ M=?-V9$A9*]4&J2NPN)4ZXF=KV>.@O\%TF'%>/1H`3%`MQTI0EAIS*9UVJ[R. M\E[E\A3&HM9RISZA+]430/JY4@S0U2_#5IUT_`%<,V;2`A>-`5ISHP;JB)'9 MQ*?C"&XIOTG"V%A>L=8P83-OWY%N,;61W*3@>]X)CP0Q!P4NG?,(/,Z`A>QI M#\R=A8LZUV%66*!(G`UZ"6+>:'?E^$;&?ZP)0/(0A],%W="1C`L. M9YS*&/&XZ&RFI\\=/=8%2GJ`JV094FZQ%/MK99G1SBR;(K-BYG3`+J#B'VW_4.M--ID/,W40LVO=3:C[&Q!(HGJ&X%TG,G=;FVC7E&\J,*15A3/ MK7/TWH'5[DU$_H@>O:^HJF_T@[6K0:!C$@'#E M#C.%G>]RVF5/]W=6NM8!`*WK]1'`74$JO)1UXG*GG@G+(M>2T=H)^M+83-/:2=3I!N&LA^+(&6^+O)?Y>XN\E M_E[B;]?B;T=SRHD*Q1M]]="P$Z26CIA(2TS(4]7&09:D@["" M;G74\]E3[//83KM@OH3!=`YUV&RG=IX#:@*LE(1TO$'EP!&?'!!DM93'`H>C MBW$$*.XG;P^GZD`'J$B"L_>4P`,1&IW3=V@:38B[;Y0O;\Y41RY[W0/YWQ-EO,,:PV:`TPM+=S[>_0.@O1:B-4(V'I M`3YX:)IO96QS?,=]6M$2AL2 M3EC>,DK1@(9,^2.=;%F,XX]Q9?8<$P%7F\L@1CYI(\*5+'EI1#'Y3%&F:*2'@DU2X;2&(Q`M+R');2 MM1'AJ/23;[R!_!FAO>7=6#UD=(_@;&(#.G#DY$36$A79H_F0I=.6/7@7[KFL)<#:D%!K=]J4D&WG M&DHT->8B1IXGXZ4-N^BYIQ4F(K2^\N(HB+9PZC&?Z)AE#A,Y!@(I77@>9S&` MW?NC7?=^PA'=1R#&(JRW-U&*8I3`,9L,:?6\#I?4U9A.04&I&(_/S\EOA>RW M079F=&_N%Z)`9])G0L#(;._,CE:?,U_^#IW2LXHL=S:ZYB>H$ M0>0'AQ!=%&$HF8>N-AODIZM-0;R*"L579-BE9TF"TJ3]8.*(/58!Q!@]VJNX MHH5R;,,1K;HN*H+G(=`8`CNY[T*4W03I;??1CNX/U<9G[8?I09.I5D\$U?DZ M.1WG&MPD28;6EUE,48SB`*]_\\(,P3F0T%,N/;D<#THUN4P/;V8,UA.M\T>,>-LLK4W2992.'I&<1H\A61@ M/J4/V5."_LCHY9L3M\[!\,#]="^&F.YG>K/P6$;O.6,/*&8YR'Z>_B`;8#P- M,'1>ZRAQ;T#4;BTZC_W\D_G47@G%K;-/\T: MX\)$=PICIE]W\QQ/!ETPPECK)RT<]_WBP$Y-PR[$=F&VSBM^Q3G`TC0.GK*4 M'K`^8C@3`5JH&&-:7\`88#J]@32(.4VLK@W(Q%H,61X5^=JM6-.UL0W\5"]P M<_QI@CACJ]87+0W.#)];OR_95J*8R-OJ"N!S3=P#GRAJ[!`H<%78")#B M.CU<#V/0$9;U4D*QQD8]S9I5"JS\._T?NGM`_O)_`%!+`P04````"``L?Z=" M=-CG]=^2`0`W81H`%0`<`&ES:7,M,C`Q,S`S,S%?;&%B+GAM;%54"0`#I%R) M4:1`L``00E#@``!#D!``#L_6MSY#B6+0I^'[/Y#YBZ8].19HK*RHBL M<[KJGN/7%`I%EQ),NF757 M*IQ[;\`=:ZV]`8+@__B_GG8)>(1Y$6?I__S#3W_\TQ\`3-?9)D[O_^9YG"3@+,OW61Z5*`!X^[8Q M_!M,8=Z8?CK\5UP6!W"1EJBE,KJ'X/_^1Y1NP(<__?3O?ZF]DCC]_:_X?^ZB M`H*G(OYKL7Z`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`'/-'_WRX0=EE$^6;XI?]!@D!5H>?_OMGN+N#.9,:$CX3EG!]#!%&HE^F MN,-O2H9&O`BK'HM:.U`9@DK`_SOX5AG__T*AEPPJ*$R3!].$=!Q7&O\\0_"W M]RH@1"7U738N5SQ@$?5Z=5J`T\U_'0I4)QPOV+KA.1*XO5.!6SFMC7V`[1T" MVR;;D[E@M@51)X-%[85_Z0U$&"E0-L7^1XS(=QX1Z;P6*:ZCY^@N@6>'/(#0+J2R>@OKAD*`B$4!<,[J7N*US#^!'WB3?38IJ-Y&YJ M9@3MK-;-H)T278SWB5.']^Y26!,C]B!.0"\8[A'HQ]93V#O"A8U"TPP\L""> M96FU().W%\-8D-(`AD@/#4##J2;F![BY2-?9#MY&3[!@5H!\NTX567:Z\.>W MKZV+S/!YB7S]<(#R6Z=O[/0[S? M4275:-A.@0V%U66DT6_'139OZ]"(P*8ZQ>6[F496E[`H\+V*)AS8].)YEPFS MX,UL`65I;)@6RQ+O4P,KLH'F)]E._1%'F!:Q(^P6N:YS(KB"RROMK?1$[O^ M5_&>EOERWJ:T3*6OQ@1+LE$I79**-1`?X@$&+LWR]QOL]<,)0(ZX&$"NP2B, M$JAH0C(#E5.UD`E"%87P4/W;SW9*8]?@1M]C`.^,P'L]@/=]%(K&PAMT=F;Q'DUI7A,8*,J>YV8>9=S^ES!1E;OHJ;*;5D^F%% MNV5J*:[G6+'?=HH=2G$O-<@B"G&+>)Z+D#;V$>1"DW6!1%%B$+@2ST*0HO[J M8OH4%Q,5GN';JK*2KR;'9O13 M5[75FN213R72JF<.MED.D,/@"*N!"_B&G;S+_!P495J#.Z:P0H@^I74@[(7B MMQE#A_"NEO(93_.S%!E>;<^R]!'F97R7P(_P;K*%W&#(J2!HA#2E$]K?RDC" M-M(=*6F9W\#J'7C_X\]@#]&OFI9@W5T&!4QC)$%I5N*'D"")!/9X:Q7>+Y=6 M.U?BHCB0NTGKK"A]/X-B$M8TA3)%EJEPS8Y,U;,E,]#8MM4ET*^JOKN4CP:3 MMQ)7A0-M/$S`7D2`0[Y24(2KQ9%P6;7&S>&N0,D"7>I%LU"`<-LQ6)4PVO$N ME-SO[U\[6=VS*ZCT5DUK[`GHVND+R/*UET\JHX(LPU^#&DUMSJQP+THI#"]. M'I5@X++L'?CSC_].GQ<=[K)\$Z=DXP*9'8$<;N!N7TV,AA.E5TDP!]0C%H6P M2KR;ARB'^-T@&_R]8%J01ZF^8F07<0EO8/X8K^$UV?#Z%:ZS^Y1$^14_VSJC MTC/1G$+!I]><=34W\6O8+_\T>ZDGZEJ-JQ2#I*&WI"70;^H$M(V!NC50-0=Z M[86O_4:8IY0"#')=(0_HM*J6#HY87)Q7C(O5&%P_]J5CW8L`X!/^V_=9V$'\?><41LJ1%4H`:6B6A=CA>_F2''E M>J0GK#)MK,Z?UO@0JS)Z`G*H@#3@3EG>N6H'-X6RE)/Q0@NDM)UG,`OL.R> MH[W-SJ+BX3K/'N,-W'QX_J7`YR=?[?$K?./T_G1=QH]QR7GMIL4F:&6*L2;, M2:?A;VU01/'3=M4-1F@0;:HFAQ\>K`_86CY8J!Y1R*V\%`>^NQ,\]XT_Q MWVNL!?N^%AP:+],L?=M^4)#GIZOW M]Q;D-6"06VT>G0&Z7=B2!\U$%G%E!L@.BQX>@=.7VWQ MKJ^/<4$>)KS.X2X^[,:UCJQ]4^:([?5(*-L?S>)&HAD.YX3>J[X)WK=-GLUH MK,";VL[W65+2@Y\IC\^(9R*W'L5\(\SL^T/L`HV\\6,$-:7MPILZWO$!D5E[ M+`F*2L6&N(*V#$949'Q!12]9(8I3Q`Q8E&W!W"N3<>D;C5"+/]M@D6P028ID M\DE0#_;:0"JK.+&)5%\ER2L@]@!%^`E=?'0S) M::X1%#E4VAQ&5]NO,$K.BQ(EV^:-0V.5%9@U"LLTTZ.)H'5-965'Y_""Y;3" M5S`3\#5076Q?S^69"J)!S&1_\!$!&-8]\+O%A=GIF$EXD,E7#9`$DG6U^E6* M_M^!K(T.YO0I.'P8GB,910A.JOM]GCW%.RP=$4'+>GW8QQ@L68Y_LBS'^>"9 MS'>R[18_P%7L(_2_;^(4%/\\(">PA;#TO5BD#RE6SC4'*9>Y-D=8J(]E2S=H MWAMUG]RBOPJ\!R)+"_JQL_.\V\RLZ*U)O%E]UI!T2ORA@>;';1W&.^W;V$.7W M[-V[4L8-K07&>BR6ZHDF:45M<#C*=UV1ZZ`S`+5%.%M-Y48Z4QN/$;NX/CTR M^0.2V84.6WC"==EEEMZ_3>)'5(A%V-AWQ6X4/\Q2RPZ"'*OO9-EX\&%?3;77 M]`:1#:BC8(&N,JG4+@1`TE;5:#]V'U[%"$9FQD!Q&2`KHT0@+#)#@:?XMSA6 M.!K!'!+FC-WBH!A7>ZE!>=<,2O@\X0JQ>%!<"RNOC.66K4:K"QMEJ4+9,"X[ M`RLR146!3!')2OEVAM&"3,P83;(8=W-S?GNSI$'D"XCR,+H6E+-#GJ,"DJHG MHVL#.6FO&8#AJ!T38M*%%*&OL:REY`34'X2`P?$`9-S?C8:_VF0,/PNCIZ@A M,O6?\B!VA<>Z_M[A5(5R8\E7$\71]*0EW!J%84/3%J.ICM&N0:U1R'ACC['V M!%;/L,:,#F&9ZF9DR@"T30!8*'FT<8#EZVP@7+X?SM48?BDEFPL`U\KV*8IS MV;4#IZ>!'*:5ZMXN&+H#H=K[L<`NIY M0YE)_^HT[%/,Q_AWB`\+=9LQF'3U7#AUG!XN^*IH"!D.U?$QBE'O$O@IRV^B M^A1SB(KOZGR!:ACT,S>:BJO>JL M;[=9_K:(ZM>:@,[K!+1^9!L[()Z>J3H76)GN8(]HK1BEQ_:PL6VV?/8)\=Z^ M^AK`)V.$OS0L,Y.4/S3[2VG52SLTDII\`$9:DPE@E/SR/3:;VJ3:E6>^1#A: M>JO?ZK6L!*<`,J8L*`.5(0OB.&QA"!#K5E.=<\C3TMT$\2\1V[))SS&Z_26^ MKIMG&7[5^2$[%+^D.8P2W&-\T-QU5I`C@5D+_L8",A+CG(!&Q6/^-S*;.&?U M0UY59H2G)=9^1NT"@2X2P*%`$RN52N-MG>93'R3.(R?Y@B'-W=Z9)6=!4]#4GZ\K`CT_N:PE*U#D;,V1^FX8KP*J1M@KL M=K@%HN.6J&1@0J["6>TY.KP>J4*$4-OAC3N?H[*Y?ZEZXX_O+JS&6.Z6I)3?6UOU$[/5.:K'"":J M>,@&N,YO`;?B!,B2$!\I;`HUA1Y%1BR"`+>C`L`!QLG#5$A1R<^_JRX_XWP< M3:'?9?&7!F_UI&D=X*&DN5X:IS\C/\];*LE1O"W*`+.O-E,"I_CJ^P0K/P=/:K M8*]0,>QHAZY5*..,]')QJKXQU2)20YC5C_I9 M[73]27IBSW<7SNU9[I:*3'YO;KD;H'J3]1P$2NR]1GHK^">@:@??GFZ-0Q5+4ZR24%6S!!:*KV9S,BI]I%+A MZ([Z(A5#ZO&(CO\7X=_%7XX"J!=@"]0`AR7=]RC?W*)63I^F)WO2KC6ET_": MGH;1VM$L448A.2(QL%R1?P+\;_`-?^+[`0#J$&3<7V[$B[Y)#\O<\7.'OP\1 M&I`3@*90%)G5WYEMI@504>MZ6.5$9\.6Z;2JKP!R"337@D"S M]&2DVY*"_,32._V$/S#.@C:_&@=J-R8+J M>H`\&(THEPG4T>=PH;+GLX$!%(=\.,3))D[O3]--\^?%;I]GCY!4SI\A+IK& MU%#Q:5@BYZ-'&)5^:7)'LBD.C:0BK)IK($HWH/U'WQ)\JVQ]LTL)%-FL,1MQ M3L:U1[]0$&ATCN\(B'CN/8#B7?./XKDHX<[S%-LF^%A37R?P972-A4H+PVA%LY1'LZ]-2QI&D=0H#J1+ M22GB%!;%Z?J?A[BZHF_T?(U0]!`5\#J/)VC2"='*TYP0 MFNB?WVM=J9O5,H]",P*N&B_07*1K?*[`9L0P2>OZ]Q1::_%B9@,;&+S5E1SM3')(AW01.';.\PLEHAK"(*G*J7HVKA.`JZXR."TXL_;8& M*)>J7#R6: MXK%+)L(*7R?+BN2/GN4)B$K0&(?PW+X:*K)9@S:FGX1KGX2!0/"WGXTJO!,D MHCYW6%SC/V!G>[S`ZX;J2*"G5%SL81YGFYLRRDO_`'S'`2#6PCMX'ZB>IYS'05VA\KT`E1!]_A+PR#CVR0D>?5?+XL,' ME?VX5;/YHZ^4^V>C>E8]ZTH^"J^*#O"0076T",@J?;B@M+N(LAXA:GC]Q"E2 MVR(G\.+:+!;5BAE+:'2;1#XEV?AE/KL&RC!PW?]CO$[)K,4K`IC4A[_)+L_0M M85X\8-ZV95[4!O_K*\E8*%H,S1R6!TE4%%?;FS);_TY]Z)%MT*1PBH&>:C!; MU$RSM+@<2D_-5^0SS$?R:2`/,7)&*!/_IB-.3.QZ*!T?49Y':7F5?XWO'\KS)YBOXWI;77NQ MJ*\RA&]6B*$N*H8P09I9O3:BJJHM"[FF%K`C8GT)OT6-7#L!C6^UD[MG4[1& MOI?N=#`W)K8.L5XHT$870X6\CI?AE`7E+2`/V:F?W&U2$;K(DB?("W]D$ MQ4.4PQ]>*MH%61=2_BX5\ MJM0)15%1B,W+LMU)D;U#9ZM(X.YY&2EW!F[Y>C2;"#QAD@\JT*BE$,M^I@Z# M7SA_MSQ!0]<^I46R=@'N\95JLWKY`,&./$M;+40\[_8/6?H,_@;3BR(NP-\S M\KAM`2XOSUZ)-KL&"(%JGBN#JT-9E%&*T223^BGFO-P^,#>O,93>6,C.PU84 MY:'OS,NO/;L`"4T;=CYCV4#A$;+G)6"<.V393T^F`(833%>GU5EEBS#69II# MND$7OU#WL8ZK M>S:2KN*IQT'U/FH*O5*#'$HJQ%D-C$'/>K`C"#L`XN'[=M,,X&0:(SIBK7R` M'H%#1*S9!.(>N.1&&`NZU5%KE_$:I@79YG:?PQ".7',%7F;2<0U?_ZF(>HR; MG+$@X1@Y'TRN)W;2BL3!80)73O((XYPXR8$6'C7WF+TW2#-U@R+M^BOPJ\"Q:-,^6])8:C"K1<.:H5LL[\ M;G:R@WIGU'FOVH:HXON"=UVS34)XDXMI7`O51X\P`I%2#"Y6,UTB+DKV+EG[ M8"V$-B>`EZ;V7%KXEMZE\%)N:Z?)AK1$$?1CAK2KV`8%3&HEBV#F!/.2LO7U M.-EK]L2C)9(8GY_T%180,:,ZB6`#'V&2[0E%<_1W>FCNDPRI'`6^LA4>7YEG M-KTR5N%'5%I0>(3Y779\G%W(Y\W[ M0W(HPGE9^(*(R#J7:WE$7-3$7^FFU.RXYJ;\5F]1S/Y^WB?[&G<\U%LQ.JC0'<"-KMLI0\EUN?:'Y#=OOAB6W^"#>?LOS3H3SD M\*(H#O@URA,!G.G?"IVROZ:@S>ROKG"I-\L3*-5HJ\JE.HC@I#GE'E1NH/$C M6SPK3]"X^M:;N?#*M$=\K!^*8?HZ$3C\U\`KU:H9/P%[O6\[[Z-Y6Z(Y? M++K9\WB/^/:2[Q@%/>/Z-%\9*K`9[1G+-U(%[]AZD"^"V1?&&AH:&_BUX,B, MBF4[XVM+:^<,V5>4<#%^$4*`Q2!(_ M4T:Q'*D<\XP2^1P*Y((]GL80_"4VW@T`ONE^5RJ>'\B'+ MXW]-7YHIMISJ_-32%-=8?3"FZY0&I$@U\1OI>+W2T1D$PQWFL-(X(\#`E"EC M!RI#W.'%\*XAX[`A[T0;:'"]B!`=&7#8.VJ"A8[I[2OFP3-)X!/PX-\0KSV% M4SKJH4BXPAM:L:J[QLHL489M&Z[JVN`*M*A]J-7<":BN!D:`T?BQP4\=:!;L*V,. MY&T"PM946A<7S(P;'P$PI)/K7&AX5$+.86$2IBQ--'B4DT0O#*NC]-E-/$>& M3H9S)IC,Z+*)(3X+C./!(8@;X-A541/X8>II=GP`DI97?0AY$=K!NW^GXCI\ M-?!$4(V\)IK1FC'AE'CC\]AX))#DP^#J2-9KF_FC-\7O^%7,=H?7W@*-^CA/ MA>S__:<__NE//W6W5/Y/@/IR\J?J_Z<+-2?@IS^]._EO?_GS"3(C>W5_^M-/ M)S__^T\G/[W_>5AEDJL]@<3O"/],'@I\_],):N6G]\3B(UQ7=Z+K3]^=X)U) M>XA?60:3YZ6!3T(^5>'G5";W,"W($V"GZ>8K+.-\=#X6Z]6LZIZ=N,I[ZA)3 MM8_:DJS0()?%TG%6Y[M]DCV3C?(?8`JWL?]'B-2AD6F,V81WL@$&E)R-2;=L MS5*\L?YJ^Q%N89[#S6WT=%H4D.RUOXRCNS@AAV5S6#LS0H^]RA&T63RSS_IL M5F^8SVK5>*O."2^"-VX`^8'*L3XMLG4-YP7(&EC+#`S^5!84`PWE(7C0FYY5 M^\9^7;I6;AC\FP;\)0)_U($_Z7Q?)N(Y):A?S+M-C3E\P$?F/L*+=)WM(&M; M.]^NE^88=MJ\YK:OG[)8X?GDI'NM!I=`=2V<;?""HH-*Y\+\[4QLF/($U!A2O8OD%EE=;).]BN1Q;L@6SLS1- MB7$?C(MFKP$E/K1^=.%\K3STYN,W(Z0EIB7YZU*?[BQ3E=5B4G,4=BZV(A5ZO%5ND-O'=K248S<[- M4A&M-N436]L,J-N9I+IA4Z!I*Z@5+)N$DE%#@\P5ZZA.8U(:?'P*87M>ME2A MF)8JN$3YZRNAS8#M2"GMMB0[H-Z<__,0[Z>LHUB/&2+,SP83T"&8-$D``*,(MN6W_%S MR?A^S4.4;[Z'<&J`%C9X6FP$'2ZU$/U*2*3)]H>O/3P)8>>73+6I3CDIC2S:+.DO3!!KWP3AW>@THT:;UHS$&7PR5+)-1Y?&$ M`0$V11H'+CN8$IL'%+5U+@/*GR^ M186H'%T_#M2P)\B&<>-1;:FOD>?++L>%I;\R+ZO7)`^G5X85F=Z2`H]H`6C% M2V<'OH4KR3PXL%DF!A&+;!1/#NO\(,^N?ML`(%71/QR*.(5%0>!XK+"35GGS MP/.H^Y?,EQ^+#%D:?VGL+6VB'AC6\TO)]Z8QW6C:'=*[?(4CRN8+:_19'+FD MO7?,.5#LRJ\N7JA2>]=(;8#E\RS`2,NJ'F0\2N@US/$'T3W\222B%%.6C`Y, MS?*#T@O#4CIL08$U?46;[\2Z>K`B*6HM9%95@Q:-JRB36P%"E0NU$*47`JM!AT. M'!OVM`%FP?VVV97-CQ40Q%&+5P@04")B%:!QXKV(!Q2HTB2^(-Z55U$XJS'"TT[.K`/WGH]IC/& M">.Q`7#<`!ABEP!.O[(/4ZG$8ANH;E-.F1_6N(L7Z76>W:/.%7_+LX)RXU%D MV4LK3$MM2@KZH)\ZV`WP^<;R6_4O(DJ!YO()(`;^.24:UDSA]Y^RAN$PY(ES MO!@7;<.P:82Y#YQ];0#665$B^'R(L\]P`[;1&A^3Y_U<:S-`X@FP42CY%EG& MX\!B4Z[,&GH05-P+&T(K]2PHQY$IM<$\+2PQN@*2\)\;9GN(2&(=.`X45Q,_ M/,T]%N"HR:L6=)P*;(E/>SA$R=5=$M^3BGNJK&R;3E)I-KJ48+>K+:+4T%ST M4SQ6O8]!][EWR'/&*Y/Z>2<0GYH.L.UF\`V?`6@$`UCZ;G%+8!>G\>ZP`_N( MO/'!O_#-1@%'ZO1QX%G80X*]8P:ATD\=+;&.U4-; MJD]I;P[U)F%$&0`[@,H#5"ZA@%$::(R#7JB M0(&#!"69(!)2L?.4(:%3Y#G*``8!6*O^S\<*+G6E-P:O$-3]]B'.U<1]XB'4 M]IZ')8)-^F1+V?L-S>%5YR_2=6(9M*Q/@2!!/!9ZA*QK'65(YQ!QO[UWHNC& M@(?ZB_7\S\>)JFXT%H\KI4KA$>9WF6]D!;ZDJ(DLY3K!$+*<5@D(1V5\E\"/ M\*[$+SP[Y/@5SM/:@&_7500L.UWV\-O7SO[,\%R",+Q6O4L`7SL!W57O9!&, M9";]HT]H03/_CS\TY96#=0TT!TSC+09J5`3P:JXT8 MCI2:PXP7V;S,TOM;F.^^X(&ZCI[I1Y?)6$\EE&YMBBF\OAB34T8C4G2A^@ZD ME5P!]:4@-98[X#3>2"!DRAV:$Y5![A%E2X%-`ZM2XS__^.]T-3[<9?DF3J,2 M;@+39",(D]!GLQCSHM4WO5'$N83UF*R<_52O6?:F^,7OCS'-9C8C12Z&]T"W M^S:D/@[G(5K)L:<12PHN4V+1W:C4\@,P6Q)N`V>+E7%C>).0P;66<:ZO),(E^Z,HWOPD>I7B>J_9RI=.=03"2+3/& MF=)0C(G#<>F3QA.`#,NS%1Q5QQ\T2-I@)!6MR?$`B*V]%B#D4G,+)/SE0[:Y M0(FA*,G#VQ.MY=BT&DNUT:0&IUU=3:6'YG&`YK'"'X/J<]"[X!OWO`'+I'[? M,)-108X;3QBI;N;9PNF=!?FDMZ9()EH0ELB> M`&P-B'GOK9H!$HP'$S[GQ`#CD9#B+>"E/V3:EW9;`,4)X+PHXQU9>^@PN;0T M8!2E2LG"#DY=II0#/J!W'^7E\Y=H!T^?XFD1S39I4P7-1)-\[%9U4P`U,H]- M%(=5_U.`/P;?\`7O*P^6?8!+C+M#,%?W63_!#VN7ZH@E\82,<#@A\5[4!J"T`,@&U#7A36_W@ MF1N2`YXICLJ(,7RG'GE\(LILS6(/6+A"J:\=%WB8588M^#B7X8MTG>V@I`H+ MC(XO3^:@^K-RX6IW<%>11`299E`DE) M-C^011+*?`.;4B]H?RYKN6&E4L0)Z&*`+@B:W-9A?$]P]8$I*1(*()>2#UX\ M66D)DB\VYA+AT(;L$JB\__H*_?7,W.D<_,YS[DT9E?`TW5RBEF37GN1\AIE4 MY&-"!.3Z920_"IL22C[?"H7Z=1?L8S\YA5,"BNYU7L%X5K^I6_X;R M;EJ\4^V=GOPKM,:FG720%=DGC+6_M@65<6_S!9KB!/-^8F6@9','<4A36>^. MJ8%ATVA:<`I1G!S(I@O\E%KO()ZB0FVVV\4A;-"TCTQ6"G&(3;>)I'JPI4!C M73_B`C<7Y*US>+AO'B+4U8NB.,#-3Y1THN[<2RHJSMKT5>^I(0HK-?;4%!+F!F-\Y3G\C&&;`\4 MT&I9B5\S>4$S3DZD@NI<3D#K!#JO$U#Y@L3TAJ;#[Q*"Y+J?TX8YC)_>)3=DQMARR0@(1;M'<<_!`5<7&S MSV&TN4I_C?(8GROQ-2K'4%3TZO%!RDN;(`I]TV>,7&-\"LG$J%)6/SD16U`9 M@RP%C3GXZGU53A4AV/\?I_>D.[Z#G)@NZ*35#C$T- M"Y.Y8-*"+,U&CJONT:7JD,N_Y5D1%(\8(\H@#W?\J7P9>K!(X@PLO_UL3:4- M80;U<'6=Q^DZWD<)B*J?+=N&N#IC!D7=D"P)1R;WS=K!$;[!>[@C31\-5*12 M=&A043H,7WAHN1VPO!^(#IKH1^MU?D"58(R?J8-%"?;5.85'`R7&H?@6H.2M MKNLRQK"'5]O;!U@]2GV6[?99"D5EWYQ(]*I0+9))4L[Y#N:+!,5>2--9*>ZJ ML4&S/'SJ`RHO8/5D_;JQ"8KGL^#'D@$-+-,U0B4@4T*6P0N3-X\"(T5[6ZF_ M1M>+@/[1D.:T+.DZKPT-; M+.[QA^!-G()-EB117N"CGJN=/YZ?*7`!4?7L8P&D`626:L_7U;9*@IW)^$BE M^0%$N883P`ZGA3VVE'UX[9S:&+M78[+;#!Q0<5\=F+UN5?DE@ETY[[F!NZ],^!$6ZSS> MXZUK5]O^?7=R0YZ;`^56![;#SR9@ MY=*2$\CZ2D6?HC64V%PU-:.FF+Z904Y.6S>9.@;194G6%VD8&)5W6A,=P^\(FC[[CI2_T/X=T@R8.21:E(+K/ M(=P%=H]F#EKD=BZ$@!>E/*ZX\447,>\D=]F![%`6991NXO1^\E*089!1`6Y4/-HL3%XAD%#"XUGT1\)2J9:S#TU^]4RTEX<6.\^T6KLOX$7:/\0E* M'BE?1M4C\#5*7ZE^FJU]1$W*X1Y!\B`JXD=ROQ/6@)E*&AT&Z M(`4X_3%)"'HSLO2@>4\S2,\*-&8A<80W]`S& MB-%"Y0_%C<4F#_B2K%3^4B$LA?=XB4^V)#8.-/(N(E@4?ZV*X#(\Y6).EG>=@$4&.P#L7:FMD[`2IWJT@H5\*9V^N$$(+^7`=S9 M*<LLB=?/O!>C,BQZ:65BH4U&1IOZE)L&YE-K;$\(=`*JC\&W^K]! MO9^4-5Z9Q`\\A?[(<`AQZP-O?#N&YOAWAXMU^RF6.>(\N=,:<[?R=0/7]:VT MSQ"?PD+1+Y9)3\"F)MI`9K6J+V&4R'P,3QRJ*J#[&'RK+@0@7LS!RF1^W"F4 MQY9#+#L8=^,*ICW\Y&4(#Z@>J59T8Z1F12AOL9LW_#PMTP2`2S7;PCR'&WQ" M+TP+LE/@-,_Q*VGQX/PC+A\NTDW\&&\.44)>,?D!WU^YCI[)V'UXOL7?_6K; M&9T^4!G M;F`VEC<;;?4%T@F/W4OL)[B!>91H']&%:DI=2 MLE*`V&.L_SP/,XP3]\F0\G,;DB`9Q[^G^945(&8GH#,,Y'6A\D"8TD\:/6/F ML1TIM/.).#L";P]XY'FYHC@0R*VQP7'B2ZCMMA#F0=6S',;WJ6)M+^4TUG:! MDQFR2?7,D,*+VI+@&C]$3^+-_=90$W^U73?+LN<*+T.H<3:'KZF*]-KEHI+T\D+HKI7S1L4 M;`O`0OU<7>?98TQ>YX;?(;!I@!970"NC)_]/TIH%5C'?=Q>E>4>;16+"UE(LF5G?Q(-ODI\QVLEJN"#LRF,S>N7)E+WD59 M!P%=%/"MB1/(=@@=>,KJA0+6Y92$%U!:9<+DC955E(#H4SV"4KG_]94"PR$/ MG`3NT_!7F)9GZ+_,A9NIP2AI]@V,<'K:HID4-X@KIE[/O$M(^$-0?1H&M2C# M,V$,_ M*2H1]]4&??P;W$$TS.OL/B7/_V>/^/FH!_S9+HI3O':!I@7;+-^1#5+H[S@+ M9(E<&@_"!*2(!V^IYZS:9\7/0",C>B)JC4Q"?=2RT;34Q9;&>^,R25(GH+X4 M%(['X\:",WU\Z9BN;9G0M@D#2Z6T)AK(T_OUK]([JZ>]GXS&JUH_"3'U*4)$ M4OCF@L2;#'8[3OE*.+6CBV'?SB01INT;E<1!>&D>]+PHPMA=#0KXE)%D89\Y MZ'3P=^9,_-N'ATVIU$4).6^P/?MU&3HY"RZ2:JD'&/>:2=Y(*UD!Z<8)L?-8+N7@DI1+G&(2_<9!_7IM"A@60SO/#.2C,!ZE%>8UD;8 M*.B+F>S!;D1,-I9OER-P,JA,3EJTU8DB#/*)QGO"-SF`C`C&<)IRR@N@K"BZ M!5R-[C\&5.B;0I%(J(WCR*,<\XXUH!NQQ-?DH^3TE@U+K?R3XB,7NK`&=`P! M8^#8^)7Q$&P[3AT7P@T<@(A9+QH.T#,Y#A&_1$VS0YQMS M1=#P=F%^3VR(HM)N7X8K1R2#V^TN&&L!3^3VK--]1*QQ`B6[E:P6-P,A-V= M;%+6K"0UMC;+6WI?#*>@22,*=!SYTA-,`&^ADAMC-M^XH&"1:^C$X9)+$-G5 M>G-8PDJ.?[5FO2:T51I-"$DKM"D0>=3?^O'4]/X2S7/.HCQ_WF;Y]RC?"->T MQ9XL7>9YFJ67N(^&]9K;H`+?.''H.MXZ`.P!!BZ!L5,".&RF2J..Q5EV``Y_ M0T"LW>1@'[A-TLA:I"88J6ML@Y^/>2$PE4XNMH'J,^F4#Y07RO&,F*FD,C+, MP7[+IA-$'5N%4L2%(?OX6FC$&0P$J;M)@1WT,8II%Z"!VMB%EH%;AFT MTNG'%6S])JSFLWKG.^YE_@B+TW1SNE[GARC!'2_SP[H\Y&B"M_0?'*\F*OFXBPOJP.&I MER;RN<)FA%4L]M=?>:<"G44SSV.%\FN4 M'*H7)2=)]AT?FR0J/=@>K)J"YF%6>]A],EP%4!M2D`F*/SUOMX:@M0Q,$#@X M8#-="!X6@:>.'&;Z`)QD%E,]>-4B\G#FZ6`6'3?,I#.%::!YT?;>Q@CQXR0< MXZFB4XU-<8O3$V,Z3F]#BD@TUZ%Z]RP"?J:$-^`T3HD!,B43Q8?*(]=XLC79 M,`NKR3,E/9MP'BPQ@",)63:))-]B7+V*&,T$3O, M",G21YB7\5T"P0;>A;,;W2HVU=*)170Z331Q"C?XS3AY?'?`DY%K!"'\MONO M[4G9TQ0C[],E%QD?79;*]TL[H4@UQ26D1(15;0;Z=@`;XE>N%27H;+U35`$3 MV:PAFY!2[#J@8Q@`-#V%<(%#G!+.=_LD>T;=`;NH7#_@ZF7=<_)?OEC#'R@RU2PS^$Z)@M2$\6?7FJ%O7])DS[35G1E>A"1QX*>X:K_+]^PIOSP&>\' M&T.TL^@CT!.1@]::"[XSH[TT[_Z":B:P8FF>ABG/K'U#6[K!X`%`_2:JQ(2+5)Q`NY(F[US M]GW+G#,Z9NX!/Q9CV^WV!?[%JX[9:943_J1^<5BSK1S6NT_G>U4`9J=4I1=C7:8A9X.":E MG(L2=BVWC%+.`#/XVFR,>CP9GM^(0'./A=KV:ZUE,!Q7483+:!:&G""F[\5= M7(`/<5:L8XC(@^9@R/R/+7W+5][.Q=J1,-=S:82?0VJ^P=_R[+!G;@:?Y\TK M;7C>YO5-W%<+I0FW445AXL1BE!;5L[MM-5$YA;/;?":B^-(B#4F><+"#"(1! M`=*>B8^TZ'R[A6LTYZ--]YAZ)B,+NK%YHC$_MGE)T?V>%@1'HTN*8\ M".?=*B2IG%C+W+QY48"*IDT&OMX9XAI/#>;#5GFCA)\.0V%U1=+HM].N=$SUAJN)9AI9#2=<1/JJ8,S%W"X@Z$4,::9F%NN9 M+9Q-E-%(]($H'A,]3999RTAZD6&Y61QJXPPD*O=<"+LC-RM M?!A(RM-@&GFY'\RYS$R_B?OL/.B#697IA=;*T8/[&LO3)0I>M:2)B7\-;>IB MZLE3('3RGKB=L`JG;S)DY%;?`B?@#BAB,H$[($F0:?PK?(3H@_FI>Q1`/5VW M`5QIRJC'SM)RUZX1T6C"S4B_M>MBM&2,L3GZ0<>INF+4<6:IA"^H^UK8MH-X M\KZ@EXM@`UG/!H8]9;>"W]NB6_&^A4_E!]2MWWFY3B,<+?/-"F=.'#2^C<&L M.*\7DHHQ)_@H8Q;BE(E,ND#@&PX%2*R0;D7K8)>N1_ILH&G3C*@,I5H>O>QE MXM!85ITC0R73*V=8H%@,:P+-]E^B'?R8[:*8LC%?)\JT&WTV,YK5Y/+C-`)[A!]$Z6.^S,`LS$P+N3M?,H3Y'P%M00S.923(^TEK>M?1&BM!7?)ONC)G[@1-O9%OJO&`"`+0$Q.`#&J M'SHF9GX9(CO@F>*H##DC<.K8XQ511J74(K"PO'8PVM2_80I+D.!;E:BL`@5V M`V]01;;)DB3*>Y]ZWE!A&G`LF;8&.7_2+2?9*!ZO"J@&+HQ)25>#("N=LZ/@3RNLLB=?/K'M[DM8,X9Q8&R4,HR]F MA73:B#QSQKY48:V,P+?ZO\'<&9,=>29U^%!A$&CDQ":24VA9U62#")/5Z.-" MEJPX&\.60[$FAR/$C]V!;U^C$IY5J\*HR]VR\%BWE1T;"5=PU*.<<@\UA5VE M/0X#Y<.L6MO>L:H`FY^`SB&8V[HS()/-'\P15:7]>ZP-#ZE&=]8[!RQY85\+ M6?0AJN6C`D0X;ZQA6OJNX9W@DYE,W"(TQ!137\+O'4S7<5*]2XQQG(WAJ,K) M21#5D1Y(?3=7:4W4&1,2PF]#.2&>M`9@&#*8HVQ,XWR&8JD02%G,N,'G*-T" MB&EVMK<//'-L@K?^6PN%`&^RYD1MTLZZT6-PT8!\921EA2Q'^*>36L40$*'"JA3.'A"PD<%'N(5Y#C?( MZ+0H8%G\&B6'ZOLE2?8]2B>$MQ1=H8)0BFY=UF9\5_N5A5JG]'1.I2V%BJ,* MBR9@H`E<[28GH4$;&[3!P]?+.;10TL[YO%-0485&U!1UL;QV7KH$2F]G"@J2OV%51Y_CE#RQ=)$BLL*BK$SI1PL; MBZ=0`0GB6==&J>]CO\H1=4-/^/C1%2J9+^A?65JB+YS$Y$3#*EY[M&$=<@$2 M*(=C)=%3H8:"R''#JLE:T&23+#W^4M$MA?OI MRR2@0B(GOJ#G'+[*,/&F)"P"U"HHR3B2FG@$`'WG7J!M):P?G)$=1*(4DR0YE73%$W\)^TN3T0$\Z MF($5DBB)079-D2@]>]_O'3$"4271D02\@O2P(JI)4(#L<9YWG9.HV1``^Z_] MQ0^W9=MV'?T.IG`;+V^RZX8V.CG;,7'"RN'HP[,<;N)94]JILT*>[CM;UY9I M3^WGXD&;>L+1"Z60;_&%VBU\G:!@24D9F%A44((NAAKW/4'9PPJP%4R3]]$A MK*[KWWYI*EZG>/SF)$LX?L_1(F.#U=,/;>)+/>J?0/SQW@-FX/SX.:L M-ZJG]_\UOP>E M#:SVF;YR=A[.CH2U2ZN*OL)]EI?X^U#?76>W$:,UTK21``25]CF&*';@6:$V[EZ(&1U#;5:7LIRRO/\)V M/[DJ^+B-VZX"&8V'*?C<7RK0>I'59P\Y@=X55Y7E2;-^L,URT.O!D689/JOM MIQX95;&=C:A]<)"BEB]JRRAM0]81_<0/XZ`52A#_P3? M'^+U`]DL`^*"E+WK^MV8=Q!TQ?.K1/E`_JM('4=QW46JG,CA"+SO%W+&DO@.'I*7L%>"G9Z@><@'J=;7FU]\/R3J&X`. M4I>BEMC.8:+N.$AGQZIJ:I6XAP6&94H:>9.GJX6'?MS*OSX'KD0=`G6/7D4S M`$R\RJ9(-CU,"/!MHL]P=P=S5JD^M1@7T7T+,XE@VJ8A@1X$EI#.GGU/TO"G MX%OU>2C[HBC#-&4]87Z7V1[J=Q..7Z-O](`$'%RC,.`-!H+OHT[F`D&4?^<"P5/.JE*H M.'/1[&CY:VAG#NRT]@WFLE%X2;P/O,:8KRZ&F-ZH8TD'/6?8:<#OFS/@[P(@ M]I*?/DY((J0AI0@I-(_/L*:G4?K5)GF.K^J!G=Z69J*62[:C\()1$R1B,3 M_(0CH`Z->O"T.9QF-SS,']7N)/WVPK(&E:D_KI#L=&&*[-=?0VBA>9C=NJQJCX&[>>A/);'';),ZA>>8GEB.D2T>/Q=X_HS M+!^RS46U1`R_1#O&D\!2Q@.DLXT-0%[4$Q/8Y[0A(@'3M6%#90`:BQ.`;8)B MAG"L,[41H7&%Y3,FC324?+*'^N(NOA63+T;>0<1OVS1#)%XAQ/"A"CC M=8$/J?_CLF'"7,$)"RBF9T*F8(*/Z-EE>4GVH.%[V2<`5GJRJ_0D/A8]X_8\33?_*XO3\E?T#]XYOO.\^=F6[6V#3J*^6LG.G$:5><>,M6C1%D)( MQ%%)#/*9RPHB9+0TAKTSO3MB]!8^E1]0!WZ7(SG'D<]OJJ,-:G-Z:(75]/:4 M"4T+PZ[,R6OV"-9``[;>B=G@&XX!2)#@)K-"&(DX+H8@G]X4?R&S?:+71>EG M#\2X0%QR2C*,5,4BTA96O2>@ZRR)U\]R.6=HRT\SC:T-;@[[8269M$TH4Z_V M9*>,$U"9@&_U?T//$:-A%Y&-BA(^N^H?0D0H^YAR(?&ZT"*;'``ZLD/B:8J.7Z[XKUEM4@;7J]71&:_PGX[X*P&@\@8D#*8E$>!=0X#H ME0"3$0^:`&$7G7A'W-7V)DJ@BA%CO[ MIN-73[PXE-`1KWY83?D*B63^D[T[KN&$WS!FJ=-UVXPQFO!=<6812?\RCN[B M)"YC,S-Z9E#]]#\(ZDN>*-_,6R$P[(L5A>HW8:0DZ`5[ M7FPCDA<:&4,I&-QRLE\Z)*_,4@/*(KD5=DU1^1BH(X:!-&J')I!SB1I^`X7C M,&[-WVML^V)6C^JPJR]PN1.7$="TQ(8*6@UYJ>LM+4GQC']C+Y8)#?6]QX>:J/]+N5=1K3Z;55Z-KFBM753M M@C>XY1\`%D_0-0ZZUL$=:1X,V@>D`\M3>@.LULH.QE1%(Y_,[X->#GHAHN9] M#^91:!NN1+%?)4Q9:_\J.3Z0_"HZP1?+9N]XF;W5Y7=9?>;-+0O*;',9?7!/ MJ]HEO^BU<^.+YE;N0QE;)`^&(C[7MASQ@[?*)3-S6O3=7IN\,EDP.&%6V"G] M"RR[\L5`4J?&TTCKHWC.58OZ?=RKUK@;9G5K&%U+M_`=K<&JS_+4BPYA+?WB ML4)#OP9A]10L*)YY7]YP2#?RMD-$F@3]_NL_`-1*4!*0@^P]T=S*D) MEF4TR)U3(P,49[5L(N-18HL8.7%I\E1W`7RK+@7Q^AOFP&5R/S.-+&/;,0^< MX,#"8=P&X-![Z4O17EHR#O@G8(>!!!LO2S&!A<%;3POP:Y0<4,GZ2X$?@+I$ MZI^`]ZALW1_"6-J?C1!N8M5&B,-T6)0Q2LWP:OLIBG,R6NT?W?M4Z4ERAFN3 M.I5<]>@SHY>::5:M10[#5`*M&FM\8#(VJZAWTOM[\*+L,-+U'`AE.D,[HJM" MA!Z)PT2OV2F>#Q"W+R-X*:ADIA'WN'27'3]--;WWV,XQP)S=7:*J( M5V]1V8`,OF1IWOSS0U3$Q66<0MJI!%9BUV-C.+:6+ECYGGIISW27V))BMJ55 M/UG6&R"B=-._^PJ:H"!+01N66/4#`Q(9?,.QJX?Y/:=7.VS(K()P*(1&F^B4 M\FBI;+0&6"BC<151\WC7\#8JP1;3_)'4P8C%$>AH>X?=7YFJCK$CX.JRRI[; MZ"X9JXCQN`;+G3JN=WTK@G0V>E-`2J^K;L*G\@/JQN]\H9-VI^N9A+M)V9+NK5%U MDFE56H3$P6A3*?K4J9XI52#'`0")$);BR".,)2RJ&*7KAS`*4R9"`[G-Z8E; MK.-)QLWZ`6X."5EQCY8]X7``=M#4NUCS)+D4Y9_ MC_*-%0GF-V54AEE-!2#%_%_!70DYMYNV=9G1\&`#ED)%"@YDEU81WZ?Q-EY' M:0D.O0Z`F&S;`F_J;5R>CSIR0C3#(B]%:Z-"3V_1M-@O3D-,'&-9E%A&-"K%XD\1Q$3VL8LT+RZV49.'N M5`R>WG8K+0\$7UH]);$3RD1DHW64A=U0)KYC"**JO"-*JQT;4AK@CBDC!#"L MH/*[IG0:,*V;"]DY)?H6>ANK5*.;U4ZW.U94OVLPMT=#YE3*NMD7UFLHT85]TP.1_6=-0+X2U-1Y>Y'308DMN=E'J@N8<"J[]M MY?0I9B[7L^S&1<_4SHR4L=HW)$F4\!+B,O%:#?:%X8]"H31S_*;D%`SUF&1C M_Y<,SJ;7X+)!PFE*"ZV2*'Q(],T86?EM2S.&%&.3: M]GIHA)*!`HU=\A":4HWC2^6="O*\D+#WB-ZG'/[S`-/U,Y^!(H\I_=@>IK@G MZI,QXG$:DF(=TW_5NP+:2Z%13CCV-+Y)`F9*-I8CE6G2(/-`L^XPG.+TKBCS M:%VR^,4Q'1.+:FJ&49Q>&*(2O04)#M$<6<\?(3T#\"V\Q0_N('/I(KOZ2'/A$\8) M@NP\K&H62,.%N,#%=BY\A.M:)@'D07*KXW!Q[[)#6GZ-2N;&!K;E6&YIEF:H MPNZ#(:FE-B#!#XI?GQO5Y1/0&`!L$0A)..,ZI8@0!&-Z3!THY'`)&#O*:@XW M]5NAT,@]PKR,\4V)#;PKP5V6Y]EW?$\CQS_BFZ@`$=A#]`ND92@W)#6A)-1: M4V#RIK-DP>?0A`X-#CG0P]K(/&NL9J8H<<5M7;6'=5/J#?[&JT':?5V7VF=?2^ML^^M4>:];9U]/Y,K[\4Z^SY@G1V/+9<@="!PZ/%>AA[6 M06-=9S6Q,];9Z9;'\#8P:T)(16.U0.1!8VFWL/G'[HD]QIK+\S!#(W&?#&DP MMR$)/G'\!YK,V)D1UJES$DB8TDL:/F.2L1TI9%.`G%_276=)O'ZN_E=X+UK6 MCT-`AI]Q&G+[9S*S2;2IQDMZE,#O0$HC@TM(&5!Q:$EUYY/3*QR-/^3B!HOL M^^$GH#(%W^K_AK?3PB)0A66:"ZCZS29%^V&[]U>ZF!/Z#MIKV-\<'6@F(@<;DMBT,.NYDA^`R71[%GEK>/GO%7Q21< M>)R>N)BG,J-7%A@\;4F1N.,`'+YVCX4&MI0F`P@^-_DPXE%RY"E@HGOLV5EW MLPE!7`=^'1XP<*PX4RGM#"/-K]3_(RX?)H\6%\-GBXW MCE)5QN>]]&_!?$>M4>]T#AL\F9X(0UH]`;A=\`:W_`.XZ*E4T_JK-+E@PHL4 MIR,I8,E^KK-LM\_A`TR+^!&%6F<[B*U*.XFR2FH#8NLAJO M.XX2W3'JWB)J]>6)GI>*OMIW/N@1N*B%\_)5.$,03B\3@J5)YR*G#3=1`BW. M!@;AS1?Y=?A0-O0:1J!S(LO:<6*IH;(T`"+1_?TM%KJD19>63X7ED?#\T661"2,O9)H$-Y\ M252'#T5P!]]61F[W,(^SS4T9Y:63PJCIH!/EK1I;?8A04VN(WW^")AC@#M[' M*;X7@*6OF!PUO8N.!J?8F-E7(5YK/1>71T-S#O.9J^RE.4?J)H^0B M+=;%+CC;1/C8P'/;PC/NC(\7@L+$8Q.$#E-$ MTZF_':(\2DL(Z0\Y"LR:1,`TTV.9H'5-N6='YY"(Y;3J9+R]%,J#B:)!S&1_ M\!$E&-8]%KC%A5G!-0D/+*MGO3/`TZR$!;AO@9+=)?$]*2>7#A6F?IH#BU.5 MC$MX&3_B?1TE&G(\>-4;2D^[79RGNPP-Z[_(\$WU8/,+/65H^3/8#&@DF MD05E@EG3"?EO8B\[2O5AGG!(A!9GS3XQZB@G`,DN MB$,]&??<95;NM6U*.-J0,[,P]@ZT.NY'U6H.F!4%7!(K`G_ M;7&:T,>1CB9,\3A?$5`L+47P!6MC&QY#P339LZ%1_Z$0+YD0!I.D#4J$G"1O M4?/Z4\E!E-EILH[B6%`&?7>M)TWC)@6EBJFC)R3"T@1EB$$-1:&!>;:@D&`Z MBN*1%)YGE=:X4<\K__RR$6XN:5K">-!I\WNFGS2[&/-3)H[A6ANZ?CM/EZ1I MHX*`(FJERN_9XF2DASL=$9G`=[Z`?,^TY,,/"7RG1QMQ!&D-7#W M#(@'("[@&W;R_YR#,G9DZ"X`GICBXP!2Q!:"-@@Z_RVG'`PN:2XF;FUNBZV# MWEBC:-/*+%Y6SL(:DY@%R[[AJ,M0CH83,<^(EQ2Y7`#+586GCR]N(CENN=BBUF37EF3[7Y+LZC5!1#5 M4M^P*2"VX9904SS(L(Z%(C'O6D\I[KF$GBMA-X=`+/"7\1I/#JO74EQ'90"/ M\5L#VPR9-P6W(.2^FSE\B7:0_F[R>=[B)$#WMD5*7E^MI09&H[,X2HTEK/?[ M4V_L%\I[RF>"2H;<$J@4LYP61(KP4J@.@?N_%'![2"[CK?R^C*F+D.5]%TO4 MGO;*%I\'+A0EMRQ&A3+_6,X M:(H;+SX'W6RW57N-K.\T5T-1.O&(9O*__8@#3/L>$]P#Q:P.FL8+T<0!8K;U M]6,`"E,NS4+%G70V+QF\2B_21UB4Y`S1$2"Y-O7OP+#1H@"W73V99(5F(Y[N ML>J_131+0>^:7[CSQRR3^HF'$*>:=NAV!H#?_FQ0_@SA`/6I0@*"0-Q]?`)2 MZ/E&MPX.NE\Z4"0H)<)]5L0EFH;;!P/*@%]AE,3_@AOROG:,BB)*R)G7ZVRW MP_\LL_7O"T8&(PT&@PREEP4]POPNX\5.^\#X^0^K-_C*#P##X&C4,;OEKS:7N?P M,K_/R?A[A\KKX`A%^R--O#/"KC M]+YZ<3>ST+;0QJ10-]J&(:I:^-ZF)@IFNR:C$"9;'$]4;NIZI(L.FO"`Q,?; M\+L60):#J@W0-'("^LV`JIU09,H&?R@R9X^F$Y$TV!1-9(]<#"Q-&A>M"?1) M*_H3?(7WA^10@-L'Y+"'AS)>%YC@?WREMSX`7PENY?=56@M0F/$MF^+OFL3? M3C/7#ZA]B%F>?4^1SCW$>_0/I'@H!'YQ[!II0'3_FL@-(/&5Z59^7[FU'?4I M_+*9_OXUF;NCN'"5ZY7B6K^OW"K=C(7]97/\YV$VQT2BYO/7-&X2@T?(<9_+ MIKAOY?,U(DZ)^[W'>4JX#LIS8BYLTIT,RQVO9Z:7'AEMJ<@0-01[<;`R!\0> MM`ZAJ0H7'1R9D$`5D_4T7QZ-O8%1`I]9-)^E[$?A MC68F^=-/J4$Q'G+!&3Q,'1!O$!NMS/;R?E"[&'4PP1-,(ZAP*XD%%FV(9/O\ M"1?WA[AXP-VZVGZ$=[0:6LJ^)Y,">VU&2/5'GQFB9O@(J:TK2>1GBTC#BSV7]68P&.7),\AA&>>P MP=CF*#'&6W59#,K,3[ALXNQ=A[,<;N!N3TZ3/EZ$<4J"Q2!LSBVP6[]R]OY% MRAGG1I$UL`54DWZ`VRR'_\CC$M716_S9%N9(9?"UBZ(X1&@TSK)"N795C2M; MX\K'M4MPU>_G)M$H]$I#*:1;69W7.M(FK3W2D_BP"UQ'E,$KKS2&K2K+A M%=1K:8PSN8*S(+(UJT0R,]\3<$>B`A(6?;JMKE21B0EH8H,S[TK:&!T M7'AB2KTM1`4CR]03FY1\Y"3:R/$\2OVR*M<2I_7(19"0[D`.?5(#A2SS>$=! M2;E*<]`=`ETJO"D@+ECMM9`W4_G-8,]Y%OAP*.(4%O1S^K@V0Y4?VYC@%+U= M(RH^"2TDR\BCI4;S.3F`]`Q-P.(2G$5Y_HRF9]^C?!.65C.&#?/BYL:*LN/+!V7N7[AR@%'_/#?8T+W[MX-"`@$$4]$#@4O4.41VD)X=5= M$M^35VH6'YZ_1.0XP.F[*F7-&RD4FNNA7[(WF@(I;H5#!I'SJK;(]$QU8$;4$7CU6*2**[^$^AP]Q;O##A4Z68%Z*,$IA@>'5A,/X\QB M],D\N:8-J?%K[,^B6&T'&L,3\$NZB8LU/CP:;L+C'`L47-KQD<1AWLB13S[G MZ#-;X]@'(:Y_KO,X7<=[5"+O\7//T7J=XU.-VD,.[ILP&WP/JWD\&H'D$>8E M>:-*FI6^CRNV!4QF/64;FGY30Y6SJ*\KDS7G)(6AN7%.TGIC/AV,6E&CX#Q^\NJ%]PD^`4W(T0K M>M6_F[27%L\4^Z9'-_G&V*R3C;'J#*M'>29O^*O?(T;,_7)0%2#9S-$;,E+2 MN2-F4(@T^@R#0V#BYQG(II&W]8:@/7E1+'D7.)ERPO;=8BDL04X>6(PP;A^C MY."['+.-5-9S#PO'JME#V5RB%I.ODL"'GNPTSV'66Q.OGZG]OX5/Y`?7T=W:N,-W" M-+.8:\&4")C^SF8%PV#OI.3%6'LKD@BK8BLB=L%(D7&4TX3+$I6F(F>J(:HD M'B]=33VX=P1<'14.60Z:P-2"]@2TX6G+R55P\*W^+VX%D&8\W^!9J@!(U#G+ ME`"'-10Y]18_Q/@)0>$L2\LX/:!^7U7'XN)=3.0AQLKN-GJ"Q?E3F4=9CKY= ME#]?E'!7?$'00IX(9DGUE6-O_#30EVVH'.=)ML=U5 M?7!T?6@O.2.U:P%T330/8]?VI)43,&@'D(;(^[QZ38&F+<\R[H!AF4,HCT3= M7H,]<7^)TJ&VIE]F991P)FC'IR#M@4RU/L3U0?31$_HDA=NX!&]@]H0:0W;(5Z?$K15YY;A9U1\YS7Q.ZZG4GGV'YD&W8I\,K M^5`G64P?@WHGZ)=QW6*W)ZM`K`BK^OW`<4HV<"7DL,=MJ*\?4T,'0S;D0$6E M/\.5162/4%3;<"@["[>&0[S/D#(WKL%9F8=SP+U-&#+W%"X5B&;/57:%QW>O MRBA\'\-B(:FTR"#>X.H(DN_Q"V'6V7U*7@F3D,/^,#KATQI6V,0X[5XC>L2` ME)J36P*DZ_KYID2*B+MR>HHG_W%\@@!.ZP MAS23_/UI[)@8C_D@QH@W!GR($GQ.Z'?7?[$]M4$VNXZ>;5E&,\W#9*YZ>U1DW2W?(O8U0][/556HQL=6'5 M[@,A/N!+M`OC:!3'1&*IHAL"TT764MM,S7:E&\>4`B[C%)(%5.=Y8-*RLV30 M:SGPC##YC4)/"_T.^\P-73^:E;6VM1-0MP=(@_71L4V3H-^4;;KS:H'+T.6A*8H>)B*4@SK)1VP&7*6F!ZF7AIO:+$C&\(#M0FZRU M>148MP!^X1)S3*7O+3ZJPWG9.VC562ES2 M\-%7MT.N.DP\-)%PEG)(XR[3#5V<7*>:V^CI]%`^9'E+BLR8 M.#=RDJBH==-8ES@YE.G$P'L0!X4*1Y&#>=[!H"QK'N[]'P3:=*E+4-S-!%S+ M,?YIEF8HP.Z#(190&Y`@`L6OQP7OIQY*C.$4_<(!'Q-@ZD#A@`0XO-*`>=J* MA"F;",8.5)#HA7$J2!YPP'/L)X;N.IHR!7/*@,SP\C@B.OB#X\%EB0OD6%B* M-@P@+TJV/M;*Z:`?VP+4,*V0:5P'1M M.P`QP!\%@N318$S!2QVM,5HK(PI`;8RF'=52']2>-N$',/?1<[6K>!=MR(K1 M8Y3'V:'`%_'R851/`N)@5$QR[(5:I3KZWA3I"V3.1#EADQ\2LC7&VJ5OJPSU4+S3@^]"2DN18 M2\J3ZFA[$:FO<`WC1^:M6(;-5*KZ-J90/&W7F&`-0DN!N.B%6GU"&.%5(E@ACCJ?3:DKDH-2[!-(5Y_\:]V`V]JQQ].&,?=?6O< M0UD8G(&V*:%G0W9,=OE`%"D(&?9VLHD_]%=G,V6/<8$^!=LLK\ML]`\8Y2GR M*:J3+=8=#<+:R>H>^\)4YPO]0:;)UA2?!9"NXR0FG^MG3\G`ZDE5&-B5Z$A^ M0[=*).Z4$8$2-;,:?@[N8/D=PK1WP&2E8O6_V1I&=EH6950>$%>>P2]_O/EC MY;T8<9,EPAS-4R.9NA`*XL_2QZ7PU]B[`I9&WN'M4NFB^Z1WNC08T7^!];A' MVAJH8$(@KO=ZYR(M\9E:>9QMT+73A/0`]5BNJ!%Y\RL7MK<->1/UU>!9:2IM M*ZL5,U9_/2[(DZG5X2,2#DG\\;6!%40H`&'@][<_ST#P[:QBV@6,T=>A`/EE MP;<;TAD.MA_BMXYZ_`;#RC-?PZ3T'K MAI*+TFLU64Z]9!'PNRU%PSEEDMQK9AG6%&:X08B=N[HF@!+HDR6S`2$L;/4A MX4$5A^N59P]HC.%%^A%N89Y#(N+D!::_1LFA6M%$FOX='\G`TD_M@&.EU0AH MAG':W\B0>NOT0X*^\\/WIP_#*">@BH//SF\B55,($@NTP4`;+1"9T(?Q5%!, M46,L/+/C4B1JN6RSDPE#)1W.KGC'_;KEUV/+I>B52S(P612;O)<&C!G?:?D) M;F`>)3?-/I3./RHEJP2]V/R"86YL&VJF]SVME!&SNZ0L;C-;XA47_&7+J`1U M:-#&'NS#0.$A-.HC$T@C;^*HYKPFA@"Z?RRZ*E-`IC4N7CI#Y*PMGX><( M>.B]IODI$/P*11#"AGA)]=I*O2%J65F#^`%YU

?&J_(!YJ>;_SKP7AXO[<7/@%,O&XQG]-B/& MH&<=)*F9^!#Q6``L/G''SD*N^@&DB\FA#5SBS$(^.V[(*68+\Z#SGA/(L?RG MZ>82M9RT-E`R-XB\^3F"[6V#FJ*^6LD9G$:5.HNEP6S? M4(24B..2F.0SG15$R/@P,.TB[;B`=K.N"'M/4H,4EB#;@FU](R"LW9^.P*R8 MN.S#V7LB0Q^=#K7]"OFI=1G.+C MG$4G[G"-QTK-,#;#(FY/3)97K(8DN$-W#7&O-G]-"7C3&/V`-_AW%)M"P=+>8VA\KICAJ;0]5GC4[/\!-;^U%0;WYGCP=9WF:YQN_ MCQ:TG=F@(OD8<5AZWR_&`]9\`63X3)7"&X^Q]``"[OK&JOTL81>RE->:O"!T M*F44F_@,(,M8'L0K2`Q[H>"W]I:H-NJ/+:'O MFIG#K<9;*/"U8:A\&P^^!-?H>!&RK':389@CA#D220,WZ;,CQ5< MZB)N`%X^Q?LB17U"K*1Q!"#SNQ9M(*E:2S]"T,CKK0'8^-39^@U`Z?U9M(_+*&'O M5%1T9"HPV]$PFT0]-*W-G/94Z,4,PU+MU@'4'B%M75-%#8>>DHAC,I7ESZ.M M=[!:KLDM8Q;GA^K0P`(C-6N1&E7'I^(G]7HK[W]]"7"53RU6`>LUZ>`'A<]W M^R1[AO`K3$CMHK`\+^G/3D$B?]/DENNO\80D;%:)XX)HS/1$SG5H'$'M&?)" MORR\>.170BA;`?AAN$(0%L9MYS&74._?-UYG.WS^#7D`Z>7A6"&7N4.R]\S6 MYN#J<&2Y=,9PXN>PB9,-4C-Z9B5;3=M2YNTX!#\O=9.GRCQ(#K.P(2(N'U-\ MKHY\A03U`47KBV26,-F>-P36AQS??:XF0EEZ_Q9EOET].SIF*"HF#M-@])DB M;LIL_?M#EFQ0C7/^ST-D4$]6HGS<.KNI2@M:4MNZ.@7)P/ M;%?M^Q/J3[R#FSH6F>`'G,"V;S0`J;W!-+XN,WM4JS*V'E>XQ''E"-*\D74O M-M=1/%W8F%X:R4QUR0@L^ZV8$9@ZHAB'Q+"#(/YG&/@;_/(3\%'&980[;#$% MG>%!^^V]V;)(?>Q0#[K1VR]H]+J?SN?X*96UCS"_R\R/X+O!"#[O`GC:2WH0 M!>*O,(@^9)^<_'!6W>(X33?XY3W5/YC90.@Q21(<#T,P%O;)5$KA-22#=;9_ M/P$%<=B)_'A3>"$+D@E9F(XT#GD$EJ6T9PU?.$DV&V+BGM22TV*R%)0/$*19 MZ7^GEQW8B5/M8H!G9^)F$WHHNU_"HO@KV,9/"'[X1OH&XKOH<4K@%\HKXBQ! M3U@@6(*>RW*B>G+FN5H\PPO99!U[4D/PS=K"@66FR2U^Z[HE`C,ZCSP,I_:) MK>>0[Q((1C.3_>7'O*!;]\G@%""&%_X-XJ3_;-\S>(R20Q";7'5QP59,8\CP MH(U?H^^?42[.XR@ID'#?'/;[)(;%%UA>;;_"`N:/G)<0:,08JZI:##.,FM-O M0WJLV+0$"94B]I4<.8+6DY1!C>\)^%*]0ZKQ#^CY0!WH3:FN@>"Q"JB$HDA$ MZ#RPDW;\TB'LA.4!XL)4YQ/DGI/DH),R&9'JP$M_(P?S'*?VR$)B&[>C2-NA M.S-E3;)4@+RE8X!/4AYN>'P<^`G(YQ9J:JN3$C=U+&,.KTYBJ.V:J\>(+/8: MY+*P9;TN,8JLL(Z_L8(KE1K"'*[<5@?5^\K_GB6;.+TO+N,47I1P1RL+!):] M>H!IJ'O-`P:<,1<7#"5BC_P7PGX<8S?XQ M9L@Z6/&0Y67U8&U\='#BI&>CC/5 MKL<])I\O<\C%.7OFH'M5K=,=JK+B?Y%;+E?;CW%!7C)ZFFZN<[B+#SNQJLE& M8*N>.()IFLCVV;AJ2C2LQ"]A/(;JGH"^)UZ_;WQ)[5U[!T=4::SQB*P(6#;- M18&X,A`>Z(WO(O6.?G+BWPCG^WILT+]ZT\H3D`98BCB!NT)>QI1G`'%TAS!$%ZP9E>_$1+K`!?^=&`BEEHC0/$FG!\B M--QK>/,0Y=3=.2)3NGB.3$VR@MH+\ZP8-R/-BZ'CJOHOR/"EH/A`'TT6(WAC M3V?$P(/)"5=`^>UG*[G6#$I0YR@9MS8Y`971L8"G&XDEP MVW=_2`Y')CR2R3@P["C=_-]G15S&C\[!\_X/J[-LMT-3[`*?AWADN!%N!3"& M&Q^%'.]Y(X;%I&PS^8P$HTU3F5?^P8:Q?8B;7`2/(O#';X)CQD,$HC'V@MH/ MSS<0_42;*'\^BTIXG^7U4M/';!?%*1O,DHY3C`L=34%?LH?&&"%N3XHHHC!] M_H"[9]!:@Z$Y^%8Y!+/U01HR-.ZIP6U*28$_E:FJ2/5"X+,D*HIX&Z.<^'Q6 MOQCZ$"6?H_*0Q^7S1]1QLNF#=Y"`;J@IR6>$,D7[V=_"F!#,Z8&4-*@''HA% MYXYUHQ<`-!$`#E%OF0KK=`1MB-)$11?P4YE1CD@5GB6QQ]*J>$`D(G/ZPVZ' M4RR:U*]K'_R`544:]&'T&,4)]GJ[S?*W183H4\`UOAS$@S)AL$>\F*LMJ6W(95X M::[]^O2DM[D!=#:AT(H[T+3\*`;&-/]1?*@9SC6.;%5Y9N&$*[7SHHQWY)7+ M'9I.^C_Q,>%)HJ(RB2@?8GR+FN*60&.#B>AV!H8(,F[1E+CVXLHPH#7OURCX MP\#JD`Q76=`>#,.?UR"3L M&>W(TH#J/J%%X.OC0@0P>".!&BJ/:'XL7DD!S37/LIS#J?'%`7^ZBP:X,F[) M6(74"RPB0FNZNBB0.EX_1/DN6L-#&:_Q^8@7Z?J/(DP;>Q&4/5 MRIBJU;TBM9LQH-V#@%D.OE6?!:%8LD/)+U&5!].AQA3%`>\QN=I^A'4$WT$,II51.E],@H8R5<'>^W<(U?NB0==07SZ81,KJ- M'J!Y[6I*&2,T!\M4CQ7^#V@^#^D8+^Z895(_\0C6--,>KET!P*RDF<$!%K5Z MSRDH'B`L0;S;XYO`*,5M\.V,(DOB3?NP;+/Q.T+_!]`O<$B(9;3)]HU)"K^# M:$V>Y8S3>U"4$;XEXGNWKP:HF&II`E;N]/(2C<,(J_V/ZN]6?:2%_7Y4/:VK M([$A30Q6^'_]PFOP0V:T'V(('7RE0XJAW]RHO$C]]*0B"OC'9S%7XN=WR\N+ MW3[/'DE-65`G9'RC'G=I1MK(8K>LSV]J;#[L*"X$AJ!_(9"YF6#@,KF?>0K? MJ>T0T(YP8%QSC,"AT25V$0\33QX4!LJA#,"H@*?IYBL2I2@Y?]K#M!C# M@6O3B`/=1@^`O'8U)8,1FH-'JL?J:@_SB$ROB4%Q`K`!J*][ABQWW#*IGWD$ M8YII#]&N0&!6D,Q@`SM)&<]?"YM/\`KU]X`A"7Z8P+5_&9$0.=Y-]C/MJ`RZCU. M`[X%\URW_.AGR@-$(P[';.8%H-!7IJ98(SK+:-B#$EN)`8$Y]5L\[4K3R%57^PQV],!\%`#RDP M-IX`WPT@;$BG"5Q@F1RO12X;#0))U,>#2_F[)T=#8#BE8%%=FL01O33<*U M3[Y`(&A8J)T@L:IU,1:O\VP-(7F?WO$"CJWP#B#G4/WCZ"Y.R#%-8XV?7FF4 MO']%CRS3-C15>1"0@_B>W:KW#\]XIOSD&>>W&B&S,^CAS\98*;Y*.BNCA"-? MZD.&#XJ^Q5%!LK2A8YT"[7#PC.:>&8/WKAF\Q?&.F1-4!\^+OJ/TSAKWJK(D.:A8%5E8[!:*M&MH])LDIS MJM(58C;)&E(-\Z8IS9,_C@76@V*HCS>`%J^/95!?_>@PPD1=* M+:"X%,XU3`N\9:3=:4A_7$ADU\HFTTZ3#(+V=463'9['`9;7JKW4V\(9RB-" MPJ',I'_U,0L8YGT2.,:'8:TT"A,RJR87_9>-^IA@:Z-!5+A4QA1>;<]RN(G+ M3]$:*_?S6;1'?Z')>?->JD]9?K.'ZW@;KZ\/^3XKX%7Y`//;ARA%EV[S:`/1 MY^L'O#MOHJB6XK=*;#R^)D,M?5]=Y3??+9X4F&YMA4/B1U*JH*")B@KU.BYH M`X-MEH,F-*AC`Q(9]]QD;ENN(X9C._1[LG[&?:O+-;'W!'QV&_U=)&N MQ@9]&&=IE'QH`"Q3',FX/EP:;//J> M@LTAQPD8:3#8PSS.?!_9YAS?*HG2$<)]ISF$:EB47Z,2GI;7!!3GT].OU3VY MR8WA:8'[W#[:2&FL!E6I3H_#2V25!\`N("I!Y03.O9_+.`,[`G[+`(]+;&H` M$:<]@]9!KK**79RA_@'C^P?\#HWH$>;1/01Q@]H5<"RDQK-!_\X67` M5BTC602NPSR416EQ'3WC&2+]_AW3H,DJ%`,]'C);U,P1M+@<.DW-R7N4"E!_ M&,I=.?8`9>*?=`3TB5T/S_;'V:RLZ@XW>7MUNR+V*4XC5,;C^[)YCD($\":M M>2//%#F]L7G]+^!'F:!_C77NXR+^Z2^)[\M:?R;J0DE,K;7). MFC10Z9FN!$JVQ>.)5(@5MGN+*+JK7CE(SHFH;*M#24#/VC>-E*"1S1NX,=ED M?/L$#`:)9G?4N@)D[RE?#$SL\%(0R!9\)Q@,+3&P]O?.'YX_9KLH3@6('AHQ,-T8&47UL&6SN&YCRR.[ M=F%@N[H:&+I'8\?$-W6,&0BO;-D89T#!'BZ_,_._,@DH0Y_$N(L/EC-\K-NTS@=0*0L*[_O/'<)ZHPDY_FY!@\A/*FJ#Z#`) MQ"D["="N-4E@>$T/A+1V3&C(*"X'@`/+5?U/S^"C_OH9]T<;0:]OTH.>K:%3 MTP].!I\W;N08ONJ#4'*XPA`R]6/.(+K3CR^PQ`7M=9X]QANX^?#\2X$+WNKM MQX,/NI!7ZU!-C%4XJR0<;40TIB#NV?P!GN@ M:>,/H',"G9=?8LW!3J8QJ$-**@3H"!LD:(T^<>P!NUCR,7HWL#J*#"_PK3&2 M\9H_^0,?O/H8)?CX\I<0Y:[SGH8URLJX["C6H6XOOR\Q#+UP:I^?VT MDHN832HSFA%)E(_Z;J%G)`&.1`27@B&?X/000HK[!['1-7E/6";O76+E([!. MHJ*(MS$^*:Y`_U=`]"&&$]CT(9YUH_8&Y;=-EB117G@^.,XEWA53FEW$>T]K M[7%9I^LR?JS>735[MJ48C)_XI(/9$!'%;V(E--VN6DMC5%@UF!C62Z.W.4&9^,Y^)7V=J MHMJ$P4(@]$6#N1@WI'.S%@T48YM2O:`HZ6+1(#QFXEKB@E(ZA+EH$`BW[-02 MSMCEO;:H^VAFT4`Q&+^6D`YF0[`4OXF5VD&^#\K*)!M:5"NT<1:Z:*`*6)%X MS2,`7[(D8PJE:@E\8W\YGX=:8FJDT8+`1"7S28BW%#.C=KT4`QMBG5"XJ2+A8-PF,FKB4Z M\H6^:!`(M^S4$L[8Y;2VN$C7V0Y>9D5Q^AC%"7ZC]6UVENUV67I39NO?'[)D M@[CT(2KB];2(F./=50MJWKH:-*>OVOE?L5&NG"C%(AF]\@!OL,\/H/7""*[\ M0-_Q!!!7[\HR"U29YDA/E$(ER$`2PD6UXEE/PNFW+W#C\Z(PO!-D_;+0RCIT MZDCQ:KCD\X;7=R\6K^Q*S`]>7=96WT_7Z^R`"[][5"*FZ,\UW,&TO,K/'A"N MX$7:-XC3=;Q/X-EA=TA0@?@(S[=;N"ZOMI7Q55J=VGR5HY_@E#QU/#X!V6&+ M;0WGH$5-Q7'VF^C6BBXZRI,T^^TC$?P.NB!@T`S("CC=8%GRG]\E0J[$'UA8A%"J5EPO]XMKIVEBTB%6,+R M4"J6)?%5^!ZV2CJY+LQ12IG(W#*L$-=AX!N)X_WVG@F@2BBA.NZ%"B<14D:[ MYK#(H2JALF:UC&FC*5Q3/Y[@:7NU> MEA/&>14:MO]A=7RZ/G3'J8%9&W_DK7O1%=DK\L@N?YHRZ^P&2Z)!-ZKODE[\[6V M^B&Q M[8'+I7:7L+B.GG&U_BF*\U^CY`#QL:9)5ASRR?1#SB^ZZ(`:@M3@"V`<0(=%:^"24WWIGBH(RIQ'7J$\DCH`PKM#5 M"92R+4`#_`CS,L;S^A0['Q>HV`IM"58.U?F`2_NK;;NG\P;>DZ67L2Z+[!I% M9MOI44?4O@G*<-K@D(7IM:HN88)T57-17_7,$.%P9M*__(@3+/,>&UQCQ-0K MP`P#A*Q,M!#I=L'?'`U$F,)I$B3NQ/)JNXW7$-\:V^.N4)=ZN3;UK\"PT0(_ MMUT]V+-"LR%/]UA5'X/V\T`6W&+6^C5['"Q8\UZGL+K:!M-2IJC/7C\ M=,'CS$I#.N/L,?TP[NL)[5CIR-!-%F'[AM.3U-T4MA-#[N:IP<3K('-9YYOKYD`A;04ZL#"@S1VCX6Q1'%J,9;#OH49H$_; M-"2!@\`2J.[9]V1O\(!X(-BF#-,4U0#DI:59>Q[%,H=?6,'[`X"5G*8!@'?'"0!1/IL+``\Y[!)&**M^.I2'''Z. MTWAWV%U'SV19_^-A##Q%KW&N$WF9H8-TSBZ(.NJIDPS2M:G-UR:46CXY`5_@4PENO\/D M$5ED:?FP#'Z/<:5*QU"FO`]8VYD[N$8W3DI(S-Z_)(AJ)B33(`TN M/>$7<3["_X11SERG4PZ@EJ8&`5QPFM)C)^EJV*XVJ?OAY-/6"ZYHU0?0FVIP<]SU;5H8;`VR&,M`QJJP*=9@Y MFN`)Y9[RFA6PUSGMYY>'6_U\9@&YP>4R?-HYC+;E]('\N?YJN:SO[X+ET_XZ MR66#9K7IW8NFFLLZUT4H`@5>JHK`1*B:'G1AE/7`'\9]9#);4"=;&5\P>C7S MF1W\AI7/OL(UC!_Q:6&B!V%G!5'(;+0@UJG/[KG]'$=M6X_]E)`*VR([[_"> MW9V'/B7I$*)803VFL=0D)!`R.$^&3CB!T^)IFAZB!&PK*HQW^H-#NL%GI;74 M24C\E\P%G5SJ@`T^LFI6%&=1GC]OL_Q[E&_82YLLPTEVG!H:(CVK!Z:R'"6^ M#&LG;OULA1\S'%P-A7[,X:103##T$Q*-[6E$<8822_)O""S-NX![*HTALSXV MR(B5UPAH0E#0RSB%%R7=(L8T!;W@JVG+T6P]MZHIN"&\A:#SM59F2 MUD)M-_&Z2\F^V-)T\2LK1;X"+0_AC9.RXRU!*LY;(P5.,E3R_>;'J_P^2N-_ M1?A4F;,L+;(DWI!_G*:;:P1C-#LF_[S:?HK3*%W'47*#/JG>:]/U#C?UJ.^T7ME2>IHC:WZ$4_`(":( MTLU`#+$XMG%!%[CW7C-44^&S1$APWX65+7*8T5$Q_4Q(*J450^H:/K_-+@`L MF>9X:>'8RALO#&6N5BR7HP$40P2:5]O^U_EP*.(4%L5'6*SS>%]_X=/U.CND M>'9ZC9S7,2R4*R.3;8G*)#-MV=%4D[^#I0+*4!=GR*R1EGFEU0F@RC'ZN&X& M]-HA=5C7$FB:6D*M991N8EFWP&Z1PIMH4D+NCUU+W!1KRY:4I95Q"R2_.3B7_1$9<'^`VRR' M7^$Z08,8;^-U-5-OKQ=?8'FUO8V>:.KGLMV^J+II5Y_$+G\?4\K@J,\"P7'2 MBT;%^FV!N'HSS!V)`O)1&)3<4KQI=0O*Z"D`P7/*P,P;N"GB[*+YD>:_RD[7 M3[621%![OAS-Z6JG06O#]\^=@+;-MRCNVP*U"KIF01?WI-&I<=,]FP*_+(%( MUNVK9+DDQ@L6K=#K7^$W,U7PJC2D5>'*->0AMZC\`MYJ6,E.FDX@4LTV[RI$ M!6?SXG%9M=1ZR;-_K1)$HV MJ6C6]%CANYAXSZ=V3^:)JTQL\K!Y<\-B#_,XVRRR=%)!IY3.J<-=0LHD@LKI M5?#T<5&S>.:.9/71K3*=@#H:Z(?#`UX%?&47'4$+X5<829]=J=2ES=6V*VXN MZ@GS18J^X M/2S8O3L+%[UU)2SG5<1EW$`P3DXI?;G0;^\=K4C@DD(YBU(%JO#[M#$I5PF3.N90M+A^97:?$O+4J3Q4>8WV6O MXH)FGY-2)AJ6,CF,DOA?2%_N(WQ'+`6H7Z!HZALTB]F7$2@>T!_%X-X9WLN% MCZUZ%1_;>']QXN-_DOQ+VM#B[UFRB=/[OR%RX.]\E?9V>^1Q@2Y]1/],[Z_) MLJCBQ-A4,X+)L'XS5K*#J6]O9])KH'?JXJ_=J,SDMFL$U*T`W$Q]':>`_H:Y MJC%0M0:JYL*?U1ICEE#S#7-8H/*ZK8F5_4C%0FUF.KM\7*1JX#EH3Q1P(5A@ M&2AZ&R!"W[J_',*KSBI?*3_WAS;^Z-_1$![-"\\>4)OD?:6',?7?X'D=+'YX M9;HI`!XMTY<[5;,_2[,_00M/>X.=EKF66I>3L:.;A3E1:6=S+ZO*'*0$!#[9 M\J`%K"E6--UVWI]U1>3.8#WQPO<'LWRACZZ$+@6N9F4O4`Q"GH;YD`+\;F*$ M@CN8PFU<5C?Z*SI/9F*#19A78NO![\B([7KJ5>W_KP[O^0QW=]V+J@?S)[;9 M8!)$,S.@7.S634Q'J-%%XD%Q:B8&]2,5U37PK;KJ^W!/T2AFLK\XC6]3ZS%I MG`'#0EXRA(^`3PG3`@9?BHU`P[$HWCY$Z2W<[;,\RI\O=OLHSO'^ATNR?GJ1 M/L+Z^;_Z$8&OJ("_3['\7Z3G49XB?<=/$;0/%J(Y0#%XL)"FL*[:[,NU_3;U M*>[J=S&02!QT5:`ZUGM0"UB)V@%M0Z!K"51-G8!>8]VS3UU[>*[;M$BV'0@> MU0Y`(YT1-/."?XIVVVYZE`A>U0C*ON_T+Y4>I?`>[R$7U"_'+TMM9?46M_26 M*4RO*F(?MR]01]Q5I]7CI]1I.NU2/1;#2UHB2&M%KW(:160KRJ^.PLM,U4NLH?`(;I(BT,_R$*%Y(=Z,4SR@ M&>%;E(]V(.ZFB2\+RNP4Y`G,'M/818JP@&!PD?ZO+$[+7]'%0SXFD:(7*VVQ MO,Q2F]\WPVF*V9@"@QDQJ&FIL<7W%H@UJ,T#8[``(&SF2B&+Q5>Z,X>G/A%I M>`;A#)@XI50+%B#[GJ)N/<1[#,=?+\[!FZ@`$3YGPAX:UFY>>PIL8X>A*GIC?@*( MPPG`"M_Z!$9,,6C8')4%'(NL3'\.;_UCU?:"DFW03I:1]BU>]]B6P!6^)+A* M9Q>[@'68<_##(.3-[60#RG56E#DL46=QOSY4#P05'^-BG60%FJWT7N8^S$": M89I\-#N,'N,U>Z^9J^:WSA&!N4%7M2?A?K5E=N@,&F_0N8-O.``@$7S?<]9% M8F8*%2,%F1FMIR?+(H?9*5-('"%+9;M]DCT/^/#2<<_,G>$@WV%>19C[$NW@ MZ5,\?F:&=JG)?X-+>K2EM**9IX81.;SJ&Z[POP#^)_B&/_"='F@_?L;[T49@ M[EGT`,H;-_>@^YCMHCAEP&YX<02\YJ(1Z`U;,@.^-J88?K5I'X#51X%`<#00 M$Q!2!VH$P\IF"D3&.#J$(HH%\QQNR);8C_%CO('IYBN:`%]7MY&B^\D-!@67 M!K92+GI@5NB5)L3E6N(`7R;`JK6J=BN?@,808,L3T-EZIHD*'+(YPS6BE(1G MCVAA(,]LD>T"@+AX;A&7HTMAW5VV!CIF=6P?=KY4G[XKGV-"574SF[PYK9I4 M;9F]WC2'L2J'LH&?-U@,^'.W\U,L6>"V-NX6-7/F\)-U^"$`ECKN=7,Z:%\R'+\K"57T%C&5&F;&AL$.ZLG)N6.TH8L\B>NT\*T,@&=34BD M8`XT@QX"8%!I,O9A$<8ICBS*IT$X#26UJ`!5OS0J&OR@<5$<@IKJZ")+3H*- M85&/5,=F0F;N%X#/OD$EFF]MH6E:Z/PJ(K>ZF)UBO/@\O(1PM9-@QCQI93I(\S+^"Z!M),&Q)94M1Q9&F0# MM0\FV3!N0)8/0[\)']K+(3SL+S&J#%+P($`EQ<"!10M'<%%[&X=2BC6"&OQN MC"%N\"(!F>1D6_`.O/_QY^9^%5CW$%7`-,YRD&9E[P6%K>LZ*[QO$C,$.-:[ M*0*&G-F7M=L`73]YYU%"(*E,;@!!?K+Y13UB5]NS;+?+4K*4QLGI M7'M*9F?8&V,/MS_FLCRK&3D"T;U'RGW14^[*+(P;;+)C3R63#%PHA**ZT6GE M!6"__6RI+K"`,]37$=+(30:P;YZ^O7L&?X/IO]`D'>$NQT>ZXB-;V[)@"WT? M#6X#@]T(+AB%]DH%&SCLSNWH3G["!W>@_^`/=]&&8+$H\6:K^W@-HB2)B2+N MH[Q,87Z$*)0H+H)'H=(<:9\5<1D_>H0AFC)]0#?TDW,+](\0P8H>XTW9"//Z"\M\$O&8-HU/&@X^WH!3)+#OC5 M8N0+7>T)&J1J8<-M<>MH8VU9D`7#OX.-^MU<%U5%R%3+G'E#O1'I@-L`;2/D M"5ERZ>T=;@?T&R)/:%3'@E=MU?LZZ]9"%$/3;!,(J1UR(%(6_B@Q#>#G`$>F`6C'VJ@3&?G<7L^7E:\&[)4Z/%JH$2K/_A2N!G^D@ M/OP:]?YS5.+SKY^OMNR3L3D3O1E1*%,XI2C&='1&W\U-N]0:EY,\E9BCL@9? M)9.AQAG7-P&_$U,7@U09FP]FBCPI!*,+3_"D,+PK.1AN3+?@E0\0$/B'^IH& MSVR02==>^>`OQ5YM^2=R2YHSDN;4W*@0L'IC-@U26I'G],29EM@0;4,[F%MV MW)G4%""%P<"Q%YMJCJ%E-9D81=@T/>`3ND&1)>0!O`]Q]CFDG?QFT"6K\`;Q MY5.SKV5/[5;W9"HYQ],P\X1]-*WOO`95B,B.PU#]ZY`/[YZ!'0Y?98'')"XS M`(_#`8#6C@`LGWLL0]A31NJM'9X_P7R-MY7S\A#/GI9] MZ/;FZ,OKC\%,PVA&DJ-4[W%6Z=_^!ZU90"SD#CV=>Q)HH?&-YL9@F0]\V4L* MYF&&$\!95#RTCP%7:(/U=;+H1)"7A;;QQ!3>I!3>-.*M"'2*5XLN(=QY+5P+,>H M%P[[$/I3\PG^)0#BE`3;N+S,"HJ6CRYT,&\OZ.)ZU((VD+MX7.0V9F0GS$6Z MSG80O,&?_-#?)WN=Y60#[6E9YO'=H<0W:?!@?D'PRM(2]2;!9LW;5+T#>SQ< M&?N'GD"WOC[`JNE15GNH3F:#EMIPXP?E\(#']8`G>,"7,&J<9]F=WN$'+->4 M>SQR]EV6%]GK(E:N/]HU@;`9+K`%WJO1O9GAK1DTQZL-_9>]DJ.?*0_0A#!\ MMP&/%"$6`+T^/-^BMNEK'[(>(HKU/>R0;-HG2S0;-#2#:#U_/M5.`#8,95%% M&@EBNC'A(R)FF)F,JOJ%0)),B*8;ZN M=0Z"Q/25?RVK0@0)0OL%K^DIHWL,5]/.[^!3M(Z3$)Z/=`1.SO35-3P#2#R7 M<0HO2KB3+O8F#J(DTW.PP\Y)CRPEE'X[,RC8N8NF5-@2$--0,\84!&(JLH`C MHE_K)T$Z=UASH_^F(%?O70MXAYH%G"D+O1FD!2#J7Z#TXEC/5"3DQ-0.K7J] ML"3>50LS.(0=11-S9!,H@?K#*Z;.%`PBRN"E<#%9["+']`$IY@%4'T_"EE]R M5.6Q0(ASIR%@$!D_6\,"C%`6_Y!EOX/'*#F0_8;;>NY&T!051;:.HQ)N\'&3 M:_3+(`O\S-/1`$LUH<\'5@!)_#I+XO6S\G(@PTV4W"=N=IC&Z)VEI#]M;0;Q MQD%$Q4!E#[[5_PU_^8^%&#$G^5@3L7/D+<%4/R!U,]6S@=6E3ON,(5(Y8YC' M9`"91#F'*&NA#UD,H M_ST/2VR<],E6`N@W-(>(G;_<=IY0'AJ1QH($ZU@`$I*N=91A'1MT`=#N%Z*G META.96DW]1#1KN]AAW;3/EFBW:"A&;3K^8MH5YF"RW`S'04)8M(QX2,B7>)E#'GD]T((**DV8*9=4IH#F3MW_XQ#E"%?)\Z]:^I[*U%QYE]UF(1F" M2MB>94`;K16A(<=7P:*:G*\D.]TBT6B=YPR0N-I;>`[1AB*K!'0$1G<9XBM" M"NV1N,GG]>_0^UR+0)/X>FK=#\?&?V>U(G\&\"J[1IX!;$$2OO5,\[/10%993"" M&6.X'`*-G%:';S<6EUEZ?POSW1D^W`75W,55CB;@]WDT>?Q#S:F!IZ23'G*5 M>J8):MFV.'B7"['JV9T`;%F]NJ*U!5D.&FO/1%C9OX$;TDO+M,2\<)!K= MG>P,D'C']O/4Y9NBQ]BTO&7QF=S6[@]^[#GX]]($W<0HV69)$N>]#=RQ# MD3&Q<@1%I\4)^HWC)"93O:OM+RD:[>P^C?\%-[?1TP>8PFU<%N=/]9%UI[OL MD);%-2*U=V&U\-6\!;MOIM`.0%FE9.0-L.J!L"74N8]4U;Q*UN#7S# M[8&Z0=^S+%<$S%R#?"+45EL=2/Q+UABCB\='+35D9^AAMXOR9_+FDOL2K9-C"[(L1#9<5Y3YZQCM(BJMM4_-^A'=X<\E9M(_+ M*&&^,'F.:UOIJ;AJ*JIZ+W4K,*46>1*G$&C569,70[9K8MACL$96N8)+&!40 M7-TE\3V!=5&]1JRY',HKD6>A+-,9_;'*R$?H*T:0`)=,_W^I()[">[PWCU<` M>$!Z]91>C/1XCV#:83X%&^1!,+RN,9P0B&<=Q%\*E-DITSF8_:2RF\-=EJ-4 MC/&+N\I)72Q32JJ:FAIC+JL7YE(1I04Y0DX<1ZFF?YUDFW!8QAQ;*JL$2*!P M:.Q!YXQ#V$C>/IDC\,;P4QWOT@@XUNM]#G?Q8=>(.=;R'&[@;M^L\>`)V#OP MYQ__'>PA^EF0"0+`(RJO8[S,7?0!F&9E2"6+'@+9]UA"QJ#9-08;"$0E1#5' MP^`B90/&&]PA_,3MZUZB]3H_D$]">)^+05!)%`>&0.4T^2.P/J!Z[_0^QR.9 MEF=X@&&^C_+R^4NTHS_6J>S7E06R?KI$4^N?=L$@W1R7>Y)15OW/`;X0ROXF M95QDLX=L0D,Y]P$G9X+1)4$+B'[W!S1I^`@?89*1YY;.G_8P+<;0E[)MBJN4P*K)X!J"U\TTMFA#.E@1C3B./2IXXG^!BNDJR@ M"-=)`QQM.I/CP0^['K*`H$`$E_$,II*/C``;>MY2J5\6!5GJV4JY"$*!#N9= M46J@D.,<_R%**5=)!KI$H#M--P=$GL8#6-EZ7T^Q!\!9XF\*@H$D`_IC-?(> M,HG`S&,X\GVRF`1D'MN1\)=(`)5ER/+/?`)(&3TRO)L\,10"XMR)OAG@+;2H MUT#:+(TW@;5`]+TZ,OK>>-ACV[!/%O6];6@FS6I_H;Z'>_:U"C;D MB$@%E`P-ZY]&CH:N0.A.\LU@<>DUO@;D9FF_"="YUWYN&<^MV(V62C;J<(7* M9U)=XV<[SG*XB4MP%N7Y\[;>W1M6=2TJ;V1J9E;)8F%XK2B@\BB'7\K*#:M( MI!0'UJGTE%%);CB>;O[K4)3X+Y8.B2P[46);ZD)8U`=MN>(TP$4UTV_5NPBZ MJ^'(EW!8,X7??X)_EL.`#.[Q8EK_3,.&'*ZZW<(UV>%T]H"/5CD.I'"TTBQ6 MW*IH'J]+N+DIT>3OES0NBZ\WOS!U5&C;4U*.K38WA/W05U->$WQBL#U7W65` MK@-B`-X@D^*'@(15/,Z9TG!,"<-T&5+&"X@,GP1C!4MX*W,/305!TR$-X"%0 M<^AA[T$.'#^F#W.Q@R`\A4&ZXG2]/NP. M2;7U>1NOX^E>&EF'-EV+'33I(MLCW<0MT0Z/+T+W56,#&B/PIF<&:COOAQY) M(R!3'Z,QNT1^?8IY!YKA^9-EO)'G17KPVE0?'R.ZV.IM%5_^=)PQR^(9,?3: M4$G#:]FL+DO5+E07BOZ&,FWB#AR3"/R)$LV6#7>+.+`JF[/AL`AY5$."K`S. MQ()+N7N$Z0%^K`3@W0"N3Z@$TJ3.W MQ[KR.J-='M>4PZWJCT#/Z02T;J#R.P$C,^3JFZNS,9;IC_J8X:IQ^NP/'NJ_ M_6PT@WA&//HVJP[>S?$!^8N&=3?"+PO8II?[?$/['0/:,'Y$0X-W._3.'XSQ MB1DDPHN$/+-:.V[(*]TAV6<%BOH8-.;?TS`/42W]0J6<>>O%*ZZ]SEX.21GO M$WB>5'?Q\QQO;2#GD8@G+F)?]IR%YVN:]^)^&I^I<)M4XC@G$F-^4GN\W<`$ MZ5-.7EW0]SL!'V&QSN/J.*@`=\O/`1I/%J1QRM8#=@BN%(2!X?0,HN8(%^_WA-W!6J&`LP]LG^FMTC;62W2E[9EI M;&)OF-2,_IA.5]-F5%@[]J:GI7`?SI(%`8>+?-PPV3=RXS'.,=(LIPRC@*M2 MPP1RQP5DW""SG\LV8>##F%(8**;,S`:FZIZO?PZA,V$4'OTR>%@JFQN2W M/RN)4%9&B5"$Y(8&M;RZQ?&"6@;DC%#W4[D>(PN)0G*,.MD/?G3XPFUQ=)26 M-&57\27'YWV7EO$/A:C$F+Y5T[9VHD:NHZ0$TX*<&XR7YK/G*"F?%\-&_D*C MQ?%6NATIO80M.>`_=P,>T"(S;YSX]_9DQLE]><0\:Y!^>50N&3N_C=Z:F?)) M\CBVD7%;3@5TU!]C3"9(%!W@-[2:XM+2L%K)[K-&MY?M_[JT016E_QG#ZE!V MXN+WXC3=_()^$/+^-?Q:&I8&R=@V@L2WU8.Q3#\TI4K0!`?97$_\XFG\1HZ\ M?2'KAP,J@V!1`.SH&?I2XYLI#<.($CR7'C^4P...+#=1`J^VY$DK-(Y%C.I: M,HY?ZWTFUS"_S:.T0+U$GXZP.\^Y_OU4G;7X-:^G>H13;I/-0,50*VQ/WLR$ M/4[`P`I,[&4Z8WPD,MJ,3IR!PQEHP]1>T,TGIG7[^O)H[A` MV+U[!G'Z"(L20E`^Y-GA_J%^^GH;IU&Z1O/PEX1GUOS]&!%M=I^G/TR_&V/Z M%<ZK`O!_S($/K'0X1H9R=KLM#E-"%DF/22"351`_PG%8U99$>F8-N MFL.J^?0$5)^'HH"\T][J^'\,6?J MF?ZHN]>P3UD.UU'!*/>X1B,=&QL9`32]98.`GC0@AO3(9=7\.PP\,\9J@FCN MF(X0/;2=8MK!T!N;D)L:=S*Y;M-9Y'[)2WV+)6*[(;21W%S@CDF>V;P3PMO!CV4Z\>[GL7P;?J MH;?5)^M^4&2(HX(W"8K[`\AA98GXH(,6:'H>*\`7!_R M&&\1]JTF9N">&<;<6)FT@O;U:\%\-%CWC00+YQR/T,C%KGL#I9>/(N*L?U13_Q2ATW3S!8TUXW+O1E?UK9AUA>D& M)J6&N08,J9WI;VQ*_@SV2T81C34WD,A!U,&A>J3D0('?KEDF_1OB12V?P6BF M<9Y09-02%R>Z:JH=FM1:H[L?]=WMLQ3W_FI;I8G;Z*E^#?L'F,)M7$I.WV9' MHNBI&:US[/'N,`;NK99WBQCE-%3M3Q1_YN'GK,-KK+D86,6>OJ@0(:XMYTRFZ27XD-P+B?Z$<^()O!+CAB%SJ=,@2 M'RGR([PK+]*BS`]DPB[.BB*'22)D.Q@2"5&/3*4[3CLR&L!T'R2URRR]?XLT M:@>P/>@Y!)S3A)B@4%021Q-.LOQH-/0&/4LIR1("QQ.SI,5@=I?$]V%-MTQB M39P!K*#-C\YO89[##9JVG:+$3Y9F+^/H+DY(YI><$LV*0LD(2E&,<75&W\WE M#K7&Y>BL$G/`\,:5K%A6SJ0H[+D'G6[FH)"J"_/A3)$*A6!T_0B>%M;RFF=V MC#-@$=^G\39>1VE))EG=2O^F84Z)F!-US$FZT"^;)C(YU2M1?&3?\^T6KLMV M+H@Z_A5-SO'[1M(UZC6IL"13\/Q0DSP\)Y0AU9G_+4QEY%D]D!&>&8$'VM/Z M]^\JXA!@&"/@!*V!48K\:"-^HD#J$6DRM"CZ6,K<`;%HG,/S(5ON8/D=PA3` MEEXX@^>85S)W&TF2+Q\@*,JH/*"$\=SZO[).-O,'PSLO- M0W(>UX>H@!N\6`S3@O3[-"%]07]=;;N7(U_#/,Z075$6'YZ_PGV6EY=Q"D^? MXO%KP5PU-ZTE+#5G2C"M_AK&:A);O9127#N-#VN;N@U0-U(=_??V#C<#^NV< M@*XE[-A[R7C5&""MG>`SFJL&`6X1?,-MAE,'V>4@3;5=L'ZJZU9:I6J_&YE9 M;G[@;_RWT(:E3&!V^[^%[QV6YJL\!&"R1:OJ'MKC`#;88TW#I1X*,-B4/;4. MY]$`0]]'O,9GIQU;4FU^>THNO:QIMCF+ MBAZZ8MA:+3T&X9C<*\7'[]9*L>Y%!+!Z/."5]^;0>,3,]U+/D8/I/\/R(=M< MM.?03S^%\$NT$RRWS@XUKTJAC3'MK5 MAT%[\]6@%V8X.Z+H0+TGG]QU("Z!2P$%--+$9P).DN:=OSRI/6#5['M,74,6 MO[^T!NJN`BI";K1>X[<_^G_#HQ-T,M]0>B3X-/Q64N<(13-'-&6(B^KI?UC@ M%[8$\"8<-]@43^)<8#.@\D=PJU+"2;;L,7PS4:)GELL=I=M]O!"R94Y@-^)D ML"'/4;E;91Q?!68&=#/K:0_7)=R<[K*\C/]%A+@^T4-V*[IJA"E?Y2.8(J]J MGXTQ6:%A*5I+QQMRO'8#?;_VT*J`[]HH8XW&_YF`G8J!;""J,H0+>EOW/7QA M?WRO`JEPO"/'8D1]^-=W*OIG9L2H-$WO8\R&ZBFOETD$B:K5#Q5\9,Q/<1J7 M\#)^Q&]0;N!1/8'&KV5E'2?Y4>QH2"%D>V@J&TJT)R,$PC`#]E?6;XDYZ.R; M!Z`#*W*E04/AMR+@)J06^=.XK(Q5+Q0^E(<W$SO04)BO9*,AY]%T("P M!/%N'ZW+ZA`J1*`B2^)-[SF,^T-R0)Q'_P?0N!T28AEMLGUCDB*QZ/:#X(,L MTDV4>W]'^)+H+BZ9%D5X'Z44ZCNJSF<5H1 MG#[8^A^'*$?)-GG^%*H.<:\/QA#NXHJC`?OA.)4`A%TXO`26"IA/?*A?&JXS];-J#2 M.WJY2!<7PAZQ[B-1,IZ'[%YV^>&Y,ZE7/D^_H^D7^9];U%%4`.!"0/BDH;66 M)DG70DN&5,G:;V`J@=OHH(RTF6]W('^L4R$&;_2]>Q[8U:T`TL))]1^`6R+3 M"-Q6_WE*\.8CW.=P3?9A=:S[(12IM<<^BB#;IOI$M(TW2)-V^[(29`(H6%^+ MO_!A**ZZN(OBNI)RN>_G3+B%W3$BTX)6E$6YX*IR:$LXIC`_1U*5Z*0NH/SP ML^12D:C>Q/%N_!V^PJ+,8[S_]P:?(8-4??3)+VE<%J?XK.>X?)9<;;+7%%U" M#3=E4E6M_`I&Y_96NBDMP&8;[M^XPP?%?[WY!42U:5#":H<<+*VU246Z_!IM MD:G(+X7W:JMZTB76<9!^O#S(/C6QBPE(4#+YG7Q(F@)-6P&OK2]=2,3KET%,ADG7K\A^E%E5G49`R>FO3$"K\U[Y;V1WPBO5C_DS78GPDKI:Z68=ZF0Q MTJD#9>E9K3(])*>SXKCR\]@%,,[2?T)L_A+7"-"/^"'1!#0?XV20[7H512'7?7ME.L&PRUQ"@IC+1G7/<._ M@?D2Q%P'U2325+O,HF5T$[0[;I^H:],*N1MZ`MJ&0*^E150TIDG&E6<[C.:H MMJ$&^7)^].IAO9Q:N(B,"[#O,+Y_0!/_M]$CS*-[OXF`6K$#Y+$$P%&T59EM/J96II2K98?3!65U`:D%*2B=\PXQ.&WST# M8A#<=DCFR-)X*X#!E()C!RJ?A)#Q08Y;N-MG>90_7^SV49QCGE]F18$?A!\> MN"V>+LP/-:'7G%"&^#?_6Y@BZ*P>R#!X1N`!Q5M_T`4`5803REGW(5;O&ABE M"(4VXB=*HAZ1)C6+HH^E&CL@%HWKY[A'E;*.%B?/Y'2:.(?!'"?CFRSBVC<8 MNKA/W<75]@P/8EKFI`:_VGZ-"U1?X/_]%*U1ZZ*,/2/"*%$K13`B,#/Z;"8M MJS4LUA&5>*UXD+<^#=S(N57(Y017WO@/4#D'FX+G@&XB)O.1.U(0A4!3X0@: M_5:RJD<2C'-H#A]A>H``HPL4\7T:;^,U/EAI'^5EBK[.RX2[*&5Z`[S#!`GO M<<;^"O?XA1CI_>E=@?J[+L=94I#JFF1ZC!:UK)BUV=`XI64ZK^@IH+X%O MS47?644TB)GL#SZB"\.ZQPFWN#`KYR;A082Y!DCX M6"=9<`P*$=U99/.&]R,/<;O M!FO]PKRU/`&5%?A6_S?80L,D#F7%WPH272:`-,[R+UD)B\]P=P?SB=@SKK?" M/KFNR2I&>[K\F8;E<65LO:H^`N0S\*WZU#OZ64.3"7_-,:9'9GW\6AY?P\6P MUC!C^7L'WO_X,]C#')>[`/W\CQ`1%]\7*2H(I-A^>2//UC.-L7>I4WD,B]-K M%!+F>7T>!T.QA):M=G$L-5$N[(.NGO$:X$&>[;>J+H)3T%ZN=^B%HG?B@$&-8(8T#IRH::^CL6^B0[=O'@1BV=AK&C&L]_2"MIUS+@9XR M+`VP@]L'$WK*:D!$"[I?0XH/0>LI?V`SA1&@<8/J,.:&8\18T%.CP.GIZ8?C M0`A?/PUBQ*%^4@^"&4LGUZA138:1'ORY+6MJ)2LV!^UTEQ7K@#'/L.>&ML!*O6]I0]%G]TB5^C,;8F8/Y=?BU(%!%3E$E='D M@$";C#",JV?S6A"IX.+IZR`5!\YBG/8;^NU?Z3<+.XLGX`**%_R2X/+Y(BW* M_$`>[KHJ'V!^^Q"E]<$&G[)\"^,2;B[2ZFN:JFWFMZQ;^LQIV8^TSO^-/!5. MLSIL09%G],-$V54U"WKM`M(P*%'+W3E/;>,@3I==G&F06#]Y:"N(;F91[X"! MQ'/,ZB59-_ZETJ\4WN/W>EJH')Q2Q6;(RJ"#X@^_Z@/?#NMSGO[&PI>?D0R]"F*X"67*MT=>[938[^[1#A'E5QE M2*F^.4R>+T@$RZ["-QCCJQ M(O]^&6MC#$(Y2#A<*EM/*,/67:2,16I(^'5Y@`+BMK:NVC[^&X:A*)7[XC^/C57?YSGX>!N(BAV MSWT>?S&B_=O[!:Y]'(EVH]]^U1BU[[Z[)PJZP0JZQ0KZ2`CPLN[+'H^P=O1Z ME=87)ZU*"T(HREWV*JXF?_W!XO2K>BY0/3VO'QV%>A[#"M27C+PY"VZ^'&BG M$+ENU_H*TJ3=0#,BX_>1R7?5`YTW9927/G+>M.<^8>J,TXT>;>/H3]+\JV:YX\4+ MUJRCFFM_S9+D4Y9C)_<3;DKC[F;=@\9#3TN47RKH6WF,CGO-4?VNK&HY0?4O M">O[?0Y^N.8R@;"Y[BZ']/K@-)$L56H65`:'J3.>"^).WL`WW"M0=\OWN?,O M2NT\ULPAZMU15<_A;)-6[Y*[2GNYFT'4?]4EW14+=1.(0@<5[Z6]G/TA,_3` M97X,;K.R?,^<9M*7()V__;R\NWO+ET[TJTO?$WR5S:7(9L>E5^$\?N%BEKZ6(%V=_JSZL@.Q_L93QG=TRJ_/ITW9'JIK_=<4O7S9>UPNYU M`\N`K5"]M"])127W(RUB+%/MCF*3]2GX&YV>>TYNU/JT:-QMH M]J;_.D%/A"9=]I%R1YU85?]^"8_$,OCD(!5QF6P]PPQ;=Y$Z%BDAX5?V`>J' MVUJ\UJJC/_(\%*5R7PT'IU7'5[^&LY=_9K\<5\#+O:$_\_==4`T=ZHU]U5[V MJ_"7<^]^+O^=Y\'@=O$K=L]]'GTQHKFT6<.1**;?><=+WZQZ/,+M>X9S%-*] M@#E2V_G3HCCLJJ]]FFX^P_(A0P57=O]\>H=^GVA=FIK]J+>H.Z]1:=%/\E7_ M33PE5:6.6DB7"NV;2(.]F]>]!D&4;D"O2?"M:72I-[5G<%(_9;VJA5V4OC"]6&BY>?ZTAVO$D(_Q8[R! MZ>8KJJEM%IN\]FR4FO3VPM%ZWN\1FLXS^NI(Y:FMKYI_@><8)AOP)D(%(EZD M7J-02UVB5N:-'8&7H*H-<:[A?GN)UH-:;6A?O%HJ2']Q&#U%S"0#VSU3Y`( M[#3K1/]Q4P'(OEUJ9>Y`3)%Y*^V-]/UE*8;YI<1C$@Y<.K;\3N)M"&7=XOG- M+>2.A^$+707\&A>_?\HAO$@1V6%1VEX%Y+5G8Q60WEXX$WW>[Q':*B"CKX[F M^M365_C3MUOT,8CKST&.)W%'NQS()9"=Z;D$9VU,SFG-6IJ<+U$E@EP.#$\B M+"\'XB8!;A,TC1[;>F`@@N-D/3`TR5EH43G:LOEKEJ!H25P^VZXNI1JV468* M&@XGDTC]0@$E%%%_'646?C=L)IC)SOZN[6/+-'+LM9-R5)3#1N;AMF\I!1V' M:(6[.W()VH7+XYZB'.VT.5AM<5+7AJ\N"ZAT+^,47I1P5YBJ8"HJ:4^G6&5/L9?+W:D!%*:"NRS(D:*O6@& MO:L95*\IK/MK#_`)_[W4!0*[?#)==!\IGY3>JV1A1=`9C]X;6,,#WW`\0`(N M]8EDNZPS_6XA-ZQ;P-3T<_04[PZ[\]T^R9XAO#G<%>L\)D65R5LNDLWH3F.% MS?B11*NKRH+6#&CU M,@4BC!L5(>H$GL9<5_<<\!W.;`M@0_;^C.8$[*HXKX0WA<2CI?P"BK8OA]T= MS*^VIYM-C%VBA-@5IX?R(V;%0@5;@B;Y&*Y-25Z3%#1K0 MZ24+@/<=U>&RW]`NZJHA+!==4Y5]`;K&7M7#+)J/7#\65.K9+O!LEW6A:;E. M"6=1O]VJ]K12,ZK4QR;/#D3942%G47Y#)WH8:VEA\!W79AU=JPD8B%[I:@!< M1T38Y55)CU&,?IP$?LIRX6"=9<P6U?Q99HT(/M+UY(PUMG"EI3^ MZX;:4SK.GV"^C@L(KO-X#?%[.BNLO@J">6B^`$E8P,'P5\TIJ03XN+B]2,L\ M3HMX38X&,'8PO'1#N@?#2S3DYYAGZ5_`T\'P,OVS<+ZSN%FCQ5^OG1/0MA3, MFY;M4DO_X&A5&O?EW4I[!HZ-7JYB*#XZ3=[,?)YN!,7>,8E'=3A\>Q5$J!AX M@`"_`2C;DC^K7^65^B;1>-3D7\XB7^]+52N9AA?VF/$-+>91XGN==#._K]]% M.UJW[,VJIZW9J\^J!@+09BLD,3;C%O'0T!Q[THRY>77P3%<[5$.VTEHNZ?'9 M&S)U%7@3-X\7+?5@2H\\-G[VQBN3\Z`6QWVS&,V.ZFL`]MC\2EHC`#LBTBYR MTC,ZS+:YNT-N[MB;"LFT:GZ"Q&\U%`F6^6V"F4P).NM$I[E]L#?Q$MP9/9JD M(,55&ZE"023,IP]>XU:2RO+%R%)V;K(DB?("?U25H,=3@08I M-@ZJU;#E9I&;-$;?\"O<17$:I_=G64JVHARB9/#*8/.[-U1[8'Y;AWP/0KE[ MJ_J;!;,11*'C3F[R2O?'887<=@+T>@%P-P)(8)XX;^.F\TSA,7\O6K8C5FY2 M'Z_XF5^??=D:^.)VP"Q*I1SLF5FF3BUNP1D6%^DU8=)M5D;)1G=5FJ2;- M+C4+F@QA*4?J5PEBD5G44^LK-_P.V"B>88%/(*W:/`&DU0!W8;NBING%'A5! M,+O.PVW9^"+/TE4HQ#T(88L1KF([G7@DJ$+E:S;=\9[]5)+UC]G2:UI[1&K'70%80Q)N!B5AI2:TI#YL1Y$R(Z+)/+),15$;AEIJPSRQ,FE%C^C&[KDXDD7MLC_(L3:K<5,P+$JOEU-Q7 MA[(HHW03I_=6-Q(*VS%41W/:\9I0A-_?;VW,ZYZ][,!NU6B]VVLFQ)-8K;+* M6$J0);`AZ6=,46Z*:.\/%X2TR=%=_`^ M3LDA(D=ZBK(71MN?%KT\1H=V'KIO/K^76^1X9;(9U!T1DQ>YH/$U2Y)/68XO MVEO5H#1B?FECT$@H(DOYYL$L<@S[YD1C^TW:6NX`WW`KH&YFX>^`%I#(AD*S MR6I>I'MM65'JT#4AJ(U-P4@#GE-U"R-5D?5*8Q,H.THB+[+N3LJ7K8/]FYF'?4K+52Y:B-SN'^EA63C5C++\L5ISA*>NT7Y MT)6*L>#'6\`_MOWPH8N.@]7"5]E1'Y6`MTL&+SJ26RE?Y<:'W-B?+HT>%OO#TTYK;CIA[0\6+$+^@WJ1S!!JXH`>97J!*V7J3SN)U:@%E^362 MS8>HGE=<;9'W+DMORFS]^S6:<"`K4]6W=$.Z1;9$0W[2B?0OX*EDENF?A:P@ M;M9$`=RT4MURPEFC:@B0EDY`W=9"$X@\N?3SA"J1=9.!L#T#FK](]>3LI%V4_P[+^@BEJ``1V#?RL`_DCO3B5(@U^B'?R8X2)6==^21A.RFY1F-6'W[IO&M[:\_6A>SS1N MILUI<$6N`7P1?*L^"WV/MP[.Y6]^Z;-)]C[7C)84;FJ9H.P2=+1>&9B\RLSD MSE`KC6MK[[S&/:FRSB_E8E._Z8[;D/-976E>=K[40TCM<,]`/C#`?>U,,:1K&X<-WY3?(6>:'UPNQE;V(_*FF;O=WK.,5M0:4SY=UT+HOG MF;Q6;^6IZSF'JO+>8QU>R:;RW%SN4Q/94SE,L5> M&,QFQRUS;@\`.&:UDWE]\=&M(2Q.GJP5V\L5J`45W-SWMEBMM=5;-E5FJ[3L M-_6H_T:>BVNE#EO,-`K],%M22[PI\*BJZ1DL-I>I9DN(J10EWP&#V>D8Y2NL MHGEY*C9^B?71E<4+T1EKQ?#2E,9W"5Q]@]-T,R2K2G$0)1N0.L*B"^HG,&W^K^W\*D$ M'Q`P?P]RLYD<_`0:IX)AKE)Q`XD4)S`>.*@UG-*!W-[&6Y!K0JS[AKXZ%(_G[67]`DZ:L5`!NHB"KC4&%8Y`\W0 MJW\'0(CQ3Y_Q?C(*@&N+$3+-CYJMP^A4AQ`?Z_8A2O`-@U2`UDMPCSYR- MI943OI1'\MVR1Y*75M1&TF4BR/(2/X5^D3["HB33O].[@CR?/DD,8M,V4?!, M-6$K[H5N(N&VP,,RQW%%KKY%=>,.]*Z#;XV%]^F&Q.AF*J,P9@';H\\*+\`Q M7/M;P$^U6;5%4-Q9'`MLV/)I'#@.Y36^3^-MO([2\G2]S@YH"I#>D^H_A@5> M:B`K#6.A57)J)%?228]#2CW3E&'9MCB$D@NQZMF!SA`TEN!;.(M":M#(Y@W< MB(!2OCTJAH-$L[KN"I!$Z_F0/&84,A.!&QPZ3`YE5.)'7"]1$\G_.N1QL8G7 M>+WH,Z2]>U[.NDD'(FL]]LGU13,!"!OA$$W@NR(&Y'X`,0%]&_"MLO*M]9(# MGBF.RHA5?*<>G7PBRJR0VP-6M3&'J79]]:7;Z;.$U[X!Q66$%U""ZK4BG^#CD\AGX!O^-`15Y0YA M)OUK4WA`,Q\Q0`H7'K!__L]#7#[CNU=92J;/'/SS;,<@^#HL6W)&=4D,""&-ZT%PH%)&"C0>:7,8IO$!_,KDQ,1@3HF=@ MA@63%@U!OQ]7`N^=^:K]#'S#GP+R<2@0GP[0%->L01R#N;6C(-C>.)LOAW6& MN]II4G^ZQ#'F5K;S1]F#.%UMSZ+BX5.2?6?>Q9,P'0L6U=0,I#F],"1B]!8D M\$US7)U=??EX_N7F_"-`?]U<75Y\/+U%_[BY1?_Y?/[E]@9&,]Y848&6-^4#PH3)&!D1?.?(K3*%W'47*=%3'9L"7DCM!ERB&. MBRDN"7MEC%.\EJ2XQ0[`XMB'T\O3+V?GX.;OY^>WX3!+C`0:PV3Q,V4:TY/* M.'G0>6'>1;K.=GA-"-?Y.7R`:1$_POI3(0E5O*=\E/,V14V5OAICJ62C4H25 MBB69'Z\^7W\]_SNRN_CU'%Q\0?\^!V\NKVYN?&_VFHDM&L-G@'-*=ID@5-[/ M`K<7"2!K8`]9LD&SE&K.+R:^V&=*=YZ/*9*+^V6,VMRFI`C-B;#BD/?F]NKL M?__]ZO+C^=>;?P/G__'+Q>U_!L-:"6#0N"J-IRE#V:Y47BJ@T`,;;]8PC?(X MXRW]TFS&;!O:F&$7K5U#;!J%EF#/P&/5_"NLE5SJ0$W1SQG/,=K[IA1T(8O_5%,\`=M&0(L4U,":A6IOT56?))*"@=CL,4GK1Q&N.2 MV%``21]&ET@#<2-#&`>K.ZQ6V` M8H`%2*XN<="[WS>L89_QO)?HV3WMP>^>_EKD2#/O(?D=Z1E/:?*?[-,>Y_?+ M'F?6\YIZX^RS*&&NMT@OLEA;6;&]G#)S#86]<*)0Q(3SZ)_2HHGJ2HG,\HAS M_!C>0&$81NW1':,*Z*_'@!/Y1*F%%)^">I&ND\.&/&V2DWMN/?[?9E_0+XS? M`)XEJ"OW%RE"%RS$XJL3E"G4\X(:)J7.-S.=`&;V187ELYJ@)I83T,8"=;!) MKAG&`TW`T)1$"]T&@F*5=&']RJKF)[._.A8JI\)=A0N*4]*K?:^<:GXR MM5M*JDLKH?+IY]=B4!&U0]YC`JX$=8_5>82/ANS#S"-`[>GSE3!`J'L5(08]*5[LUCJR0VO9*5O&I#OMQC MV+/I.;8WS4MZ?XP33641`@GEP9'- M&SH*&86^(T:&@46U&Z(RFN\"DOAF9KU4U+T8`[]L&_T'?[B+-A"_J1NO2I;P M/EZ#*$EB\IZA?927*M^05-"^"3,EC;Y5I7I\M%D-SUYX4XTF524$O M2LU$FYP&*"]5J062U(8P%[!8O:6_8U9%*/@19(2"%<&>4/#[;%$HF`W/%`I& M/"FA8+_:_`LL=`S+@'^Y*1#"L0RTD$/)"D=H1#!_#*=7SY4 M;SK$UT%<46*;Y=6!$"#;UV\OA_DZ+I`%?H'/^^?9M&G=J(14037S*@FR.#498E%'4FBH MGJ\J))J6M/BDA[ME4=]0#DIGQ MPE6QD)4J)V29M;AZE'1QN"3KG##OIH0I7@FCB9-@"1-*_8HOUK`[;V1:J7+E M!9"J6>D!+.H+K\HU:JDUKOG@?UZ77T3#X^_1[E MJ(2M@YZ`\U:&D+14;8>L+%PD2FJ*!)JEM(061U9%@B"$9*K]2T6)%-Y')10] MO^R3&3B]=B.QD%QI"]'S\J-U3'O/B;]&R0$J;@>C^_`SW]C'!K?I_;*2WR9- M*1-W%(&[PD)L@]\(QH"%B+1<-/%9.G05$M,]!EW<4#`-1<9FFFHFAG[BO\'T M7ZAX.EX(*J8*LR`,(R%HK_'+1I%(&L[79&3[;B^Q&%Z($<:423Y+7-V71J&4 M0)A:VQ<%DY.0X&CA+-V$HUB)ON+C[#.L.Y!WBTPS$XY3.*#*-X((;Y53QL5 M3`TTAPMOBDBOR'DV="TTD\YY[9J'NDQ*IWI,(!X4PIFY76)4Z9'A78Z\F M=-(Y<.[`T]0ME)F:!@8D]6T>"KPI6\$ZUE9@1M>WPM11MH+6C>*\D#N^EN44 M>":?CAP+YJPQIN.\H)Q1*PL&?VAG'D\FLF/@W=@94:+VS2)>\C`HIM<4\R$= M%2L<2R8#1(>*L-/(6G\K/E\>!"5T9 M:Q.3F!^T:E0/F\C2$*\<*%4NN1"6_@T'BX5NVI#287W;O/"0%R<8,*/V3I]B MP4KFV(H!Z=;***I';9L%=A=<'MN-SQ3>^!+XAB\&!O'Q^#%13A]H!M!K8S;6 M68#P"O>/V2Z*)V>5B.S8D&_L3(-^V+YQV+?AE8!?>[&@7UT.#_RCL>3!GSKL M;`)4YEP*,`#BE@3Q)H[RYZN\.IWP,RP?\&E#^(A"""\Y][.4_'HDD?33)HU2 M_PS-`&3;Y#-++LKJ)DK(1N)JE]3=<_T&=K`C#O4QD]#WAF)EI&2S!W%*22GW M(46#@J?:SA*^RCO$)MF$TAJ#+&_>DE/9@\8AL'N[MG'*W-!R#$@UO#'&,6#Q MV>Q1\7`"UNA_B9`^(G7%JW-X0VKQD.7E6Z3_N][AO0$LQU@'+&>YQAE@PZF& MKO-X#:]A3K;!*E9$5%_)JFCD:Y70U'XZJ([&[W MW3VWQ1)YG'>3)4F4%V`/\^K17M]/]L["EC3=>="4)/P@A#SIO0';Y'U_#ZAN M[@Z(ZJL30-S>(K^WQ/'EX'ANZK*"Y'!2&)XS7FW)#MH/SU/CQHQU)\-T:,D$ MJ!;:JHS,^99V-4:Q1_,E2*DA27UJUC!NFC4,JELW7PSE+I%Q(DBKG`;-)"50 MI05YA=3BL$L!W>UPM[87*2H547>>SK*TC--[F*YCR-D%H^;6"I^LFZ:HJ?5. M5["D6^.)D62056V)5:2R!<@8#*QKW0CH;7ZJ<,GF#N68^G+>?5H'A5##>W8< M`K6JV5NHE@\0W),G;Z-==L`+3>C#0YK#=7:?QO_"QR$A%-_!%&YC_TM-MM'* MKM:=X=5EBMGO$W)Z7I3@1<=/2?;](MUF^8X\3LW<5JSDU28822]-]BKU33>] MR#;&(ZUWXI,(LA5T+]\`BH#OUR2&=9,X?.8\:VFTZW/0CNNDNIO M?Q:V;T-%15N@V5XL!0UB&[1X+`5D8&Z%9IJ+:.!W.S2U3Y>,[9]RQCPZ7!K: MGR37$PO$N)3:@"1P95/D,I1]<9)#S6<+"QH\REQ.]Q!Y1)+]PL,$H!96?LR& MD5(1H@\DSRK\)=K1'TV1M.;I<-_:/'VF?;&@Q(-&%)G3\V5/^+!1(`^PR(XX MGT=,B/!HU#D)>,2!E&\&X;BQRY80MF=(C"B? M'IRM$VQ[`2E\;VNXQ5\#WQ3;Q(_QYA`E_XC+AZ\P(2N:Q4.\O\W.4_1=G^F) M9IYWPQQ5;STZS>NK)L>4&^403S'6BCA4VQ\:%_`=^8"^$\9GY19**IN)J4QS MH$>$5@O28[DFJ!U2'S5PM3W=9.P3LGDF#8FI)GI,Y;2J24=Z9`[G:`XK\N0R MXE7S>2C,X8U6)O/KCCA`L>P!76;@G:.Y>P,A;:&69S/$\]C&!*#I[1I!]"2T M$-(CCP[3O7L9@EBQY0[J&/;Z0_TN:PRC!6\/^AC3H,BN*J_2B>QIQA$A)Z_H7$5IK\4*R+WH,$3?"YHK( M=]49`&P!WF";'P!*"3TSO_R0'?!,<52&G!$X=>SQBBBCJ[46@877:WO0NDR`,!Z>F"6KYQTCWUMTH[>3ZNR/FER-A='D>0D M/[@'"^8A29:^7"#*47D80IK8_F#L,I?80O/HV8.EI!>C:)V9>NS@U6U::AXI MN8V>/M0/E%`2$,>JEVJH5MILY+2MGS[HP?G4HOFL^A?(0V8?@G@\1S1XF>0O M/>4%Q7C(`&=H4#L(:U^]+[Z,\I*OQ8:@@<^[^@#OXS3%+WB]BY+F'<^!/M"E MBQC605:!848I8.4\W;A"#,C)JZX7`A9-ZC<#%>SK]"->H'"A@\146AP0_ M;O@)_7+7"%%Y]?I49'N=%3%93I7+O;-"\A.U8D@;G)SUK:R4`*H]4::X6@/L MXN($M)%`&PI@9@(2K'ZA./%IXP4I&/,@+5(7':+PA4@ILE"UEL8^R?3YEXI_ M*;R/2JB>/,.B(4[+C0/8(F[M"<.JVH!DY/TKPV1ALSB.>2\C+E):]\\.>0[3 M2='&&I<4=;CE%!5SX2T2/3W: M\$5/,;90]I;(1N/KZHL@)2XP&A=28*QKOBVFQ`B$;XIE1FB,"[34T%JQF!5R M3IGA=,XTZULY+#$,3I74&IA57BQLQ6(>I.=)G8D5"Z7(,T4N7/;Y*RE\D7!2 M3BQLO2(`?ADI)/PPS&$14<"K[7E1QKNHA)-R@'JQ2>RCBWHB06U),]F.8W(8 M.S1=H7_CNW;M)R89Z2AR_J`UP_PKOR!J)9,])$6%"?9E-U M:Y1*VDT/X8J]TU0W^=8X=)`-LOKE!G2FH+$%V!ATUN!;9>];%%5QDLT=PQ'O M)+U[C`P+FF9EV25"J_M["(Q%!\;N)5"__/'FC^"^PV]41SIVF#(3A#N@NDPJ M-R7.:Z?I!E=I9;R.DIO#'7Z,N\!5-B.EJ#BU"47.29.S*CW332:2;?&(*A4" M)Y+*D#RBC^?:OO(^9A"S$XX3&+M,-K=X?>>0/POG+"+#-JFP#379*NJ! M;O+@Q.?1D>F&DT1S,<0T(!S13/ZW'_.$9=_GAG.@&)9RPWCA2S81:ES_-^[' M@!ZVSAK%CSL]_37*8_QDW46*T`.+LCIBZ0OZ'9':HPRPP7M0R;EK<7I?'2Q^ M6A1P\KR;=ISZ]]2(H\5![?X;(*A.']C\G1]UU7P*'J/D`$=5;/1W M%1Q`'-W[#%\?C9DQ8`R%8G:X3D<61Q%3[X8.C!\X_37.H/&NCP0\`:,`)Z`E M4Q7C!%117HG"RJE!4<5_1BZO\QB?-U#=Z5[C5[U^[-Y1Q7C'G9E@@MPL&\R* M^JA]$SL")-T'=162#,T5HA+404`OR@GHQ0GFE7N&\"H4I5GX%^B27$RQ."V` M3D;GI<&R"B?XLS91X.-*406\M)+7#W-4<[IG[KC+[O^`\?T#*CI.'V$>W<,O M!SS_O]I^C),#^O3F(4+=O#J411F1LPQ&W)WI78^!LK>6PLSLJUZ&5F^4+1ZJ ML5:-`Z@]0.6"5:.R!CUSG'])(+^R,1=1F>8P#V5!,4BG`T%#VFB6](AL!#@>`=IV"=[?8'\A#"IG("*2Q!@M^^OD>(+[`U>(,,R5_%#R\+Y*SLYPWF MWO/;I(L?HB)>RV4WOB\_M[%\;<@`OY]6\AJS267N,R*IYC3B%239!2@245T* MA'R:TT,(2>X?PB[RF&TDTP<^5Q":^V6Y16X1;F M.=S@>]L717'`A\F=9<5X;57>H?DFB\($R]-D9J=-B$@CCJX-F"6GW4ZZ+D/V&4GZ>;CU$YQH3( MK/Z&;#,M+(I:UX,E)SH;H4RG57/Z6W4)X&L`703XJE_H"@7$<)]84<'>LS((]4G;)H'>#RX+ M\\YG`G(BZ<%!?#IZ#("SAID*[]:8!6XV'&Q#^[IYVP2E7N':C&`]LC$":FJ[ M9B`]#BT&]-"C@W,MUF$4)_P1FT"9-[`C(`],IS#F#[]M$.,WY#*PV[\T@FQU MR0A2^ZV8`6@=48Q+8MC!$?\S#`P.?OD)]"CC,D(<>4'T!&C40;.%KVI[W!EJ M-H^2BW0#G_XW?!X!@6M3?S.&C1;TN.WJ89`5F@U&NL>J^AC4GP-R`:`K?@'* M'[%,Z@<>0I9JVF%7;O@M@SC;[;+TILS6OXMV2\H[#.'-=3"!=8D>&0$^OQTA M"WCN+26($2!6)Y0M(4$P1`8!8[K(HV;('8[?A$@J0+/,JFI)YBOZ3T^ M!6(R/Y0Q'3*)86J"0]Q>&&$/JP4A;^B.+6/J%<'V.J@,@F`*?VS'')%!PI`= M5(\)+^1@8Y<1'[-=%(_O#](N#1#?7#*`\&$K)A#=1A0AN#9L$/NM^K?G1\.H MOWW&^\UH"*PLQHAC#)M=A'V*$YB?H6GF?9;3BW&JQ0!O(PL#L*.V:0)]X\`B M$`[M&RR23T'S<0B(I`]2)O&KTO`Y,!S#E#_:=M%Z?;A+XO6G)(O&^^"8UP=( M'5PW@%-*>R90.@PKPFC?ND%H]1D@'X:`3]K`9,+?DH;-GMD8F;S1M8O+K_`^ MQD_UI>67:#<&#,]D@,ZQB0&`TELU@=%)9!%,1PX-4KN/`?X\!+`RABJ3^6EI MD!U:CE$K&'6[P/TU2PYI&>65JM/G6@R;`70G-@:PRVC7!'BGH47H'7LT\&T_ MKXJ"("90K`'+I'Y?&H)'IF,(BT;?+H;_`9/D?Z?9]_0&1D66P@W>V#DYBE'* M=H!IIJT!;`OZ80+C["9$6&=Y-IC'U]_^C@U`8P$JDQ#0+QKB3&DD:&Q@N(Q9 M(8L?6^RXA/=14G7E]"D>:SOC:OU])U>U,,]H2P_ETZ!L7(]M5^0#T"PMX,\\ M+RRPAB,3_(9#?(Z,.D2*QG,N!JNC^"H85G^/D5A]^MM%>V9?Q0(*(GDF]=>D MFVAAD]>J'D`9D=DHI3JLND]KD0T"K]S!RF1^W"%R:98=?*7&W3F&J:NS?",& MCHVLV/);-HMEB55._L>F#W/_'CC0X$N:Q`GN&T-::"U.-"FCFLU M,,K5VSA;T?H6S.O_YHXYZY%*[5&7T:FXB`NL0N__]+[1(/3);Z=W=UE9?D;? M>'U(HOPB75-?J"`RJ[\0VTSO`31!ZYK/HK&CT^TN07&;S^K0.,1YG<9+V4910CJ&Q4C?UPZ-KH?/71TF#R= MP"PV4,H[_7RQ>"0P$EUX2'BO@H1-O7L[8CU);A@,[_^P^@KWZ(OA,I>\4B5. MMUF^JXZCW<.\1).6>FOA<2K*>^LXTBF=UN1,D.(K7,/X$1](>Q/?I_$V7D=I M>1WE90KSJQ32ZZDYODV1I>:K1YPY_=0LQQ2;Y!!+*=*J,0>=/>@Y@-H#()=0 MZKE9*,JT!G?$1)40/7J&"F&UA"`J#?P@&><-&FY_>CE@92:.8X.K4B4K4;]X M0NR[0:53],"[;\`+4.4#OC_$ZP=2"<'J%N*F.M\=5N4101]^/JDYKS]J)#UO MN^&[*'+)`E89[H,%E@LM^GM`9W@J%%EF7@`YHX_V"RR9=T.JQ)$MKD)YW>@< MX"B1E/M"4H4`:O1TCECC$VSWV*5,PRD)JGA!^A=NKY6B?DI)_VZZ=^DWIL["+1:J@3 MZ@H5\EE0'36%D1)A62A4(&P;0HVR7C#L?(7*`I19*U3O7@Y8=>J?1<'5PPJ5 M#<2*5ZC>O:`9@#$6:%19QEF@5VD==H<$OU#Z"@US?I;M$%8>8%K$C_`B76<[ M>)D5Q1=87FUOHZ>O69)\RO+O4;Z9EEV:@;H:;'8@7770_`;:U=G\]KEJ,3?L MJN<+B#,8>(/*';S!`7X`*`06!A0$?,-A0!W'?R6GB\S,'$8F!37/,)O\_+\ZN[PF`- M)\V&Q!O["?@Z2^+U,^M9"[T@:HEW$L2%AC!Z[DX]IAW05HYQR$&V/0YU8`%. M51GXP%73A%$L93T(`?\6;DZ%00*\OO*QFG<>*T[`\EHVM5\U'(3WCQAR:3/AKCF$\,NLCU/+X&K[+HS7, MN)IH/CP)X;F2&2/,SM\>Q]CXK1&]87ZG\KC1TO'`3%T:>-!+.#%\A'B`K[:? MXP06999"RF$]8L,N!3$-=7$LZ(%V4F+'Y^*9Y;;J7<.3H?9J$"?Z2(QH)O_; M3^#,L!_@VC50+"B?6F&3!A)'1G$=5Q_C[1:2MU8,.1`-5;6C1)!, M8!TKI0`2+A?&1TQY0I2Y51H+6*I67%BY.(C3R,R!1TU*M>"C(Z>;38P%)4H^ MYH?[XOQIG1SP*XA.TS)&$X$"XH]OH_P>XL7CO]_>7N=9">.4OBQB)%@CR9K! M]"AFY)MH4E"W#QR2ZH5>=?Z`!`!M!-"&(%=`&P2@**`.$\I2D1FX9F9!,U(+ MK9@]/5DNFXS?I@N55Z,GS:*.9!M",MB2+$K1_S4\PQ=!V?(,+]Q@KNVKT+Z+ ML:`XQEP&?&69VTODA*N`&WX]$?249YOQICZ[#R3YN.]';TMAP M=$W=L?)==8MGTYWB29+9ME:]@.1F2R=8.";>`EM');O$J[@`RTGU#EY`0H-^ M;-`$]RUV=FB16<;B6`R--M)7QR/FM=E;VLNE-Z[RVZ&/TW4.D27F=('='K)D M@[[ZOP'XSP-^?.S[`TS!!FYAGF.D(+I'10&1+B!.IUGZ]I^'*(FW,;I6X%=) M@VR/VT*3AY0$QP^A/<+Q-201AZ2,=U$)DV>`.I#$_WJ5AKEP?A4'`[^FZ3N" M"]:'Z3X,-/&'14'8?P=3N(WQZD!19.N8;%S\'IC)&:\=$?3**RU&/@>6J_J=G5E%__8S[HXWPW#?IH='6 MT!E?(YXW?N,5W#6JOK"&YK#:8HXG"CC=904U48ZWVJJ,.[, M^L?UR)NZX3USQ-^UG`WEKI;*(++2T9Q!U$D%NRPOXW\1/EYM/\*[$C^^A)]8 MNL[A+C[LKM(Q%%1:>)5KB4.C&4"K/I6>+\&M@.-(:@M\9'H MGD&O@H9LSFB-""+AV>--&,`SNP+C`G_DT8,1`M^!/__X[W@[^IIL2!'`"T7<$HH=J.UN*0!`5 M#V2*G9)E/7R#BRSTH?]#E()%V5Y$OW]4M0#!!NMJ@U:R>K>OM74\T2>6<5J4 M^:':1)=Z/S'*'KQ9]8E]>-NL9FZ_9ZK53,]%MIHA+G9)V^N5Y6JF:DF#JCB` M7#5S@L_/#)Q1?3C(,VH*(ED^X1-%Y?GD!GENRQD3`*27,^]__/G(RIG9Z)Q= MS@2)3]?EC!&(^BYGRN]9Z.7,?'C/+6?TX6VLG/F$!"E=Q^G]65:4Q37,XVRR M^4G:@5K*T!T,TI77(Y-E#*,=68)2W2?YH[4"Q.P$5(8A48B+``:!)%!#)0_- MCT4=+T"S6+58P!LY28HH=%$8M3X_U]#N_1G+J;B]=;_=8/^%F:#;*(\!R[VDT8Y?@8 M)_);1@D1=5B_G*(H^P)#SMH&Q7-10GP.RIK,XZM75T0)V$5I6FT.P+Y50A[N M+:PW#%9/)A2']4.U=SFH#*T,5ZE,/!NNYC)NEM[?PGS7YOG+.+J+D[A\_I3E MEWC'Y^93M"8?\).R>AQZWE:)8Y+#ZOTW*OA*S4OS7R'J-&D@9X"]>TL'K3^I MJ*L(H`D1%%UGP)'%Z-G(IE->/AQ3%<+GB,75"^]4H558"7)_6V*R=-/,9$"6 MI"++]I4L$XB\TL5RY>B=,=15&L:]H_[M(65:A54S^N&57.7IEU?&ZM=K-"E! MF.+6IB,;:MW9VA@4@%&[QC-A%U^6LXW')'_MJPLAL6<\:@QFT`>7BOG:E(5G MBQ"PLTHT>_QI%0E+0XHPE4K/,V&JEU8/ M^`S)\R2^Q]O*VK,DKZ-G#,3N7:G37*OHV"5@:4==.BKVT$RJEF^4RUG9,+W] M6/OJ8O]MP=X9HPJ2;/[P39@EZ3^@6VC8-%A#N`5F76W4T&SL>R?ZUA[@ZXL" M*Z=>.0JXFB]W',-VNFA19O@LK?8`7FW@ MI$_9PZ@7=.+TW$,]=4Z05CVB,QPH&C_5PQ4HQ^>`+.>X9JL`999&"X:HT6.3 MG>$3U4`?ASCL8?"H(<@J2MQ`T$0QV18[WGM27")[:[PQL0V`?2C@3I<*+(OALJ4;[+P&C.-Z4=AF3]$&EN> ML8U%LAS#!5EH1;!1L`EKBX7`S4H]80US[T28.TJHB6H(.U#3J1V*`J7*S=D# M&FAXD9X7U>'/FQN8(.?[ZSQ>PZLM*ETVAW4Y+B/F^#85A9JO'K?F]%-3TQ6; MY%!-*=*J-@>5/;X9VWJ`V@40'[(#H/+RS,19*,JT!G?$3I40/:*&"F&S6W'] M()G4+#66URV688OEHL;ROL'RQ#;F:A;:LQ&".T=Z,GYZV.X1WA)AHQ75+,$[XW%=4-7\,5A-8P5Y5`^^'RAI>=ECT.L/$4JC?& MPU3(62OM/+WGM1E(8.8G#23HY)DRP7/.V$`SVPR=8$_DG(%"#S!$XX= MS)/G=E3`WV&4E`]K_!:H-[_\[Q\"6>FUAE%F8E\D2DU7!$Z`.IU"M5 M"F\?\NQP_W#[/?M/&.7XC+-ZU65<[)B.VU1$YN+JZ8+I[V2'%^,%^Z^9^2S(JP5:>.@SJSA:21"IL+WE.K8F&A\8^RR MZ(@KU]OA0CI>+&_"OT49_FV!&J@.%R_:9JI'7W>X(?PZT^@N%\QO!Q[^=J5L-5T9L6$]4&$/4&@)SJ+*WX5>V5"8WR&.1&2[\R>FW_@JC[D5\W6N_@6M2E$I:A0;[&'(69[2QQBS/)_KDWO'&5W? M:(4,.;^1. M>6WIVC"4T+8;!)GC78@3IEF/O+C%CUU?FCV:ZM,Z>V90E7]CG9J[B"E<;74Y M8DU190JMS>)D1MYE'M4IKH2^JQ'95E:A><<8YNC`U/K&I<=@J^QHY'B@Z&X$ M1M7=CI.\6F1L>0%Z@9"]*Q:EL)M0DG6.%L]%&EV->^&T64C[+L$<$R.[>:PJ MEX6M?01W-A9J:N7963B;=C:V`'W,W"3UO-@:N+&WF5,_6UKO)C2NJ*`+IU0N M;%NI@#:YG$V2#).\D(FE:XZR:T$5/3/)0$??CRF!F@@`CE&-70Q]L=L_07I3 M<5!;$?Y&-[-+,BZ?<(OJ[[DY9U"!7\XFC!G9:$2$S\I&+1F.8VKR0\8OGGLD MM^1X"G&=.J7"'DU9BN>!E)J.9+0.NI)WJ(`ATHOS7>=4^UHG=_W@94!'+'6?!8EQ_F,=+]WP'OPV? MQ4.](?P(`[1A_.B'U5^][\$Q.XIOVJ)!_3XF3[%W[(^V$PPT@["2`1/\F5!C M(R%;K=Q1CJF8*P-\GFGP^D88=D)Y3B?X.`5B;9I.AVF3NPIV.I1V&>DVU,9R M@&<[='+('W/(#U_\2.,/G,+[6C$_HG@N%O5V9-."P.^*+*_%`Z^\S%>:$6N[ M^'09"@V+OJ4HI"$1WP?D"4>?=]CO/3Y4]#A__>YC+7*+2M.39CU6Q73L)+[F MOR#XR9%3/(6-0L8^9!.U[505)BVWJU$AHM6\(")J#;RV=A6%].5:UG"PU6M< MV5.J:PA8.*Q-@(`@)&E`0"^<_(IWW^`4SK,HH`@25"&EDT`7HH(2S3B?KO%! MA+:37_/?$/]Q@[[\=+\\!D5-1,8_:@>%K70-'-IN:=.GZVDW=^LZZ1VF7BA, MNNZHC0B^IN'E0(Y,H=/,L+#AX"7P3QS3U$%$4N+_=G<"I]`?TB23 M%P%N-+D>;B5K8R+XC1>$"-L!'TT!&W>@"P$_!Q$L@X'Q M,9C@Q%'"7F3I<&L;M7(GPY@$FBO[V`*:C#.(@24GX MZYD&QH=_9L%VVZ\(1I(52D"83(\2(Z5K$D%L?8``HDS7^1/$'B'^S!6PC[4B MD?WB+6@+4M<@/2\PS`['FL0'&Y[ES][5$;)V8`C#JG/0,#V>:Q0=*K<)]<%H M:;FFCR-1]#2'(ZUH2;S=>R_!NX^TA/3\N=#,][2AZ4?ZO2!X*N4J8ZED+DV: M*-7-B#N5+7&(/W(VKN'?B*5&+#GBZ5&9`4&.I4FC!@\RL>W:A)+*7.>70W@T MWC6?#Y2M`7/P\15*WPV@%&YB?SD$_@%%)'KWS\P+@WU`$R?-7G],8T:29%7' MGP^M_RY!^'@*R1G#)MY=-080[6B'/TJR,/5H?18/(':Y()8IJV:#J2&!&5D` M`P1C?ID3PY6^DV5D"H7/3,C4D$6WWBE(J3OZ%][=DB1-;J+=IR#R(I\JU2^! MMPU"6H\6P)7RY)]$,H\6Y93JI4WT&4+\&60`KI-F7@`W+ MMO&2A/B!!Q>2YX
S0%5?V7R!=J*%W5$W%'\AT=,CCH_O21R3%UIR\I5$MUD< M4V?6+W*4LS?UCD)V$R15KJTYMJH4/4I<>6/7\/0=K>(1D6T8/+%`27O)[(P= MGR=")Q(O?ZS`9$"UZ3H5DDW>2EOI4-A53%M25LL`&_16!>TJ(%4@IS(L9.$H M'RLZT0]Y@/66<,(41#$^X/3B)2C)M@G^9T;-AF>4D'"'MI[_6Y$1J$+B#2SH M9,-):9SYS&Z^8=Z+8`3J%`='+SXC4'X4[0<6*'?X&8?DQ%1AJ=K0`ZQ'J6=G M:T/A;S[2!067M67J,,^Z@94L8;9CLR10,UK&IF.(UC$-H@P2!=$S"9^Y*F57 M).'ZJ\?TG8,8)PT+L##5]YEBW9.X^>4@*SM'*#\:B-GB*VW*!DAC+TH\WX$% M-O,[E!'5>H$NQ=#HW+*NI-*YZ`LN<,ZR(:]=>E__3BA_S`5*O7D&V#X']1+3?S"RP_=PDU"^COW`8"(XA9 M67A07Q^2Q!@ZVJYBHKFZSU@93\QK;Z<8`VK\0Y#X(4G@*$DX?))K2%"$)\X, M4),^XQ7\+\)5&1LN+*$8+N>#JJ"?..$ZOZ.C=\[5,"[[L52`_X93=EA"=1Z*=>DK9*+9D5BW:'A5A*XVQ088]D8/L:9UB!Z:*O=32%X^TQZ^G_[E M1**;'1]IN-M_Q2\WI:M^2"E,O'C7HVXGY:^I6L7\VKYA4GWU5:QJL<-.0,T: MHSZ"/(AG0AG-A8IL$)5I1E3E1$76Y5W`-'@1[1;O$E[)3)/H3F-<4H'^B:,\ M8I=:[H8CWX)@YRL-=YE?()L%O%W&CLS>81BFI?YTYQ6/O^&G+,P2]'C`L7?" M61KX":S(^HESQ*MQQ$,194E-OR:OEB5#NO%B>6)X$\721+FR1A0!31SH;\W. MDP$!N1A/=`3C@:(/?XYNV,JEN_TW_(RC#'^B'_@^)@"F3R2^21(*_5V1]@&' MU/#3?1QTF&C*7"$GM11#;Z,I-O5K,>!E=(U?\U]ASO&F7/V66T'`4Y3; M8:-"N2549/?P>//X,WHA6;A#/B?:EJW0@ZB>$]`O"8B3-#BRU1-) M3L73&Q6'L/9&QOX/9%I-.\W'GK.>J[7?);?@]X*?,57@3Q%;7LNHZL$)SRPP MLJNY.%VIP2Q,>0*V5*=AJD'08F5.8:5@-H39!$Z%3H-GMEHW\L(SE7I+BW7W M&"V2\NXR6D?H_\>'SY]H-7C_CW;S>C=YCZ0J9+DHE9X#&BY;4T0+C0\X"4&> M:WB`JB?0:79D?]]8^Q')C]UB1'_B&M#G!(19U6<.%^Q2KB8R-FP\9=V0$`H? MMT!A6GT8Q(7*<2B7""!1G#4%()VH2),$OA?>1#LV'`H9S^5=#TE_C%3)4T1, MN3QZS%"IER&62!8YP!DI"W+'Q?O\+^3G-ME*B+BTBD!]40,DRB^[I0``$!"J#IT%`9<"TFCN?O MTM$AK%H1*;-!MBY7-G6M4FP:39Q3+7:Q.J9?UHY6TV,KLP-6]L*Q=@]2@.X+ MZ$A:)L2(D)J)$#J2BH2[AU-,<[JL-?,^QDBM M79U!UFM:;SN%B.6%WL,.<@/&M[@X3"H_-=1OF$!9M,-Q?I!3K3K5Y:(;M@:, M]T;*7@@Z\8OKDWREV9:M2,.!`UT28XP@QD'9\5!Z9ALN;-VT-:WT7&8M:,6O MRD1]8Y48,V^\$GXC4W.'CE/JBG6_:N'KI@I?%=<^U+CVH<&UVS>N2>)H15RS MJ]/_`L+I2^#C*,'\)DIU;2ZV(:_'^VS8=CKB>EMW,[U%:[F6'HORSH1E1GGN M_!I7Y]W'`.Q47,8H>N6=1->4DF-P@P-SB]@YJ-`G5FL=Q6?H"<9I1!_#N6IA MSH.J4YE@^MQ+<76\\2DF3[%W?+TDT="MET$3\R.O3C"E.T;;&8YICK+4R-,] MQ[M))4\T.N/^:(L]'DW7I/9Y9$U[WG/WR>OP-QB58U6ZB;'!@6/=0J34Z_1" M+/HLW3>WJ7\UZC;5UTTN4D9!%\9S$^44,7$'!+/@Z MU)+K'F-:O^7-9ZA\8J-G3%^,P[BJCT&H>8@WPIM`XT42WDP7[1G?Q#$LB0%=(C6]2IEZW:C1K*9/MF2EA^AN->43%9PKT%U?31BZ.[++W/]]#<8\HB"NDG?+>_ MS8ZP+YVF_XI3MB]=4E!-LCFBM11M6G$8D][+CD)3K8JZR31!ZLI(V28(?S13*PSY*MF:76^(5R2;:ESP,O/B/Z#*YE M96(`[O[$>`,6/-`8-5XSC5%Q.Z+*OWA58 MFM!VV@_0_L#'#ODY[=D5XSVT%5$V@;,<*K*^$7,<:"LDIH4NQJ<@\B*?=CR_ M>4$RM/I7)M=(-Z&3RXK?$=3-CM3O%J;N--HVQ')]@\JTB"=VD^@B>(Q2>1A7 M(U1M91XGXR)XG&7(U0(L:W?!Q?S[;L_]FU0N&Y.JRFXEJ)QI<-4&,(67HN4X M#2+D147?A>SWF)UXE0^<]B+8T8Z-,0@K:B#C$+:@8_ZG%V54^-)/_$>E^65A MOA$MTY//"D^%];.C9_J*4V=HU\K`$&2>&%9Y_-'QF64Q6$8I.(:S$0IVLH^3 M<#&$SJ)P+`%U>$JY#M7+1ZBJTED51F?2.[9@>F5E'6@=WXYJ(*,`5]1!5@!N M4PLIKK43YI/50I;7A`CK9UD+::T#Z5J1TD+.K[(3@T6>B-/6V'6R*]!P;H3. M-<5I":N6]AO48>YZG#$`[\E":@T`GV/BSA:ZK^3$OJO+1XUB=*H6,HE1&UHH MB["Z$.K--*:"6IGL\*^W9I;T3[NL"91KFAA2/C3E*F1//S3&"3<$J3&N-?)* M$&U^),XSYF,:D".C/04D+QF)RMID!5B<:VS'.!PMC>H4.'95:IL!LJJ`,0MD M"]+E5^][<,R.]S@.R.X3B>\I+PY>@N_VWX*G0YJ\/UH% MH.P$)P%61;CIMLQ09]3+F63HB$O4*FK<@UZ<'YA%]*[,'8"D+MD>AN2%G:L7 M(:^&E)<@/5!=DE]<6V<^G`U^*AQ$S+T#Q56^%:)<)/WF$/0A^^82K'S?F?H> M:_,*W35Z)^XD&KZ@N2"O[0^\,"QV)_'.S>^2`1]1._*S=D5=P"_/9E=I-[I) MO%))MOT']E.VJ:KALQSM.JW"Y2AVS%;E2I;5$ MDMT[)5LCW3A)6U9\LM)[V.F6R59!W;/*61[J9A464&$"53;J*=UT8FH@'756 M4S`_XI*D3(Z['N<9-$N'9F$BL1O8JUV4I5R`;=CE0>'"L5;DI85RP9&CNZ^6 MX)-JO^+5,&JF_L#2I+IJD"K??P.'<#>W-0^=Q%\G65()_5WQSQB?2)S"<`(G MH*.2?!'V*4KL1=EG0S*7VZ@?#EY,I?ROQ?WC116IT._\]I?3(_GY__D]_3V4 MGS`Q6=28X#92E!W?9_`K6':,9FHZP6^:*+@]:%*.>]1.A4C`/'.2)/5"="Q, M]AXI,;3K,9'QS1LVB=-32'8"A_%?:>7A:>CNF(E1!H_[;_/^8LRY&RA1PO=? MMG-2ZPE-&$U8LUMB7:B!T8C*-ST4OJFT6(U5@!_I^9G[$7`C>6EO7L0TI-_\ MR'Q^9([E\>MV)IT;`.H]P3Z=TR,^I#7)FS,QC>N+=R9V^JL!V3VD]`%^"OQ[ MKK__1BOPE:1LNBG&-[L=FW+RPH],],,E521Z2(G_V]^"%#K9Q>]1@N4GA.R5 M/-Z;-5^R+;]OZQM9$Y,6*CPI'!BOQXC0A('XLD"4EXA>:)&(EHGR0E%5*N+F M$2\7L8+9(@28*BN?L;*=C176&"P3.BR[C_$X8KH"4F'E];JN>>8$+]>#-19$ M%M>0>I4_8K*6S7=\II(!^=PO);E?HGXLHGYLB\ME4+O26_EO;FH)&KPY*D<= MU5Q3K1?LJX3+-*NUW(T%E6A'"Z_Y-;:&LI1C^;P"X-8;F.T]P#G78)&=+`CN MSLME6Z^;;,R#M-PE=XRM%.S5-BB+:+\O?RE>,?J4O,#$QR$XE2M#>RWOO3!, MJ!>.L)<>X+S]$_:#?4!K7`U0N#O=<5F.6'WDX3(=L85QB6^P+CK#W[!/GB*X M"[N:T7_(MF%`D9Y0'Z"^#G6ZX9%1A2F&K02TZ6]H9TQ@4GW4@]"$8H9Z]+DY M5-FKKV2M6W1_6:L&YD?]JC:?1IRFNOUQG[ABJLYUBI>SI&TMFJW6]U5\C'/J MQA5U^7*2(>FWYH5^;O%;M7_ZQO#FYYMCGM9=>C>7[TJ06DCI-ZZJ@&W57+70 M`4ENHMV7LNQBE"'Y$"1^2)*,=IJV,+S@R_8[E.V-=#<4[%EQ;,KO8Z=SH5(- M=?\E;UWH7H"$@UPSOV=9..`PO6',Y*LJHV$J MC7:Z()X!@6G&#I7?V*N&OC?^3OR"2D,B$SH1#E.WLR:]T;6X*RF9FT2Y3<2, MHMPJJLPB;O>-NFK`6SEU+?12V/1PL=]:LO_1FV>D9]'*8\4G]=;+HE9HEZ?N M2IH6KOGBX?)D`ZJ]86$)NZ9=../Q0Q#E:UE^=-,;]*-EE.=#(!OA;R/K.#-G MAZ;MO:"&<3FR.Y.#MDA\N1A4%8#.HW"FY8VFT4BEU..A/F6<"+WFX,$#CHY: M&(&JHN`Q"E4+(N61YDH.)-Q5C7)8'ZPBO!PR-L]PIP,\R]CAN[@$$%8J>CV0>6V4:\JO2X(]S.)M#FAW]T3$N)GS([B M]GLHP<[.!C(<<0SG:2?!+H!K%($=_\SXE43/.$DQ1EG"Y2Y#(KBK43)]*0Q'TVMZ M!\GZF/($X\4-\7XL=YOC@?@>,OX7VR!5V*0\9D?J4_;S;51;#S:S4E>07_*1 MYRG/:$D0'.;B^8<`NT!K66@1Y=9O$W8D6YV>"^/7L(:S"E\^YM5*5$/;Y>%+ MK+%6A#!C,XQVP775!ZXJE3,WUEI`F5!X6$29EJB(DC3.?"CGD^<'(=6;[\^/ MU,[-]Z`[^"23N)03PXDUF2)3$UV2C)0QQ)#!K-?UYZA(`$?-0A+T=TBT.#>D MFIJH-4B;$T-YZH18#$GFNZ>6,#5\$^XNV.]QS+8YT/1,9H8D>GH7LO'PT^&< M!+X7(B]),#O]F'9B>$>33S#4P+K/2UY<@)J$I]AI6P&H87?]YY@D,IZZD6[` M2>?IC+.J4;YYUUR85V,0S]7OD#>(/74/ZA1J(JIZ"3]'=(@5@2![M(W38>Q+T($@/(+[,,HW\6`!D^`\`*CL`A M?W4Z6D_%C(J_U$:-8;_Y"'?K2/C,1KH!?YFG,P[U1OGV!$=1C!K&>:YK]I^F MEMA<2I^^V?Z#O.B#R@`C^%<;9(-54)D;RC<*)SYTWQMXV7,'8ZXJ1E3\YF24 MF/:7U,H'SU,A017V45@)Z/Q_,T+D*_V]+# M^!..QU'HLDJN+IC\>+62`/2-YZ\N'RT7Q&P2)$$WERAH"R28G MBNW2(L9PIAHSEL24V<%[>]`2K4U'T*3HO_[AE_+R,W89VM5/?T!;)RY#,XPU MX;#_.M!F6@A8!%QW17CBX\B+`P*GZ.Z;?O(%*.*DMOZFO!LZE M)8)I=(I$@BUT&I<)CR]$029T4@_*A%IJ"R3KU,6&3*@7HDJM*N^03*"IG)8) MW28?(8<((X/4*#.-46,F3,T@$XQ`2R@3N$-V7!9,QY::+'`.7;/(`C,`,R`+ M7(__&C!4BO\&8*@1_S_@;?J9C4D`F*I[:K[A'3ZR8Y'NX\#']SBF_XW\X.2% M-VQY2`OAVG;R3Z5A1XN;VO77TQDZQ8M9/-WJ-61%5=Y-_5K5*CMB^>%R5E1: M0-S$LI36AR,QAHRF$YALKG(/J^.(Z3M5'&,+R*U6-(2=MJ0XYZ9VM5U<4>?$ MJ$,;]50RISHX![+M@()!6:&%@Z0+C!+INU?)*9,KF%PC%,C+@D%#[*&/6RSI M(]0;<42*U"GB&%.QMR2B/8R$%GVW#8,G%D=J-R[>A@0N(6"ZFM6-'^EYMW^, MO1U]\,$[MQ?%6K/?JWJ-V#?HE0R^KTF5;*9:LN[+1&EM58TJHZBRND'<;GY\ M8VZ9#P]RP;U!U6'CN7T$!;CDZ$R21.``S?.PURT:*$;D+B^0Z4;'2%=.>.@8 MP/V^081^_CV_G=K/V(!8FK-V1U-M:I>!P-_L;FODY[0OA8[XQFHO12'VDA31 ML/C?JL,U2]=2]C32.'AZ@H&FYG-^[<";\Y@.]3?W8>R;&AX$7[L'N2H]B)=? MD0H$'_0FP.YC$`7'[%CS+/4TW,-X*CZ&5@!_]W&2G_F6G+`?[`-8$H@I-F@+ M/&&AY\E.I)@3Z/4\"':D<]>T^/E0J_1#4KV[E?DAR[W!XK>B$*_;\22 M0@]/:,FZBQYY!_N]-G$%])RMR&YW?D/8%2M_+N M@4$U)^,<9V;O_\Q,';:V1*%ODD@HA`T_'I9=:%@_8KF6#M.*!5N^M87^S$<9 M5S#@,0<%=?HA%TK"!7H1<_,POVRCI%T((P`Q/I$8=N3`:IN*GVU*>C*R/3UX M*4CS@IN>%#M7H-]GX:2&)I^5DU9U=B'T;ZO.JLXDBYPY:<4]9LZR]Y)[&]O: M>[06.MYKQ+BT"J^F.VJ65C7U(0E=!=>C1`9I[S-L5<4%.KIRO]U\+KV87_ MDM3NKL*/%)G.6*C,^FMA4MYW2I!U/:V,G65*Q7/$ M$[A$0T';"B@VB(1>\C1SB(@Q&VPLZE9#Z`&]6>+E=%%XD5-?KB'&JB(R!9JN MDCDV,;2&31%:V)(*Y4:P92P$UY9XLY)Z[EV1S]`;COLS&.3*4(UL\$50GBQK M>K.S:0#.DGR'=Z7M.SLF@H0MY=GOL>\6>0:Q(:"0!)YZ:=273T2F12!HZHA- MZ^`#Q]T9Q*WO#^6.RH5[@>S`3<-1_^'J?\#;.O/C\AS]2`UPV'LXC'G#4C%!S;!%XDYY0^,J7K-24WV!4C'7Q:_H#W_<($C)SH6J M?OV%_?JSR_YB$IPE_8H&5:2\CXI]62^U2A:J]::GAED'*0B==(FPO>4F:\S\ M8Q];P:XCIU6M@[1R`PEOM!5]/JM#&FN@[U6]T]='TZ&PZG2WSQF*3M+USE%T MUG["S^U:_6*HGS!F>'(_06QX9EZ\^VSJ>RUGF65R! MYS#QH",PQK,WFLF@YHUHLI]LEC4P+G%,;BU-?V>;D[$RN=I^]JRL-";>%V&E M-='>>U^O2A8IP6WDRE656MGT(Q*7KDH9D%I-Y\2MODIXD"3NT`V_,CEE*3<; M].8=@C($PM:PT<4L*=;!Y+108025UMS\7707WT!\^9]9>/[]'VCV/TT8C!FU M(A4,!JQ8).EHW6V&C*'"IQ)8;+.SJ:\;5V#;?8RX?(3\Z/=_@'[>GU:A)<=A M*,EW63Q+.0"A,5F?X!@O9AS]F)4>,+YQUX;_']@PQY]>-^JGC5Q<'.YGU7'S M0K^E]@0L<%K9S4"#2?IO1AK85XEW?DIHR;^'\8E_UQ&*`X;4M&*OH3GOFF_HL:?L'EQB@MW;'AV@ M`XA%0<1L<6,=0=,R.305Y,718Y9YK25HT9V_&AED*-CR^S\RMJQKG,$V:_0$ MYURL,28['W%\')23]02],I$G,,CJ>HDFN9K;E>4@2]Z=%X*?72)*HWT$!.AI MPUY80SH17*TTL\5QK0FM72Z[WP6)#W>E;N`FVS@-_N7Q>1?&TS4VOIP6F+_Y MK0[O3$%`]T`L_/V$?3C:/X6OTW\C,4Q>80B]!&,() MFSFT'+MZ2QI14G%2&5&:<>T!^W`$5X"3_#`N^!>)\>/!B^XB_+^Q)U[WK)RW M%@T5\FI32+F>AERK2KG#G).WQ-WQL4P%_*.T89=D4$$;872FB9?GCSIVB%:3 M=CDG;:))1R>!:V,D8P'T\O$*6*:1XB-<$5.$%18/DM),?BUD5(6:\A#&7K@C MP!T+-%N/UM/'*#E@3".,E[IP5O-<7!C2-!?%!H,#%TNPH!B>J'*@*@OZM80W MS84@FT/#$;-!>4!,S0YE"Q(L+_`N_H*31$F`#>0[RNA#8A32I&ZRX4B MRS3V5076"M%O65K91/VPK"K%%(4S9')<5!F'KJ*@L@9=+3&UQW&,=X_>]YLD MP6GR)?#879^TZ/=X3[7<7[TP8Z[X)@S)"SBICJJ:;J*45U-,:!)X>JV-"*Y) MQ0^Q>H+!ZZ\0;/*<*/6^(P_R+DU?#3P1$^W;IK.ZI3JO5P%M\Q+-`7R#:&M- MM'A'-CU"M5@7]@GZ8S<7"SV7-A&'F%Y1_9CMRPJ@+W%\IO5\\>(=NY`]]8*(62;%>X';>TYBG,5(E*1=DH*2F9ZH9W*#")/T7&&7QNS3+_BH,LS\JT[F#<\9O&>1" MGT,S3K6NG],OHM0H0_`S9MAZ-9^\4I%Y8R'IP$4'E M(FJ_\KJIY/+)\91!=0/:S?%]$N_8B['A["<\HUZOY$W=0$7X"2DH-RZW*/]'N4$TK\%&!.NG? MB*D.J`L@IEZ?*HCP[I9$/%3!#A):FX_'4TC.&-=__Q(<@_0]J^R]%Z$PX$ZU,)"@EP-! M'E5T[.RL/_Z>)65"RWM:?M;>'J?(#"#N^%S3!34\[^4[!W.7FZS>+?!]5\PL MJN=G(S$;5)AN/F/&P0U`(E2WS]G/2F!K(!)$RW@COQY(W^AO^,LJS?F,+UE8 MO0^@_:2/?4(@EPM=!0#SOU7D[XOX;YS70^:%<7[1+M=?HIWM/I>X"&.=KKXB M%O:LXK=VPK'V5L^F9^TI4,NQ9F#OTCSK`%4,NM910AKSK-V23+K65;#>PGS8 M^JE?S([-,.32ZR=6/^:RE*.PU_%Z&8'O84DX>OU>E8B9BS2P@+$ M./!"V'Y.\98$-&"R;Y+\5`-[N3`PKA]$1^#XN!C3S/^B?Y*8&:!?=9>?[UKN M9?^!/H,:1"0^TEX?K%SQV,)`_^R'>(."/0I)](3C'Q?OJ!FGE5`Y6:.5EJ)Y MQB$IUA%]PT]9"'G/OP8A3E+:GJ)34]2RE0I'-INFXU"KG6YTDBYMR'U(&KFN MI61NH4J+JL3.[+I7A`F9VH1MKLGEKG/.*60:/IYV1H!R.=6$:%Q!]%@FOW1D MBN75VK%I7';-"<_F.;M!M`>%PH:6FKND??X756-"+-,G;-%/U-Q:P?=U%_DK MP#,MY?F'@.9;_NA=Z_`7RJ#9X&]&%LDK(7GQ8X^Y.A)'/HQ,I>:PFG$P-BCQ M05F;2&%^/JR8G\@T#IC6Z1UJ[OLR_+46)"5$B6N@-#9E9AZ,5TW_Y7+W2P\U MX['<#&K,1.Q*(E"]<$N.1QS[@1?*!W)%`]WX+FW`%&L4:VR,2O+E2C%,UER= M=IOZ"`@H]"J?TXQ4!5D?4:23N]I'85Z[:&4):!?&M895/OA[*MO17H M'931,V)=0N%<)-KM#2Y497.E MAS456$2WL5OL5;128[+;V#8^2KPDREOCR1[:`>@S!OIOQ#_@WR7H5`/_EH$_ MR<&?EM:65H:S@U[8S;I8V!O=-K\HYJ]RWZX.\U>'KK0LB_@\0]?+\0=.^;E68PF0V=NDO1`2`UX-]^D\QR4[@E\IK#.&/O<=.IMZ2+&7W%])?83](PTNZY<-4 ML"+GQR:A1<>7L?/`@V?\.?+)$3]ZW[]Y*?X&']T/PH#AH79";-O-3$#5 MW'HDF5973;^I7.@`H11M79<9$,_!+H.`/*B9:5,>+0PI%N;71$01S69N<5+- M2(VN+D/:Z!J%!9&=GZ-9W9V6QAE^EYW0#QX,JITP_5Y1^N/K`K)HB.Q"H6Q: MW2R(YEP3L:X:B8J^F^`R#ESZ](#[]/*6/IC$W-%?:-?11WL,^VQ#E-!WSMC" MA$[RU@4@]?5M<)O'1/I],Q??-U MCOFZ!;K=K\G=N3$4<(K)'HY1CE%(WQ!\;T+?DFO4D8[-B5I6R&B/[LP>%D[.@Q M/ID-AW\EM1.^^+NL8,#BXMV\QB#*JW'SE@=V/D9?+E07Z2_/3Q8U>2R!D M[`IZ!S-Q5$.CS\Q1RTKY*T[O"JT.LO\6#L;>D_C%BW?)Q^^G(,:[":I9Q:R" M@I8S:]W+J;S=?/Y.LE9ZOD^JD"6\(!LA\;T(CDK'WT^AQ[8);,\HPFEMF(0- MY/CU2D-JJ#7:93$[VP+JSHBY`G>IQ#,EUSF!P0I.5,:ZFD-=D6N8O>/@C&>` M#D71NE_OOOPN65T?8EG"Z?0M7C?E#!UGN2ZV7:F,@5&+J#2)P.8&-:RBW.P; M266QMEJ2ZG0Z\DOC>H^?Z7]8=`!:#_4<1V])FN1OVQR@<#-I=2&S&Z>U"-J! M#'^]%IP;:6J@M->,9H73U-9D(J:X#G=-[2A4#PNTI.GQP,F-"?>#4:#0CNJA M<*ZGF#S#7'R"X^?`QVP[M0>'&9Z\Z`RK`+S\H,,X/\@PB&@GTC_0\C"[3!V2 MXBAQ8LQ-#2&BT#4-(3IAA&WS9%/-=R\1;:!#<+KGO03O"7\B\4,*W?ZGP(=K M2&F"1W+C_S.C37BSVP7PX;V0V[@EQR.)F*6_!>F!9&GQ>P3[;;_@)'FD3=>. M5$N57P3#^0 M%XVJLHO3#'CIN=$77G[UC-5@@Z`.""JQL(-ZTG/S0<_DZ3AR2E_P@HJ3T?Z?<_QV],_)R!^A5#C`Y M>#$<7Y3[O%,UXJ4O,GZ-?D[8X7GS=.YZ.M,]PU?N[/(U*2GM;24'$NX: M#J_T@ODD+3]9Z'<).[D?EKLS3WC`(9M)]7K\8-U+@@553SE8<.%&6RG8"]*2 MJ3+%^;-=82@Y83_8!WB7S^$6L[JY'\_H_[#*)*P>_)X!`B?+O00)AI[_(=@& MZ>)W#KQ*;RT:?'C-WEIG"(56I+B^DQ9_RJ@L?"#[](5BOG]T7CI#,4@AD4$O M^DC7R(0LEBELP+6/9[\NTQ37H[!4*,F3+>QSY)N?J#=0B].C^6HD7!YEI@]? MMPZUU@'K$!E3:BN`):(G-MQ-0S`6D6XPV+ MP&@?1#0DHC!XI@$[2\I!\EWF8_1$R"YA<"Z'R^$/JA5@W=6^`GD046V0^2SL M;I#W]!3CIV+K6DHV;)P)?_>.IY"62YVP=SJ%0;ZTDA;V%'O'#03_E'YC=*2% MPWD0<6UI5W).4DS3L)5@]%>XAP.1B*4Z@E0`11+X;-Q^GT6\)O`P]9+?DJ4# MOA7R"3M`*Z.?J=4;UFEWU?;Q13I4)'1E!M@.WD02SB[>-$52"G=@?0F\;1!R MI7:B7H.ZS0]XFWYF7HL=)BVXHTK#0DU&*5O0IMS$.NLS4+W@84JJVKO.SP4" M>I;94)4/0494RXG^7N1U@+13H48,M'V7U(J&FBQW'O-&+Q]Q`/H0GAZRXY&= MC[4OCB4`'H0E#_R*!_F0RA7Z^=]^*8:-6.HK],=_^^_E+Q%)%U\'LQ`QAN+= MHM30CHB?(VA;JOCO*?QHHC\(1PQ&TS:BG#"M`6Z/U,-/\GA%$IUJ_A:Y,2UEV"='`F@P>[:BA;ZWEH'XO_2?M1,?;S0_7BX.F0 M)G!1*P5.X*?EJ24>6P_:\R"C?;_R*9`_[UFQ,GTO.90/JT'@3UE'DQ4(S'8 M]"+J@C`T*%T,8\B`'"G.//QS3)+DDQ?$?_7"K'/8LE3BEB`1)3;"@^&:F'&G MPC+&*2#(6KG3\JA)E@)!$L32N,&$D8;N4$$*&"TF].?I4F$!'-F8E[""J)[Y MB"<&J#T`ZIE]T&(I0/VPO.*4TVKY/9N1:$M-F!?897!ITA9NU\2)"\/YYO`Y M%N]=1JB-D&\>GC3H_[D'CQ4(+PI.(Z'?,)P,!O_/477JX`/M,L(1A?>TNSJF M`T;S"23!0#ZCG!FMGUFA,%2F'QS%"]Z@X1-Y`KU,X5@%$""X"=.^=H#F!+2AZKP#8HA)([6+,, M*T;YDU]Q>B"[GC6J(\)(V8Y`*"G8,@1A>X4<$/O23ANT:\I`BBQYPUI&>KX!MK*JR\\<:VLER:./D6LCXB5/?6 M\\,V&[/_'37*3DKA`[E!ODLV'\H-TNX0+ELAP!_#NED@JN?[)&-EP?*'+-KA MN*Y[.65!#.<)JV9?(/^2>_HH4K&QG"A7$8#U%>IH3$9*%GH&*6E MS%RS_^3;:]EY&?PTC1C[F'JD?(,NWN,8CK3,']:NK(03/5S@N1*4R/1&[N.Q M3/XV<9U"L-E5V3/"M[9>FR>OC5]O\E,#JRR(Y7D-:!WNI:P?KU:&R>;$;7<* M-F[[80;>MC?.%S"6B&YZYWJ6EH]F.:/6\!;OON#%[_J=AQ.#8U>S<<*\VF+; M,(-_X=VG(/(B/_#"SQ';5\5O!\O/\W^/([P/TH_?X3SI_LEM MFX%VMBNLBH:@?6$RS3O"_!0H!W;Z8/TZNPXY89*-Q/D,FT`.L,5>C<,4W90' MSG%:472_L;K[!0V>SK0V-E^)>[*HLHA*DZAF\+B;.,S_@-!6OVJ,#M7&!G(_HAVW157AUXP)S\ME&SV()/L_ZC9FMWA==YC.0=7KXI9EU99;KFP"*?(8T]>C"+,TGX:6RT@,,E([B!MZXU$7,6],:GP7M=.:2.J%9KO" M<]"):NRO94AZXT2W[5?`B;E%+8ENO>3`E@J]]Q+,+J8H;GC/];<1P:M2CHX8 MEBMG?D>D\OX+BFC):AKV8%*EML4WB=ZQ4[K9,L-W6\C'MN`6&8MA!=B;ZX?9 MCB]7K&Y5*D8=\GVZKTC#*W%1SP=/H+V.=Y8I3M-SK]G!+-J?<->UZ/9#J*^! M0O(%_JP85"^GF/];HR9SS%<8[=^\>8OA;VW^A-O+<1G0US*D0-Z\@CFD7K!7 MF+EG>%?`U&`O4&A3H\?78W-V=RI\K_EE5E]5S/K';@D:BZ1*8RO62&)4:WF^ M,;)H^+B.:3U_YB0%+9R'Y#P3V3E);7GQQB@)C+QQ2NI[.;"0:0E:=18O=33\ MZQD]G(V;!C7][-Q<2JOSI5-?2&)4K7>MFM#K=:O+N;;NNRVHV1N5L>34:F48 MT>WY`FLPN&)GU@-Q,^Y,R!T3[JPR;LBAN<9)11%O?MG&0M0$(<^:%:!=J`T2 MO3%,$BUO'%/X:BZ)^IEI-B#L\_T)/X0TW>O9D#`K76TH_#GI.K?*A_,T3([& M]]G34?9->_/[MK[W6="GM:ICV)LUK/>>O/+ZAB9Z`:WGM@8XHN.NZF8U'95+ MK%MR@=&,?--:,)3?8[7B^2[+-#,JXR^5:'*BW>;F_CGY1G7Z73VFO9%&#(@5 MD68)` M+@R,+\*P[K!X+]]>U\#2/#0U+>/GI:F.H$_2X`B]U%^][\$Q.]Z3%/#BA9^R M-(OQO7>&&B9_@:M1OV`OP3=/,<;P6UO$:QLJA+N&(3WWI?T&)O2`3B4&/-1T ML]=E7G3DF=&IR(WV+#LZY?D7]C'Z$"3FP-#R))/MU;S'^IAA["QOUVC!3NHN MB9%G1V5^Q`V@PD)^MS2S@4HC;W2)Q.?BN448G1#[W??"P(MW]P>/QG0?9VE` M?TEH3/\5'[<8O\@JQ#D4A?Z8"RU M'J_DZJ*I#48+&6#22-[K/('+JD"RO8EBH[2X,9RIQHPE`656"]C#%=,!_F&&^6FDC[$7)7L< MO\?I"\;1%_R,PS_<1#OVCZL;-AW40K6&A?SS3+*@Q4&-.NNIAVD%BQDZQ=XU M9$(L5WYZ]@85&5&>$[$9U^)#`'_G% M)D?L)5F,=\A+T1XBQS.+'%3@>2C&?A;'H/"V'E43@S3*EX#43!P"'%/8'Y9> M$+(8KP0Z<7%>F="3GZ-3EB9?//^WN_VO7OP;3KUM$`;I^4.0^$,R4CIC6SU* M9#3C/Z1K:$@KRI0GX2/&S=25(4^-(#E0MY$!%3DQ?]#D<0OW/+/!_"YT14W8Q M/R:=YL&\AE#Z,X[^=3[B6Q*?"#_;IW=^;2Q9_OKB9%HL'2M=3^`,6!?S3ICI M.G^":H\EKK`],RZ,R@FC\`"IT`.0M>-"%/O=0X;A*&X6 M',,363$.V=):^NUZ(+1PO#6`(4$L-8@AG3@9>M_)PS%(#_^+)L;]07(H31$A M^]/H@7VH7!,>4&!_`.&].:[9SXC]CMB#A3$[V%Y$ZO.VL-J7M`;4N1K_/W\Q M[.;,((!62];!-;,O[=PT@%(UA:-0,;0?Q11$KGK%CQEHAD72MZ;'#S+MH.E/M2@P03=/V=?EO5%G8 M(&X#!@QK5A`S@RH[J#*T,*D-0988QDW+3>@9K3F4-7/*['".N]2":%?1R*_1 M*&(TBFAKDNB)/GYZ8]$(4MYXU/-U3`]^.4RE[E!:-,"L($DR?GH,[Y/"2CL: MWV#=T*F*7=LL[>5@D<^)8V6=;\GC`L7=B:^6%F]7&DN4? M2IQ,RXF,E:ZG7`>LB\DNS'0=W!)4?^30%K315B2R7[Q)#%'J"O$S`\.H_#** M#Q!,?0A9V`7K(T.D8]S#AF%)818>*AO#+A-'@N!K$$<4S[2_]QWL;!#@8''?"E!K$EC,ZNH\MTL+8$,)6P_P_.GDMNHMU]#-?=I>=["I>4_@V'PIYZ3E35-5/H M@\EF]+BI6?M!Z,E>L*)1B0$Z3S5Z_95$[]BJ\9!EKB\!.?'\&Q0&/HX2X#L? MC^/&-N@$YMAON#"X,+-UX4E,0:7E#29:JSF*=3'&U.U?3I&%Z:[\X'.>^T?T MK:)+;H'QX;[DR'W)D8]O'&F#X[6SQ+0<=(HM^=4!$56,]0"3'CS*AQCW1AK? M.P6I%[+;=(+H715X?)*DX]%G:6&Y/+5$+!6)$5;.`,CQCYYBIA+VV7LX@U6H]P=XN\^QCO6EZ;%G.(@\H.3%U+OEB50 M2)PQ5\AW>;HZY3V16SWN;@(W.RY.QD:?8W..VF8'(Y=B-LCFZKL7/%WZNMMY M(3LN>2\'M(:V,RR'UZMF-^]'!(A!H@L@J6HML[XJ2(]*S5DAK2TK'[WOWS!\ MW2`,F#[Z@/.@"U:000-3;J(]00_G:)%H4:!9$BT6\@3@I897"IZ2"^UUVND1X#8N0 M]0#,RJB938SE(V%Y+[;HO.Z"/4V"*0C*XQ)3DM*N7\`](*`QOU\3$3B9-,+[ M((6>;'G99A`Q2[G+?*`OR6^;@NXLZQS2[#Y/.&22/CMEQ>6=M"=[+KJC.YHI M20,?[3%,5(8HH45D-*Z>ZQ9C+^67P]/^._R=/V*JB7X2VD?.P"`,$+%/0_NU M:1H'VRSU8`$XS;BK,=")KJQQZ@V*)6O4,R^*_NP%$6BTN^C!"_'=OEK0_9>( MK^%_2(G_V_OS0S&\4"L&AMEFS*!BQDL$_5V6#!\\[I47QJ%Y^ M[ER<=*=VN3SFF.?P),,.WDH-1D/%:W=C,@P&M1=U6[U9W^\`T_ M93!EX=H*_E?C?Q1[=V\>:)%&FJ?O>N%.Z*T_/=*??F+",BR$99(+R]I.ZJP0 MEDDA+).&L,SGNXM9]#/5>W/S@Q>=CC*I>3WFL43V,.2!*0PQY$9&34 M";@!Z#FZ='/@FJ\MK_`+<=][I?A5[,FL'<'S=`EF`?&;,!\1YH&0XFXJ;'L< M5].Y]CEN7FU^Q>E=(7%!+=]Z<7S>D_C%BW?)Q^^G(!:L4=>R-*Q"Y2S9<'\J M[V`OE$O60MDC2MF]SO^!OMY]^9T3RU_UD#;&_0FP'?8",@9'/8+;%%#3LY/5 MP)(\`*G[IA*&5`*LD:^F<=FN%K_^(:'2#.N[+"YWCK`8YZ:*F-VK*/8@7H-? M,;HJWRU_*T M5<,$F=I>'3I*Y6YPSR486M"Y\R&Q4+"@T_P#M87K2HS+4?@K'^C)9:E77M"^ MQ50(AB'7HEP79DE*76,,^Y;9UN)XYX$2?H$;>-A.Y[PB&6P-CLDS=62@'*EV MAL.PW]'>\+%,DX"8I8F>8N\(!OTP8QN,>042M`UHV3NFBK.H^",I=/C6"UG1 MR0'3UX.]TLN+2LL<&Y"+*V>9.=4W([NXGF-IT`]%ZA^!&54`J'(PA7?Q"!7+ MLKD0JB6X@C3PP@_X&8>$G0IR2Y(T805#OQ>.$KFE#M';LMLCG_%-'(-7[3V` M3M]4*Y#5LDC2/&L)#C7NL`N.E]K!R;X'WK>K8I-7%;IX1\H9W@GEK'.\ MTY>]C[1O?K?_`F*[7\SV)&A*U$8"$WZAIT0C1EW((?82R"_>P$ M8?K:ITT#<1LVH5U+UP&LS68V/]ZFV>`@500..,T1`+^%[$M5OI7_[3W%V"&/ MJ@B0$=6Q&$24XKZZ9X- M57?BTU"B,D;U)])$YU#)NK%*8'L(GKU9KHO?$3Q`\`3Q1TN#=+#=B-Q7;D.U M+VT=KK/!P'`_WA`:\A7\'`\Q.ZH6\,#G@#8H2_C`E>^%/IQ9B\M#7=>,%7$H MV%CZ9O]M`%)C&&C3?J)YNI^864L,:Q@G"(+Z*"[EXC6^1"< MRAC&%K:#+TT.LI5XA08R+-K#'6:5'3$5^C4;O1N6IC M6%B]R_S%!V!4&UL4>J8VMF:8>$QC89#H/*N%B-HS;?1URM$/#W63PWBK4O+0 M0/]V*"YTFX`,?KDNJ,HD34A9:3_CT6!",Y:1X/'QVWK:;R@&S-J"%KS_E$84 M>'[:I@[Y?>G&'?#YRHVKX>^_\(56)#[?1+N[_3[P\K%V5[V)H,.Z`?LA/L?O[DP>D.,-8X&.(GV.A$?B4;AH@U MH=Y&=8):^3),5+%X71VGPKW\.^3M_D'A%J5HFP5\#@$F':HHL6F&""#UL5X0 M2GA)KI!Z"C![N#X=WQT'H&"JSR\XSA)[.FA1JO0L:GT[A"NW!"&9=YRQ*I*0IS00@T:.1%>694 MY'9.+2[`A%%MN2`3M)1HM+NGI#E0MWG#MFQV9*8H0:DANPDTF2HJ49>$/7:' M&-9)?@V_H>)'Q']=FA/"YB'C'[2-Y7:Z.E"MM[)Y]:+9WCVZXU2T_2D&UPF[ MJ0`2GO_/#,[76UPJ3`&#.,@O"P>3&^GTL4!#YWUOXV_0^X#\NO1I$!.;7AC5 MM)I>)QZ!?M_=)`E.DR]!A#^G^)BT0])0FB(J]:?1P^A0N29`*K`_@-/>'+61 M!99@X57!P\U%I+YN"YY]26L(G:OMC74/S#0\D_?L`>)/T-_A&6(/E];N&B`0 M>BD3,-#U57[KUG?2.U8NKK/ZD^GC]VA\@WIK8%B1I#_NWJTP7C3$^E6Z@%_7_(6`>;$TW_^T:`_-((/X9/Q!-L$$^R?I14WWX%.%&*F\\XWI)1W600+E?=N9G2GVQJ;B@-CCA! M`8P`@J_F0 M]G/NF(I-1?5%'U60`SA%^*4%*0#GY8!*-`;A(JA^,=WG,XBH7_[+]=?20;6! ME*NE"X#++S/`Q6S/H/=HH-%TXIZ!D;,^1LNW@W")PS[$N60]YEH"L.C0#UEL MB*'?/OAC=A2I>EQUF+6E,'C+RXGPX87;66P)I?V.)_MPV# M)WZE9/^Z6[G4=>4VE%H?]^-U,>`C!PL9@?Y`7NXM$[X^G9W^5$OCRK(CR08G MBJW20P9QIA8EED*4T3VB%H%5CJQP:!$&+5*ENBQ$#3I8]S%E>->J35A1??2%]S'Q,6:V/W"%D\58<+*S?(8RCHYGT.2%;(UTHZM$ M.4,<&PRR4XF785F?A"F:6[U`ZP23B\\QKY9'3+ MKF-DNJJ"#["G(HT*8=[X(A2?+O'%DG#%*NH4JTA0;)/SV.ARX+&"IG$7[YKT M+(*;NX3#BJSJX$&".%B2'9;A,Z?.TL)0CV+R^/$'L#ZO3SMU/#SKC"39]A^8 MCS4VH@-YQN4E0C2`'+T(SI$HY[+=5U7JH)VBCUR!K:G1*FMPO1KO$%^6"YRB M'C30I*\#DJ^X,_?5?=*,\/R)"6#7RS`7NW.KHZAEZ0J`)ANXG,T)+#:^?!MX M/N%3'(D!TS3[>`64?K$YRL941P\':CJ*0XS@P]V@FE0 M..SJY%$7"5>NQ^PRTC"D\B:#:Q9Y'JI=O`CA[WZ8)=2KTH+@-AX(0[R/3/_8 MP7P<,WKP:`H/5CT&M`*8-C\Y!C[55WOLAO09A]MP&)*'FW:`HV$:-"F-O(U*^G!2XMKB/.!!X$;HBKM%)-]D-*@[L5YHG\C,;NX&)&LNM;X MIZJMBLSTO^5@1_$3Y.L=V(AQR!?1T':E<$N"'5M50T-_-9/$7B3B.R!`,IS+ M:Y.94("L&>R.W=)ZP:X(\A)M2OU1[+IFJS5_!\N!4_I%`KA`V6,K#>IOT/Q< MYU/@>V%X+KX9+\&+,2LE#(Y!RK3'IA`LO")-+4._(VSJ.'?4#)R_0J)W+7GS M4T%SZ19@%:)?K?:MX./"E0_>$RN&[?_8U0:=X"+H!.S#*K4$DA3M](0C^/[5 M*M?T$,2[_*MG2=%X]:_9?54G]):V:QI48\9!Q-Z;;"4`9(1SN\A5BD^T;9]@4#$,O"T_ M?(O=P43+>$?5P+'M2NO[I;',@%OR-X@.!)=3#(6MM>>*J6$ZUO=,&>$0C02/I(4B]< M;7L+`Z0+[:VV(1S:P79[_\PI7\6'U3:\4%!K-[QA+?2U#.$2JJB;>$`?U1,; M!V^W)N9#5J,,-237L@J#V`95J=S#>4]3#R)>"(T!Y%=YACDP$Y+,CU18PE3/ M>$57B;]B(3X=NRI^VS7TJLDW]7!N!KJ%I&.?]!USBW?.',5F%DL*XL\`E@SK M@EJC?(2I+C@5X5/A`+X4GN03B?GNW^';Z6W9'U`?FO:-$]7(^UKJF.G63M_6FE+%4UWIAV%6MC14CFWSQ![#?]TX!*([.L9S]@G93RZ3U%1WF]>1?*;&ILD7;GX:4&'? ME4/)U\AWA=[1:OANJ`_V#>_PD=US<`^7B]\D]^6ZP+L]_8E6[N2%S9N]>[I: M4\ST]*C4S!CS@%-J;[A_I%@%.9>F9/2Z2IU?-.\EK76B>WC`,[GCA29!K]?9 M:("XQZ.H6.MW'"M@@\W.Q.*4@*[!(U^'WD>!8K5T5CM1'XY@R5*O/B@>=VB5 MUDX]XET(=I,K),1'%*1PDDOTC..4+4%O=SX<$OS+4$]&OK\.\EG0W,N3KJ.@ M-Z@6F>Z+R'3?(&5I!'$KKYXC$I)W88X8$+"ZDP2ZDP!S]]:M#.*/^P6S?6W% M\7?N!];923;0"38T4*[1A746Y&9O&5D6Z\WE:".S23!635%X8$-+._R,0W(" M:>C8--.)?]-;C1>F0/>ZE2!BAY451Y35KSU3G7EUI-NX8AWI:5K?CS5SBME1X+P0[W8 M02'T2QS@]ATX+;4Z_`O.Q$ZR;8+_F=%W",\H(>$.;3W_MR)CB).$Q!N:GA\M MDL:9S^SF0[E>!"=8G.+@Z,7G<=W]$WH(X)BS6G9$Z\7^YK>JL[/-BMK"ST76 M^B(25C-:QJ9CB-8Q#:(,$@71,PF?V3*28O"Y]NHQ9F>I)0T+<"JL[[/AG.)T ME+(ND!7._"A&K9DM-@%4-4`:>U$"Y[*1R#4Y-96_LA))E[\:LN=7+\HH2E)V M+LY'VJP,<[WC6C))\Q<=3JKE?61J8<;YC)0D]CZ#&1N]D.(@(-K]2$A4.\%F MP_9!4)^1'3U(0#D8>=0@IMXD2`_%*8-A\$Q9R*:(V+&&9)=1!_%$R(ZO#DMP M_!SX-`DP\EBO%G#S1)*ECR:4PA11:?LFU89R5%Q;"*ZFCGZS`E3078WGJ$S@ MR#BH.>R(A);;Z#&YR]D.A*[:$,)%@HM!CB#$6T".J2#_D-'(D7PB\8_I0 MZ[Q8.?:0=Z=>! M9BDELFX\&QXB6@+2W;FD8J`%9=&.-@%I`GZ3CYL<2`;[=H3@;YQL*F2"2UTV MFU20D59S4,&L\)*56;*BRA9_K8^HM(I18F;/6$HOJ3@;P];=Z>X12($NBJI' M@@AV$61ED$,?.]WAC5Q2.ZN>E3&BH"661XFUP0P#4.D,8W#O<@$(D0^QTQ&B M%3Z_!\?LR)?XWNU_#4*?H?&!SOQ%*53&5@E(Z3Y>OC82M\\H9()K>?34;)'L. M73CF&*VNH#B6&"WOL3CEC<%5(Y_;#FG!!/IRSWP6NW9K2:$G%Y>3-E$M%A'K MQ;59K3$7J*\J3ZN`XB2%VU2>`A^.&@G@FKR+1JM0T,R"5NM2YQZS,8M)BJ>5 M5TGXE'EGH&>KGK-QM"I7EZJ%)36^GG`^^KUFXK9!ILC??HPJD3@WHS]*P*RECXS#&1S M:BTO[QN[,')\2$J8O%^3]20W24EA;60X^(SC+5'07GV%2;.OF_FZHED95^+R ML5.\$C>ZB$IC,.GG3B>7D"YSXTKM4AXU36\65W!C3U>[OP*$B:[U60_&["@( MP_#JU0F%.OAVN>B2B_X.H\MNC\TPRF3Z9?3QN^2$_6`?X%V?AUMWK\P$:.7Z M7B9!:U&8?HZ^XN_IXPOYW]B+$T69VI]94K2V,ULE:G]-[8:$3IG3J=LR)14L M8(L8Y$(T&V+YW&:B`$S2O!P$HR1'FS;D&;L@E@TO!U\(TGSUE83`1H3V,%$$ MN$XIKL^O#==3H\\:D6U\8?A2X.XN#Y]!>+%]P?E6_29?')=DA@DSL8]AB3`6 MI9S47/!8+DGQ9F4N8*QN\[B!";,`0AL2M.\A^F5,@(TB39K0*I/`HLSR!)X5 MVK.J-X/(EM=KZUK%8!RT4_6:X["=:535)&(EQUC=G(0UC\N)LL@8+O6%T-<, MMA?`R=_D*?:.R5_`P3P4_N4F=R_]8U042U>AHAHW21HY24M%32 MDJ?GY^OS''G0*/.@&Y>"AB*(VA2=A,$F3>5,=,CJ'H)MZ*"Y@5S71%$)Y5,3 MRH[JGUF@/**%+@?,=@:N9L>S>-BJ!]X^#,SB70[S%?57YX'^L-R:%_HZTJM8 M49?D0B_A=6BKK)%DA:`2)M,CZTCIAE@I+F6`@*),;:95#"M72B=E_WIIXHRU M+I%MB189!*EKN)\7,,:.*C`)%28S*DP4#S>Y?%X[-(0BP3EP&-TU:!0A-'!_ M'?(?J\>(*)J:PXA6C(S8B$@495[X%:??\#..,IP\DH]>S&:'VNO2.^MNIELH M(^L$"YHTF5QG7>`A5JG;N\XS(9X+T6RHR`?@@YQ\,4YG\\?B9)P.-6*@ M[=L$5C94Y_8*,&]VH&-YZ',UPL'OP\?OIO+T&,%22E1@*:)XV#IR*$M-Z.&>=ON(K`#D#7QH'L/J%)70J[@."9%X]!-^/C]A&F9<`=8>_Q0(45!N)9I8?8HX(),:+@6 MC\8SUMCD`@!-S??-@#[FHTGT#M*AVQKH>%+T\>)!)W3?ZX.=X5&Q.>!'Y>:G M#/Z)&`))ENY#\L(NG?3X#7G^KU-*-0E,H=I*N"I6OX-ZKE064FQ'(AG@U!OL6I.`%"1*ME M.^24-]&@J9OX-7U>S4(@[CG)ID#UNX\2L"ZNWSK%Y#G8Y*0%,WO+![?9@SRZ+4Z8& M!A?BTA7K2,A$`TXR1\82YT2R6+K-CV0=.9$NB)XZPT:BYX4LZS[7 MHYFH/$TB]9@=($LG=6WM9/GCPF`7-@P9_98MR+:3U6!INW7-#GWK-3(;/BF; M>5M^#>B$G@*\6U]["\/MDBUN>F!#L]&[2W6B'@Q4.J^`P](;+B;A012T=/!@ M(/CIDT,D-ES;.@*'\-3?HE\F: M-S3@Y^77*:N`H4,*>02U2#*0L4N;15%GO&=O'WH]O?A($HN.^&/38!R+X2N" MHZE.\0PP;.R6NFW@KMJM\?&"?>"85+`&.P-RXG.TPS#Y0>W?QV27^6ERXQ\" MZB;`O\'6:/Q0G*K8JLY-LC#MI!50L86V?50#'^9Q;`R1#457B\3JW#3MO1 M'4ZN)O&.CYGQH^0P2JHJ]5P>YH@@6,(7=#S]<@ZI%3=FK$@W#KTYQ8$:6QF* M>\4^L3F<:,@-OKFT9:GQYM16YM0,]SE?LS]K](EK!:.B9%0KFI_8B%%9>J?? M#!MSD MBHR[[XFF:W[X5%AX=Z`F8%T9MP']9;Z@K39U>?!@H37"S!XB+Q']`(?@1-/2 M3T&-@T$*>+8"&U;V_#5$MLRNN8@+>>AS$9-1VG(*\I3Y7X#3TKN<9B@R)* M`N^-!.-Z\Y)I8&G%][),&%HW+K@`0^&:5J8\7VA>QJ`DV_X#^RF?)JR`4#^+ MYT3?K2`B[4!Z],==H9_8^7..7+"Q(`=']>EB'#2A1;,M!9*A,60=6VUU.LV6 M&2>E\QXF0_;$>DAXK$F6ZR$\-W#)H\=::.ZZ'`/D:'N>*29[7-#:J*9V#J>" M,'"+;W"0YRCCEA\UAJ*>O2"$"SK?T1_>)5Z(48+]+`Y2=_:[N4!GX7FEKYW0 MIL>.'2-R<^0X-['F@6,7N#0FRU\KEY0&C\8/J7:44C^;4:-%0'SCE?04ITN\ M,M`!?@B>HF`?^%Z4WGMQ"DI)T+T=2-GJO/:F-.(2!NI@5@OW%S3.YKY\X@&O MI$J-3GER1_3B4&MWF#8.C1:+>C)T.3(KC*Q,.AA$4=/C]P'G,G`SYG\=1(YA M]6X2-`WE74N`[B\+-"-BV!AH3`3'%6.-WR2$'ES8_ M!+EZ2+(,OFRME;4"LL'#6`91YXKV,P:[T6CN//!,!W8$0V03W3?5LL:2"26`(.I.PI`D-H03P;K8C3^BTJ2(4I_WOH! M;8TGKM!BN*%[6"&#C`XE>C/U,6(!)-F:W+0`)YB@'(CSQ:J^)M)@'):M;0HB M^L%W6,H[^JK!!E*O!*[O MN;;"[<*&=UI'E0_-U5GX>]N+SBRCO=G#(/*@-A\].(GG":? M2'Q;)_Y-P7N!ZI3-UI*?X]F,T$:V=@8%J421XUP:-5*C5,K3NL$@:3ATJ*0( MI!:CQG)WJ>4(`FT-6I'R<$35 MVH/X6-A8+\@-#X_-`^Z&&GZLH;F1'I49+AZ>(U)Y!GAJZ)R[R"=_QA'^WGMW MHN!I_J*=IUJL$91E0(-T+8MIT$Y[7?ZP+(Y%+4%&/E\3DZU$%?2L-J7I8*[1 MGCVA.8BH\SJRTF@P#HN=5F7&A>.K:L.+HN5"36\HQ.DT^56-Q(Y<&J?"'[_9X-R+;#R82L1:Q1RJH' MX0FUU$2W6HD#T%Z9#T`=J&#JBSTCIL_E35X:!9H2V2`O-#VT=%44;,X8M*FRPK[_S/9"D4$6] M2?0(.%"JILKIMSQ`H[X,U^Q75/[LBJ(?:BPB\W%;:.Y)64/M/.UN5B.8:'Z( M^1P`N'BPUG87AF@G6MYT:#72^,U021@.4IH_V(8L3B8DHF'S%$.03,\H2_A0 M#K_Z!*,G0G8)FV=)*C/JXT MXMT]_;Y1>DL3!KX7WD2[;_@I"R'[N3SO/ND-@Q-RYB^NE%.+0A/JJ!=+U0H4 MTTS%SC5/O$%%`AVBT:9-PBD8J'CH)&:-ZH`%H`NJH0"O M7P=O7(&WO/1JX24C7ZO)=Q]=,!HZ]'0#",+_*"+PDA%A?S$)G:MS=**:#9B"/33[,305EO)5]Q> MG]A]T-!*_($!@M9+,!8S9$_+7Z0`?/VY@RVE2F M%DPKMU,5F6E+?5U'2PU'3OMM926LJ;09#4I_CDF2(-^+XS,[1/@(9_IM^+&` MGD^+S/A""OH@3H-_\9`%L/*"F`W>^0=8ZT3;/A_>AKMCDE9L8^@TV.`YG%8(I+P^$\`!_/X4D2.'/3@+BM9FBW$$ M)D7M,<0!OII?L MS8`\D!*/L!4TQQ]WN7"P+'CPVB%^^Q*8\..>@=.OP,E.H,W#47YI-IP%R`P\ MLY@BVE^*:&>J?FH^1+?H"?-=@U%*/]7B;MT.ZL6*:'6X5Q)7H[T6^Z"_JAQN MA6LAIDL\[PML4F3GV.QN;LUA?:&8%8H7RYC5ESOYE<&[S]$G$A_O]@_E<=E_ M]<),H'@D,S5%SV@F$WR4K)D1Z3->UB@=QTR4?"P2`L<@*=OH6R;>();<"7+) M8J/-+S5,-0DVDK?#,1>@:'@>9"9$\C&6NBCBF-SGF*Q.V[]D,(YHE%7"T?A( MT%R([*YYY"-(N51.@AV.BQTY/GF*@G_!S5.=XUYR65X`F1_+[8;&MH7B8=5B M&\7ZVB5Y)#=\N.L+NX(,)S?1CBT^N4D2G+9/\5+,U50OX[E,D%2V;H/0^A/G M:(2?8-AT-&A(E#G*T5$;U^QQ$O`!TWU^9QSF*ZCXXBN/I71BCD4-)VW:*0*L MR;JQS!W:N0%,Q(K>F54O`K4PNYKMV70[T%6V:4)7#O7NR=<)8&?H(^ M1[YKGD,7QF+78H8@(L\ST?J`:UHW\]0.GE70DBZ3#HZP[5.CE3E4V$/,(`*+ M,!M9V80E((V+^K`;0\(.4U1T[NT;2<<^G&UA[319^Z0Y%=W$#]A*M?+HZ!-M MAP-LK6;SI263LX+)"6-RDC,Y*0J$*P-)7%T-R$M=?B&7\VR6%?MO;&Y].`N3 M42NA,HP"U5@*"QUHOYH3TX-)A#UF4P6GF/;WW@@HBZ/5$E"GOXXI3R.XO>26 M+8CY'-VPF:B[_3=8[97A3[09[_FRF4\$!@QH4-P5:1]P2(MXN@>":"WU^4P/$*R.V=V%2:>*Z!5%^<']G.:U%4J,\5ZYRCH]T,X(9SVUF(4I M3\#V#S1,-7C>WGM0.`B(^[1:,(GX#$,,7N2%9RIAEQYA6(=C$(TRK,LQ&.GH M?`F.0;3SC!^][U\";QN$%%=W^WV"T[\%Z>%;?C/%3;3[4-U+0=/> MQG@7I+>P^9."\L6+V^?\SE)6ISMDI2Q#GMGB=S#MJNU45<9[VRAYP)V'4!QB M`T>T0.J+H4188T&?Y&7"4!(ME`\."V]J@2P^*YKOB,[+3JCKAO**I1O%.1QP MN*0S3MLF07O\N'U_T''L%HKL\_6OS/L86SQXF7ZGU47\PET-NUZ:NAI>"*(Y M45G,!MW5?,VWNJ^I%<;R\.)0O;PW=V(>V&\.95:'8G3G[85Z%=H]O?7"@/X9 M!9X%Q;+IZ",F5]Z\BWF4OP+O8J2W^G#P8GRW;VQ8@D,=W@N7RD[(VNE+RF0U MY$OE:VE*:4F5*./B)`S551!+#BJHN4.Z.*+#D?5O4^#3XSR4P=?Q!.,6^HCM M%'(MS1/-"."6D$\*")^*=9_-8V:"5X;A<;5\"2BV-BTR)Y"[4QN8G8?TNZ2& M:@*GM,&),?LLS6(L@GE^EAYK/;>O)YZ1"J/2;C8JZ`FO@.P^D?ANFQ_!6)U8 M>W,ZQ>39"[N"2SI+);0DLN@27+I6VL)*IJ1!&H\;N,YO+H)IP#)=_?3](N7B M?),'`YG26!UVC>9LL,H%W)F61?;AQP[7@V-1Z:!N0-BM$G'D) M,P/HNI*%?@YVK'U^``R,ZG] M$XVP.WXQ4+8]!FFZ_&'W]F`MEBFV86U"EMRSUJ+EW42[!]Y8[-P]UJHB82*5 MJ2U-1C*9H:Q4S4P&B;$")1@[;*(,$SFO:K3JX:$C+),#2)=G*L!J\VPP;P_3 MEL>C\4.!YP(EJ!>%0-(3+@#(;@<**Q`>U4`K!+&2$I+H]5D'[U6C[U>F93"L M4J-/E^]11[6+73CJZ!?8JW@7X?X;#GL?%GJD]5"/(KTE:1*A;7,`\,VDU^QO M1']PY;[`_H8@PY^OA<5&FAKF[+6CV>&$J='JW M(\GJ\:,WF3YR!THWB.#^4D:PW)?I^G,-Q-LS1RZ[_[`&VL679H\U*Y%M@AX< M]Z1N(7H^I!@3XB8QPL1V"8OZ4_1W>.Z"0-$"QZ";,P,/PZ[O`SG28"/A_)H) M!]Q?D=`XK)LU,`_KTKX:L/-L0F#SYPY"N]6B@^#N;?T!L\D M9,`;?@C@-!U8K;>:<*D.&Q6OJ`$<7<_X2),,#"'T/*Y[P<9C?4CWE&;`XS6M MCH"VGCCO>[*?7!I.Z&L4,O8A>U!82]7"GKUV-3^P,+5YJ\&%G]?6IH,##(NT MJHVP,[EAU8<:?G9TJ$$-%4,19QHJM*/+"WE_'@LQ@C2-.--)8P"^@G*-^:6N M_3$,MW/D_NGJWYSP4*)V(E*?M0^3K:1M8,[0Z,;GG\VT?&MV>K:L>1R*'8CCJQ(L;\;B[J]'X-0IRD),))?^202%K$D<&D>BB4 MJ(6F?QDN80":0QFOZT]1]=@5/R33N$2E$5K('LA1P_DRN#'>S[*!(.E>E\__ M@N6[[RK$P4F,-!OA!W!NO21@,QM\`7"1Y5C!DJUD]P\!S;?XDE]CV!3&3Z?1 M:3326H'F%7-O-;150+H8Z(A"MGGHZ(7S8Y`=BVNN;Z+=S9'$:?`OYBANR?$4 MXA3O/K";Q1\/F"\,[@9Z#2.5!)AD1)=&&C77E@W3RA[DW!23UWD^5&1D*^?K M65&9%WVH+IGGV1+0%8+U`L)>S!5TM=$!_C70*7\\%UX^R>@T]!Y$4^G`]3K7;KJ`S%?*7:D,ZGR5'% M^NFJ#_GBAI@J:^6Z2,KOUBP3HS)U?;/KTC13A0J9W(IMTDEFKY//,7P:EB^S MPI0/6=2!BDN@[DN@>J\)J&)YI MC)1:+4[-KO:=%ZQ7;;`63C@I@1J\*J!*Z"3K0-732?L@915NT$^EY!I>F1H/H#F<@8@FA00/34@ZE<035X#1`>T MS,I!:GY,:$:<4B53WMY[8ID:5T+R.R#9>MAB;&B3SX4UT.R%80?1Q8$"S?LC M:2&[S'=@\,@VWL62:"Z\ZPDB6%1UOJ?X2F^B73EB]>>8),G'[WZ8[8+HZ8L7 M=3=5*>>L9)%\3EUJJ]916QPI%#A(:VD[UT7B#6+)V?A/-8W&$\E>,N9APUZ@DRO`ZT#PNE2\&I> M0?'=5X/B9^@CJ`KC?HM^!74K+'!#]E?X(#[S=,8@"-LC.^I)9 M?")P='VC.OC["?O<]T#)SP%U>)A2FAP#'VUQA&%4!JP=20S+&VBU8<7F&7OQ M_XLBS/RJY]/6@+LB8;LG+!R%65=:_Y^*=?#)FR^UYTN%/!_WI",N8LR+MK-+ M^-"EG(O!B=XYW4I3W/?U3&F.E?1+#>)46>6O":EJ4[V$^OX)_5%+<+VJX-K7 M%6T%Q0T$D%>`5E5U:@.M>LH4-B"`B"A/J;KG.S:Z6G0L9:4^Q2EUB396!V,* M1*%A.OP096@P8GX@F1XS-(TCD`U? MA>"Y#,P,:`!746/J!'X+@.&!N\1*^1SE"2X$,^)(;!8S.M$VWSV0R*T]ETM= M1-VQU'K0EZN+)OA'"QD@P$C>ZS*!J\MH)5N;*#9)BPW#F6J,6!).DC'X3QQ0 M$7Z"X:F!*&P/5ZP37T>6B^M>#2-+&)W7@2W3`9G2#C76\@=.O$)=OG?="6#'A72+$1'[9,L@TO/.W]P\W,`_,]RSCSY'? M>QKJ6++\=<7)M&@Q5KJ>UQVP+L:^,-,U?8+8H_Q,$TR[9;XCQZ&.-B.1_>1- M?(M25ZB>&1E&!SZ-`H1=A-.&R`8PLG9HB+I2[H'#<*_)+#Y4;MCN!]+"G1T# M2!*$48-(T@F9Y48:?CCY)Q+GPZN?2$A[M;1M/@5QDC8WQC-"*+\'.)\#A0%C4U8VS/+4*ZMRPMA/^ZA MI/;6JV+G5;[NKEB&EQ]8V-V2165D1+E!2TVR[3\PUY@>HOW^J-BL&*7T@R_M M+O280,S@LN5H)MFJN:'U$-/4@C-G*,EO&BQIEE]``2M#BYFR,C=BV=O[RE\S M'80:[A41PN0(BSNL@(ES3H5=AAD=BK!4A1YAV,E#SJMFADB3NL$,+3W[!&OB M27P>N4)Y/&&I2\4)-1D]5@/=(#9@?XB2PFS7U3/WKDV6:%`B_^G;O!"EKV-_ M=IR8'1@R#1>N74K`N'(/K1F#SCV3CA+`W\@,@^EJP?F_G3Z+!HJWT!8%I@?84YOKNO\$:H_ M;P+QM.0ZG<- M3[^HX.E$D@!F6N;S/+_T>YX+`,DO,X!$2X<'QVU&HPSXCWQX+GDDM^6$&XG; M&UY4LI3J7":+)O3E:Z6KV:5*&J*!A('K1JIBAH@H[>CLTVB1>(0')XVH0P[+[AV$YJYP4W+=1N0%M/*V&')!^HAEW"41R.PX\A+LN:J'@/4M MV9H-SD*9-CN!_CYX!DR=>L=]97*G4ISD92:[)2JBZF MXMA884/D&\[+8E7$_@TTBHOD*,G34V;Q#.$Y?XIWS?BU>`R1@P51;+LVL08S MU;FT(.X,#RI9@QT["&T8=`%A'Y4ZC3]<%K[$2F05"#-T6)I-$FVGV@/9B0L*-2OT%G)L-_@<&WVWIOYJ:X MM*L[YZ1IIY0*D^UH4DVS_D:<_/0Z##%TJM7K(BL[[&A79:91@N7.1V=;([.E M@:59K8M(8@P<;3\PT5S=0ZR,)FKK&X9BE5,LB:BRI94??&BQI6$`W;RSI MP<8;3\S/"KK%%Z8'.2UB[).G*/@7W(B2Q<60:[Z+G5V"7@LL)$K0RP&S^U7* MP5H^BHN3:LH1)A39W.&.W6"2\)5N^4:$6!3./#BQ-D@#N.6$#<;2'S(O[)XE MGM^"`E4X>E&VAW3Y/2G%X-Z71`HG5Z&[1_N<^VK\Q0#S^X!`##/0N/WE^$%*/+=A!-)2HU2]L)S+"UOZ2 MS0;@3AGC-&ME:2^\*<&$(1]\0Y<(I'SNP_T\'"F"]U M`0UFYX1-0>*J!HG"EZP:"2.Z4A,)6O&0A=]/]"7O>3_@1A`21]*545&83A.^ M(^4;P:^XC"$(BW)=YW^CFZ6Q.]9V1/HSM_$K2%Z'\,R`,+].S"@J6OO@BK58 M-VR@@,NEVGC"CI]WC/.%S=#&49KWV]G<*"ME<<6DCR]QK'008<9F.*J'+%$\?>]L M/)V`$^EXJH$3H_'T5C*>WDK&TUM+X+Y5CZ'J/8V@![PG?[3^R)NJ/I^)TS7C:E\X$+<3E&XFGO>9'R="3JXRG MU3/`-7_J!*H'6K*-ZM%&;V*ZF[R#Z?G@82.8FD()"Z;\5[9CEZ1>6+B^]6-D M)+:ZA1([L=484+IGFIP:?J4!G6+W-W9COYT!)`W'4#-(TH^AW_BR,0#%EX`6 MEP31TTVT^T;.7IB>/V&ET78WB`("J';#-HU;GN^3+&++X4^<$M!]+`);7!7`?@]+1NTQK(SG MWZ%Q'Z+&:=UG-UY%?P=&`GH60) MWJ!MEB*:#)$72N7B`H!&I/U=@@+ZZ:.G``YM\>"FQ>2G.NNK`\$@I1]FN]PN M7!X`ML/@&/!#;S>\]"0O'GFT;BG-"*O_3V?V;(-2[!\B$I*G\Z:VV)]]NYCX M.*%?!%XE]G;XZ,6__81NPH04)7,9L=/X^G'NP0:_/4WGH>3@Q?5#:7R,=PEO MEL[7S]N)?F:^W=O+V^&'].#!+8&;VA?_D=4CH)^)?B,WA,Z"'G-$<+\BGVEV M$:-+#I-V!)HRHB"A2]W&)3DPW%5P@0-&.QKE_2J_XO1`=LT$_\([VO$ID^3' M]8SV.C1L"KL@DVP:=AX:[V6Z6>#<+$E>?E;RMSEI[R2?F,H^UYV!;>;]*12_(93L\9$2K\NY=Z(-@Z< M%1+-K)#/PI3Z]I!ZYA@._;VI!HOXD5IW^[_0E,G=_J853@PY%<.?UJ@_(Q_F<6E%+?"UG( MJ9V84'4.1./VIRP^D>:M)<>.0W#IYA*7*:_037@C??[)+/<4'&7\5?T`XQYF MO[%,!C*K9)E.+X'X!]R_NZ7[I-#K]2=ZA.^6H:F<&P8'.%=+=\W^<&4;2L]7 M)P.?JX77*D$-=#::R^R:5_568P('_EQ'WIEW3Q@699&(CBC"H,M#T^?2$_ M"[WXX9RD^)@,1(#!E(V(($AI`,&#=3`1,40%C.&Z/U\>4B MT`!]6.[-T,;VS("Q$+.,XJ:,:5WD7`9@AJ.@DY"Q$C7-HJ:[<4,<607P"+<]21OPAXC`_.VT!0:R`]+N%$O]X6 MEPM=`%U>'[X6]ZRF`":.W2Y#S-0I/U:@==5R3\U]W`^7Y)[$D=DX>K1C\_D# MV\P9D!TX]Y*)9S5_*6"UNV5*-QM3(B$16Z;"8R/L.C\I\>C:"U>]$A2__=Z$&4 M7]P1XF0?;KH9+=^@6WLSKD*C%F+?,=GH=94/G_W)= MQ88@HD]IAMJ,Q*MG@6`DPB$6:/70(K(/;IY!1/E)H$E58II'( MU&=]B%K=]-?\QZ7)(6X:(O$MVX#N)*QC=88V-G7=IX$&!K?(?T;Y[XZLP9O: MYF(WMGBK&QX4-='ZPTNC8AQZ_"B\_/.]\W*,_)"WSW_YE-"($R[)X/%!H9F$,F-#, M^G[_\8!C[X2S-/"3SY$_%`8&DS:C@B"I"9`.UL)(S!"5,`K<_HQE1*D_WL#F M*;=BS'#SML$L`X8FLGMS=(`^-W)LA"NS`*H%LRZ$W'!\!J`S$OT#!'`L^87!81F1 MZ$82@Q8+96#"HAZ3S;V3ILXP4I$!;V#`_G5AA%U>QB?W8*MW:0A5EA"80C5; MZ._,FCN7FIB$,[&`IY9ST3=<\T&7P#NS*LU]^C'-EQV/7GRNK>`"_H4E__R* M?S3)#B@85/;>^#:,HS?&C7PIT])V!:2C0IG^PG9@-V_'F<`_Y*7Y^LE=>?T- M6QB\M#1VE9DBH>TZ,PW*=GXB,5^A`$73O@(YX@?**G;R&*WM>X_"W\C3[(*)Y8/-9?6(/ MW,$V=P<)

P_>T;?LK"S+$>S=JX+]OS>6._UE>VW&M:LP,0]JX"K@J2ABIH MNH'F[/^)Q&FY'27>BK]QZ2O;/5>@\CO;A/64J+^C6(@F-V M_`;$#O,;9))/)/Z"O00GM(9?\=3LF.FRG#G;Z:OF%#7MC4&YKJD1FH MCXR'U2ZFT>_BUE!N#G%[Q9V,"=-2W"3SL-0H*JPZW-4RAOT>'VF85QVGJ&N_ MSP]>#&4M]916PES6'ZIQUXNBC))USRE\S"E\*KC++VT)*_9&E+W[W/(;5570 M]D;6*9_/6L=F+7P5=E\$E-W`V8%Y'P26*R=IJT^SHS]NBF-WO*>G&#_![4]` M[O(.USS_/GBFN3+?QW@'Z[;VM`+469RQ%_.P3D[L^B?ZB+N(#?*]4P#1O^8R MV'53-;>!#MXS9`G@SA.:E%T<=-&1%C+X(:PP[$N#IZ M0A(]O8,[L'8;M(.M.'[`;PGD<$H/7HJ\&"+3]A_8Y[?NLD#AT6"&\V40-/!` MF@QPF`>[",;R0KBW<)?Y;*!NFR5!!"&%FCC%A/Z,T1,A.YX_P?%SX"]^:K,I MY(Z'`4/8->2H:0E8Q5T/IN]QVH+TQH@X6!]S#EQ4C!P5^W.WG#DD.)SB$_.C!@89^F.V@=Q71 M*FZS((3.$>W['&G7B9J+^8H]F"`Z064V[,_\?$/:O@GOO<6T^P,=N$;:W#BU M!Y936N44A<$QX-M.-S3GGM:H;KMI:!]\AW\GO$Q8*IC!N7"5??9>9)^^T(_C M4%PSQ5Z9&&>;;@`3MNE!5,*/-).+ZP(I%VD.X#.W38,GAA)99?= M:5OLQ$P-BX9<:66&17)J"($EOG,&?`$SAFK6')Z2 MT0=TCR,QQ9*.HYELN,\5K9AYEN9;G"6@8(9E5S"."P%29J>RH2AI4X5_B.1P MD1#-L,,P`!I$C);%67YOG!S&VALK1[Z4M4Z"N\043J5`YX!JY6T`!Y/7ID2. MSI((%#]@^*BMF?WE!O?H%/)KW*$SIFPO2R% MQI7\JR.1T7L<'&10:QY@D"6PS=TG[G2#%R;+J*9UA"Q&-"S?SA?\"^\^%;OY M:N>,]>W8P)@/W]?VW0?2N]?M%M=1P[:*,^2V['X-HY[-6E5EW)^EPAL>,BG+ M$.QKK8X0:6Q3PWA3S*9ZM:-%@J4OF)Z-K="OV^AT7 MZ%N&>S`U7R/>(LMF.]:V,_92?,UXC^G-V]AM`*4.FLSPX"5ZF58OKRH%E<6@ MSTV?TG>N#VB8FTK#U,IS>%3R8ES-:'_SXES-8CW7KS@_;.`+26QV627*,=)7 M'2QG0?\N\?Z+]TZ'ZVC+J0^5:JP_&E$I217GJGN@,A0RY*/EV6K$-0\49\HG MK]`ON-6]=,XY2'PTXO\LU_]'YK)SJ,[OD-@UU$6DQQ^NL/ M4-*/%]8[=,1I6.D/.N8T='J`V,\7`=X<29Q"'6])DK[WZ,-V)TXB:=$/&TRJ MY_(D:J'ILX9+&'`[0QFOJZ>H?(S@^0:Q%`MS7:9QB4HCM/@VD*-&F65P8W8? MB`WX@&!MHZ8Z\O%BL".4>$ZCQ_1^!2L`@AT&!_JU`MJ1@0-CZW>-PW*E\L:. M8C$3U2Q):7"#7@Z!?V#[EFEPP4^$JYX(!VS7@)>@`PYW[U+R+M^0<(8]S2B- M/;YC&`91H+^T^T>68[:VH](Z^TXG$<)!V<#QY0P%T=LK\,/(6RK]J(S MHBU!NX!I\(S?X?T>=FS7ZU=E9P=7[?`>-F'\R/$X1U@ M2P9[GI]RTFZO:!N)[<7QF M1?+](/G^[W);>6,^=.DNJ#DO(=)TYKV$CK(Z4+*\APW:L`8-1PG#]$T<4_*R ML83WYRI)?OS4S8L7[_C_L*UY?Z4XH54?]"[;[;LE-8/+"VM*^QR@LR M"PQ;OLU&436G^%I(;E;J7P;'6>="Q/`W(NM#[8W*5KZOJ3'J"V$QC$U#+L2R MH;II5+,-EX34T^7V$;.]X?]!N3O("T'W;^[`(%POT!TLUD_Z^/T4Q"S'!]HA M-MH]ZC=MI%?4-KV@<^U_RR4]:J=&MAQIJR!SWK,RC,#RFGVF@`2&7.4@Q8SX MQV8)IMRBL_QUJ'NS$(U99X:Q$,ZX>:.>*F[>R#?](YJ>"%HE_Z[XD"&_VITM M@@N.N%HH5Q\E1$$"4IR5RU8Z&HMP>8EN M17XMR'\0=G;R/8.QJ7[%D&W=CD6_[665>NW)3-3WZ)I.0-?7JQ9O(`Y2TTN0[X4^[#^`@\O.R#N=PG-Y MH0+?E$Z?<*OH%`<^/.1;`DA(GA;?4OX*O)OQ#NF;?S/7-DLO_UNI7S.S3#`O M%I7EPJQ=WCLX7+ZW5R M(*]OROWY+4_TYGZ6@?2;`S*BBK?C5=^J5KTEZ;_AHQ?`,1VW)&(OD7DAW$LY M))<=JE9=1SM1+?T0Y,1K&%/>;KS-2+1RH9)+M4>U>IYN@E;OC!65-4.U MJB&HFULZWH5&ZH^P+M6L&W@=J%TK(CM0HPMQU.8[$0Z\U"K\->MVC'K0-[?I MMML<[+$X4+\5.,XE1O[O\Z6C?)+B0Q8W%E'HCNP/6]<=N1=97V;L:OA=%QIY M%U;*PJ"3H"P3(^>%Z6*6MC#N0%"P0`O]02MU4=65'D0-L[>XJ.HV3]T+V M$RU%9M-3.4N3V7@WY>-W^">^2=,XV&8INR^$?*4(@'X3":G9I\\1#:$XD5MR M-,'>8%=$R9X%SS?A?6QT-]2JH>K35*R+NQ2YE0VJVP%J-"VAPI2+KFP*?$>< MUW1&##HK!;-C[FE%')M!^CM#-9#W],D[N+X"-$'%-,R-H!CS72"T?;E8*+:2 MU.]S*"^/*"\D!8WQ#3]E89:@QP..O1/.TL!/X%HQ)P7&LJQ4ZQ&\4E[.HO/= MH69^6%E^?0I<%`S\RZ>S>[GJM8(B*/JH&1B#`A>U_5^\BU#>@U,RWON.^-4S M&[9M%7O^@>]=+:X/;70BV!4Q`;50FU$?V&3VY@0&`+XB)V"KM_")-A-,K`11 M1HN_HZ!A3SL7_^G8D.D5B&W8\X9C]9[!_PU48:+/$UI4]7([ZC^>X5(J:A#Y MI44J3`J3$YQ;Z=-BN7B*G699C8,9^/DM`K&.N" M<_I5N5&5_?6R8)*,OR0>V-^I,3\9KHQTD7L#U2MFRA2M.Q=3;&K:#T&20P'O MIJO:82NRNE9DQ:[C&*[['(Y#6`,-UR&P*7`=6QSA/1664JYC5S.]'N&%<";-?D\])0LLMSM"YCP,??X/5*U(R6,[$ MH`8>,V'!.\C5VIKZ'2U>U36,&+PN?F.G`^(5G8$J":\1ZBN!=)#UPY;&*.\< MTNT.E5;E*V=FUR+-01$D9SDH1'4T8/$7! M/O"]*/W(EHQ]CIYQD@+`V])O/&6A\(92ZK%[O`Z:,6RP@`&&#N2[KCU$_"FJ M'B],)XE&)0I?OT4-<88:`Y9`B]D5I>9!`S*F]K&H5'=UZ:8A``D%B+L0,JT: M+*"HN?G(JRT+KD/+8Z.W7G1&+T%Z0"^'P#^P,5/Z'%+3YM]E/C6PS9(@PDG" MSN4)Z']04G-M3$S`54DXOA10BD*^:5#J!'"0:*)QI:\XI2Z"'/$7DB0RBPGO M<H[-9"[Q`D"N(D"D(+Z82&I9_9FFQ@6KA'5T7 ML;1EW3Y+U.>[#)\U2T]3M*Q7NW";?+_N&OFK=&-?:LC[U7ON-#H]KZ5#_(LRE?MCI$3?)VM`]2_GMM(%TC.]*1. MT)CI&;V?W%O.J5I&:V3*]8T4-%VW"/9\K%.Y2-)@HB]4(MDD7SA(]DVN7\DLR5\SO8_7SN#%)I]<(K&EB::WS=.7X&:, M=)J<<#.S=)RTNT?:G:#9W>Q2'1K#CE*O<[*Z_H<)]V&J+Z'C"!:#NZ+Z)ZD7 MFE#_EE#/#D>!.JYP%Q/%MK!M1^"^*55[S--6G5:89TM!%@6V MKVR5$8^BO#*ZL9O7GJL1U=/VT%E/N1-]2\?2-4T9^&POV2X(,W`!XSZC=`S_ MPV%B"T$EQ^D13,J0N6U"DL=+(MK865S+P)F=NS72\ZFZ.>CO1;[_\WIP/"DL MV4*R;C#BAS-\8,KCGDD-5E[R-P^N?4N3XMB&75\T4LY<#T<*F?79JUQ34P%) MI>`1"LN;NBY^*D]+V;$.'8LXB0N].'7D$+WV[*&JM(T65]T$KM$%D$N@MEK( MF!]LQ?/D-W=O\E.O-JC$=IGS->%Y<#3BPA!M8P1B$63G(P]1=MQ2Y01'#K.$ MY>'#Q<=%E^BO#8(/UQ/>])+6*XRTP66>H27D^0<` MI<:/QE\&JL4Q^,_PM!.(9,).-UJY&8BL8%U1AJT7[29'LQ9`^=5PGX+E6DV7 MP@Z2U025723KRJD[=G[*/87.'_[TW_]TLZB6=#?>2871IS5 M8$.F-V@/-Z7RMXCI%EJM2*DY<0LBJG8P97%ZTQ,D+`^B!GW$P-S%.(?WK]X9 M7?W[!M%7_663'UMYBLESL,,)RPVBS*-`9&L62/3NGYD7!ON`EL`.L*1/HC1X MQJTSI.!@;*;-BF.OVTL0"FW'3L?\75(>EYULT"Z(L4\]+S\BD[(@R<+4E;$& MZZ0;%'<70#OC6VYGY1R5=`(ZO!W2-+-AU^S8NX]I@X- M3U%S8SG%J'"\"(?-2?CA&-B/Z(_4-$0O)TOO%] MG"2?,/Z&?0Q'0+0`)I$R?\7!E%KPEJB#F<@^7)`8XT/YVM&]VMB8EKF0Q[*A M/0VQ*,YS+AQ091J>*+10DP@#&2HJ+((HHP=%60`46Q+4AYS+@(LHNCH,&$.+ M;VQ@Y:J!%?XDS!-&>Q$>^N_N$X]0+(K:F MFZ`!^"W/WO?W.,+[($T^1WZ,O01_P/R_ MGZ,/>(_CF"6Z26AE.B)`TTXI#R;;T22E9OU-D75Z-89H/-5JE]X\*?IAEV?Z MD9W%F^=C9Q5YD!-V<[!3SQ-B]]<=+K`I88PT[;34PT5W<@*V.1J5D" MQ_C#95>-`/0!*K*CSR69/M3)5!AAB9F9-Z:()=TKY(J<0/P3YTJ$G^`4N:%> MAUN4R6^PX2?>(2HC(>[T!1CZ=;.0'6G'CH(6!IHW]H@%J4/LT1&QIT\QB=)/ MN,VT[H-"9M8>Z+&X4X(A(5BW.T"S*IEX]B8[[2%1<\Z&+8K@?[`K>ZL%B"F. MCTEQ6J4/1[9N"1R"_8Q9GC#P<<0.M?2>8HSA-9:69QC:Y:DZ_Q:\JG4$= M1>DG5MG@HQ%L4H-K1;1]R_K[\^?H&2=I3[]G/&D9Y8:2:L)UO!9&8#M8S!"` M!S+V`AEMSRC(4RP-:HD6)BHMT8:Y.$<=\(N`QUR(LX"<>F>K'O4`.Y\O##OB MJ.@R>DQ/L%M!47=J?4R,4WSQ*;K\.TN)\_6,\1C#K#"P&\>LT6#_.?I$XN/= M_N,_LR`]/V"?-F\:X(2=A#4:_Z5R"R7!2&[#5)6JJRWNCA6N0N=A6_J=[8!/ MCL"*&\B&63$H*-#)$=8=H8'A`>3$6U-42*.TQ2+\N M1,OKJXO`M+$1]N7@?"40_Q37GW),\XRHRID?&_K*H"TMPV:"MH98^ZL7!S") M^CFBCI9*P8]L-_I7DM['P=&+SWQ6W`_H/[^R(_MIG2`)K4N+-P8LY9]3RY(6 MZPV\@Q[_]2H@]@4Z=J^+S*C(C7CV#:(&4&X!U4S0!^7U#H6995V$"7`2@RAI M.@X-@Y43625KC&I!!\D#&K'BPG-!I*`@$BZ:D099?O)(=20("A(448*=R-0$SQN=\B]B>'S0149=U1DE"$W0DC_\]?/''^%NX1-)@5!>B.@O@TSS M^KBV\$B$,V03B%[GR*8CAG'\[-T?O/CH^3A+`]\+DR_IKG?KL%3:0M`.I]7S M%C+U,.0-1HH:X/M@3OF->,P.:AE"U-+2))4"`U%JLQ;-AK+4B+04TDS-:UK" M&.@P(7@0ZC$PN"K*%I:L!+%V0(Q)&?!L8THC:Q54Z[2NM<]2) M'NL<>J&+R=Q-5-?*Y<42YL$S+V'9M0;*>JT&>Y68WZ*:W6 M!6]4_+:V1A5Y&(UFU?`C_S^.2-1R6)\COU?]2Z7-7VHDK18NI>JAYWO&BA!# M=3CG-7O&UL550)``.D7(E1I%R)475X"P`!!"4.```$ M.0$``.V]6Y?DMI$N^G[6.O]!Q_O9DEJR)?>LF;-77>7R5%?65%7+V^?%B\5$ M9M)B$FE>JCOUZP_`2R8O"-P($B"+#S-N508"$8$O@K@$`O_YO[_NPV_>4)P$ M./JO/WSX]OL_?(,B'Z^#:/M??\B2/WJ)'P1_^-__[__]?_WG__/'/WYS%2,O M1>MO7H_??$)Q'(3A-UH+SCUPN'EK7=C0&CB)F@$H6O= MR`H=)$%RV'GQ_EL?[XM.KH/$#W&2Q6@5;[TH^#UW/^+?S\$V"C:![T7IA>_C M+$I)6'G$8>`'*+E&J1>$R8<_BU6D?1(5/OSX_8^%!_ZOWET:5_="LN_OS:FK MT*4U=7\:7]V?+*A;_>]XVIY[-**LC&7_U$\[R2Z,J',7O:$DW:,HO8N>T#8+ ML^1E1R81!Y2E@9_<1?Z+]QKV'2_Y7D92JK3BCT.K=>['#/A2[/^VP^&:?(]N M_IT%Z;'LX.>>B./P'=YKS,2$,8/`K1?$OWIAACXAC_XWA4!BPE&XC(V(?H^C M+9G.[%>O8;#-`VA"(N@5WN^#U)@:TIT8P,RUFZ5T]9W1, MA@.)^H-I47\83-2>,RDF0\.?)4,X[;`S(N;_9%Z`'7GCMI9X) MB?F8')F_H(HZ]:%NX,^GU/B#?`_(1 MV%YL8V0P?.CV.>ZNQ4B;%B-ZV_#.9DB92X_\NMH\QB@A!LR]P(@*/+ZFUQZ& M4328%QA;>C(8CH;LGCN,DET,N[G89*BU^-HH.SK6')=F%$G>TW0OS,"EILW8Q\1D*EQ/Z(]!>O`BX]F@"7B/6Q` M'B@>#PN5OF`'N9I91"$O0897$Q#/T>)+SYUPR2Z&Q7I?'3A\AQ6\[\R/PW=8 MP?MF+W#X#B2XB3UFF*NMN4_/,WV]'H>/348&2Z:#T<)LW^2+$4=&!10F!DJG MOU$W17M&:85NA@W:??>K.7R'/B$TM',KYF]$D0?TY=;S@]#4;)S%;Z##S-[9 M;@R&`XG:>WG&8#C4!K#QG=_1]I&&WC\:+.B9#G9C3!8&G"0,>2P_P'G\6)_X M@3_MYH.?L:!G_BS&V!G,H'E>0R1X#9;993JER\ZY^Z@'[L-/1@>;A?82_=(+ MZ=7%YQU"Z:,7DRYVB'QC/8E;;UUQ.[Y;+WR,L8\0O<;;>[>WS:V'D%=>LKL-\18B7"]OV<0)R-VH__"=+&5H?7J4%97Z#G"$,^ZP(?:?L`] M^4.C0_0U1=$:K:LNJ/6\P[?$=/\\!T*TZ3Z"S76#W_\_D-9.N)_E7_^9UU:,KU*B&#K:CNYOFFR MVIQF[:>XE%R\)F0RYI^^7R&]PO]??S#*D\Q-J/4-\?S.EIV+]01"SRA^"^AG MV\OWIA!=\1[(I['094OB$JV(<$839&-C_$K[&N#7M&W=PR[BIIV]^+0W1O[9 M<:]F89&2XKM#'G[^Z.^"\.29FQCO3>,-FS=NW1;_\8T1<;])\3<&Q,P2(AX^ MY+&*Q'0$AY*3=>,Y_U\D-_':`.A7%$D-J)_F`2B'U!Z7A_=DA&^*N8Q9,9P MGLA4*JO`78NQC"\H,K;F*'JX%CE$'[,VO45)/J%7*,HUY8]`0]6+-(V#URRE MF0XO^`%'=!U`)"-];/.:;RA)>[N/3B?*KJ36R9S=JH>Y1W,Q-1EG]85B+[:- M?*/D6&M]I42LY^Q0RJ8=]4LEDHSM/#].SWEZNTAO1W@?<+<-:A%T_Z0!W4Z- M3R/096X?E"K!KMG&;S\N%8AUN6I>(,*/QF_ MD./W3CQ$P[@V?$5.3'-?CO&]!MI^4/UN\'C(?C78/-Z)1T@:T=87@RT:&_E_ M=@7Y%[Z?[;.0UC!?I3L4`ZDN9$*XVKQX7Y^(8]_B^(L7KUOP[\^H'+X^C.;C M",;,.9`W])&O](&?3/C`?W[7&>I[\H?Q$R7D2\@OB1)+HL22*.%(G%T2)1R9 MB"R)$DNBQ)(HL21*3&%'?DF4L.XR2Z+$_-QJ291PUMV61(DI.M22*.&$\RR) M$DNBQ)(HL21*+(D2+H7O)5%B)AZR)$HXXC5+HH0C'K$D2BR)$DNBQ)(H,>E$ MB9^61(F9)TJC?GPA,+LD7?[6,I\,:6D5/NE\PIF"208*9GP)7#D_-X/5 M)V(7,L@[8J-K](9"?*#FJ/;"<]U;D%5H40Z35(OY`%C=0`/A6$H05W:;C(7> M?(*Z(\!UZ8@N(G;) MZW0GS`F%4IMRV"3;S`?>.D8:"-N2H@#SY.\GBNQN]6I^Z):FKV?R\.GG@V95 MXPQYV8`O1@5;(QOP-@-R[7&=0DD^?)7;M0.SN-U\X*QKK*$#M%@<($A_G"C: M3]O0?'"+R-I'"#.&KJ0IACXVD`3F#T9F#U9/#&0./O^D<43P#G,61@PLBD+W MLUT_@UF,3@8PHI[.P8U4^A)I)&X8/!LXH#C`:Q(TX]3V-W54Z/_SAP7\O>SE M(/PU]FP+^-]$:]O@Y^E]\4:^U325EYCLV0O1,_*S.,CS'M;_RHJG+"_1!L?H M"?FAER3Y9S]'XNEWR&U&[[A^OWXD[JJT1,NG@(^K@RC78X<,";([2DJO- MV9:D69B1M<1==+I&IA$13'Y MR1HW?HK'!Q4<6X&;A,]*<9NQ.ZI;)GX7<16^H4.PN>D+;+,R2%V(V[X"R-/#IE/*%FLG>C8DB*>`32G=X?18V MN8C6?\-!E/Y*_H-7M56O=56C5;6UP2O>_@ZM,SJ_9PM10/ETI$=$NO1"+Z)% M21%*:Z5'\^$#,V2&[:7*JQFJ%VM141=6>"R3-^.DHKAY7LY08KHRBQ'ZW7.V MWWMQ\#M:UU+LR+=A7YZK=^V"FH6()#UOH'XZOF>\GVE[W[!F-^A_Q@4%TIV_ M_W[\O-!!G/`B25!NW/O`>PW"?%8WH"_*=V?$)66Z>W^>J3P(EAU41E[03Z>Z MY#^;[`%]J:W=8AR1?_JHLOG5SHNV=#N[3A,0PQ[(0D3LQ":9=US6#/-I.^@` M!C;HCF:D`YW/R'FIXTO^,@?R1\<6_?Q`J[0#H,:*NQT@R\K>2S@:8E_A)"5? M-H_N_/2W)X-;#Y,VN#D6215QA4W;4R:.RLF8OW?35[:)YYCHZ"]^!Z+88;[Y M2LQ,[$-8Q,>[%.U-.%K_SGOX99_.WZ4;&QLM^U[?1Y4>J2B#U.76T3\_:RJ, M4!;W,.#-,-,>7LIB^BZ]3VA=^U[%$M&U6L3ZT>+%^WJ)(K0)4G,N(^#<^^O& MX/PNG4?.SO8]")33M<+&.LH]H+381S3@.!U>/5REQNM=.@=D2_ON4).L.GB= M]+3K@:PWO63'?1S&B'>H]-/'<^3Z>9]>I3$&#GB2.G\Q MN)'=^[2EGRSZ.3]O*'[%+IVE=,L7E6''MPQ6OHYU+.[L]VW]L3VQ<+=6JZ+)\M]=`NNXG?%[BB^=BK3:G7*GX* MMKOT(=N_HKA^!^[*"T.TOCQ6^I>$[4F@(6Y5>=J^W*SA$T0=-FVC)H#;_>;% M9_OVYTIJZ8"`O_F*8C](T&,<^.CTHQ+*)5GPH"UD,1T\JUE#$\3"3@:\FN]N MI2WKCW'8O`XYZOL";RC*Z)4F3$:#CC*_-)\T_>EM`2&]X]?75#56N84FP=N5 M[Q8P&:?[%_3_Z$3SS0O+M>'S#L?I"XKWM26CX*&5OGRJ3Y(^'\=Q:,I"*OCL MT>>\"LI032/"6U"55T1V*EP*D3F.04G]5"`&LYQ749([8H]H&[R&97K_;4`" M/KH/WM":675?FOZ$*2&]\^!2TU@-94+>\WIHYVY_\(*8AN953*;D!SW:8L9T M*5K^L=5$8KF*IBJ`%/!E0VNJ;T-\3N@-^R0-]E[:R51@_UB:M/VCXVCAZJ(" MCS8C-AY^GB@>;KPX(HHGCRA^WA&3\[_/DM15N!%1.PXA-6V50HZ(\[Q>"&N\ M%_&K%P?TXC'YLB-BLO2&6*EZA*>]@:/:CO5L+K^=XQ#4M8#2AHQ\'VQ8CO]R M3+^'+_@QKA\3M1+V4XN(1FPS0/E"V1WNJ>:Z7:-7P:NA'(K2[$P*Q_$FUDH% M3$QN`%*F>HC_C+9T]?*$#K2L;&D'T;.%*FVJU"RY-H[C2T=S%<1)\@A%D-$FW!#`=N6\=QV\<2_3(?N/VX7Y:N MJ]!]X-.Y;[0E'OB$CUZ8'F\1$JQH^K(!02G+9G+XU+)//ZC*=CELD3:KR7NL M-VP3R]6@3S+5*LP"27LRI.T7DYFD]A^.+L[:RF%8KZ(GF@P=$W"2^4``5L33 M;=XVBG1S:W%%:JAQ;XLT(PJOT\83T-*=N9('."IZ/T?X-4'Q6['+>6%OA.\XEJNZ4L(@=JV5+1[B(B4%:87%B?5M2@4W,6;F`MK`@& M#6OHVXP1[`Z:E5YAQJZET+=?4Z@5?C[2[1P<407:^JB\W-&#(_!*AQ;'20#2 ME,74$=NC9VO9]4)(?_+2\FIFD3=(OTA4&:)F?DA8^SI)0KHWQPZD>W">GW_$=%#=@S$? MW5J,IX?R_O;KB78M`4S>!+#\B$)96!+97F2?)!&NM"4H3S?-.)0.?'#/L^;5 MYB1K64VMK/0I&9.T.76"D`8G:U%'!@G8I)F:L8;3?3/@:'0[\5WSVEIQLT%^ M>LJKI*]!>REJ[7%*;A%HL^KN#6BPF@[,>QM*$^]4\0K&%D4TVP0$L&*S"K'2S9R' MJ)X!U#`IW8?)5;DKZY.R(NF?EQ7*"`FJ]2_V:O,YBHN4LM_S,%A.69.;K^5U M^HL]34JC]P[)$-$KB"_XYJNW#Z*<_`F1Y7:4/.$P),OK+UZ\;IEKK.Y.&8=# M=^=ZL!K9X$I!;GC9YI6?!-BGY6("JNHR/D1E#="C(17+VJ@)YJ'ERTL%0'(9 M`_(!Q0%>/Z=>G$X:SO_\80&T&-`=*SD/:8U]]@+2-]':44!?(S_.#QJ>4$*O MDT1;^N+@(Q$Z?LQ%)[2/.,F3^"71K\62[RB*+-^S5_6QOC,.J*B$QM[=Q\(] M([2EM^\==4XR137MG%HL^M M1Z=&+K9SIG^.G3/\L)PSC*=I,Q>F.-7*2/1188PQ;MO1 M`&/7`]1@1E2*6":EF-M+#TQU`8-=I+>(J.N%S\3P&7W&H)&D`SF02=YM'S+# MV[X;F?,//*SE`#6[\/ MAY*TG@67@25[%]^OJQVMIM5=@22TED)APS#$7[S(E_QH:3#DNXX2P_?A3?HV MMN!@2L*Z\K83L&$#J/B+%T2TA/$J>O9H$NMCC-X"G"7A\7,4)$F&UOG;RY?' MY^PU"=8!32N,BVO=Q6,5"#W@"!?&IN^ET%[DW&W0KOF..5#7[\.%QQ@W"\X^ MD%HS>X.+;3ORARNB1S?_1IJ>[Z]U^O?A9*"%+'A&79;^>3=N'>P#*G\*(ASG MGEV\0U&0E4:6P[@4"S[L!2S>AR>HV-&"K8H#&>7V>B_6_LO*)/3E@0ZWXZ.ZV>A\0%UC+`LZ[ M$KGRNIE:1"8?F-@[5*DA=./!S_\N>R##;RTZ\'*?W@7X-JUKP!#DIAWV_ MP,8+JLQ2&BS3OK"J;`!Y,8:Y5B^RFN)JW^_X&3'#F$\I'<:8"*Z<:PSI+BW= ME3)@#'+DNHDB1VLN8AK[H#OU,7'3E0R)#+N=HJCSRFF1,8ED@HL)5@I.YF#J MBR7OTDJ"&=FMWDLZC(PM]'-C!N*NX'73R)JQY(BF\F=&]LTY9=+(Z#M&6HUU M.11\>FX)-Y:\?_S4FY'CQ*A).#]^^V&V$X!N_HA"U`"33U0;OS?_!`UGU:E> MA/D[*NEH;N7OR.BODLQCC)^"Q[B:YF/)B?03?D;V*ZW4'QNID&9K M!;]P(T/(DA?(Y@J-C'F)K"&5Y+:I3:L$*41]6"@XAD/)19:\0RG-:&07D4TX MFFIVG;PYM0^5M<^-WX,G2!AL9/RS)3*79H?IJW(V9C^2.7S\2Q] M!K3R\D;^'$PJ0T]&(8UT/=-L%9S%\40^2X[3.Z5O9"=R(;G/L;IC/RUUQURJ M.]:_P%C_2F+329#L;Y:A:H/-M0A865NT/Z+[,RI'L`\C^_C64!L;-)YV@GW= M+?I(,_&DQ%+U,A&SHSL;\R+J)K!A:FOH-0`_K&J-)E+U):@!%NYY7IFSI;J- MQ$9)J,JU:0)6U&8>L%6RS`#@%?4_ZWF&TEQ":;XP%WC*V6(`7((=]\B_[+=Q M:P:0U8EE_YFO`4[E\/7B--6YKSGS&9G\]A)G7FO#RA3EO$HN=JLU:@%?U,@: MQDV`%&L:IPGK'I+4X2V28%XSYDIK]ET@*3RK-&VA6J[I7+"M8:A!$"XGQSPC MMAJTU=`\>P!;Q*PB3*<^][[%,0JV4(U_:&(AU:@]L1`TF@MVE8PSS,1"((&1 M9Z`&379X1+%/S;)%]\$^2%>;_$MR4N@^\%Z#,$B/J\TF0>G?@W3W1.Q(AGI' MOC;7Z`V%^$`S_%ZJ^Q7U4^D6J$?IJQSN@?NRO_[DGRV.:6JE4\B!!7/(X0R? MOM-G$GT4O'FO(5A\ET73/D%OTKB.8QG5]$[!FPQ!W$QUAER3!)D#KRR.=6%+),B_\Y*49O3EW3;Y_N?E?R&A>$I%^@U779M6U MD08KBV$`'GQLU$#M6-'IMX@1??J;UV8C?2/7"^D+N>>R!>VX`@%;JVWMK6.% MMJY"MX\)I+"JV,&\=@B?_1U:9[2&Q@O:'W#LQ<>[_<$+8JH[M05*9+%J@E4Y M;OU8N8ID@P:2`G:__@8LKV1U2O<_F1<3D<+C;1!YD1]X(?D$>99G=UVA[B*R M8M\7EZE%^?.:K4LL*;=V(%AQ99:,4AH\.N%)B8>UN*2+#VS&7,U@I2A,,Y`I M"6%RWNA@R"HO^"PQ:Z"8!1P'G+I^0DE&S"2OJ;!!6SE.@RG&$F5#]`X<,CW. M)DK<[`\A/M*Y7'FXEMB.$%=X3P_["EA&ZR>4!C&B`@I]1J-EE?ZKTM)<5+@F M!H_0.M_@"%XSVOMCZ$7%F"!4_WM^JG-YI#\_$G@&?G#PR/S[,QGY^#;8I,=_ M("].+K;M,XPANS@?CP_0A;V,:PT4X5$,W4K,EI>S/%H?0#YKNVR#>=3J;6B' M`GLPYD^,'MZ?.XG,;-F;&.)-?%<0L,D53E):<&$;T=U2.6]BM^'[1[O-3!#/ M-<40&&YW.)L]/*(H39$ITLY6F\LL(>HGR5.0_&9Y(X^*D)`1^TP$C,GL.TH# M!!W82M&6\!#06M^22U:;UJ!0B2^/]/_?$A%Q+-J0T^#0VHY3XF`MILB-.C9A MF&9,X79J)` MI-"[],@0?H[P:X+B/&7\+CID:?N)D6YJ_@"R#SB"8L+Q)`,3U%Z8!T*X0 M3L.ME_9U7:_QGLPC!@G#<#=&8S*K&_N^`H+:6'06FA=PG+9DYN(T2R(7O:AX M_.\\:_Z$]J\H;OD`GZBJ)@X0VTU[A/W*'CV,XCYQYDSF1)]7K=HS)CGR@O]+,S_^83# M\)99(6*,KHPZ--35Q+V[ZX;&/%QJ<(9P]Y-.YEP>TF5>5SQ9&Y2T,$?'.$G3 M.DU3YH;.V4`^;YA]V\^-L9^X;PL<$`\^(D,X-UNIAJ<;4\:8=Q>'A\^I%Z>+ MCRNQ_^[YN6=,9FGGZN\7=WP\YO(^D/Q!FU4'=;>17Z8K6DAO1LOC@A) M\F$XWY?HU'P\X':Z1(DA1F^RD8.KXDQW!8:P&I0S0JG&#"\R45SB:SU@>91IAZIGC]Z_&"P"-=B;#RPE^R5>]!N1R8:!4IG2G?\T^6L, MO-1)^YF3!1[HHPQE4>/\++>##D+P@*.X,5H2J83]^;(/0OKPM1_A+X\U*-S& MZ-\9BOPC/W]-U**;R0:W<"6T&D`'UC$2-S3J"]7*;(.%<3$[AQ6E3F+ST]7$ M+3B3A$X+^^"4P!'P^>:K#V:&0=U!']9.-U,!5')R(F;RETH3#J2Z3>QC2@(D M`*8$!@!`!?<'@:K;STP/B"^/IW_^-4`Q?;7A>$_?;.!_@"4:=;_!W$;V43G0 M9UC>5.-\B;GR<#8\[6.U[I]=+:0_R\*VO&@*M[4/8#FL09%5TBK@=YO3-QAE MX3Y=_(C?)&FP]U*TVISD9EP^8F=R:S2M\KN5FMI'H1*F<"_3B#_WH`1YUK92 MSS.=`!3[4+FK?N#/0V'*=L!D44X/F/**]\0AMZ.9'D'65/U!&G8_2,/NAWG! MCJWX`+#[@0^[R1\GU53]41IV/TK#[L=YP8ZM^`"P^Y$/.R/''A9@]\G[%XY? M2"_):G.-7E.R1&O?%&,LLQ5;E:,BW!*6UH@3H1U&;#,9;9R M.WG06E]>JR),#I02:VO)CB5!Y_+"^@K']#F@%%'9!7>BI6A/M=>YM"Y#JON! M5E%<&4CGS[.@FWFM@C\__X+?4!S12Y[5\_OS\$N?S$5'E"#'A"9,PX=10**ER+]S!?^)R]KH.W("$:0JA3:71"H%RCJ:%1PQ2]D"G7W[P6V#.NHJ.%.HVR.$HH M@_@;NW?G!*KN<;0E@NRI.:AE&'LT/)+2S&R2>>V^2)AAP*T6=N^<".<,HIB; M*'PB`%76MT>X$&!`1&+C@\62-=XN;VD\HRC`\0-.@8\2^'OUAD3W=V>&N/O= M$6G#']_S]X7!Q\4-AP3YWV[QVW=!_EIU`8KBWVTX%'_]Y_E9Z[LDR5#,^*+P M2$XO`K!(YO5%D3##@%\4=N^RY5K-_=*M1J^33"`X<>X=&!&;+:C_C111[WRDAU1F/X/W55[\\)&XM0Y_[A] M_JW:KCH+EV\W:>?IXASK&\V\<]S72YHJB.7*K,4,^"_>O""D8>(6Q[3"P7E' M6>P`6FW+\51L.S]'Z&.\@9U!4317IFW0*B_81L$F\+TH+0Y-SG/3]B)/3%FM M\7B4\\.JO&$&1B97D'D=^Q!3)XLKF`P#+]J4JS_]MM?GDQ;^AM##+D7X&<-:9 M?:HW!*Z_\1K.#[K:9AL8QBIRL2']\T1GKGG2P*-WS%>0POFK)'4Y:$+J^0%< MS4`#HUHH#!O*?YDHE&E>S%V4I'&6'V5%1"CR57KR4I3G^*X?4>Q3:V_;J%9O M6(Z?2L/Y85W;;`/#7D4NM@=\G*@',)S>V/UNIKUX6]PE%" MY%I7DC_6;+3:W`:1%_F!%^9?N'Q+"(C[1GF66#/$T_YG\[W7,1\Q/IK%X6B! MU(C8HT1<1PHW+V7JES+USH)S*5._E*E?RM2;QM12IMZ9?:"E3/W0GV%Y4RUE MZIG<_XDN9^J5,_>PF`$N9^J5,_5*FWG'8+67JES+U2YGZR<%N*5,_ M^$)[NF7JE[KT2UWZI2[]4I=^J4N_U*6?&#*7NO3CX76I2[_4I1\':4M=^J4N MO>LH7>K2+W7I(50MQ8.7XL%&RM$OQ8//<'HOQ8.7ZK#OM#HLOY@TKWHTKUST M!,::IX5B0>AY[A4-E[CZT+HJ@7!K^C-2U^=8^39!7! M9ES/B\HWJ]>PV"; M=T`->H7W^Z#0OKQ_;.WZ\7CON2U/BID(&0X\*>;$\?/RAIC\@$[N#;$^60GD MPQ*G`9ES/6>O1)D@HM6`J"6`S`1)^E-V@I#>81BI:BL+*PF^CN\55-_I\D)_ MM*WF/,=;'-^320]:WWI^_@9WXWF,OJHK_ M`;B$"$[`ZQ(XC2R!/O+0Z3)RY9P5BE$4T'3YL$IW**ZM*-@C+T==P4!$[3(F ME#25!HB(Z[PV8)Z\:,M:_'7^7AV.G/]N5V;V$4_WE[K:+SABN@BY/^VXVG-?RZY/W M%1YLUF^G.P5?G1YLCNC\P6XV=&41-$0I9E9M/`X%L[BR[7IU/'D9>VO"%!H& M/];&6N,R$2-:NV,!:#8@I7:ML=D:)0;,-'+ M;N#J4"HK*S7&,EQ[WIK3&FWF"8!*$ZD1MWXZH#"H0@A(G!R(NQ-CPM"I@A8J M5M$JOMB04+SR4TR^T-__F7#XB3E[Z<]("D%\1H[BJKLD-V8M%;R=U^Y]NG?M MS7M)7?Z6A4HTS M+SY^H-[WPT6T/OWA3Y2C!HIU&$L!6XWQ3+#>PYI#P%]-G',*T??3=8H?V^K] MR9!3B!AK.P7,>,9.(6G-L9P"%N?L%!.9W+#4^Q-1C]Y%0![]%AIR"!Y3;6=@ M,YVQ(TA8<2PG8(MR=H!Y;+G>`S<3!%1,1-\[<%M`:<<*4DMCFZK&:N*GN%5" M3'DI^,H[!/0MXE<`DV]@1D'51A'L:@H>_^WI:O&HOKFU, MM.3/TR3XB&J0L'%3DEC--M$8^BYH6+IV4T_DNV(@INS"E1-D!9@\X(C>%D&= MMQWEB#G0J1//!$2@_D/`J=Z9N51)3"6Q_&E\C+&/T#JY)4-4RU>FRK=`*$%9 MC@"7\+_:X/;&!]Y,Z\`C;5VQ_5G9=RERD*:,KG*3)V=%^B7'2G<%+ MMSC-YB5:3!"2ZI;H"TVI'MD0_7FBRX;V`ON0Q?ZNS)Y'S$>8%5H`&RC,%I,$ MJ*HE^@-4HD?@3NU$`4J4]([Y?=G5IGW#J(5,&=)3@1<>Z02QJ*![7Q#RNV*C M[^-$T4>OK2?TWCI*5M'-5_I\=!8D.ZI]47^M!4%I^G(L).@G"$95*_1%I$1_ MP%)9Y8SP8X'+"&TIVFTC\^]Q0-\^VE`%"^GSCT.29-74I05-^0;EJ,@TF"`X ME>W0%YTR'0+PG.IE`*%#7J(-CI$RAHWSE0W#\GPGZ!%#677PL"XO%^!?*H>! M;H7_YDJ@MH_RD-$3S]6FJ/UZ)N&?%*HP8*[JY!A,T#EZV\GLFD].``#N4[WK M#IJ@^">MF/T8!S[Z((MQJ)T(VMUV7OM'66"LQ'^'(#WY#\31S!IY2$< MIJ=\@&.-G_2B[5B56N2W!/E9&KRA/GXDQT[:;43L9NDE2C8EG+C?$1`"4!H#[^8:44U"_6ZZ`0 MM9;H6ZI$_C?R@X,72IQ):O!APER)S^1!KF\ULQ!7D@,`^/B'G1(I<"UU+I*S MIZXV?'SW9<-(FU-C,T%T&[*9R50[-3$`;(]_E`I@F\A)UN^_YRJO-J="C'G6 M3'$_HX5B^0:E[64:3!"9RG;HBT&9#H&Z+.-?HC3\_$?Q3CTMRTZ]ZLE+VY-D M"A9\[XF/03Q)^J%0%# M\M:%$U.9VA4[[1KSE&*M?ZIWK[&D[[:BS$5YN7 M'2K,>#*==#J?-"=A@I\$IZF"VISY!HA/BN*X_EX/]J*+;8P05>TZ]KY^?,7[\!$$9^H-"-$ M-$'L2.G;%S90)P!BYE$!('_#^9FHX:U7T:]>'-"Z:8Q3,\56S.\NI]4$,:EG M$;-G&YQ>`=1.M2S`?1"AU>:*R!RDU4./=Y$?4U.=,X@N<1SC+V0NT7G86K-Y M]2U6;CY!0/>T4>^OMG+W`,2G6GN@Z=KUK]'-9H-\FM@:0 M/-4T'Y;NQ&3D7^GQXLT+0CKUNL7Q\P'YP2;P'[/X@(DEZ1;?R\Z+R$_T5@IZ M+$LXR$5/_C/Q'9-6'L+#>LH'^.$\ZJ)?H\2/@T.1^%!?`.4K(^XD M2:XI+/._(>">TO@E: MLRH>J#>N@5JE\41AK6T?$\!6Z1R$]OC9@U+W]Z@UN"&V3L!^!3@GF"BNN'J: M#8I%!Q`^)EWGA68GA#C)8@1D]?&):K!B$5E]>X(C=1="C!>SN^]+=#DRL%)P MZCZR^I_?=8Q`IIN_%;\Q?VH8"'U-4;1&)ST[)J(1XD`BVOY;'^\+E)WE?0ZV M$9VP>E%ZX>?I*$&T?<1AX`X^6R;2AC^^YS?'&'Q<>6C%#"QJN3;M^LU,F$C3EX:6H'<8 M1JK:RL)*@F__+$R78-;]K@,S.C%A=3N(0^C(!E1CWL9>!#%F=DP*:SXB,1X: M\U68*SAGE?ZFCCR1Y[Q4*#$M[$[C&<\4LOFX.,EH*G"_/$QI^F'*>7T5X//O MYY1^#S52&J"&PGR&;D-'<-8%$C=K06``'OSNZ^]2JO0PKREQ6W/I1#+UA@`J MG4P>TT"E9GZ8`BIY/4P\.#ZC+=7Q"1WH7:UH"TR8162GY3M$YOC44E(_E?DE MS')V!XA5_=/5`<4>U;74O1VZA'2EF3ETUG`D1`B6UZ\)(X@S!1&'HT,H`L[J M3AI50C_&Z"W`65)HU0*')/7Y.34^M=-`4=-5'BY"ON`!GA'06#W?J4XXZ\>9 MT9K6*P_2W!;E&<\/RQG/GOLM@AJQI[J,IWNTMSC.H? MNWVKSI=">V=`T-V^[VL-V>U\C7ZL+4XDBA-7U0=J\?KFJQ]FM&Q^7V`:Y\\H M4&>(_P2`/90U58%O4(Y9;1[-X03(ZB''WS'.-70_Q@Z4C?K"D?Y2B_S MPG/XNZ8ECA_(TNGE"PK?T"="LVN#1KWA.:]"NJ$CT&)N&6L;0'K+6*6'>1UD MP)H_(Q]'ZW\@CY'>(]U$B,1ZDVEB$%3:`/KJO.=UK`OK_+(+8C78=5H(45=K M,4W002H;P%R-M;G"O= MAINJNIKIF4S&P!:;2I:+:U@K9'XB&A?%>3K@@@A.:.H2N`T?@4(*>.ER`@`R MU4U8N?(._--R02/V$3C8R&5H:2DN#3=9[@`$=?9C79B"+:4TABNE(;R%9S7S M\@J'9'@Q35!^0Q=Q[$5;5#R^0%]H\%&4T#35JAQ^E8?9,PTS0?ZW6_SV71"] MD7EG`=/BWVV`%G\E2P3Z/_F%#EKN*&9D7_)(3HL`%DE/I^NM"S/IDD\$Z&,] MZ9([!EA2JZ:SL5@6BQ8V*[-W7L'D^&T69LG+#L7>`65IX+,K9@CI3@GQ()TS M8]E-,9/5CC^@YU0Q#K]YG;H_T2#+"&&=OU?P./_=KLQLD'=_J MT$VTGAKG`*TWY/R0EF+!)["P%T*%\'..T*M25D[F@HMSM?%I=M9\WAN*.(]75O.ABK ME_+BN"SW8;9#+@.\1='=&OG,H`K]7"K9_=G>E%1YG+!0O=:<5;8'.K!=SJZL M8``@_(*BWX][=(7C0Q[4<<0$A(BLM!Q,-BV`2*K;`RAP#ZZL@B#`A-Y7_+P/ MTMU_$V+V_A*7IH(*FV9B.)%0M`](V.Q=R?('$'+SU??"P(O7C_0$R_/S?6$O M3.XB]L=&FKXTJ`3]M%"D:H`>B)+HRIE4#>@D!_L[8%N[^TLU(ZW_,BUPP$KU M@$&#J;7;&L``7_WU^NZ6B+[.-8.BAH"J6HE!5-,"@9RR/0`!=N#*-0MH'1,' M28K#3T?"_?G?6?#ZRE[/",BJ=0U(-BVX2*K;9YT#]N#*K0@`,!=$PWR)!H05 M\/=3A?K.[]/"ADC!'J!@L#9W[6$8-(31,?38!W+,WRH4-'^;&`(XBO49_29; MH/2A,R,?I0'1-$'UW)7[@*RUT)H-!^D&%48D&DP,.*HFZ(,FB;[Z7W`9%F)I MZ!$M_-92BPLRA285S*2:3`QHZF;H`S6IW@Q<<1D4;7=7N.XJT/Q&1%;EJ8)D MTT*2I+H]T`/W8/#"P2"(644^_@5%Z"L3*,"OI<$ZOTX+%GSE>J"APQ@`@3.; MM?\'13B2W*B5HBUM**"=%EQ4%.\!'D$W`)2[>'W%:?J)=.!GH1>#*VP! M636O``,1H[-[U+LD(G14=48K\G>Q)D1QU=4XDHIX6D-24 M[W-&).H(@)4S>WS%Z4;E#\_'A%X5Y9P8<2D;)T@`Y;2`)*]T[Q,FH!,`0,YL M"]X1>3S)F"1%6ZVJ^+33@I&*XGW65_QN`"@YL\_X.0K(MS,)TN-J\\E+$L_? M$9'3E!V/)*E+JPJIIP4H->5[0$K8$0`J9W86?T7Q6]LG[E/VEJ(4;6E3`>VT MX*2B>`\P";H!LOF% M*47U^R1D"'L"D.5,GM:S%^%-T\!WP<_TB$^OMEN$ZJ%`\0`?VWEL[U'L!UX8_%Y<4^8#0YK^M$,HI'<>)JHZ MJZ%%@KOCE[2N"`G=%RH`NFO_9#5P]>BG= M'=5`ET;+:IZCTM)YI.G;07$6I-(/<'.(:.Y*0*O-]\^*T-KSIU`MO^!29-!= MATDST01R2^N?,/69U>FH?,8U+:"W@=8 MIAL0<\Y,\&J>I/(55FW6C7U3__YJ6D`[SNE^>9U)[7VD!^-)XV0N89R,B4:[. MRQ?,W@U@_EAWZ]J/CH\X5Q>5(6XSP#*[1K3-ZEV4T"-A@64X237Q\2?<2%*K3,_7<7/*'X+?%8>)H_DE![!(IGK M*E-LCU%6F$PQ.!7I;&.,*EG*"JQ%171-M+'H[,4N'BBPO&ZM*,7@6AM[%K=1 MGIN\(__O)8W9-X99OU4WA)N_V1XMSFA@OB+,8>JRRV_X-MDXGE5)I7TF>OT( MCBWCU]KH-GYU?WQA911'N,$(W&AVYE[DJ?[@=9QM7[QXBU)Z%^_EA2B:HH#] M2H9:HW:=2$$CM[&BI;H"A&3YNY9M>[%>!P7,J>#)S5<_S-;T?6XM?!EA5N&N M)S/'\6C25"HX[=FO:]ML5-S/-'F9R'F(`Y1Z\?$R)LH^[[*4&.<%^;L(AWC+ MOB^NV[PZZE5N[C8J>YI#`8?J/5G;ZS-T39B8)5\+/OLH\N(`,Q;J7)KJLBZ; M9J9+=1F+C+%6!^3@%!&W>!^]D/!SE%37PIB+=2'=Z78X2&P!I7FVWDN`XA7P"IXD=95%*:)V&Q)JRBI@0\@8W$MP'#90-H(D M-1[&^)B9S'0(3G.YO=`GLKSQ` M*&`)E8!E1YMG<1.CRXM_/&$OT*`X0,G%8_5MRF5FKSW$E%6PX5%:0P%G@+&* M=DT<=+GF#L_C-LY!U6P"^5WTAI*4DMTE289B2S&<+0;O86-[/IV])NC?&1$U MKRU$Z\ZQI@Y\JLJ7(:J9HDW.*J-,&B!)&H\^N00R]I:EB`X&FOV)@P`,;+S( MS![8C(%A-W3+99!Q9T\5>#3L\;8^/1`/9'>T9384(+:,L;:^16EH]=`_"-X' M$;JCKWNTUQT#L#Z7%3?(>J9?QP'M/\8GU:SXYI[A&^J&VD-&`\IJ4^2&)+\C+59M6U1NEF]M:`0^`7:UNLM90T*%Q^H5):*,?38S\?;F,%9"O6&5 MF*O0<'9HU;;:L/A5$0O:,_[1F8_T?5Z1&-7"/S$+43%.@]\['VPYXG(41,2S MPZN2=8;%J$@4-BZGFN_[&&,?H75")C)[NLOO17Z^`MWO<90?X;1@+$U_OD,I MHI\=F%5M-"R>):0Q5L.@]ZK>5"H)42L_LUI?9_3QMT<4!WC]O"-02![0E_RG M;EZ)2J-3DHEK[N0#C3][78)_MJQTYHMO%"3C%-AQ`5\RZGQ@-,+ MWT-TDZ&ZAZ#,XO:*DSF!VOM+;BL-ZBHYXG.L,+GPJ(!-5>_C5/M/+ M+L;9=H>SM$8DF0ZBQ$N0_R'):W:>8=*VPSI)3TEY-S!<<)ARIEB=%HB.B&3) MFRL$#OGLD*UHH5'6`1QA>"GF+N"3S.+H74FJ4`8.A0+D>4.U(495[X@-)R9I2\X!LOCA[0U[2M4WO3L`>'4P:(!H?9 MP;F_'8?.&]&0SURRYV`O,.^#;-\]I(7WAQ"EU5G`RPX5QP&=`-V'R?G5 M9BTFL_,#(]8<.N+KB0AZP\%5YJM/.7-9F M4&4P:S"8'69[6W'@C&8-\0#D.W.T_82"_6M&.->WE%_PV70X[LX;Y9NM[ ME\>BY@T#16+2$ZYXI#-$FK1EAL8>3Y`)E#>%[+'*I7[!Y<64LEY]_EK<YKHYU5LD@NB>%2\6/*"R_!#*]VD7L0Z6FS/GBU* MT,HC'56"V3F\_7$<)XMU5/W``#+^0:3Y*Y>\-;60CG'%E4FJ= M3-#JS./?W7GR772+X_UJ<_/O+$B/S\C/8N*@*/G5"SM;Z)JMP;61H/7L`-S/ M?F.OH`2R@6!WYOGSFHD(9*KR3]5W+'];[@5?HFORZ0KQ(4\'.%^T8UQ!,,:O MNX#2Y3<[%S%MX]$62[K2@F[DS(G`^9D[>C\I2>"Z9!*4Y;!P*6<':GF[#`M7 MKAP@$)W9YF_ECK>7"^1_Q/<#!(W8MP3`1K-#JI:U1KTQ`(H$XM?YJV"=2VWG MFSMD=1SF^VWT^5OE>V'ZC`5;O#J,9^32$L?=_[V^?""?_SY>_+W MD*@LB7B378GN'1OIZMWXUP`C8^G6LA%%0&]VYJ#Q"1^]D&Z?-2L[L:IYR9!6 M>718R!70B80Q,X<9I4?@UMB`OR%+$W$`%9H49VORK28'7#5[33PF:N, M/"!@G3F0:MP(H+Z'8W4,]V-RRK_78S([I!NQYM`Y^GHB@O[@S"VK)T1?AJ/% M>C6\0+WI"?LJ36>(>&W+#8US%<%`=(]_;FJH;KE'GW_+=ZFNB&F"-2J.E:LM M*^+\-=.UW$&O<57'7+'Q[%RBE_4&KFNN*!KH%LZ/T=!7L$]5_<9A^O+(TT/#=:!%Q]7<9&(!%S2,23SLXI%"PS+-#Y M@D#@_4'CX+9_[1DS^/V%S![O<9*LHN*C"7@VSZN)H?$A_\)&VSMB\WW[*S-H M'R4N!NIC=JXVQE@,ZZ,#:0`ZM\;1]E!/-7>._3I%,\#KV#I-J]F<4M/9>4P/ MRPT\*U,2#,2W,X>]=1^E>MQ%9P^F,TOJ[H]QT'G[1KE=.3H*[68':EV;#8MH M!:E`.#MS6@P9A]:/766GNC&-%ZNR?1;F]`\H924Y&.4IR"U2Y#D[%QG"UG:R MA10E!EW+F3-L2-$7TBK9D4"A[4@2'`1NP^7P;IQ$WHYV7((K'^@`SIR)-V9Z MYTNG_(O(:HV:6[G"1K-#MI:U1MF&%8H$XM>9,VRYZTGD0T5O@VK=36NU5;JB M=FH[.U#WL9T+%]9.DH$0=^8",/^6<^-5P[_O`G^7WWN^B)'!R_5].Y&Z<:_? MR>R\:Y31L'DW7U\%T%^=.6$7O;%UES_Z\O(%_P-YG<)#>HTE7U=K-YZ=W_2R MWJB?):%H(,Z=OT]]&T1>Y`?1]LD+$NG;G4`KP1JYTVIVD-:SEYVU<$'*G&%DY06RDOCX#5+T;I>CKNI;B6^+X\X'@D"9_ M)0$CDW;0/@0?DYY]S,[MQA@+.Q^JGAJ`COJ3VXY:Z/N.\D28OP`)J7&R2XXG(]P21ALV^.4I:UHBGN4)"\[ MK_UMM]9_E:8S?O^S"Q2VQW#@M*'QM0.#QE_<"!KE>Q.U6I5ZCSWWYE,"H`>? MV3FC*9L.ZU0]I(0??O[@AG>(=G6E#IY%K21W]]_-8;.DO>SNYPL.F#_\X,JN M3G4D=_JT-4[NH.=R!-2MIVU`ZME!5GSP]NCB:\`?3?/B%`M:EACUD;-V`="`FG6C"G:4 M-+F*'L]3Y3I;M`]A]7$H^]0FI/$NIR]><7U5\ISPU:&#?C#LQ MS6U\_D`%-^1%E<#5A%?3CQ2/./[F19D7'ZD[*0$?;"<`-J/=E(';TIT#79'! MC$.SZ(4'3H9(P.++E>P34),L0NH09C82X;?5Z)V`EV]B7"[G>Q$^-SN?6!89#";$^&S2&P4.W,- MF6>6^]/;5]4MHN0Z2/P0)UF,+EZ3-":&4=C?4.(GL:\AR<]);U"S!1YTVU'5 M7:1DSXNX#B!S=U?C/[_K#.P]^4/Q&_.GQJ"CKRF*UN>+')UAIWYRV'GQ_EL? M[PM?/*M;KW3SA+99F"4O.Q1[!Y2E@9_<1?XU2KT@3/[0;RY*>_Q=:[UJ&9(YKK0:3CY2O)`.5IOZ MYD$W:G!I2J,!--;TZDZ,/86C9/4PQ;A1[Y=Z9[!VVG7AF@9?'=P*<,-6/36)O_H<. MY0W6TUY(6T+F8E6YW6D5)-W.XK879Q2QON[M#:IN+\4*29K[,`O?7T+O*W[> M!^GNOPDQ>W'`I:F>0V#3V)N4*@\;EE.T-765[29_2(#-WK6SSHLP.H8>>SW" M_*V:DS5_F];0\Q3K,>0MMJYE:#Q[$=X$%V]$AX`]3>=0G-ZE8U!,:_#%2O:` M`)/YQ&='PQWO5+`;^OQHB`YFFN0OLSEEOV#(CJJ(Y?B?3W!/U#?B;9MM\5-S'QZSO-76IAQ?>F%7N07SQ7#^>0P:2FF^>Y0_91Y4+,$P?L_.S,<9B6`<=2`/'[]+69K+U MIXT+C7!\*@E\L4DE5SI:;+IK'D4VLW,H0Q8=;1VD**0KY3Z,[Q+4[=#3>WIZ MS>(MTA:TXB7*WC%^5IUQ[SC59\WGO?F^_/HNDO(,Z:9=KY!H.F>/4+7<:-X@ M(9@K11P,>4)GZO@)I3N\KB:0CW'@TS+:N4':KJ#3MO(%M;;SMAO8&]0D M8[N#,T_3=S6@RE?[Y&^D3[I)3DW9`K=ZP^J!&X6&LX.UMM4&?E)&02S@N=2) MQG=`\VR_]V+ZEG?Y6JP7WD4;'._+,Z,W%&7M:&^`$]]#Y#B]%Y?1L*L5'Y*3 M$SAN=.8%8AWE5M7&VLW7`WU;IWT$8I1G#]=A\%R<2,+6[KD30V+`L9PYR.^E M9K%C3;?`3;I6EZL)YZIS7=Q+RMX..UA=9O#M*'47PZD7NN%BZ0[%)K];+'Y] MW*K);W$H@8T==*6FM.`C@O).]+%PH@AMO;2DM>U&19AX\;Z6BEZB"&V"=AW4 M`3CW<"V0\^)DTG9WS]U`N0''4SGN-^5X]G8T'E!J="[)Y-?#)UO\%D\4V-@] M_VM)"WB=SBE1OSFC/9^[RF(*LXLD0:D)GV/RZ^%S+7Z+SPEL[)[/M:0%?&[\ MHRB+WSEB><-N!['L\[7KL%R<3VQI]_RO*S#@@E.][Z!C%&..9\S=%B<36=4] MUQ(XE,YI],3GD?>!]QJ$01H8V:^$F?:?43:8+DXG8VWW')`E,N",&G>B)OMU M.W_RS?HCEZ^1J>;BE3HV=\\Q`:F!VQOC)YC8\TVS'FG6#Q?OD[>O>SXGXVDZ M&2=3G9(6;0PX69-1#_^J&"VN!5G5/:^JQ`0<2B6_I'E"]^*"7[6J"URDMUX0 M_^J%G;QB,2&[3D2#<':XE[;*J#4B&F(`B?+??^],5N_Y1.Z6#!;;1Y/G+#DT M'OT\X5*G\0FK:HUGB-\>UAL:TVJBG8&]%-=DUQ<4OM0S3IU`EABG:_P?G)MC M4B7_AH,H_97\1T8L!#RCK=F:.YODM+:&4ET]QW\06U'2=_+\]7.PC8)-X'M1 M>N'[U!N#:/N(P\`GZ\;EY>OEY6NG7[[F%,1<'L*>[$/8QLJ<.O+:[9,7+>]B M3_U=;+.AQM`SV4$$/Y/-^JUZ)KOYFW//9'-$9PQ7[9GL9L.)5P-;'D%OC6ZS M(53Z[<,D!WMY$7UY$1T:66=?1'?QFPBMU)<'TMU_(-V5]PV6]]*7]]*7]])E M]T5H/)0O4:\UH55Y)[G)VI=HQ`(1?4/3[<8^N M<'S`Q4,V3$"(R*J2^2#9M``BJ6X/H,`]N%(`&`),Z'W%S_L@W?TW(69O-W%I M*JBP:2:&$PE%^X"$S=[8NP*]]UH!C%S0X[C_#T7(]]A+1.CW:A'8_7U:N!`I MV`,3#-;SFH)WCS2!XWHQ804G#J&]>M"#G:27YAG\J'Z(#NRMQ\5@&C_]`19J MJ$P'Z=VAV215R6S0CI%5!<@QRFGY!;$Z>LM[76T^!2%]P25B[7V("4\A%R:< M*9"D;3,&FGC"'>OQL&TI]//7/ M2;?A$M;S;0!"QX892+N1T5)FF%O9-P!;5Y8``$"N\'Z/8GHM)_B]V.S@XT2: M_K3A+J1W'C6J.JN!1X*[XSN5CW2!G#2F2`ECBB(BJUZ2!LEF.CV1M,L8DQ-8 M%,[.UK!`8DY,Q(0<,%F?E`@''`"%Q(0$8@T-[JB3D0?TY9I$PA`?\HTT+UH' M:R]E;U1+T98F$-`Z-<[=KXN*IN+!/G]7!'P=GY?DNKU\P4QPL'^LNWSM1\>' MGZN+RGBW&3E^6E6(2TC8_@_]W!CD^L^3&&90'_6!KK-R_#GK7.`5<"+)_K$^ MS"L'SB`5!AG217F(5Z)SQ:FF8C\3(^0:/_LH\N(`,Q8+7)KJF(--,]-E@HQ% MQE@C`')PWH2U>))72/@Y2@[(#S8!6C.7$T*ZT[D:2&XACY7L).7.83M0:_360QW(@&%DNJU@X;`-_Z\+?YC;"W77N^H>"UO?MTCB"RR)]6`NNENBQ MGJDO#&C_<4K=F!3?]2=$'S+ZE5UM7KQXB]*$?'R;^E?)B>U-5,5FU7ZJ=+/9 MU>S2M-BPU;KDA7)\4_?SX3;&47J+T!/R$1&]77`.)B@-S2*8'0B%5A@6;JSN MY[4!5;[)3M3#VRAHG+D7%:V:!+]W<*K/X)1%H\Y@=CCO;<5A_4!'/(./E3CD M*)U2.ZT_-T$]Q_+F@,:C`)"_N:J&J@-.`MJ];6!=ET*7*K;P!?Q:&KWSZ^S0 MQM=_6-!U^N9L$[DPIZPFQ\\IT1%M`[]F$*(;L"(24+<60B#U[)"G9I]QECV@ M+,#'5J/V]E#7+1L2G]9IE6+7<;9-/D=$ZOO`IR]6KW)=X(TR=1[='3$5'K.# MMPE;#@MZ30D=3_9A3*6S,`W6*"1FB>F>7LTVE;*?"27-D#A=M1,OPGHPA1=F M6DQGYSJ#6'OT!9R6R(ZG5ZFO4Q]1?")Y](Z,G6.C/+7W/)@\WX-G];:U:SLC M3(G!UU.F6B#AE\PC)DL16KV&P;:8II9U-F^^'O(*\2T_4VA156>1:3$['U&W MT[`>("4/B&]G;FXQU*B^@U&K4WA4WQ`T& MNAJW]^`$/>P[NH.HR>K,D;RIG?0$$>3LB#EKMW)(K*"K.*",CE*;TR1+JLWL M?$/'5D-/DJ0D"&1I\\DZ*!D0^6Y1*6FBL M)`U(&`"?SIQ-7]"SP"VZSHHS]Q=\A?>'$#$R,20HJZD`CW)V@)2WR\"?>9X< M``R=.<4EZ]L`K\G4^S%&9`C)M(18X3E[W0A,I5-23:G1>7=$JM'L M<*IEK<%W-:1$`M"KD0$\,'I7KZD71$3H$#>^/<_6:)4;^3..6"",T04),L0NH09C82 MX;?5Z)V`EV-*11)%V%XC/U=`&;IP0P%\60W?!X2%)K,`8Y9,KES> M'.X2S"59IZ=9S'JX3I:<<_VE23[3U:BBG<989HI%XF32.(7/0F9F;6A9<@X^ MF^36\"F-(`!M'*V;:!-U!&&GV8&+U:1O@\B+Z%-=)_&9WW`166DUF,PIC##' M'4MK*<9&O0.*#9CQ@&N5__RN8^M[\H?B-^9/C7%`7U,4K<^7K#HC06>%AYT7 M[[_U\;X0XCI(_#"_*WCID5]I!N*YAVN4>D&8_*$?U!/D?[O%;]\%>R[ECP*AT+1&U62Q9U:HK M5@,^6)HE+SL4>P>4I8'/>:^41U=_KI1-Y\S@`>^42FC''\'6`Z5L?JYL_YCY M0*_BK1>5[VA>D4\+#NFC9W1(HW4]NJXVIX_,Z:6+SKOR)=2,\BP'SA!/:W8^ M0^VO.%S3'*7&@J436YE4G>#:HK+FH&9'',L:HNG-1H1H!O!6YW`$MQ(,V:;1 M>;8!X`F_O>#$XN*)+K89\ZW.WZM/V_GO+H\>)+[TD-48<#9][0X;>X[2_:4^ M=-;G(=V1P3RAFP-V:GP:HF$.-\T,4EF;A3E,S-]*G5N_V1VJ[LXW3W3&<)VW MIUL-YS4)[,:2>^`1&@E*<))2HW0Y_,JKJ/$-9;`T>7IA=4_FK&6R[,4L>S'O M<"_FF:A\2+WZKL%=Y+-?4)0@K=Y1Y)(Z,XJ,IQ3E=93=E^&SG/M7>4Y;!LLR M=EG&]ES&_LG^L"W+V&49NRQCG?U@+LO8L9>Q&A>LAWI+I+8>O?EW%J3'VA]6 M*9E!ONR\J/BE*,(-'&?UYM.!DC(?AX#611$V9R(1%._KEU5[=.I*W`.0*Z?. MZDM$>M\%AW.EQQ9R>_,IAZ4''P>0JPM);,Z`$*X51:.H[R&2/LR'"M%5,:3' M.'CS4A0>_XK"-2U"XT4!(BO[O^\"?W<3$2L>_^IUC-5"NQEFK3)9NLRLX;X_ M9+%A4S;!KRU?O7B6KERN!?J3/MEK&/B&X-^'5QO]>KQF`GX#AAP"^WIB3?P% MZE^\(+K'2;**:N9K>0"7IKINP*9Q8)K"G6#+J*8T>088&KLDZ,J[N2^D@]6F M=C&'L='*I2F-"]`XA)O.#H",6M)K?X"9B_E%W4M:GD)1"\W651U+U=;6`,1' M!^YKB":PF)WE%2A5.W%QDQFZ(JAT75GIBK)U].B"@W/Y6`)&BKWRKA7/

< M5V_LA#]A23(VB!I-M9+)#`&7JLKWN[U$&WE^*>D#3W85*.;K[Z7AAX\?J1IN5Y?IX3XX5@ MWI$T?;7U*Z:W=SBJ/+18W0"MXU39+O.M6G%7\_K\U):2XK,T\2F9`]>V+MZ\ M(*1?AELDT_T7O8^7\!ZNHV/U7%5VWNP$>:>9^KIR'` M\Y/ZR8AZ'ZYX'_C0@IQ"?P_271"M(O0/Y,7@8:`A;HK0!+G96[KH0E$!QG(V M;"UN%.52@3PHSTP\X&)#^B?JO>QBG&UW+U\P533I[0O2?%4#MICOK/U#U:[C M>8J$9*Y5SE-2C2A4J4:8(H-N(L=9QU%$G.?O*DJV'=E91+)9J\[7TUU><.J% MO5T#X*+H!ATNLX8\WV;CP;LC!^<:@B*R*6?+ZP5CDR01.ZT5P[N;$DE:<>PU M`V<"9/0M+7>V*G1*SP`[$J)",K5SKFZ_IZO;2QF]D,0 M4KHPP'*J*:4M`PQ=.<88$#2W7A#_ZH49.D_;97#$:<:#%K/9)-$F-D!_`#+[ M<.6]G6$2(>A>P7GGX&*/XS3X':VI>?+:[(*])-GFP-Z1N+GK6.UI$"7,JO>`8!?&0930["R47IA6*8WSF,Z+AQ$*0!0P:K3!M50\.'S M+9'QEZG'MPV.D\:._B\Q3I+/48R\D*K\2W<;4JMM.ZK)M74=>WU,H1?+Y#IB MA[&/4P=KY_BII3R]G8J2#]*'DOSFPD-(J/ED4*MGD%X?87%?O/?0)<'[L0!O MA+9>6M+:?"^ENK'_@O8'''OQ\6Y_(,L_:K-"Z]JZ\)%^:G#TA'R\C:A=[J(; M+XZH71]0"H>!%N9'[;-Z;V6Y[(J= M'>P*1VD093AKS>@>\X-W`@35RVZJ#(6A4YZAZW`V;C1#05:^=\`M=+)BW7:+ MNXAMBN1_,O+'-*\P<8X7IW)=%96TMQCJ1^A$O?MQ,!]7V6FX+FAV)&13=V5U MX#MP;]DG?HBN;]][E"3YBNH+"M_0)T*].T\(C'WSI'KI_2$4]#)[#S8Y"N/Z M;T_)YY)NT-F+D+7+AQ\*FUQLMW&^`U'LAOP@??YAJB/A84G_CN;FQD./Q:"> M/(#P$\^_."]":!U`[LV.-D%GT^),X-#*CI,E"RBDD1Q[YN1$T<.F8%<$KEL< MEZ]O,V].R#=@#CJ[@0,@Z(QP9_PE=(7P4#'O0H'-U`EH-//+F&#@D90F89,X M,N#<(<52^O&&G,6>0H#-=F[9SS$]R$J1!(RD:$]YSEQ::\#BBH[5=&QBBM6@ MR&'FW*/++B\X"9*DV*P=`OIFS>-/47`YZ\LSGE3[_ M^?F%3/V3+#X*<2O%/;/S\_$&(A6O7[$89#7$7W. M7M?!6Y`$4"E[M48G7,DU+8%T11':R\^-@W"W1F2:-/9-^"V<0!T$OM'\FIK;"EQ MF3OQEDLM)^?R"(@K**\BV[";'R5LZ`"$9/"!>Y@#0A6GWU8NE;"_80JZM+[A MI[)691'<54RWW67VIF1:LK>L^"T=`(\T%KH[6@I6`4ME"7IG;'CQ>W6M>C$D M_"<<(WK@4RJA!$)N6P$,@;8S`:*,98:`(M#OQ"=KEU[H13YZWB&4WM-NV/,S M$5EI=YC,`?"!LS!)Y:0G7C"_^@K1J2%GSJW$A)QAMSYW$HXJ,/(2TR.(-33X MAF9`!F^V764QM=M%DJ"4/3L2D=7OCS')G!KX[N=%4C_QP)^_'##+B9^MC/3> MS_NJ#2M\X=)JJ=CG8!L%F\#W")1]GSY]142GFZ'%24Y>//;'GL5C>SR01Y]W M9$Q3.G^OJG2>_V[O43\J`[O6:/>7NMS6`VK7JI@G=.LEM:IQ7B>TWLC%)UX_ M>5^#?;9G#A/SMU+GUF]VAZJ[H\T3G3%2*RI>RO7&.PHKU(DV8&+ M$5(D>_>O"`%/%)M@)8D\/BMK>%1$F@0V%6S61*R<*#+HY8O@(J8AB9F[(G+$ MC9-PF-A9Y$GA""M:0PUQ/!'.I^EPUV:1]H[?$Y`<8^UW!?C\!>\+C#`E=<@M MNQ\$:,FK&]UK_#AI*H-92>U]PY4]#<_D9"L]V]NVE#OT)6D3B#H M%PK41#]5YZJKMOH2D=YWP0%\>:TWG\8L0XN/NXCMX@^;LY@BB._KQ51ZR##Q M#1-:IY1>5EU%]/[L:O,8H[<`9TEX_!P%]#F7]7.*_=\NC\_9:Q*L`R\^KN*Z MNNI)P#,RP%]:J21CE)MZBN`4[J4.YRLH9C0PA5P[K` MDDV@]Y-0T1FZDLWK3`LR!?GX10F)(VM:H_?*B^,C"2P7>QIABE052;>1YB-P M&@D^,W8952N.Y3`2<@WXX;";\$+GDCL<$G628A)IZ(GD)Y.''`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`?-B*F#*%T7\^SHDS/^]>Z6D MY9UR35CFB:?/]+7(S5N].JC8-3OBL4O2J5]MYBE"W^\E'MG+"<>M*.Z&P_4T9P<>8RQ&,R5!Q*^.D'5*%SJ MV%[O25D4!WA]G14;;Z8^K'SN?;^G$/=]@5G?JZPE)7/F9.W40M.<'1=VK M\B7*0D]CTU<.[]YS5B;O]^YA$A9WRK_8\E;>-=GZ7/2;?)?7(R.KT(O21@?78V6I6&46CIP259ZW'$?JT#7746]4^=5 MZM7%]]$Y"IS%!VOP:+86PY'=VAHD=<#%QZ2$>9JX5!!!`$QVUX[.#N\#GRSN MZ%-%VQ@5"SOFS$%(5QJ50^CV&&HQ'V>FZ_S$1;7JC,RTI%M6QFXY0([,G9UQ\=2BNYDNG$_< M.U7\Q="\%K+#0!/:6G>N5&Q,6/1A=G7%R" M%I#^@-S7CZ/D.IK=)(1CGE]BG"B$RP:Y.%26Y#,`(E-STR"L.IG=OAU'Y0O? MS_992%^2O=CC.`U^9^6^Z#,0@Q1D,`?8REG'.)#!;D%H3S6OBV>$FN8W7^G! M,GI`7].7+RA\0Y]PE.X4(J\",PG(RS";!?R5K6;>%61$`-UB?O-@ED'^@;SX MY0ONY0TM'EI.<.(Q4^RS;30&Y$\]@TB?:K*7AAU(]_*+0"DN^F@ON,P9[PP[ MC8;XHF\0\U,M$Z1NB5N_^S'11GS!9,:`9UAI++P778-PGVK5'0U#$-K^ M<*\QT8=[SF3.<.]::32XYUV#<)]J$9N[_<$+8GHNN]JT+5$8*:1&:N%;L54Y M5-*M)H-@/3OH05:Z+Q"C&E5:'*E\WTUM!RY8B`FK!^4XA/8>VA)+CWOD-[;> MT@([:]Z8$'?B8GY:+N#99:YV7KR%42-%7"%'0.PX>I1T54&,B/'L3MKJ`?D> M1]O<10K'^"L*U[[B30Q36T[X%06Y?[<\DIX]AT6CU M2MA=](:2E%K@+GI"VRS,DI<=BKT#RM+`3^XBO[P7]L-R+VRY%Z9_+\R)[_QR M*XA[*VCR#T[^DGFTTB1"J]:-" MEIRC>)/>Y&4&1!'9>>,1(',* M%,R!QM):BL%0[Z#<-`083_WALM-BORB?\`FE.[P^SR,%URQE&G6N6/(;.6N* M[E\1HK<5&-\B$ZPDS<9GY4#FNA1$L%&;0=GL/%&:.U\Z(KBX%P9)S)Q(R!&7 M-A81.XL\*1QA16NH(8XG`L6AJ&MII#ED]OZWF$3>V[W!9/EA;)'D]]`#V,H- M93^Q]T[=:3+U95"^U=3W.U#O<.(O@;$5?,[V>R]_Q_,T\;V+-CC>%P!A'Z68 M8`5^7%18N0OM+E"9'QIMNRD"_KY^R-Q/C(DO@\IJ;\D+OO")'>A..I&+V.`N M^AL.HO17\B-9$+80K]CJ=.=;LI4U'!M!)-:U3Q/$?60I;I!+RN#*J62"_&^W M^.V[-0H*_))_M&%+_O3/>[3UPIN(&.W(6($"OU8E+=J_NALR.[,!OF:ZG_P. M5_8-D!+J1AK]08/U6?SL9/UL85&B7,%;XY>BT>^4>JT;;G$ALJ<^Q% M>!-?)[/:#S$3<#H@*1X\Z48H M<3?UQ[X=6U`D%]&Z_KF%TK$T6W.7#9S6CLVPQ'K*K(;%^7^*O4LMB=VLD;R* MMUY49G03]61*)O]I28U94F-,ETRVG"FSU$M6KY<\U:V,)2U*HUCR5,M2U+]O M5V1"2#YEZ^IC]UBS2I[+7^R3/)._%-48@3F849[E"!GBZU#FR^,+ MZ9LQQ51H4>UBR[1P8!4OB2:L8P-H*<_O,]^5ENEK4M"B8C/W*A5:B*!5;V$- M6BHPX:$*5+^)*HGNN("J=V,64,#VZ:EG(@5]:"DC$Z5GO$F_$(LR)Z7R#6K; M/*(&[L&#,=Y80WE)=)Q[J\YV1;W,:Q5TF07YNZ)$X>J?=_M#C-\X!>&5VI3# M(=EF*G#4,8$6(B4[FM=J[=Z+UD(4\HFJ`UR`:"HXDU)2"U@0YWG5G[Y'7H+H MNX=B.(DI3TD!',K)`$M:73UT\=BS(3;9@G=9'`7YX6*TO@V^YB="[*M%0L+J MUF$#AD53[A$R2J8!#0D$M6+#Y ML@$Q?O$U`!"?O"C;>'Z:OW?.!X8,Z>F4@D'@+L5,#7,<)7JM;CG(^3CQ!$B MO9\DO8DTY877.-M%\LNN#T:S^!T_NE*]2BD^H*IQ'"X3?H!CJ'O@3J5\`]$A MU+U3=R@-'&]"%AC@=/-^KN_!T5U'QCXN8]?6Q8C>10!FRB\9NN_KUPH+-M9. MDX#%*2A[_C37S5<_S.CGAC&L&BU%$875&#I:4>IO7T5'MI:UK1.3W M@]QRY-\A*A.RHXR3F1.G_B?Y8>%"$ME2< M\:+X`TJU8CC43A3!N^TF@EM=2QB-WMV^S)VDX=0+;<=N4''PK6"%%B)H.O%2 ML"%02CX3W!..]5Y,'JI8O0@G<_/-7E'H\SW"O^)\GX=9=E!`5=5,AZCLWI$S M<:]O1(\5V5IZTPE@-($]IN5JXU+U>Z"Q&;SJ]U27N=UH`6WH2E""'P07MG`E M`JR\BM(AE\M2?P^V=\5XSEV"]%BK,I!GPKSLO*A>A6#U)2+8W06'1Q3[U`S; M]LRA-Y]&@0DM/@X!C3GI-F4B$13ONS7GM#K5WU$^X"1(@S?KL6YYV8P;Z_H^ M8P9R=/%:'14V(KR/3]Z73Q[Y%`=>2.NQ/&>'0T@4>T#I:O-$E(_?0)CTXE'[ M5FKPF`"X^EI&%7H:_X^6?::H']GA/L--4.U-69M9XRF0:TV%W%,5WWY#<[N/A*7 MI@0'0&-O\G.6A*+R@0#I_)<7\J^$P)&6N&,N]#5;5],DU=;6@@A_9'%?0S0C M!K.S_$11M1,79UA7."3@P;%'I_XUC8!L<1GB4](XG]C>Y$@3'%C1`*VID5JO M16HYO[=Y74V_HC-'%)-Q2X_`^T$\DA/J6"3V-LO1(8O]G9>@BVV,\M%K2\BL M#J+GOLPA4!^0='OQSVZPO$A=VT<,6.M MB*QZMA`DL[>5KSQ^6%K=UIZ_;$]YH6"P!U?B*`28T/N*G_=!NOMO0LP^>N/2 M5%!ATTP,)Q**]@$)F_V\MB!:BSF@]IF`JJK)!U&YI!WS$RND@S6T_@D5C0V6 M5Z]UG8'-.*_]!S-T8B73DH_]0@&/ACW>UL.D>""[HRT1%D&VC+&>RZ.NK4TL MX,!`1,;&B1/E6%MCRBJ]RB$!`I[EDJK"X6`$.^$9&<24%>B@"O[V;=%]$E#J MF\T/!*?7_B!>3CZS*3",S%ZPG%D`3IQ+`:Z$@WOH74T!&3LLW#N0+*3H#I!F M6OYP+[JS:;3BC$-&E=B$DS,HF]'I4L,')PZ^SND2=Q%5)%@'7GRT_B;*J3SW MLX\B+PXP:P''HZFO(GH3B7C03I[#L8=%RRO M7,O-6&R+HNT@.R<6;H\Q>@MPEIR31W[)@K47^>RM+EGRTPT@$;G%<@6B<<;* MZK:K$P`]%#=]1)Q=V1@U&ULN_#3S0O;^`(>D%5&:)&YC2$(M!=RPN4U\3_2) M?.7+^'FQ_E=6?/+9MUS$E*?#.`ZEVXB15U(!.%RF\RI\4L_3GMASCR-:Z0%] MJ66,QC@B__2+%(E5?+6C*^R[J$X11'YP"!%K8\L(K]*"/7E-\?E,D^9KA@1% MH6B@Z"F,$[/:AB,^T*43A1KHZ<3-9H-\6F,*NB[.HZGN$[%IIH\7&>4-XP7H]"KTD66UR"7F')Q!=^P"E2V+_'$8P5\/?S$T+MWQW] MXH@TD?G<,'A,?/R[,_D'G"(H@UJ*^#2#YA-;S!>HGG;(1;P\YF/-3*H64YZR M!SB4%F?84N.%531MS[=Y/119!1S.;N082^B.Y5>.[8-SD'ECGZG+U(F525TL M:*^)2\-8>+JPUR0YYC*J*8TWP'#B'Y'FS.AYY]%SWRS=X3CX_;S%Q%S)0L3, M-6V7V(FY1A<9G06N0$UX[G'?K.'-YSFOO+ZFMM?!6[!&T?J)!$RP\*5*$R;" MH"93P9F4REIH@SC/ZPIU;8)_Y1V"U`L++RMK@:UO<7R;T;R6NR3):$HMO%Q2 M:]]=3LFV=Q>:?8TAB5.-;JP]'FUPT4:U0>OK_,UCXI`!7A=JY___TDO0FCYA MBZ(DMU_^9!1K.=>#37VAI\7&7>@:,HTD@O5[,_:V]50J$]I[M&.IKK%4UY"\ M"3FAZAK5-W&UN4:O[(L1/)(JE81)XM)`=_>#)=12J*S!YC;Q%=A26&,IK+$4 MUNA=6,.)0+\4C1BG:(2U"VY`E4'Z.;J+B+-F^:T\CRR$@_18+#!:8R]#6EJ) M3^H*!IA+.P4MN5AHK.#X3">^*5:^N76/HFVZ6VU>@CWZ*UIOT?HNNJ.5/E"2 MTEW!*R_9W8;X2_[;AQ:V>O%HOFFFRL-I-)JPBSQ,-7MS+:;=^#C"^\"_B8@% MCHQ5.$Q0W:5E$+B"D\Z72ZB-W#>+Q:;GA0:I\6'N(_!(F&-D??>`,PJ=,9+8 M,^BRZX[1L`6KGRZ?+Y($I;=!1%>N=Y'/KHL@(*N*(H!DCHP8HQB"G&:\<:L5 M00"9F=P$L+HE>X_JQ9:MOQ4#OFA]>00V9Q5:B-X9K[=P[Z5U]]726G)X6_N!8MZ<.TA@D]>E&T\/\V/'I^S($7L9ZB$=*=U&DAG#222 MHX[EM6Q"@\^_6'N!?%W)VX(FBD118N'=K><'85[SA5T^BT-TKIS%))I*[)!2 M4BMF0)Q=3*]*D/_M%K]]MT9!,5$[BOT=D35\L?-?Y\EYP3TA` MW[DM!-);C"%,DV-U+=MQI3,(Y.?&&;*TWKP5)KC%`-T?`3KCKB_KG3CY MG(.**?D3!`VS=1AR)E<&5^0=@>Z!LW<)RE/HXU!.971EE=4::0YSUTZS'C+Z M(5]M+C-B4;(V;,,"_+VJ:MK]W>+70SRJ6*Q2^],!,LVKBG:9.;Z@OHN"-/#" M%Q3O*8R)7JTAAPFJA$L&@>N#+E1*:=19W*RMCJ%ST"0-]EZ*UN6Y^R-.B7Y$ MZN(^RJ-WS`]2/D=$[.;A2GOIV9M1M5#MPL[%&'$8^`&JCJ-_LG8>W14)V-40$W8*ZG8)72B?PKR95GM"+[D\GFE* MU%Y\\>*UH-B*&;[=TBQ]^=JK>RU&#![.@LW@!,O2*O?25P;I#8PQ?3R7CYU= MPORM\N3F;PXLT4U!!/,5!ZNC].L^+ZK=[-9%N.AK>58N6M-MOO-S]NVP.6`7 M500=I`M[P90)5SR**5NAM"Y)'CT'D7WSV0UGSP]?P9? MYA+2UM[FXM#:"[Q#8@NKV:@5DP>0K'H5C",1&Y1_,E.YP,;+8/M#B(^H*(V^ M@A]=$=)5.S4PW6Q!+&N;<0#,D<;Q_>5+3/1:;:Z#&/FDC0B2LN15HH60?+8` M5;34.#@5"^5B$IFA2"N.L>+H.GO8BNUA(:+.\X%0H>D@RW4VD677=](,95=S M$@SGM7]AW,0#;GJ8D-68QSDR]=:VR:T7Q+]Z888NDB3;YP:A[Y<6;YKB$&^/ M4,6;\7KLZ[4J/;K[`93WP#[^K#TZBI]/H3:]/%U%"U<6,@X&@J<@^>TV1JA> M&&'(,,#K;X@@P.YO>B%`PVE-QPB)H3,4(>25-1Y"V$HN`00TV,W70_X>9+UR M]I`!A-??$`&$W=\20(89NND'$+:2\]J;,FJPOZ-@NR,&NR#K+&^+?L4AX48O MAPX=2:0Z'B*D"#I>8LO`@SG]("/0=H:;C:]BR[VJA&>:4=^NWC=\1_5H,E!' M[RIZC#%8]J+%0-H9RTEP)SKH#$CQD-^YG&FR2GYL3(,.N^X8C)>HDHO0=D6D&!J<_$WSV[+B4&3/'W(-W=16NZO925 MC\#5S9)<'E_H2*XV9R+&-8YA.SG5SQ^FDWDE9HPR%`,F:PPEO]FZ)69\LR,J MU>X)A;G2R2XXO.`;N+::9NMR")5;6W.3@1&-^UJRZ0S#2$L]0UE*%^^P5!FW MS!Q4]H]5^&_]:`V/NFC!`@6;.%+L)0^=+>ZNG#-#E3[*S%9N.C(W$WG*4.`J MV!L*;>X#GAC:K6Y`LZ)W."3J),62WGI)@^6N_W+%W(F5P'+%?+EBKM[%JRQ-4B^B M;YT_X3"\Q3']T9072G72US,%G;C[&1OG#%EE#)PZ-A8(/J^38H-6>LA8\[^A M^)OWWHK_]!Q7SM7,.C-S-`SY,5H:=F[),G0^CJ+3]7LS5_C+M$%1L#Z%HP,:4D>QO&SBDQ4.4I5_15;(M7\9;41;2&+?.$ MZ%UE0G6%HWP@,B]\0?&>=T+LD%CU2..$6-,+1?"YLQ,&'>>(V@E59UB4WHQ= M)2WYPW#!2E4"\W%)7@*[(<@)3QHDD&EB@!&S'+"1X<@G;YLYW.'N83/U$?M@ M.*KUD,!05-.28(EJ!J-:?PS,-ZIIV<;::1MO^6@FHZ$Y('=$\R!*`K]X[&&8 M/&+-WLWG_\CU/JY5U\S7--APX8+=C_G`T.YG>B&@ MI].:C1?<81OL_I&,PH;#2%O1ONG%KF0`FIEO-:TSX,('Z,C\^J;3T;L-%&,, MG!N18B!-]9<8;H6*'B/"S7_,?[SV4G1ZBF[0HCO2O0]2E4>B]^E%FD%6)?U& MS<55B;)&QFX=S&)5TDEP?,&I%PZZ0%'ITFSNC*#+)4;HCH^+@4%.#6/)+TY$ M@\<8^PBMDUL"*YGB7M+TY3A+T,_$B50M,X0'2,C`AN_/<]EX%Z7?#S6Y5>YW MJ.\4W.],_,S62$WBBP7KPO;[OTSTL[6\S/B^7F:8I0$T_(4X_(4 MXX!/,3KY_IRVEF?EEI<9EY<9^TG@A"L\(3)-"'PR4\T_I9^C($V>GC\SGV64 MHBTM*J!U=PG4\[E&%1N-\W2C0*+E&1 M@)3EQE^E.Q2_[+RHW$9YP-$;"5=H/<#SCKTZ[^O)FIV[^YD<9Z?0Q)@YM5VH MJ=#R?*2B]:1%SFZ_ MYL,T>N1A=SMXY&EWNT2>L<9TOI&GK?:R?RQGM[((JX7@`_8\>/QA]+R$H!%' M=KY1B*%Y_[H0,WE@5GZXA/?:K)YUZ4@WWGZ2FG33"WNV3LMZC/I$C]/4-%Y6 M>J;-ZV!D1U@W^P/(3XB](SBM\!';".?QBRW9Y*7 M,*O_?H63]`&G_T#I$_+Q-@I^1^LSIZ)1V^BM(&I=CM(-+,HQO5#)//-Q922' M.-VQJ-N\GC&X+B4&!N/O0;J[B];!6[#.O+`S,,GE\84.\FIS)F*42QFVDQ)F M0W4RKUO2HPS%@#>GAY*?LSRSYIL=4:EV3RC,E4YVP>$%WT0IK4_%JA:CV;H< M0N76UMQD8$3COI9L.L,PTE+/4);2Q2I*UT&,?,*;62N&_6,5_EL_6L.C+EJP M0,$FCA1[R4-GB[LK.U)`L=AJBL>$`OO'UM)ARE#@*M@;"FWN,ZL%L-0/7>J' MM@>`+!^MU0_-Y4R6ZJ&24%JJAR[50P>L'NK$1%=?K:58:2*V@9ANY^F=1NOIJV[2"750T(.;,]W*9%7ML6:56@ M)U][5DUZ'>\;I"NV7QKN:IX>.^1XC.#+AL5WY=!N.:E93FJT3VI^=N2D9A5O MO2CXO=`B6C\'VRC8!+Y'A/9]G$5I$&T?<1CX`4K*-^!^7DYQEE.:<[YQIWC5S9.5_6^^]Q MO>],9B9O@6\Y2;,K$.`68L)J$7?F\;HB8_$P>$@DY;C3N7@9XD/:U73Q-W M.W-6-NF#O:2:5WG>LZFD2H]>A+DLY%^KS;FX:%$LGI8=3<3N.%`_'6\YRV^R>7YVQL MH>E(3N9RKOKNSU4U=AT=`>^[RYHTM#[@9E`.T,=0J\Z)958.9UFKJTTHV7L& MGG)Y?$(''*?TT)&QEANKNX'\I]N=`^?A0SC)`%XH&"KHY-R@=D/X3!;;B(!J M1Q8RU^@-A?A`%SDW7ZF>[*<_%%J^E;YS/6IY^A MW[6?IRN.-2R#>^^`BLPK]7TP0Q4CA\B1>&!W"Z M0030;L#)\V0*?UNN"U87]0I'"9%J79;8-\337(&&\Q+U,<8'%*='FBF5$G%HV;M\HYEZ!8ZH`))7I+0Y=<[O-3A9 M"]=FX8)-&K09<8T(VCQ5UQ!P7NLOT`"0M\@W*,=0IL%\L*]LGH$@+B/'O!86 M9ZT#8@'7R0)$F5&RC;LA'MQP_D@7-M<@P=SL3PN5HWD M2'UY_.3]"\=7H9\4A4J]NIBIPU'@ M+#YXVT^SM1B.[-;6(*D#+CXF)PV";=Y!<1/0`;1^D^82E+![SH[4C'W!K[O((E)11:"':=*VW<'#3 MF?3,7%\JM!!N.]=:6`LM*B/*W56&U&]&$HGN^)O&M6YZ+@B!X[Q/7I1M/#_- M8K*Z>,Y(W$MN<7P=9]O:S1'F=%RC96DCI9;N084Q]KB/.20A<^Z60D:I.VN+ M0@!TA"&.*?5QM=F0I2U1LZ7/@=[MN/7\(`S2(WO+H0^/:CM"C\=4(&G"1%K@ MU.S8VC(4@FDYI2D/0J+M?>"]YA(35[M'-$&(#U'=]A4\U=M/!IH]3:,'2_5. M)[[VO$:OZ7F*#J0M\8E*@T-$0R06%4,A!'"D!NR*Q#R/WM@IOJ*W64J6%)^"*-AG^[)H;O*$?!2\ MT1D6="6F%Y/J#HPF$W=1:<0LDI#5[8N3LSO!.9*,%:XS=)7%=%`U4-QMK(#> M>F-[&>O]0"D):]!.K31U+6%D\5X78N*3?TEU[Z*7+_@?R(O;*TGM]FKPKK>? M/\)!:XT,\KH<$T_RD]>8](KZ(;W#01GK-0[O`NV0Q<;'>TV2B1_>2.M\B[.X M%^`[#%3Q7F/P'N`.V6MTM-<$,?D"G=-@#][Z1?<.`V6PGQF\"[`#]AH?[&=! MWL=B]&6'8N1MTL[^K79[-:C7V\\?Z:"U1@9Z78X2YS_-&^=ZZ-;#]'M`LEW\ MGE#[LP9J:5$MVZC-U;N(UD_4:"&[]BN7IGY>TJ5Q=U=:1BF5\E3# MVW4I,57RBOQOT,VL@PA.675=`G?Q(51'$APL/FQDZ(00%Y!QX?O9/@MI5>%K M1.3W@]PFY-\A*FNMU*^*@5EF[0P.PVS/;S,:8NLN=@V7[RT9F< M`R]:/V:QOZ/A?T]+/K8_G"#!Z4Y&E\!=6`G5D?U>,O@`26K?NS+6K?E@[>+G M':UT2B9R]._,E!.=INQYOJ"IN\CI80*]@W]!#VRT_>7[[\?'FYEO,"UNEL:9 M3S6ZHR%U2\R6_!+CI+UU*$%96IY+Z2[6Y!64A!:7(8BDZ5]RSY_^WN&0:)30 MCW)Z+&^U_]G:K?;E#6N%-ZPG/"[+B\DC1=/EQ>3EQ>3EQ>3EQ61I-UM>3%Y> M3%Y>3%Y>3)[8^GAY,7EY,=FE%Y,G-VOK;+4L+_>ZM=!:7NZ5?[EWJJ[$+N.LIBPFI!R"!U""C#Z6$%3$4:: M7>2S2@[K>6W;E2\IUW+TF:@2D9U3/P&R22!*4DMU/,&,Y[5\9L1?X"T$"4IX M_@.]?>#ZU$>JA*C2K.?,D0,D=^``/@PA00DNDUQX"$)FL)DK);F''SCLV8NE M&ENSLQD@>;?\5MX28SQZ<1JA^`(XY!30G8XV03IWQIA=BUQ619'7-VJ-DZGO3-H(0PI6X<+V(JH\LJDET#2;15P%VMK37DZ4!*$HF0:9I85!!` M%INUCAW_5LIH\_(%:Z.STU8!G;6VF<24YD[N2G,E= M64>8]DR.K6+/F=P5'QFF[D"YL#-P#V0_B0FA?8%[!W*2-':)(/VT-XGN1;DZ M4RUHV-'T$<7T#]X6?1"AB$$*X:A!Z@Z2NCAAH0G64X"G^];]3`Y;QR=5U7LM MC"]U"R42E*7QN)2.8T1>2Q6(<+D..+&QFH?U@+Y4+_S9SKL":WP`N5?2]*)W MF(=XNZ]^'[PR,)!7Q:=CW+-OT;GWPB60826E:--CA5VT[]ZW6(]R\B@M[##+##19:D=MIX'0!EURQ_L*[H9*;7K0& M7GEO_U`K$S8A8(!ZJ,*@SLBU_4:6])QM(C$MYXOAR&:1WK1`>LM(;5908SL% M:(A*<3'I.)"P789+;J0!2(B+<7'90Y`HV9K\/%A=P-]%Y(_HQ?N*DG(!_Z.U M%?Q)%O@M]Q+5$I3ED',I+<[V]@<"^1L2@,1]:I]X'W2N$&WQSK MP>'D\1H6'3WSD`C`5(ZX5;P;(K;X(=)' M%58T0OL;I=QSO2`XU*,K!Q8#(?)7%\7&#XR]>O&[/CC1:0ECEM;0& M7$GDL3`J;8DF8/D],K')ZVGF0"7_*.KU-]2N:B>)P"K7&@*LJ/440:MDD=[` M%?7F2C;30.#--\U\6G6!6>M+A%[)YA!\A:7+=/2O_E#, M\D6`95-#^&Q33Q&.7(U[HZ_-G0VVJ;Z_R?I:5'\K:\%1KXO?$)W'7_A^G'DA M=<1\QRF+R7SH:N?%6R2(MI-V='$O$)7$+8/3?59S^Y2(=UU M3K3X1.!RK2":(DY9^O5?A!5,Y_F>7-,.4EM44EM3T\2/^&1$`S_QQMHOPFK:W0>1%/ID'7,2Q%VU1_G*L M%#RY+;E8!5JZ$!"U,"IC"3!**F$3Z$EC;_-C@E#B,9S#-CBPSFUT9I6 MBOH2A+3Z]1VQ4[0-Z)/'N0=+P;$G;RY@M7E/%M)FK&D&]-JR](_?XWE)];#; M2>M+M,$Q^M4+LP(O88B_$-\7;C4IL(`FJ%(LI@5M7=OT0+!"EW/;'%5'K3I( MG<*DZ5-^15R:.NIG==M_'W_@('JQ_E>6I/E,Z`5?K-=!(>JC%Y!/PI5W",AJ MD&AXL]D@/Z7WP]G%S>EVF9^><^&JRA##<*]J1YCF/E4/&-;,1KS%N(@S/[2H MF?$!"8]TV=02,Y2<>JJP5S/#,$&_W>7L'I^&DX18UV(EJ3LOH`/4KF>]JJFK ME.$J9.U$F=63$A=9NL-QD!X95V?Y1.U\\1:1-0C(CBV65+`Y^@+N%`$05R>N M37:%8]ZG%9&!@V_]#JU@3)FC+G%KELV6/=Q.W9,EPJ`D#?PK6E8L/C+O.')I MJMD(F\:A<>[>>9312S3,YXN/`+>)I]@^$]41G3B1+L*_97&0K(/\`A?[J0@Y MZM,#9@)JI]&CIJL\CH1\)W[D=HMC%&PC7L#AD93V9),X#1@)K>11PF8VYW7) M/7!16Z&%<'UR[\"E;84)JKKJRK-5J2XF'I&DKS=)W^%Q\O*2"EJXX-+$U'W] M+CB/^XPO@__)_F7PD9;TRZ)UEHM6%U^R6]:P`Z]AYW5K=%G2.K>DG5=2Z;+" M75:X2U6>PS]?6/>Y6<>+8L)23QZA?<_@'RI**ZETGLCC*CU7&]%8$E;0.WF# M&?,.W5RGB@Z=,<1^\/;O.L20U#QAU M:K?@T5[SJBDK@9%J]2MD[&+4J$I.``\HL7X\O9K4_-&M46<,*!8H)#'49Z[% M.TE-;O-:[_Z"(A1[X666!!%4`YM+4YH5H)D"7&344T8-P'1VJ8),4W2.#'A? MH`XQ[P-T[\`97(_I":1K[SG*_5Q?W6)_B_=TW2\UXVU0\):5;L.H"!ISY MLC25P-5]_>"-RWG`#Y_5@[A+C_RZVCS6>K!V$+>*MUX4_)X+02MBXS!8%^"+ MUG4!5YOR8K,7YONG^24+8*?(*,_J#-L,3WNG^GWD/T/GA2#ODHCYFTF3<]B; ML#Z3O;V\`Z/@Q(.;OI7/8$+Z/./!N-15>)[JQ!*T""-<5[/L:Y3X<7`H[58^ MAQQ$VT?2V`]0HNRN)OL2^:Z9OMZ!(P\P*&-[M1D5AEU,6DZ.>D/%U=&[Z`EM MLS!+7G9D07U`61KXR5WD6YNBT6(:Z?$32G=X?1:3WA_\&PZB]%?R'T0!:#*F MV;K$J7)K:^$;D%0\=5)OR+>-6],=W>''/0S3#&Z*$M`PIM(SL$B4!YQ">0)RQ*<,)3ZQQ;0LEF#B:*+_OR*52[J?^<:)\XODWF.`9'XP12HVJ`"'9 MR%ITD!A(K*E[,RS`'>4A0;*#V<:#6R^(:94H]`EY]+^+`I36LD\K:K9/?XVC[@N+] MZC4,MGD'=$%UA??[(+7K\-?H-17F$O.)3B6EV$06ZV>]TH*F92&Q>Q)>42+A MZ:K-:NK+-;-8YY,[C%A;]W9-3U8W1:4L6?;S#I`O?92SYJ[=<6YBS8XWN>J"[^IFJU+."BWMO;MY4H*N;=:(QF;N!`$=(<< M:QJD&3,4>Z?Q1+;7V7[5;_:'$!]I0+U$$=H$%C_N]=K69+7TA-*@V!841AJ- MEB6`E%I:BS"/1,1"P/R%O$=,)#I)6HV;>.;?ETUI,WTV5HMKJP($&S-8M]JV MI"PT0NG+,-N8=85#@FA,2V&]H?K[57FM;&.D?:@`/!"AV+%$W#+$ M[Q3->O.S%N,@V<5A3:.EP%ZN!2]3*,%]C-6.8CV%HK%-29@YQ:^(&"B-RV39 M*L/U*4A^LS;YHIW3L?M,1(M3+X@XCXQ*T5;WI/FT%L--;0RHD#)Q1K[)*<#( M-+$66>0&$FNIW@P7W)Z*4"#3P]1CP*47TK>PGG<(I8_YL.S(7,XGTS.K==UH MS*TE[9,Y9OXD$9@Y*=^D7N%-V,1B,-CO<91GZ9%16<6YN.O\P/X1Q?GK2]T5 MIVR+\TI3W,)BSJ3"F&(=_=LYD^+^BK`@T<_4KW35E,PU2LIZ2[]WWI"3H.S" MK4LY19@)].T-KR[_JI31;&!UER29&%)-*@A.%=5TH<34TQ",*MY5D8G90&B5 MI4GJ16NRN!/AB$$*@:E!.EU$P1H;@E6C@^J5QZG.A:^QGY5O;]^0Y4!ZK)V\ MF-NRX_4"9?TI-#D5P99I8BC)8(V"PH/)/]J.2_[TST*")[0-:,=12@LPM53D MD537!IDD]G+X5`8%2VG8RMZ3Z""_],=DW)B"CCK.5_FJ.;PC[O?UO]&1.=`` M36.D.S03&VJ^CGW&NL.Y,3$<:;`KD5\(6R!>U7]JQ:7BI\F,*$/[)J#3`1=GU-Y@#`0#)I6B/:HIG7II#>8+8[E(/[9RB#6*H]`8\D@:0]I@V1Z(PMKV'.` M&XS++DT#!!V:B0T^7\<^@][A7`[V1PN+Z"(J/:$#CNE%?+I# ME[''G$_:7%(#I!-#@)3&O1;80`>G397Q`9%#\HI\E[8X9N^I,"D:P]^BF-BH M\_3K,]@MOM486]@Y>\Q>P\"_#;'7*48'_=X8W\;O$QM=6+<^8]O@6HWLJ-MD M94"1/[:2;]`,[6X>86D&>-V#+,4P+W.<]<'*KMQY.7)+_M+^\`NH6CMS':K) MH$%.SWZ[U;B/ND'7E*;8,12//(...?8-NHF./JRKB?%O<*\04-_=LUNU M!FV)B#'V$:*QR>`%DC9GX0T1^0;EZ,@TL)9.D@OWR4MI_D%>!RBO>H8B7A4Z MI39U(XC;6'--A5'%>A9H.JFX/^JBDOW,[%K9E9?LR(SUB[U[K[5TH),PXM1K MD+2;/R=H?1>M#HBF_D?;"S\-W@)Z.Z#`7T;^ M5OZ(H_;GV0RSTF!]F;F0MP:#`ANV%IC1UA&!AI:^71N,.9A6X+*<5@F8HRAN M(C0'$!O,,N4[A3+3J3I'/^L9<1)E$::>M_[HY?4HDA=\X?\["\@DYS=*KS<;6!K='VBWY<*O_0Y3(G/S%B MR<'\152A@U< MIUWE#(UI`+@KK2KN/8&S"/,7H+<):$Q\]1D!?Z*7):<4BL]YR] M)L$Z\.+C*BZ>>BTLB3JAVC!;>!-2D^V,/&8@6X^X@:DI+N1?3FUP9K&_HR^B MR>T.R5%7WB"BGA/(E2PS&'9%4D"0M+)U.>C.3UG;RVPZCR93_DZ0,M.IIO/T MLYZ1=!YE$:9>0["^X*'7NFD!9!(<\AM`GR.BVUU>^9E6@(_6^9\O2?Q8UY_) MH"O]A)"%V3J?/I)OW^K`VC8=I2_&XGF`OES[,NFZ#AYW5*2^:XJZM)?M`^@P M9%*]C=<$T*&M6,+N?/L]=N#!QI9KFB]]D1SWRS0OI9^6"6"".CT37_$TK1IZ$=)M: M;H1$&^=!J*.[&OPD>S"7IGS(J]X0L>)TMFC\YP_O&8\=[4=$I$Y^[Z&JE6\; MC\_9X1#FIO'"4QZ1\*4>Q59591395LYC4D]_-4Q*]\%&Y<]3G4;>140,E*2/ M7M!.7V3]5-JV^9,]`"D"`W.5:@%&CC?%3I/GU`^U[B(?[]&+]Q4E5"$R>^W@ M`B(XH:-+,"V,"!3L@90NYYE=2*\L\(`CG_SSG%L5K1DK?&%E0%/L6BG5^NR< M_UH:MICZU*Y?Y]!&C2N7`DK-RM-=HM@SY%!]QJ$0=I^E4*I31.0 MHC9S@J62?08#IT@*AZX`NE#V52U%7I.ID3*P$YH.#V*],D7G!3\@G(28($;%/L3"^QPGYNZ2M`&\9LHMR](?IPK4\`5T/P:.,@51* M@:(*^8.=@XCNT%S,C"-?(R*T'^3V:SD@ZZ?J_9#&3]8`/R@\,=<"3=@.(4C^ M"DE#`(?`!RP$+O;T1;S?" M7E6&D(N]-A$3?&>B=X(^P"HVX'<69799?^<[YH7%B.F:NM/U.*T_0KOZCY/VBN&LQ1U"<"P:A6*M^[QA+P_)V?_<6O?FP%Y@J?-Z)$^C;ULHR545:R%TFFWC,+A[3SGSG$E6)[@#1 M;$$O995Q$`V)`L'50AZ?&;C^X@41M=(JJJIS,VM5\NI4/N`(5]8LS-Y"^Z!] ME+`8J(_9^MH88S*.JPZD">3I'Z>[140ME5!3(6*LFZ]4VRQ(=D6&!Z.JA31] MS0<%]+/V)Q5;C><;`JD`G']0.D5MXOS%S0];[=D)Z,41M4;@IX?=:-;85[:: MK8\#6S3("URJ!7,V!4J>4)A[&BZ/I//##;E7=?JR:5R&TV$S6S\P9-FQSLUT MA85\9<+U'HDQ8KHQ<8V*_ZU9K[H^P\[*5&]X=A_IAG-V&#WKC>8BTN)!3F&A M[C?\^6AI0W-&J?3$_WT4O-&'I9FWHI6:@?B&FEE#MP;ZF)B5LD<3L?)=LW$( M=6DD)=+UT$Q7[1'IK5M\6HH6!&B#=O*HA#4W"\5&/TZ55!QL:D`?>TGCV`U"PT0:GE] M.Y2K.&#,C3.ZOJP519*.OOR6O#@,M9P\GF6M8CPV0[TZE*DX%(:O*QT4(C.G M#8A;9IO)(U9L";-89?;G4";BP)%6!:1P$U%LG1=$A788))I*`72RN7^P8SZA M-Q1U2C)+TPO#YXE^\KCD6V"8L'GJ:]CTOO_\KC,H]^0/Q6_,GQH#AKZF*%J? M2W!UAHQN\Q]V7KS_EDQ9"B$NO9`^=?B\0RC]@[64V',=F3(GV`L?<1+DJ`1* M0RLTJ=)EI9K8NY^7[SI!Q5V8/U;Y\:T?72A-)!X4+-`*+#4$LLXSS5LL9U:^ ML%#OBE:ZBU(N5@":!F0Z-/8.DME(P'+:M$Y[&[S.H.CPF!DVEA=(ZEB"$&/D MZ1%F%[U?>)@L\B[>O""D.Q^W.*9I=.>G7VD*Z?F_2H.UXY5>ZRJ2J;9V%Y?] M#"&)4.5.IEZ7_9P!D507ST[9$:OX,<;;V-MW7ZE6:71ZN5&ND;L(U%);$GBR MO`T^:.L"_*KTA^.3]^43F@VT4;`*_S#VO+B`QDK0E**ME+X_275S(*R@)""Y#G)!;]'5)ASTV1'F5UF6_%QK7$#NX+@KZBA"@YC=S";\S$L&S,1YZY<$1$<] M6F<[1J?I+DS2:GDP!,1Y@9(=#HE.2;%X!<[^5)N=/N>RS29SMJQI";U39_G. MG)D,&H+N#B"Z9HX8M%-`T="#35PQ.+IS.Z1 MH1EZF6M!LWORS#3FZ\EL;&FUK>;Q:FT=QV`?2ZC@4K&?F>UBM:Y;L$'))SIM M@K*)'(>9E&XJ>((8SNQ06SC;$DY")CB_,CJQDI]13?;'F:W^KG#TAN(T>`T1_82#&!/25752;3PMY_:S3`Y#*'3NS M\H02A=KO]IR7),#"D4/96B8R*2<%-'F=>QSX\/J8V6(0KMD!EZ1PHP)'S]/" M(8X'9Y M_MEB`HW<1)VK3SL]AC\C;[,R=[1,IOJOV#XX+M;KH-#FT0O6=U$YYZMIWCZM MD6Y0'=M(-'`<4LHZJX!,AOG,]A@N?#_;9_EY>KZHH`\0QFB'HB1X0^<7#?*[ MCB_>U^YYH4[K\RFB6FO7L=G+&DI`5>W)F5T+4]?P4R^(T/K&BR.Z\*W9XQIM M`C]H3]SD&YRNWXL;.`Y'99U5$"C#W)DMB*%6"<+5@7!5X#R(A#JI@(;%S.!& M@PM+2='"!]Y]X))+IM9/;'&IJ+V1S0N@(Z@6XT1A6*CU":4[O#Z7)FCO?0FH MJJ14B&I26)/351]B(/\9OI)4.QZK-I$?<`H5GI>D[AY2LJDGA3HUW8T<6++[ M,?)6DDNU9FNWJ8#5CPL5:`MI:/)=5T9Q,5J5UMVZM'*MK061QHN)IT)R+[BV MVU+"_=)+`K]E)D!]Z M29)7D,I!='I3M"RDN-J
29F&VIOGE)Y,"VW%C=EDO[31XEU-T/PN#T=MG MQY&YQ^ZC(T*N#"L!'B=!>3Z,ARFGB'MYU7M# ME]N5P5.#SDZ8/DIH#J_#<2FLG@DF%\'@-X\@7X^'?>U M?[;YM!%W`+!0F:9_`OR*0[PV'V?68$#6,"VW3$Q(GT6X)L*'.*^,6.KQF?@F M^2*&9,@Q?9?I#5UL8X18.]^]^9QPH\W'&L!`]&!S=FE"L-UC@3WMGEP':5'U MD;[]':V?\-$+TR/[138Q8:-")IO021Q):R8&"H_5U+.O*GV!CQ7PD7)TS`&I M94)!U=!@FI(+I["G]P%OOA[R.K#`Y$1(5RW483J7IRNRZDG/6S@,9Y:>R?Y* MEFI+S6E:M-QYRXG6&IK$4`$G*6Q%FY@"V<,SDA-;9V8=9I#U"XJ(+4*B[,5Z M'T0!M0.=:+&Q)4E=&EU([3:^U)150)B0\Z'OG.G)$"BE@A<%J MKK.C6LH&@(\N11LA=8I)S(5`E=1G0756,\/(`XYP4\W2'8"9M#1]E0@BIG<9 M3:KJ2F-+@O',LOO/3G1+K"^7/ZO4IK%S+FQC#77RD,)Z!FAB4-A=\?R>5#&DQ=#`O,JM'/YS5@C\?>/25&M]-LTT<".CH`9Z`+93GR+5$HGR=+_' M&+T%.$O"X^[F,4;&,7+YRS0<3:BA$3'7SE>J:!^W*^C+Y"D=$ZXS6CBNLA:/D$FUPC&K%\(EE8H]H'D3$:>]2M,_? MSB,MB59A;M]BKL5=7`_2$W-);K@GE[>/QC.Q],;3H"+-K-;`R09E;+I$$=H$ M9&5+[''(<[K);Q=A+D&WK*9FZX;/*+1VWP]T3:&(;85N=.HJNK7*7"YYFMKI M-WB9D[?O;^;2YF3+^E?EC!Y1_+PCXY5K21-"@C!+SXG_5?T,.>JJCH:(VF7\ MJ:DJC3SBC4QGMN@AV[^B>+7)=4]669JD7D3O;+&B MH5;;>I9]5P/Q7BDEP*+T!(M;%OAQ=&R3[VCVW-7BP7Y%,;%BQ0"ZQJ(*II MV^3I1C@]254(3`LNX`B8:DC1ML>>36L?"LV1Q6K:`1#(>3;&FLW+C:%OR7:- M]U[0WOOGTC3*OG9H[`\Q=R"QG'+`2+-8GXN[=EBZ,>"/N)LY.OF)B0(3U?U.20NCM]55!1?'7R M-%EH'[!#T-[\JQ$X./)"/:2W^6H,ICY'(VX?(R]!UZCXW[NHNZW]1#XI!,]? MO+B=Z*;9^IPKK-;:/JBZT,%]K0"@[M13F2&LUL/4-S:ZZA4O!]!(BN-\Q-,T M#EZSM,A#E;HY8I8I^':C'E.;Z4I:Z&4^`FG`H)WL)A7IV*])ZDEEKFQ$D<1/ M7#M.%\<"F?[SA\6U#+M6QZ2N.Y?.^K3PKIO(^J66(J'R+K^5W/80QD\5RAL_ M31*KL'+]\=;@;:XBBTLA60XVW?`X*^`,$*HDH/-!9^'F3,"!=QA6\=7.B[;$ M3'6"(/*#0XBNB@,(6F!TLT$^?2DS)UY%A1U7\0-*+Y($I#V>;NN- MT.,4G6?\H>CMD:.(;+#2I0LK86*F39`RBJ!V?Z@R>&H_3!'8H&*]\5?G/+,R ME;GNQ;>N_GC;KUZ8H>H&)SN"-!N^)TBPL;C5W0_/L$NH&J^],:XE%\)4T%@F MXKJ$5#VXB:*K&E"59!!&4D;?4S^&K"5TO&`@-;B57D,6ISAZ0W$:O(:(%ONC MA2G1OS/R4XU;)S=[X'ZZ-\!-]S/%D#^6V7M_'@84=.HU24R89@!O',#QWJ^/ MN>A.IJNC..HZ^:?]M;T\>B*!A$ST4O2,XK?`1\4TX`GY>!OE7/(IA(9;F>A. MP>7Z=3=7=S0X"*.X:C]Y@8/!R4<]:)\G#4XR"S$^`<2)61)MH)T`"JK`S"G0"H;S?J(O!V/1[0 ME_P7E8.Q3AN)/=-:F\G&145S#+I'6NMT^F]YR,QY:+7P/!F"EL-GGV%H3+\5 MN"K,LJ6X3M$-AC'I*'-F*;&@8P8SR306ZH%>!XD?XB2+T7DW[.8MWPBS]C5J M"0*5FA.05=\Y[8ET@L9N$O2WV\"#3MT@(HU.GNS-]'H8'G]6G,R@'/^ M080Y#ON^E57/O:=1\&(;H^(JK37'S>6`W)7]8SG"[1^MN68AR&ISCY($H;.) M(1>5IF\HRJ6WYK+`"&%U+9L.V^1+W52"WXS=EE%Z$:WIK.G`JLU^3JV5HS]GW(KH;>8/LV43N[M.4Y%%W`H"\@.->YFC5?%' MU&N9JZS0V_0CQI67[&Y#_"4IZB'M4!KX)!9:KXJQVIPD$U>!!DF[Q9\9I#9? MXZ+B$,B]!638+H^?R5+P+J)(*Q[:0^OS.WN=&T$:;<\O<:FTM5_^@3?"N)\M MP#+3G1[+][A4>II^>#A'/4!'6[[#%B=_JBHYX,0+?XEQ=H!BAV;K$C/*K:U% MF*9`IROC;`7$,Q-3[,YV[,G.6FC2!1`V;L1F`%.4B\:T_O+86D:5O]#_1],0 MR%_^?U!+`P04````"``L?Z="4M^GIC,C```MMP$`$0`<`&ES:7,M,C`Q,S`S M,S$N>'-D550)``.D7(E1I%R)475X"P`!!"4.```$.0$``.Q=6W/C-K)^/U7G M/_#XY>0\>&SY,A-/9;(EVW)&N[+EM32;[-,61$(2-B2@@*1MY=>?!DB*I$"" M%\DC>(M;E1V9[&ZB\>'2:#0:/_WEU7.M9\Q]PNB7H]Z'TR,+4YLYA"Z^'(7^ M,?)M0H[^\O-__]=/_W-\;-UPC`+L6+.U=8\Y)ZYKW3"^8AP%(,`Z/DX(?\$4 M\X3T+OPW"?S0&M(`OA2@!;9^^Q51Q[H^[?UXE7+EF(9/PXGUV_73*)$E/C"@ M"T)QQ/#J.Y]]>XD]9`6(+W#P@#SLKY"-OQPM@V#U^>3DY>7E`_&)OUHB[GVP MF7=R=MH[/ST_[QU9*`@XF84!OF/"Y>SXM'><,KF$_I[[QNN,NTF9SD_$ZQGR\:9(]!G[P89!$OO8_K!@SR?1 MNX)O<#PO_<3'$WB;$-+0*R9T`GXB-#@!"LR)O6%@M`8/H\=;?(+(V5(C+M#E M2?1R\PF\$(VL5(&K$\Y<^$A$EG`YF!17$KPHJ*%75X/!;R,`(6U`I+H!'1,* M'8?:.*LOT7QBF[Y&<]^TN05"J\(F)UX4ZKK=Y&(=>E=75R?R[1'T6,N2?191 MR@+9G>6SY.EJ1>B#ZG#36)SRWI)S/`O\O1S[Q5J[033Y;RN8HNM)Q MTH/^M>+X`Y0N(1&(:FI+`@XL/G1W6;11^N%$!.*V(D71$X2P%>8!@:Z9]K23 MO:EE([>I6L!BAZ[16CEXWE0K8"&4F*R4BV9-E0(6[+ZM/D+.%#2PQ(]O3T/- M;"2+=,OL4$R"?>H,:$""]1!Z*?=DYU6/J,^8;93%?_#3!84=X MKI$K1OG)$N,@@B/W1%_]/5']$Z@A'-?_S?CA=O`P&=R*7Y/Q:'C;G\(?U_U1 M_^%F8$V^#@;328>"%H5'Q$'?)0X(**!"DG]=@<]E&WRL'W+?^+\.+P6O39V. MYT-8[7@XPDE]K,?GK&;_F4SAG_O!`V`SOK/&CX.G_G0(!!TR.F1NF`@*J/38W?>"KN;\?WCT^`KT`W_,;"&#_#WP/IA-)Y,NFZF@GF# M_.6=RUYBS-(_]=!F(]6&<*6!EI5BK.2N1UL&E@&TH7F1BH%)"RK_20G"N09'B[ZM=4_QTB_!_( M#?$]1N+O0B"*B?207"B0""F6%&-EY73P:."Y8;#NH4'DO1_/KT.?4.S[3\3_ M?1LD':D>JDL%JIPL,0LETBPAKD-,.YX)`WJ*7M5))_M*C\C'@O%,\%J2N:M_ M;8]Q7323&VK/N,\YHHMHG.E39T1LL=%FM8:TO,.TETAO6@#Z445I.>M(;WH(-T5TLLVD%Y607K1&M++#M)=(?W8!M*/ M59!>MH;T8P?IKI!^:@/IIRI(/[:&]%,':4U_3LERI8!"#U:%1Z=;B+2"15EV M%)%4`*,L,HJ`Z184+;QM)7U'2ZL'JX&_K>M1.\*F]"T]<05P2B^K`J[K<:U] MI27]K@:''L3FWM*N$S8+I2BU-A0*/5+ZP(H.E[<(L2CM=:VDZ/'=2\!%UPSJ MQ*07G-,I>:>#[,?H#-M6M'IUC'IW2*=!AWW`+W?()BX)UMN],/M*CY.ZBP2\ M5L+=B4`;$$BH]*NKR.2O&2N5T`&D`&H&ACXF9+T)'K,/C4P(2;3\MUFNWUDMF4.U%'KXU!/(61$P44HA'2HUNV:_ M9J\ZU77-^D+TV*H+DAVZYFG7-6NZ6DK\G@44>OC4W86LXZ5S5K99X9=@4T*E MQT==,6ZO]SN,&J\T)N',)PY!/.DD2HAF!;4>,W6?H/8JOXO1W-.RL3I4I9)3 M#W+K962WU[YOD)68^0:<>I#5169CD+L`^HJIUYF*)'3[83H@54W"'=89G2QU=I&,/!6+EN+,>X:4RB'ZKPK MH-##I^XDIB*L1$8'B@:4OX>(!YB[ZSM"$;4)B0`#M=%]KI3'6O\:'J7@6*;4]5]SHDM>Y06/WA/T+0>/"LB],M MI=.CIJ[O4T%6)*E;,+2$J@JB"FC49;P"30='LV2F)9XQ#:4>(G417IC:M'.1 M[6G7Y]/"J[I&:DU\'[A[! M5=9T]1GU\!8$;3>"MUOX[0=@9:.H/J,>8-7WTA#@;I>HH?U:EM"NE%`/8($; MIM""[<;;7=!2G6;EE'J\"GPS.KRZ`;0E8FHZNG)*/6*JJT:/6#L7J1\5U6N%T1 M4U/!E5/J$2O(=ZQ%K$OZUC`-B]*YBDCT&!6E?2M(Q-+UIJ;8%(33JB1Z;%1? M2#$VG<7>$)N"*%B51(^-ZL8HQJ:SS1MB4W"^0"718U,SN51GA3?%1C&_BTCT MV!0=^"C"IK.W&\:=EGCYR@GU.*D^B((HU,[)MT,\:@E@>F(]:*H;HDYT:H?B M6\7[*W-9*QE:S"_W>=Z_FQ#;Q+?6#&^MP+'`O5$:W=K!M.>.JO@\6LG0`[S/ M8SF=IV1O+:#L;M)6,O0M0/6U-&\!W=VE;S0$7.UA"+BJ:`#[3`!RU;6`?;6` MXN#1%A+TZ*LNH^;H=Q&H;9=;Q2!K:?5PJEZF>HNM#L+]7%FD#-C[&*$+@F6Z M`5D^??6=SVBU(G3.Y+/X":4L4B%Z*)X1;\5X8%'D87^%;+R!?8[\V0?&%R>A M?[Q`:'5R=MH[.S[M'9_WCBS?7F(/C9@MI6UX7F?<_5#(>(+=P$^>'*>B/D`9 MCJR3&N41S5#*%Z*=@)\$H/`)#3W,B5U:(BT7E./TZAB*TONXYL1M1L-710O$`SO M]8!R.<]QM4(IIYR#2>,*27C$C[U4Q3G4JQ_`O(?K58-D$7\=)WRB(LY%131N M'+&\2_F7$]0N0,(@OGRI?!.[42)C\=$O1_'H[S]A&Y-G,8MGYH9'F/HIYM,7 M=H^]&>;1Y"0FN7\UY!/=Y,L1]&'H_)\=YB%"AP'VQ&`,:H4S/R!!*)3ZA;-P M]>5(*$`^@W'A'5D(WG)D!U^.`AX".27BT@T7)W]'M"L8&I@SE=]QPNC,NT;O M">)X!491_C".HJ:>S#BM-I=%]7T?!_Z4(^K/,;_&P0O&=(2?L=L3-Z"('V=] M3R"84;85=U0'46D]1L%NX.L6E3!'KE]:"S/DBI[TYEN@:^FS M&0N">QBBA)W!B]`N)S$.Z3K]SV_5:WV#=5XBML"T$#KUG8GE)]!WHCST]P06 M3`%TF/XK\?.*E!)E^QJ4#TSV2H6K0I6L7>6J'S3\W#WL/++/8C36>1S=YX5Q' M+2%X2R06^J.ILH'9C+&!7IBB7'4.0[BD6AU[[K MQL9R1M'&G*9601ZQ6SP+A)-'3/"/''LD],``+P6XC/Q]*)L[!)E1#SAEU7'W!K$Y@W$`503%/11 M^%5AC1S*._G*=:Q%;IZ6SXA(*=#V)@CLTW7+HU402*GRBRY!CO MJ7JJI+Z/"IHRL"MWJ@Q%POM0_%<2+`F%-BZ`VZD"2B6]IXK8R[!1+NK050&3 MVP+?QH/NE(D5DXNWK$`M57:V3P;O/>I0:SZ0Q;M'K\0+OQ02.&7G!6%_N#?*7XC_1\9[!,J12A MT@$4P!/A2A/LNB*RDA,;BTSDS`GM[*35D.\M5\!U,(R+&05IC.=/^!G3$(N- MQ+B(L+;?4BFK21;CG469ZCI//19[K*Y]"CUT(V)"B.C08%SW.1=%%*^%`]07 M^6YN0D]&[#[C!QS(X2T_-C3G-G>Z*]%F8[X](>+G=OAK<[P[G?^*:`AE%-&5 M13-"71[CIH;2LH<4-U-VB^'=:!H[#!^E-!B='D-N+V&5!H,762P#_WJ=PXDNY7^.0#"Z0.'*=1/@,P\H.U MR`/,J/0X"4\Z"X/D.?6W%LS?\ZL[57+->,X]U?H`<3H.@]BMG=F!&,];34T- MY1DZ/:?%EC%CF3B[1#'H>GUY/Y\Y\$Y1;)H-7+(@(*M\ MIR0?1%*;R=!-E3),8Q-5Q$4MJ/!2Q5O>,$I,PIDK0]S`C$Q&>6TFK<_U4TQIG#O9M.YK><.2,%SOA'"\%5,]Q-K01\S4^W;8" MC'#H@N$#[+8@2\+]KM>"?2LPOXJP1:O]3L'Y126'4OA5VL4TQDYB:HE'A&)1 MM"K-,G3F#39J<:=;)HB&IETK7*Z%^17.\'=NA8)9.21216C<^"G"HH:RS.)A MNN)ZP@[VY/Z.=.C):!M";;)"KG+V;@<96NM- M9L5Y`S.]V-X2ZR>ISD,HIL3Q?,J1`R]NT=HOK9.]R,[6%:&P;,;\^TXW=71* MGB6(JR%Z.TDY\+JUNNP)[=RD\P2+0(WEP`0_.E77#/H4:/D'6 M4>Y\6[F+/=18N=#_@!J[`.7$L1Z,Q'&%/=16L^U1OX:NFL8*T][5VVK0Y5@9%VDIS32$QKWC./I$B6G M50IKH`'?N]$[+O>8C["ONN@:<1FH\QQSCN4999FF)0D.0,Q8!R+@Z`PB8E(TY5<55/G%\:<%R@/_!S" MB8+('2+[D3`./M<'I^]EJJ+;68B M'!`T\,>PX+HC\V`MCX#UM]:H;R#=U%BRW97]1IVWK,LB\>96YHKY1.X8R>V$ MJ!\],&HK9PFJ27=2LFE^JIW&LF?LLF0\J15379_%P%EL4_1Z"KX#G1XYWNQF M:Y32DQFG50:#7#A[NM%9#\#:S.;5`+/#N(]%L5)#"G:2%]E(Z@9X/7+3MIT& M-J/,(W94Y"U_7=%+<_US^=(J'H#BU\:UNBCUUV;_7*0K0@'.IRS*V*E9!9MR M'GA#H$YY:Z1UVDW,.ZB#!QR,02P2)\1$.,4-XGP-0\L+XHX_>%T1GHL]VI_( M0]>-[*C1T>P7D:!R25;I?I9(4K$5`3ME[8)?Q;I?N#VRE?C]OWW8D,CLHE:$ M\80!YA,V#Z!%J&D`ZA";-[`6G1KO]0J5T]`9JU=R?G9(Q5U;Q"&PX)F(@WK( MQ=NGE1KP',:)45OO>PQ]RDDUF82>A[@(-]U<6Y&QPS9#8GSIH\BC27VU9O8D M]3^J[F#.4!QF.\HQU+W82BM&Q3%O.'JX0/KXHK4827YVMI1V$F.K!'KS:"$Q9 M[FQE>RS*K5*#UKPY?8T#;"_K:%=%:9QNOV#Z)S2Y&\97+")6E"HG,4\;%[VR MB0>6_=]<0E53N>2]<7H,;UC5G1CE).9I`V,9JM%[*NC,TVMSID*D$RB>__Q) MZ,/$YN2<`DT93;4A4CVP_X3ER9,IBW.6PV*T=*NVL"J:BC#63BC);%[L)JQ# M;#;\2MD;>LAVDF)PU7!AO=WBZ-\AE;O#,`)E;GT!%?/U4)/%X)9/A"F;V6^2 M"=8V&^.B;Y>=3,S5Q"YBS&T24BN17FT\EZ:]JG+N95:1PX239V:C;1^5+Y=N MPE>:G;X*-N)VD&':[ER:6$L$.LSGQ,83<5^<8LA4$1IGR8P03+5Q&A#E4%31 M2U,[F>PZFSB4]`2*NBE>26D>2'B!7#"(;(S%T1G]`?`ZQ,;U+PQ6(([N_$C" M(M63I%HJXU2*+B2ZPSC),P`M+GL!2ISO'#NWH2@M+.F40T<[R##64M#IA.LJ M;W3>KN0JJKR1EWMJJ,,]S0]!G2>V%FG=X^PABB+%1.9BPA#=^%-O.7JY92]4 M[6\ZJL,;9;'C.$F`H^2[&<+2Z35(+H3(Z-64<2<8OV/,YI`&F(-)*0(K)B]H MI0!:1G!X+).$V^(P1&**Y%IBT6M3MP&*2EL8+EQ%^!X4W,H(T,_E*2M/,-!> MQ('#?QIT3#.=27-!XW#E8%13V9<8#E MBCL)X4OJ&E!#8Z`^N=E[.]\=_+.5GJ8N@[G-4F^N-+!LC#6UOZWFG-$@L[JY MCOUC.*N?GLQ8E:E4I*#E_X!OV0][8@ZQ($J5@;+"CKC!LQ'X:\428@8GS+Y!RQMH"VQN4Q$ M8^.5.L$*Y#XDJG=E8W]=WA1]8D M[968L1@7R0U2,VSPC/,WO]>B-D8G&".?H:#N^BMV9>0KHE#B(?UU2>QE=*;B M*U)V_`K4;2OH;6NBVG3;E%]F3]Y#/;238THU3,B"DCFQD5A9R#,X16V[D,J8 M-CT1KA?H=2,RQS=KV\4P5_"P<)@I)SVX-F-JLU\PQ:_*^*^\,6Z$E\Z@:#:: MLL$K6"2.8DIK:`Y>]P5E4[<7RFD,<$C+77'=1%M*M.;_QIQ&3_=\QD=4)VMP=X7Z0 MYF$0)_UR&M:@-C44)^>%P\Z0WC$1W);F_!(IK@JTK60P=E6:N'8VIX^3W?Y\ M7AQ5Y6J.[]J^=ZN$S2:6S($D3:4@/?V^V?H9S^>@FCB$_81]C+B]!)TS#B:@ MO9'ER`;^%E[Q]R;?.?!V6^J[CB8><4U7HZ&CK8##SV]/6,PWXO[%A@HW83-V MT)07L16<7-I^8=X4+;VE2XY+RIY[96CI7]CU6J>"\MY8/4H5,+ODL*+.75:4 M3X!43I+MSF:E02HJLY(,24=D'E`<3U;_W]W5]K9M`^&?M+;#@!78%SM-VPRM MD\5.-^R;(M.V4$4R2"JK]^O'(_5"BI1$2;9UVI>AB\D3[R@=C_?R'`FC742V MRBWI`E=K&(*1&U8L57:M*#OCWOX((*W69*MK+%[;5`4ZAFZW;'V&< M@1\+:EU,QOUG(1A17AOONTY>+D&70W5@?7,)Y//YE%X-5=>C,6Z/]RN MD6AY_",+*"Q9W=+OT&3S`1+RHX?&X7$OGCCH]B`L/H7D(.C/*RP<] M*Y>S7&S&=(P--T/N,0CYB5Z>,\I(GOR9^QWU5N_,8,UG.%KU\4B.8)PF^S79 MRZ4+\_4U2C,[,Z]SY.1Q+;??,J^VDDF19C%\V=77X'(PC?FXG@LF&PL1F@8@ M_%CEQH"]G>=)+!S,-(Z9`3]+#WZ6,^+GQH.?&^S\Z`5(*N?(YL;:^^-+`4IH8YX%\"&2Y2N3TP\T6'=M8W"]PG+=S0BS*PCE'Y*@ZFV85-_R.H[^Y`504NA.SNB M?KXSIH]K%EXSH1UTR:OK>$I+8'/9[FY#@X0%H2)93O#M M9\_D@N'.:O%:1\>=J^!?R[/TV/\1U'#M?Z-GO7J?/<0Q@,I(,7A>Y`?+I0,G M?&>#I)*\LZ.F%,3KX2&\2ST*UXLVA,L5X14>ZX4DV?H,%"(L\TU+F"F`GUP& MS$A&:1^&-"JV/@246,T*M+CU\E0-R+X((SE)_ M/UMQ2+`+R1'9#A-($X5YB43^E=TQ)K@HSC,)O?<(*J-3'EW3#2M5#IY`>SQW M*\3GOF=-[:@O*VV*_@29`JYO.OY0+`G=N=C6-LZX(_OHZH?\A=-%?Z$'3/Z6 M>_/5I,E'":N;Z+P$Y-;LHT74178^0AHEBIDP7"S3I<'[S4.I9M61K2I3E-&O MCO(_`SB(>'FWW=;Y[C'18%P9"M??7WN]\G8X@,^F>6A3.FHX9F_?__I^278I M)9^`!7"1N:IJ>\W"%Y&V5R\C_WU9;IPT!XY]&$3+SX:$AR2-T_UI$89$')T5 MPJO&4>LHM%_D4R(62)F$8/@:,!:$AXP1[B@7[1R);M^>$EJFOE6=QIG=PDWK MXR=#B`;7@VE@O78_'3_6<(H-$&/[1[POKX6X7,#1J)AF,XI-[YEH9?`MH%'N M:I9W0)7MNTKY`XU>Q"+5&QM&XI\%')@<$AD)AZ.HZ+*9I/;B&Z&O]9:T7_C6 M4F$=X]`IL,*T^OL^27B7`+VQ#7,0=\)&'FEJ3C5U2W9 MR+@V$Y1KU?:>4X;G15R&61-GN\1%D-U;K;"^S^#I0W)FI,N25ZN*Q%WJ@.@UB7S#+0F-[4[TKI+V)$Q'NGNFSN+CKF.GEQB#^`5U@K7?3IY-<]"MW5ZR8=?8F_BQQ]E^\V77,0EAXT7!'9RT/1HREC.NNO$C"F?\FFEV"J)K MWFR^@P4\ZF^2D#"P5+_C-W3JOPI&.2-4:'9BA`K_(+XVD/Z[-V_M5G!])J'; MO.+PW01T3V1YO!N\RG%>=T^9SQG-BB9">=,(88MLLY!+,.DU%_=9PG)87C'* MPCT[*U5\0BLV_$X89M#2$I2MXH0MPD,D+H4P&`RX"JJZUFUO(1B%7IA2&KD! MLP9>A&IT`(:ZVH1=]>GX-B$OP%-UG2M2X,VQ37H;T&1%?O`V(0Z:C3::7G6. MRR\)AL_.W6.N822^C6[W/QJ7)-G04'HD%Y2SVE*[*$;[!;]CE_ M1GBX_Y&A:.%02X,5-43)A(*R)%WWSER)KRY MFDMUCD3'6]W^D/T\7+@970/G8K:42[Y+CAEG7X+P.R3;T^]BQ2K2+4OV,L-@ MZS/I&H+H:Y4&E!RY[:"L_1W=R_DI"R`#EY`J1:$P;%0N%H_$(U;B7&"5I5A. MTJ]-HRGALY<W:<2IF3?5!E=3[9+I6G6!T)XU43%'Z#S;$\PODDL:(4-.9+M('C'O+MX M7C++K+-E-#T<1]"EY5=E]YU+@CK%^5R@%-6O_KEZ_L)IWSF]?H MC91@(]69R=(+C=E18#1H-K8TQ=O=3O6-*W?S41QR8$0DD"&UL550%``.D7(E1=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`+'^G0HK@;*#?#````:<``!4`&````````0```*2!H1P!`&ES M:7,M,C`Q,S`S,S%?8V%L+GAM;%54!0`#I%R)475X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`"Q_IT(3"*3TRW,``,Y?"``5`!@```````$```"D@<\I`0!I M`L``00E#@``!#D!``!0 M2P$"'@,4````"``L?Z="=-CG]=^2`0`W81H`%0`8```````!````I('IG0$` M:7-I&UL550%``.D7(E1=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`+'^G0OR$*D#GK@``R>\,`!4`&````````0```*2!%S$# M`&ES:7,M,C`Q,S`S,S%?<')E+GAM;%54!0`#I%R)475X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`"Q_IT)2WZ>F,R,``"VW`0`1`!@```````$```"D@4W@ M`P!I XML 45 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements
3 Months Ended
Mar. 31, 2013
Fair Value Measurements  
Fair Value Measurements

4.                                    Fair Value Measurements

 

We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements.  These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and an investment in equity securities in a publicly-held biotechnology company; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Our Level 3 investments include investments in the equity securities of publicly-held biotechnology companies for which we calculated a lack of marketability discount because there are restrictions on when we can trade the securities. The majority of our securities have been classified as Level 2. We obtain the fair value of our Level 2 investments from our custodian banks or from a professional pricing service.  We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian bank or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.  During the three months ended March 31, 2013 and 2012 there were no transfers between our Level 1 and Level 2 investments. We use the end of reporting period method for determining transfers between levels.

 

We measure the following major security types at fair value on a recurring basis. We break down the inputs used to measure fair value for these assets at March 31, 2013 and December 31, 2012 as follows (in thousands):

 

 

 

At March 31,
2013

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

96,072

 

$

91,072

 

$

5,000

 

$

 

Corporate debt securities (2)

 

205,098

 

 

205,098

 

 

Debt securities issued by U.S. government agencies (2)

 

24,939

 

 

24,939

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,424

 

13,424

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

20,800

 

 

20,800

 

 

Investment in Regulus Therapeutics Inc.

 

44,863

 

 

 

44,863

 

Equity securities (3)

 

2,619

 

2,619

 

 

 

Total

 

$

407,815

 

$

107,115

 

$

255,837

 

$

44,863

 

 

 

 

At December 31,
2012

 

Quoted Prices in
Active Markets
(Level 1)

 

Significant Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Cash equivalents (1)

 

$

105,496

 

$

101,496

 

$

4,000

 

$

 

Corporate debt securities (2)

 

193,507

 

 

193,507

 

 

Debt securities issued by U.S. government agencies (2)

 

18,108

 

 

18,108

 

 

Debt securities issued by the U.S. Treasury (2)

 

13,452

 

13,452

 

 

 

Debt securities issued by states of the United States and political subdivisions of the states (2)

 

24,897

 

 

24,897

 

 

Investment in Regulus Therapeutics Inc.

 

33,622

 

 

 

33,622

 

Equity securities (3)

 

4,874

 

4,146

 

 

728

 

Total

 

$

393,956

 

$

119,094

 

$

240,512

 

$

34,350

 

 

(1)         Included in cash and cash equivalents on our consolidated balance sheet.

 

(2)         Included in short-term investments on our consolidated balance sheet.

 

(3)         Included in other current assets on our consolidated balance sheet.

 

We classified the fair value measurements of our investments in the equity securities of Regulus and Sarepta Therapeutics, Inc., or Sarepta, as Level 3.  We calculated a lack of marketability discount on the fair value of these investments because there were restrictions on when we could trade the securities. We consider the inputs we used to calculate the lack of marketability discount Level 3 inputs and, as a result, we categorized these investments as Level 3.  We determined the lack of marketability discount by using a Black-Scholes model to value a hypothetical put option to approximate the cost of hedging the stock until the restriction ends. In the first quarter of 2013, we sold all of the common stock of Sarepta Therapeutics, Inc. that we owned resulting in a realized gain of $1.1 million. As of March 31, 2013, our Level 3 investments consisted of our investment in Regulus, with a gross fair value of $54.6 million and a lack of marketability discount of $9.7 million.  As of December 31, 2012, our Level 3 investments consisted of our investment in Regulus and Sarepta with a gross fair value of $44.4 million and $1.0 million, respectively, and a lack of marketability discount of $10.8 million and $296,000, respectively.

 

The following is a summary of our investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2013 (in thousands):

 

 

 

Investments

Valued Using

Level 3 Inputs

 

Balance at December 31, 2012

 

$

34,350

 

Total gains and losses:

 

 

 

Included in gain on investments

 

(1,163

)

Included in accumulated other comprehensive income (loss)

 

11,716

 

Cost basis of shares sold

 

(40

)

Balance at March 31, 2013

 

$

44,863

 

 

Other Fair Value Disclosures

 

Our 2¾ percent convertible notes had a fair value of $258.0 million at March 31, 2013.  We determine the fair value of our 2¾ percent convertible notes based on quoted market prices for these notes, which is a Level 2 measurement.

 

XML 46 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments (Details 2) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended
Mar. 31, 2013
security
Dec. 31, 2012
Investments    
Amortized Cost, Long-term Equity Securities $ 625 $ 625
Estimated Fair Value, Long-term Equity Securities 625 625
Amortized Cost, Investments 281,899 267,569
Unrealized Gains 31,597 22,581
Unrealized Losses (248) (185)
Other-Than-Temporary Impairment Loss (880) (880)
Estimated Fair Value, Investments 312,368 289,085
Temporarily impaired investments    
Temporarily impaired securities, Number of Investments 77  
Temporarily impaired securities, Less than 12 months of temporary impairment, Estimated Fair Value 114,028  
Total temporarily impaired securities, less than 12 months of temporary impairment, Unrealized Losses (248)  
Short-term investments
   
Investments    
Amortized Cost, Debt Securities 264,211 249,839
Unrealized Gains 298 310
Unrealized Losses (248) (185)
Estimated Fair Value 264,261 249,964
Short-term investments | Debt maturities of one year or less
   
Investments    
Amortized Cost, Debt Securities 124,464 140,909
Unrealized Gains 116 102
Unrealized Losses (86) (77)
Estimated Fair Value 124,494 140,934
Short-term investments | Debt maturities of more than one year
   
Investments    
Amortized Cost, Debt Securities 139,747 108,930
Unrealized Gains 182 208
Unrealized Losses (162) (108)
Estimated Fair Value 139,767 109,030
Corporate debt securities
   
Temporarily impaired investments    
Temporarily impaired securities, Number of Investments 70  
Temporarily impaired securities, Less than 12 months of temporary impairment, Estimated Fair Value 95,606  
Total temporarily impaired securities, less than 12 months of temporary impairment, Unrealized Losses (185)  
Corporate debt securities | Debt maturities of one year or less
   
Investments    
Amortized Cost, Debt Securities 97,983 113,249
Unrealized Gains 59 81
Unrealized Losses (29) (9)
Estimated Fair Value 98,013 113,321
Corporate debt securities | Debt maturities of more than one year
   
Investments    
Amortized Cost, Debt Securities 107,131 80,166
Unrealized Gains 110 112
Unrealized Losses (156) (92)
Estimated Fair Value 107,085 80,186
Debt securities issued by U.S. government agencies
   
Temporarily impaired investments    
Temporarily impaired securities, Number of Investments 4  
Temporarily impaired securities, Less than 12 months of temporary impairment, Estimated Fair Value 13,885  
Total temporarily impaired securities, less than 12 months of temporary impairment, Unrealized Losses (49)  
Debt securities issued by U.S. government agencies | Debt maturities of one year or less
   
Investments    
Amortized Cost, Debt Securities 9,932 10,100
Unrealized Gains 1 2
Unrealized Losses (46) (66)
Estimated Fair Value 9,887 10,036
Debt securities issued by U.S. government agencies | Debt maturities of more than one year
   
Investments    
Amortized Cost, Debt Securities 15,020 8,034
Unrealized Gains 35 38
Unrealized Losses (3)  
Estimated Fair Value 15,052 8,072
Debt securities issued by the U.S. Treasury | Debt maturities of one year or less
   
Investments    
Amortized Cost, Debt Securities 1,000 1,000
Unrealized Gains 1 1
Estimated Fair Value 1,001 1,001
Debt securities issued by the U.S. Treasury | Debt maturities of more than one year
   
Investments    
Amortized Cost, Debt Securities 12,393 12,424
Unrealized Gains 30 27
Estimated Fair Value 12,423 12,451
Debt securities issued by states of the United States and political subdivisions of the states
   
Temporarily impaired investments    
Temporarily impaired securities, Number of Investments 3  
Temporarily impaired securities, Less than 12 months of temporary impairment, Estimated Fair Value 4,537  
Total temporarily impaired securities, less than 12 months of temporary impairment, Unrealized Losses (14)  
Debt securities issued by states of the United States and political subdivisions of the states | Debt maturities of one year or less
   
Investments    
Amortized Cost, Debt Securities 15,549 16,560
Unrealized Gains 55 18
Unrealized Losses (11) (2)
Estimated Fair Value 15,593 16,576
Debt securities issued by states of the United States and political subdivisions of the states | Debt maturities of more than one year
   
Investments    
Amortized Cost, Debt Securities 5,203 8,306
Unrealized Gains 7 31
Unrealized Losses (3) (16)
Estimated Fair Value 5,207 8,321
Equity securities
   
Investments    
Amortized Cost, Investments 17,688 17,730
Unrealized Gains 31,299 22,271
Other-Than-Temporary Impairment Loss (880) (880)
Estimated Fair Value, Investments 48,107 39,121
Equity securities | Other current assets
   
Investments    
Amortized Cost, Equity Securities 1,538 1,579
Unrealized Gains 1,961 4,175
Other-Than-Temporary Impairment Loss (880) (880)
Estimated Fair Value 2,619 4,874
Equity securities | Regulus Therapeutics
   
Investments    
Amortized Cost, Equity Securities 15,525 15,526
Unrealized Gains 29,338 18,096
Estimated Fair Value $ 44,863 $ 33,622
XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 184 198 1 false 67 0 false 7 false false R1.htm 0000 - Document - Document and Entity Information Sheet http://www.isispharm.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.isispharm.com/role/BalanceSheet CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.isispharm.com/role/BalanceSheetParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.isispharm.com/role/StatementOfIncome CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.isispharm.com/role/StatementOfComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) false false R6.htm 0040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.isispharm.com/role/CashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 1010 - Disclosure - Basis of Presentation Sheet http://www.isispharm.com/role/DisclosureBasisOfPresentation Basis of Presentation false false R8.htm 1020 - Disclosure - Significant Accounting Policies Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies false false R9.htm 1030 - Disclosure - Investments Sheet http://www.isispharm.com/role/DisclosureInvestments Investments false false R10.htm 1040 - Disclosure - Fair Value Measurements Sheet http://www.isispharm.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R11.htm 1050 - Disclosure - Concentration of Business Risk Sheet http://www.isispharm.com/role/DisclosureConcentrationOfBusinessRisk Concentration of Business Risk false false R12.htm 1060 - Disclosure - Income Taxes Sheet http://www.isispharm.com/role/DisclosureIncomeTaxes Income Taxes false false R13.htm 1070 - Disclosure - Collaborative Arrangements and Licensing Agreements Sheet http://www.isispharm.com/role/DisclosureCollaborativeArrangementsAndLicensingAgreements Collaborative Arrangements and Licensing Agreements false false R14.htm 2020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) false false R15.htm 3020 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) false false R16.htm 3030 - Disclosure - Investments (Tables) Sheet http://www.isispharm.com/role/DisclosureInvestmentsTables Investments (Tables) false false R17.htm 3040 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.isispharm.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) false false R18.htm 3050 - Disclosure - Concentration of Business Risk (Tables) Sheet http://www.isispharm.com/role/DisclosureConcentrationOfBusinessRiskTables Concentration of Business Risk (Tables) false false R19.htm 4020 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails Significant Accounting Policies (Details) false false R20.htm 4021 - Disclosure - Significant Accounting Policies (Details 2) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails2 Significant Accounting Policies (Details 2) false false R21.htm 4022 - Disclosure - Significant Accounting Policies (Details 3) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails3 Significant Accounting Policies (Details 3) false false R22.htm 4023 - Disclosure - Significant Accounting Policies (Details 4) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails4 Significant Accounting Policies (Details 4) false false R23.htm 4024 - Disclosure - Significant Accounting Policies (Details 5) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails5 Significant Accounting Policies (Details 5) false false R24.htm 4025 - Disclosure - Significant Accounting Policies (Details 6) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails6 Significant Accounting Policies (Details 6) false false R25.htm 4026 - Disclosure - Significant Accounting Policies (Details 7) Sheet http://www.isispharm.com/role/DisclosureSignificantAccountingPoliciesDetails7 Significant Accounting Policies (Details 7) false false R26.htm 4030 - Disclosure - Investments (Details) Sheet http://www.isispharm.com/role/DisclosureInvestmentsDetails Investments (Details) false false R27.htm 4031 - Disclosure - Investments (Details 2) Sheet http://www.isispharm.com/role/DisclosureInvestmentsDetails2 Investments (Details 2) false false R28.htm 4040 - Disclosure - Fair Value Measurements (Details) Sheet http://www.isispharm.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) false false R29.htm 4041 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.isispharm.com/role/DisclosureFairValueMeasurementsDetails2 Fair Value Measurements (Details 2) false false R30.htm 4050 - Disclosure - Concentration of Business Risk (Details) Sheet http://www.isispharm.com/role/DisclosureConcentrationOfBusinessRiskDetails Concentration of Business Risk (Details) false false R31.htm 4060 - Disclosure - Income Taxes (Details) Sheet http://www.isispharm.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) false false R32.htm 4070 - Disclosure - Collaborative Arrangements and Licensing Agreements (Details) Sheet http://www.isispharm.com/role/DisclosureCollaborativeArrangementsAndLicensingAgreementsDetails Collaborative Arrangements and Licensing Agreements (Details) false false All Reports Book All Reports Element isis_FairValueInputsLackOfMarketabilityDiscount had a mix of decimals attribute values: -5 0. Element isis_MaximumAmountOfPaymentReceivable had a mix of decimals attribute values: -6 -5. Element isis_MaximumAmountOfPaymentReceivablePerDrug had a mix of decimals attribute values: -6 -5. Element isis_ProspectiveMilestonePayment had a mix of decimals attribute values: -6 -5. Element isis_UpFrontFeeReceived had a mix of decimals attribute values: -6 -5. Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0. Element us-gaap_GainLossOnInvestments had a mix of decimals attribute values: -5 -3. Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -6 -5. Element us-gaap_Revenues had a mix of decimals attribute values: -5 -3 0. 'Monetary' elements on report '4020 - Disclosure - Significant Accounting Policies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '4023 - Disclosure - Significant Accounting Policies (Details 4)' had a mix of different decimal attribute values. 'Monetary' elements on report '4026 - Disclosure - Significant Accounting Policies (Details 7)' had a mix of different decimal attribute values. 'Monetary' elements on report '4040 - Disclosure - Fair Value Measurements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '4060 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '4070 - Disclosure - Collaborative Arrangements and Licensing Agreements (Details)' had a mix of different decimal attribute values. Process Flow-Through: 0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Process Flow-Through: 0040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS isis-20130331.xml isis-20130331.xsd isis-20130331_cal.xml isis-20130331_def.xml isis-20130331_lab.xml isis-20130331_pre.xml true true XML 48 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Details 2) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Mar. 31, 2013
Maximum
Cash, cash equivalents and short-term investments      
Ownership percentage in equity investments     20.00%
Inventory valuation      
Raw materials $ 5,809 $ 6,121